<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Diagnosis | mesothelioma</title>
    <link>/mesothelioma/syntax_summary/diagnsosis/</link>
      <atom:link href="/mesothelioma/syntax_summary/diagnsosis/index.xml" rel="self" type="application/rss+xml" />
    <description>Diagnosis</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Sun, 09 Sep 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/mesothelioma/images/icon_hu3365e08ad5ef6cb6d886bc511b9ad2b3_313689_512x512_fill_lanczos_center_2.png</url>
      <title>Diagnosis</title>
      <link>/mesothelioma/syntax_summary/diagnsosis/</link>
    </image>
    
    <item>
      <title>Diagnsose Sentence Context</title>
      <link>/mesothelioma/syntax_summary/diagnsosis/info/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/syntax_summary/diagnsosis/info/</guid>
      <description> 

&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 1.&lt;/strong&gt; Analysis of context sentence of 2367 absracts clustered as diagnosis.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Title
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Gene Context Sentence
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
ePubDate
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10023021&#34; target=&#34;_blank&#34;&gt;P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignancy in peritoneal and pleural effusions can be difficult, because activated mesothelial cells may resemble malignant cells. […] In this study, we investigated the sensitivity and specificity of 4 different monoclonal antibodies (moAB) against p53 for the diagnosis of malignancy in effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10028349&#34; target=&#34;_blank&#34;&gt;[Diagnostic examination for causes of exudative pleurisy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In two patients, men aged 65 and 57 years with complaints of exertional dyspnoea, dry cough, diminished appetite and weight loss, the cause of pleural fluid formation was not discovered despite several diagnostic procedures. […] The second patient had pleurisy secondary to an adenocarcinoma in the upper lobe of the right lung; he died from lung embolism after the second, diagnostic, thoracoscopy. […] It can be difficult to establish the diagnosis in patients with a pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1004744&#34; target=&#34;_blank&#34;&gt;[Primary malignant tumors of the pleura. Pleural Mesothelioma (P.M.)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conventional and more recent instrumental, cytohistological and bioptic methods of diagnosis are explained, with particular reference to pioneering experience gained with fibropleuroscopy in the Genoa Clinical Department. […] While dependable diagnosis can now be virtually assured, surgical and pneumological management holds out few prospects of success.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10048474&#34; target=&#34;_blank&#34;&gt;The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This emphasises the need for accurate staging procedures at diagnosis and reliable imaging methods to assess response to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10100235&#34; target=&#34;_blank&#34;&gt;Pelvic and lumbar metastasis detected by bone scintigraphy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of bone scintigraphy and NMR findings allowed the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1010182&#34; target=&#34;_blank&#34;&gt;[Primary pericardial mesothelioma: report of a case (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postmortem examination confirmed the diagnosis and revealed thoracic and extrathoracic metastasis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10202948&#34; target=&#34;_blank&#34;&gt;Ga-67 tumor scan in malignant diffuse mesothelioma–comparison with CT and pathological findings.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant diffuse mesothelioma is characterized by more difficult diagnosis and worse prognosis than other pleural tumors. […] Regarding the use of Ga-67 scan imaging for the diagnosis of this disease, a number of related findings must be considered, such as an encircled wide Ga-67 uptake in the thickened pleural involvement and a diffuse slight Ga-67 uptake on the affected side with very slight involvement of the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10204666&#34; target=&#34;_blank&#34;&gt;Magnetic resonance appearance of asbestos-related benign and malignant pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was established by means of percutaneous biopsy, thoracotomy, and combined clinical and radiological follow-up for at least 3 years. […] The sensitivity, specificity, and diagnostic accuracy of the magnetic resonance imaging in classifying a lesion as suggestive of malignancy were 100%, 95% and 97%, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10217936&#34; target=&#34;_blank&#34;&gt;Health effects of asbestos exposure in humans: a quantitative assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic uncertainties regarding pleural plaques and the substantial degree of misclassification make it difficult to precisely estimate the shape of the dose-response relationship.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10230223&#34; target=&#34;_blank&#34;&gt;[Video thoracoscopy in the diagnosis of pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At present video thoracoscopy is a primary diagnostic procedure in the diagnosis of pleural diseases, particularly when pleural effusions have unknown origin. […] In this article the personal experience is reported about 20 patients in which video thoracoscopy was very important in the diagnosis of pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10232420&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Exposure data, i.e. the time residing in Karain, and hospital records including pathological diagnosis, were recorded.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10234882&#34; target=&#34;_blank&#34;&gt;[Case series of mesotheliomas from hospital archives as contribution to preventive intervention].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Each case was assigned to first (fine needle aspiration, cytologic exam), second (multiple biopsies during thoracoscopy or laparoscopy) or third (operation) diagnostic level and asbestos exposure was analysed. […] Malignant mesotheliomas were histologically confirmed in 16 cases: 1 patient was classified as malignant pleural tumor (cytology and CT scan), 1 patient as suspicious malignant pleural tumor (only radiological diagnosis) and both were excluded for analysis. […] Second level diagnosis was assigned to 9 patients and third level to 7 patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10341795&#34; target=&#34;_blank&#34;&gt;[MRT, CT and sonography in the preoperative assessment of the primary tumor spread in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Evaluation of the diagnostic value of the imaging modalities computed tomography (CT), magnetic resonance imaging (MRI), and thoracic sonography in the preoperative staging of malignant pleural mesothelioma. […] The diagnostic accuracy of CT (n = 41), MRI (n = 24), and thoracic sonography (n = 37) were evaluated in 51 patients with histologically proven diffuse malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10347962&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In order to assess our own experience, we reviewed all medical records and biopsies of patients who were seen with this diagnosis in Hospital Maria Ferrer between January 1986 and December 1997. […] Diagnosis was performed by thoracotomy (47%), needle biopsy (23.5%) and videothoracoscopy (29.5%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10352588&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: US-guided histologic core-needle biopsy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the clinical use of ultrasonographically (US) guided core-needle biopsy, performed with a one-hand automatic sampling technique, in the diagnosis of malignant pleural mesothelioma (MPM). […] The authors reviewed the findings in 70 patients with a tentative diagnosis of MPM who underwent US-guided core-needle biopsy at our institution during the past 10 years. […] The correct diagnosis was made in 56 patients. […] US-guided core-needle biopsy is highly effective in the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10358454&#34; target=&#34;_blank&#34;&gt;[CA 125 in the department of internal medicine–a marker of ovarian tumor, thoracic fluid or ascites?].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore in patients with elevated CA 125 and fluidothorax or ascites, unless ovarian carcinoma is proved, this fact should be taken into account in diagnostic considerations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10359850&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous carcinoma involving pleura and peritoneum: A clinicopathologic and immunohistochemical study of three cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of these, Ber-EP4 and B 72.3 rendered the most reliable diagnostic results. […] The clinical, radiologic, and gross and routine histologic findings were similar to those of a malignant mesothelioma; the final diagnosis could be made based mainly on immunocytochemical results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10390966&#34; target=&#34;_blank&#34;&gt;[Horner’s syndrome in a patient with diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was malignant mesothelioma of sarcomatous type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10390968&#34; target=&#34;_blank&#34;&gt;[A case of diffuse pleural mesothelioma disclosed by a 7 mm tumor shadow on chest X-ray film during a regular physical checkup].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient was referred to the respiratory medicine department of our hospital, where further bronchoscopic examinations were performed but no conclusive diagnosis was obtained. […] Our conclusion was that a thoracoscopic examination should have been performed for diagnostic purposes at an earlier stage.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10399473&#34; target=&#34;_blank&#34;&gt;[Chronic pleuropathy due to asbestos and malignant mesothelioma of the pleura: a differential diagnosis not always easy. A case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was made only at autopsy. […] In absence of a sure histological diagnosis, the differential diagnosis of the two diseases (chronic asbestos pleuritis and malignant pleural mesothelioma) is not easy, so that necropsy retains a fundamental role in patients without a certain diagnosis in vita.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10407698&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MPM is easier because of new immunohistochemical markers that recognize the mesothelial cells with good specificity and sensitivity on pleural biopsy samples ideally obtained by thoracoscopy. […] Moreover, this endoscopic procedure allows the physician to make the diagnosis of MPM at an early stage, which is the key of the therapeutic management of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10412176&#34; target=&#34;_blank&#34;&gt;[Peritoneal mesothelioma–incidence and etiology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Age at first diagnosis of malignant mesotheliomas is about 59 years; the women are on average 4 years younger than the men.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10421502&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a problematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A clinicopathologic review is performed in light of several problematic issues involving diagnosis, staging, natural history, and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10434546&#34; target=&#34;_blank&#34;&gt;[Pleural malignant mesothelioma complicated by multiple myeloma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of multiple myeloma was made on the basis of blood tests and bone marrow aspiration biopsy findings. […] However, a postmortem diagnosis of malignant mesothelioma of the pleura was made on the basis of histological and immunohistological studies of autopsy specimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10437690&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT plays an important role in the diagnosis, assessment, and evaluation of treatment response of this tumour, although it has some limitations in specific areas in evaluating patients for surgical resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10439104&#34; target=&#34;_blank&#34;&gt;How should we treat malignant pleural mesothelioma (MPM)?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival time in the diagnosis/exploration group is 6 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10441977&#34; target=&#34;_blank&#34;&gt;Preoperative work-up of a solitary diaphragmatic mass in a patient with right shoulder pain: a case for diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy proved to play an essential part in the diagnostic work-up, avoiding a futile thoracotomy for a presumed solitary soft tissue tumour.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10442339&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleural space.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma is resistant to standard modes of therapy and, if untreated, results in death 4 to 12 months from the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10450672&#34; target=&#34;_blank&#34;&gt;Prognostic value of FDG PET imaging in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of mesothelioma was confirmed in 22.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10453882&#34; target=&#34;_blank&#34;&gt;Advances in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review will discuss the roles of chemotherapy, radiotherapy, surgery, and combined modality approaches in the treatment of pleural mesothelioma, as well as scientific advances made in the past decade that have led to the development of experimental techniques, such as photodynamic therapy, immunotherapy, and gene therapy, that are currently undergoing human clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10471051&#34; target=&#34;_blank&#34;&gt;p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the first step, this study investigated the possible diagnostic value of serum EGF-R, p53-protein and anti-p53 antibodies, measured by an enzyme-linked immunosorbent assay, in lung tumour patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10476113&#34; target=&#34;_blank&#34;&gt;Cerebral metastases in malignant mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Four months after diagnosis the patient commenced chemotherapy with liposomal doxorubicin as part of an EORTC phase II trial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10478545&#34; target=&#34;_blank&#34;&gt;[Clinical comparison of diffuse malignant mesothelioma of the pleura and pseudomesotheliomatous carcinoma of the lung for each case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
But the pathologic diagnosis was adenocarcinoma of the lung, what is so called pseudomesotheliomatous carcinoma. […] The pathologic final diagnosis was diffuse malignant mesothelioma of the pleura. […] In clinical differential diagnosis of diffuse malignant mesothelioma of the pleura and pseudomesotheliomatous carcinoma of the lung, history of inhalation of asbestos and concentrations of hyaluronic acid in pleural effusion are helpful. […] And thoracoscopic biopsy is necessary in established diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10481335&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma with an unusual radiologic manifestation].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Definitive diagnostic was achieved by thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10495318&#34; target=&#34;_blank&#34;&gt;Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In one case, LSM in direct contact with collagen fiber bundles in the tumor tissue matrix were observed, supporting the diagnosis of an invasive EMM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10544967&#34; target=&#34;_blank&#34;&gt;Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Using 125I-uPA binding and ligand blotting techniques, uPAR was expressed by phenotypically diverse lung carcinoma cell lines, including the H460, H157 and H1395 non-small cell lines and the H146 small cell lung carcinoma line.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10547262&#34; target=&#34;_blank&#34;&gt;Localized benign fibrous mesothelioma mimicking a malignant tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of the considerable overlap of imaging characteristics between the two entities, the authors conclude that determination of resectability rather than differentiation between benign and malignant mesothelioma should be the primary goal to be achieved by imaging techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10547583&#34; target=&#34;_blank&#34;&gt;The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Distinguishing malignant mesothelioma from reactive mesothelial hyperplasia and reactive fibrosis can be a diagnostic problem in small pleural biopsies, made more difficult by the recent recognition of mesothelioma-in-situ.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10585573&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is difficult. […] The histological diagnosis is made on thoracoscopic biopsy. […] Analysis of the histochemical profile (PAS-D, hyaluronidase, vimentine), the use of immunochemistry (CEA, keratines), and electron microscopy can facilitate the making of the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10587144&#34; target=&#34;_blank&#34;&gt;Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT and MR imaging are of nearly equivalent diagnostic accuracy in staging malignant pleural mesothelioma. […] For cost reasons, CT should be considered the standard diagnostic study before therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10590773&#34; target=&#34;_blank&#34;&gt;[Diagnosis of malignant pleural mesothelioma and asbestosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural mesothelioma in practice is based on histological examination in about 80%, on cytological examination in 15% and on other forms of examination, e.g., high resolution computer tomography (HRCT), in 6% of the cases. […] Using a combination of various noninvasive methods, such as anamnesis, physical and röntgenologic examination, HRCT and spirometry, the diagnosis of asbestosis is made erroneously in 5% of the patients examined. […] With regard to allowance of financial compensation to patients with pleural mesothelioma and asbestosis, a part is played by the fact that views differ internationally concerning the criteria on which the diagnosis should be based.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10596313&#34; target=&#34;_blank&#34;&gt;Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Video-assisted Thoracic Surgery (VATS) today can be employed in the diagnosis and treatment of idiopatic and known MPE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10605410&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Careful histological examination remains the mainstay of the diagnosis of early mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10615665&#34; target=&#34;_blank&#34;&gt;[F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In all cases the diagnosis was confirmed histologically.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10619505&#34; target=&#34;_blank&#34;&gt;Surgical treatment of mesothelioma: pleurectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant diffuse mesothelioma is the most common type of mesothelioma, with a median survival ranging from 8.5 to 18 months after diagnosis. […] Several investigators have described staging systems for this tumor and have emphasized the importance of thoracoscopy in the diagnosis and staging of the disease. […] However, neither of these techniques has demonstrated any significant benefit to date and thus should not be considered as standards of care. […] A randomized comparison of these techniques may be beneficial in identifying the most effective procedure for patients with malignant diffuse mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10619506&#34; target=&#34;_blank&#34;&gt;Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The technique of pleuropneumonectomy traditionally has been linked with high perioperative mortality and morbidity when compared with that of other cytoreductive techniques such as pleurectomy/decortication.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10619507&#34; target=&#34;_blank&#34;&gt;Emerging translational therapies for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma remains a therapeutic and diagnostic problem.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10624771&#34; target=&#34;_blank&#34;&gt;Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Simian vacuolating virus 40 viral deoxyribonucleic acid and antigens may be potential markers for neoplastic mesothelium that may prove useful in the rather difficult histopathological differential diagnosis between malignant mesothelioma and reactive mesothelium or pleural carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10626691&#34; target=&#34;_blank&#34;&gt;Glycogen-rich mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ultrastructural and immunohistochemical studies can be helpful in establishing the correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10628804&#34; target=&#34;_blank&#34;&gt;Kaposi’s sarcoma following malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Seropositivity to human herpes virus 8 (HHV8) was documented at the time of mesothelioma diagnosis and preceded the onset of Kaposi’ sarcoma with a time lapse of 13 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10629562&#34; target=&#34;_blank&#34;&gt;Value of morphometry, texture analysis, densitometry, and histometry in the differential diagnosis and prognosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since genetic and immunohistochemical markers are not absolutely differentiating, the diagnosis is based on the histology complemented with (immuno)histochemistry. […] In order to evaluate the prognostic and diagnostic performance of syntactic structure analysis (SSA), chromatin texture analysis, densitometry, and morphometry, an automated KNN-classification system has been used to compare Feulgen-stained tissue sections of hyperplastic mesothelium, malignant mesothelioma, and pulmonary adenocarcinoma. […] The results indicate that for the diagnosis of malignant mesothelioma, chromatin texture parameters outperform SSA, densitometry, and morphometry (recognition score=96.8 per cent).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10631693&#34; target=&#34;_blank&#34;&gt;Contemporary management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Consensus in mesothelioma management currently remains elusive but it seems clear that the way forward will involve striving for much earlier diagnosis, the use of multimodality therapy and collaboration between centers with special expertise in mesothelioma treatment to organize multicenter trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10661621&#34; target=&#34;_blank&#34;&gt;Immunocytochemistry and DNA-image cytometry in diagnostic effusion cytology I. Prevalence of markers in tumour cell positive and negative smears.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine the prevalence of immunocytochemical positivities for a panel of antibodies in benign and malignant cells in effusions with known follow-up in order to use these as diagnostic markers. […] Besides their ability to identify malignant epithelial cells their contribution to the differential diagnosis between carcinomatoses and mesotheliomas was investigated. 101 tumour cell positive and 53 negative effusions were stained with 12 different antibodies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10665909&#34; target=&#34;_blank&#34;&gt;Malignant epithelioid vascular tumors of the pleura: report of a series and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Almost all of the patients died of disease shortly after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10667164&#34; target=&#34;_blank&#34;&gt;Diagnosis of malignant mesothelioma by fine needle aspiration of a cervical lymph node. A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinically documented distant metastases are rare in mesothelioma and tend to occur late in the course of the disease, well after the diagnosis has been made. […] In this instance, diagnosis was not made until a metastatic deposit was identified microscopically in the enlarged lymph node. […] It serves to remind the pathologist that when confronted with a lymph node involved by tumor, the possibility of mesothelioma should be included in the differential diagnosis. […] The case also demonstrates the usefulness of fine needle aspiration in the diagnosis of metastatic tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10677119&#34; target=&#34;_blank&#34;&gt;Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serum level of Cyfra 21-1, a marker of cytokeratin 19 fragments, has been used in the diagnosis and monitoring of epithelial tumours, especially bronchogenic carcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10678010&#34; target=&#34;_blank&#34;&gt;[VATS in malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, VATS has provided a high positive diagnosis of patients with malignant pleural effusions not diagnosed by conventional methods and good results in pleurodesis, but some operating skills must be emphasized.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10689819&#34; target=&#34;_blank&#34;&gt;[Endoscopic approach to pulmonary diseases: Clinical utility of medical thoracoscopy in diagnosis of pleural diseases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy is useful for diagnosis of a number of lung diseases. […] Especially in malignant mesothelioma, thoracoscopy allowed accurate diagnosis. […] Since medical thoracoscopy under local anesthesia is a rapid, easy, safe, and well-tolerated procedure with an excellent diagnostic yield, it is recommended as a diagnostic procedure for cases with pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10692217&#34; target=&#34;_blank&#34;&gt;Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis between reactive mesothelial cells (RMs), malignant mesotheliomas (MMs), and adenocarcinomas (ACs) is often difficult in cytologic specimens, and the utility of various immunohistochemical markers have been explored. […] Because recent immunohistologic studies have suggested that E-cadherin (E-cad) and calretinin (Cal) may be useful markers for epithelial and mesothelial differentiations, respectively, the authors investigated their utility in cytologic diagnosis. […] In contrast to the results of previous immunohistochemical studies, the current study indicates that MMs constantly express E-cad, whereas RMs lack its expression in cytologic specimens, which would be useful in the differential diagnosis between the two. […] The combined immunostaining for E-cad and Cal has utility in differential diagnosis among RM, MM, and AC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10699694&#34; target=&#34;_blank&#34;&gt;Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin’s disease treated with 90yttrium-silicate.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient remains in a good clinical condition now 6 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10703192&#34; target=&#34;_blank&#34;&gt;[The incidence of malignant mesothelioma (1977-1996) and asbestos exposure in the population of an area neighboring Lake Iseo, northern Italy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the study was: identification of malignant mesotheliomas occurring between 1977 and 1996 among the residents of 11 villages, which constituted the recruitment area of the work-force; estimation of the incidence of malignant pleural mesothelioma; collection of working histories of all cases to evaluate previous exposure to asbestos and radiation therapy. 21 cases of mesothelioma were detected (20 pleural, 1 peritoneal; 9 among males), and 20 were supported by histopathologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10714371&#34; target=&#34;_blank&#34;&gt;Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Stepwise logistic regression analysis selected three criteria of major importance for distinguishing between adenocarcinoma and mesothelioma: BerEp4, CEA and EMA accentuated at the cell membrane (mEMA), these three being of similar diagnostic value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10730472&#34; target=&#34;_blank&#34;&gt;[Malignant Mesothelioma Registry from Piedmont. Incidence in 1990-1995].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Possible cases of m.m. (cytological and/or x-ray diagnosis) have been searched in the file of hospital admission and discharges (SDO) in 1994-95: 46 additional cases were found, with a 25% increase in incidence rates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10737384&#34; target=&#34;_blank&#34;&gt;Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although several immunohistochemical markers are available, differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura is difficult. […] The aim of the present study was to investigate whether MnSOD can be used in the differential diagnosis of malignant mesothelioma and metastatic adenocarcinoma of the pleura. […] In conclusion, MnSOD immunoreactivity can, combined with other markers, aid the differential diagnosis between malignant mesothelioma and metastatic adenocarcinoma of the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10741777&#34; target=&#34;_blank&#34;&gt;Mesothelioma: new concepts in diagnosis and management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Generally perceived as a death sentence, this cancer is associated with a median survival of 9 months from the time of diagnosis in most series, but newer therapeutic strategies show promise for improved and even long-term survival in select cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10757409&#34; target=&#34;_blank&#34;&gt;Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction between malignant pleural mesotheliomas and adenocarcinomas, particularly those originating in the lung, is a difficult diagnostic problem that can be facilitated by the use of immunohistochemical markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10773558&#34; target=&#34;_blank&#34;&gt;18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic approach to pleural diseases may be difficult. […] The CT scan, which is the current diagnostic technique, has limited accuracy both in the differentiation between benign and malignant pleural diseases and in the diagnosis of primary and metastatic pleural neoplasms. […] Invasive procedures, such as thoracoscopy, are therefore frequently required to complete the diagnostic approach. […] There is, therefore, a need for new diagnostic techniques that can lead to a definite diagnosis and a satisfactory evaluation of the response to treatment. […] The aim of this study was to evaluate the role of 18-FDG PET in the diagnostic assessment of pleural diseases. […] These preliminary results demonstrate that 18-FDG PET may have a great potential, both in the differential diagnosis of pleural diseases and in the evaluation of the response to treatment. […] At present, however, histological thoracoscopic diagnosis remains mandatory before planning treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10783640&#34; target=&#34;_blank&#34;&gt;[Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The sensitivity (100%) and specificity (100%) of reactivity for Calretinin and Ber-EP4 showed that the immunocytochemical results on paraffin embedded material from cavity effusions are very reliable, so that the tested immunocytochemical panel can be useful in cytological differential diagnosis between reactive mesothelial hyperplasia/mesothelioma and metastatic carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10783675&#34; target=&#34;_blank&#34;&gt;The diagnostic yield of pleural fluid cytology in malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis of the cause of the pleural effusion in such a patient is essential as the treatment and prognosis may vary. […] Currently, thoracentesis and cytologic analysis of pleural fluid cytology is usually the initial diagnostic step. […] To assess the diagnostic yield of pleural fluid cytologic examination in patients with suspected malignant pleural effusions seen at our centre. […] The yield of this diagnostic procedure was improved with repeated pleural fluid cytologic specimens and when combined with a percutaneous pleural biopsy. […] Pleural fluid cytologic examination is a useful initial step in the diagnostic work-up of patients with suspected malignant pleural effusions. […] The diagnostic yield of such examination is improved with repeated pleural fluid cytologic specimens and when combined with a percutaneous pleural biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10786419&#34; target=&#34;_blank&#34;&gt;Malignant pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic work-up lies in cytology, whose average yield is approximately 50%, and a biopsy technique (either by blind needle biopsy or thoracoscopy) is recommended when the effusion persists, for &amp;gt; 2 weeks, and the first cytology has been negative.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10800396&#34; target=&#34;_blank&#34;&gt;Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One case initially was misdiagnosed as a ganglioneuroma, a second case was misinterpreted as malignant lymphoma, and a third case was sent in consultation with the differential diagnosis of inflammatory pseudotumor vs mesothelioma. […] In lymphohistiocytoid mesothelioma, as in the usual examples of sarcomatoid mesothelioma, the demonstration of cytokeratin expression by the neoplastic cells is the most useful diagnostic finding that allows exclusion of other neoplasms with which this entity may be confused.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10810369&#34; target=&#34;_blank&#34;&gt;Simian virus 40: the link with human malignant mesothelioma is well established.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesotheliomas are malignancies of the pleural, pericardial, and peritoneal surfaces with a mean survival of less than 1 year from the time of diagnosis (1).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10812006&#34; target=&#34;_blank&#34;&gt;Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural malignant mesothelioma (MM) shows poor survival, regardless of tumour stage at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10820527&#34; target=&#34;_blank&#34;&gt;Relation between natural killer cells and neoplastic cells in serous fluids.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Investigation of the NK% could be useful in cytologically doubtful cases and in the differential diagnosis between MM and adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10833989&#34; target=&#34;_blank&#34;&gt;Computed tomography-guided fine needle aspiration of peripheral lung opacities. An initial diagnostic procedure?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
FNA under CT guidance may be applied as the initial procedure in the diagnosis of peripheral malignant pulmonary lesions, rendering a high diagnostic yield.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10849094&#34; target=&#34;_blank&#34;&gt;Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Expression of N-cadherin supports the diagnosis of malignant mesothelioma and use of appropriate antibodies would be a useful addition to a diagnostic antibody panel.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10859770&#34; target=&#34;_blank&#34;&gt;[Primary biphasic synovial sarcoma of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the atypical clinical course, the early development of lung metastases and a new reading of histologic documents led to the diagnosis of primary pleural synovial sarcoma. […] Only a complete immuno-histochemical study confronted with the clinical course can lead to the correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10888787&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with CD30-positivity. A case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The activation marker CD3O is useful in the diagnosis of Hodgkin and non-Hodgkin lymphomas. […] This finding has not previously been described and is important in broadening the differential diagnosis of a CD30(+) cohesive large cell malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10896333&#34; target=&#34;_blank&#34;&gt;Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differentiation between malignant mesothelioma and adenocarcinoma based on morphology alone can be a diagnostic challenge.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10898540&#34; target=&#34;_blank&#34;&gt;Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma–a feasibility study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival in all the patients was 8.5 months from the first chemotherapy cycle and 11 months from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10921040&#34; target=&#34;_blank&#34;&gt;[Clinical analysis of 19 patients with pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To summarize the experience in the diagnosis of pleural mesothelioma. […] CT and B ultrasonography are of good help in the diagnosis of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10931239&#34; target=&#34;_blank&#34;&gt;Primary malignant gonadal mesotheliomas and asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry has an important role in confirmation of the diagnosis. […] The accurate diagnosis of primary gonadal mesothelioma has potentially important medicolegal compensation considerations as a significant proportion of these cases are associated with asbestos.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10941335&#34; target=&#34;_blank&#34;&gt;An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most diagnostic information was obtained with 8 of the parameters studied.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10958862&#34; target=&#34;_blank&#34;&gt;Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural effusion is a common diagnostic problem. […] The analysis of serum and body fluids for tumor markers has been intensively applied to clinical diagnosis. […] A total of 61 pleural effusions were collected from the patients, who were subjected either to simple needle aspiration or to tube drainage for the diagnosis of pleural effusion. […] Therefore, sensitivity, specificity, positive predictive value, and negative predictive value were defined as diagnostic parameters. […] Our data imply that the co-measurement of MCA+CA-19.9+CA-125 levels may further improve their diagnostic value in malignant pleural effusion compared with that of each tumour marker alone and may be useful in distinguishing malignant from benign pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10959097&#34; target=&#34;_blank&#34;&gt;Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nevertheless, average survival of 4 to 10 months from diagnosis is sometimes not sufficient for full expression of these factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-10-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/10976692&#34; target=&#34;_blank&#34;&gt;The separation of benign and malignant mesothelial proliferations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Densely packed mesothelial cells within the pleural space are frequent in benign reactions, but densely packed mesothelial cells within the stroma favor a diagnosis of malignancy. […] The combination of a paucicellular storiform pattern, plus invasion of the stroma (including fat and adjacent tissues), or bland necrosis, overtly sarcomatous foci, or distant metastases, is required for the diagnosis of desmoplastic mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11013806&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura, pericardium and peritoneum. 1: Etiology, pathogenesis, pathology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this first part of the series on mesotheliomas, current concepts on etiology and pathogenesis as well as diagnostic procedures and standards are discussed. […] A reliable diagnosis is the basis for therapeutic, prognostic and medicolegal consequences; in general, it can be achieved by thoracoscopic inspection with selected biopsy. […] Surgery may gain a more important role in the therapy of malignant tumors of serosal membranes not only in palliative, but also in potential curative approaches if the diagnosis can be made at earlier tumor stages.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11018693&#34; target=&#34;_blank&#34;&gt;Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the study was to assess diagnosis value of tumor markers for differential diagnosis between mesothelioma and other pleural tumors. […] The diagnostic approach involved routine pleurocentesis followed by pleural needle. […] When precise diagnosis was not achieved, thoracoscopy with pleural biopsies was performed. […] By using receiver operating characteristics curves and area under curves, the best diagnostic characteristics were obtained with pleural and serum CEA concentrations. […] The sensitivity and specificity of a pleural CEA level exceeding 3 ng/mL for ruling out the diagnosis of mesothelioma were 100% and 77%, respectively. […] A CEA level above 3 ng/mL in pleural fluid eliminated the diagnosis of mesothelioma, whereas the other markers were not sufficiently discriminant. […] However, despite a negative predictive value of 100% at a cutoff of 3 ng/mL, CEA assay in pleural fluid only avoids a small number of diagnostic thoracoscopies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11029888&#34; target=&#34;_blank&#34;&gt;[Metastasis of pleural malignant mesothelioma to the brain and upper maxilla: description of 2 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis resided primarily on immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11034307&#34; target=&#34;_blank&#34;&gt;Differential gene expression in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Expression levels of several of these genes were confirmed by RT-PCR and could be useful as diagnostic markers of human mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2000-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11065243&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma associated with deep vein thrombosis following radiotherapy for seminoma of the testis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, the patient suffered a deep vein thrombosis four years before the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11099791&#34; target=&#34;_blank&#34;&gt;The difficult diagnostic approach of the intraperitoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical exploration, either by laparotomy, or preferably by laparoscopy, has been proven valuable as a diagnostic method.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11100950&#34; target=&#34;_blank&#34;&gt;Role of occupational asbestos exposure in Hungarian lung cancer patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For improving this situation, diagnostic assistance by a self-interview with a questionnaire covering the working history for all newly diagnosed lung cancer patients would be helpful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11124643&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The CT scans of 117 patients who had a diagnosis of MPM were retrospectively evaluated. […] These results suggest that although CT findings of MPM vary, they may provide valuable clues to the diagnosis, at least in patients with a history of asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11127555&#34; target=&#34;_blank&#34;&gt;[Surgical treatment for malignant pleural mesothelioma in eight cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ol start=&#34;3&#34; style=&#34;list-style-type: decimal&#34;&gt;
&lt;li&gt;Because recurrent pattern for localized type was diffuse type, diagnosis and surgical treatment in early stage was essential for long time survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11127563&#34; target=&#34;_blank&#34;&gt;[A case of panpleuropneumonectomy for diffuse pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
First, mediastinal lymph node dissection was performed and we identified that there was no lymph node metastasis by frozen section diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11139313&#34; target=&#34;_blank&#34;&gt;p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As the level of antibodies directed against p53 is thought to be of prognostic value in some cancers and as MM is known to be immunogenic, we studied a cohort of Western Australian patients to determine the prevalence of anti-p53 antibodies and their value as diagnostic markers or prognostic indicators. 6/88 (7%) of patients had high titres (&amp;gt;2 SD above the mean of controls) of anti-p53 antibodies. […] Although 3/38 (8%) of sera obtained from patients exposed to asbestos but prior to a diagnosis of MM contained antibodies, the same proportion of sera obtained from patients exposed to asbestos but who remained disease free also contained antibodies (2/40; 8%). […] The occurrence of anti-p53 antibodies does not serve as either a useful prognostic or diagnostic indicator in MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11145250&#34; target=&#34;_blank&#34;&gt;Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry provides an important indicator for differential diagnosis between pleural malignant mesothelioma and lung adenocarcinoma, which have complex therapeutic and medicolegal implications. […] To pinpoint a reliable, restricted panel of markers, the authors evaluated the efficacy of select commercial antibodies in a series of patients with confirmed clinicopathologic diagnosis of mesothelioma or lung adenocarcinoma with the aid of multiple logistic classification tables.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11149649&#34; target=&#34;_blank&#34;&gt;Huge malignant localized fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The malignant variant of the pleura is exceptional and differential diagnosis with the more frequent benign type or with other neoplasms such as soft tissue sarcoma and mesothelioma is rarely possible in a preoperative setting. […] We report a case of a giant right intrathoracic mass whose preoperative diagnosis, from an open biopsy, was consistent with sarcoma and, in a second review, with fibrous tumor of the pleura without any indication about malignancy. […] Preoperative diagnosis of malignancy has an important role as a therapeutic strategy in management of fibrous tumours of the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11162861&#34; target=&#34;_blank&#34;&gt;Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the individual and combined diagnostic utility of six tumor markers in patients with pleural effusion. […] According to our results, tumor markers are not suitable for the differential diagnosis of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11162868&#34; target=&#34;_blank&#34;&gt;A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two patients achieved a partial response (8%, 95% CI 1-26%) surviving 18.1 and 18.7 months from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11165411&#34; target=&#34;_blank&#34;&gt;Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is often unresectable at diagnosis, is refractory to cytotoxic agents and is frequently complicated by pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11213409&#34; target=&#34;_blank&#34;&gt;[Pleural and parenchymal lung diseases from asbestos exposure. CT diagnosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The CT patterns of these two diseases are typical and no other finding is necessary to confirm the diagnosis. […] Malignant pleural mesothelioma is strongly associated with previous occupational exposure and presents typical CT findings only in an advanced stage (irregular and nodular pleural thickening, pleural effusion, mediastinal and pulmonary contraction for tumor encasement, parenchymal and lymph node metastases), but the differential diagnosis with pleural metastatic disease can be difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11223742&#34; target=&#34;_blank&#34;&gt;Radicular involvement and medullary invasion from a malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only 5 months after the diagnosis of mesothelioma, a medullar section appeared to be totally invaded by a tumor in the medullar canal, thus causing paraplegia and affecting the bladder and anal sphincters. […] The patient underwent radiotherapy and chemotherapy, and achieved partial recovery, but died 9 months after the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11224994&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, the best chance for long-term survival lies with early diagnosis and aggressive surgical extirpation, but given the typically long delay between the onset of symptoms and diagnosis, this is only possible with a high index of suspicion and an aggressive diagnosis workup. […] Early referral to a tertiary center experienced in the treatment of MPM may be important for several reasons: (1) decreased risk of tumor spread along multiple thoracenesis/biopsy tracts, (2) the availability of specialized pathologic assays for definitive diagnosis, (3) the availability of critical staging modalities (aggressive mediastinoscopy +/- thoracoscopy, MRI scans performed according to specific mesothelioma protocols, and perhaps PET scans), (4) surgical experience with pleurectomy/decortication and/or extrapleural pneumonectomy, that may decrease morbidity and mortality, and (5) the availability of novel adjuvant protocols. […] Hyperthermia, photodynamic therapy, intracavitary therapy, and gene therapy are all relatively new techniques under active investigation that should be supported by enrollment in on-going protocols. […] Predictably, many of these techniques provide greater benefit when used in the setting of adjuvant protocols or minimal residual disease, emphasizing the importance of multimodality therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11243900&#34; target=&#34;_blank&#34;&gt;SV40 and the pathogenesis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current therapy is ineffective in slowing the course of the disease, and median survival from the time of diagnosis is rarely greater than 1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11243901&#34; target=&#34;_blank&#34;&gt;Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Abrogation of SV40 T/t expression by antisense techniques induces apoptosis in part via restoration of p53 function, and enhances chemosensitivity in SV40 (+) MPM cells by mechanisms which have not been fully elucidated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11244723&#34; target=&#34;_blank&#34;&gt;[Thoracoscopic pleural biopsy under local anesthesia using a 2 mm laparoscope].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, it is an invasive diagnostic technique. […] These findings suggest that thoracoscopy using a 2 mm laparoscope is (1) a useful diagnostic tool in cases of pleural malignancy; (2) a minimally invasive method with the advantage of being easily performed under local anesthesia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11249674&#34; target=&#34;_blank&#34;&gt;Immunotherapy-based treatment strategies for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is an almost universally fatal disease, regardless of tumor stage at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11251277&#34; target=&#34;_blank&#34;&gt;Trimodality management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From September 1998 to August 2000, 32 consecutive patients with histological diagnosis of MPM underwent trimodality therapy, including surgery followed by adjuvant chemotherapy and radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11283936&#34; target=&#34;_blank&#34;&gt;Expression and prognostic significance of catalase in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Higher catalase expression in mesothelioma was associated with a better prognosis, mean survival rate from diagnosis being 6 and 24 months for negative/low expression and moderate/high expression, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11295061&#34; target=&#34;_blank&#34;&gt;Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The expression of angiogenic factors may represent useful markers for diagnosis and prediction of disease outcome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11296181&#34; target=&#34;_blank&#34;&gt;Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of our study was to assess the clinical value of CYFRA 21-1 tumor marker and carcinoembryonic antigen (CEA) as diagnostic tools that are complementary to cytology in the diagnosis of malignant mesotheliomas. […] The cutoff levels of CYFRA 21–1 and CEA in malignant PEs, selected on the basis of the best diagnostic efficacy, were 41.9 ng/mL and 5.0 ng/mL, respectively. […] The association of the tumor marker assay and the cytology allowed a correct diagnosis in 30 of 32 cases of mesothelioma (93.7%). […] This study suggests that CYFRA 21–1 would provide a useful parameter for the differential diagnosis between benign and malignant PE from mesothelioma when the result of cytology is negative or uncertain and the clinical context does not allow a more aggressive approach. […] Moreover, the association of CYFRA 21–1 with CEA could provide details for a differential diagnosis between mesotheliomas and carcinomas. […] In fact, an elevated CYFRA 21–1 level with a low CEA level is highly suggestive of mesothelioma, whereas high levels of CEA alone or high levels of both the markers suggest a diagnosis of malignant PE, excluding mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11302347&#34; target=&#34;_blank&#34;&gt;Nodular thickening of interlobar fissures: an early manifestation of malignant mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conclude that HRCT is helpful in the diagnosis of malignant mesothelioma, particularly in its early manifestation such as nodular opacities of interlobar fissures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11313208&#34; target=&#34;_blank&#34;&gt;[Gene expression profiling in human mesothelioma cells using DNA microarray and high-density filter array technologies].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They could be useful for diagnostic, prognostic and therapeutic.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11319288&#34; target=&#34;_blank&#34;&gt;Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of malignant pleural mesothelioma is poor, with a median survival time from diagnosis of 7 to 17 months. […] The characteristics of patients were: 16 men and 6 women; median age 61 years (range, 49-77 years); stage (according to Butchart): 8 patients stage I, 10 stage II, 2 stage III, and 2 stage IV; cytologic diagnosis in 5 cases and histologic diagnosis in 17 cases. […] This treatment produced a considerable clinical benefit, with improvement of dyspnea (68.4%) and pain (33.3%); 15 of 19 patients (78.9%) with pleural effusion at the time of diagnosis showed an important reduction in pleural fluid during chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11323480&#34; target=&#34;_blank&#34;&gt;Percutaneous image-guided cutting-needle biopsy of the pleura in the presence of a suspected malignant effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the diagnostic accuracy of percutaneous image-guided cutting-needle biopsy of pleural thickening in the presence of a suspected malignant pleural effusion. […] A final diagnosis of benign or malignant disease was established with radiologic and clinical follow-up findings and with other histologic or cytologic findings, when available. […] A correct histologic diagnosis of malignant disease was made in 21 of 24 patients (sensitivity, 88%; specificity, 100%), including 13 of 14 patients with mesothelioma (sensitivity, 93%). […] A correct histologic diagnosis of benign pleural disease was made in nine patients. […] Image-guided percutaneous cutting-needle biopsy of pleural thickening in the presence of a pleural effusion is a safe procedure, with an overall accuracy of 91% in the diagnosis of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11332082&#34; target=&#34;_blank&#34;&gt;Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare the results of conventional cytology, DNA image cytometry, immunocytochemistry and argyrophilic nucleolar organizer region (AgNOR) analysis for the diagnosis of malignant cells in serous effusions. […] AgNOR analysis may be a useful adjunct to other methods in the routine diagnosis of malignant serous effusions. […] It seems to be the most sensitive method in early cytologic diagnosis of mesotheliomas in effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11338024&#34; target=&#34;_blank&#34;&gt;Treatment of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Obtaining a diagnosis of MPM has been greatly assisted by video-assisted surgery and the use of immunohistochemistry and electron microscopic techniques, which help distinguish MPM from other tumor pathologies such as adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11341549&#34; target=&#34;_blank&#34;&gt;Pathology of human malignant mesothelioma–preliminary analysis of 1,517 mesothelioma cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These mesothelioma cases were definite or probable in diagnostic certainty.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11358011&#34; target=&#34;_blank&#34;&gt;Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a tumour that usually presents a short survival time from diagnosis, but in a small number of patients a longer survival time has been observed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11358044&#34; target=&#34;_blank&#34;&gt;Synovial sarcoma and malignant mesothelioma of the pleura: review, differential diagnosis and possible role of apoptosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mucin and immunohistochemical stains were all performed on formalin-fixed, paraffin-embedded tissue using standard techniques, with appropriate positive and negative controls. […] The diagnosis of BSS or BMM of the pleural should be made only after total consideration of clinical, radiological, histochemical and immunohistochemical findings. […] Although mucin stains are useful in differential diagnosis, reliance solely on immunohistochemical markers, with the possible exception of calretinin, Ber-Ep4 and bcl-2, is not dependable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11417405&#34; target=&#34;_blank&#34;&gt;[Occupational exposure to asbestos and recognition of pleural mesothelioma as occupational disease in the province of Genoa].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among these, 43 subjects were included in a subgroup of 98 patients registered in the REM as cases with definite diagnosis and ascertained asbestos exposure; 32 were awarded compensation, while 11 are under evaluation. […] The data collected by REM do not show proven asbestos exposure and/or PM diagnosis for five other subjects (two compensated and three under judgment). […] This study reveals that: a) only a 24% of the patients with a diagnosis of PM and asbestos exposure apply for compensation; b) an exchange of information among institutions involved in primary prevention, in the evaluation of occupational exposures to carcinogens and in insurance compensation is useful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11422496&#34; target=&#34;_blank&#34;&gt;Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A combination of MOC-31 (an anti- epithelial marker) and HBME-1 (an anti-mesothelial marker) has a diagnostic efficiency of 76.1% for the distinction between carcinoma and mesothelioma in pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11470972&#34; target=&#34;_blank&#34;&gt;Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The immunohistochemical diagnosis of atypical epithelial proliferations in pleural fluid is a challenging topic in cytopathology and surgical pathology. […] Mesothelioma may be simulated clinically and radiologically by several other nonneoplastic and neoplastic disorders, mandating that strict histologic, histochemical, immunohistochemical, and ultrastructural guidelines be followed for its diagnosis. […] Because of its availability to most laboratories, immunohistochemistry has emerged as the most commonly used procedure for the diagnosis of pleural malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11488073&#34; target=&#34;_blank&#34;&gt;Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of mesothelioma from adenocarcinoma is based on negative markers. […] However, diagnostic accuracy is improved by the use of antibody panels.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11505411&#34; target=&#34;_blank&#34;&gt;Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Inclusion criteria were histologic diagnosis of MPM and measurable disease defined by computed tomography scan or magnetic resonance imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11510005&#34; target=&#34;_blank&#34;&gt;Pleural amyloidosis mimicking mesothelioma: a clinicopathologic study of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cases discussed herein represent an unusual presentation of amyloid and one that needs to be considered in the differential diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11510098&#34; target=&#34;_blank&#34;&gt;[A case of desmoplastic malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings led to the diagnosis of desmoplastic malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11523570&#34; target=&#34;_blank&#34;&gt;Information about occupational exposure to asbestos given to cases in an etiological study: ethical aspects.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Out of 43 cases in which the age at diagnosis was &amp;lt; or = 65 years and the exposure to asbestos was certain/probable, only two (4.6%) were signed off work owing to occupational disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11536437&#34; target=&#34;_blank&#34;&gt;Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction of mesothelial cells in cytologic samples is often a diagnostic challenge.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-10-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11552888&#34; target=&#34;_blank&#34;&gt;Evaluation of pleural disease using MR and CT. With special reference to malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Comparisons were made between the diagnostic groups and the imaging methods.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11563601&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma–German mesothelioma register 1987-1999.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean age at first diagnosis was 60.4 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11577123&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma in pleural biopsies can be difficult. […] All available information should be taken into account in the histological diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11599101&#34; target=&#34;_blank&#34;&gt;Absence of SV-40 large T antigen (Tag) in malignant mesothelioma effusions: an immunocytochemical study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We sought to determine the clinical utility of SV-40 Tag IHC in pleural effusion cytology as an ancillary tool in the cytologic diagnosis of malignant mesothelioma (MM). […] The role of SV-40 Tag IHC in diagnostic cytopathology remains unclear unless further studies reliably show its detection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11604996&#34; target=&#34;_blank&#34;&gt;K-ras and rho A mutations in malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The K-ras codon 12 mutation is readily detected in pleural effusion, and the demonstration of this mutation has potentially important implications for the diagnosis of malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11668464&#34; target=&#34;_blank&#34;&gt;Immunocytochemistry in effusion cytology: a contemporary review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytology plays a pivotal role in the diagnosis of pleural effusions. […] Through the utilization of cell block preparations and a panel of antibodies appropriate for the differential diagnosis in question, ICC conditions utilized in surgical pathology can be most closely replicated. […] ICC may provide reliable insights into various diagnostic dilemmas in effusion cytology, provided that laboratory standardization practices are followed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11676187&#34; target=&#34;_blank&#34;&gt;[Incidence of malignant mesothelioma (1980-1999) and asbestos exposure in 190 cases diagnosed among residents of the province of Brescia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the same period, this trend was not observed for peritoneal location, with an incidence ratio of 0.17 and 0.37 for males and females respectively. 161 pleural MM (84.7%) and 28 peritoneal MM (14.7%) are described; histopathologic diagnosis was performed in 161 cases (84.7%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11717014&#34; target=&#34;_blank&#34;&gt;Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the UK surgical intervention has been mostly reserved for tissue diagnosis or chemical pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11721205&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Up today, no treatment has been demonstrated as effective in influencing disease-related survival and the median prognosis ranges between 9 and 17 months after the diagnosis. […] The diagnosis of the disease, often by exclusion, is obtained after macroscopic sampling of the pathological tissue, best accomplished by thoracoscopy, which also allows the intracavitary evaluation of the extension of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11735696&#34; target=&#34;_blank&#34;&gt;Unusual clear cell variant of epithelioid mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The morphologic, immunohistochemical, and ultrastructural features reported for this case are consistent with the diagnosis of clear cell mesothelioma. […] The differential diagnosis and immunohistochemical features in comparison with other clear cell neoplasms are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11742904&#34; target=&#34;_blank&#34;&gt;Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of immunohistochemical stains allows a firm diagnosis to be made from relatively small samples. […] Twenty-one adult patients with a final diagnosis of malignant mesothelioma were identified from 53 consecutive patients who underwent percutaneous image-guided CNB. […] All 21 patients had pleural thickening identified on contrast-enhanced CT, and all had a final histologic diagnosis of mesothelioma confirmed by postmortem examination or thoracoscopy. […] A correct histologic diagnosis of malignant mesothelioma was made by CNB in 18 patients (86% sensitivity and 100% specificity). […] Four patients with a pleural thickness of &amp;lt; or = 5 mm underwent biopsy, and all specimens were diagnostic for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11745209&#34; target=&#34;_blank&#34;&gt;The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry is a useful method in the differential diagnosis between pleural mesotheliomas and metastatic adenocarcinomas to the pleura. […] In the current study, the value of these CKs in differential diagnosis of malignant pleural lesions was examined. […] Adding CK20 and CK7 to the panel of antibodies in the differential diagnosis of pleural mesothelioma versus metastatic adenocarcinomas is useful because diffuse CK20 positivity seems to be an indicator of metastasis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11745800&#34; target=&#34;_blank&#34;&gt;Survival after conservative (palliative) management of pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We performed a retrospective review of all patients with a diagnosis of malignant mesothelioma seen at our center between 1987 and 1999. […] Symptoms of disease were present for a median time of 5 months before the diagnosis was established.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2001-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11776609&#34; target=&#34;_blank&#34;&gt;[Numerical alteration of chromosome 8 in pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 15 pleural effusions which were reportedly negative in previous cytological diagnosis, hyperdiploid chromosome 8 was found in 3 cases, and diploid chromosome 8 in another 12 cases by in situ hybridization.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11795833&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous adenocarcinoma of the lung with rhabdoid features.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of pseudomesotheliomatous adenocarcinoma in this case was based on the finding of the subpleural nodule.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11796835&#34; target=&#34;_blank&#34;&gt;Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our study confirms the diagnostic utility of CK 5/6 immunohistochemistry in distinguishing biphasic mesothelioma from pulmonary adenocarcinoma but raises caution about its use for the differential diagnosis of pleural or peritoneal malignant mesothelioma versus pleural or peritoneal metastatic nonpulmonary adenocarcinoma, because many types of nonpulmonary adenocarcinomas may be positive for CK 5/6.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11828289&#34; target=&#34;_blank&#34;&gt;Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The caspase components of the Fas-mediated apoptotic pathway were evaluated by means of Western blot techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11828734&#34; target=&#34;_blank&#34;&gt;[Chylothorax as the initial manifestation of malignant pleural mesothelioma–a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Repeated thoracentesis did not yield a diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836666&#34; target=&#34;_blank&#34;&gt;The role of imaging in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging plays an essential role in the diagnosis, staging, and follow-up of patients with malignant pleural mesothelioma (MPM). […] The diagnosis is often suggested by a unilateral pleural mass with a moderate to large pleural effusion seen on chest radiographs, but computerized tomography (CT) is the most frequently used technique for evaluation of the lungs in patients with MPM. […] These imaging modalities help triage patients to the most appropriate diagnostic and treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836668&#34; target=&#34;_blank&#34;&gt;Multimodality treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma (DMPM) is a challenging disease in all of its aspects, from presentation and diagnosis to staging and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11836702&#34; target=&#34;_blank&#34;&gt;Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A provisional diagnosis of the primary site was deduced for each of the 36 cases by clinical, radiologic, and/or histologic correlation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11845101&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A special care was taken in the validation of the diagnosis of each case.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11847028&#34; target=&#34;_blank&#34;&gt;[Current insights in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article tries to summarize current insights concerning epidemiology, diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11852361&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma with osteoblastic heterologous elements].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most difficult differential diagnosis is primary pleural osteosarcoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11862420&#34; target=&#34;_blank&#34;&gt;SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive cancer, with survival of less than one year following diagnosis and treatment with current protocols.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11875804&#34; target=&#34;_blank&#34;&gt;[Clinical utility and safety of diagnostic thoracoscopy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing use of thoracoscopy performed under local anesthesia has made contributions to the diagnosis of pleural disease with effusion. […] Therefore, we concluded that this method is very useful for the diagnosis of pleural effusions and has few complications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11881736&#34; target=&#34;_blank&#34;&gt;Localized pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The final diagnosis was localized malignant mesothelioma (epithelial type).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11903576&#34; target=&#34;_blank&#34;&gt;Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CD44H is not of particular use in the diagnosis of malignant epithelioid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11905410&#34; target=&#34;_blank&#34;&gt;Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients in the two groups were similar in terms of age at diagnosis (median ages, 50.7 years and 49.9 years), presentation, initial tumor burden, and treatment. […] One patient was alive with disease 15 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11924190&#34; target=&#34;_blank&#34;&gt;[Meningeal metastasis of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we present a differential diagnosis and a review of the literature to give prominence to diagnostic pitfalls in this rare disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11954027&#34; target=&#34;_blank&#34;&gt;The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It has been shown that detection of the Wilms tumor susceptibility gene 1 protein (WT1) has diagnostic utility in the distinction of mesothelioma from adenocarcinoma in tissue sections of pleural tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11981504&#34; target=&#34;_blank&#34;&gt;[Solitary fibrous thoracic tumor: a rare tumor with unpredictable course].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was a thoracic solitary fibrous tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11996173&#34; target=&#34;_blank&#34;&gt;Cytopathology of pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Additionally, the handling of cytologic specimens, diagnostic problems, and the value and limitations of immunocytochemical and electron microscopic studies and other ancillary techniques in the cytologic identification of pleural mesotheliomas are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/11996274&#34; target=&#34;_blank&#34;&gt;Flow cytometric analysis of a localized malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Localized malignant mesothelioma must be included in the differential diagnosis in chest wall-based neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12006460&#34; target=&#34;_blank&#34;&gt;Diagnostic value of medical thoracoscopy in pleural disease: a 6-year retrospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In a 6-year retrospective study of patients having undergone at least one medical thoracoscopy, we analyzed the diagnostic yield of thoracoscopy and its value in the management of pleural disease. […] From January 1, 1989, to December 31, 1994, 168 medical thoracoscopies were performed on 154 patients (123 men; mean age +/- SE, 61 +/- 1 years), of which 149 were diagnostic and 19 were indicated for therapeutic assessment in malignant mesothelioma (MM). […] Prior to thoracoscopy, at least one CPB had been performed in 120 of 149 cases, yielding a diagnosis in 96 cases. […] Thoracoscopy challenged the CPB-based diagnosis in 43 of 96 cases. […] In 18 cases in which the CPB diagnosis was MM, thoracoscopy, performed for precise staging, challenged the diagnosis in 4 cases. […] Pleural adhesions can lower its diagnostic value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12006691&#34; target=&#34;_blank&#34;&gt;Primary thoracic sarcomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is established only after sarcomalike primary lung malignancies and metastatic disease have been excluded. […] However, differences in clinical presentation and the location of the tumor, as well as morphologic features such as calcification within the mass and rib involvement, can be useful in suggesting the appropriate diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12015746&#34; target=&#34;_blank&#34;&gt;Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This is the first report in MM of the expression of 90K and of its potential diagnostic and prognostic application.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12057155&#34; target=&#34;_blank&#34;&gt;Pericardial mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In most cases the diagnosis is made at autopsy or postoperatively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12063622&#34; target=&#34;_blank&#34;&gt;[Diagnosis and staging of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One deciding factor for the poor prognosis with a median survival of 4 - 18 month is a late diagnosis at an advanced stage. […] Therefore, apart of improved stage related therapeutic options, early diagnostic procedures in suspected MPM play a key role. […] The diagnosis of MPM is made by the clinician as a synopsis of clinical, imaging and pathological findings. […] Computed tomography of the thorax and thoracoscopy with biopsy are the most important diagnostic procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12122279&#34; target=&#34;_blank&#34;&gt;Diagnostic DNA-flow- vs. -image-cytometry in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Positive predictive value of DNA-aneuploidy for the identification of malignant cells was 100.0% for both techniques, negative predictive value of DNA-euploidy was 48.6% for DNA-flow- and 72.0% for -image-cytometry. […] Searching for DNA-aneuploidy as a diagnostic marker for neoplastic cells in serous effusions image-cytometry revealed superior sensitivity as compared with monoparametric flow cytometry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12140157&#34; target=&#34;_blank&#34;&gt;Pitfalls in diagnosis of early stage malignant peritoneal mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic pitfalls in early stage disease are discussed and the radiological literature of MPM is reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12146029&#34; target=&#34;_blank&#34;&gt;Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the diagnostic utility of the immunohistochemical expression of thyroid transcription factor-1 (TTF-1) in adenocarcinomas from serous fluid specimens. […] Anti-TTF-1 can be used as a reliable component of an antibody panel to support the diagnosis of adenocarcinoma of pulmonary origin in patients presenting with metastatic adenocarcinoma in serous fluid with an unknown primary site.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12164558&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of the pleural space and its management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Difficulties in diagnosis, staging, and treatment set this disease apartfrom other malignancies. […] The variable clinical presentation and problems in establishing a definite histopathologic diagnosis result in significant delays in treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12181266&#34; target=&#34;_blank&#34;&gt;The potential value of comparative genomic hybridization analysis in effusion-and fine needle aspiration cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conclude that CGH analysis from cytologic specimens may support the primary cytologic diagnosis of malignancy, especially in the differential diagnosis of benign proliferating mesothelium, malignant mesothelioma, and metastatic adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12187531&#34; target=&#34;_blank&#34;&gt;Incidence of malignant pleural mesothelioma in coastal and continental Croatia: epidemiological study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In each case, the tumor diagnosis was histologically verified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12189542&#34; target=&#34;_blank&#34;&gt;A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and median survival from diagnosis 17.3 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12194801&#34; target=&#34;_blank&#34;&gt;Malignant gonadal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The principle reasons for this are difficulty in making a preoperative diagnosis and advanced stage at the time of treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12207788&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: PAS-diastase positivity and inversion of polarity in intravascular tumour.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pseudoluminal PAS-diastase-positive material in malignant mesothelioma may easily be mistaken for epithelial mucin, leading to an erroneous diagnosis of adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12208747&#34; target=&#34;_blank&#34;&gt;Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We propose that a simple technique, based on the expression levels of a small number of genes, can be useful in the early and accurate diagnosis of MPM and lung cancer. […] Here we have tested the fidelity of ratio-based diagnosis in differentiating between MPM and lung cancer in 181 tissue samples (31 MPM and 150 ADCA). […] A training set of 32 samples (16 MPM and 16 ADCA) was used to identify pairs of genes with highly significant, inversely correlated expression levels to form a total of 15 diagnostic ratios using expression profiling data. […] Any single ratio of the 15 examined was at least 90% accurate in predicting diagnosis for the remaining 149 samples (e.g., test set). […] We then examined (in the test set) the accuracy of multiple ratios combined to form a simple diagnostic tool.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12209878&#34; target=&#34;_blank&#34;&gt;Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) still remains a therapeutic and diagnostic problem to which new therapeutic perspectives are being continuously tried and tested.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12215551&#34; target=&#34;_blank&#34;&gt;Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is an aggressive primary neoplasm for which early detection and accurate staging are known diagnostic challenges. […] The results of (18)F-FDG-CI scans were compared with CT and with histopathologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12216539&#34; target=&#34;_blank&#34;&gt;Additional techniques in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological examination is a valuable diagnostic tool in case of a serous effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1222214&#34; target=&#34;_blank&#34;&gt;[Report on the study of hyaluronic acid in the diagnosis of pleural mesotheliomas: study of 100 hyaluronic acid rich effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Correlations betueen clinical, radiological and histological diagnosis of mesothelioma and the characterization of hyaluronate are discussed. […] These data suggest the possibility of a biochemical approach for the diagnosis of pleural malignant tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12229245&#34; target=&#34;_blank&#34;&gt;[Prognosis, staging and therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Due to careful patient selection and improved operation techniques mortality could be reduced.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1224688&#34; target=&#34;_blank&#34;&gt;[Etiology and clinical diagnosis of diffuse pleural mesothelioma (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Possibilities of an exact clinical diagnosis will be discussed on the basis of the experience gained with 100 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12324743&#34; target=&#34;_blank&#34;&gt;Synovial sarcoma of the pleura: a clinical and pathologic study of three cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical findings are correlated with pathologic features, including immunohistochemical stains and fluorescence in situ hybridization (FISH) for the identification of the diagnostic chromosomal translocation, t(X;18)(p11.2;q11.2).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12400973&#34; target=&#34;_blank&#34;&gt;Survival after pleural malignant mesothelioma: a population-based study in Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It focused on possible differences related to period of diagnosis a proxy of changes in diagnostic or therapeutic procedures. […] In 1990-1998, 693 incident cases were diagnosed in residents in the region: 590 of them had a histologic diagnosis of pleural mesothelioma in life and were included in the study. […] Survival was associated to age (longer survival for younger subjects at diagnosis; P &amp;lt;0.0001) and to histology (longer survival for epithelial mesothelioma, shorter for fibrous and intermediate for mixed or unspecified types; P &amp;lt;0.0001). […] There was no difference in survival for period of diagnosis. […] The most striking effect of the present study was the absence of improvement in survival with period of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12405438&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in a child: long-term survival with ICE-WAC chemotherapy regimen.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histopathological diagnosis was sarcomatoid pleural malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12417972&#34; target=&#34;_blank&#34;&gt;[Small-cell mesothelioma of the pleura: description of a case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient died of the disease 4 months after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12418586&#34; target=&#34;_blank&#34;&gt;Closed pleural needle biopsy: predicting diagnostic yield by examining pleural fluid parameters.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural fluid parameters that predict a diagnostic closed pleural needle biopsy were investigated. […] Pleural fluid values of protein, glucose, lactate dehydrogenase (LDH), pH, and white blood cell count with differential cell counts, from patients with diagnostic and non-diagnostic pleural biopsies were compared. […] Thirteen patients (29%) had diagnostic biopsies. […] Three other patients had non-malignant specific diagnosis. […] LDH levels in pleural fluid from patients with diagnostic pleural biopsy were higher than in patients with non-diagnostic pleural biopsies (1436 +/- 333 U l(-1) vs. […] Follow up revealed malignancy including mesothelioma and lymphoma, in 10 of 30 (33%) patients with non-diagnostic biopsies, and one patient died of unrelated cause, while the pleural effusion either resolved, remained stable or an alternative benign process was identified in 19 patients (63%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12445141&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pericardium: case reports and immunohistochemical studies including Ki-67 expression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Microscopic observations of all cases led to a diagnosis of epithelial-type malignant mesothelioma (MM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12472131&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: options for management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As with other tumors, early diagnosis-while the disease is still in stage I, or even at an in situ stage-must be the goal so that therapy can be maximized, particularly if immunotherapy or gene therapy is to be used.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2002-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12475867&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cohort members’ details of age, sex, ambient exposure data, duration of residence in the villages, and hospital records, including pathologic diagnosis, were recorded.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12482127&#34; target=&#34;_blank&#34;&gt;Leptomeningeal infiltration of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse leptomeningeal infiltration is the only constant radiological finding reported as a diagnostic criteria for CNS involvement and histopathological confirmation is usually possible only at autopsy, so clinical and radiological diagnosis is essential after exclusion of other possible causes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-05-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12502242&#34; target=&#34;_blank&#34;&gt;Concurrent malignant mesothelioma of the pleura and hepatocellular carcinoma in the same patient: a report of five cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was established at necropsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-01-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12525529&#34; target=&#34;_blank&#34;&gt;Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In chemotherapy-naive patients, median survival was 31 weeks (95% CI, 23 to 40 weeks) from the start of treatment and 49 weeks (95% CI, 40 to 52 weeks) from diagnosis of mesothelioma. […] In pretreated patients, median survival was 44 weeks (95% CI, 24 to 40 weeks) from the start of treatment and 226 weeks (95% CI, 63 to 292 weeks) from the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12552937&#34; target=&#34;_blank&#34;&gt;Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Detection of the t(X:18) translocation using RT-PCR, Southern blot, and DNA sequencing definitively confirmed the diagnosis of SS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12558747&#34; target=&#34;_blank&#34;&gt;Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic pitfalls associated with these findings are described and their potential medico-legal implications are highlighted. […] In each case diagnosis was morphologically confirmed with ancillary immunohistochemistry using a broad panel of both mesothelial and epithelial markers. […] Immunohistochemistry played an important role in the definitive diagnosis of each unusual parenchymal tumour deposit.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12560629&#34; target=&#34;_blank&#34;&gt;[Diagnosis and treatment of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the Department of Thoracic Surgery of Oncology Institute at Vilnius University from 1980 till 01.06.2002, 33 patients (pts), to whom diagnosis of pleural mesothelioma was confirmed by pathologist, were treated in the Clinic. […] Diagnosis of malignant pleural mesothelioma is difficult and confirmation of the disease is possible only after histological examination of tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12571809&#34; target=&#34;_blank&#34;&gt;Emerging insights into the biology and therapy of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis relies on radiographic studies as well as histology and molecular biologic analyses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12579319&#34; target=&#34;_blank&#34;&gt;The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
TF SPECT appears a highly accurate diagnostic method in the detection of intrathoracic malignant lesions, in lungs and pleura, as well as in NSCLC mediastinal lymph node staging and in monitoring treatment effectiveness, playing a complementary role to CT in selected cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12589646&#34; target=&#34;_blank&#34;&gt;The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, detection of CDKN2A deletion by fluorescence in situ hybridization (FISH) was evaluated as an ancillary test in the cytologic diagnosis of malignant mesothelioma. […] The detection of homozygous CDKN2A deletion by FISH would have been helpful in confirming a diagnosis of mesothelioma over reactive mesothelial cells in 12 of 13 samples with positive or suspicious cytology. […] Further studies on larger series of patients with suspicious cytology are needed to evaluate the validity and efficiency of this approach for improving the diagnostic accuracy of effusion cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/125920&#34; target=&#34;_blank&#34;&gt;[Localized malignant mesethelioma of the peritoneum revealed by a parietal mass].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On the basis of this observation the authors point out the main features of these rare tumors, the diagnostic difficulties they involve, and their possible relationship to asbestos dust exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1975-11-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12594815&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conventional treatments for MM, consisting of chemotherapy or surgery give little survival benefit to patients, who generally die within 1 year of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12601277&#34; target=&#34;_blank&#34;&gt;The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The chest film is the initial diagnostic tool of choice because it is easy to perform, inexpensive, and widely available. […] Unfortunately, it demonstrates malignant pleural mesothelioma in later stages of disease and is not suitable for an early sensitive and specific diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12601278&#34; target=&#34;_blank&#34;&gt;The role of surgery in diagnosis and treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of surgery in the management of mesothelioma has largely been confined to obtaining a tissue diagnosis or to effect symptom control by pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1260651&#34; target=&#34;_blank&#34;&gt;Chemotherapy of malignant diffuse mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival from diagnosis ranged from 2 to 39 months, with a median of 9 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12633032&#34; target=&#34;_blank&#34;&gt;[Pleuro-pneumonectomy, RT and CT for pleural mesothelioma. Prospective study].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis, accurate staging, preoperative induction and better local monitoring are avenues to be explored when seeking to achieve curability of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1263545&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma. Report of 19 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a rapidly fatal tumor that poses serious diagnostic and therapeutic problems. […] Exploratory thoracotomy was the most accurate means of diagnosis but was frequently followed by seeding into the incision and severe, intractable incisional pain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12649954&#34; target=&#34;_blank&#34;&gt;[Cardiac tamponade due to pericardial mesothelioma in an 11-year-old dog: diagnosis, medical and interventional treatments].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After partial pericardectomy by thoracoscopy and after obtaining a histological diagnosis of mesothelioma adjuvant intracavitary chemotherapy using cisplatin was performed. […] Diagnostic and therapeutic aspects of (recurrent) pericardial effusion are discussed based on this case.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12697881&#34; target=&#34;_blank&#34;&gt;Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with a histologically proven diagnosis of MPM, chemotherapy-naive measurable lesions, and adequate organ function received pemetrexed (500 mg/m2) intravenously over 10 minutes every 3 weeks.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12710098&#34; target=&#34;_blank&#34;&gt;[VEGF (vascular endothelial growth factor) concentration in serum and pleural fluid of patients with pleural malignancy and pleural tuberculosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was comparison of VEGF (vascular endothelial growth factor) levels in serum and pleural fluid and estimation of this test usefulness in diagnosis of pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12711467&#34; target=&#34;_blank&#34;&gt;Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sensitivity for pleural malignancy from the biopsy specimen was the primary endpoint, with the patient’s clinical outcome after 1 year being the diagnostic gold standard. […] Diagnostic advantage was similar in patients proving to have mesothelioma. […] In cytology-negative suspected malignant pleural effusions, CT-guided pleural biopsy is a better diagnostic test than Abrams’ pleural biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12713628&#34; target=&#34;_blank&#34;&gt;Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have tested the hypothesis that assessment of the cell cycle status is of value in the histopathological diagnosis of such biopsies, by comparing 33 malignant mesotheliomas with 36 cases of reactive mesothelial hyperplasia and reactive pleural fibrosis. […] We consider MCM2 to be a useful adjunct in the differential diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12722691&#34; target=&#34;_blank&#34;&gt;[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Though diagnostic imaging indicated SD (stable disease), a high efficacy was observed in terms of reduced subjective symptoms such as a feeling of difficulty in breathing and pain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12744636&#34; target=&#34;_blank&#34;&gt;[Mesothelioma–asbestos in Lebanon: a problem to be considered].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean latency period between exposition and diagnosis was 29 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12763219&#34; target=&#34;_blank&#34;&gt;Analysis of survival of mesothelioma cases in the Italian register (ReNaM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The Kaplan-Meier method was used to estimate survival rates, the log rank non-parametric test and Cox proportional hazard model to assess the role of prognostic factors such as age, gender, morphology, level of diagnostic certainty and modality of exposure. […] Survival after diagnosis of malignant pleural mesothelioma showed a statistically significant linear trend for age group at diagnosis, for males and females (P=0.006 and 0.008, respectively).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12781427&#34; target=&#34;_blank&#34;&gt;Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study is to determine the diagnostic value of carbohydrate antigen 549 (CA 549) levels in pleural fluid, and to compare it with another previously studied tumor markers: carcinoembryonic antigen (CEA), CA 15.3 and CA 72.4. […] The addition of any one tumor marker assay consistently improved the diagnostic value of cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-09-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12795087&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM is a challenging disease in all aspects, including diagnosis, staging and treatment. […] Its diagnosis requires a panel of immunohistochemical stains.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12795187&#34; target=&#34;_blank&#34;&gt;[A case of triple malignancies (gastric cancer, lung cancer and malignant pleural mesothelioma) after asbestos exposure].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma appeared after one year of pleural effusion and the patient died of mesothelioma one year after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1281957&#34; target=&#34;_blank&#34;&gt;Diagnostic criteria for human diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pathologists are required to provide a reliable diagnosis of the tumor for clinicians who are responsible for the treatment of affected patients. […] Pathological diagnosis of diffuse malignant mesothelioma is not always easy; however, it has improved over the last few decades. […] Currently, comprehensive analysis, including gross appearance, histology, histochemistry, immunocytochemistry and electron microscopy is recommended as the best approach to an accurate diagnosis of diffuse malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12822605&#34; target=&#34;_blank&#34;&gt;The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study cervical mediastinoscopy (CM) is compared with computer tomography (CT) scanning for its diagnostic accuracy in assessing mediastinal lymph nodes during preoperative workup. […] This resulted in a sensitivity of 60% and 80%, a specificity of 71% and 100%, and a diagnostic accuracy of 67% and 93% for CT and CM, respectively. […] Cervical mediastinoscopy is a valuable diagnostic procedure for patients with MPM who are considered candidates for surgical-based therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12833842&#34; target=&#34;_blank&#34;&gt;[A case of benign asbestos pleural effusion suspected on thoracoscopic examination under local anesthesia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy aided in the differential diagnosis of this case.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12839939&#34; target=&#34;_blank&#34;&gt;Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mechanisms of asbestos-induced mesotheliomas are unclear, and studies are required to find diagnostic tools and therapies to improve the survival rates of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12843860&#34; target=&#34;_blank&#34;&gt;[Cutaneous metastasis of pleural mesothelioma: two cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 60 year-old man, 6 months after the initial diagnosis of a pleural mesothelioma, developed a right latero-thoracic subcutaneous nodule. […] Cutaneous manifestations usually occur when the diagnosis of primitive pleural cancer has been already established. […] The majority of cutaneous lesions are distributed near the tumoral site and represent either a direct extension of the tumor to the thoracic wall, or a malignant seeding by diffusion of the pleural fluid at the time of the diagnostic and therapeutic procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12847573&#34; target=&#34;_blank&#34;&gt;Mesothelioma: Drug treatment and other interventions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was also reported to be almost universally fatal, regardless of the stage of the tumor at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12853097&#34; target=&#34;_blank&#34;&gt;Surgical experience of 15 solitary benign fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of benign fibrous tumor of the pleura and lung and pleural malignancy depends upon immunohistochemistry of the surgical specimen so that prognosis could be formulated only after surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12854383&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: experience at the Singapore General Hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy confirmed the histologic diagnosis and allowed simultaneous talc pleurodesis in 9 patients. […] Thoracoscopy is an invaluable diagnostic modality in the evaluation of a patient with occupational asbestos exposure and an undiagnosed pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12910119&#34; target=&#34;_blank&#34;&gt;[Isolated pleural metastases from an atypical meningioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For this reason the diagnosis of pleural metastase from a meningioma cannot be made without knowledge of the primary meningeal tumour and its histological type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12912960&#34; target=&#34;_blank&#34;&gt;Gene expression profiling of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several challenging clinical problems include poor understanding of the pathophysiology, inaccurate diagnosis from tissue samples, and unsuccessful treatment strategies. […] Additional genes that could be important in our understanding of the pathogenesis of mesothelioma, aiding in diagnosis, or improving targets for therapy were also identified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12913849&#34; target=&#34;_blank&#34;&gt;Miliary pulmonary metastases from a clinically occult pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical and electron microscopy studies performed on wedge biopsies of parenchymal pulmonary nodules led to the diagnosis of metastatic mesothelioma. […] Subsequent pleural evaluation and biopsy of pleural thickening noted at a site of prior chest wall trauma identified the primary neoplasm and confirmed the diagnosis as malignant epithelioid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12925985&#34; target=&#34;_blank&#34;&gt;Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis of malignant mesothelioma (MM) in effusion fluid specimens can be challenging. […] The authors attempted to determine whether the detection of numerical chromosomal aberrations in the effusion fluid specimens could be a useful diagnostic adjunct in morphologically inconclusive cases for MM. […] Therefore, in conjunction with cytomorphologic and clinical suspicion of MM, detection of numerical chromosomal aberrations of chromosome 7 using FISH with routine cytologic smears can be a valuable diagnostic adjunct.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12929277&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma: Part I. An overview of diagnosis, staging, and treatment options.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article reviews the risk factors, incidence, signs, symptoms, diagnosis, staging, treatment options, and follow-up care of diffuse malignant pleural mesothelioma (DMPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/12958733&#34; target=&#34;_blank&#34;&gt;[Surveillance of malignant mesothelioma cases and definition of asbestos exposure: 1997 ReNaM data].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The exposure to asbestos has been defined for 198 mesothelioma cases with histological diagnosis: 125 cases (63%) refer to professional exposure, 10 (5%) to environmental exposure, 5 (2.5%) to domestic exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1325339&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most significant factors suggesting the diagnosis of MPM were the village where the patient resided and the typical presenting symptoms and signs of unilateral exudative pleural effusion associated with nonpleuritic chest pain. […] The tissue diagnosis was established by either thoracoscopy (39 percent) or pleural biopsy (39 percent) in the majority of the cases. […] The median survival after diagnosis was 13.52 months for erionite-associated MPM and 21.56 months for asbestos-associated MPM. […] The actuarial survival curves for the fibrous minerals were significantly different for survival computed both from onset of the symptoms and after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1344148&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma: its evolution and outlook].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a case and show the most recent concepts about histology, pathology, diagnosis and medical-surgical therapy of these diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1357974&#34; target=&#34;_blank&#34;&gt;Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, the authors tested the possibility of using anti-TM to facilitate the diagnosis of mesothelioma. […] Therefore, immunohistochemical staining with antibodies to TM yielded 100% sensitivity and 92% specificity for diagnosis of mesothelioma. […] These findings suggest that immunocytochemical staining with anti-TM should be added to the battery of tests to increase the diagnostic sensitivity and specificity for differentiating mesothelioma from pulmonary adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1376598&#34; target=&#34;_blank&#34;&gt;The differential diagnosis of primary peritoneal papillary tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
If two or all three markers are detectable, primary peritoneal carcinomatosis or metastatic ovarian carcinoma is the possible diagnosis. […] If none of the three markers are found, a diagnosis of mesothelioma is highly probable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1384016&#34; target=&#34;_blank&#34;&gt;Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis may be perplexing because of its rarity and its pathologic similarities to other papillary or spindle cell neoplasms in the pediatric age group. […] We have studied eight cases of mesothelial or submesothelial-derived neoplasms of pleural (four cases) and peritoneal (four cases) origin in patients 4 to 17 years of age at diagnosis. […] These results indicate that the immunohistochemical profile delineated for mesothelioma in adults is equally applicable to mesothelial neoplasms in younger patients and is useful in establishing a diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1384371&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma producing human chorionic gonadotropin. Report of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histological diagnosis was diffuse, malignant, monophasic mesothelioma of the epithelial type. […] A diagnosis of malignant mesothelioma with trophoblastic differentiation seemed most likely in both cases in view of the clinical and pathological findings. […] In both cases, results of mucin histochemistry and various immunohistochemical stains for antigens or with antibodies were consistent with diagnosis of mesothelioma except in a few cells in the choriocarcinomatous portion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1395753&#34; target=&#34;_blank&#34;&gt;The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma of the pleura is a disease that requires a biopsy procedure for a definitive diagnosis. […] In the past, closed pleural needle biopsy (CPNB) has given poor yields due to the small amount of tissue obtained, and the patient has subsequently been subjected to a diagnostic thoracotomy. […] In recent years, the availability of more accurate histopathologic tests have enabled the pathologist to make a diagnosis more easily on samples obtained at CPNB. […] In this retrospective study of 20 consecutive cases of malignant mesothelioma of the pleura diagnosed between 1980 and 1990, we found that a blind CPNB was diagnostic in five of seven procedures and CT-guided CPNB was diagnostic in five of six procedures. […] An open pleural biopsy (OPB) was diagnostic in ten of ten procedures performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1398535&#34; target=&#34;_blank&#34;&gt;p53 expression is common in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have investigated the possibility that the differential diagnosis between reactive and neoplastic mesothelium might be resolved using a polyclonal serum raised to human p53 protein, CM-1.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1418271&#34; target=&#34;_blank&#34;&gt;Prognostic importance of the DNA ploidy pattern in malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesotheliomas often raise a difficult diagnostic problem: once the diagnosis is made, the possibilities of predicting the biologic activity and prognosis of the tumor are limited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1418272&#34; target=&#34;_blank&#34;&gt;DNA analysis of malignant effusions. Comparison with cytologic diagnosis and carcinoembryonic antigen content.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The study was undertaken to determine if the addition of DNA analysis would improve the sensitivity of cytologic diagnosis and CEA assay. […] The sensitivity of cytologic diagnosis was 100% and specificity 100%. […] DNA analysis of cells in malignant effusions is less sensitive than cytologic diagnosis, and CEA assay and is not recommended for routine use in the diagnosis of malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1419863&#34; target=&#34;_blank&#34;&gt;Survival of asbestos insulation workers with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean survival time from diagnosis to death was shorter for both groups of patients: 8.4 months for pleural mesothelioma v 5.8 months for the peritoneal cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1439021&#34; target=&#34;_blank&#34;&gt;Imaging manifestations of pleural tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although radiologic assessment of pleural tumors may be accomplished with several imaging modalities, the standard noninvasive techniques include chest radiography and computed tomography (CT).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1439223&#34; target=&#34;_blank&#34;&gt;Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival from diagnosis was 12 months, and from the onset of symptoms 18 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14499718&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the vulva. About one case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The preoperative diagnosis was that of a cyst of the Bartholin’s gland or a fibroma. […] The microscopic and immunohistochemical exam confirmed the diagnosis of a biphasic malignant mesothelioma of the vulva. […] Our objective about this particular case is to discuss the clinical and pathologic aspects and the diagnostic problems of this exceptional tumour of the vulva.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14505061&#34; target=&#34;_blank&#34;&gt;Desmoplastic malignant mesothelioma: two cases and a literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, pathological, ultrastructural, and immunohistochemical findings led us a diagnosis of DMM in each case. […] Widespread immunohistological panels of malignant mesothelioma were not evaluated; Immunohistological markers commonly used for the diagnosis of malignant mesothelioma were not evaluated; however, the high ki-67 LI results and positive HBME-1 staining were helpful factors for the diagnoses of DMM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14507319&#34; target=&#34;_blank&#34;&gt;Localized pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pathological examinations revealed that it consisted of large polygonal cells, partially showing myxoid patterns, which led to a diagnosis of localized pleural MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14507409&#34; target=&#34;_blank&#34;&gt;Widespread cutaneous and perioral metastases of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Positive immunohistochemical stains for anti-cytokeratin, anti-calretinin, and HBME-1 and negative stains for anti-CEA, Leu-M1, B72.3, and Ber-Ep4 confirmed the diagnosis. […] Metastatic mesothelioma to the skin or lip is a very rare occurrence but should be considered in the differential diagnosis of malignant epithelioid neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14509952&#34; target=&#34;_blank&#34;&gt;Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients were positioned using noninvasive patient fixation techniques which can be attached to the applied extracranial stereotactic system. […] Median survival after diagnosis was 20 months and after IMRT 6.5 months. […] Therefore, both the 1-year actuarial overall survival from the start of radiotherapy and the 2-year actuarial overall survival since diagnosis were 28%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2003-10-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1451080&#34; target=&#34;_blank&#34;&gt;New strategies are needed in diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median time from first symptom to diagnosis was 3 months (range, 0-23 months). […] The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13, 10, and 8 months, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14516539&#34; target=&#34;_blank&#34;&gt;Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We identified 6 patients over the last 18 months with rare tumors who were referred for PET imaging at the time of initial diagnosis, for tumor surveillance or for posttherapy reevaluation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/145715&#34; target=&#34;_blank&#34;&gt;Benign pleural lesion and malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In a series of eighteen diffuse malignant mesotheliomas, five cases were encountered in which thoracic surgery with benign nontumorous diagnosis preceded the development of a malignant mesothelioma by several years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1978-02-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1462024&#34; target=&#34;_blank&#34;&gt;Pleural effusions: is thoracoscopy a reliable investigation? A retrospective review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recourse to thoracoscopy was only taken in the absence of a diagnosis or non-resolution of the patients symptoms and signs. […] Of these 620 patients only 48 (8%) remained without a diagnosis and were referred for thoracoscopy. […] In eight patients (17%) no conclusive diagnosis was established; in this latter group, six patients continued with their symptoms and further invasive investigations revealed malignancy. […] In conclusion, from our experience, the majority of pleural disease may be diagnosed using simple techniques but thoracoscopy can be very helpful in the more complex cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1462468&#34; target=&#34;_blank&#34;&gt;[Primary malignant pleural neoplasms. Diagnostic code 163.09].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We find that code 163.09 frequently has been used as a working diagnosis, which could not invariably be substantiated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1462582&#34; target=&#34;_blank&#34;&gt;[Diagnostic difficulties in pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 16 cases the diagnosis was confirmed by histological examination, and in 13 cases the diagnosis of mesothelioma was based on the whole clinical picture and cytological examination of pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14630441&#34; target=&#34;_blank&#34;&gt;Mesothelin-family proteins and diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Identification of such a marker would be useful in diagnosis of mesothelioma and for monitoring responses to treatment and screening at-risk individuals. […] Determination of SMR in serum could be a useful marker for diagnosis of mesothelioma and to monitor disease progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14634783&#34; target=&#34;_blank&#34;&gt;CT findings and serum ca 125 levels in malignant peritoneal mesothelioma: report of 11 new cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to review and reappraise the clinical and CT features of malignant peritoneal mesothelioma (MPM), and to discuss differential diagnosis. […] The history, clinical, and laboratory data, and imaging studies of 11 patients with a histologically proven diagnosis of MPM, were retrospectively reviewed. […] Computed tomography findings of MPM are nonspecific and inadequate to pinpoint specific diagnosis. […] The diagnosis requires histological demonstration which is commonly made by an image or laparoscopic-guided biopsy. […] Pleural changes suggesting asbestosis combined with CT findings and high CA-125 levels can suggest, but are not diagnostic of, mesothelioma. […] Suggesting the diagnosis of MPM is important because histological and immunohistochemical tests are needed for diagnostic accuracy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14635508&#34; target=&#34;_blank&#34;&gt;Localized benign pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical differential diagnosis of benign and malign mesotheliomas is not clear.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14636270&#34; target=&#34;_blank&#34;&gt;‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tissue diagnosis should be obtained in all cases of suspected diffuse pleural neoplasia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14644341&#34; target=&#34;_blank&#34;&gt;Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This approach, known as molecular epidemiology has a great potential in the study of MM, contributing to the understanding of susceptibility factors, to the evaluation of cancer risk in people occupationally or environmentally exposed to carcinogens, and to the enhancement of diagnosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14657954&#34; target=&#34;_blank&#34;&gt;Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We determined the diagnostic value of MUC4 immunostaining in this issue. […] We conclude that MUC4 is a very specific (100%) and sensitive (91.4%) marker of lung adenocarcinomas on paraffin-embedded tissue that could be useful in diagnostic practice in the distinction between malignant mesothelioma and adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14658085&#34; target=&#34;_blank&#34;&gt;[“Disappearance” of retroperitoneal vessels - a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article discusses the characteristic sonomorphologic features of pneumo-retroperitoneum and its differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-03-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14674071&#34; target=&#34;_blank&#34;&gt;Bronchial cytology in pleural mesothelioma. A report of 3 positive cases, including 1 diagnosed initially on bronchial brushings.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although no single criterion appears diagnostic, their combined documentation could ensure correct interpretation, especially if supported by a limited immunocytochemical panel.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14691969&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in Italy, 1997.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Exposure was defined for 198 mesotheliomas with a histological diagnosis: 125 (63%) refer to occupational exposure, 10 (5%) to environmental exposure, and 5 (2.5%) to household exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-05-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14720142&#34; target=&#34;_blank&#34;&gt;Disseminated malignant solitary fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of malignant mesothelioma was suspected, based on clinical, radiological and needle biopsy findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14725101&#34; target=&#34;_blank&#34;&gt;Peritoneal mesothelioma after environmental asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This report of a patient from Anatolia with peritoneal mesothelioma after environmental exposure outlines the importance of considering this pathology in the differential diagnosis of a Turkish patient presenting with ascites.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-05-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14730040&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Computed tomography is the primary imaging modality used for the diagnosis and staging of MPM. […] Magnetic resonance (MR) imaging and, more recently, positron emission tomography (PET) have emerged as modalities that can provide additional important diagnostic and prognostic information to help further delineate the extent of disease, especially in surgical candidates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14732480&#34; target=&#34;_blank&#34;&gt;Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These molecular markers should improve the accuracy of mesothelioma diagnosis, prognosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1480298&#34; target=&#34;_blank&#34;&gt;[Localized pleural mesotheliomas. Clinicopathological considerations on a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural mesotheliomas are rare, and their diagnosis and treatment not clear. […] This showed that differential diagnosis with pulmonary carcinoma is very difficult, even in cases of parietal mesothelioma; however local treatment may be performed even in malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1484319&#34; target=&#34;_blank&#34;&gt;p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The object of this study was to examine the frequency of immunohistochemically detectable p53 overexpression in routinely processed, paraffin-embedded tissue from pleural mesotheliomas and from pleura showing reactive mesothelial hyperplasia, using a polyclonal antibody to formalin-resistant p53 epitopes, and to consider the diagnostic utility of this antibody in the distinction between mesothelioma and reactive mesothelium in pleural biopsy specimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-02-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1487570&#34; target=&#34;_blank&#34;&gt;Distant cutaneous metastasis of pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was not established pre-mortem. […] Electron microscopic examination of tissue from the pleural tumor was diagnostic for mesothelioma. […] Inclusion of this entity in the differential diagnosis of certain cutaneous tumors is important, in part because this lesion may be confused with angiosarcoma, particularly when it occurs in the skin of the face or head in older patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14976533&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant mesothelioma of the peritoneum is a rare diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14978915&#34; target=&#34;_blank&#34;&gt;[Localized fibrous mesothelioma with bloody pleural effusion; report of a case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A preoperative diagnosis of localized fibrous mesothelioma was made based on chest computed tomography and examination of computed tomographic guided percutaneous needle biopsy specimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/14987796&#34; target=&#34;_blank&#34;&gt;Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our approach allowed a comprehensive in situ examination of mesothelioma and provided an accurate way to find new marker genes that may be useful for diagnosis and treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15014036&#34; target=&#34;_blank&#34;&gt;Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Proliferation and apoptosis in drug-treated, virally transduced, or control cells were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Apo-bromodeoxyuridine techniques. […] Western blot and ELISA techniques were used to examine signal transduction and cell cycle-related protein levels in MPM cells exposed to DP and/or FLA in the presence or absence of calphostin, phorbol-12,13-dibutyrate, 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole, or adenoviral p21 transduction. […] Overexpression of p21 by adenoviral gene transfer techniques rendered MPM cells refractory to the cytotoxic effects of this treatment regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15043457&#34; target=&#34;_blank&#34;&gt;Recurrent solitary fibrous tumor of the pleura with malignant transformation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The accurate diagnosis of solitary fibrous tumor is aided by ancillary techniques, such as immunohistochemical staining; however, with malignant transformation, such tools may be of limited value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15070023&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma–an update.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis may be complicated by histologic difficulties. […] Thoracoscopic techniques are proving beneficial, but no one method of imaging has proven superior, and disease staging is inconsistent. […] New radiotherapeutic techniques to improve local control are promising.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15079127&#34; target=&#34;_blank&#34;&gt;[Possibilities of diagnosis and treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Objective of our work was to evaluate: incidence, ethiology, diagnostic and treatment methods of malignant pleural mesothelioma. […] Various surgical diagnostic methods were used: videothoracoscopy in 35 (28.0%) cases, pleural biopsies 72 (57.6%) cases, diagnostic “mini” thoracotomies - 18 (14.4%) cases. […] Twenty two patients were treated conservatively when diagnosis was confirmed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15084919&#34; target=&#34;_blank&#34;&gt;High-grade neuroendocrine carcinoma of the lung presenting an unusual spread mimicking pleural mesothelioma associated with dermatomyositis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a case in which a high-grade neuroendocrine carcinoma, associated with dermatomyositis, presented an unusual pattern of progression, mimicking malignant pleural mesothelioma on diagnostic imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15086967&#34; target=&#34;_blank&#34;&gt;Integration of multimodality approaches in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Advances have been made in understanding the pathogenesis, diagnosis, and staging, but they have not translated into markedly improved survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1509143&#34; target=&#34;_blank&#34;&gt;[The computed tomographic diagnosis of malignant pleural mesothelioma. A multicenter study].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT features are described and accuracy of the method is discussed in the diagnosis of malignant pleural mesothelioma. […] Ninety-eight patients suffering from pleural disease mimicking mesothelioma were examined by means of III-generation CT scanners; according to the final diagnosis, 37 patients suffered from malignant pleural mesothelioma, 27 from other malignant pleural diseases and 34 from various benign diseases. […] In the diagnosis of mesothelioma CT showed 72.5% sensitivity, 63.8% specificity, 68.3% diagnostic accuracy, 68.5% positive predictive value and 68.2% negative predictive value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1509283&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: diagnostic and management strategies for 1992.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Independent pathologic review can be useful, and a variety of special stains should be used, if diagnosis is unclear.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15112747&#34; target=&#34;_blank&#34;&gt;[Estimates of pleural mesothelioma incidence in the Lazio region (Italy), 1997-2000].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a systematic study of hospital admissions in the region with diagnosis of cancer of the pleura (ICD-IX 163) in the period 1997-2000. […] Clinical information and results of diagnostic tests were requested for 530 patients from the hospitals involved. […] After careful review of clinical documentation, the diagnosis of malignant mesothelioma of the pleura was confirmed in 31.6% of cases (156 cases diagnosed).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15117424&#34; target=&#34;_blank&#34;&gt;Pathogenesis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MM is made histologically and confirmed through electron microscopy and immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15143397&#34; target=&#34;_blank&#34;&gt;[Gene therapy in malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In malignant mesothelioma, there is no standard treatment protocol and the main cause of death is local spread of tumor and the pathological effects of its mass rather than metastasis and the diagnosis and treatment results are evaluated from the same localization (pleural space).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15152842&#34; target=&#34;_blank&#34;&gt;Use of immunohistochemical marker calretinin in the diagnosis of a diffuse malignant metastatic mesothelioma in an equine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this report, calretinin was used as an immunohistochemical marker in the diagnosis of mesothelioma in an equine species for the first time.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15186594&#34; target=&#34;_blank&#34;&gt;Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We studied 15 consecutive patients (13 male and 2 female) with a histological diagnosis of MPM, with a mean age of 69.9 years (range: 38-78 years old) and a recent total-body CT scan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15188066&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma–a diagnostic challenge].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment is palliative in most cases because of the extension of the disease at the time of diagnosis. […] The diagnostic hypothesis were metastatic, infectious and primitive neoplasm origin. […] Finally, we discussed new differential diagnostic techniques with metastatic adenocarcinoma and target therapies under study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15191298&#34; target=&#34;_blank&#34;&gt;Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have developed computerized techniques for the measurement of mesothelioma tumor thickness in CT scans. […] These techniques achieved varying levels of agreement with measurements made by human observers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15205913&#34; target=&#34;_blank&#34;&gt;[Mesotheliomas with leucocytic infiltration].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These different forms of malignant mesotheliomas are difficult to distinguish and may lead to diagnostic misinterpretations and consequently therapeutic mismanagement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15232743&#34; target=&#34;_blank&#34;&gt;Localised pleural malignant mesothelioma. Report of two cases simulating pulmonary carcinoma and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To describe two cases of localised malignant mesothelioma with a predominantly intrapulmonary growth which led to a pre-operative diagnosis of pulmonary carcinoma. […] In both cases, a preoperative biopsy showed a proliferation of large cells leading to a diagnosis of non-small-cell lung carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261431&#34; target=&#34;_blank&#34;&gt;Pathology of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma relies firstly on the identification of the mesothelial nature of the neoplastic cell and secondly on the demonstration of the invasive properties of the proliferation. […] The latter aspect cannot be achieved by studying cellular material yet, in the right clinical setting, it is often possible to make a presumptive diagnosis of malignant mesothelioma based on exudates. […] Differentiation between mesothelial hyperplasia and metastatic adenocarcinoma by cytological examination alone is unreliable, so further evidence can be gathered from techniques such as histopathology, histochemistry and electron microscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15261438&#34; target=&#34;_blank&#34;&gt;Positron emission tomography in the diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing incidence of malignant pleural mesothelioma has led to the development of new treatment strategies and a need for new diagnostic techniques to identify the extent of the disease at an early stage and to evaluate treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15290457&#34; target=&#34;_blank&#34;&gt;Thoracic actinomycosis with mainly pleural involvement.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although a CT-guided lung biopsy was performed, no definite diagnosis was made. […] Histological examination of the surgically resected tissue led to a diagnosis of thoracic actinomycosis in the main component of the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15343490&#34; target=&#34;_blank&#34;&gt;[Pleuromesothelioma – psychology and pathogenesis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Investigations into the anatomical pathology are of crucial importance for the diagnosis and therapy of pleural tumours. […] Given the absence of distinct morphological features displayed by pleural mesotheliomas, specific additional immunohistochemical and cytometric tests can provide valuable clues for the differential diagnosis of primary and secondary pleural neoplasms. […] Confirmation of the diagnosis during the initial stages of tumour development i. e. mesothelioma in-situ and early mesothelioma necessitates invasive diagnostic procedure as early as possible. […] However, in order to firmly establish the diagnosis considering the afore mentioned problems, the tissue specimens to be examined by a pathologist must be of adequate size. 90 % of all pleural mesotheliomas are asbestos associated due to occupational exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15371657&#34; target=&#34;_blank&#34;&gt;Diagnostic and prognostic value of Ki67 proliferation fraction in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Yet, due to its low sensitivity this marker seems not to be useful for differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15372243&#34; target=&#34;_blank&#34;&gt;Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Interestingly, while the macrophage marker CD14 was negative, immunoreactivity for a mature macrophage marker (CD68) was expressed by all cell types, suggesting that this marker might constitute an additional tool useful in the differential diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15389250&#34; target=&#34;_blank&#34;&gt;Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conclude that D2-40 immunoreactivity is sensitive for cells of mesothelial origin, and may be useful in the differential diagnosis of epithelioid malignant mesothelioma vs adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15451229&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma: little evidence, still time to do trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With the increase in the number of cases there is increasing awareness of the disease, leading to earlier diagnosis, and an expectation that something must be done.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15452897&#34; target=&#34;_blank&#34;&gt;Malignant effusions: from diagnosis to biology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, extensive research has resulted in expansion of the antibody panel that is available for effusion diagnosis, thereby reducing the risk for error. […] The diagnosis of a malignant effusion signifies disease progression and is associated with a worse prognosis regardless of the tumor site of origin. […] The case also is made for potential applications of this rapidly evolving body of knowledge in the diagnosis, classification, and prediction of biological behavior of processes resulting in cryptic effusions at the clinical level.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15473932&#34; target=&#34;_blank&#34;&gt;[Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sometimes, it is difficult to make a correct diagnosis just based on the cytological characteristics. […] Although now immunocytochemistry has been widely used in this field,yet only a few antibodies were reported in China,which can’t help to make a correct differential diagnosis. […] This study was to evaluate the value of combining detection of E-cadherin,carcinoembryonic antigen (CEA),and calretinin in cytological differential diagnosis of serous effusion. […] The combination of E-cadherin, CEA, and calretinin is a very useful antibody panel in cytological differential diagnosis for metastatic adenocarcinoma and mesothelial cells in serous effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15486399&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis and management of malignant pleural mesothelioma are major challenges that often frustrate both patient and clinician alike. […] In addition, the discovery of elevated levels of various markers such as folic acid receptor alpha, cyclooxygenase 2, and multidrug resistance proteins 1 and 2 in mesothelioma tissue have opened up new areas of potential diagnostic and therapeutic importance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510595&#34; target=&#34;_blank&#34;&gt;A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At times, the diagnosis of mesothelioma may be problematic. […] The final diagnosis of mesothelioma relies on histology and often is dependent upon immunohistochemistry. […] It is generally assumed that mesotheliomas must stain positive for cytokeratin and calretinin and negative staining for these markers would rule out the diagnosis. […] These negative stainings would rule out the diagnosis of mesothelioma but, after careful consideration of the patient’s clinical records, and additional histological and immunohistochemical studies, we conclude that this patient suffered from mesothelioma of the sarcomatoid type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15510820&#34; target=&#34;_blank&#34;&gt;[Diaphragm reconstruction after extrapleural pneumonectomy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We retrospectively reviewed techniques and results in 4 patients where the pedicled latissimus dorsi flap, the expanded polytetrafluoroethylene (ePTFE) sheet and the composite mesh sheet consisting of the ePTFE sheet and 2 layers of polypropylene mesh sheets were successfully used to replace the resected diaphragm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15511473&#34; target=&#34;_blank&#34;&gt;Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, pathologic diagnosis of malignant pleural mesothelioma (MPM) and subclassification into one of the three histologic subtypes (epithelial, mixed, sarcomatoid) can be challenging. […] Pleural biopsy has been proposed as the diagnostic gold standard. […] We investigated the accuracy of open pleural biopsy for diagnosis and subtype identification in MPM. […] Patients with suspected MPM routinely undergo open pleural biopsy to establish diagnosis. […] We reviewed medical records for all patients undergoing EPP at our institution, comparing tissue and subtype diagnosis at initial diagnostic biopsy versus definitive resection. […] Most patients (174/192) with epithelial subtype at final diagnosis were diagnosed correctly at pleural biopsy. […] However, 44% (45/103) with pathologic diagnosis of nonepithelial subtype at resection were initially misdiagnosed with the epithelial subtype. […] Open pleural biopsy is accurate and should be considered the gold standard diagnostic method for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15532964&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura in a worker with brief atypical exposure to chrysotile asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Examination of all clinical files confirmed the diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1553915&#34; target=&#34;_blank&#34;&gt;Extraskeletal myxoid chondrosarcoma of the pleura. Report of a case clinically simulating mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although exceedingly rare in this location, the characteristic histologic features, immunohistochemical reactivities, and ultrastructural features support the diagnosis of extraskeletal myxoid chondrosarcoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15545953&#34; target=&#34;_blank&#34;&gt;[Spontaneous pneumothorax revealing malignant pleural mesothelioma. Three case reports].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was suggested at medical imaging and was confirmed at histological analysis of biopsies obtained by thoracoscopy in two patients and thoracotomy in one. […] The first patient (age 65 years) died two months after the initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15553434&#34; target=&#34;_blank&#34;&gt;[Small bowel metastases from lung cancer].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiological techniques such as small bowel enema and CT enteroclysis were used with positive results. […] Intestinal metastases from lung cancer are rare and the diagnosis is often late. […] However, in the presence of small bowel occlusion and intestinal bleeding of uncertain origin, clinical history-taking is very important and diagnostic procedures must be performed to exclude a secondary pathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559050&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: overview of the North American and European experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis, a standardized staging system, early referral to centers experienced in MPM, and efforts to develop collaborative multicenter trials are essential to improving treatment for patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559052&#34; target=&#34;_blank&#34;&gt;Genetics of malignant pleural mesothelioma: molecular markers and biologic targets.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Related efforts to identify the molecular markers of mesothelioma are pursued with the aim of refining current diagnostic capabilities, predicting prognosis, and designing appropriate trimodality programs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559057&#34; target=&#34;_blank&#34;&gt;Preoperative assessment and therapeutic options for patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical recognition of the cancer is confounded by numerous factors, including long latency between exposure to asbestos and expression of the disease, nonspecific nature of the presenting symptoms, rarity of the disease, a lack of experience in clinical diagnosis, and rapidly deteriorating clinical course after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15559059&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although mesothelioma remains a difficult disease to treat, the techniques of surgical resection for mesothelioma have improved dramatically.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2004-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15581753&#34; target=&#34;_blank&#34;&gt;Primary synovial sarcoma of the pleura: beware of misdiagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis with new molecular techniques may improve the outcome of this tumour, which is believed to have a grave prognosis at present.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15595200&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura among women].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was based on/or confirmed by necropsy findings in 30 cases. […] The latency periods (time intervals elapsed between first exposure to asbestos and diagnosis of the tumour), calculated in 23 cases, ranged from 34 to 62 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15607312&#34; target=&#34;_blank&#34;&gt;Role of biochemical tests in the diagnosis of exudative pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To examine the diagnostic utility of pleural adenosine deaminase (PADA), pleural lactate dehydrogenase (PLDH), and several other biochemical tests in bronchogenic carcinoma and malignant mesothelioma, and to compare biochemical characteristics of their fluid with nonmalignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1561440&#34; target=&#34;_blank&#34;&gt;[Carcinoembryonic antigen in pleural effusion. Adenocarcinoma versus mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One hundred and thirty six patients presenting pleural effusion and whose diagnosis was obtained by clinical, biochemical, bacteriological, cytological and histological methods have been studied and classified into seven groups: 20 transudates, 29 inflammatory, 25 tuberculosis, 25 non adenocarcinoid neoplasias, 24 adenocarcinomas, 10 mesotheliomas and 3 miscellaneous.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15614737&#34; target=&#34;_blank&#34;&gt;TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are numerous immunohistochemical markers being used, but none of them were proved to be effective enough to reach a certain diagnosis. […] The current study was performed to evaluate the utility of thyroid transcription factor-1 (TTF-1) and surfactant protein-B (SP-B) expression in the differential diagnosis between lung adenocarcinomas and pleural mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15625372&#34; target=&#34;_blank&#34;&gt;Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
EPS was determined by a five-parameter model incorporating age, sex, histology, probability of diagnosis, and leukocyte count.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15628770&#34; target=&#34;_blank&#34;&gt;[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a rare neoplasm that is commonly fatal within 12-17 months after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15639718&#34; target=&#34;_blank&#34;&gt;Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our observations support the strong potential of methylation markers as tools for accurate diagnosis of neoplasms in and around the lung.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1565787&#34; target=&#34;_blank&#34;&gt;[Asbestosis accompanied by primary peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On the basis of these CT findings, a peritoneal mesothelioma was suspected, which was confirmed by diagnostic laparotomy. […] In cases of suspected occupational illness such as that presented here, each physician concerned including the radiologist involved in the diagnosis, is required to advise the social insurance institution responsible.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15690333&#34; target=&#34;_blank&#34;&gt;The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma requires an integration of the clinical presentation, radiological studies, and immunohistochemical stain of histological sections. […] Cytological diagnosis on pleural effusions of mesothelioma and pulmonary adenocarcinoma is highly desirable but debatable. […] The current study is designed to assess whether the introduction of a liquid-based technology such as ThinPrep (TP) can provide additional diagnostic value in addition to the conventional cytospin Diff-Quik (DQ) preparations. […] All other cytological features evaluated distinguishing mesotheliomas (20 features) and pleural adenocarcinomas (19 features) were seen equally readily in both types of specimen preparation techniques. […] This study suggests that the liquid-based TP preparation of pleural effusions does not appear to provide additional diagnostic value when compared with the DQ cytospin preparation in the cytological distinction between mesothelioma and adenocarcinoma in pleural effusions. […] Most cytological features evaluated, 20 of 25 (mesothelioma) and 19 of 22 (adenocarcinoma), can be seen in both preparation techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15690334&#34; target=&#34;_blank&#34;&gt;The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of MM was confirmed by surgical decortication or pneumonectomy with immunostaining studies and/or electron microscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15690335&#34; target=&#34;_blank&#34;&gt;Image cytometry: an aid for cytological diagnosis of pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this retrospective study based on 42 available cases with a histological diagnosis, we have examined 13 reactive mesothelial proliferations and 29 cases of malignant tumors (adenocarcinoma [ACA] or mesothelioma).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15690337&#34; target=&#34;_blank&#34;&gt;Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differentiating cells of mesothelial origin from adenocarcinoma (ACA) based on morphology alone can be a diagnostic challenge, especially in cytological specimens. […] The CD44S staining pattern of cells of mesothelial origin is of diagnostic significance. […] CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15690338&#34; target=&#34;_blank&#34;&gt;Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The morphological evaluation of cytological specimens from body cavity fluids presents difficulties in the differential diagnosis between benign reactive mesothelial (RM) cells and adenocarcinoma (AC) or malignant mesothelioma (MM). […] The aim of our study was to investigate whether a panel of five different antibodies can offer reliable markers in the differential diagnosis of RM, AC, and MM in serous effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15690708&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura–diagnostic difficulties].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Noncharacteristic clinical signs, radiological features and similarity to other neoplasma (adenocarcinoma) in a microscopical evaluation lead to often diagnostic problems. […] Thoracoscopy followed by biopsy is routinely performed and is considered a main diagnostic procedure. […] In this report, presented is a case of malignant pleural mesothelioma, in which final diagnosis was delayed because of difficulties in diagnosis based on thoracoscopic biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15691231&#34; target=&#34;_blank&#34;&gt;Pathogenesis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite a ban on asbestos use in Western countries, the incidence of MPM is increasing, due to the long delay between asbestos exposure and diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15693854&#34; target=&#34;_blank&#34;&gt;Podoplanin as a marker for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The utility of podoplanin for the histological diagnosis of tumors was then investigated, especially for mesothelioma. […] Among the many antibodies used for differential diagnosis of malignant mesothelioma, podoplanin has the potential to be an excellent tumor marker in both specificity and sensitivity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15722797&#34; target=&#34;_blank&#34;&gt;Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We compared specificity and sensitivity of this polyclonal antibody for diagnosis of diffuse malignant mesothelioma with a new monoclonal antibody from DAKO. […] Both antibodies are useful in the diagnosis of epithelial malignant mesothelioma, although monoclonal antibody is slightly less sensitive.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15724226&#34; target=&#34;_blank&#34;&gt;[Management of malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this overview, which is based on the ERS/ATS Statement 2001, the diagnostic approach, the differential diagnosis including causes of paramalignant effusions, as well as the therapeutic possibilities are described. […] A special emphasis is put on the epidemiology, diagnosis, treatment, and prognosis of malignant effusions in patients with lung and breast carcinomas, and with lymphomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15729603&#34; target=&#34;_blank&#34;&gt;Granulocyte colony-stimulating factor-producing malignant pleural mesothelioma with the expression of other cytokines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At autopsy, a diagnosis of malignant pleural mesothelioma was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15737040&#34; target=&#34;_blank&#34;&gt;Malignant deciduoid mesothelioma: a diagnostic challenge.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This observation confirms the poor prognosis of this entity and the importance of the differential diagnosis of pseudotumoral deciduosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15753650&#34; target=&#34;_blank&#34;&gt;Analysis of chromosomes 9 and 11 aneuploidy frequency in pleural effusion of patients with and without malignancy: interphase FISH technique.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of effusion from the patients is frequently troublesome for the cytologist because of the differentiation and biological behavior of different cells type in effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15754636&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma–case with effusion in both pleural cavities].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Etiology of the pleural exudate is not always easy to establish with the routine diagnostic procedures. […] Rapid accumulation of the fluid, deterioration of general condition of the patient, presence of dysplasia in the cells of the sediment of the exudate indicated possibility of diagnosis of neoplasm of the pleura. […] Final diagnosis was possible only after pleural biopsy (with Abrams needle) was performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15764788&#34; target=&#34;_blank&#34;&gt;Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopic pleural biopsy is highly accurate in the diagnosis of pleural malignancy. […] After thoracoscopy, all patients without a diagnosis were sent for long-term follow-up. […] Thoracoscopy demonstrated 94% sensitivity and 100% specificity in the diagnosis of pleural malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15772581&#34; target=&#34;_blank&#34;&gt;[Lung cancer and peritoneal mesothelioma: two complications of asbestos exposure in the same patient].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After exploration of an intra-pulmonary opacity, with inspissated pleura, the diagnosis of primary pulmonary adenocarcinoma was obtained by thoracotomy in April 1999. […] In February 2002, the diagnosis of peritoneal mesothelioma was made by laparoscopy. […] The course was marked by irreducible ascites and was fatal 7 months after the diagnosis of peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1577967&#34; target=&#34;_blank&#34;&gt;Desmoplastic malignant mesothelioma: a review of 17 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of desmoplastic mesothelioma was only accepted if acellular connective tissue comprised 50% or more of the tumour bulk.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1580116&#34; target=&#34;_blank&#34;&gt;The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The first morphologic diagnosis was a cytologic one in 86 cases (60.1%), especially regarding lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1580261&#34; target=&#34;_blank&#34;&gt;Pleural malignant mesothelioma in Tuscany, Italy (1970-1988): I. Anatomo-pathologic aspects.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our investigation did not confirm the general experience that significant numbers of cases initially considered malignant mesothelioma or metastatic carcinoma are actually found to be metastatic carcinoma or malignant mesothelioma, respectively, upon deeper investigation using ancillary techniques (e.g., histochemistry, immunohistochemistry, electron microscopy).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15829331&#34; target=&#34;_blank&#34;&gt;Thalidomide in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with a histological confirmed diagnosis of malignant mesothelioma received thalidomide orally at night.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15835628&#34; target=&#34;_blank&#34;&gt;[Problematic cases of mesothelioma reported to the Dutch Institute for Asbestos Victims: evaluation by the Mesothelioma Working Group of the Netherlands Association of Pulmonologists and Specialists in Tuberculosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When no definitive diagnosis can be made on histological or cytological grounds, three pulmonologists reach a conclusion on the basis of correspondence, X-ray examination and other information.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15901986&#34; target=&#34;_blank&#34;&gt;Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988-2000: a population-based study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim was to establish the prognostic role of demographic, diagnostic and asbestos exposure variables. […] Gender, age, period of diagnosis, hospital of diagnosis and asbestos exposure did not show significant effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1591306&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Distinguishing between DMM and peripheral adenocarcinoma with pleural involvement is a frequent diagnostic problem. […] Immunohistochemical markers (positive for vimentin and negative for carcinoembryonic antigen and Leu M1) and electronmicroscopy aid in the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15914055&#34; target=&#34;_blank&#34;&gt;Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological examination of the pleural fluid and fine needle aspirates of the thickened pleura suggested a diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15920167&#34; target=&#34;_blank&#34;&gt;Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In global expression analysis using unsupervised clustering techniques, we found two potential subclasses of mesothelioma that correlated loosely with tumor histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15941656&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in Hong Kong.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Restricting analysis to 48 patients with accessible medical records and using 67 occupational asbestosis patients for comparison, the epidemiology of mesothelioma in Hong Kong shares similarities with the literature: mean age of 63 years upon diagnosis, mean latency of 46 years, median survival of 9.5 months, male predominance, selective presentation among women, high prevalence among workers in ships and dockyards, predominantly epithelioid type, lower prevalence of asbestos bodies, and negative association with pleural plaques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950790&#34; target=&#34;_blank&#34;&gt;Clinical trials in malignant pleural mesothelioma in Australasia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two current and three proposed trials in mesothelioma in this region are discussed, covering the diverse clinical scenarios of diagnosis and staging, health-related quality of life, maintenance therapy, prediction of response and combined modality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15950811&#34; target=&#34;_blank&#34;&gt;Implications of P16/CDKN2A deletion in pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In terms of diagnostic applications, its high prevalence makes it a useful marker to distinguish malignant mesothelial cells from benign reactive ones in pleural fluid cytologic preparations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15955137&#34; target=&#34;_blank&#34;&gt;Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical markers such as calretinin, WT-1, and cytokeratin 5/6 are becoming established diagnostic markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15958850&#34; target=&#34;_blank&#34;&gt;Localized malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After surgical excision of the tumor, 10 of 21 patients with follow-up data were alive without evidence of disease from 18 months to 11 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15976368&#34; target=&#34;_blank&#34;&gt;Residential proximity to naturally occurring asbestos and mesothelioma risk in California.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We located 93.7% of subjects at the house or street level at initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15988688&#34; target=&#34;_blank&#34;&gt;New agents in the management of advanced mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MPM patients remains dramatically poor (12 to 18 months’ median survival from diagnosis), although exceptional cases of long-survivors are reported in all literature series.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1599018&#34; target=&#34;_blank&#34;&gt;Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These data indicate that K1 can be useful as a mesothelial cell marker for the differential pathological diagnosis of the epithelial form of mesothelioma; K1 may also be useful in the study of the pathogenesis, immunodiagnosis, and immunotherapy of epithelial-type and mixed-type human malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/15993904&#34; target=&#34;_blank&#34;&gt;Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of mEH, GSTM1, GSTT1, NAT2, and CYP1A1 genotypes in modulating susceptibility to MM was examined in a case-control study of 80 subjects with a confirmed diagnosis of MM and 255 controls.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16007670&#34; target=&#34;_blank&#34;&gt;Primary diagnosis of malignant mesothelioma by fine-needle aspiration of a supraclavicular lymph node.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To our knowledge, there have only been two reported cases in the literature where fine-needle aspiration (FNA) of a lymph node was the primary mode of diagnosis of malignant mesothelioma. […] We describe a 40-yr-old male in whom the primary diagnosis of malignant mesothelioma was made by FNA of a supraclavicular lymph node. […] Most patients with clinically documented lymph node metastases of malignant mesothelioma have had a previously established diagnosis of mesothelioma. […] Our case demonstrates that FNA can be a simple and invaluable method of diagnosis in those unusual cases where diagnosis of malignant mesothelioma has not already been made before lymphadenopathy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16012365&#34; target=&#34;_blank&#34;&gt;[Spinal cord compression from a malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy-talc led to the diagnosis of epithelial pleural mesothelioma in a 58-year-old man who presented with pleurisy. […] Dorsal pain revealed invasion of the spine and spinal canal leading to cord compression three months after the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16012715&#34; target=&#34;_blank&#34;&gt;Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, we examined the usefulness of its soluble protein (sRCAS1) in pleural effusion for the diagnosis of malignant mesothelioma. […] In addition, sRCAS1 in pleural fluid may be useful for the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16012846&#34; target=&#34;_blank&#34;&gt;Chromosomal alterations in early stages of malignant mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The molecular cytogenetic findings support the histological diagnosis of a pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16035560&#34; target=&#34;_blank&#34;&gt;CT in differential diagnosis of benign and malignant pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT plays a valuable role in assessment of patients with a wide variety of diseases of the pleura, and pulmonologists should be aware of the significance of different CT findings for the differential diagnosis of benign and malignant pleural diseases. 155 patients with pleural disease who had undergone CT scans of the lungs and thorax before treatment were enrolled. […] CT is helpful in the differential diagnosis of pleural diseases, particularly in differentiating malignant from benign conditions and metastatic pleural disease from malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16050468&#34; target=&#34;_blank&#34;&gt;[A case of malignant mesothelioma showing rapid progression during one month].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We performed thoracoscopy again one month later under general anesthesia to make a definitive diagnosis. […] While we managed to make a definitive diagnosis, the tumor progressed rapidly during one month.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16054941&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytopathology of mesothelioma effusions or fine-needle aspirations are often sufficient to establish a diagnosis, but histopathology is also often required. […] Median survival is now 12 months from diagnosis. […] Patterns identified from microarray studies could be useful for diagnosis as well as prognostication.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1606507&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma: prognostic factors in a series of 125 patients studied from 1973 to 1987].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnostic thoracoscopy was carried out in every patient and the histopathological diagnosis confirmed by the French Mesothelioma Panel of Pathologists.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16086544&#34; target=&#34;_blank&#34;&gt;PET in lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PET-CT is superior in diagnostic accuracy for T staging and differentiation between tumor and peritumoral atelectasis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1609155&#34; target=&#34;_blank&#34;&gt;Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis between mesothelioma and adenocarcinoma is a common and troublesome one, necessitating the correlation between clinical history, radiographic findings, and pathologic examination of tissues and cells. […] Once a malignant diagnosis is arrived at by careful pathological examination, the tumor is classified as mesothelioma if mesothelial cells are identified as the constituent cells of the neoplasm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1609156&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While several cytologic features are of predictive value in separating these entities, immunostaining and ultrastructural examination are important adjuncts that increase the diagnostic yield.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1609158&#34; target=&#34;_blank&#34;&gt;Quantitative and analytical studies in the diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The vast majority of patients with malignant mesothelioma of the pleura or peritoneum have an abnormal tissue asbestos content as assessed by digestion techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1609159&#34; target=&#34;_blank&#34;&gt;The spectrum of histologic growth patterns in benign and malignant fibrous tumors of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Due to the extreme variability in morphologic appearances and the lack of distinctive ultrastructural or immunohistochemical characteristics, these tumors can pose a significant diagnostic problem. […] Familiarity with their histologic appearances and correlation with the gross findings and clinical setting are essential for arriving at the correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16103743&#34; target=&#34;_blank&#34;&gt;Serum PDGF-AB in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1610769&#34; target=&#34;_blank&#34;&gt;[The problems of early diagnosis of diffuse malignant mesothelioma from the pathologo-anatomic view].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An account is given in this paper of particular problems associated with early detection of mesotheliomatous alterations and differential diagnosis for their distinction from reactive mesothelial cell proliferations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16125958&#34; target=&#34;_blank&#34;&gt;Pseudomesothelioma resulting from metastatic malignant melanoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical diagnosis can be difficult and therapeutic options are limited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16148873&#34; target=&#34;_blank&#34;&gt;A case of diffuse pleural mesothelioma in which contralateral exploratory thoracoscopy assisted the selection of therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present a case of successful diagnosis of bilateral pleural mesothelioma by thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16149874&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: current status of histopathologic diagnosis and molecular profile.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surprisingly, for a disease that currently has no known cure, one of the major problems still lies in establishing the correct diagnosis. […] Diagnosis acquires a particular relevance in light of the medicolegal ramifications of this disease, and diagnosis of malignant mesothelioma is still fraught with difficulties. […] Despite the advances in modern diagnostic techniques, no specific markers or morphologic features exist that are exclusive to these tumors. […] Herein, the current status of malignant mesothelioma diagnosis is reviewed, including the possible contributions of modern molecular techniques for their diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1617160&#34; target=&#34;_blank&#34;&gt;Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings suggest that Ber-EP4 is a valuable addition to antibodies available for the differential diagnosis of mesothelial cells and adenocarcinoma cells in serous effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16174857&#34; target=&#34;_blank&#34;&gt;Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The relative risk and EAR decreased with increasing age at testicular cancer diagnosis (P &amp;lt; .001); the EAR increased with attained age (P &amp;lt; .001) but the excess RR decreased.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16219479&#34; target=&#34;_blank&#34;&gt;[Recent progress in treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Incidence of malignant pleural mesothelioma will rise until 2030-2040 because the elapsed time between exposure and diagnostic is up to several decades. […] As compared to 1999, standart treatment adds chemotherapy with cisplatin and pemetrexed to local radiotherapy for prevention of local seeding after invasive diagnostic procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16240396&#34; target=&#34;_blank&#34;&gt;The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On the basis of our findings, identification of beta-catenin staining pattern offers a useful marker in the diagnosis of mesothelial lesions and may help identify neoplastic change.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16240397&#34; target=&#34;_blank&#34;&gt;Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our results suggest that the 67-kd LR may aid in the differential diagnosis between metastatic carcinoma, mainly of ovarian origin, and MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16240402&#34; target=&#34;_blank&#34;&gt;Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have previously shown that flow cytometric (FCM) immunophenotyping is a useful adjunct to morphology, in the diagnosis of serous effusions. […] Results (percentage of cells expressing the antigen) were analyzed for relationship with the morphologic diagnosis. […] Frequent expression of the alphaV, alpha6, and beta1 subunits was seen in all diagnostic groups, with significantly higher expression of the alpha6 subunit in MM (P = 0.029, Kruskal-Wallis H test).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16253022&#34; target=&#34;_blank&#34;&gt;Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histologic patterns of diffuse malignant mesothelioma provide a wide variation of features for the pathologist to consider in the differential diagnosis of a pleural biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16253023&#34; target=&#34;_blank&#34;&gt;Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although much of the pathology literature focuses on differential diagnosis of diffuse malignant mesothelioma from other types of cancer, the primary diagnostic challenge facing the pathologist is often whether a mesothelial proliferation on a pleural biopsy represents a malignancy or a benign reactive hyperplasia. […] When there is any doubt that a pleural biopsy represents a malignancy, we recommend a diagnosis of atypical mesothelial proliferation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16253024&#34; target=&#34;_blank&#34;&gt;Review and update of uncommon primary pleural tumors: a practical approach to diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A practical approach to the diagnosis of these neoplasms in surgical pathology specimens is offered. […] The differential diagnosis, including metastatic pleural neoplasms, is also briefly addressed. […] Correct diagnosis is important because of different prognosis and treatment implications for the various neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16266800&#34; target=&#34;_blank&#34;&gt;Needle-track metastases and prophylactic radiotherapy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirty-seven (95%) patients received radiotherapy to their chest instrumentation site between 6 and 42 days (median 26 days) following the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16268920&#34; target=&#34;_blank&#34;&gt;Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We reviewed all 26 patients with a final diagnosis of malignant pleural mesothelioma from our prospective database of 228 consecutive patients who received thoracoscopy from the same physician for recurrent symptomatic pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16268922&#34; target=&#34;_blank&#34;&gt;Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, a clinical diagnosis was difficult and these cancers could only be distinguished from malignant pleural mesothelioma by thoracentesis in two cases, pleural biopsy in two, thoracotomy in two, and in case 7 at autopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16291305&#34; target=&#34;_blank&#34;&gt;Use of imaging in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, even with adequate sampling and the use of immunocytochemistry, histological diagnosis is known to be difficult; definitive diagnosis may involve a combination of clinical presentation, radiological and histological appearances.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16304288&#34; target=&#34;_blank&#34;&gt;Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The routinely processed formalin-fixed, paraffin-embedded, hematoxylin-eosin-stained tumor sections that had been used for the original diagnostic purposes were retrieved.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2005-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16316830&#34; target=&#34;_blank&#34;&gt;[Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural mesothelioma is difficult and the current treatments did not show significant improvement of the survival. […] These data should improve the accuracy of mesothelioma diagnosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16319326&#34; target=&#34;_blank&#34;&gt;Autofluorescence videothoracoscopy in exudative pleural effusions: preliminary results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Videothoracoscopy has been proven to be a safe tool to establish the diagnosis in &amp;gt;90% of patients with exudative pleural effusions of unknown origin. […] The aim of the present study was to estimate whether the combination of thoracoscopy with autofluorescence modalities would be useful to further improve the diagnostic accuracy of the conventional method.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16326244&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An extrapleural pneumonectomy was performed, and specimens of parietal and visceral pleura were sent for pathological, which revealed a definitive diagnosis of spindle cell mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16330935&#34; target=&#34;_blank&#34;&gt;The immunohistochemical profile of malignant mesotheliomas of the tunica vaginalis: a study of 20 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In all cases, the morphologic light microscopy criteria for a diagnosis of malignant mesothelioma were present. […] Four of the 18 cases were examined by electron microscopy, which revealed long thin microvilli supporting a diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16332304&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: early diagnosis and multimodality management].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this work the Authors are reporting their experience with malignant pleural mesothelioma, stressing the role of videothoracoscopy in the early diagnosis, weighing the radical cancer resection option and the effectiveness of multimodal treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16343925&#34; target=&#34;_blank&#34;&gt;Multimodality approach in management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis depends on the stage of the tumor at the time of diagnosis, its histological type, lymph node status, and resection margins. […] While the diagnosis is often delayed, earlier intervention may improve life expectancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16355399&#34; target=&#34;_blank&#34;&gt;Malignant biphasic pleural mesothelioma metastatic to the liver diagnosed by fine-needle aspiration.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we report a unique case in which the diagnosis of metastatic pleural mesothelioma was made via cytologic examination of a fine-needle aspiration (FNA) of the liver. […] To the best of our knowledge, the diagnosis of malignant pleural mesothelioma metastatic to the liver made by FNA has not been previously documented.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16366102&#34; target=&#34;_blank&#34;&gt;Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration–a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
FNAC is accurate and efficient, in conjugation with clinical history, and it also prevents surgical biopsy in the diagnosis of metastatic subcutaneous lesion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1638933&#34; target=&#34;_blank&#34;&gt;Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of regression analysis suggest that many of the previously described cytologic features are not important diagnostic discriminators.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1638937&#34; target=&#34;_blank&#34;&gt;Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differentiating mesothelioma, reactive mesothelium, and adenocarcinoma in serous effusions is often difficult, despite the application of ancillary techniques in support of the traditional cytomorphologic criteria.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16395604&#34; target=&#34;_blank&#34;&gt;[Magnetic resonance imaging in the evaluation of pneumonia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, fast imaging techniques are required which should also allow for high spatial resolution so that small lesions can be detected. […] Thin section CT is standard for the diagnosis of pneumonia. […] With parallel imaging techniques, MRI examination of the lungs can be performed with short periods of breath holding, which allow for sub-centimeter resolution in the z-axis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1643319&#34; target=&#34;_blank&#34;&gt;Chemotherapy for intrathoracic cancer in dogs and cats.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Neoplasms arising from these structures are frequently advanced at the time of diagnosis, and surgery is rarely curative for malignant processes. […] This article reviews the epidemiology, clinical features, and diagnosis of pulmonary neoplasia; mediastinal neoplasia, particularly thymoma; and pleural neoplasia, with emphasis on mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16434257&#34; target=&#34;_blank&#34;&gt;Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Quantitative reverse transcription-polymerase chain reaction, Western blotting, trypan blue exclusion, and ApoBrdU techniques were used to evaluate DNMT expression, proliferation, and apoptosis after antisense oligo transfections. […] Gene expression profiles were assessed by using long-oligo array techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16435096&#34; target=&#34;_blank&#34;&gt;[Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The morphological diagnosis of small mesothelial lesions in pleural biopsies is gaining importance in view of more aggressive, multimodal therapeutic options and of medicolegal aspects if a malignant mesothelioma is diagnosed. […] In case of atypical mesothelial proliferations, further diagnostic procedures have to be performed to obtain a clear diagnosis of malignancy. […] Mesothelioma in situ is the first morphological step in neoplastic mesothelial changes, also with regard to medicolegal aspects for the unambiguous diagnosis of a mesothelioma. […] A useful immunohistochemical panel for the differential diagnosis consists of anti-cytokeratin, Ck 5/6, calretinin, EMA and MiB-1, whereas the immunohistochemical detection of telomerase is not helpful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16447785&#34; target=&#34;_blank&#34;&gt;[Adenosine deaminase 2 in the diagnosis of tuberculous pleuritis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We examined the usefulness of adenosine deaminase 2 (ADA2) in the diagnosis of tuberculous pleuritis. […] In the diagnosis of tuberculous pleuritis, pleural ADA showed 100% sensitivity and 88% specificity, whereas pleural ADA2 showed 100% sensitivity and 91% specificity. […] Pleural ADA2 is useful in the diagnosis of tuberculous pleuritis, which has similar sensitivity and a little better specificity compared with pleural ADA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16456138&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of malignant pleural mesothelioma is a challenging issue. […] Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet. […] We show that SMRPs may be a promising marker for mesothelioma diagnosis when measured either in serum or pleural fluid. […] The diagnostic value of SMRPs was similar in both types of samples, but pleural fluid SMRPs may better discriminate mesothelioma from pleural metastasis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16457428&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma and the working environment: the viewpoint of the occupational physician.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A prompt and thorough assessment of exposure is essential to evaluate and manage MM cases, from diagnostic and epidemiological points of view. […] The main areas of interest of the OP are exposure assessment, diagnosis (clinical, etiological), medico-legal issues, social consequences, preventive strategies, risk communication, scientific dispute/uncertainties. […] The main outcomes of OP activity are the high percentage of direct interviews, individual case management, expert exposure assessment, etiological diagnosis, counselling, medico-legal assistance, better knowledge of occupational risks, enhanced cooperation among health professionals (oncologists, pathologists, surgeons, pneumologists, general practitioners and OP), important contribution to Registries and to epidemiology (estimates of attributable risks, incidence, survival rates), with positive social and scientific consequences (insurance agencies, trade union organizations, public events, teaching opportunities).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16457432&#34; target=&#34;_blank&#34;&gt;Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For each “possible case” reported to the Registry by Lombardy hospitals, diagnosis is ascertained according to ISPESL Guidelines. […] After revision of clinical records, diagnosis was judged as “certain” MM in 307 (60%) subjects, probable in 63 (12%) and possible in 33 (6%) subjects. 21 were peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16457433&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite unquestionable improvement in the diagnostic methods at our disposal and the availability of new treatment strategies, the prognosis of MMe patients remains dramatically poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16459635&#34; target=&#34;_blank&#34;&gt;Computed tomographic characterization of malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With the use of the Z-score and interpretative small bowel findings a radiologic characterization of this disease for primary radiologic diagnosis is possible.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1646682&#34; target=&#34;_blank&#34;&gt;Lung asbestos fiber content and mesothelioma cell type, site, and survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival from time of provisional diagnosis was significantly longer for epithelial (mean, 13 months; standard deviation [SD], 12.8) and mixed (mean, 10.2 months; SD, 8.7) types than sarcomatous cell types (mean, 5.8 months; SD, 6.5; P less than 0.0001, by analysis of variance on log10 survival time).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16469823&#34; target=&#34;_blank&#34;&gt;The French National Mesothelioma Surveillance Program.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its objectives are to estimate the trends in mesothelioma incidence and the proportion attributable to occupational asbestos exposure, to help improve its pathology diagnosis, to assess its compensation as an occupational disease, and to contribute to research. […] A standardised procedure of pathological and clinical diagnosis ascertainment is used. […] The initial pathologist’s diagnosis was confirmed in 67% of cases, ruled out in 13%, and left uncertain in the others; for half of the latter, the clinical findings supported a mesothelioma diagnosis. […] The NMSP is a large scale epidemiological surveillance system with several original aspects, providing important information to improve the knowledge of malignant pleural mesothelioma, such as monitoring the evolution of its incidence, of high risk occupations and economic sectors, and improving pathology techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16500906&#34; target=&#34;_blank&#34;&gt;Occupational asbestos exposure: how to deal with suspected mesothelioma cases–the Dutch approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the majority of cases, the diagnosis is clear but in some, uncertainty remains. […] These cases were presented to the Mesothelioma Group to obtain a clinical diagnosis based on clinical reports, occupational history, X-ray examination and other factors. […] The majority view was binding for acceptance or rejection of the diagnosis. […] In 161 cases no definitive diagnosis could be made on pathology and were presented to the Mesothelioma Group. […] Of these cases, 117 (73%) were considered to be compatible with the clinical diagnosis malignant pleural mesothelioma. […] In 75% of the cases (112 of 150), the conclusion of the three independent specialists was unanimous; in 11 cases one specialist refrained from a diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16505274&#34; target=&#34;_blank&#34;&gt;Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results show that malignant mesotheliomas have a lower expression of claudins 1, 3, 4, 5, and 7 than adenocarcinomas, and their expression could thus be used as an adjunct in differential diagnosis between the two.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1651579&#34; target=&#34;_blank&#34;&gt;Confronting cisternae and ciliated cells in malignant pleural mesothelioma: an ultrastructural study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The incidence of malignant mesothelioma of the pleura has recently increased in Japan, and ultrastructural and immunohistochemical studies can help in the histopathologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16535801&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis can be made only on the basis of excised tumor tissue.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16537873&#34; target=&#34;_blank&#34;&gt;Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the use of video-assisted thoracoscopy has improved the diagnostic accuracy in patients presenting with pleural diseases, not all biopsies performed are conclusive and staging of the disease is not always optimal. […] Fluorescence diagnosis (FD) with 5-aminolaevulinic acid (5-ALA) has been used in the diagnostic workup for various malignancies. […] The impact of 5-ALA-mediated FD on diagnosis and staging during video-assisted thoracoscopy was examined. […] A definitive diagnosis was obtained in 24 of 25 cases, with malignant mesothelioma in 15 cases, other malignancies in 5 cases, one infection, and three benign diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16612848&#34; target=&#34;_blank&#34;&gt;[Thoracoscopic pleurodesis in malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The surgical procedure consist in diagnostic of thoracoscopy with drainage of pleural effusion, multiply pleural biopsy, pleurodesis and continuous pleural drainage.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16625092&#34; target=&#34;_blank&#34;&gt;h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although a large number of immunohistochemical markers that can facilitate the differential diagnosis between epithelioid pleural mesothelioma and lung adenocarcinoma involving the pleura have proven to be valuable, no single antibody has demonstrated absolute sensitivity and/or specificity in making this distinction. […] We conclude that h-caldesmon is a highly sensitive and specific marker and suggest its inclusion in the immunohistochemical panel for the differential diagnosis of epithelioid mesothelioma versus lung adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16632152&#34; target=&#34;_blank&#34;&gt;Computed tomography findings in 66 patients with malignant pleural mesothelioma due to environmental exposure to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although none of these findings are pathognomonic for MPM, they may provide valuable clues for the differential diagnosis, at least in patients with a history of asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16670667&#34; target=&#34;_blank&#34;&gt;[18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
FDG-PET can discriminate between malignant and benign pleural tumors FDG uptake in the pleura is the best diagnostic criteria of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16679752&#34; target=&#34;_blank&#34;&gt;Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We reviewed survival data in patients treated with thoracoscopic talc pleurodesis whose final diagnosis was epithelial malignant pleural mesothelioma and whose chart recorded a ppH determination performed just before thoracoscopy. […] Patients with ppH&amp;gt;.32 lived a median of 21.2 months (95% confidence interval 16.5-30.0 months) after diagnosis compared with patients who had ppH &amp;lt;or=7.32 and lived a median of 13.4 months (95% confidence interval 4.5-16.2 months; p=0.0194).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16683083&#34; target=&#34;_blank&#34;&gt;Imaging before and after multimodal treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Computed tomography (CT), magnetic resonance (MR) and positron emission tomography (PET) have a very important role in the diagnosis of malignant pleural mesothelioma (MPM) in the choice of chemoradiotherapy alone or in combination with surgery and in evaluating possible recurrence. […] We considered 28 patients suffering from MPM whose mean survival after diagnosis was 15-18 months. […] CT, PET and CT-PET are indicated for diagnosis and, above all, for staging of MPM, in the selection of patients who might benefit from surgery after neoadjuvant therapy and also in identifying small recurrences and/or remote metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16683892&#34; target=&#34;_blank&#34;&gt;Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The average survival after diagnosis was 6 weeks or less. […] Length of survival following diagnosis is bleak.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16698098&#34; target=&#34;_blank&#34;&gt;A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For all patients, the PTV was well covered and doses to critical structures were clinically acceptable for all patients with both techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16716813&#34; target=&#34;_blank&#34;&gt;Imaging of pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging plays an important role in the diagnosis and subsequent management of patients with pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16716822&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article summarizes important advances in the management of mesothelioma, especially diagnostic and therapeutic aspects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1672261&#34; target=&#34;_blank&#34;&gt;Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was made by thoracoscopic examination and all cases were confirmed by the French Mesothelioma Panel of Pathologist.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16731600&#34; target=&#34;_blank&#34;&gt;My approach to the diagnosis of mesothelial lesions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies. […] In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16738897&#34; target=&#34;_blank&#34;&gt;Nodular glomeruloid pleuroblastoma: a biphasic pleural-based malignant tumor with immature elements.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic problems and medicolegal issues surrounding the diagnosis and differentiation from malignant pleural mesothelioma and other tumors are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16740034&#34; target=&#34;_blank&#34;&gt;Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differences in expression may potentially help distinguish MRCC from DMM inasmuch as strong and diffuse expression of RCCMa and CD10 supports a diagnosis of MRCC over DMM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16770231&#34; target=&#34;_blank&#34;&gt;Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis is poor with a median survival of 8 to 18 months after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16771925&#34; target=&#34;_blank&#34;&gt;Subarachnoid-pleural fistula as a complication of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A subarachnoid-pleural fistula has to be included in the differential diagnosis of patients with recurrent pleural effusions after surgical debulkment of malignant pleural mesothelioma. […] The beta-trace protein may help to establish this diagnosis especially in cases where important therapeutic consequences may need to be drawn.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16778273&#34; target=&#34;_blank&#34;&gt;The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Blind percutaneous pleural biopsy has traditionally been performed to investigate the etiology of exudative pleural effusion in which the initial thoracentesis has been nondiagnostic. […] All patients had presented to respiratory teams with an exudative pleural effusion and had initial nondiagnostic thoracentesis. […] For all diagnoses, blind biopsy had a sensitivity of 38%, which rose to 43% when reviewing patients in whom sufficient pleural tissue was obtained (for malignant diagnosis alone, sensitivity values were 43% and 51%, respectively; specificity, 100%; negative and positive predictive values, 51%). […] Blind Abrams needle biopsy obtaining pleural tissue was diagnostic in approximately 50% of patients presenting with malignant effusion in the sample, and can be performed safely by all grades of medical staff with due attention to technique and supervision.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16778277&#34; target=&#34;_blank&#34;&gt;Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nineteen patients with a diagnosis of MPM who were scheduled to receive chemotherapy with gemcitabine were enrolled in the study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16785767&#34; target=&#34;_blank&#34;&gt;D2-40: a reliable marker in the diagnosis of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We regard D2-40 as a valid marker in the differential diagnosis of epithelioid mesotheliomas versus pulmonary adenocarcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16795078&#34; target=&#34;_blank&#34;&gt;Cellular and molecular parameters of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These have revealed expression profiles that allow more accurate diagnosis and prognosis of MMs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16814945&#34; target=&#34;_blank&#34;&gt;Epithelioid and sarcomatoid malignant pleural mesothelioma in endoscopic gastric biopsies: a diagnostic pitfall.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Encountering MM in endoscopic GI biopsies is an exceptionally rare event in surgical pathology practice and may therefore pose great diagnostic challenges if not considered, in particular if the clinical history is not informative or the GI symptoms are the presenting signs of the disease. […] We herein present the first two cases of MM (one each of EM and SM) of the pleura, presenting in endoscopic gastric biopsies as small polypoid lesions and poorly healing ulcers 30 and 35 months after the initial diagnosis of pleural MM, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16819331&#34; target=&#34;_blank&#34;&gt;D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Another challenging issue especially in the field of serous effusions is the differential diagnosis between malignant mesothelioma and metastatic adenocarcinoma. […] The aim of this study was to evaluate the potential use of the D2-40 antibody detecting the M2A oncofetal antigen in the diagnosis of malignant serous effusions. […] The results from the present study suggest low specificity for D2-40 as a mesothelial marker, especially in the context of differentiating mesothelial cells from ovarian carcinoma, and argue against its inclusion in the diagnostic panel of serous effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16820238&#34; target=&#34;_blank&#34;&gt;The role of radiation therapy in malignant pleural mesothelioma: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three small randomized controlled trials compared prophylactic external beam radiation therapy to no radiation therapy for patients with thoracic tracts caused by drainage tubes or diagnostic procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16850492&#34; target=&#34;_blank&#34;&gt;The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the study was to establish in a prospective and blinded manner the diagnostic yield of morphology, immunocytochemistry (ICH) and electron microscopy (EM) in the cytological analysis of malignant pleural mesothelioma (MPM). […] We concluded that the high post-test probability of a combined morphological and ICH diagnosis of MPM warrants to cease further diagnostic procedures in these patients. […] Electron microscopy did not add to accuracy of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16858151&#34; target=&#34;_blank&#34;&gt;The diagnosis of malignancy in effusion cytology: a pattern recognition approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review presents a pattern recognition approach for the diagnosis of malignant effusions. […] An algorithmic approach to the workup of serous effusions as well as pitfalls for false-positive diagnosis are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-09-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1689538&#34; target=&#34;_blank&#34;&gt;The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival from time of diagnosis for all 38 patients was 9 months, with an estimated 2-year survival rate of 16%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1690413&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although no other primary tumors were detected, in 10 cases the differential diagnosis of adenocarcinoma had to be considered, and in 3 cases tumors of non-epithelial origin had to be excluded. 35 of 43 mesothelioma were CEA-negative, 38 out of 43 cytokeratin-positive, and 33 out of 43 were EMA-positive. […] Although CEA may not be negative in every mesothelioma, this marker seems to be a valid tool for the differential diagnosis of adenocarcinoma. […] In order to safeguard against a mistaken diagnosis of pleural mesothelioma, the exclusion of other tumors is always indispensable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16916393&#34; target=&#34;_blank&#34;&gt;Diagnostic value of thoracoscopic pleural biopsy for pleurisy under local anaesthesia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, it is difficult to make a diagnosis definitively by thoracocentesis or closed pleural biopsy. […] We directly examine the thoracic cavity by thoracoscopy under local anaesthesia, carry out pleural biopsy and make a definitive pathological diagnosis in pleurisy. […] The overall diagnostic efficacy was 97.1% (134/138). […] The diagnostic efficacy in the cases of carcinoma was 92.6% (25/27), in malignant pleural mesothelioma it was 100% (10/10) and in tuberculosis it was 93.8% (30/32). […] Pleural biopsy by thoracoscopy under local anaesthesia should be actively carried out in patients with pleurisy, because the technique has a high diagnostic rate and can be easily and safely carried out.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16925806&#34; target=&#34;_blank&#34;&gt;Tumor suppressor gene alterations in patients with malignant mesothelioma due to environmental asbestos exposure in Turkey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We believe that this study will provide important support for other research into molecular-genetic variations, both on this subject and other malignancies, and may also constitute a base for early diagnosis and gene therapy research in the future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16959711&#34; target=&#34;_blank&#34;&gt;Exclusive intrapulmonary lepidic growth of a malignant pleural mesothelioma presenting with pneumothorax and involving the peritoneum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The morphologic clues leading to the correct diagnosis of mesothelioma with prominent intrapulmonary growth are briefly discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16982467&#34; target=&#34;_blank&#34;&gt;An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On most occasions, radiological diagnosis is easy, owing to current imaging studies like computerized tomography. […] Additionally, the radiological diagnosis of thymoma can be differentiated easily from malignant pleural mesothelioma in most cases. […] However, thymoma’s differentiation from lymphoma, thymic hyperplasia, or thymic remnants sometimes may pose diagnostic challenges.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/16983974&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura among seafarers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of mesothelioma was confirmed by necropsy in 38 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1700353&#34; target=&#34;_blank&#34;&gt;[New challenges in thoracic surgery as exemplified in asbestos exposure and mesothelioma treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic difficulties persist and the disease may remain undiagnosed in spite of multiple fluid aspirations and percutaneous needle biopsies. […] Thoracic surgery efficiently contributes to the diagnostic yield by thoracoscopy and, with unilateral disease, in functionally operable patients, preferably by diagnostic thoracotomy. […] This will facilitate not only the differential diagnosis but also the answer to the question of aetiology in support of the patients’ and their families’ claim for compensation to be paid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17005770&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To retrospectively compare the sensitivity of image-guided core-needle biopsy, thoracoscopy, and thoracotomy in the diagnosis of malignant pleural mesothelioma and to retrospectively determine the incidence of needle track seeding after these procedures. […] The sensitivity of diagnostic procedures and the incidence of needle track seeding as a result of intervention were calculated. […] Image-guided core-needle biopsy in patients with malignant pleural mesothelioma has a lower incidence of needle track seeding than surgical biopsy and has a high sensitivity for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17009682&#34; target=&#34;_blank&#34;&gt;Diagnosis of asbestos-related pleuropolmonary diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A revision of criteria for diagnosis of asbestos-related pathological conditions was performed studying specially asbestosis, pleural plaques and malignant mesothelioma, also taking into account the problems connected with histopathology. […] As regards the histological diagnosis of asbestosis, it requires the presence of diffuse interstitialfibrosis in a well inflated tissue remote from the site of a tumour or other large lesion, plus the presence of two or more asbestos bodies in a 1 cm2 section. […] As regards the imaging diagnosis, the HRTC 4-point scale proposed by Paris et al. (2004) has been adopted:–0 images not suggestive of interstitial pneumonia;–1 modest unilateral or bilateral interstitial abnormalities, involving restricted areas if bilateral;–2 interstitial abnormalities of limited extent, but consistent with a diagnosis of asbestosis, i.e. honeycombing, even without other parenchymal changes and even though unilateral, or else any two abnormal findings among thickened interlobular septa, intralobular lines or subpleural curved lines;–3 numerous bilateral changes on several slices involving more than 2/3 of the posterior third of each hemi thorax. […] Only points 2 and 3 were considered consistent with the diagnosis of lung fibrosis. […] Such HRCT findings are not specific for asbestosis, changes in the pleural wall such as diffuse plaques and thickenings contribute to the diagnosis of asbestosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17020984&#34; target=&#34;_blank&#34;&gt;Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Plasma DAC levels were evaluated by liquid chromatography-mass spectrometry techniques. […] Quantitative reverse transcription-PCR, methylation-specific PCR, and immunohistochemical techniques were used to evaluate NY-ESO-1, MAGE-3, and p16 expression in tumor biopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1703129&#34; target=&#34;_blank&#34;&gt;Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All 5 patients were males with known crocidolite asbestos exposure, who had received no treatment for their disease and in whom the diagnosis was confirmed by cytology, histology and electron microscopy (EM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17033611&#34; target=&#34;_blank&#34;&gt;5-year prospective results of trimodality treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most of the disease recurrences are loco-regional and the current insufficiency of intraoperative or postsurgical radicality needs improvement, along with earlier diagnosis, more accurate staging, and preoperative induction for the multimodality treatment of pleural mesothelioma to become an established curative option.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17044190&#34; target=&#34;_blank&#34;&gt;Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This paper examines the spectrum of challenges that confront the diagnostic surgical pathologist in distinguishing benign mesothelial hyperplasia from malignant mesothelioma. […] Practical guidelines are offered that should reduce the risk of diagnostic error in this problematic area of surgical pathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17044195&#34; target=&#34;_blank&#34;&gt;Spindle cell tumors of the pleura: differential diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Spindle cell tumors that arise in or metastasize to the pleura must be thoroughly evaluated to arrive at a definitive diagnosis. […] It is crucial to arrive at a correct diagnosis since many of these neoplasms show different prognoses and require varying treatment modalities. […] Here, we review morphological, clinical, histological, immunohistochemical, ultrastructural, and molecular methods that aid in the diagnosis of spindle cell tumors of the pleura, and we provide specific examples of patients in which this multi-modal approach proved to be helpful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1705090&#34; target=&#34;_blank&#34;&gt;The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors assessed its value in the diagnosis of lung carcinomas metastatic to lung/pleura and pleural malignant mesothelioma (MM), using cell blocks derived from cytologic specimens. […] The occurrence of one positive MM predicates caution in interpreting 44-3A6 positivity in isolation, but, judiciously used with other discriminating antibodies such as Leu-M1 and anti-CEA, 44-3A6 is of value in the differential diagnosis of ACs and MMs. […] Further, its applicability to cytologic specimens may obviate the need for more invasive diagnostic procedures and lead to rapid, accurate diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17067119&#34; target=&#34;_blank&#34;&gt;Can pemetrexed help in malignant mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is typically fatal, with a median survival of about 8-14 months after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17075297&#34; target=&#34;_blank&#34;&gt;Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma is complex and usually requires a multimodal approach that includes careful clinical history and physical examination, imaging studies, and tissue sampling for multimodal evaluation including routine histology, histochemistry, electron microscopy, and immunohistochemical tests. […] The immunohistochemical diagnosis of malignant mesothelioma therefore depends on the use of a panel of stains that includes markers that are commonly expected to react with these tumors (“positive” markers) and markers that are not commonly expected to react with these tumors (“negative” markers). […] Herein, we will review the currently available immunohistochemical markers used for the diagnosis of malignant mesothelioma and offer suggestions for the use of appropriate panels of stains based on specific morphologic types and clinical circumstances.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17075562&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a comprehensive review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors review the pathogenesis, incidence, clinical presentation, diagnosis, pathology, and both standard and experimental treatments for mesothelioma. […] The disease is expected to increase in incidence till 2020, so awareness of this entity as a possible diagnosis should be heightened.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17075563&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17075713&#34; target=&#34;_blank&#34;&gt;[Video-assisted diagnostic thoracoscopy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Transbronchial and transthoracal fine-needle aspiration biopsy usually cannot yield detailed diagnostic results because of its small size. […] Video-assisted thoracoscopy allows safe and fast diagnosis of diffuse lung diseases, pleural diseases including malignant mesothelioma, indeterminate peripheral lung nodule, and mediastinal masses. […] This gentle diagnostic method can give invaluable information guiding further management of the thoracic injury.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17078889&#34; target=&#34;_blank&#34;&gt;Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report four cases of female patients with MPM referred for palliation of symptoms thought to be due to previous non-pleural malignancy.With emerging novel treatments for MPM, this article discusses four unusual cases of MPM occurring in the setting of other malignancy, highlights the importance of considering a primary diagnosis of MPM even in patients with other malignancy, and reinforces the benefits of video-assisted surgical biopsy which allows simultaneous diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17087330&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in a 14-year-old boy with right aortic arch.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural biopsy by video-assisted thoracic surgery yielded a diagnosis of MPM, epithelial type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17087333&#34; target=&#34;_blank&#34;&gt;[Autopsy case of sarcomatoid malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differential diagnosis of sarcomatoid mesothelioma or rhabdomyosarcoma is made by immunohistochemical staining, but it is sometimes difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17088053&#34; target=&#34;_blank&#34;&gt;The Portsmouth thoracoscopy experience, an evaluation of service by retrospective case note analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical thoracoscopy is safe and effective in the diagnosis of benign and malignant pleural disease particularly in this high risk population.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17092602&#34; target=&#34;_blank&#34;&gt;Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eligible patients had a histologic or cytologic diagnosis of malignant mesothelioma that was not amenable to curative treatment with surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1710103&#34; target=&#34;_blank&#34;&gt;Intracranial metastases from malignant pleural mesothelioma. Report of three autopsy cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They are seen concomitantly with high-grade tumors, and by mimicking a primary tumor on a clinical, instrumental, and histologic ground, they may occasionally represent a potential source of diagnostic pitfall.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1710419&#34; target=&#34;_blank&#34;&gt;Immunocytochemical panel for the identification of malignant cells in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cytologic diagnosis of malignancy in serous effusions can be challenging. […] Use of this approach can improve the diagnostic accuracy of cytologic examination of serous fluids.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-07-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17117322&#34; target=&#34;_blank&#34;&gt;CT-guided percutaneous transthoracic biopsy in the evaluation of undetermined pulmonary lesions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
72 FNAB were considered adequate for cytology diagnosis; 72% of them positive for malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1712181&#34; target=&#34;_blank&#34;&gt;Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas–a clinicomorphological study of 158 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Formalin-fixed paraffin-embedded material of 158 diffuse malignant pleural mesotheliomas (DMPMs) was used in order to determine the differential diagnostic value of immunocytochemical probes against 9 different antigens. […] CEA and Leu-M1 staining of a given pleural tumour, on the other hand, is indicative of a carcinoma secondarily afflicting the pleura, thus making the diagnosis of primary DMPM unlikely.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17137779&#34; target=&#34;_blank&#34;&gt;Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MPM may be difficult because of differential diagnosis such as pleural benign disease induced by asbestos exposure or pleural metastasis of adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17163840&#34; target=&#34;_blank&#34;&gt;Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Individual results of immunohistochemistry for five diagnostic antibodies were extracted to calculate diagnostic sensitivity and specificity. results from five of these studies that had evaluated proliferation markers or AgNOR staining techniques were also summarized. […] Most antibodies demonstrated poor to moderate diagnostic ability. […] The combination of EMA and AgNOR was reported as having 95% diagnostic sensitivity. […] Immunohistochemistry is of limited value, but newer diagnostic methods may be useful additions in this area of pathology. […] The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17188885&#34; target=&#34;_blank&#34;&gt;A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All the patients had a diagnosis of MPM by thoracoscopy before inclusion. […] Only the Performance Status at the diagnosis affected survival significantly.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17192790&#34; target=&#34;_blank&#34;&gt;Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of the present study was to evaluate the diagnostic utility of GLUT-1 expression for diagnostic differentiation between RM and MPM. […] GLUT-1 is a sensitive and specific immunohistochemical marker enabling differential diagnosis of RM from MPM, whereas it cannot discriminate MPM from lung carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17203752&#34; target=&#34;_blank&#34;&gt;Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive treatment-resistant tumor with a median survival from diagnosis of 12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17233200&#34; target=&#34;_blank&#34;&gt;Metastatic malignant pleural mesothelioma to the breast.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleura biopsy was performed and the histologic diagnosis was malignant mesothelioma. […] The final histologic diagnosis was metastatic malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17237002&#34; target=&#34;_blank&#34;&gt;[Immunotherapy and malignant mesothelioma: clinical perspectives].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, recent progresses in early detection techniques also provide hope that patients can be treated efficiently, at an earlier stage and well monitored.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17242414&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: a case presentation and review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article describes a rare subtype of mesothelioma and illustrates the difficulty in establishing the diagnosis. […] Also included is a discussion of the clinical features, diagnostic dilemmas, and unsatisfactory outcome associated with this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249530&#34; target=&#34;_blank&#34;&gt;[Histopathologic diagnosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, confirming histopathologic diagnosis as mesothelioma, it should need not only histological examination but several methods such as special stain, immunohistochemical study, cytology of pleural effusion and electromicroscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249531&#34; target=&#34;_blank&#34;&gt;[Clinical diagnosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate and rapid diagnosis of malignant pleural mesothelioma is important because of its rapid progress. […] But diagnosis of this disease is often difficult. […] We reviewed 64 cases with a pathological diagnosis of malignant pleural mesothelioma in the past 14 years in our hospital. […] We made diagnosis of this disease by cytologic study of pleural fluid (11 cases), percutaneous needle biopsy (16), thoracoscopic biopsy (34), or surgery (2). […] When cytologic findings are inconclusive, thoracoscopic biopsy is the most effective method for diagnosis and should be done without delay.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249532&#34; target=&#34;_blank&#34;&gt;[Current problems in the diagnosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural mesothelioma (MPM) is challenging although MPM is highly aggressive tumor. […] The current diagnostic gold standard is principally based on light microscopic examination of hematoxylin-eosin and immunohistochemical stains of large tissue sections. […] However, pathological diagnosis of MPM and classification of histological findings into 1 of the 3 subtypes (epithelial, sarcomatoid, biphasic) are difficult. […] We studied correlation between initial and final histological diagnosis retrospectively from the records of 21 cases with MPM from 1989 to 2005. […] The diagnosis of MPM was confirmed by histopathological examination of pleural tissue samples obtained by closed biopsy under computed tomography (CT) or ultrasonography-guided (5 cases), by biopsy under thoracoscopy with local anesthesia (9), by open biopsy via thoracotomy (2), and by video-assisted thoracoscopic surgery (VATS) [5] . […] Pleural biopsy under those diagnostic methods led to initial diagnosis of MPM in 15 of 21 cases (71.4%) . […] In 6 cases (28.6%) , initial diagnosis of MPM were not confirmed because of missing malignant tissue (1 case) and relatively small and sarcomatous element (5). […] In 2 cases examined by closed biopsy and in 3 examined by thoracoscopy under local anesthesia, initial diagnosis of MPM were not confirmed. […] To get the accurate diagnosis of MPM, obtaining large tissue samples in the initial examination by less invasive thoracoscopy is recommended.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249536&#34; target=&#34;_blank&#34;&gt;[Diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A definitive diagnosis was made by closed pleural biopsy in 8 patients, pleural fluid cytology in 2, and autopsy in 1. […] Median period between presentation and diagnosis was 1 (range, 0 to 22) month. […] Median survival time after diagnosis was 3 (range, 0 to 51) months. […] Of the 11 patients, 7 (64%) died within 6 months after the first presentation, and only 1 (9%) lived longer than 2 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17249537&#34; target=&#34;_blank&#34;&gt;[Extrapleural pneumonectomy for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Preoperarive histological diagnosis was as follows: epithelial 12, biphasic 1, sarcomatous 1. […] Postoperative diagnosis was: 8, 5, 1, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17268732&#34; target=&#34;_blank&#34;&gt;Morphological aspects as prognostic factors in malignant mesothelioma: a study of 58 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Various markers have shown promise as diagnostic markers and prognostic predictors in malignant mesothelioma (MM). […] Through morphometric and immunological studies of markers in stromal components (calretinin, CEA, Leu-M1 and thrombomodulin) and nuclear components (p53 and Ki-67), we evaluated post-diagnosis survival in 58 patients with MM. […] Immunohistochemical quantification of thrombomodulin facilitated the diagnosis of mesothelioma in patients testing positive for both calretinin and CEA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17269529&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma with scalp, cerebellar, and finger metastases: a rare case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Distant metastases can be seen in MPM and a biopsy of metastatic regions can yield the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17279584&#34; target=&#34;_blank&#34;&gt;Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a challenging disease with regard to diagnosis and treatment; early and accurate diagnosis would lead to appropriate therapeutic strategies, including extrapleural pneumonectomy. […] Immunohistochemistry has proven valuable for the diagnosis of the most common epithelioid mesothelioma, although it is often difficult to differentiate it from pulmonary or metastatic adenocarcinoma with absolute certainty if a single antibody is employed. […] The current study was designed to identify an immunodiagnostic panel for pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17283842&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The symptomatology is insidious and poses difficult problems in diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17334349&#34; target=&#34;_blank&#34;&gt;Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of 328 cases included in our study, synovial sarcoma was either the primary diagnosis or was very high in the differential diagnosis in 134 cases: of these, amplifiable cDNA was obtained from 131. […] Following clinical input, a diagnosis of mesothelioma was favored in one case, a sarcoma, not otherwise specified in another and a solitary fibrous tumor in the third case.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17337201&#34; target=&#34;_blank&#34;&gt;Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean survival from diagnosis was 15 months in the EPP group and 16 months for those who underwent P/D (p=0.4).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17339766&#34; target=&#34;_blank&#34;&gt;Palliative intravenous cisplatin treatment for concurrent peritoneal and pleural mesothelioma in a dog.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The survival time from diagnosis to sudden death by unknown cause was 153 days.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17349242&#34; target=&#34;_blank&#34;&gt;[Immunohistochemistry and surgical approaches in solitary fibrous tumor of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only four patients were symptomatic at diagnosis. […] In our opinion, VTC is a less invasive diagnostic and therapeutic approach than thoracotomy that provides an adequate approach for the resection of SFTP in selected patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17352172&#34; target=&#34;_blank&#34;&gt;[Clinico-pathological prognostic factors in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Univariate analysis of subgroups showed that age over 70 years, non-epithelial histologic type, patients treated with supportive care only, and delayed diagnosis were individually associated with lower survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17356060&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma is frequently difficult, the most common differential diagnosis being reactive pleural conditions and metastatic adenocarcinoma. […] In 7 out of 10 cases mesothelin levels were raised in the effusion collected 3 weeks to 10 months before the diagnosis of mesothelioma was made; in 4 out of 8 of these, mesothelin levels were increased in the effusion but not in the serum. […] Measurement of mesothelin concentrations in the pleural and/or peritoneal effusion of patients may aid in the differential diagnosis of mesothelioma in patients presenting with effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17361207&#34; target=&#34;_blank&#34;&gt;D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These data indicate that a combination of calretinin and D2-40 will improve diagnostic accuracy for spindle cell lesions of the pleura, whereas almost all epithelioid mesotheliomas are identified by calretinin alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17375514&#34; target=&#34;_blank&#34;&gt;Asbestos-related lung disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with a history of significant asbestos exposure may warrant diagnostic testing and follow-up assessment, although it is unclear whether this improves outcomes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17377812&#34; target=&#34;_blank&#34;&gt;Cytological diagnosis of malignant mesothelioma–improvement by additional analysis of hyaluronic acid in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytology allows the diagnosis of malignant mesothelioma (MM) from effusions with high specificity but low sensitivity. […] We studied whether the cytological diagnosis of MM could be improved by HA analysis. […] The cut-off value of HA showing maximum diagnostic reliability (86%) regarding MM was 30 mg/l (sensitivity 87%, specificity 86%). […] We conclude that the combined cytological and HA analysis of pleural effusions had the potential to improve the diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17385835&#34; target=&#34;_blank&#34;&gt;Retroperitoneal malignant schwannoma and peritoneal malignant mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
She died 3 years after the first diagnosis. […] Early diagnosis of these two types of tumors is very difficult because of unspecific clinical symptoms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17388868&#34; target=&#34;_blank&#34;&gt;Medical thoracoscopy in an Australian regional hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The sensitivity for a malignant diagnosis was 94.5%, with 100% specificity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17407142&#34; target=&#34;_blank&#34;&gt;Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mesothelioma profile in consanguineous is the same as in non-consanguineous subjects (male prevalence; pleural site; age at diagnosis &amp;gt;50 years; asbestos exposure).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17415849&#34; target=&#34;_blank&#34;&gt;Diagnostic procedures of pleural malignant mesothelioma: our experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the value of immunohistochemistry in the accurate diagnosis of MM, especially of the epithelioid type with needle biopsy of the pleura. […] The diagnosis of MM was established with pleural needle biopsy and tumor immunophenotyping in 30 patients. […] The accurate diagnosis of MM is mandatory for appropriate treatment decision (surgical or nonsurgical). […] Our results demonstrate that HMBE-1 is a most useful diagnostic antibody for epithelioid MM, and TTF-1 for lung adenocarcinoma (its thyroid origin excluded) involving pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17415923&#34; target=&#34;_blank&#34;&gt;Fine-needle aspiration of malignant mesothelioma with unusual morphologic features: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was confirmed by immuno-histochemical and electron microscopic studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17419436&#34; target=&#34;_blank&#34;&gt;[A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of squamous cell lung cancer was made based on bronchial washing cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17435414&#34; target=&#34;_blank&#34;&gt;A large abdominal wall mass as an initial manifestation of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite further radiotherapy, the patient died of cardiac tamponade due to tumor invasion 38 months after the initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17444175&#34; target=&#34;_blank&#34;&gt;Late-onset chylothorax following extrapleural pneumonectomy for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We made a diagnosis of postoperative late-onset chylothorax based on the laboratory data obtained from tests of the pleural fluid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1744496&#34; target=&#34;_blank&#34;&gt;Superior vena cava syndrome associated with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 70-year-old former shipyard worker presented with dyspnea and edema of the upper thorax suggesting the diagnosis of superior vena cava syndrome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-01-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1744800&#34; target=&#34;_blank&#34;&gt;Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In pleural or ascitic effusions the cytomorphological distinction of adenocarcinoma cells, reactive mesothelial cells, and malignant mesothelioma cells often causes a diagnostic dilemma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17455100&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with intracytoplasmic crystalline inclusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical information initially received was poor and electron microscopy was essential in making the correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17475364&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma following thoracic radiotherapy for lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Opacification of the lung field from prior therapy made determination of the diagnosis more challenging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17484626&#34; target=&#34;_blank&#34;&gt;Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We assessed the analytical performance of the Mesomark (Fujirebio Diagnostic) two-step ELISA on an automated analyser and performed a preliminary clinical evaluation. […] The serum marker was analysed in 109 healthy subjects never exposed to asbestos, 26 healthy subjects exposed to asbestos, 33 patients with asbestosis, 33 with asbestos-related pleural plaques, 10 with non-malignant pleural diseases, 30 with lung cancer and 24 with histological diagnosis of pleural mesothelioma. […] SMRP measured on automated systems could be useful for the diagnosis of mesothelioma in routine clinical practice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17492119&#34; target=&#34;_blank&#34;&gt;Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is based on a visual investigation of CT images, which is a time-consuming and subjective procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17497664&#34; target=&#34;_blank&#34;&gt;Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction between malignant mesothelioma and adenocarcinoma is a diagnostic challenge in cytologic specimens of effusion fluids.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17504993&#34; target=&#34;_blank&#34;&gt;Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects. […] Results were correlated with patient’s diagnosis and survival. […] Osteopontin has a lower diagnostic accuracy than mesothelin in patients suspected of MPM. […] Insufficient specificity limits osteopontin utility as diagnostic marker.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17509990&#34; target=&#34;_blank&#34;&gt;The diagnostic role of claudins in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analyzed the diagnostic role of claudins in effusion cytology in 325 effusions, including 218 ovarian, 49 breast, 15 cervical or endometrial, 10 gastrointestinal, and 8 lung adenocarcinomas and 25 malignant mesotheliomas (MMs). […] Our data suggest that expression of claudin-3 or claudin-7 is specific for adenocarcinoma and rules out the diagnosis of cells as mesothelial and that absence of claudin-1 expression excludes ovarian carcinoma as the possible origin of metastatic adenocarcinoma. […] Claudins may, therefore, be of diagnostic value in effusion cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17521217&#34; target=&#34;_blank&#34;&gt;Management options for malignant pleural mesothelioma: clinical and cost considerations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While surgical resection and radiotherapy techniques have been refined in recent years, neither has been proven to significantly extend patient survival compared with untreated controls.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17525624&#34; target=&#34;_blank&#34;&gt;Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for their individual practices. […] Odds ratios (ORs) were employed to compare the effectiveness of any single test, and chosen combinations thereof, in the differential diagnosis of malignant mesothelioma and metastatic pulmonary adenocarcinoma. […] These results support the potential value of systematic reviews, meta-analysis, and OR calculations for development of EBG in diagnostic immunohistology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17536770&#34; target=&#34;_blank&#34;&gt;MN/CA9: a potential gene marker for detection of malignant cells in effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The presence of malignant cells in effusions has implications in diagnosis, tumour staging and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17541913&#34; target=&#34;_blank&#34;&gt;[A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult. […] In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory. […] Immunohistochemical staining fails to identify a reactive process, but a diffuse, positive stain for EMA and the presence of protein p53 support the diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17583136&#34; target=&#34;_blank&#34;&gt;[Management of malignant pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histological diagnosis is difficult, relying on a standardized immunohistochemical analysis. […] PET imaging could be of major interest in the diagnosis of mesothelioma and prognosis evaluation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17588698&#34; target=&#34;_blank&#34;&gt;A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with a histological diagnosis of pleural mesothelioma and an invasive procedure within the preceding 21 days were stratified by age, performance status and treatment centre.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17590095&#34; target=&#34;_blank&#34;&gt;[Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Positron emission tomography combined with computed tomography (PET/TC) was useful for a supporting diagnosis and to determine the extension.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17607128&#34; target=&#34;_blank&#34;&gt;Constrictive pericarditis after left extrapleural pneumonectomy and radiotherapy for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of constrictive pericarditis was made late in the clinical course after exhaustive investigation to exclude primary disease recurrence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17610473&#34; target=&#34;_blank&#34;&gt;Evaluation of simian virus-40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of the present paper was to investigate 40 Egyptian MPM patients for the presence of SV40 DNA, altered Rb expression and p53 gene status using immunohistochemistry and molecular techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17642217&#34; target=&#34;_blank&#34;&gt;[Pseudomesotheliomatous carcinoma of the lung].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pseudomesotheliomatous carcinoma is the lung cancer with marked pleural extension resembling malignant pleural mesothelioma on diagnostic imaging. […] Pleural tissue sampling was performed to obtain definitive diagnosis by video-assisted thoracoscopic surgery. […] Final diagnosis was adenocarcinoma of the lung.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17646232&#34; target=&#34;_blank&#34;&gt;Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serum markers would be useful for the diagnosis of this disease. […] The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma. […] Serum levels of mesothelin and CA125 were determined by commercially available assays in 117 samples obtained at diagnosis from patients with pleural malignant mesothelioma, 33 healthy, asbestos-exposed individuals, 53 patients with asbestos-related lung or pleural disease, and 30 patients presenting with benign pleural effusions. […] Cross-validated sensitivities were determined, and receiver operator characteristic curves were generated to compare the diagnostic accuracy of the biomarkers. […] Combining mesothelin and CA125 data does not improve the sensitivity of mesothelioma diagnosis over mesothelin alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17659810&#34; target=&#34;_blank&#34;&gt;DNA methylation profile of 28 potential marker loci in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MM is difficult to diagnose without invasive techniques; the development of non-invasively detectable molecular markers would therefore be highly beneficial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17663051&#34; target=&#34;_blank&#34;&gt;[Case of asbestosis with massive benign pleural involvement].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For diagnosis verification, videothoracoscopy with target biopsy of the nodes was performed. […] Histologic diagnosis - fragments of dense fibrous connective tissue. […] The authors stress importance of contemporary diagnostic techniques in occupational pathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17669981&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: outcome of limited surgical management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Fifteen patients received only diagnostic direct pleural biopsy, 40 had video-assisted thoracoscopic, pleural biopsy and talc pleurodesis while 15 patients underwent thoracotomy and pleurectomy for disease confined to the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17673616&#34; target=&#34;_blank&#34;&gt;Multidisciplinary treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Difficulties in MPM diagnosis and staging, especially of early disease, have thwarted the development of a universally accepted therapeutic approach. […] In the past few years, there have been several major advances in the management of patients with MPM, including more accurate staging and patient selection, improvements in surgical techniques and postoperative care, novel chemotherapy regimens with definite activity such as antifolate (pemetrexed or raltitrexed)-platinum combinations, and new radiotherapy techniques such as intensity-modulated radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17685935&#34; target=&#34;_blank&#34;&gt;D2-40-positive solitary fibrous tumors of the pleura: diagnostic pitfall of biopsy specimen.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
D2-40 is a new monoclonal antibody recognizing podoplanin and several studies have confirmed the reliability of D2-40 in the diagnosis of pleural mesothelioma. […] Percutaneous needle biopsy indicated a spindle-cell tumor showing positive immunoreactivity for CD34, supporting the diagnosis of SFTP. […] The tumor was surgically resected to make a definitive pathological diagnosis. […] Therefore a pathological diagnosis of SFTP was made. […] Care is required in diagnosing biopsy specimens of D2-40-positive pleural spindle-cell tumors, especially in making the differential diagnosis between SFTP and malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17686442&#34; target=&#34;_blank&#34;&gt;Optimising survival in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, early diagnosis by means of tumour markers and genomic analysis is still under investigation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17702624&#34; target=&#34;_blank&#34;&gt;Accuracy and reproducibility of pleural effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic accuracy, interobserver and intraobserver agreement in the distinction of benign vs malignant cases, and in the differentiation of primary from metastatic malignancies, were evaluated. […] Cytology is a useful and reliable tool in the identification of malignancies, but when the distinction of primary from metastatic tumors is addressed morphological criteria alone are not sufficient for a definite diagnosis of MM and the use of cell blocks, immunohistochemistry (IHC) and molecular ancillary techniques are recommended.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17723954&#34; target=&#34;_blank&#34;&gt;[Family mesotheliomas: genetic interaction with environmental carcinogenic exposure?].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our patient was refered to hospital for a malignant mesthelioma 22 years after the prior diagnosis of a mesothelioma in his brother.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17763671&#34; target=&#34;_blank&#34;&gt;[Clinical utility of thoracoscopy under local anesthesia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy has been recently established as an indispensable technique for diagnosis and treatment of respiratory diseases. […] The main objective of medical thoracoscopy under local anesthesia is to establish a diagnosis of pleural effusions by means of observation and biopsy in the thoracic cavity. […] These 3 diseases are the diseases with which medical thoracoscopy is most useful because they can be reliably diagnosed by biopsies and because early diagnosis and early treatment are essential. […] Scince medical thoracoscopy under local anesthesia is rapid, easy, safe, and well-tolerated procedure with an excellent diagnostic yield, it is recommended as a diagnostic procedure for cases with pleural diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-10-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17764849&#34; target=&#34;_blank&#34;&gt;Assessment of tumor response in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Computer-assisted techniques for CT measurement are being developed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1783086&#34; target=&#34;_blank&#34;&gt;Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This finding was a valuable diagnostic tool, especially in cases of large amounts of pleural effusion and/or only thin layers of tumour barely or not at all visible on plain film chest X-rays.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1788224&#34; target=&#34;_blank&#34;&gt;[Differential diagnosis of pleurisy of tuberculous etiology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A combined ++clinico-roentgenological+ examination of 367 patients with a pleurisy syndrome was aimed at the study of a potential establishment of the etiologic diagnosis of the disease. […] The etiologic diagnosis of tuberculous pleurisy was most difficult in 96% of the patients who exhibited prolonged and stable maintenance of exudation or, on the contrary, very rapid regression of the pleural exudate without residual changes. […] Simultaneous morphologic and bacteriological examination of a pleural biopsy specimen contributed to the most efficacious and reliable diagnosis of tuberculous etiology of pleurisy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17886249&#34; target=&#34;_blank&#34;&gt;Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the current study was to analyze retrospectively the accuracy, sensitivity, and specificity of preoperative thoracoscopy for diagnosis of the histologic subtype of MPM. […] The histologic reports from all consecutive patients undergoing ‘intent-to-treat’ surgery from 3 institutions as well as the initial pathologic diagnosis obtained using thoracoscopy were reviewed and compared after institutional review board approval. […] Of the 95 patients with a final diagnosis of MPM, 80 (84.2%) were classified as having epithelial and 15 (15.8%) as having biphasic subtype. […] Among the 87 patients classified as having MPM of epithelial subtype after the initial thoracoscopy, 75 cases (86.2%) were confirmed to be a true histologic diagnosis and 12 cases (13.8%) were found to be of biphasic subtype at final diagnosis. […] The sensitivity and specificity values of an epithelial subtype diagnosis after thoracoscopy were 94% and 20%, respectively, with a positive predictive value of 86% and a negative predictive value of 37%. […] Conversely, the sensitivity and specificity values of a biphasic subtype diagnosis after thoracoscopy were 20% and 98%, respectively, with a positive predictive value of 75% and a negative predictive value of 87%. […] Pleural biopsy performed using thoracoscopy is considered to be the cornerstone of the diagnosis and pleural staging of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17909360&#34; target=&#34;_blank&#34;&gt;Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most studies describing the natural history and prognostic factors for malignant pleural mesothelioma antedate accurate pathologic diagnosis, staging by computed tomography, and a universal staging system.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17925668&#34; target=&#34;_blank&#34;&gt;[Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to determine the feasibility and the diagnostic contribution of genomic analysis of cells contained in pleural fluid, using DNA microarray techniques. […] Patients with pleural effusion requiring diagnostic thoracocentesis were eligible to participate in the study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17931793&#34; target=&#34;_blank&#34;&gt;Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both techniques yielded acceptable plans.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17947722&#34; target=&#34;_blank&#34;&gt;Phase II study of vinflunine in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with a histologically confirmed diagnosis of MPM were eligible for enrollment onto this multicenter phase II trial if they had not received prior chemotherapy or radiotherapy and had measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17951200&#34; target=&#34;_blank&#34;&gt;Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
XIAP immunostaining, when strong, allows for distinction of malignant from benign and hyperplastic mesothelial cell populations and is a potentially useful immunodiagnostic marker in small samples and morphologically controversial cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-11-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17962615&#34; target=&#34;_blank&#34;&gt;Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial–an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the feasibility of using low-dose computed tomography (LDCT) for the early diagnosis of lung cancer and malignant pleural mesothelioma in an asbestos-exposed population. […] Participants with positive findings received high-resolution CT and additional diagnostic workup as appropriate. […] Our findings first suggest that LDCT may be at least as useful in asbestos workers as in heavy smokers for the early diagnosis of lung cancer; this benefit is evident even in a poor-risk population, with low rates of smoking prevalence and a previous history of radiological surveillance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/17980576&#34; target=&#34;_blank&#34;&gt;Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present an analysis of latency period among the case list collected by the Italian mesothelioma register (ReNaM) in the period of diagnosis 1993-2001 (2544 malignant mesothelioma (MM) cases with asbestos exposure history). […] Statistical univariate analyses were performed to estimate median and variability measures of latency time by anatomical site, gender and diagnosis period. […] The role of diagnostic confidence level, the morphology of the tumour and the modalities of asbestos exposure were verified in a regression multivariate model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18008346&#34; target=&#34;_blank&#34;&gt;Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This similarity is important to improve the diagnosis and prognosis of malignant mesothelioma (MM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18036404&#34; target=&#34;_blank&#34;&gt;Dedifferentiated liposarcoma of the pleura mimicking a malignant solitary fibrous tumor and associated with dedifferentiated liposarcoma of the mediastinum: usefulness of cytogenetic and molecular genetic analyses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of the pleural mass included malignant solitary fibrous tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18038314&#34; target=&#34;_blank&#34;&gt;Role of fragile histidine triad protein expression in pathogenesis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Formalin-fixed, paraffin-embedded tissue sections of 30 asbestos induced MPM (epithelial and biphasic) patients were examined for FHIT and Ki-67 expression using immunohistochemical techniques and results were compared with clinicopathological variables.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18038888&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumor of the anterior mediastinum: a rare extrapleural neoplasm.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Spindle cells were immunoreactive for CD34, CD99, desmin, vimentin and bcl-2 protein and a diagnosis of mediastinal solitary fibrous tumor was confirmed. […] The differential diagnosis of mediastinal solitary fibrous tumors is extensive and includes spindle cell thymoma, sarcomatoid carcinoma, malignant mesothelioma, inflammatory myofibroblastic tumor, peripheral nerve sheath tumors and various sarcomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18051806&#34; target=&#34;_blank&#34;&gt;[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pathological diagnosis was renal cell carcinoma. […] Pathological diagnosis was malignant pleural mesothelioma based on using mesothelium-associated antibodies: calretinin (+), CK5/6 (+), D2-40 (+), HBME-1 (+), TTF-1 (-), MOC31 (-), CEA (-).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18064685&#34; target=&#34;_blank&#34;&gt;Endoscopic ultrasound-guided fine needle aspiration is useful for nodal staging in patients with pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two false negative EUS-FNAs were observed and were attributed to sampling error not diagnostic error.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18064689&#34; target=&#34;_blank&#34;&gt;Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To distinguish carcinoma, either adenocarcinoma (ADC) or squamous cell carcinoma (SCC), and malignant mesothelioma (MM) in effusion can be a diagnostic challenge based on morphology alone. […] This study evaluates the utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in effusions when ADC and SCC of the lung are in the differential diagnosis with MM. […] Mesothelin, on the other hand, is not useful in the differential diagnosis of ADC, SCC, and MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18077985&#34; target=&#34;_blank&#34;&gt;Fine needle aspiration of follicular variant of papillary thyroid carcinoma presenting with pleural effusion: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this case, although pleural fluid cytology suggested involvement of pleura, a definitive diagnosis could be rendered only on pleural biopsy. […] In our case, initial diagnosis of FVPTC could be made only on correlating FNA features of thyroid aspirate with those of lymph node aspirate.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18084678&#34; target=&#34;_blank&#34;&gt;Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Final histological diagnosis confirmed 9 epithelial type, 2 sarcomatoid type and 6 biphasic type MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18089874&#34; target=&#34;_blank&#34;&gt;Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Included were the EORTC prognostic index (PI) composed of stage of disease, histology type, time since diagnosis, and WBC, and, in addition, 10 selected key symptoms and HRQOL scales.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2007-12-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1809132&#34; target=&#34;_blank&#34;&gt;Absence of evidence for a significant background incidence of diffuse malignant mesothelioma apart from asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Modern pathology has ascribed specific requirements for the diagnosis of diffuse malignant mesothelioma. […] A priori one cannot assume that these requirements have increased the likelihood of the diagnosis because the requirements also can serve to exclude the diagnosis depending on the findings. […] Most cases of diffuse malignant mesothelioma are suspected by macroscopic and routine microscopic techniques that have been available since the last part of the nineteenth century.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18166941&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our knowledge of MPM has improved regularly in terms of pathologic diagnosis and the mechanisms underlying the mesothelial carcinogenesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18167128&#34; target=&#34;_blank&#34;&gt;Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Elevated amounts of soluble mesothelin-related proteins (SMRP) have already been reported in sera and pleural effusions from mesothelioma patients, providing a useful diagnostic marker for malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18176007&#34; target=&#34;_blank&#34;&gt;Presence of malignant mesothelial cells in the sputum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, the appearance of tumor cells in sputum more likely supports the diagnosis of peripheral lung cancer. […] For the differential diagnosis of a mass involving both the pleura and lung, physicians should consider that malignant mesothelial cells can be found in the sputum, although this is very rare.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18181669&#34; target=&#34;_blank&#34;&gt;Cytologic malignancy versus benignancy: how useful are the “newer” markers in body fluid cytology?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the efficacy of 5 immunohistochemical markers in the differential diagnosis of reactive mesothelial proliferation, malignant mesothelioma, and metastatic adenocarcinoma in body cavity fluids. […] We recommend using a panel to include MOC-31 and D2-40 to improve diagnostic accuracy in body cavity effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18202164&#34; target=&#34;_blank&#34;&gt;Population based epidemiology and prognosis of mesothelioma in Leeds, UK.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients’ hospital records and the Trust histology database were reviewed, as well as coroner’s reports on all patients with a post mortem diagnosis of mesothelioma. […] Median survival from diagnosis was 8.9 months. 92% and 8% had histological or cytological confirmation, respectively. 85% had documented evidence of definite or probable exposure to asbestos. 110/146 (75%) had symptomatic pleural effusions at presentation. […] Median time to seeding was 174 days. 92/146 (63%) had a performance status of 2 or better at diagnosis but only 54/146 were considered fit for chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18202798&#34; target=&#34;_blank&#34;&gt;Tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in adenocarcinoma pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant effusion signifies disease progression and is associated with a worsening patient prognosis. […] In conclusion, immunocytochemical detection of TIMP-2 could be considered an interesting marker in metastatic adenocarcinoma pleural effusions, and could possibly be used as a component of an antibody panel in diagnostic cytopathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18223309&#34; target=&#34;_blank&#34;&gt;Xanthomatous pleuritis mimicking mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recurrent non-malignant exudative effusions remain a diagnostic and potentially management dilemma. […] Fluid characteristics frequently narrow the differential but fail to offer a definitive diagnosis. […] Following extensive immunohistochemistry, the diagnosis of xanthomatous pleuritis was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18230573&#34; target=&#34;_blank&#34;&gt;[Environmental cancer: malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant advances are observed in the pathologic diagnosis, the staging, the knowledge of the mesothelial carcinogenesis, the identification of biological markers with potential interest in diagnosis or in treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18235408&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma: impact of the staging for the therapeutic strategy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Besides new findings for the epidemiology of the disease, medico-social impact for patients, the knowledge of biological parameters for diagnosis, prognosis and future therapeutic targets as well, the early diagnosis of the disease mainly based on more extended practice of thoracoscopy allows in association with new imaging techniques a careful staging of the disease and consequently new therapeutic implications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18235409&#34; target=&#34;_blank&#34;&gt;[Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological diagnosis remains difficult and depends on immunohistochemical analysis as described by the French Mesopath group. […] Clinical diagnosis relies on thoracoscopy and large pleural biopsies, with increasing use of CT-PET for the evaluation of disease extent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18274232&#34; target=&#34;_blank&#34;&gt;[The Lombardy Mesothelioma Register, Regional Operating Centre (ROC) of National Mesothelioma Register: organizational aspects].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For each “possible case” reported to the Registry by Lombardy hospitals, diagnosis is ascertained through examination of clinical records (including histology reports) according to ISPESL Guidelines. […] In the period 2000-2004, 1563 cases were collected, of whom 887 have been evaluated: the diagnosis was confirmed for 626 (70.6%) 9 out of 887 evaluated cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18278371&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the cases studied, an integrated multidisciplinary approach was used, and a highly complex hospital infrastructure was available for the diagnosis and treatment of MPM, as recommended in the literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18279069&#34; target=&#34;_blank&#34;&gt;Current concepts in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The molecular and genetic profiling of MPM tumors and patients, and improved understanding of the pathogenesis of MPM may lead to novel diagnostic, preventative and therapeutic strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18280176&#34; target=&#34;_blank&#34;&gt;Pericardial malignant mesothelioma: a latent complication of radiotherapy?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis can be challenging and often requires the use of different imaging modalities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18281122&#34; target=&#34;_blank&#34;&gt;Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. […] Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. […] Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. […] Biomarker levels &amp;lt;10, 10-19 and &amp;gt;or=20 years before diagnosis were not significantly associated to mesothelioma risk.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18294289&#34; target=&#34;_blank&#34;&gt;Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, several enzyme-linked immunosorbent assay (ELISA) systems for ERC/mesothelin have been developed, the reported usefulness of which has been assessed and demonstrated as a diagnostic tool.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18298385&#34; target=&#34;_blank&#34;&gt;Biological characteristics of cancers involving the serosal cavities.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In ovarian carcinoma, several of these molecules are differentially expressed in primary diagnosis (prechemotherapy) and disease recurrence (postchemotherapy) specimens, reflecting the effect of disease progression and chemotherapy, and have different prognostic significance as function of disease progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18301236&#34; target=&#34;_blank&#34;&gt;Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MPM metastatic to MLNs may not be straightforward. […] Unexpectedly, immunohistochemical studies supported the diagnosis of MPM metastatic to the MLN on biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18301454&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry and ultrastructural features aid in the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18304688&#34; target=&#34;_blank&#34;&gt;Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18304902&#34; target=&#34;_blank&#34;&gt;[New diagnostic markers for malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Some serum markers have been previously proposed for MPM diagnosis but none had sufficient sensitivity and specificity for being use in routine. […] Recently, soluble mesothelin and osteopontin have been proposed as diagnostic markers for mesothelioma. […] The authors reviewed recent data concerning the utility of these two molecules in the diagnosis and the treatment of MPM. […] Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18306350&#34; target=&#34;_blank&#34;&gt;9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma (MM) in serous effusions is difficult but may be achieved by the application of adjuvant methods. […] Because of these results, the authors propose the sequential application of immunocytochemistry, DNA-ICM, and AgNOR analysis to establish a cytological diagnosis of malignant mesothelioma in serous effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18323273&#34; target=&#34;_blank&#34;&gt;Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the expression of these markers individually and to find out which markers would be the most effective in a diagnostic panel to reliably discriminate these lesions. […] A preliminary diagnosis was formulated based on cytomorphologic criteria. […] Subsequently, results of all 6 immunocytochemical stainings were evaluated, the most effective diagnostic pane of antibodies was proposed and staining results using this panel were compared to results obtained by solely cytomorphologic evaluation and to the ultimate diagnosis. […] Overall, diagnostic accuracy increased from 76% to 94%. […] Immunocytochemical staining of standardized cell block reparations of serous fluid cells with a small panel of 4 antibodies significantly improves diagnostic results compared to cytomorphologic evaluation alone.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18323865&#34; target=&#34;_blank&#34;&gt;Advances in the molecular biology of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Epigenetic alterations including DNA methylation have been found in the MM, the profile of which is different from that of lung cancer, although differential diagnosis is sometimes clinically difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18324917&#34; target=&#34;_blank&#34;&gt;Localized malignant mesenteric mesothelioma causing small bowel obstruction.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma was obtained on repeat double balloon endoscopic biopsy. […] Mesothelioma should be considered as the differential diagnosis when small bowel obstruction occurs with unknown primary neoplasm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18326422&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma in the Veneto Region (north-east of Italy), 1988-2002: incidence, geographical analysis, trends and comparison with mortality].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The study also aims at identifying areas at high risk, by applying geographical analysis techniques. […] Incidence and trends are estimated on MM diagnosed between 1988 and 2002 by means of histological or cytological techniques. […] Mortality from TPP turns out to be higher than incidence and tends to approach incidence in more recent years; this may be explained by the increasing application of diagnostic procedures, inclusive of histopathological tests, among old patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18327208&#34; target=&#34;_blank&#34;&gt;Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Definitive diagnosis of malignant mesothelioma in small specimens can be extremely difficult based on morphology alone. […] The aim of this study was to evaluate the diagnostic utility of homozygous deletion of 9p21 assessed by fluorescence in situ hybridization (FISH) in mesothelial proliferations involving serosal surfaces in paraffin-embedded tissue. p16 protein immunoexpression was also explored as a potential diagnostic aid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18338545&#34; target=&#34;_blank&#34;&gt;[Malignant pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Video Assisted Thoracoscopy (VATS) is a safe and well tolerated technique, a complication rate is lower than 0.5%, VATS can be used to obtain diagnosis and to treat patients with malignant pleural effusion and better expectation of life.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18338546&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: utility of 18 F-FDG PET.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
18F-fluorodeoxiglucose Positron Emission Tomography (18F-FDG PET) is become a useful tool in the diagnosis of many neoplasms, such as Malignant Pleural Mesothelioma. […] In particular it has been shown to be useful in the evaluation of the extent of pleural disease, in the establishment of lymph node involvement, in the evaluation of tumour invasion into the lung and thoracic wall, in the diagnosis of extrathoracic metastases, in the assessment of the response to treatment, and in planning radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18349397&#34; target=&#34;_blank&#34;&gt;Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with histologic or cytologic diagnosis of MPM were included.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18359180&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: computed tomography and correlation with histology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was based on histologic findings in specimens obtained by transthoracic needle biopsy, surgical biopsy or resection. […] Eighty patients in whom there was no significant delay between CT imaging and histological diagnosis were assessed by logistic regression analysis to correlate CT and histologic findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18369634&#34; target=&#34;_blank&#34;&gt;Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate and compare early therapy response according to RECIST (response evaluation criteria in solid tumours) and modified RECIST criteria using MRI techniques in patients with malignant pleural mesothelioma (MPM) in comparison with CT. […] Additionally patients were examined before chemotherapy, 4 weeks after early therapy response evaluation and after six cycles to evaluate diagnostic follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18381361&#34; target=&#34;_blank&#34;&gt;The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical techniques using muscle flap seems to play a major role in the prevention of bronchus stump insufficiency especially after neo-adjuvant chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18381869&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural effusion associated with trapped lung syndrome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most frequent diagnosis was breast cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18394747&#34; target=&#34;_blank&#34;&gt;Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An early and reliable blood test is one deficiency in diagnosis of malignant pleural mesothelioma (MPM). […] We developed a novel enzyme-linked immunosorbent assay (ELISA) system to compare the diagnostic efficacy of MPF and MSLN in MPM and control groups. […] These findings suggest that diagnostic value of MPF for MPM was better than that of MSLN although both markers showed almost equal specificity for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409711&#34; target=&#34;_blank&#34;&gt;[Work related mesothelioma: analysis of cases discovered at the Section for Occupational Medicine and Toxicology of Siena University during the years 2000-2007].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was made through histopathological and immunoistochemical or cytological and immunoistochemical analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409712&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma (MM) in women: findings of the Mesothelioma Register of the Friuli Venezia Giulia Region].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 36 cases the diagnosis was “certain” and in 8 “probable” or “possible”. […] Mean age at diagnosis was 72.8 years (SD = 12.7), and the site of the disease was the pleura in 93% of cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409713&#34; target=&#34;_blank&#34;&gt;[Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Improved detection methods for diagnosis of asymptomatic malignant pleural mesothelioma (MPM) are essential for an early and reliable detection and treatment of this disease. […] No diagnostic value was observed for MMP2, MMP9, TIMP1, TIMP2.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409715&#34; target=&#34;_blank&#34;&gt;[Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural Malignant Mesothelioma (MM) is a highly aggressive neoplasm with a poor survival rate, hard diagnosis and treatment. […] In spite of this drammatic scenario, at this time the only instruments for screening and early diagnosis are based on radiological tests with evident ethical and economical problems. […] For this reason, some authors are evaluating biological indicators with the significance of screening and early diagnosis markers. […] SMRP levels appeares to be significantly related to MM and its clinical (diagnostic/prognostic) usefulnes has been suggested.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409716&#34; target=&#34;_blank&#34;&gt;[Serum mesothelin dosages in follow-up of previously exposed workers].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We recently demonstrated that Serum Mesothelin may be clinically helpful both for diagnostic and prognostic purposes, with the best cut-off corresponding to 1 nM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18409882&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma in barman with probable occupational exposure to asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Italian National Mesothelioma Register have reported a MM case with a professional origin arised in a barman with a certain diagnosis in 1999 (Tuscany Region).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18420450&#34; target=&#34;_blank&#34;&gt;Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Technical improvements such as the use of high-throughput techniques will help to identify molecular pathways regulated by candidate genes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18422869&#34; target=&#34;_blank&#34;&gt;Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conventional tests are not always helpful in making a diagnosis of malignant pleural effusion (MPE). […] Many studies have investigated the utility of pleural carcinoembryonic antigen (CEA) in the early diagnosis of MPE. […] The present meta-analysis determined the accuracy of CEA measurement in the diagnosis of MPE. […] A systematic review of English language studies was conducted and data on the accuracy of pleural CEA concentrations in the diagnosis of MPE were pooled using random effects models. […] The summary estimates for CEA in the diagnosis of MPE were: sensitivity 0.54 (95% CI: 0.52-0.55), specificity 0.94 (95% CI: 0.93-0.95), positive likelihood ratio 9.52 (95% CI: 6.97-13.01), negative likelihood ratio 0.49 (95% CI: 0.44-0.54) and diagnostic odds ratio 22.5 (95% CI: 15.6-32.5). […] Analysis of a subset of 11 studies which examined the value of pleural CEA in ruling out a diagnosis of malignant mesothelioma found that the sensitivity and specificity of a CEA level exceeding cut-off values were 0.97 (95% CI: 0.93-0.99) and 0.60 (95% CI: 0.55-0.65), respectively. […] Measurement of pleural CEA is likely to be a useful diagnostic tool for confirming MPE, and is also helpful in the differential diagnosis between malignant pleural mesothelioma and metastatic lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18434338&#34; target=&#34;_blank&#34;&gt;Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Key eligibility criteria were histologic diagnosis of MPM incurable by surgery, no prior chemotherapy, and a performance status 0-1.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1843649&#34; target=&#34;_blank&#34;&gt;[Incidence of pleural mesotheliomas in Poland (preliminary report)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors have also concluded that “at-life” diagnosis of mesothelioma rises, mainly due to the use of open pleural biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18439258&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma as a rare cause of ascites: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Peritoneal mesothelioma is a rare tumor with diagnostic and therapeutic problems. […] Clinical symptoms and findings may be confusing and diagnosis can be easily overlooked especially in cases where there is no previous asbestos exposure. […] We report a case of malignant peritoneal mesothelioma in a 75-year-old woman who presented with ascites which, in the absence of inhalational exposure to asbestos, caused diagnostic confusion, and evaded radiological detection. […] We concluded from this case that Peritoneal Mesothelioma although rare but should be considered among the differential diagnosis of Ascites.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18443531&#34; target=&#34;_blank&#34;&gt;[Video-assisted thoracoscopic surgery in diagnostic and treatment of non-operable malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is characterized by aggressive follow-up, difficult diagnosis and treatment fatal issue. […] Before operation in this patients in help of diagnosis, we have information by image examination (radiography, CT of thorax and if it necessary to mark pleural effusion - sonography of pleural cavity ) abdominal sonohography or CT of abdomen for exclusion of distant metastasis, fibrobronchoscopy (FBS) for confirmation or exclusion of endobronchial cancer and transthoracic aspiration biopsy (TTAB). […] Early diagnosis of malignant pleural mesothelioma is difficult, in some times impossible. […] After histological verification the diagnosis is proven. […] Surgical treatment is decisive for diagnosis and treatment of malignant pleural mesothelioma even in advanced cases and have evident positive effects. […] VATS surgery is modern method for diagnosis and treatment and if it necessary we can continue by conventional operation for definitive treatment of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18449002&#34; target=&#34;_blank&#34;&gt;Trimodality treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel techniques are needed for preoperative assessment of extrapleural lymph nodes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18449075&#34; target=&#34;_blank&#34;&gt;[The contribution of positron emission tomography in pleural disease].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the light of our experience and a revue of the literature we define precisely the role of metabolic imaging in the diagnosis of pleural pathology. […] It is justified, therefore, that PET joins the diagnostic armamentarium of pleural pathology, solid or liquid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18450462&#34; target=&#34;_blank&#34;&gt;Video-assisted cervical thoracoscopy: a novel approach for diagnosis, staging and pleurodesis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the preoperative workup for radical surgery for malignant pleural mesothelioma (MPM), mediastinal lymph node staging, diagnostic pleural biopsies and effusion control with talc pleurodesis are required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18454162&#34; target=&#34;_blank&#34;&gt;Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18474335&#34; target=&#34;_blank&#34;&gt;MR imaging of benign and malignant pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MR imaging serves as a problem-solving tool in the diagnosis of inflammatory and infectious pleural diseases and primary and secondary pleural malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18480485&#34; target=&#34;_blank&#34;&gt;Neoplastic and nonneoplastic conditions of serosal membrane origin: CT findings.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Computed tomography (CT) is an important imaging modality for diagnosis and follow-up of neoplastic or nonneoplastic conditions of the serosal membrane. […] Although the CT findings of some of the conditions overlap, knowledge of the typical findings is helpful in narrowing the differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1848247&#34; target=&#34;_blank&#34;&gt;CT findings in malignant pleural mesothelioma related to nonoccupational exposure to asbestos and fibrous zeolite (erionite).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The early radiological diagnosis of erionite-related MPM may be even more difficult because of the similarity of the pleural lesions to chronic fibrosing pleuritis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18493429&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in pleural malignant mesothelioma diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On the basis of our personal experience in 70 cases (66 pleural effusions) observed during the period January 1984- January 1996 we are here illustrating and discussing the diagnostic role of thoracoscopy in malignant pleural mesothelioma.A histological diagnosis was achieved in 94.2% of cases. […] In all cases fluid cytology (diagnostic yield: 18.5%) and needle biopsy (diagnostic yield 17.1%) were performed.The extension of pleural involvement (endoscopic staging according to Boutin) was also determined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18506411&#34; target=&#34;_blank&#34;&gt;[Erionite-induced pleural plaques. Exposition to urban pollution in a female Turkish migrant in Germany].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of inflammatory pleural plaques was assumed radiologically and confirmed by video-assisted thoracoscopic biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18507198&#34; target=&#34;_blank&#34;&gt;Two cases of asbestosis and one case of rounded atelectasis due to non-occupational asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These unusual environmental diseases raise the diagnostic problem of differentiating them from other, more common respiratory illnesses, and impose the duties of patient notification, assessment and follow-up, to assess the possibility of progression of disease and increased neoplastic risk.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18517012&#34; target=&#34;_blank&#34;&gt;[Autopsy case of diffuse pleural thickening presenting respiratory impairment and benign asbestos pleurisy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After 3-year observation and excluding other causes, he was given a diagnosis of benign asbestos pleurisy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18520267&#34; target=&#34;_blank&#34;&gt;Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, two recent randomized controlled trials did not support the widely held belief that all patients undergoing diagnostic or therapeutic pleural puncture should receive prophylactic drain site irradiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18520268&#34; target=&#34;_blank&#34;&gt;Image-guided pleural biopsy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Establishing accurate diagnosis is an essential step in management of these patients, and approximately 40% of pleural effusions will remain undiagnosed after initial diagnostic thoracocentesis. […] Recent evidence provides important information on the relative value of each of these techniques. […] For the diagnosis of malignant pleural disease, both thoracoscopic and image-guided biopsy have a far higher diagnostic yield than blind pleural biopsy. […] Cutting needle biopsies have a higher diagnostic yield in malignancy (and especially mesothelioma) compared with fine needle aspiration. […] Blind pleural biopsy should no longer be conducted for the study of malignant pleural disease if facilities for other techniques are available. […] Image-guided and thoracoscopic biopsies have similarly high diagnostic rates, and are complementary techniques used in different clinical situations. […] Further studies assessing biopsy tract site invasion from mesothelioma with different biopsy techniques are required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18523361&#34; target=&#34;_blank&#34;&gt;Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis and staging of the disease was done by medical thoracoscopy with biopsies of the right pleura in December 2003, when he was treated with talc pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18528285&#34; target=&#34;_blank&#34;&gt;Uroplakin is not a reliable immunohistochemical marker for malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analyzed URO expression in PMM using similar immunohistochemical techniques at 2 separate institutions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18549935&#34; target=&#34;_blank&#34;&gt;Prognostic significance of pleural fluid data in patients with malignant effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median overall survival of MPE patients was 5.4 months following diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18560526&#34; target=&#34;_blank&#34;&gt;Asbestos burden predicts survival in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rapidly fatal asbestos-associated malignancy with a median survival time of &amp;lt;1 year following diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18577116&#34; target=&#34;_blank&#34;&gt;Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Preoperative diagnosis of adenocarcinoma was made on transbronchial biopsy. […] The former was positive for adenocarcinoma markers such as CEA, Ber-EP4, PE-10, thyroid transcription factor-1 and Napsin A, and negative for mesothelial markers including calretinin, D2-40, WT-1 and HBME, while the latter was the opposite, resulting in a diagnosis of coalescing malignant mesothelioma and adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18577247&#34; target=&#34;_blank&#34;&gt;Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was obtained by ultrasonographic exam of the body cavities that evidenced thickening of the mesothelium. […] A surgical biopsy further substantiated the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18580246&#34; target=&#34;_blank&#34;&gt;Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The intense FDG uptake in an osseous lesion on FDG-PET in our case reminds us of the variable nature of FDG uptake in Paget disease, the possibility of false-positive findings on FDG-PET in patients with cancer, and the usefulness of the fusion techniques in the evaluation of skeletal lesions, with the potential for discriminating between benign Paget disease and other pathologic bone findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18583923&#34; target=&#34;_blank&#34;&gt;Mesothelioma and asbestos-related pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18585112&#34; target=&#34;_blank&#34;&gt;Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was made by pleural biopsy via needle, open, or VATS biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18587319&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are currently no criteria for diagnosis and little data regarding prognosis. […] The median age at diagnosis was 68 years, ranging from 27 to 85 years. […] Median survival was 6 months after diagnosis, similar to the survival seen in sarcomatoid mesotheliomas. […] The differential diagnosis includes primary and secondary pleural sarcomas, including osteosarcomas and chondrosarcomas. […] Immunohistochemical labelling for cytokeratins is helpful in the distinction, but lack of labelling for cytokeratins in a spindle cell/sarcomatoid tumour does not exclude the diagnosis of mesothelioma, irrespective of the presence of heterologous elements. […] We suggest that if the anatomical distribution conforms to that of mesothelioma, a diagnosis of heterologous mesothelioma should be made in preference to a diagnosis of primary pleural osteosarcoma or chondrosarcoma, regardless of cytokeratin positivity, as for conventional non-heterologous sarcomatoid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18605768&#34; target=&#34;_blank&#34;&gt;Primary pleural neoplasia: entities other than diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To review primary pleural neoplasms other than diffuse malignant mesothelioma, to better ensure correct diagnosis and optimal assessment of prognosis and treatment. […] A nonexhaustive group of uncommon to rare benign and malignant primary pleural neoplasms–other than diffuse malignant mesothelioma–are presented, of which one must be aware in order to maintain an appropriate index of suspicion to include them in the differential diagnosis of a pleural tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18607677&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: current status and perspective in Japan and the world.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical management of MPM is comprised of two aspects: diagnosis and resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18647189&#34; target=&#34;_blank&#34;&gt;The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the diagnostic accuracy of closed and open pleural biopsies in diagnosing malignant pleural mesothelioma. […] Forty-one of 45 (91%) had had an antemortem diagnosis of malignant mesothelioma. […] In these 41 cases, 57 prior diagnostic pleural biopsies had been performed [36 closed needle biopsies: 31 blind; five computed tomography (CT)-guided and 21 open pleural biopsies]. […] For definitive diagnosis open pleural biopsy yielded a sensitivity of 95% and specificity of 100%. […] For definitive diagnosis closed blind pleural biopsies yielded a sensitivity of 16% and specificity of 94%. […] CT-guided pleural biopsies yielded a definitive diagnostic accuracy of 100% (5/5). […] Biopsy specimen size was important in obtaining a positive definitive diagnosis. […] Diagnosis was attained in 75% of specimens &amp;gt;10 mm in size compared with 8% &amp;lt;10 mm in size. […] Overall, all procedures had utility but definitive diagnostic accuracy for ‘blind’ closed pleural biopsy was low (16%), dependent on biopsy specimen size and tumour subtype. […] Sarcomatoid subtype malignant mesothelioma yielded the lowest diagnostic accuracy. […] For all subtypes of malignant mesothelioma, open pleural biopsy produced the highest diagnostic accuracy (100% sensitivity, 95% specificity).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1866206&#34; target=&#34;_blank&#34;&gt;Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The value of monoclonal antibody B72.3 as a diagnostic discriminator between mesothelioma and carcinoma cells in malignant effusions was assessed using the ABC method in a series of cell blocks prepared from centrifuged fluids. […] These results suggest that B72.3 positivity in greater than 10% of tumour cells is certainly indicative, but not absolutely diagnostic, of a metastatic origin of malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18662397&#34; target=&#34;_blank&#34;&gt;Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the late stage of MPM diagnosis and the long latency that exists between some exposures and diagnosis have made it difficult to comprehensively evaluate the role of risk factors and their downstream molecular effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18667024&#34; target=&#34;_blank&#34;&gt;Establishment of a human malignant fibrous mesothelioma cell line and the biological characteristics compared with malignant epithelial mesothelioma cell line.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These cell lines were separated by the colonial techniques from the initiation of the primary cultures and grew well without interruption for 12 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18670302&#34; target=&#34;_blank&#34;&gt;Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers. […] Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18677861&#34; target=&#34;_blank&#34;&gt;[Use of hospital discharge records to estimate the incidence of malignant mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We assessed the number of cases identified only through HDRs and their influence on MM incidence. cases identified through HDRs were about 10% of those with histologic confirmation of the diagnosis, 34% of those with cytologic confirmation, and 72% of those without morphologic examination. […] The age-standardised (standard: Italian pop. at the 1981 census) incidence rate of pleural MM increases from 2.2 to 2.7 per 100,000 per year among men, and from 1.1 to 1.2 among women, when including all cases identified from HDRs, irrespective of their diagnostic confirmation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18677862&#34; target=&#34;_blank&#34;&gt;[Incidence of malignant mesothelioma in Piedmont, 1990-2001].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No changes were observed in peritoneal MM incidence. the rise in incidence might be due to increased diagnostic awareness for MM. […] An analysis by birth-cohort, however, revealed a cohort-effect, therefore it is unlikely that diagnostic bias alone could explain the observed trend. […] Among men residing at diagnosis in the province of Turin, but not among women nor in both sexes outside Turin province, the increase in incidence has levelled off in the most recent calendar period; for them exposures stopped on average seven years earlier than those of residents in other areas of Piedmont.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18697458&#34; target=&#34;_blank&#34;&gt;[Full-thickness pleural biopsy using an Insulation-tipped Diathermic Knife in a patient with malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This biopsy technique using IT knife through semiflexible thoracoscopy enabled to obtain a full-thickness pleura It is thought to be useful for the diagnosis of malignant pleural mesothelioma (MPM) in which standard forceps are difficult to grasp.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1873966&#34; target=&#34;_blank&#34;&gt;Effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although a positive diagnosis is highly reliable, a negative result does not rule out a malignant cause. […] The definitive diagnosis of malignant mesothelioma, small-cell lymphomas, and chronic leukemias, and subclassification of sarcomas and poorly differentiated neoplasms are difficult and may require additional diagnostic techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18758965&#34; target=&#34;_blank&#34;&gt;Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The process to obtain the correct diagnosis can be challenging and requires a high index of suspicion. […] Once the diagnosis is made, there is no universally accepted standard of care and treatment decisions are strongly influenced by physician bias.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1876593&#34; target=&#34;_blank&#34;&gt;[Diagnosis of diffuse pleural mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Particularly in case of fibrous growth, it is sometimes only thoracotomy that enables final diagnostic clarification.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1876594&#34; target=&#34;_blank&#34;&gt;[Therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival of untreated patients is 6 months from the date of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18770063&#34; target=&#34;_blank&#34;&gt;Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients underwent surgery and/or thoracoscopy for diagnosis, staging or talc pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18775081&#34; target=&#34;_blank&#34;&gt;Clinical consequences of asbestos-related diffuse pleural thickening: A review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High resolution computed tomography (CT) is more sensitive and specific than chest radiography for the diagnosis of diffuse pleural thickening, and several classification systems for asbestos-related disorders have been devised.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18787841&#34; target=&#34;_blank&#34;&gt;Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The late stage of MPM diagnosis and the long latency that exist between some exposures and diagnosis have made it difficult to comprehensively evaluate the role of risk factors and their downstream molecular effects.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18791416&#34; target=&#34;_blank&#34;&gt;Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PET/CT was significantly more accurate (P &amp;lt; 0.05) in stages II and III compared with all other techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18792097&#34; target=&#34;_blank&#34;&gt;Survival of pleural malignant mesothelioma in Italy: a population-based study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In multivariate analysis, younger age at diagnosis and epithelioid histotype were associated with significantly reduced hazard ratios. […] No association with calendar period of diagnosis or asbestos exposure was present.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18792099&#34; target=&#34;_blank&#34;&gt;Survival of peritoneal malignant mesothelioma in Italy: a population-based study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Epithelioid histotype, younger age at diagnosis and, to a lesser degree, gender (women), and being diagnosed in a hospital with a thoracic surgery unit positively and significantly affected survival. […] No trend in the risk of death according to calendar period of diagnosis was present.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18844940&#34; target=&#34;_blank&#34;&gt;Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Initial bronchoscopic and transthoracic biopsies failed to obtain diagnostic material. […] The patient failed to respond to radiochemotherapy, and died 11 months following the diagnosis with tamponade and metastasis to the skin of the thoracoabdominal wall. […] Epithelioid hemangioendothelioma is a rare tumor in the lung that can mimic other more common pathological entities, and should be included in the differential diagnosis of unusual pulmonary neoplasms with epithelioid or biphasic morphology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18854268&#34; target=&#34;_blank&#34;&gt;Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Agreement between the histologic type from the EPP review and the diagnostic procedure (DP) reports was evaluated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18854270&#34; target=&#34;_blank&#34;&gt;A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the accurate pathologic diagnosis of pleural or peritoneal mesothelioma (PM) is sometimes difficult if adequate histologic and immunohistochemical analyses are not undertaken. […] The results identified calretinin and thrombomodulin as positive markers and Ber-EP4, MOC-31, CA19-9, and estrogen receptor as negative markers with relatively high sensitivity and specificity for the differential diagnosis of PM and SC. […] The combination of these positive and negative markers may contribute to accurate diagnosis and adequate therapy for PM and ovarian SC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2008-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18854655&#34; target=&#34;_blank&#34;&gt;Cardiac tamponade as primary manifestation of angioimmunoblastic T-cell lymphoma (AILT). Coexistence with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
AILT diagnosis was confirmed by thoracoscopic mediastinal lymph node and bone marrow biopsy. […] Despite the presence of pleural effusion, the diagnosis of mesothelioma was initially established by cytologic ex-amination of pericardial fluid, due to the patient’s critical cardiac condition requiring prompt subxiphoid pericardiocentesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18931959&#34; target=&#34;_blank&#34;&gt;A case of solid pseudopapillary tumour of the pancreas and malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient developed liver metastases and died 2 years from the diagnosis of metastatic disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18958493&#34; target=&#34;_blank&#34;&gt;Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Long survival (LS) was defined as survival greater than 3 years from the time of diagnosis, and short survival was defined as less than 3 years from the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18958556&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, we performed a multiinstitutional study to evaluate the current status of diagnosis and treatment in Japan. […] It took a median period of 2 months from the initial visit to establish the diagnosis. […] The overall survival rates of 33 patients with unresectable MPM 1, 2, and 3 years after the diagnosis were 40.5%, 10.8%, and 0%, respectively, whereas those of 32 patients who underwent surgery were 67.9%, 35.0% and 10.9%, respectively (P=0.0035). […] The definitive diagnosis of early MPM is difficult, but establishing the best diagnostic modality would improve survival rates, since radical surgery is likely to be effective for resectable disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1896908&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma in data from the Surgical Clinic in Hradec Králové 1971-1987].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors describe a group of 12 patients operated at the Surgical Clinic in Hradec Králové in 1971-1987 with the diagnosis of a pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18971844&#34; target=&#34;_blank&#34;&gt;[Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore an earlier diagnosis of MPM is needed to significantly increase the survival of patients. […] Some soluble markers, including soluble mesothelin and osteopontin, have been previously proposed for MPM diagnosis but none has been validated yet. […] However, even if it has a good diagnostic and prognostic value, it is quite specific for the epithelioid subtype, the most frequent one of mesothelioma, thus limiting its usefulness in practice. […] Despite sometimes a good sensitivity, other potential markers as osteopontin are of little interest for MPM diagnosis because of a low specificity. […] In conclusion, the present data do not justify the use of biology for MPM diagnosis in routine yet but rather suggest a need for a continuing evaluation of soluble mesothelin in clinical studies and the search for other potential tumor markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18973123&#34; target=&#34;_blank&#34;&gt;Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Distinguishing malignant mesothelioma, adenocarcinoma and reactive mesothelial proliferation in both cytologic and surgical pathologic specimens is often a diagnostic challenge. […] Conventional cytomorphologic assessment is an important step in the differential diagnosis of these entities.The pleural effusion cytologies from 40 cases of malignant mesothelioma, 40 cases of adenocarcinoma and 30 cases of reactive mesothelial proliferation diagnosed between 1997 and 2007 were reviewed. […] Twenty-seven cytologic features which are regarded as useful in the differential diagnosis of mesothelioma, adenocarcinoma and benign mesothelial proliferation were assessed. […] When these selected variables were subjected to a stepwise logistic regression analysis, the logistic model correctly predicted 90% of cases of benign mesothelial proliferation versus 97.5% of malignant mesothelioma and 92.5% of malignant mesothelioma versus 92.5% of adenocarcinoma.Conventional cytomorphologic assessment is the first step to establish an accurate diagnosis in pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18978568&#34; target=&#34;_blank&#34;&gt;Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated the diagnostic and prognostic value of soluble mesothelin-related proteins (SMRP) in sera from patients with newly diagnosed malignant pleural mesothelioma (MPM) (n = 100), MPM patients at tumor relapse (n = 29), primary lung cancer (n = 139), and benign asbestosis (n = 75) using Mesomark–enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA). […] In conclusion, SMRP add limited information to the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/18978574&#34; target=&#34;_blank&#34;&gt;Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this case, we describe a 57-year-old man with MPM who developed sensory-motor polyneuropathy 18 days after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19004520&#34; target=&#34;_blank&#34;&gt;Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Characteristics of the entire cohort include: age at diagnosis, mean 65 years (median 66, range 43-84); gender, male 70 (86%); laterality of disease, right-sided 51 (63%); histology, epithelioid or not otherwise specified 69 (85%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19014568&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the tunica vaginalis of the testis without exposure to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ultrasound findings are helpful and fine needle aspiration of the tumor may assist in arrival at a diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19020484&#34; target=&#34;_blank&#34;&gt;Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These plans showed acceptably conformal dose distributions as confirmed by multiple measurement techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19035624&#34; target=&#34;_blank&#34;&gt;Biomarkers for malignant pleural mesothelioma: current status.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Biomarkers would be helpful in managing three clinical aspects of MPM: early diagnosis, prognosis, and treatment outcome prediction. […] The aims of the present review are to summarize the published and recently presented data on MPM biomarkers and to identify the prospects for future translational research projects.Among the ‘classical’ diagnostic biomarkers measured in biological fluids, such as cytokeratins and cell surface antigens, none discriminate patients with MPM from those with other malignancies and nonmalignant diseases. […] Panels consisting of a small set of biomarkers do not improve the diagnostic yield, and results from molecular profiling are too preliminary to be brought into daily clinical practice. […] In contrast, data concerning predictive biomarkers are very limited, even though they are most interesting from the perspective of clinicians.Additional prospective studies, in large and independent samples of patients, with rigorous statistical methodology and standardized laboratory techniques are now warranted to validate and define the precise value of diagnostic and prognostic MPM biomarkers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19054156&#34; target=&#34;_blank&#34;&gt;Problems in mesothelioma diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This presents pathologists involved in making the diagnosis with a number of problems, which can be divided into those encountered in making the distinction between mesothelioma and benign changes and those experienced in separating mesotheliomas from other types of epithelial and connective tissue tumours. […] Immunohistochemistry plays a major role in helping to make the diagnosis, but it should be interpreted with due regard to the clinical setting and radiological features, and with a knowledge of the wide morphological variations seen in mesothelioma. […] It includes a discussion of some of the less common variants of mesothelioma and other pleural-based tumours that enter into the differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19061286&#34; target=&#34;_blank&#34;&gt;Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We previously found telomere repeat amplification protocol (TRAP) in situ helpful in the diagnosis of malignancy in effusions, whereas varying sensitivities and specificities for malignancy were reported by investigators using extract-based TRAP.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19088405&#34; target=&#34;_blank&#34;&gt;Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Experience of asbestos use and its adverse heath effects in developed countries such as Australia have resulted in development of expertise in the diagnosis and treatment of asbestos-related diseases as well as in screening and this can be used to help developing countries facing the issue of asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19099560&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A combination of accurate exposure history, along with examination radiology and pathology are essential to make the diagnosis. […] Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19106906&#34; target=&#34;_blank&#34;&gt;[Malignant pleural effusion as the presenting site of cancer: comparison with metastatic pleural effusions from known cancers].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients were selected retrospectively from the database of the Pathology Department of the University Hospital of Nantes (France), which contained only the patients in whom a diagnosis of malignant effusion was made as the result of cytology of pleural fluid or pleural biopsy, between January 1999 and December 2001.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19118434&#34; target=&#34;_blank&#34;&gt;A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We compared the diagnosis of specimens obtained using the IT knife and SFF in 20 subjects with unexplained pleural effusion, and reviewed pleuroscopic parameters such as complications, procedure time, and diameter of the specimens. […] Diagnostic yields from specimens obtained with the IT knife and SFF were 85% (17 of 20 cases) and 60% (12 of 20 cases), respectively. […] The overall diagnostic yield for both IT knife and SFF was 100%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19129058&#34; target=&#34;_blank&#34;&gt;Duodenal metastasis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Metastatic malignant mesothelioma of the pleura is uncommon at the time of initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19136533&#34; target=&#34;_blank&#34;&gt;Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
VATS provides a diagnostic tool, yielding tissue for histological diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19142050&#34; target=&#34;_blank&#34;&gt;[Malignant pleural diseases: diagnosis and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate efficacy of diagnostic procedures, results of surgery, and complications in malignant pleural diseases. […] We used noninvasive and invasive methods for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19152187&#34; target=&#34;_blank&#34;&gt;Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Labelling for calretinin and lack of labelling for BG8 were sufficient for definite correlation with a diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19160697&#34; target=&#34;_blank&#34;&gt;Texture- and object-related automated information analysis in histological still images of various organs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A generalized algorithm was developed that permits the evaluation of diagnosis-associated image features obtained from hematoxylin-eosin-stained histopathologic slides. […] The accuracy of automated crude classification was between 95% and 100% based upon a learning set of 10 cases per diagnosis class. […] It is a promising technique that can assist tissue-based diagnosis and be expanded to virtual slide evaluation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19174489&#34; target=&#34;_blank&#34;&gt;Osteopontin levels in an asbestos-exposed population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Subjects were classified into six different diagnostic groups, including asbestosis (n=23), silicosis (n=20), diffuse pleural thickening (n=110), asbestosis and diffuse pleural thickening (n=13), pleural plaques (n=142), and healthy subjects with a history of asbestos exposure (n=217).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19190155&#34; target=&#34;_blank&#34;&gt;Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The SMRP level at 0.55 nmol/L/L was determined as the most optimal cutoff value with resulting sensitivity and specificity of 72% and 72% for the diagnosis of MPM. […] These data attest to good diagnostic sensitivity and specificity of SMRP for the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1921345&#34; target=&#34;_blank&#34;&gt;Death certificate categorization of malignant pleural and peritoneal mesothelioma in a cohort of asbestos insulation workers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accuracy of diagnosis of malignant mesothelioma (pleural and peritoneal) was studied in a cohort of asbestos insulation workers in the United States and Canada. […] Initial clinical diagnosis, clinical diagnosis at death and death certificate diagnosis were compared with the diagnosis of malignant mesothelioma ascertained by full data review at the Division of Environmental and Occupational Medicine, Mount Sinai Medical Center, New York (‘best evidence’). […] In both groups the death certificate diagnosis was somewhat less frequently accurate than clinical diagnosis at death. […] Knowledge of the patients’ occupational history by the attending physician and its relation to accuracy of diagnosis of malignant mesothelioma is considered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1921399&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in the diagnosis of pleural effusion of ambiguous etiology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prior thoracocentesis (in all patients) and a needle pleural biopsy (in 15 patients) had been nondiagnostic. […] Thoracoscopy was diagnostic in 24 of the 27 patients (4 benign, 20 malignant). […] We conclude that thoracoscopy is an important diagnostic aid in the management of a pleural effusion of ambiguous origin and that it is a relatively safe procedure that can be performed with an acceptable morbidity and mortality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1923633&#34; target=&#34;_blank&#34;&gt;Malignant sarcomatoid mesothelioma of the pleura: a histological and immunohistological study of a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only at immunohistochemistry was the differential diagnosis made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1926028&#34; target=&#34;_blank&#34;&gt;Pneumothorax and malignant mesothelioma in patients over the age of 40.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma was not suspected at surgery but was made by histological examination of the pleurectomy specimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19261093&#34; target=&#34;_blank&#34;&gt;Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The immunohistochemical diagnosis of epithelioid mesothelioma from biopsy or surgically resected specimens has been actively pursued, using markers such as mesothelin. […] Several markers have indeed been helpful for confirming the diagnosis of mesothelioma and distinguishing between mesothelioma and adenocarcinoma. […] The authors have developed a novel mAb to human C-ERC/mesothelin, which performed well when used in western blotting, fluorescence-activated cell sorting, immunocytochemistry and immunohistochemistry, and which therefore will be useful in studying the molecular biology of mesothelin, in addition to improving the diagnosis and therapy of mesothelin-expressing cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19262009&#34; target=&#34;_blank&#34;&gt;Is FDG-PET/CT useful for managing malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging techniques such as CT, MRI and PET/CT have essential pre- and post-treatment roles in detecting tumors and evaluating the extension of malignant pleural mesothelioma (MPM). […] We performed 13 FDG-PET/CT studies in 9 patients with MPM (8 males, 1 female, aged 51 to 84 years, 9 at the initial diagnosis, 4 follow up studies). […] The uptake patterns at initial diagnosis were; diffuse+multi-nodular uptake pattern in 5, diffuse irregular thickened uptake pattern in 2, some focal thickened pattern in one, and a slight diffuse uptake pattern in one.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19285954&#34; target=&#34;_blank&#34;&gt;Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Osteopontin (SPP1) is an inflammatory cytokine that we previously characterized as a diagnostic marker in patients with asbestos-induced malignant mesothelioma (MM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19289587&#34; target=&#34;_blank&#34;&gt;Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Based on these findings, EMA is a better marker than XIAP or GLUT-1 for the diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19299498&#34; target=&#34;_blank&#34;&gt;Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serum mesothelin is a new biomarker for the diagnosis of mesothelioma. […] To assess the diagnostic role of pleural fluid mesothelin and the effect of common clinical factors that may influence measurement accuracy. […] Mesothelin measurement was superior to cytological examination in the diagnosis and exclusion of mesothelioma (sensitivity, 71 vs. 35%; specificity, 89 vs. 100%; negative predictive value, 95 vs. 82%, respectively). […] Pleural fluid mesothelin provides additional diagnostic value relative to cytological examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19301253&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma: an unusual case diagnosed on pleural fluid cytology and immunocytochemistry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its accurate and early diagnosis is often difficult. […] We present an unusual clinical presentation and diagnostic dilemma in a 30-year-male, who presented with neck pain and diffuse edema of left upper limb. […] The patient had mild bilateral pleural effusion, the characteristic cytomorphological features of mesothelioma on fluid cytology were helpful in establishing the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19302997&#34; target=&#34;_blank&#34;&gt;Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We assessed comparatively the diagnostic value of two potential malignant pleural mesothelioma (MPM) markers: hyaluronic acid (HA) and soluble mesothelin. […] In pleural fluid, both markers had similar diagnostic values.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19303526&#34; target=&#34;_blank&#34;&gt;[Update in respiratory disease and environmental exposure: an invisible relationship].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A consensus article has been published on occupational asthma, in which some clinical evidenced-based recommendations are established, directed at the diagnosis and management of work-related asthma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19306511&#34; target=&#34;_blank&#34;&gt;Dual time point FDG PET for evaluation of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate whether 2-deoxy-2-18F-fluoro-D-glucose (FDG) positron emission tomography (PET) is more useful in differentiating malignant from benign pleural lesions, and whether delayed FDG PET imaging can improve the diagnostic performance in patients with suspicion of malignant pleural mesothelioma (MPM). […] The final diagnosis was MPM in 17 patients and benign pleural disease in 16 patients. […] FDG PET seems to be a useful imaging modality for differential diagnosis of MPM. […] In addition, the diagnostic performance on delayed PET was the same as that on early PET, although SUVdelayed was significantly higher than SUVearly in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-04-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19319590&#34; target=&#34;_blank&#34;&gt;Recurrent malignant peritoneal mesothelioma: radiological manifestations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The history, clinical and laboratory data, and imaging studies of 13 patients with histologically proven diagnosis of Malignant Peritoneal Mesothelioma (MPM) and their recurrence following cytoreductive surgery were reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19357540&#34; target=&#34;_blank&#34;&gt;Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An interim limited computed tomography of the observed abnormality prompted 10 diagnostic biopsies, resulting in a diagnosis of six lung cancers, two pleural mesothelioma and two peritoneal mesothelioma; overall rate of screen-detected malignancies is 2.1%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19373910&#34; target=&#34;_blank&#34;&gt;Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is important to recognize this entity in the differential diagnosis, because the clinical management of WDPM is quite different from that of malignant neoplasm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19373913&#34; target=&#34;_blank&#34;&gt;Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These cells in contrast to the usual mesothelial cells were not arranged in sheets but rather were huddled in places and formed a pseudoacinar pattern and blended with the myxoid substance.After the diagnosis of a mesothelioma, patient received pemetrexed and cisplatin based chemotherapy with partial response. […] Attention to the cytomorphology of tumor cells will also assist in confirming the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19374545&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis and treatment of patients with malignant pleural mesothelioma requires a multidisciplinary approach. […] The diagnosis is best made by thoracoscopic biopsy and the aid of immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19374599&#34; target=&#34;_blank&#34;&gt;Future developments in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the past few years, there have been several developments in the management of patients with MPM, including more accurate staging and patient selection, improvements in surgical techniques and postoperative care, novel chemotherapy regimens and new radiotherapy techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19398862&#34; target=&#34;_blank&#34;&gt;Pleural malignant mesothelioma causing cord infiltration through the nerve root. Case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
He had previous occupational exposure to asbestos while working at a car repair shop and had undergone right panpleuropneumonectomy under a diagnosis of sarcomatous type mesothelioma in the right pleural space. […] He died of respiratory failure 3 months after the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19401544&#34; target=&#34;_blank&#34;&gt;Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Technical robustness was determined by using up to 30 specimens per patient, two biopsy techniques, and two performance sites.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19404212&#34; target=&#34;_blank&#34;&gt;Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We studied patterns of local and nodal recurrence in patients treated at our institution with EPP and RT, and whether advanced treatment planning techniques, such as intensity modulated radiotherapy (IMRT), could have been of potential benefit.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19417672&#34; target=&#34;_blank&#34;&gt;Serum and pleural fluid biomarkers for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring. […] The majority of recent studies have evaluated the commercial MESOMARK assay in a diagnostic setting. […] The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19425525&#34; target=&#34;_blank&#34;&gt;Asbestos–a legacy and a persistent problem.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Following diagnosis of an asbestos related disease, financial recompense for ex-service personnel is limited, and the civilian legal implications continue to change.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1943191&#34; target=&#34;_blank&#34;&gt;Expanded applications of diagnostic and therapeutic thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The operative mortality rate was low (1%) and the diagnostic accuracy high (99%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19432887&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among the antigen-antibody relationships, the clinical usefulness of antibody titers in the sera was evaluated from the viewpoint of diagnosis of MPM and monitoring of therapeutic effects. […] The titers of the antibodies against Gene-X and THBS-2 could be used as tumor markers for the diagnosis and follow up of patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19433159&#34; target=&#34;_blank&#34;&gt;Benign cystic mesothelioma in a child.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Grossly, it resembled lymphangioma; however, histopathologic diagnosis was benign cystic mesothelioma (BCM), an entity that presents mainly in women of childbearing age.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19440826&#34; target=&#34;_blank&#34;&gt;Stage Ia malignant pleural mesothelioma: clinical course and appropriate diagnostic process.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early-stage malignant pleural mesothelioma (MPM) is difficult for physicians to diagnose, and the disease is usually advanced at the time of diagnosis. […] Because MPM could not be ruled out, video-assisted thoracoscopic surgery with pleural biopsy was performed for a definitive diagnosis. […] The postoperative histological diagnosis was early-stage MPM classified as T1a N0M0 disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19450893&#34; target=&#34;_blank&#34;&gt;COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis remains very poor with an average survival of 10 months from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19454358&#34; target=&#34;_blank&#34;&gt;Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The objective of this study was to analyze the diagnostic and clinical role of the folate receptor-alpha (FOLR1) and folate receptor-gamma (FOLR3) genes in effusion cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19461404&#34; target=&#34;_blank&#34;&gt;Spontaneous pneumothorax and lung carcinoma: should one consider synchronous malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The accurate diagnosis of synchronous tumors can be extremely challenging and the identification of a concomitant mesothelioma in our case was not made until an extensive immunohistochemical analysis was done on the resection specimen. […] Consequently, although synchronous pleural mesotheliomas and lung carcinomas are infrequent, this diagnosis should be considered when a patient with a lung mass and a history of asbestos exposure presents with spontaneous pneumothorax and pleural thickening on imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19472014&#34; target=&#34;_blank&#34;&gt;Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, dual time point imaging appears to be an effective approach in differentiating benign from malignant pleural disease, which increases the sensitivity and is also helpful in guiding the biopsy site for a successful diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19487281&#34; target=&#34;_blank&#34;&gt;Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multivariate analysis of 78 malignant mesothelioma patients with pathologic stage, histologic type, therapy, sex, and age at diagnosis indicated that ERbeta expression is an independent prognostic factor of better survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19499669&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The paraclinical investigations (echography) were not able to specify the diagnosis before the operation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19514493&#34; target=&#34;_blank&#34;&gt;[Twenty-one patients of malignant pleural mesothelioma in the Senshu district].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Twenty-one patients (15 men, 6 women, median age 67) were given a diagnosis of malignant pleural mesothelioma between March 1998 and December 2007 in our hospital. […] Mean period recuired for diagnosis was 60 days with VATS and percutaneous needle biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19514499&#34; target=&#34;_blank&#34;&gt;[Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was made by cytological examination of pleural effusion, using the cell block method for immunochemical staining. […] During these periods, diagnostic imaging indicated stable disease or progressive disease, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19514505&#34; target=&#34;_blank&#34;&gt;[Case of pemetrexed-induced acute lung injury].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural mesothelioma was made by CT-guided needle biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19516197&#34; target=&#34;_blank&#34;&gt;Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare specificity and sensitivity of the conventionally used clone 6F-H2 for the diagnosis of MPM to those of the new clone WT49.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19522163&#34; target=&#34;_blank&#34;&gt;Clinical utility of diagnostic markers for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma has a very dismal prognosis with very few patients surviving one year after diagnosis. […] More recently new molecules, such as soluble mesothelin and osteopontin, have been proposed for diagnostic purposes. […] Combining different markers together does not lead to an improvement in diagnostic accuracy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19523712&#34; target=&#34;_blank&#34;&gt;Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In effusion cytology, adjuvant techniques are often needed for the differentiation of reactive proliferating mesothelial cells and malignant cells. […] The first objective of this study was to adapt the commercial FISH-test, UroVysion originally designed for the cytological diagnosis of bladder cancer, to the analysis of cells in effusions. […] The cytological diagnosis was malignant in 29 cases, inconclusive in 24 cases and benign in 15 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19525027&#34; target=&#34;_blank&#34;&gt;Closed pleural biopsy to diagnose mesothelioma: dead or alive?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This letter explores the role of closed pleural biopsy in the diagnosis of malignant mesothelioma. […] Through retrospective analysis of local data, we found that closed pleural biopsy had a sensitivity of 44% in the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19527361&#34; target=&#34;_blank&#34;&gt;18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its diagnosis, staging and response assessment are challenging for imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19532013&#34; target=&#34;_blank&#34;&gt;Improving the outcome in malignant pleural mesothelioma: nonaggressive or aggressive approach?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
More than ever, the diagnosis and treatment of patients with malignant pleural mesothelioma mandate a multidisciplinary approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19535165&#34; target=&#34;_blank&#34;&gt;Impact of malignant mesothelioma in Taiwan: a 27-year review of population-based cancer registry data.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing incidence and significant EYLL for MM were observed for both males and females during 1979-2005 in Taiwan, although under-diagnosis and under-estimation were likely.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19536878&#34; target=&#34;_blank&#34;&gt;Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These aberrations are absent in benign mesothelial cells, and therefore their presence can be used to confirm a diagnosis of MM. […] The combination of FISH and karyotyping was found to improve on the diagnostic sensitivity of karyotyping alone in detecting MM in effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19550246&#34; target=&#34;_blank&#34;&gt;Pleural well-differentiated papillary mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This case report also highlights the role of fluid cytology, immunohistochemistry, and electron microscopy in the diagnosis of well-differentiated papillary mesothelioma and the potential use of serum CA-125 as a marker of progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19569174&#34; target=&#34;_blank&#34;&gt;Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma proportions in pleural cancers were calculated by diagnosis year in the 1980-2000 period. […] Finally, the increased trend observed in the incidence of pleural mesothelioma and cancers in women is credibly due to their under diagnosis in the 1980-1997 period.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19572412&#34; target=&#34;_blank&#34;&gt;Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ancillary use of immunocytochemistry, such as podoplanin (D2-40) and calretinin, supported the diagnostic accuracy of the SSMM. […] SSMM is useful for the differential diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19573998&#34; target=&#34;_blank&#34;&gt;Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since pulmonary adenocarcinomas, malignant mesotheliomas (MM), and sometimes benign mesothelial proliferations show a great histomorphological resemblance to each other, an immunohistochemical panel is usually necessary for differential diagnosis. […] The diagnosis of MM had previously been confirmed by a panel including calretinin, CK5/6, and CEA. […] We believe that D2-40 may be helpful in the differential diagnosis of MM from pleural involvement of pulmonary adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19581213&#34; target=&#34;_blank&#34;&gt;Interobserver variations in diagnosing asbestosis according to the ILO classification.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most important role in its diagnosis is that of chest radiographs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19588835&#34; target=&#34;_blank&#34;&gt;[Early malignant pleural mesothelioma; report of a case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
She received a diagnosis of epithelial type MPM which had been confirmed from a pleural biopsy spacemen obtained by thoracoscopy under local anesthesia. […] An early diagnosis of the MPM is very difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19605332&#34; target=&#34;_blank&#34;&gt;Isolated pancreatic metastasis of a malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Metastatic malignant mesothelioma of the pleura is uncommon at the time of initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19615083&#34; target=&#34;_blank&#34;&gt;Lung cancer gene expression database analysis incorporating prior knowledge with support vector machine-based classification method.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A reliable and precise classification is essential for successful diagnosis and treatment of cancer. […] Gene expression microarrays have provided the high-throughput platform to discover genomic biomarkers for cancer diagnosis and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19618209&#34; target=&#34;_blank&#34;&gt;Lymphangiomatoid pattern in diffuse malignant mesothelioma of the pleura: a report of six cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Identification of the multiplicity of patterns may help in the diagnosis of diffuse malignant mesothelioma. […] When seen in more solid areas of tumor, the lymphangiomatoid structures generally did not produce diagnostic difficulty.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19626629&#34; target=&#34;_blank&#34;&gt;Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We used Bayesian statistics and an evidence-based pathology (EBP) approach to retrospectively review the use of immunohistochemistry (IHC) in 153 consecutive pleural effusions evaluated in our laboratory from 2005-2007 for the differential diagnosis of malignant mesothelial cells versus carcinoma cells and to estimate the likely site of origin of a carcinoma. […] Cytopathologists had used 6 +/- 4.5 IHC tests per case for the diagnosis of malignant mesothelioma (n = 9) and carcinomas of lung (n = 60), breast (n = 47), Müllerian (n = 25), and other origins in the “training set”. […] The antibodies that provided the best PTO to diagnose the most prevalent tumors in our population were included in diagnostic panels for male (calretinin, TTF-1, PSA and CDX-2) and female (calretinin, TTF-1, ER and CA125) patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19627545&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma initially diagnosed on cervical lymph node biopsy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
F-18 fluorodeoxyglucose positron emission tomography/CT established the diagnosis of malignant pleural mesothelioma. […] Two conclusions emerge from this report: (i) cervical lymph node metastasis of pleural mesothelioma, although rare, should be included in differential diagnosis; and (ii) positron emission tomography/CT is useful for establishing a diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19632941&#34; target=&#34;_blank&#34;&gt;Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mayo Clinic databases were queried to identify cases with a histologic diagnosis of MPM from 2000 to 2006. […] Inclusion criteria were a diagnosis of MPM, an available CT scan, and an initial staging integrated CT-PET scan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19634115&#34; target=&#34;_blank&#34;&gt;Osteopontin is not a specific marker in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study is to define the role of OPN in the diagnosis of MPM by determining its prognostic and diagnostic value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19642427&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The interest for this cancer has been stimulated by recent improvements in the diagnosis and in the treatment of mesothelioma, including new cytotoxic drugs and multimodal treatment, associating chemotherapy, radical surgery and radiotherapy in prospective, randomised and multicentric trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19650163&#34; target=&#34;_blank&#34;&gt;The role of surgery in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery can be used in MPM for diagnostic and therapeutic purposes. […] Thoracoscopy is a useful tool to obtain tissue biopsy to establish a definitive diagnosis and to perform talc poudrage of the pleural cavity in order to prevent reaccumulation of fluid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19653732&#34; target=&#34;_blank&#34;&gt;Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To develop practical guidelines for the pathologic diagnosis of MM. […] There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. […] Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19660355&#34; target=&#34;_blank&#34;&gt;Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The risk of postoperative complications or death was not increased in patients undergoing surgery despite a preoperative diagnosis of venous thromboembolism. […] Patients with a venous thromboembolism diagnosis during induction therapy may potentially benefit from a temporary inferior vena cava filter before surgery to limit the risk of recurrent pulmonary embolism. […] A preoperative diagnosis of venous thromboembolism, however, does not affect early and late outcomes after surgery and should not be viewed as a negative prognostic marker.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19670115&#34; target=&#34;_blank&#34;&gt;The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the study was to assess the role of F-18 fluoro-2-D-deoxyglucose positron emission tomography ( (18)FDG-PET)/computed tomography (CT) in patients with undiagnosed pleural diseases and to compare the findings with those of invasive diagnostic procedures. […] For histopathological diagnosis, video-assisted thoracoscopic surgery was performed in 76 patients and a mini-thoracotomy was performed for the remaining 7 patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19699913&#34; target=&#34;_blank&#34;&gt;Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic yield (specimens containing lymphocytes or tumor cells) was 100% for mediastinoscopy and 84% for EBUS (p &amp;lt; 0.001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19708533&#34; target=&#34;_blank&#34;&gt;[Epidermal growth factor receptor aberrations in malignant mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition, we searched for ser473 p-Akt (p-Akt), which is activated by EGFR, and Epithelial Membrane Antigen (EMA), which is generally used as differential diagnosis marker of mesothelial cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19717482&#34; target=&#34;_blank&#34;&gt;Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To obtain an earlier and reliable diagnosis of MPM, the experts recommend performing thoracoscopy, except in cases of pre-operative contraindication or pleural symphysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19727362&#34; target=&#34;_blank&#34;&gt;Update on pleural diseases–2007.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors selected articles to make recommendations on diagnostic and treatment aspects of pleural diseases. […] 5-Amino-laevulinic acid with fluorescent light combined with white light may allow further diagnostic yield in undiagnosed pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19736192&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: an update on biomarkers and treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis can be challenging, since the results of pleural fluid cytology testing are often negative despite repeated sampling.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19738457&#34; target=&#34;_blank&#34;&gt;Tenascin-X is a novel diagnostic marker of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our data suggest that tenascin-X may be a new diagnostic marker of malignant mesothelioma in the differential diagnosis of cancers involving the serosal cavities, particularly in the differential diagnosis between this tumor and ovarian/peritoneal serous carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19745767&#34; target=&#34;_blank&#34;&gt;Hemithoracic radiotherapy after extrapleural pneumonectomy for malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Dose coverage of planning target volume and doses to spinal cord, liver, and ipsilateral kidney were similar with use of the two techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19754208&#34; target=&#34;_blank&#34;&gt;Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of malignant pleural mesothelioma (MM) is limited. […] Novel proteomic techno_logies can be utilized to discover changes in expression of pleural proteins that might have diagnostic value. […] Our study validates the use of SMRP as a diagnostic marker for pleural mesothelioma and furthermore suggests that Apo CI levels could be used in the future to discriminate pleural mesothelioma from other causes of exudates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19756620&#34; target=&#34;_blank&#34;&gt;[Immunocytochemical identification of carcinomas of unknown primaries on fine-needle-aspiration-biopsies].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical investigations with imaging- and endoscopic techniques in order to identify the primary tumor sites in patients with CUP syndrome generally entail a significant diagnostic effort. […] Therefore, immunocytochemical investigation of metastatic cancer cells from fine needle aspiration biopsies or in serous effusions offers an efficient, cost-effective diagnostic alternative to imaging and endoscopic techniques in the workup of patients with CUP syndrome.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19758456&#34; target=&#34;_blank&#34;&gt;Comparison of CT and integrated PET-CT based radiation therapy planning in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, 18-fluorodeoxyglucose positron emission tomography (PET) has demonstrated significant improvements in diagnosis and accurate staging of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19783262&#34; target=&#34;_blank&#34;&gt;Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is a highly aggressive tumor that can be difficult to diagnose, resulting in a delayed diagnosis in some cases. […] Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in the diagnosis of MM. […] Soluble mesothelin-related peptide measurement in pleural fluid may aid in the diagnosis of patients presenting with pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19821496&#34; target=&#34;_blank&#34;&gt;Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate whether immunocytochemical expressions of proliferation markers, such as minichromosome maintenance protein 7 (MCM 7), topoisomerase IIalpha (topo IIalpha), and Ki-67, in reactive mesothelial cells and malignant cells obtained from cavital fluids could be useful for their differential diagnosis. […] MCM 7 and topo IIalpha, in particular, could be reliable tools for differential diagnosis between reactive mesothelial cells and malignant cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822280&#34; target=&#34;_blank&#34;&gt;Current status of screening for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is characterized by its association with asbestos, its long latency period, and the propensity for the diagnosis to be obtained in the later stages of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822282&#34; target=&#34;_blank&#34;&gt;Current trends in radiologic management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging plays a crucial role in diagnosis and management. […] Perfusion and diffusion MRI are promising new techniques for the assessment of tumor cellularity and microvasculature and can be used for quantitative and qualitative assessment of treatment response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822283&#34; target=&#34;_blank&#34;&gt;Pathologic evaluation of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pathologists play an important role in the surgical management of diffuse malignant pleural mesothelioma, which relies heavily on accurate diagnosis and staging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822285&#34; target=&#34;_blank&#34;&gt;Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Knowledge of the similarities and differences between the two operations that have evolved-extrapleural pneumonectomy and pleurectomy/decortication-is prerequisite to understanding the complex issues associated with patient selection, diagnosis, pathologic staging, preoperative assessment, perioperative management, and adjuvant treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822288&#34; target=&#34;_blank&#34;&gt;Radiation therapy options for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New techniques such as helical tomotherapy and/or IMRT with the addition of electrons may also have a role in future treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19822290&#34; target=&#34;_blank&#34;&gt;Multimodality strategies in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Over the last decade, several improvements have been made in the diagnosis and treatment of malignant pleural mesothelioma, including better understanding of tumor biology, availability of more potent chemotherapeutic drugs, improved surgical management, and optimized multidisciplinary therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19824125&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the greater omentum mimicking omental infarction: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We recommend that primary omental mesothelioma should be included in the differential diagnosis of patients with omental infarction, despite its rarity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19827900&#34; target=&#34;_blank&#34;&gt;Asbestos exposure and malignant mesothelioma in Korea.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The magnitude of asbestos-related health problems in Korea has been underestimated due to under-diagnosis, incomplete reports, and shorter duration of exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-11-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/1983657&#34; target=&#34;_blank&#34;&gt;[Treatment of pleural metastases in an interdisciplinary concept].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy with histologic confirmation played a central role in our diagnostic procedures in 97% of the cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1992-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19856150&#34; target=&#34;_blank&#34;&gt;[Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant peritoneal mesotheliomas arise mainly in male patients and the median age of initial diagnosis is about 56 years. […] The mean latency period between exposure and diagnosis of peritoneal mesothelioma ranges from 35 to 40 years and is comparable to that of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19859843&#34; target=&#34;_blank&#34;&gt;Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, a diagnosis of pleural small cell carcinoma was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19864204&#34; target=&#34;_blank&#34;&gt;Porcelain factory worker with asbestos-related mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A chest X-ray revealed right-side pleural effusion; however, pleural biopsy from drainage treatment confirmed a diagnosis of malignant mesothelioma. […] Asbestos is a significant source of hazardous exposure in old buildings, and this case serves as a reminder of the importance of asbestos-related exposure history, which facilitated the correct diagnosis of pulmonary malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19875971&#34; target=&#34;_blank&#34;&gt;Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy or image-guided pleural needle biopsy were systematically performed to reveal pathologic diagnosis and/or clinical follow-up for at least 3 years for presence or absence of malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19885311&#34; target=&#34;_blank&#34;&gt;Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the patients with MPM, there was global diminished motion of the tumor bearing hemithorax, which improved significantly after chemotherapy (CHT) (assessed by the 2D- and 3D-techniques) (p &amp;lt; 0.01).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19887624&#34; target=&#34;_blank&#34;&gt;Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among the DNA hypermethylated genes, three (TMEM30B, KAZALD1, and MAPK13) were specifically methylated only in MPM and could serve as potential diagnostic markers. […] Our findings show a characteristic epigenetic profile of MPM and uncover multiple distinct epigenetic abnormalities that lead to the silencing of tumor suppressor genes in MPM and could serve as diagnostic or prognostic targets.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2009-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19934799&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It also indicates the usefulness of F-18 FDG PET/CT study in MPM in a difficult histopathological diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19945835&#34; target=&#34;_blank&#34;&gt;Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the present meta-analysis was to establish the overall diagnostic accuracy of the measurement of SMRPs for diagnosing malignant mesothelioma. […] After a systematic review of English language studies, sensitivity, specificity, and other measures of accuracy of serum SMRPs in the diagnosis of malignant mesothelioma were pooled using random-effects models. […] The summary estimates for SMRPs in the diagnosis of malignant mesothelioma in the studies included were sensitivity 0.64 (95% confidence interval 0.61-0.68), specificity 0.89 (0.88-0.90), positive likelihood ratio 7.10 (4.44-11.35), negative likelihood ratio 0.39 (0.31-0.48), and diagnostic odds ratio 19.35 (10.95-34.17). […] Serum SMRP determination plays a role in the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19999328&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: contribution and limitation of imaging for its diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although imaging features can be suggestive of malignant peritoneal mesothelioma, histologic examination of tissue with specific immunohistologic markers are mandatory for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/19999567&#34; target=&#34;_blank&#34;&gt;[Diagnosis of malignant pleural mesothelioma–thoracoscopic biopsy and tumor marker].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis and treatment of malignant pleural mesotheliomav (MPM) are quite difficult. […] However, for the definitive diagnosis of MPM, video-assisted thoracoscopic surgery (VATS) is necessary. […] Differential diagnosis between MPM and other malignancy is sometimes difficult, and erroneous results could be found without enough tissue. […] Sensitivity in the diagnosis of MPM with VATS is reported to be over 90%. […] Tumor markers, such as osteopontin and mesothelin, could be candidates for evaluating MPM without invasive diagnostic workup.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20021458&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: biology, diagnosis and therapeutic approaches.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The long promotion phase observed in MM pathogenesis and the absence of early symptoms both contribute to late diagnosis of the disease. […] There have been several developments in MM management, principally based on early detection, improved diagnosis, development of more effective therapies, and new insights into the pathobiology of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20033528&#34; target=&#34;_blank&#34;&gt;Comparison of diagnostic quality and accuracy in color-coded versus gray-scale DCE-MR imaging display.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to evaluate the diagnostic value and tumor-vascular display properties (microcirculation) of two different functional MRI post-processing and display (color and gray-scale display) techniques used in oncology. […] Eight raters, blinded to diagnosis, by visual assessment of post-processed images evaluated both diagnostic quality of the images and vasculature of the tumor using a rating scale ranging from -5 to +5. […] Color coded images were rated as significantly higher in diagnostic quality and tumor vascular score than gray-scale images (p &amp;lt; 0.001, 0.005). […] Color coded images were shown to have higher diagnostic quality and accuracy with respect to tumor vasculature in DCE-MRI, therefore their implementation in clinical assessment and follow-up should be considered for wider application.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2003429&#34; target=&#34;_blank&#34;&gt;Chest CT combined with artificial pneumothorax: value in determining origin and extent of tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study suggests that chest CT combined with artificial pneumothorax is useful for the evaluation of the extension of lung cancer into the chest wall and mediastinum and for the diagnosis of the site of origin of intrathoracic tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20043850&#34; target=&#34;_blank&#34;&gt;Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The alternatively spliced genes discovered in the study could serve as useful diagnostic markers as well as potential therapeutic targets for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20049969&#34; target=&#34;_blank&#34;&gt;The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The sensitivity of cytologic examination for its diagnosis varies widely in literature and most of the figures are from earlier studies with conventional cytologic preparations. […] The objective of this study was to provide the current evidence on the role and sensitivity of cytologic examination of pleural fluid in the diagnosis of MM. […] A specific diagnosis of MM was rendered or suspected in 53% (79 patients). […] On review of the cytology slides, only four cases were upgraded from benign to suspicious compared to four cases downgraded from suspicious to atypical but no significant improvement to the diagnosis could be made on revision. […] These data suggested that a cytologic diagnosis contributed useful information in patients with epithelioid and biphasic pleural MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20060157&#34; target=&#34;_blank&#34;&gt;IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall specificity for the diagnosis of malignancy was 94.9%, whereas the sensitivity was 72.6%. […] In the peritoneal effusions, the sensitivity for the diagnosis of metastatic adenocarcinoma to distinguish reactive mesothelial cells was 92.3%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20075387&#34; target=&#34;_blank&#34;&gt;Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To analyze the diagnostic performance of MPF as an MPM biomarker and compare this performance with SM. […] Combining both markers did not improve the diagnostic performance. […] The similar AUC values of SM and MPF, together with the limited difference in sensitivity, show that both serum biomarkers have an equivalent diagnostic performance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20081811&#34; target=&#34;_blank&#34;&gt;Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study represents the largest series of sarcomatoid and desmoplastic malignant mesotheliomas to date and confirms the diagnostic usefulness of CK immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20089367&#34; target=&#34;_blank&#34;&gt;Primary pleural epithelioid angiosarcoma. A case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean age at diagnosis was 58 years, and the male to female ratio was 6:1. […] The overall prognosis was poor, and most of the patients died of disease soon after diagnosis. […] Histological features and clinical presentation often cause several problems in the differential diagnosis, particularly with mesothelioma and metastasis from poorly differentiated carcinomas. […] The overall pathological and immunohistochemical features of the pleural specimens supported the diagnosis of epithelioid angiosarcoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2009740&#34; target=&#34;_blank&#34;&gt;Computed tomography of asbestos-related pulmonary parenchymal and pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ideally, imaging strategies that include CT should emphasize those problematic situations in which additional information will serve a differential or diagnostic function, alter the management or habits of the individuals, modify the working environment, or improve our understanding of asbestos-induced diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20104527&#34; target=&#34;_blank&#34;&gt;Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review examines the prospects for novel approaches in the prevention, diagnosis and treatment of malignant disease based on ASS1 pathophysiology and its rate-limiting product, arginine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20116740&#34; target=&#34;_blank&#34;&gt;[Management of pleural disease].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The yield of the distinct techniques for the diagnosis of tuberculous pleural effusion is assessed, with emphasis on analysis of sputum and pleural samples (fluid and tissue) for Mycobacteriumtuberculosis. […] The utility of adenosine deaminase (ADA) (in the absence of empyema, ADA &amp;gt; 70 U/l is diagnostic of tuberculous pleurisy, while values of less than 40 U/l exclude this diagnosis) and interferon gamma in pleural fluid (cut off: 3.7 Ul/ml) is also discussed. […] A multicenter study currently being performed in Spain found that soluble mesothelin-related protein (SMRP) levels higher than 0.55 nmol/L showed a sensitivity and specificity of 72% for the diagnosis of epithelial malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20117025&#34; target=&#34;_blank&#34;&gt;Primary malignant mesothelioma of the pericardium.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A malignant tumor was found on autopsy and a final diagnosis of primary malignant pericardial mesothelioma was made following histopathological examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20139227&#34; target=&#34;_blank&#34;&gt;Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of our study was to test chromosomal aberrations detected by fluorescence in situ hybridization (FISH) in the diagnosis of MM in effusion cytology and to explore the potential role of p16, p14, and p15 gene methylation as an alternative mechanism of tumor suppressor gene inactivation. […] FISH is a sensitive and highly specific method for the definitive diagnosis of MM in effusion cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20146302&#34; target=&#34;_blank&#34;&gt;Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma in serosal effusions continues to be a major challenge because some of its cytomorphological features closely resemble adenocarcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20148337&#34; target=&#34;_blank&#34;&gt;Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Circumscribed or localized malignant mesothelioma has been described in these locations, as well as the viscera, in which case it may cause diagnostic confusion with other, more common entities. […] This report also describes the clinical and pathologic characteristics of an intrapancreatic mesothelioma and provides a review of the literature regarding entities that may be considered in the differential diagnosis of this tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20153416&#34; target=&#34;_blank&#34;&gt;Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, COPA may have the potential of a therapeutic target and a new diagnostic marker of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20154079&#34; target=&#34;_blank&#34;&gt;Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aimed to compare the diagnostic efficiency and reliability of ANPB under CT scan guidance (CT-ANPB) with that of medical thoracoscopy in patients with pleural effusion. […] The two groups were compared in terms of diagnostic sensitivity and complications associated with the methods used. […] In the CT-ANPB group, the diagnostic sensitivity was 87.5%, as compared with 94.1% in the thoracoscopy group; the difference was not statistically significant (P = .252). […] We recommend the use of CT-ANPB as the primary method of diagnosis in patients with pleural thickening or lesions observed by CT scan. […] In patients with only pleural fluid appearance on CT scan and in those who may have benign pleural pathologies other than TB, the primary method of diagnosis should be medical thoracoscopy. clinicaltrials.gov; Identifier: NCT00720954.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20155346&#34; target=&#34;_blank&#34;&gt;Minute localized malignant pleural mesothelioma coexisting with multiple adenocarcinomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With a diagnosis of primary lung cancer, right upper lobectomy and wedge resection of the right lower lobe with systematic lymph node dissection was performed using video-assisted thoracoscopic surgery. […] The postoperative histological diagnosis was minute LMPM coexisting with multiple adenocarcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20165656&#34; target=&#34;_blank&#34;&gt;25-year old male with pleural thickening.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Their differentiation on the basis of histopathology can pose diagnostic difficulties; hence immunohistochemistry and electron microscopy may be required for further differentiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20175889&#34; target=&#34;_blank&#34;&gt;In vitro and in vivo characterization of highly purified human mesothelioma derived cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The identification of new mesothelioma markers may be useful for diagnosis and/or prognosis of this neoplasia as well as for isolation of mesothelioma tumor initiating cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20219385&#34; target=&#34;_blank&#34;&gt;Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A definitive histological diagnosis was achieved in 98 (69%) patients. […] The false-negative rate of thoracoscopic biopsy for the detection of pleural malignancy was 5%, with a diagnostic sensitivity of 95% and negative predictive value of 90%. […] Thoracoscopic pleural biopsy is valuable in the diagnosis of pleural malignancies. […] Patients with ‘nonspecific pleuritis/fibrosis’ require follow-up as a malignant diagnosis (especially mesothelioma) may eventually be established in approximately 12% of cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20228599&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma presenting as an acute surgical abdomen due to metastatic jejunal perforation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, he complained of acute abdominal pain 7 days after the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2024452&#34; target=&#34;_blank&#34;&gt;The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study the relationship between the histopathological diagnosis and the amount of tissue examined was investigated. […] In cases where the decisive diagnostic procedure had been an Abrams biopsy (the “small-specimen” technique) mixed-type histology was found in 36%. […] If thoracoscopy, thoracotomy or autopsy (the “large-specimen” techniques) had delivered a definite diagnosis, mixed-type histology was found in 63%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-06-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20298508&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of MM can be difficult. […] Definitive pathological diagnosis is required and it often requires an experienced pathologist to differentiate MM from other benign or malignant processes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2033489&#34; target=&#34;_blank&#34;&gt;The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was found in 13/14 of the adenocarcinomas but not in benign or malignant mesothelial tissue, making it a potential substitute for carcinoembyronic antigen (CEA) in the differential diagnosis of mesotheliomas from adenocarcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20338867&#34; target=&#34;_blank&#34;&gt;Mesothelioma risk associated with asbestos production in Slovenia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The probability of a mesothelioma case in the studied population was 8.5 times the probability of the same diagnosis in the whole of Slovenia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20345230&#34; target=&#34;_blank&#34;&gt;Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related protein (SMRP) is increased in the sera of patients with malignant mesothelioma (MM), and has been suggested as a diagnostic tool for MM in an asbestos exposed population.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20356754&#34; target=&#34;_blank&#34;&gt;Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aimed to obtain an upper estimate of any survival benefit conferred by resection in patients with a diagnosis of malignant pleural mesothelioma. […] We analysed published data concerning survival from diagnosis among four groups of patients with mesothelioma, identified by ascending level of intervention: (A) no surgery; (B) thoracotomy but no resection; (C) resection but no adjuvant treatment; and (D) resection as part of multimodality treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20371957&#34; target=&#34;_blank&#34;&gt;Localized malignant pleural mesothelioma showing a thoracic mass and metastasizing to the stomach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Total gastrectomy was performed and the histopathological diagnosis of metastasis of mesothelioma was made. […] Though it was very difficult to distinguish mesothelioma from sarcoma and other chest wall tumors, immunochemical staining was able to facilitate making the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20381267&#34; target=&#34;_blank&#34;&gt;Volumetric modulation arc radiotherapy compared with static gantry intensity-modulated radiotherapy for malignant pleural mesothelioma tumor: a feasibility study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both techniques fulfilled objectives on organs at risk with a tendency of RA to improve sparing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20386624&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was based on histological examination in 801 cases, and cytological findings in 10.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20403196&#34; target=&#34;_blank&#34;&gt;Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A poor Karnofsky Performance Status and delay between diagnosis of pleural effusion and pleurodesis were statistically significant factors for in-hospital mortality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20414089&#34; target=&#34;_blank&#34;&gt;Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Stage diagnosis and definition may be difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20414098&#34; target=&#34;_blank&#34;&gt;PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The presence of weak staining for PAX8 in the 3 “noninvasive” mesotheliomas questions the use for PAX8 in this differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20419999&#34; target=&#34;_blank&#34;&gt;[Radiologic manifestation of primary pleural tumors].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The imaging methods have a key role in the diagnosis of pleural tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20424652&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin-related protein in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Building-up evidence suggests that soluble mesothelinrelated protein (SMRP) carries a diagnostic and a prognostic value in malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20436345&#34; target=&#34;_blank&#34;&gt;Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several studies have confirmed the reliability of D2-40 in the diagnosis of pleural malignant mesothelioma, but the evaluation of this antibody in other pleural neoplasms is limited. […] The aim of this study was to determine the diagnostic value of D2-40 in segregation of malignant mesothelioma from other pleural or lung neoplasms. […] These results indicate that D2-40 is a valuable marker for malignant mesothelioma, but caution should be taken when evaluating D2-40-positive pleural spindle cell neoplasms in limited small biopsy specimens, especially when the differential diagnosis includes solitary fibrous tumor and malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20439224&#34; target=&#34;_blank&#34;&gt;Prognostic factors for 100 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One hundred consecutive patients with a pathologically proven diagnosis of malignant pleural mesothelioma treated between 1993 and 2005 were included in the study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20445731&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The peritoneal mesothelioma is a rare pathology with unspecific symptoms reason to be a difficult diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2046183&#34; target=&#34;_blank&#34;&gt;[A case of malignant pericardial mesothelioma detected by gallium-67 scintigraphy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Autopsy confirmed diagnosis of malignant pericardial mesothelioma. […] 67Ga scintigraphy may be useful in diagnosis of malignant pericardial mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20466560&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: the standard of care and challenges for future management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In an introductory section, the etiology, epidemiology, presentation, diagnosis and staging of MPM will be reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2047635&#34; target=&#34;_blank&#34;&gt;[Thoracic pain, dyspnea].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The suspected diagnosis of a malignant mesothelioma was confirmed by needle biopsy of a paraaortic lymph node.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20502186&#34; target=&#34;_blank&#34;&gt;Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin. […] Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P). […] In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated. […] A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P&amp;lt;0.001) and in the male (DOR=15.00, P&amp;lt;0.001) or female (DOR=12.77, P&amp;lt;0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs. […] Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20518890&#34; target=&#34;_blank&#34;&gt;9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the diagnostic utility of 9p21 homozygous deletion by fluorescence in situ hybridization (FISH) analysis has been reported only recently, it has not been well demonstrated. […] The purpose of this study is to evaluate the diagnostic utility of 9p21 homozygous deletion assessed by FISH in mesothelial neoplasm and hyperplasia of Japanese patients using paraffin-embedded tissue. […] Simultaneously, p16 protein immunoexpression was explored as a potential diagnostic aid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20524919&#34; target=&#34;_blank&#34;&gt;Surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding of this rare and aggressive malignancy. […] The influence of surgery goes beyond diagnosis and resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20532500&#34; target=&#34;_blank&#34;&gt;WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The transcription factor, WT1, is highly overexpressed in malignant pleural mesothelioma (MPM) and immunohistochemical stains for WT1 are used routinely to aid in its diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20541834&#34; target=&#34;_blank&#34;&gt;Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nevertheless, imaging in MPM plays a critical role in diagnosis, prognostication, prediction or measurement of response to therapy, and monitoring of disease recurrence after aggressive surgical management. […] These uses included FDG-PET imaging at the point of diagnosis, in prognostication, and in the assessment of response to chemotherapy. […] At diagnosis, FDG-PET parameters had a high sensitivity and specificity for differentiation of benign from malignant pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20560442&#34; target=&#34;_blank&#34;&gt;[A case of pulmonary epithelioid hemangioendothelioma that required differentiation from malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This disease should be included in the differential diagnosis together with malignant pleural mesothelioma, in cases demonstrating unusual pleural thickening.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20567102&#34; target=&#34;_blank&#34;&gt;[Osteoarthropathy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The presentation of HOA sometimes precedes the diagnosis of underlining malignancies, and consists of finger clubbing, polyarthralgia, and pain and swelling of forearms and lower thighs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20573057&#34; target=&#34;_blank&#34;&gt;Pearls and myths in pleural fluid analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Virtually all patients with a newly discovered pleural effusion should undergo thoracentesis to aid in diagnosis and management. […] If the effusion is an exudate, various PF tests have proven diagnostic utility: adenosine deaminase levels &amp;gt;35 IU/L usually indicate tuberculosis in lymphocyte-predominant PF; pH &amp;lt; 7.2 or glucose less than 60 mg/dL allow the clinician to identify complicated parapneumonic effusions; and conventional cytology may reveal malignant cells in 60% of the patients with malignant effusions. […] A number of optional PF tests may complement the diagnostic approach to an undiagnosed pleural effusion. […] For example, natriuretic peptide assays significantly improve the accuracy of a diagnosis of cardiac pleural effusion, whereas PF mesothelin levels greater than 20 nmol/L are highly suggestive of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20591913&#34; target=&#34;_blank&#34;&gt;FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
FISH for p16/CDKN2A deletion is a useful test for confirming the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20593749&#34; target=&#34;_blank&#34;&gt;Multimodality approach to malignant pleural mesothelioma. A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The disease free period was of about one year and the patient died after 31 months from diagnosis for septic complications related to chronic effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20613995&#34; target=&#34;_blank&#34;&gt;Predominantly fibrous malignant mesothelioma in a cat.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histopathological diagnosis can be quite challenging, as these neoplasms may resemble other epithelial or mesenchymal neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20617513&#34; target=&#34;_blank&#34;&gt;Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis of MM is critical for a better prognosis, but this is often difficult because of the lack of disease-specific diagnostic imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20628387&#34; target=&#34;_blank&#34;&gt;Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although most MPM patients show pleural effusion at even the early stage, it is hard to diagnose as MPM at the early stage because a sensitive and reliable diagnostic marker for MPM has not been found in plasma or pleural effusion. […] These results suggest that detection of intelectin-1 may be useful for a differential diagnosis of epithelioid-type MPM in immunohistochemistry and that a high concentration of intelectin-1 in pleural effusion can be used as a new marker for clinical diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20651171&#34; target=&#34;_blank&#34;&gt;Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathologic diagnosis was confirmed by surgical procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2065276&#34; target=&#34;_blank&#34;&gt;Usefulness of the nude mouse model in mesothelioma based on a direct patient-xenograft comparison.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient survived 18 months from onset of chemotherapy and 24 months from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20657552&#34; target=&#34;_blank&#34;&gt;Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, to evaluate the diagnostic utility of CD146 for discrimination between malignant pleural mesothelioma and reactive mesothelium, we examined immunocytochemical expression of CD146 in malignant pleural mesothelioma and reactive mesothelium using two clones of CD146 antibody, OJ79 and EPR3208, on smear specimens of effusion fluids. […] We propose that CD146 is a sensitive and specific immunocytochemical marker enabling differential diagnosis of malignant pleural mesothelioma from reactive mesothelium.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2068061&#34; target=&#34;_blank&#34;&gt;Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The light microscopic diagnosis, histochemical findings, immunohistochemical findings, and electron microscopic features of malignant mesotheliomas are reviewed in the context of differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20684215&#34; target=&#34;_blank&#34;&gt;[A case of localized malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Transbronchial lung biopsy was performed twice, but no definitive diagnosis was achieved. 18-fluorodeoxyglucose positron emission tomography showed abnormal uptake in the chest lesion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20684435&#34; target=&#34;_blank&#34;&gt;[Pulmonary concentration of asbestos fibers in steel workers with pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In all cases the diagnosis was given with histological analyses supplemented with immunohistochemistry. […] In 7 cases autopsied the diagnosis was confirmed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20715664&#34; target=&#34;_blank&#34;&gt;Pleural liposarcoma mimicking carcinoma in pleural effusion cytology: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytologic diagnosis of pleural liposarcoma is difficult due to its rarity and resemblance to malignant mesothelioma. […] Cytologic properties of liposarcoma in pleural fluid should be well known and considered in the differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20722572&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma with associated minimal change disease and acute renal failure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 58-year-old man with occupational exposure to asbestos presented with severe peripheral edema, heavy proteinuria, and acute renal failure shortly after the diagnosis of mesothelioma had been confirmed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2072707&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients had the pathologic diagnosis reviewed before treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20737138&#34; target=&#34;_blank&#34;&gt;Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The average time between sample collection and diagnosis was 4.7 years. […] Even in those cases, where biomarker concentrations were available within 36 months before diagnosis, no trend for increasing biomarker levels was observed. […] SMRP, CA125, and CYFRA21-1 alone or in combination were less suitable to serve as predictors for the diagnosis of lung cancer or malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20740175&#34; target=&#34;_blank&#34;&gt;Primary Pericardial Mesothelioma: Report of a Patient and Literature Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
During the postoperative period the patient’s condition ameliorated, but symptoms recurred and the patient died 3 months after diagnosis and 15 months after the first symptoms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20798014&#34; target=&#34;_blank&#34;&gt;Incidence of extrapleural malignant mesothelioma and asbestos exposure, from the Italian national register.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Classification and code criteria for certainty of diagnosis and exposure modalities are set by national guidelines. […] Mean age at diagnosis for all extrapleural malignant mesothelioma cases was 64.4 years and the men/women ratio was 1.57:1. […] The rarity of the disease, the low specificity of diagnosis and difficulties in identifying the modalities of asbestos exposure call for caution in discussing aetiological factors other than asbestos.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20798232&#34; target=&#34;_blank&#34;&gt;Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three hundred and fourteen patients with an adjudicated diagnosis of mesothelioma were examined. […] Of 314 patients, 223 (71%) died and only 40 (13%) were still alive at the end of the observation period starting from the day of diagnosis, while 51 (16%) were transferred to other hospitals or had the last health service contact before the end of the study period yielding the median survival of 308 days.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20815094&#34; target=&#34;_blank&#34;&gt;Sensitivity of urinary mesothelin in patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sensitivities were determined and receiver operator characteristic curves were generated to compare the diagnostic accuracy of mesothelin in the serum and urine. […] The sensitivity of urinary mesothelin does not warrant the use of urine as a biomarker specimen for MM diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20819444&#34; target=&#34;_blank&#34;&gt;The diagnostic utility of maspin in the distinction between malignant mesothelioma and pulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study investigated the presence of the serine protease, maspin, in epithelioid MMs and evaluated the diagnostic utility of maspin for the differential diagnosis between epithelioid MM and pulmonary AC with pleural involvement. […] Despite these findings, the sensitivity and specificity of maspin positivity to detect AC were only 59% and 73%, respectively, indicating that detection of maspin is of no value for the differential diagnosis of AC and MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20836004&#34; target=&#34;_blank&#34;&gt;Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The objective of the study is to estimate the expression of some antibodies in the metastatic adenocarcinomas, malignant epithelial mesotheliomas, and reactive mesothelial cells in serous effusions and to choose effective panel to the differential diagnosis. […] In our opinion, the antibody panel that consists of E-cadherin, CEA, calretinin, and thrombomodulin should be the best for differential diagnosis between metastatic adenocarcinomas and RM/MM in serous effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20846704&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in a female lion (Panthera leo).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological and immunohistochemical findings were consistent with the diagnosis of an epithelial malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20853774&#34; target=&#34;_blank&#34;&gt;[Expectations after ban on asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sadly, the diagnosis of mesothelioma is seldom timely, and treatment is usually unsuccessful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20853778&#34; target=&#34;_blank&#34;&gt;[Immunological aspects of asbestos-related diseases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no specific antibody for malignant mesothelioma as yet which could act as a single diagnostic tool.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20853780&#34; target=&#34;_blank&#34;&gt;[Croatian and international regulations on the protection and rights of workers exposed to asbestos at work].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The 2008 Croatian regulation on conditions of health surveillance, diagnostic procedures and criteria for confirmation of occupational asbestos-related diseases &amp;quot;defines the terms and the content of medical examination of workers exposed to asbestos, and criteria for the confirmation of occupational asbestos-related diseases which are harmonised with the Helsinki criteria acknowledged by ILO and EU, particularly concerning the level and length of exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20864637&#34; target=&#34;_blank&#34;&gt;A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The definitive identification of malignant pleural mesothelioma (MPM) has significant clinical implications, yet other malignancies often involve the lung pleura, confounding the diagnosis of MPM. […] We identified microRNA biomarkers for the differential diagnosis of MPM and developed a standardized microRNA-based assay. […] We developed a standardized diagnostic assay based on the expression of these microRNAs. […] This diagnostic assay can provide a useful tool in the differential diagnosis of MPM from other malignancies in the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20868849&#34; target=&#34;_blank&#34;&gt;A rare cause of dysphagia: malignant pleural mesothelioma in the posterior mediastinum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopic biopsies of the mediastinal mass failed to yield a pathologic diagnosis. […] The histopathologic and immunohistochemical findings of the biopsy were consistent with the diagnosis of pleural malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20871264&#34; target=&#34;_blank&#34;&gt;Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Variables analyzed included age, sex, race, year of diagnosis, region, vital status, stage, surgery, and reasons for no surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20878622&#34; target=&#34;_blank&#34;&gt;Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A potential role of serum osteopontin (OPN) and serum mesothelin-related peptide (SMRP) in the diagnosis of malignant pleural mesothelioma (MPM) has been recently reported. […] Our study aimed to evaluate the influence of preanalytic variables on serum and plasma OPN, to compare serum and plasma OPN in the same population, and to assess whether OPN levels can aid in the diagnostic distinction of patients with MPM versus benign respiratory disease (BRD) and healthy subjects exposed to asbestos. […] Plasma and serum OPN may be useful markers in the diagnosis of epithelial MPM in addition to traditional radiological exams.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20881372&#34; target=&#34;_blank&#34;&gt;A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pretreatment clinical, laboratory and radiographic features of each patient at the time of diagnosis were obtained from patients’ charts.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20887499&#34; target=&#34;_blank&#34;&gt;Prevention of malignant seeding at drain sites by hypofractionated radiotherapy in patients with pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients underwent surgery or thoracoscopy and/or talc pleurodesis, for diagnosis, staging procedures or as a treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20920392&#34; target=&#34;_blank&#34;&gt;[Sarcomatoid mesothelioma–a diagnostic challenge].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis has important legal implications for the relatives, we therefore find it important to stress that sarcomatoid mesothelioma is usually calretinin-negative.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-10-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20924566&#34; target=&#34;_blank&#34;&gt;Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic procedure of MPM is difficult and often requires invasive approaches; therefore, it is clinically important to find accurate markers for MPM by new noninvasive methods that may facilitate the diagnostic process and identify patients at an earlier stage. […] In the present study, the exhaled breath of 13 patients with histology-established diagnosis of MPM, 13 subjects with long-term certified professional exposure to asbestos (EXP) and 13 healthy subjects without exposure to asbestos (healthy controls, HC) were analysed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20948267&#34; target=&#34;_blank&#34;&gt;[A case of diffuse peritoneal malignant mesothelioma–intraabdominal administration of cisplatin is useful for diminishing ascites].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We performed laparoscopic observation for definite diagnosis and found fine white particles at the peritoneum. […] He lived for a year with no recurrence but died 23 months after diagnosis because of progression of pleural mesothelioma and liver metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20965393&#34; target=&#34;_blank&#34;&gt;Contribution of positron emission tomography in pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PET should therefore be considered as a useful tool in the diagnosis of liquid or solid pleural pathologies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20968144&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiation therapy with simultaneous integrated boost in unresected left-sided pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three years from the diagnosis, the patient is alive and in good general condition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/20970161&#34; target=&#34;_blank&#34;&gt;The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This is especially the case when the diagnostic material is a small biopsy specimen or a cytology specimen with scant cellularity. […] In addition, suboptimal processing and crush artifact may limit accurate diagnosis. […] A reliable diagnostic biomarker that preferentially highlights malignant processes and high-grade tumors would be very valuable in segregating these entities from reactive processes and low-grade lesions. […] Recent extensive studies have shown that an oncoprotein, insulin like-growth factor II messenger RNA binding protein-3, is not only a prognostic biomarker but also a diagnostic molecule. […] This review focuses on discussing the value of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology, with a focus on utilization of insulin like-growth factor II messenger RNA binding protein-3 in the discrimination of benign effusions from malignant effusions, malignant mesothelioma from mesothelial hyperplasia, carcinoids from high-grade neuroendocrine carcinomas, low-grade dysplasia from high-grade dysplasia, hepatocellular carcinoma from hepatic adenoma, cholangiocarcinoma and metastatic pancreatic ductal carcinoma from benign bile duct lesions, melanoma from nevi, and follicular thyroid carcinoma from follicular adenoma of the thyroid, as well as examining insulin like-growth factor II messenger RNA binding protein-3 expression in lymphomas of germinal center origin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2102353&#34; target=&#34;_blank&#34;&gt;Cytopathology of malignant mesothelioma. Reappraisal of the diagnostic value of collagen cores.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We examined the diagnostic value of collagen cores within clusters of tumour cells in cytological smears prepared from effusions from 43 patients with malignant mesothelioma and of 62 cases of metastatic adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21041073&#34; target=&#34;_blank&#34;&gt;Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM has a limited response to conventional chemotherapy and radiotherapy so early diagnosis of MPM is very important. […] Our data suggest that the pleural effusion VEGF concentration could be useful as an aid for the diagnosis of MPM and as a prognostic factor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21043818&#34; target=&#34;_blank&#34;&gt;Sarcomatoid neoplasms of the lung and pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sarcomatoid neoplasms of the lung and pleura are rare tumors that present a complex differential diagnosis, making them challenging for surgical pathologists. […] Diagnosis is difficult in small biopsy specimens and typically requires a resection specimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-11-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21044972&#34; target=&#34;_blank&#34;&gt;What is the best way to diagnose and stage malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The question addressed was which diagnostic modality [computed tomography (CT), positron emission tomography (PET), combination PET/CT and magnetic resonance imaging (MRI)] provides the best diagnostic and staging information in patients with malignant pleural mesothelioma (MPM). […] We conclude that fluorodeoxyglucose (FDG)-PET is superior to MRI and CT but inferior to PET-CT, in terms of diagnostic specificity, sensitivity and staging of MPM. […] Overall, the high specificity and sensitivity rates seen with open pleural biopsy make it a superior diagnostic modality to CT, MRI or PET for diagnosing patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21053546&#34; target=&#34;_blank&#34;&gt;Cutaneous needle track seeding of mesothelioma diagnosed by fine needle aspiration cytology: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic and therapeutic procedures for mesothelioma require surgical biopsy or the usage of different-sized needles. […] Thoracentesis was performed using a 22-gauge needle; the cytologic diagnosis was malignant pleural mesothelioma. […] A diagnosis of chest wall involvement from mesothelioma was established and histologically confirmed. […] Chest wall infiltration is a definite risk in the management of pleural mesothelioma, and FNAC is a useful procedure for a timely diagnosis of this ominous complication.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2106209&#34; target=&#34;_blank&#34;&gt;CT in differential diagnosis of diffuse pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the accuracy of these features in the differential diagnosis of diffuse pleural disease has not been assessed before. […] We conclude that CT is helpful in the differential diagnosis of diffuse pleural disease, particularly in differentiation of malignant from benign conditions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21079519&#34; target=&#34;_blank&#34;&gt;The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We examined the diagnostic performance of soluble (s) CD44v6 and CD44 standard (sCD44std) as biomarkers for nonmesothelioma pleural malignancies in a retrospective series. […] The pleural fluid sCD44v6/std ratio may be a new diagnostic marker in the differential diagnosis between primary mesothelioma and other pleural malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21086578&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma: a case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In both cases the diagnosis was establishes through both biopsy conducted by laparoscopy and ascites fluid cytology. […] Peritoneal mesothelioma, although rare, should be considered among the differential diagnosis of ascites differential diagnosis work up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2010-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21088255&#34; target=&#34;_blank&#34;&gt;Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The correct diagnosis of MPM is sometimes challenging and usually requires solid tissue biopsies rather than fine-needle aspiration biopsies (FNA). […] We postulated that the accuracy of FNA-based diagnosis might be improved by the addition of molecular tests using a gene expression ratio-based algorithm and that prognostic tests could be similarly performed. […] On the basis of these results, 276 ex vivo FNA biopsies from 63 MPM patients and 250 ex vivo FNA samples from 92 lung cancer patients were analyzed using previously described diagnostic and prognostic tests based on gene expression ratios. […] We found that the sensitivity of the diagnostic test for MPM was 100% [95% confidence interval (CI): 95%-100%] and the specificity in primary lung adenocarcinoma was 90% (95% CI: 81%-95%). […] In particular, we show that the gene expression ratio algorithms performed well when applied to diagnosis and prognosis in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21106421&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical follow-up in 7 of 7 patients demonstrated a mean survival of 10 months from time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21115893&#34; target=&#34;_blank&#34;&gt;Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The up-regulation of 14-3-3 sigma may play an important role in SGC carcinogenesis and progression and may be used as a diagnostic biomarker of SGC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21132036&#34; target=&#34;_blank&#34;&gt;Delayed bronchial stump dehiscence following trimodality treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Delayed fistula following tri modality treatment for mesothelioma is a serious problem regarding diagnosis and treatment. […] Prophylactic augmentation of right sided stumps with vascularised muscle flap, shielding of pathology proven negative stumps during radiotherapy and improvement of radiation techniques may improve the dose distribution.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21156353&#34; target=&#34;_blank&#34;&gt;Pericardial mesothelioma and asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We identified 8 cases (6 men and 2 women), with a median age at diagnosis of 55.5 years, representing 0.3% of all mesothelioma cases (n = 3059).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21172937&#34; target=&#34;_blank&#34;&gt;Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
VEGF increased the diagnostic rate of cytological examination by 24%. […] VEGF may represent a helpful adjunct to conventional diagnostic tools in ruling out malignancy as a probable diagnosis, thus guiding the selection of patients who might benefit from further invasive procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21173534&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: a clinical study of 238 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean age at diagnosis was 70.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21173562&#34; target=&#34;_blank&#34;&gt;[A case of peritoneal mesothelioma with direct invasion to gastric mucosa].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological studies with immunohistochemical stain is helpful for the diagnosis of peritoneal mesothelioma and imaging modality alone is not sufficient for diagnosis, so it is difficult to confirm diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2117478&#34; target=&#34;_blank&#34;&gt;[Treatment of malignant mesothelioma using intrapleural gamma interferon].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was achieved by thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21183177&#34; target=&#34;_blank&#34;&gt;Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer–Occam’s razor or the “third man”.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To illustrate pitfalls in the diagnosis of endometriosis and cervical cancer. […] Steps to the correct diagnosis. […] Usually, the simplest diagnosis explaining a complex of symptoms and clinical and diagnostic findings is the one most likely to be correct. […] Our case illustrates that occasionally the simplest and therefore most probable diagnosis can be wrong, and on these occasions one should consider a “third man.”
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21194504&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma in paraoccupational, environmental and occupational patients exposed to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was confirmed by cytohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21205078&#34; target=&#34;_blank&#34;&gt;Establishment of a cell line from a Japanese patient useful for generating an in vivo model of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The in vivo model using MM56 cells may be useful for studying the biological behavior of malignant pleural mesothelioma and developing its diagnostic and therapeutic strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21210110&#34; target=&#34;_blank&#34;&gt;FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study investigated the diagnostic performance and prognostic value of fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in suspected malignant pleural mesothelioma (MPM) recurrence, in the context of patterns and intensity of FDG uptake, histologic type, and treatment algorithm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21213198&#34; target=&#34;_blank&#34;&gt;The pleura in health and disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Knowledge of the clinical setting (e.g., disease tempo) and radiological picture (e.g., laterality) is often of great value to the pathologist in arriving at a correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21239356&#34; target=&#34;_blank&#34;&gt;Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to investigate the effectiveness of thoracoscopy in the diagnosis of non-affiliated pleural effusions (PE). […] Malignant diagnosis was established according to a pleural biopsy, compatible cytology and/or clinical features. […] Thoracoscopy confirmed previous clinical diagnosis of benignity and malignity. […] Our results indicate that thoracoscopy is a cost-effective and reliable technique for obtaining histological diagnosis in PE and also allows a directed pleurodesis if indicated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21258257&#34; target=&#34;_blank&#34;&gt;Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In patients with inoperable intrathoracic malignancies, computed tomography-guided IRT-HDR-BRT is a safe and effective alternative to other locally ablative techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21266493&#34; target=&#34;_blank&#34;&gt;Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The question addressed was whether positron emission tomography is useful in the diagnosis and prognosis of malignant pleural mesothelioma (MPM). […] Eleven studies evaluated the role of FDG-PET in the diagnosis and prognosis of MPM. […] Four studies observed the role of FDG-PET-CT in the diagnosis and prognosis of MPM. […] One study compared the utility of PET and PET-CT in the diagnosis and prognosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21266919&#34; target=&#34;_blank&#34;&gt;Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We retrospectively investigated the accuracy of classifying histological subtype on diagnostic biopsies and examined the impact of different diagnostic procedures on the outcome. […] The histological subtype obtained at review was compared with the initial diagnosis. […] Different diagnostic methods were used before EPP: 81% thoracoscopy; 7% thoracotomy; 11% computed tomography-guided procedure; and 1% other. […] Patients determined to have an epithelial subtype (n = 64) at EPP were diagnosed correctly at initial diagnostic biopsy in 84% of cases, whereas patients considered to have a biphasic subtype (n = 19) at EPP were diagnosed correctly at diagnostic biopsy in 26% of cases. […] The sensitivity and specificity of diagnostic biopsy for epithelial MPM was 93% and 31%, respectively. […] The determination of histological subtype from a diagnostic biopsy is difficult due to sampling error, but an adequate specimen obtained from surgical biopsy increases the accuracy of subtype classification compared with radiological-guided biopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21309996&#34; target=&#34;_blank&#34;&gt;Asbestos-related disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review provides insight into the history and epidemiology of asbestos-related disease in Australia and discusses relevant clinical aspects in their diagnosis and management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21329571&#34; target=&#34;_blank&#34;&gt;Peritoneal mesothelioma: description of a case and review of literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient subsequently was subjected to cycles of chemotherapy and multiple palliative paracentesis, the patient died after about 12 months from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21351265&#34; target=&#34;_blank&#34;&gt;Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a rapidly fatal disease whose diagnosis, particularly through less invasive techniques such as analysis of pleural effusion, can be challenging. […] Currently, a commercially available diagnostic test based on microRNA (miRNA) expression patterns is purported to distinguish between mesothelioma and lung adenocarcinoma. […] Statistical analysis reveals that these miRNAs exceed the current recommendations for biomarkers and could greatly aid in the differential diagnosis. […] This research points to novel approaches using miRNAs whose decreased expression is unique to mesothelioma as potentially suitable for rapid diagnosis and reveals prospective new targets for the treatment of this deadly disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21353719&#34; target=&#34;_blank&#34;&gt;5-Aminolevulinic acid-induced fluorescence diagnosis of pleural malignant tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is known that endogenously synthesized protoporphyrin IX (PpIX) following the administration of 5-aminolevulinic acid (5-ALA) is an effective photosensitizer for photodynamic diagnosis (PDD). […] We tested in vivo and in vitro susceptibility of human lung cancer and mesothelioma cells to photodynamic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA) as a photosensitizer. […] In vivo, the tumor detection rate of fluorescence diagnosis was 1.1-4.5 times higher than that of white light. […] Small lesions were detected by fluorescence diagnosis even though the lesions were invisible macroscopically under white light. […] Our results suggest the possibility of clinical application of fluorescence diagnosis with intrapleural malignant tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21356356&#34; target=&#34;_blank&#34;&gt;Identification of novel markers for the diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural mesothelioma is difficult, with the most common differential diagnoses being benign pleural diseases and metastatic adenocarcinomas (ADCA). […] To identify novel markers that would be able to improve diagnostic accuracy, we performed a genome-wide gene expression analysis on tumor cell lines established from pleural effusions (malignant pleural mesothelioma and lung ADCA). […] In conclusion, type III collagen, CCL2, and galectin-3 are promising new diagnostic markers for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21362105&#34; target=&#34;_blank&#34;&gt;Pathology of the pleura: what the pulmonologists need to know.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis of pleural disease is therefore extremely important, and histological interpretation of pleural biopsies is vital to rendering an accurate diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21362728&#34; target=&#34;_blank&#34;&gt;Tumor extension along chest wall tract after diagnostic intervention in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between 2006 and 2010, 14 patients with MPM underwent chest wall intervention for diagnosis in Kyoto University Hospital. […] Seven of them underwent extrapleural pneumonectomy (EPP) after the diagnosis, while seven did not undergo EPP. […] Despite the small number of cases, the importance of resection of the chest wall tract for the diagnostic intervention might be implied at EPP.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21368492&#34; target=&#34;_blank&#34;&gt;[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Transcutaneous pleural biopsy yielded a diagnosis of malignant mesothelioma(IMIG cT4N0M0, Stage IV ). […] Transbronchial lung biopsy yielded a diagnosis of squamous cell carcinoma of the lung (cT3N0M0, Stage III B). […] Our diagnosis was double cancer, malignant mesothelioma and lung cancer. […] More attention must be paid in making a diagnosis of malignant mesothelioma and lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21397972&#34; target=&#34;_blank&#34;&gt;Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma–which is best?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Plasma osteopontin has a superior diagnostic accuracy to serum.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21411785&#34; target=&#34;_blank&#34;&gt;The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two promising ancillary tests used in the diagnosis of mesothelioma include GLUT-1 immunohistochemical analysis and fluorescence in situ hybridization (FISH) testing for the p16 deletion. […] This study compared the diagnostic usefulness of p16 FISH and GLUT-1 immunohistochemical analysis in the diagnosis of mesothelial proliferations in 158 cases with a diagnosis of benign (45.4%), atypical (10.4%), or malignant/mesothelioma (44.2%). […] Our results demonstrate that p16 FISH is a more sensitive and specific test than GLUT-1 immunohistochemical analysis and can be a more reliable ancillary tool to support the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21436629&#34; target=&#34;_blank&#34;&gt;Molecular biomarkers in malignant mesothelioma: state of the art.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MM can be difficult, both from a clinical and pathological perspective. […] It is not unusual for patients to undergo several medical investigations without definitive diagnosis early in their course of illness. […] Understandably, there is intense interest in the discovery of markers that can be assessed in pleural effusions, histological specimens, and serum to assist with the difficult early diagnosis of MM. […] In this review we focus on biomarkers that have been examined in the setting of either early diagnosis of MM in symptomatic patients or screening of asbestos-exposed individuals.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21448170&#34; target=&#34;_blank&#34;&gt;Markers for the non-invasive diagnosis of mesothelioma: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Numerous markers have been evaluated to facilitate the non-invasive diagnostic work-up of mesothelioma. […] The purpose of this study was to conduct a structured review of the diagnostic performance of non-invasive marker tests for the detection of mesothelioma in patients with suspected mesothelioma. […] Studies on the diagnostic accuracy of serum and cytological markers published till 31 December 2009, available in either PUBMED or Embase, to detect or exclude the presence of mesothelioma were extracted. […] Currently, there is only limited evidence to properly assess the value of non-invasive marker tests in the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21461290&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the spermatic cord.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Following the diagnosis after surgery, he was found to have a contralateral right inguinal mass and died in 6 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21465419&#34; target=&#34;_blank&#34;&gt;Surgical treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, over the last fifteen years there have been substantial improvements in the diagnosis and treatment of MPM, including easier and more accurate diagnostic techniques, improved methods of staging, more effective systemic therapy, a remarkable decrease in operative mortality, marked improvements in local control with adjuvant therapy, and perhaps most important, an emphasis on multidisciplinary care and multimodality clinical trials.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21469421&#34; target=&#34;_blank&#34;&gt;Cytopathologic diagnosis in pleural effusion and cyto-histopathologic correlation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological examination of pleural fluids is a fast, efficient and non-invasive diagnostic method. […] Cytological examination is the most valuable diagnostic method for pleural effusions which may have various etiological causes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2147220&#34; target=&#34;_blank&#34;&gt;Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For this reason immunologic methods are being increasingly used as diagnostic adjuncts. […] Thus, together with identification of the antigen in serum, pleural fluid, or ascitic fluid, immunohistochemical and immunocytochemical techniques for detecting carcinoembryonic antigen provide a valuable aid for distinguishing malignant mesothelioma from metastatic carcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21473730&#34; target=&#34;_blank&#34;&gt;Soluble markers for diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM has a poor prognosis, in part, owing to a difficult and often late diagnosis hindered by a lack of available tests able to diagnose or predict this cancer in its early stages. […] Recently, there has been increased interest in noninvasive, economic and well-accepted diagnostic tests for screening of asbestos-exposed subjects, as well as for monitoring response of MPM patients to treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21479894&#34; target=&#34;_blank&#34;&gt;Imaging of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging plays a crucial role in diagnosis and optimal management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21479898&#34; target=&#34;_blank&#34;&gt;Surgical therapy of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Though well accepted as a diagnostic modality, surgery is also frequently used to establish stage, provide palliation, and perhaps most controversially, to offer cytoreduction with the putative goal of delaying tumor progression and prolonging survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21483773&#34; target=&#34;_blank&#34;&gt;Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Improved detection methods for diagnosis of malignant pleural mesothelioma (MPM) are essential for early and reliable detection as well as treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21488172&#34; target=&#34;_blank&#34;&gt;Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The identification of metastatic cells in serous effusions has prognostic and therapeutic implications, thus leading to a continuous search for improvement of the existing diagnostic procedures, including immunocytochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21501299&#34; target=&#34;_blank&#34;&gt;Multicystic mesothelioma of the pericardium.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pericardial biopsy showed micro-cystic tumor lined by single layer of mesothelial cells without atypia, and the diagnosis was multicystic mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21513537&#34; target=&#34;_blank&#34;&gt;A case report of metastasis of malignant mesothelioma to the oral gingiva.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article highlights the importance of biopsy and histopathological diagnosis of oral lesions especially in case of a malignant history.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21519267&#34; target=&#34;_blank&#34;&gt;Outcome of patients with nonspecific pleuritis at thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Additional features, such as malignant cells, caseating granulomas and evidence of vasculitis, are required to make an aetiological histological diagnosis; in the absence of these features, the term ‘nonspecific pleuritis/fibrosis’ (NSP) is used. […] NSP is a histological diagnosis made in approximately 30-40% of patients with an undiagnosed exudative pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21532523&#34; target=&#34;_blank&#34;&gt;Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The sensitivity of positive calretinin labelling to confirm the diagnosis of MPM was 97.5%, while the ‘diagnostic sensitivities’ of lack of labelling for BG8 and CD15 were 91.3% and 97.5%, respectively. […] We have validated the usefulness of a minimal panel of antibodies with calretinin, BG8 and CD15 as the initial step to the diagnosis of MPM. […] D2-40 emerged as a helpful diagnostic tool for cases where our initial approach failed to conclusively diagnose MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21537191&#34; target=&#34;_blank&#34;&gt;The diminishing role of surgery in pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Traditionally, many patients were subjected to surgery for diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21573909&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review explores the clinical presentation of MPM, its diagnostic approach and the relevant and recent studies that define the role of chemotherapy, radiation, and various surgical options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21574259&#34; target=&#34;_blank&#34;&gt;Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To differentiate reactive mesothelial cells (RMs) from metastatic carcinoma and malignant mesothelioma (MM) in effusion cytology is crucial for the cytologic diagnosis and the management of the patients. […] The findings of the present study indicate that the immunocytochemical staining for EMA, IMP3, and GLUT-1 is a useful diagnostic tool for distinguishing effusions containing malignant cells from those that contain benign cells, and in particular, we suggest that the combination of mGLUT-1 and EMA, and IMP3 and EMA are extremely useful in pleural effusion and in ascites, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21619970&#34; target=&#34;_blank&#34;&gt;Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study reviewed the results of patients who underwent a macroscopic complete resection, by two different surgical techniques, and intraoperative PDT as a treatment for malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21620418&#34; target=&#34;_blank&#34;&gt;Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study asks whether integrin-linked kinase can also be detected in serum of patients with malignant pleural mesothelioma and whether serum level has diagnostic or prognostic relevance for that disease. […] Serum integrin-linked kinase concentration greater than 2.48 ng/mL had diagnostic sensitivity of 80%, specificity of 95%, positive predictive value of 85.7%, negative predictive value of 92.7%, and overall accuracy of 91% for distinction between malignant pleural mesothelioma and other diseases. […] Integrin-linked kinase can be detected in serum of patients with malignant pleural mesothelioma and may be a diagnostic marker for the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21620489&#34; target=&#34;_blank&#34;&gt;Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Human malignant pleural mesothelioma (hMPM) is an aggressive asbestos-associated cancer, the incidence of which is increasing and which, despite progress in diagnosis and therapy, continues to have a poor prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21641092&#34; target=&#34;_blank&#34;&gt;[Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, these techniques cannot predict early response to therapy, because of the slow structural change of the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21642872&#34; target=&#34;_blank&#34;&gt;Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At present, the only instruments for screening and diagnosis are based on radiological tests, posing evident economic and radio-protectionist problems. […] This study aimed to evaluate whether a combination of these two markers could increase sensitivity and specificity in diagnosis of epithelioid MPM. […] The performance in MPM diagnosis resulted improved by the combination of the two markers. […] We combined SMRP and pOPN dosages to increase diagnostic accuracy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21645831&#34; target=&#34;_blank&#34;&gt;[Value of tomotherapy in malignant pleural mesothelioma: first clinical results].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After initial diagnosis, the median survival was 18.4 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21651745&#34; target=&#34;_blank&#34;&gt;Outcomes and complications following medical thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Four patients died within 1 month of the procedure, three had a malignant diagnosis, all had suffered HAI.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21658936&#34; target=&#34;_blank&#34;&gt;Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survivals from diagnosis and from the start of radiotherapy were 11.3 months and 5.2 months, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21686530&#34; target=&#34;_blank&#34;&gt;Pleural effusion: what lies underneath?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis encompasses multiple problems as there is no pathognomonic hallmark for the disease, there are multiple histological types and the differentiation from other tumours, such as adenocarcinoma or metastatic pleural disease, can represent quite a challenge. […] Usually a diagnosis of malignant mesothelioma carries a dismal prognosis with scarce therapeutical options.The present report concerns a patient with a diagnosis of malignant pleural mesothelioma with endobronchial extension. […] The final diagnosis was only possible after careful histological evaluation with a combination of immunohistochemical markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21692685&#34; target=&#34;_blank&#34;&gt;Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM has a limited response to conventional chemotherapy and radiotherapy, so early diagnosis of MPM is very important. […] The data suggest that the pleural effusion mesothelin concentration could be useful as an aid for the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21696568&#34; target=&#34;_blank&#34;&gt;Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While radical or postoperative radiotherapy using conventional techniques has resulted in severe toxicity with no impact on survival, recent advances in radiotherapy delivery may be more effective. […] Median survival was 25months from diagnosis and 17months after starting radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21697793&#34; target=&#34;_blank&#34;&gt;A case of diffused malignant pleural mesothelioma forming small multiple disseminations with intraoperatively suspicious carcinoid tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The intraoperative observation of a frozen section typed the tumor as carcinoid; however, hematoxylin-eosin staining and immunohistological findings provided the definitive diagnosis of diffused, malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21737558&#34; target=&#34;_blank&#34;&gt;Predicting survival in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sex, age, date and method of diagnosis, site of disease and histological type were recorded. […] Cox regression was used to examine the association of the clinical variables and the 10-yr periods of disease onset with survival after diagnosis. […] Median (interquartile range) survival by decade, from 1960 until 2005, was 64 (0-198), 177 (48-350), 221 (97-504), 238 (108-502) and 301 (134-611) days; ~4 weeks of this apparent improvement can be attributed to earlier diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21739769&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, 40 patients with a definitive diagnosis, who had been followed up for at least 3 years were studied according to these: epidemiologic factors, stage and pathological types, treatment method and complications, and by using factors that influence patients survival, we evaluated them statistically.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21755828&#34; target=&#34;_blank&#34;&gt;Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Procalcitonin (PCT) and C-reactive protein (CRP) measurements in pleural fluid and plasma have been proposed to facilitate differential diagnosis of pleural effusion (PE). […] We prospectively studied 100 patients with the specific diagnosis of exudative PE. […] Pleural fluid CRP levels &amp;gt; or = 16.7 mg/L had 75% sensitivity and 68% specificity in the diagnosis of BPE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21817877&#34; target=&#34;_blank&#34;&gt;Missed opportunities to counsel patients with malignant pleural mesothelioma about causation and potential compensation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors conducted a structured retrospective chart review of patients with a diagnosis of MPM. […] The authors identified 16 patients with a new diagnosis of MPM during the study period.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21835491&#34; target=&#34;_blank&#34;&gt;Proteomic surfaceome analysis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we propose a quantitative proteomics primary screen of the cell surface exposed MPM N-glycoproteins, which provides the basis for the development of new protein-based diagnostic assays.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21841505&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Blood samples and matched computed tomography scans were collected at diagnosis and, when possible, during and after therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21847060&#34; target=&#34;_blank&#34;&gt;Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A web-based survey was administered to surgeons who operated on malignant pleural mesothelioma (MPM) for diagnosis, staging, palliation, or cytoreduction.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21855111&#34; target=&#34;_blank&#34;&gt;Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analyzed the diagnostic role of EHF in 98 ovarian serous carcinoma effusions, 23 malignant mesothelioma specimens (20 effusions, 3 surgical specimens), and 28 primary ovarian serous carcinomas using quantitative real-time polymerase chain reaction. […] In univariate analysis for all patients with effusions, higher EHF mRNA levels were associated with a trend for shorter progression-free survival (P = .066), which became significant in analysis of 45 patients with primary diagnosis pre-chemotherapy effusions (P = .01). […] In Cox multivariate analysis, EHF mRNA expression was an independent predictor of poor progression-free survival for all patients and patients with primary diagnosis pre-chemotherapy effusions (P = .033 and P = .009, respectively). […] EHF mRNA levels differentiate ovarian carcinoma from malignant mesothelioma and may thus be of diagnostic value in this setting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21860532&#34; target=&#34;_blank&#34;&gt;Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The objective of this study was to evaluate the utility of the determination of adenosine deaminase (ADA) level in pleural fluid for the differential diagnosis between tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) in Japan, a country with intermediate incidence of tuberculosis (TB). […] Although the ADA activity in pleural fluid can help in the diagnosis of TPE, it should be noted that some cases of lung cancer or mesothelioma show high ADA activity in geographical regions with intermediate incidence of TB, in contrast to high prevalence areas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21861135&#34; target=&#34;_blank&#34;&gt;BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of our study was to elucidate the effects of BIRC5 promoter single nucleotide polymorphisms on survivin expression, patient survival and age at diagnosis in malignant pleural mesothelioma. […] Polymorphism -241C &amp;gt; T affected patients’ age at diagnosis. […] Survival analysis confirmed that younger age at diagnosis and epitheloid histological type improved survival, but no significant effects of nuclear survivin expression or genotype/haplotype on overall survival were observed. […] We observed that BIRC5 -241C &amp;gt; T polymorphism had a significant effect on patient age at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21886962&#34; target=&#34;_blank&#34;&gt;Desmoplastic malignant mesothelioma of the pericardium: Description of a case and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histopathological diagnosis was performed by surgical pericardial biopsy and confirmed by autopsy. […] The diagnosis is difficult and often needing a surgical pericardial biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21895596&#34; target=&#34;_blank&#34;&gt;Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Latency periods and age at diagnosis for each group were calculated and compared. […] After controlling for sex and both year and age at diagnosis, the latency period for people exposed to asbestos during home renovation was significantly shorter than that for all other exposure groups, but the shorter follow-up and difficulty recalling when exposure first occurred in this group may partly explain this.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21918389&#34; target=&#34;_blank&#34;&gt;Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, new presentations of the disease are appearing with new diagnostic and therapeutic challenges. […] Diagnostic assessment and therapeutic strategy are discussed taking into account the different evolutions of each patient.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21924516&#34; target=&#34;_blank&#34;&gt;An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We tested the hypothesis that an electronic nose can discriminate exhaled air of patients with MPM from subjects with a similar long-term professional exposure to asbestos without MPM and from healthy controls. 13 patients with a histology confirmed diagnosis of MPM (age 60.9±12.2 year), 13 subjects with certified, long-term professional asbestos exposure (age 67.2±9.8), and 13 healthy subjects without asbestos exposure (age 52.2±16.2) participated in a cross-sectional study. […] This suggests that breathprints obtained by electronic nose have diagnostic potential for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21928246&#34; target=&#34;_blank&#34;&gt;Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related peptide (SMRP) is a biomarker that has been proposed for differential diagnosis from pleural metastatic cancer, as well as prognosis and treatment monitoring of malignant pleural mesothelioma (MM). […] Our data confirm previous experiences with the use of SMRP as a diagnostic marker of MM. […] Low SMRP levels at diagnosis seem to have a positive prognostic significance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2193875&#34; target=&#34;_blank&#34;&gt;Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction between malignant epithelioid pleural mesothelioma (MEPM) and peripheral adenocarcinoma of the lung with pleural invasion (PAL) continues to represent a diagnostic challenge in selected cases. […] These findings suggest that immunohistology parallels electron microscopy in efficacy in the diagnostic separation of MEPM and PAL. […] Using antibodies to Leu M1, CEA, and the B72.3 antigen, reactivity for at least two of these three markers appears to exclude a diagnosis of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2194259&#34; target=&#34;_blank&#34;&gt;Benign pulmonary lesions that may be misdiagnosed as malignant.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In three lesions, diagnostic problems arise when a spindle cell component is dominant and obscures other characteristic histologic features. […] In the inflammatory pseudotumor, correct diagnosis relies on recognition of the benign cytology of the spindle cells and identifying a typical admixture of plasma cell-rich inflammatory cells. […] For spindle cell carcinoids, useful diagnostic features are the organoid pattern, benign cytology, and neuroendocrine differentiation features of the spindle cells. […] Observation of solid and papillary areas of benign tumor cells, as well as sclerosis of vessel walls and intervening areas, will allow correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21953993&#34; target=&#34;_blank&#34;&gt;Metastatic proximal epithelioid sarcoma in pleural effusion: cytopathologic findings and differential diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present a rare occurrence of metastatic proximal epithelioid sarcoma (PES) in the pleural effusion of a 23-year-old man, developed within one year of diagnosis in his gluteal soft tissue. […] Knowledge of its cytomorphology in serous cavity effusions, a patient’s clinical history and ancillary studies may lead to an accurate diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2195531&#34; target=&#34;_blank&#34;&gt;[Leu-M1, CEA and intermediate filament proteins in histochemical differential diagnosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis “pleuramesothelioma” vs “metastatic adenocarcinoma” can mostly not be decided clearly by conventional histological methods in malignant pleuraneoplasias. […] Leu-M1 is employed in immunhistochemical diagnosis of lymphomas in Hodgkin’s disease but it also reacts with adenocarcinoma cells. […] Intermediary filament proteins, CEA and Leu-M1 are important “markers” in the diagnosis of malignant pleuraneoplasias. 25 pleura biopsies of malignant pleura processes were subjected to immunhistochemical examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21961533&#34; target=&#34;_blank&#34;&gt;Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Frequently, the diagnosis of malignancy is made on cytologic effusion samples.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21969119&#34; target=&#34;_blank&#34;&gt;The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patients were 23 men and one woman with a median age at diagnosis of 64.7 years (range 47 to 76). […] This panel of antibodies may be helpful in establishing a pathologic diagnosis of sarcomatoid mesothelioma. […] Additional studies are required to define their role in the differential diagnosis of other spindle cell tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21978187&#34; target=&#34;_blank&#34;&gt;Primary pleural epithelioid mesothelioma of clear cell type: a case report and review of current literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological examination of the resected, via VATS, plural specimens was consistent with the diagnosis of clear cell epithelioid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/21981876&#34; target=&#34;_blank&#34;&gt;Prophylactic irradiation of intervention sites in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A retrospective review was conducted of 171 patients with a histological diagnosis of pleural mesothelioma with some undergoing prophylactic irradiation of intervention sites.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22011668&#34; target=&#34;_blank&#34;&gt;Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical analysis of tumor biopsies from 89 subjects with confirmed histological diagnosis of MPM and biopsies from 3 normal control subjects was performed to detect the expression of SRC-1, SRC-2 (TIF-2), SRC-3 (AIB-1), and ERβ.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22020536&#34; target=&#34;_blank&#34;&gt;Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This was independent of established prognostic factors, including histologic subtype, pathologic stage, sex, and age at time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22021116&#34; target=&#34;_blank&#34;&gt;Lymphohistiocytoid mesothelioma of the pleura: a case report with cytological findings.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its cytological diagnosis is difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22024889&#34; target=&#34;_blank&#34;&gt;Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, the clinical significance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) was evaluated for the differential diagnosis, staging and prognosis in MPM patients. […] Ninety patients who underwent 18F-FDG PET/CT scanning due to a clinical diagnosis or suspicion of MPM prior to therapy were reviewed. […] The results showed that 18F-FDG PET/CT at delayed phase is very useful for the diagnosis of pleural diseases, and SUVmax on PET/CT in the delayed phase is a more reliable prognostic factor than that in the early phase.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22028491&#34; target=&#34;_blank&#34;&gt;Polycomb repressor complex-2 is a novel target for mesothelioma therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Microarray, quantitative reverse transcriptase PCR (qRT-PCR), immunoblot, and immunohistochemistry techniques were used to examine PcG protein expression in cultured MPM, mesothelioma specimens, and normal mesothelial cells. […] Lentiviral short hairpin RNA techniques were used to inhibit EZH2 and EED expression in MPM cells. […] Microarray and qRT-PCR techniques were used to examine gene expression profiles mediated by knockdown of EZH2 or EED, or DZNep.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22031231&#34; target=&#34;_blank&#34;&gt;Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ERCC1 expression was evaluated by immunohistochemistry (IHC) on the formalin-fixed paraffin-embedded diagnostic biopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22040794&#34; target=&#34;_blank&#34;&gt;PET-CT in the diagnosis of localized malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe the use of 18-fluorodeoxyglucose-positron emission tomography (PET-CT) in the diagnosis and management of localized malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22043159&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma presenting as a giant chest, abdominal and pelvic wall mass.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was confirmed by the pathology and immunohistochemistry. […] Though rare, accurate investigation of the radiological features of a body wall MM may help make an exact diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22051293&#34; target=&#34;_blank&#34;&gt;Metastasis of pleural mesothelioma presenting as bleeding colonic polyp.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
She underwent a right hemicolectomy; a pathologic examination found neoplastic cell population positive to anti-cytokeratin7, anti-calretinin, anti-vimentin, and negative for anti-cytokeratin 20, MOC-31, and thyroid transcription factor 1, providing a diagnosis of metastatic mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2011-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2207031&#34; target=&#34;_blank&#34;&gt;Mortality and cancer morbidity in cohorts of asbestos cement workers and referents.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A significant dose response relation was found for cumulative exposure 40 years or more before the diagnosis, with a multiplicative relative risk (RR) of 1.9 for each f-year/ml.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22104079&#34; target=&#34;_blank&#34;&gt;Diffuse malignant peritoneal mesothelioma–an update on treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Electron microscopy, immunohistochemistry, computed tomography scan, echotomography, magnetic resonance imaging, positron emission tomography and laparoscopy are used in diagnosis and follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22123142&#34; target=&#34;_blank&#34;&gt;[Pleuro-pulmonary metastases from a malignant mesothelioma of the tunica vaginalis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of pleuro-pulmonary metastases from previous malignant MTV was made. […] This case report emphasizes the difficulties of the differential diagnosis between pleural mesothelioma and pleural metastases from MTV.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22126592&#34; target=&#34;_blank&#34;&gt;National survey of malignant mesothelioma and asbestos exposure in Japan.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of all these cases, a clinical diagnosis of MM was confirmed for 929. […] We compared patient characteristics and the diagnostic procedures for MM before and after the “Kubota shock”. […] Compared with the early phase of this study (2003-2005), the median age at diagnosis of MM was higher, the number of cases without definite diagnosis of MM was lower, the proportion of cases diagnosed by thoracoscopy was higher, and the percentage of cases in which the occupational history was described in the medical records was significantly higher in the later phase (2006-2008).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22135721&#34; target=&#34;_blank&#34;&gt;β-catenin expression in benign and malignant pleural disorders.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Benign and malignant pleural processes display a large and overlapping spectrum of morphological appearances, and can be difficult to distinguish, histologically, from each other. β-catenin, a participant in the wingless-type (Wnt) transduction pathway, is involved in the pathogenesis of malignant mesothelioma and has received limited evaluation for its ability to serve as a diagnostic aid for distinguishing between individual pleural disorders. […] Although IHC for β-catenin does not appear to be conclusive for separating benign from malignant mesothelial proliferations, it may be valuable for assisting in the differential diagnosis of mesothelial and spindle cell proliferations in the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22152931&#34; target=&#34;_blank&#34;&gt;[Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current data on potential predictors for efficacy are disappointing, but some biomarkers or radiological techniques might be useful for guiding the use of anti-angiogenic therapies in the future.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22152932&#34; target=&#34;_blank&#34;&gt;[Follow-up of subjects occupationally exposed to asbestos, what are the objectives, the benefits, and the possible risks?].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The early diagnosis of primary bronchial carcinoma can theoretically improve the prognosis of the subjects screened, particularly by identification of stage I disease on CT (pulmonary nodules). […] Post-occupational follow-up may involve risks to health, particularly repeated irradiation and invasive diagnostic procedures. […] The theoretical benefits, that have not yet been demonstrated, have to be seen in perspective with the risks to physical and psychological health related to both screening and diagnostic procedures.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2218347&#34; target=&#34;_blank&#34;&gt;[Tumoral markers and monoclonal antibodies].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The frequency of malignant pleuritis in general practice and its often difficult diagnosis have led to the ever increasing use of tumoral markers (TMs) which may overcome these difficulties and of immunocytochemical methods which may improve the results obtained by routine cytology. […] TMs are used in the diagnosis: a) to detect false-negative results and sometimes exclude false-positive results of cytology (“reactive” mesothelial cells); b) to distinguish reliably between malignant mesothelioma and metastatic pleuritis from an undetected adenocarcinoma, and c) to provide additional information, if needed, on the nature and origin of a malignant pleuritis. […] When assayed separately their diagnostic sensitivity is low, but when used in batteries and combined with routine cytology they may fulfill the objectives listed above and fairly significantly improve the results of cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2218349&#34; target=&#34;_blank&#34;&gt;[Diagnosis and prognosis of malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The early diagnosis of mesothelioma rests on very common clinical evidence, including pleuritis of recent onset, history of contact with asbestos, chest pain, often moderate loss of weight and slight changes in old pleural fluid cytology, 24% for Adams’ needle biopsy and 93% for thoracoscopy, where the only negative results are obtained in patients with adhesive pleuritis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22237726&#34; target=&#34;_blank&#34;&gt;Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) remains suffering poor prognosis in spite of recent diagnostic and therapeutic progress. […] Although there is currently no established evidence, early diagnosis and early intervention may play a key role to improve prognosis of MPM, similarly to other malignancies. […] As pleural effusion is usually the first clinical sign of MPM, pleural effusion cytology is often the first diagnostic examination to be carried out. […] Since the sensitivity of pleural effusion cytology is approximately 60%, however, false-negative diagnosis is given to almost half of true MPM patients at this clinical step. […] One practical way to reduce the number of misdiagnosed MPM is to encourage performing thoracoscopic pleural biopsy unless definitive diagnosis other than MPM is established. […] Currently, we are performing diagnostic total parietal pleurectomy in highly selected patients, who are characterized with strong clinical suspicion, positive pleural effusion cytology but uncertain pathological diagnosis, excellent cardiopulmonary reserve, and with written informed consent for highly invasive diagnostic surgery for pathologically unproven disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22237727&#34; target=&#34;_blank&#34;&gt;Pathological and molecular biological approaches to early mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this review, we discuss major issues on pathological and molecular biological approaches for diagnosis of early-stage MPM of epithelial type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22246193&#34; target=&#34;_blank&#34;&gt;Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall survival correlations of c-MET and phospho-c-MET immunostainings were investigated in 157 malignant pleural mesothelioma patients for whom paraffin-embedded specimens were referred to our center for pathological diagnosis certification (MESOPATH French National group).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22290929&#34; target=&#34;_blank&#34;&gt;The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Subgroup analysis of patients with nodal metastases revealed no significant survival difference between group CM and group EBUS/EUS: achieving maximum theoretical diagnostic yield CM could detect 63 (54%) of patients with nodal disease and the median survival of this group was 13.6 months (SE 2, 95% CI 9.6-17.6).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22305134&#34; target=&#34;_blank&#34;&gt;[Desmoplastic mesothelioma with bony metastases. A case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of desmoplastic mesothelioma represents one of the most difficult exercises in pleural pathology (with poor interobservers agreement) because of their abundant collagen with relatively low cellularity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22307010&#34; target=&#34;_blank&#34;&gt;Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural fluid (PF) cytology is often the first diagnostic test, but the sensitivity in the literature varies from 4 to 77%. […] However, no data are available for the diagnostic yield of cytological PF analysis with regard to the visceral pleural involvement. […] Patients were selected if they initially underwent a diagnostic thoracentesis before thoracoscopy, if visceral pleural appearance during thoracoscopy was clearly documented, and MPM confirmed on pleural tissue biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22318326&#34; target=&#34;_blank&#34;&gt;Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For both techniques, conventional dose comparisons and normal tissue complication probability (NTCP) analysis were performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22336237&#34; target=&#34;_blank&#34;&gt;[Clinical analysis of 45 patients with malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy was one of the main diagnosis methods, and epithelium cell type was the main pathologic type. […] However, CT scan can provide an important basis for the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22345186&#34; target=&#34;_blank&#34;&gt;Fluorescence thoracoscopy in the detection of pleural malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Fluorescence diagnosis (FD) with 5-aminolaevulinic acid (5-ALA) has been used in the diagnostic purpose for various malignancies. […] The impact of fluorescence thoracoscopy on diagnosis and staging of pleural malignancies was examined. […] A definitive diagnosis was obtained in all cases: malignant mesothelioma in 13 cases, other malignancies (pleural metastases) in 8 cases and non-specific inflammation in 3 patients. […] Comparing the results of histological examination of specimens detected by conventional thoracoscopy with that by fluorescence thoracoscopy, we obtained 82 true positive, 10 false-negative, 23 true negative, 3 false-positive results with a specificity of 88.4%, sensitivity of 89.1% and diagnostic accuracy of 88.9%. […] FD using 5-ALA in the pleural cavity is a feasible diagnostic tool when used in addition to white-light thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22345416&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PURPOSE The etiology, diagnosis, staging, and management of malignant pleural mesothelioma (MPM) are reviewed, with an emphasis on clinical trials of newer approaches to first-line, second-line, and adjuvant chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22352060&#34; target=&#34;_blank&#34;&gt;[An autopsied case of primary malignant pericardial mesothelioma diagnosed antemortally].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We created a pericardial window in order to make a diagnosis and to relieve the symptoms using video-assisted thoracoscopic surgery and performed biopsies of the pericardium and the pleura. […] Immunohistologic analysis of the pericardium confirmed a diagnosis of biphasic pericardial mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22372900&#34; target=&#34;_blank&#34;&gt;Epithelioid lesions of the serosa.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Earlier reviews are principally referred to for established diagnostic criteria. […] Immunohistochemistry with a panel of antibodies has made the diagnosis of epithelioid serosal lesions very reliable. […] When deciding on antibodies used in differential diagnosis, it is important to consider tumor location, clinical and radiologic information, and morphologic features. […] Immunohistochemistry is less useful in the differential diagnosis of benign versus malignant mesothelial lesions. […] The diagnosis of benign versus malignant mesothelial proliferations still relies on the histologic criteria of invasion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22372901&#34; target=&#34;_blank&#34;&gt;Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathologic approach to pleural-based lesions is stepwise and uses morphologic assessment, correlated with clinical and imaging data supplemented by immunohistochemistry (IHC), and more recently, molecular tests, as an aid for 2 main diagnostic problems: malignant mesothelioma (MM) versus other malignant tumors and malignant versus reactive mesothelial proliferations. […] To present the current knowledge regarding IHC and molecular tests with respect to MM diagnosis, and in particular, the differentiation of the epithelioid type of MM from carcinoma metastatic to the pleural cavity. […] A survey of biomedical journal literature from MedLine/PubMed (US National Library of Medicine) focused on MM and associated tissue-based diagnostic IHC markers and molecular tests. […] The search for a single diagnostic marker of MM has so far been discouraging, given the biologic and phenotypic tumor heterogeneity of MM. […] The use of antibody panels has gained unanimous acceptance especially in the differential diagnosis between MM and metastatic carcinoma, whereas the usefulness of IHC is more limited when dealing with spindle cell malignancies or distinguishing malignant from reactive mesothelium. […] A great degree of interlaboratory variability in antibody combinations and clone selection within diagnostic panels still exists. […] Current investigations aim at selecting the most suitable and cost-effective combination of antibodies by using novel statistical approaches for assessing diagnostic performance beyond the traditional measures of sensitivity and specificity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22372904&#34; target=&#34;_blank&#34;&gt;Molecular changes in mesothelioma with an impact on prognosis and treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In recent decades, research on malignant pleural mesothelioma (MPM) has been developed to improve patients’ outcomes by increasing the level of confidence in MPM diagnosis and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22374657&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite the progress made in diagnosis and therapy of this entity the optimal treatment remains a subject of debate. […] In this article we review the current state of treatment and diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22394205&#34; target=&#34;_blank&#34;&gt;The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) often causes diagnostic difficulties for pathologists. […] We assessed whether loss of methylthioadenosine phosphorylase (MTAP), a key enzyme in the intracellular recycling of adenosine triphosphate (ATP) often deleted in MPM, could be detected with immunohistochemistry (IHC) and used as a diagnostic marker for MPM. […] Decreased MTAP expression could potentially be useful in combination with other markers in the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22412141&#34; target=&#34;_blank&#34;&gt;Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To examine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individual patient data (IPD) meta-analysis. […] The literature search identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked immunosorbent assay. […] Mesothelin levels were standardized for between-study differences and age, after which the diagnostic accuracy and the factors affecting it were examined with receiver operating characteristic (ROC) regression analysis. […] At a common diagnostic threshold of 2.00 nmol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 19% to 68% and 88% to 100%, respectively. […] This heterogeneity can be explained by differences in study population, because type of control group, mesothelioma stage, and histologic subtype significantly affected the diagnostic accuracy. […] The use of mesothelin in early diagnosis was evaluated by differentiating 217 patients with stage I or II epithelioid and biphasic mesothelioma from 1,612 symptomatic or high-risk controls. […] In patients suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong incentive to urge further diagnostic steps. […] However, the poor sensitivity of mesothelin clearly limits its added value to early diagnosis and emphasizes the need for further biomarker research.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22432060&#34; target=&#34;_blank&#34;&gt;Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite advances in the diagnostic and treatment approaches the median survival rate for MPM is between 9 to 17 months. […] In this review we give an update on the conventional treatment modalities and discuss about various molecular targets including receptor EphA2, a novel target gene which may be considered as a biomarker for the diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22452101&#34; target=&#34;_blank&#34;&gt;[microRNAs as biological indicators of environmental and occupational exposure to asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The lack of tumor biomarkers for diagnosis and medical survey plays a fundamental role for the development of a universally accepted therapeutic approach. […] The identification of dysregulated miRNAs or frequent genetic polymorphisms as potential diagnostic biomarkers or as prognostic factors for malignant mesothelioma could facilitate the surveillance procedure of subjects exposed to asbestos.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22452231&#34; target=&#34;_blank&#34;&gt;The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This paper was aimed at determining the role of cytological evaluation of pleural fluid in the diagnosis of malignant mesothelioma. […] To sum up, 7 of 49 cytological examinations were positive and the sensitivity of our cytological study for the diagnosis of malignancy was 29%. […] Due to the low sensitivity of the cytological examinations, it has been recommended to perform biopsy of the pleura for definitive diagnosis in every patient with clinical symptoms and suspicious radiography.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22453539&#34; target=&#34;_blank&#34;&gt;Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy’s and St Thomas’ hospitals.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival from diagnosis was 12.8 months (95% confidence interval 7.8-17.7 months).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22459200&#34; target=&#34;_blank&#34;&gt;An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22475902&#34; target=&#34;_blank&#34;&gt;18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis of the disease is difficult, delaying effective treatment. […] An abdominal exploratory laparotomy found widespread malignancy within the peritoneum with a pathological diagnosis of peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2247997&#34; target=&#34;_blank&#34;&gt;[Bilateral pleural mesothelioma–case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the female was suspected in a malignant tumor and many diagnostic investigations were performed, diagnosis could be ensured morphologically only a short time before her death. […] Causes and development of mesothelioma, histological types, clinical symptoms and diagnostic procedures are described.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22493390&#34; target=&#34;_blank&#34;&gt;Complete response and long-term survival in malignant pleural mesothelioma: case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After the diagnosis of pleural mesothelioma by thoracoscopic talc insufflation, combined with pleural biopsy, and total body computed tomographic scan, the patient underwent two cycles of neoadjuvant chemotherapy with pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)), followed by an extra-pleural pneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22495008&#34; target=&#34;_blank&#34;&gt;[‘Malignant peritoneal mesothelioma’: a condition difficult to diagnose].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Additional investigation included a CT scan, 2 PET-CT scans, 2 diagnostic laparoscopies and histological examination of peritoneum biopsies. […] After 7 months the diagnosis of malignant peritoneal mesothelioma was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22504106&#34; target=&#34;_blank&#34;&gt;Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Aberrant expression of p14(ARF), p16(INK4A), p21(waf), p27(KIP), p53, mdm2 and Rb was assessed in 55 MPM cases from Egypt using immunohistochemistry and PCR techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22511568&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in a child with ataxia-telangiectasia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hence, delayed diagnosis of respiratory neoplasms can occur in these patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22541196&#34; target=&#34;_blank&#34;&gt;Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard statistical techniques were used for analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22549950&#34; target=&#34;_blank&#34;&gt;The application of immunocytochemistry to direct smears in the diagnosis of effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, we sought to investigate the utility of direct smear preparations as a platform for ICC in the diagnosis of effusions. […] In conclusion, direct smears represent an effective platform for the performance of ICC in the diagnosis of malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22558888&#34; target=&#34;_blank&#34;&gt;Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For each effusion, we evaluated the background and calculated a score considering the following items: amount of mesothelial cells, architectural pattern and atypical features, and a revised diagnosis was rendered. […] More than half of the effusions initially called “negative” (but mesothelioma by histology) were considered atypical/ suspicious (false-negative diagnosis); the remaining cases were true-negative or inadequate. […] The present study has highlighted the following pitfalls: (i) to report effusions devoid of mesothelial cells as negative that instead should be reported as inadequate/non-diagnostic; (ii) to underestimate low cellular effusions containing atypical mesothelial cells or high cellular effusions containing bland mesothelial cells with a morular pattern; (iii) to consider that an inflammatory background may obscure a scant number of mesothelial cells. […] A categorized system (inadequate (M1), negative (M2), atypical (M3) and suspicious (M4)) for reporting effusion cytology may be of help in the diagnostic work-up of patients with effusions suspicious for mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22566249&#34; target=&#34;_blank&#34;&gt;Huge malignant solitary fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A positive staining of vimentin, negative staining of cytoplasmic keratin, and expression of the CD34 antigen can confirm their diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22608353&#34; target=&#34;_blank&#34;&gt;Outcome of patients diagnosed with fibrinous pleuritis after medical thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We aimed to identify false negatives among patients where mesothelioma was common due to asbestos exposure whose histopathological diagnosis following thoracoscopy was fibrinous pleuritis. […] We also determined risk factors associated with patients that required additional advanced invasive procedures for diagnosis. […] In regions where mesothelioma is prevalent and one of the above-stated risk factors is present, patients whose post-thoracoscopy histopathological diagnosis is fibrinous pleuritis should be treated with a more advanced invasive diagnosis procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22617246&#34; target=&#34;_blank&#34;&gt;Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our data confirm the potential of miR-29c* and miR-92a as candidate tumor markers and reveal that miR-625-3p is a promising novel diagnostic marker for MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22617814&#34; target=&#34;_blank&#34;&gt;Asbestos-related pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several recent studies are highlighted throughout this review, including a comparative analysis of diagnostic imaging modalities for identifying and characterizing pleural plaques, the effect of pleural plaques on lung volumes and flows, and how pain is a relatively common feature in patients with pleural plaques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2261973&#34; target=&#34;_blank&#34;&gt;Bilateral pleural effusion due to malignant mesothelioma, diagnosed by means of immunostaining.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunostaining and DNA-flow cytometry confirmed the diagnosis. […] The usefulness of these rather new diagnostic techniques is discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22644294&#34; target=&#34;_blank&#34;&gt;Prognosis and prognostic factors of patients with mesothelioma: a population-based study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management. […] We assessed overall (baseline) survival as well as related prognostic variables in a large cohort of 1353 patients with a confirmed diagnosis of malignant mesothelioma between 2005 and 2008. […] About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. […] One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. […] In addition, a substantial part of the patients had a long latency time between asbestos exposure and diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22658812&#34; target=&#34;_blank&#34;&gt;Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient characteristics were median age of 73 years; 93% men; 59% epithelial subtype; median NLR of 3.5 at diagnosis (n = 79); median overall survival of 10.6 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22677982&#34; target=&#34;_blank&#34;&gt;PET scan contribution in chest tumor management: a systematic review for thoracic surgeons.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the last 10 years, PET scan has been widely adopted in thoracic oncology, showing high accuracy in diagnosis and staging and with promising issues in defining prognosis. […] The search was restricted to publications in English, using in the same string the word “PET” with 9 different chest tumors; results were then filtered by eliminating technical articles, focusing only on papers in which surgery was considered as a potential diagnostic or therapeutic tool. […] Glucose uptake is a metabolic marker useful in the diagnosis and staging of chest tumors. […] PET scan has a crucial role in thoracic oncology due to its impact on diagnosis, staging and prognosis. […] It anticipates the diagnosis in long-incubating diseases such as mesothelioma and increases biological knowledge of rare diseases, such as thymoma and other mediastinal tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22677987&#34; target=&#34;_blank&#34;&gt;Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Kaplan-Meier survival analyses and Cox proportional risks model were used to test sex, age at diagnosis, histological type and treatments, as prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2268125&#34; target=&#34;_blank&#34;&gt;[Radiologic aspect of benign pleural fibrous mesothelioma. Reports of 4 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ultrasonic diagnosis, CT-Scan and MR Imaging are very useful but non specific: the differential diagnosis between benign and malignant tissue is still based on histological study of the whole surgical specimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2269029&#34; target=&#34;_blank&#34;&gt;[Mesothelioma and mesothelial hyperplasia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is difficult because mesothelial hyperplasia and other malignant tumors may mimic mesothelioma in some clinical aspects. […] Roentgenography, CT scan, cytology of serosal fluid and biopsy world help to establish the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22710421&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: from the bench to the bedside.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, this review is an overview of the recent advances in the biology of MPM and their potential therapeutic applications in the field of MPM diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22729037&#34; target=&#34;_blank&#34;&gt;CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One major challenge for this disease is the development of new, early, and highly reliable diagnostic markers. […] The aim of this study was to compare the diagnostic value of the chemokine chemokine (C-C motif) ligand 2 (CCL2), galectin-3, and the secretory leukocyte peptidase inhibitor (SLPI) with soluble mesothelin-related peptides (SMRP), and to evaluate the diagnostic performance of marker combinations. […] Of interest, we showed that the combination of SMRP/CCL2/galectin-3 greatly improved MPM diagnosis (AUC = 0.9680), when compared with SMRP alone. […] The combination of SMRP/CCL2/galectin-3 seems to represent a promising panel of biomarkers for the reliable diagnosis of MPM in pleural fluids.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22740956&#34; target=&#34;_blank&#34;&gt;Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This, early diagnosis of MPM is essential.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22742553&#34; target=&#34;_blank&#34;&gt;Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is often difficult to make, in part because of the overlapping morphology of reactive and malignant mesothelial cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22753293&#34; target=&#34;_blank&#34;&gt;[Chemotherapy for malignant tumors of lung and pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is also increasingly becoming a disease of the elderly, with a median age at diagnosis of 70 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22768319&#34; target=&#34;_blank&#34;&gt;Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural intelectin-1 could be a useful diagnostic marker for MPM with applications in histopathological identification of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22777314&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in a patient with systemic sclerosis: the first report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural fluid cytological examination along with nuclear and membranous positivity for Wilms tumor-1 antigen and epithelial membrane antigen on immunocytochemistry confirmed the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22790919&#34; target=&#34;_blank&#34;&gt;A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelin has been proposed as a useful tool in the diagnosis of malignant pleural mesothelioma (MPM). […] We aimed to examine its diagnostic utility and the impact of renal impairment on results. […] In a matched comparison, diagnostic characteristics of pleural fluid mesothelin were superior to serum (p=0.0001). […] The diagnostic accuracy of pleural fluid mesothelin is superior to that of serum and is unaffected by renal function.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22791848&#34; target=&#34;_blank&#34;&gt;Meningeal and brainstem infiltration by a malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Postmortem examination favoured a diagnosis of an early sarcomatoid malignant mesothelioma of pleural origin with leptomeningeal metastatic deposits.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22825770&#34; target=&#34;_blank&#34;&gt;Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to investigate the diagnostic and prognostic value of circulating endothelial cell (CEC), a potential surrogate of tumor angiogenesis, in malignant pleural mesothelioma (MPM). […] CEC count was significantly higher in MPM patients than in NM patients (mean CEC count, 120.3 and 39.9, respectively; P = 0.001), and a receiver operating characteristic (ROC) curve analysis showed that CEC provided a significant diagnostic performance in discrimination between MPM and nonmalignant diseases with an area under curve (AUC-ROC) of 0.700 (95 % confidence interval [95 % CI], 0.595-0.806; P = 0.001). […] CEC, as a surrogate of tumor angiogenesis, was a promising marker in diagnosis and prediction of prognosis in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22826778&#34; target=&#34;_blank&#34;&gt;A case report of an extremely rare and aggressive tumor: primary malignant pericardial mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With the exception of several case reports, the outcome is uniformly fatal, and patients typically die within six months of diagnosis. […] He died 1 month after diagnosis and 6 months after the first symptoms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22833290&#34; target=&#34;_blank&#34;&gt;Cytomorphologic features of metastatic urothelial carcinoma in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our results demonstrated that while certain features could suggest the diagnosis of UC, the cytomorphological features are not specific and often overlap with those of reactive mesothelium, mesothelioma, metastatic adenocarcinoma, or squamous cell carcinoma in SEs. […] Accurate diagnosis of UC rests on the combination of clinical history, cytomorphologic features and appropriate immunohistochemical panel.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22835614&#34; target=&#34;_blank&#34;&gt;Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) is an aggressive tumour with poor prognosis whose early diagnosis is difficult. […] Several patient characteristics influence the diagnostic accuracy of biomarkers and make the establishment of the “optimal” diagnostic threshold difficult. […] Combining different markers together may lead to an improvement in diagnostic accuracy, but there is still need for research in this area. […] In the near future, their application in clinical practice is probably in monitoring response to therapy, rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed populations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2284143&#34; target=&#34;_blank&#34;&gt;Immunoperoxidase staining of malignant cells in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These data suggest that the use of immunostaining against CEA and alpha 1ACT seems to improve the cytologic differential diagnosis between malignant mesothelioma and metastatic carcinoma in pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2284446&#34; target=&#34;_blank&#34;&gt;[Diffuse malignant mesothelioma. Presentation of 10 cases and review of the literature].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To make a definitive diagnosis it was necessary to use an invasive procedure. […] Examination of sputum, bronchial washings and endobronchial biopsies did not contribute to the diagnosis. […] The cytological examination of pleural and ascitic fluid resulted in a diagnosis of malignancy. […] In four cases the diagnosis was made by closed pleural biopsy; in five other cases it was necessary to obtain specimens by thoracotomy. […] In the last case the diagnosis was made at autopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22849735&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant mesothelioma (DMM) is an uncommon cancer with great clinical significance because it currently remains an incurable disease, and most patients die within months after diagnosis. […] These two issues are the topic of discussion in this review, along with a brief presentation of a case of DMM that presented in a 66-year-old man with recurrent, right pleural effusions, and in whom, diagnosis of DMM had not been suspected clinically, radiographically, surgically, grossly, or initially, on frozen section. […] It was not until focal invasion into the skeletal muscle was discovered on permanent sections that a diagnosis of DMM could be established.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2286397&#34; target=&#34;_blank&#34;&gt;[Cisplatin and cytosine arabinoside (ARA-C) for the therapy of primary and secondary pleural neoplasms].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
15 patients with primary or metastatic pleural effusion were studied: 2 had diagnosis of malignant mesothelioma and 13 of metastatic pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1991-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22870590&#34; target=&#34;_blank&#34;&gt;Asbestos-related disease: screening and diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, it is highly important to develop an early diagnostic method with the greatest challenge on screening techniques to detect the disease at a subclinical stage. […] Of these, SM has demonstrated the greatest diagnostic potential although MPF may serve as an equal alternative.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22879552&#34; target=&#34;_blank&#34;&gt;Prognostic factors in malignant pleural mesothelioma: role of talc pleurodesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cox regression analysis was used to estimate the hazard ratios for possible prognostic factors. 105 (86%) patients had complete survival follow-up; 91 died and 14 (13.3%) were alive at the end of the observation period starting from the day of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22903737&#34; target=&#34;_blank&#34;&gt;‘It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study explores patient’s experience during the first 3 months following a diagnosis of malignant pleural mesothelioma. […] This study uses a grounded theory approach with semi-structured, face-to-face interviews with 10 patients during the first 3 months following diagnosis. […] Patients receive insufficient psychosocial support during the first 3 months following diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22909129&#34; target=&#34;_blank&#34;&gt;Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival from time of diagnosis was determined by the Kaplan-Meier method. […] Thoracoscopy (59.4%) was the most commonly used diagnostic procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22919425&#34; target=&#34;_blank&#34;&gt;Parakeratotic-like cells in effusions - A clue to diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the cytological diagnosis of MM can be difficult. […] Our data showed that the presence of PK-like cells has a specificity of 90%, sensitivity of 83%, positive predictive value of 81%, and negative predictive value of 84% for the diagnosis of malignant mesothelioma in body cavity fluids. […] The presence of PK-like cells in the effusion specimen, especially in pleural effusions, is a highly specific and moderately sensitive cytological feature for diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22929121&#34; target=&#34;_blank&#34;&gt;Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To provide updated practical guidelines for the pathologic diagnosis of MM. […] There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. […] Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22933897&#34; target=&#34;_blank&#34;&gt;3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the diagnostic potential of 3 T MRI as a complementary imaging modality to CT in detecting the pathological changes of asbestos-related thoracic diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22937937&#34; target=&#34;_blank&#34;&gt;Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of vasculitis requires a search for malignancies as well as other possible etiologies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22981348&#34; target=&#34;_blank&#34;&gt;Development of a guideline on reading CT images of malignant pleural mesothelioma and selection of the reference CT films.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The evidence-based mesothelioma CT Guideline developed may serve as a good educational tool to facilitate physicians in recognising mesothelioma and improve their proficiency in diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/22993544&#34; target=&#34;_blank&#34;&gt;Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, cytological diagnosis using pleural fluid is usually difficult and has limited utility. […] A useful molecular marker for differential diagnosis particularly with lung cancer (LC) is urgently needed. […] The aim of the present study was to investigate the diagnostic value of soluble mesothelin-related protein (SMRP) in pleural fluid. […] The area under the ROC curve (AUC) values of the MPM diagnosis was 0.75 for the differential diagnosis from the other groups. […] Based on the cut-off value of 8 nmol/l, the sensitivity and specificity for diagnosis of MPM were 70.0 and 68.4%, respectively. […] These results indicate that the SMRP concentration in pleural fluid is a useful marker for the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23002041&#34; target=&#34;_blank&#34;&gt;Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The study illustrates principles of evidence-based pathology concerning internal and external test performance in the differential diagnosis of MM versus RM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23005599&#34; target=&#34;_blank&#34;&gt;Case reports of primary pulmonary adenocarcinoma with pleural spread: so-called pseudomesotheliomatous adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This is the first report of pseudomesotheliomatous adenocarcinoma displaying variable immunoprofile with a diagnosis using electron microscopical examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23009708&#34; target=&#34;_blank&#34;&gt;Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural effusions (MPE) is often clinically challenging, especially if the cytology is negative for malignancy. […] The aim of this study was to evaluate the utility of pleural fluid DNA integrity index in the diagnosis of MPE. […] Pleural fluid DNA integrity index is a promising diagnostic biomarker for identification of MPEs, including mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23017190&#34; target=&#34;_blank&#34;&gt;Evaluation of the efficacy of the guideline on reading CT images of malignant pleural mesothelioma with reference CT films for improving the proficiency of radiologists.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The developed mesothelioma CT Guideline was suggested to have substantial effect in improving the radiologists’ proficiency for reading CT images of mesothelioma, and may contribute to accurate diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23020727&#34; target=&#34;_blank&#34;&gt;The separation of benign and malignant mesothelial proliferations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma in situ is a diagnosis that currently cannot be accurately made by any type of histologic examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23021044&#34; target=&#34;_blank&#34;&gt;Analysis of “dry” mesothelioma with ultrasound guided biopsies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma presenting without effusion however is more of a diagnostic challenge. […] In this study we report the diagnostic yield and complications of ultrasound-guided cutting needle biopsies in this particular category of patients. […] Clinical characteristics and results of diagnostic evaluations were analysed. […] Ultrasound-guided cutting needle biopsy was performed in 14/20 patients with a diagnostic accuracy of 80%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23036697&#34; target=&#34;_blank&#34;&gt;Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study shows the malignant transformation of WDPMP in a Japanese female patient, who was alive for 54 months after the initial diagnosis by a laparoscopic biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23038233&#34; target=&#34;_blank&#34;&gt;Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The characteristic clinical appearance, the histopathological findings, and the clinical course were decisive for the diagnosis of TEN.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23045294&#34; target=&#34;_blank&#34;&gt;Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Interestingly, average serum ILK concentrations were 10 times higher in MPM patients when compared with the rest of the study population, and a diagnostic test solely based on serum ILK concentration could discriminate between MPM and non-MPM with considerable accuracy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23052177&#34; target=&#34;_blank&#34;&gt;Spinal cord compression: an unusual presentation of malignant pleural mesothelioma. A case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Metastases to the nervous system are rare, and clinical signs of nervous system involvement typically appear between 2 months and 6 years after the primary diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23055748&#34; target=&#34;_blank&#34;&gt;Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a rare and aggressive malignancy of the pleura correlated with exposure to asbestos, with a medium survival of 11-12 months after diagnosis. […] The computed tomography evaluation revealed a right pleural mass with pleural thickening, and the pleural biopsy confirmed a diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23056237&#34; target=&#34;_blank&#34;&gt;Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because diagnosis is difficult and the disease is relatively rare, most patients present at a clinically advanced stage where possibility of cure is minimal. […] The SOMAmer biomarker panel discovered and validated in these studies provides a solid foundation for surveillance and diagnosis of MM in those at highest risk for this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2305835&#34; target=&#34;_blank&#34;&gt;ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our results with ME1, the first monoclonal antibody that recognizes malignant mesothelial cells, provides a basis for using this reagent in the differential diagnosis of tumors of the pleura and peritoneum.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23064068&#34; target=&#34;_blank&#34;&gt;[One case of malignant mesothelioma that developed right pneumothorax after a diagnosis with left pneumothorax].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have made a diagnosis of malignant pleural mesothelioma with left pneumothorax here, and report our experience with this rare case that complicated the right pneumothorax throughout treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23067687&#34; target=&#34;_blank&#34;&gt;The role of FDG PET-CT in differential diagnosis of pleural pathologies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study has aimed to evaluate the impact of (F18) Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG PET-CT) in the differential diagnosis of malignant and benign pleural lesions in patients with suspected malignant pleural mesothelioma (MPM). […] FDG PET-CT findings were compared with histopathologic diagnosis. […] FDG PET-CT is a useful imaging modality in differential diagnosis of malignant and benign pleural lesions. […] Delayed imaging seems to be useful if there is a decrease in SUV suggesting a benign pathology but does not seem to contribute to the differential diagnosis if the SUV is increased.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23072703&#34; target=&#34;_blank&#34;&gt;Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All consecutive patients referred for surgical diagnosis and/or pleurodesis for malignant pleural mesothelioma between 2000 and 2010 were studied. […] The following parameters were prospectively recorded: age, sex, tobacco consumption, asbestos exposure, type and duration of symptoms, American Society of Anesthesiologists (ASA) score, body mass index, preoperative C-reactive protein levels, white blood cells and platelet count, pachypleuritis on chest radiograph, type of diagnostic surgical procedure, histologic type, modality of pleurodesis, and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23077450&#34; target=&#34;_blank&#34;&gt;Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PATIENTS AND METHODS.: A retrospective study included all patients in Slovenia with histologically confirmed diagnosis of malignant pleural mesothelioma in the period from 1974 till 2008.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-10-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23085037&#34; target=&#34;_blank&#34;&gt;Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
TS and ERCC1 protein expression was evaluated by immunohistochemical techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23093275&#34; target=&#34;_blank&#34;&gt;A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Linear regression analyses were used to quantify the strength and “ direction ” of the relationship between SMRP and several independent variables,and 2 × 2 tables were used to determine the diagnostic accuracy of SMRP levels, taking into account clinical variables. […] The present study proposes an equation based on age and GFR to improve diagnostic accuracy of SMRP.The poor sensitivity of SMRP found in this study suggests that further work is needed to fi nd new candidate biomarkers for diagnosing early stage MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23121607&#34; target=&#34;_blank&#34;&gt;The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histological diagnosis was epithelioid mesothelioma with T2N0M0, and no sarcomatoid component was observed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23126055&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma–case report].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most common clinical manifestation of pleural mesothelioma is pleural effusion with dyspnea, which makes it a diagnostic problem since many cardiac diseases can have the same presentation. […] Clinical presentation also included metabolic disorders and deep vein thrombosis, and the patient’s epidemiologic history was negative, so diagnostic procedures including pleurocentesis were directed towards detection of the possible malignant disease. […] Cytologic analysis followed by biopsy pointed to the diagnosis of pleural mesothelioma. […] Persistent pleural effusions that do not coincide with cardiac disease, especially if accompanied by metabolic disorders and paraneoplastic syndromes, require additional diagnostic workup to identify the etiology of pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23135895&#34; target=&#34;_blank&#34;&gt;Long term survival after trimodal therapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis and nodal status were confirmed by surgery. 21 patients (51%) underwent trimodal therapy with 655 days (63-2,567 days) of median follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23136224&#34; target=&#34;_blank&#34;&gt;Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median overall survival (OS) from diagnosis was 20.5 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23139709&#34; target=&#34;_blank&#34;&gt;Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM has a limited response to conventional chemotherapy and radiotherapy, thus early diagnosis of MPM is extremely critical. […] Our data suggest that SUVmax levels are useful as an aid for diagnosis and prognosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23154557&#34; target=&#34;_blank&#34;&gt;Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There has been a significant increase in survival, most likely because of earlier diagnosis and improvements in cytostatic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23166110&#34; target=&#34;_blank&#34;&gt;Adenomatoid mesothelioma with intranuclear inclusion bodies: a case report with cytological and histological findings.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On the basis of this observation, we propose that the adenomatoid type of malignant mesothelioma be added to the differential diagnosis of malignant effusions when tumor cells with nuclear grooves and intranuclear inclusions are found in pleural aspiration cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23167246&#34; target=&#34;_blank&#34;&gt;Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The accurate diagnosis of malignant pleural mesothelioma (MPM) is essential for therapeutic and legal reasons. […] We assessed the changing use of IHC for the diagnosis of MPM in Australia over two decades in the context of current best practice. […] Patients with a confirmed clinico-pathological diagnosis of MPM who underwent extrapleural pneumonectomy or pleurectomy and/or decortication between 1988 and 2006 were identified from the cardiothoracic database at Royal Prince Alfred Hospital and combined with consecutive patients reviewed by the Dust Diseases Board between March 2007 and March 2009. […] Initial diagnostic pathology reports were reviewed. […] Reflecting the acceptance of diagnostic panels and increased availability of antibodies, an increase in the use of IHC stains for MPM diagnosis has occurred over the past two decades although uncertainty persists as to the optimal panel composition.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23168556&#34; target=&#34;_blank&#34;&gt;Diagnosis of Mesothelioma Using Flexible Bronchoscopy With Endobronchial Ultrasound-guided Biopsy of Mediastinal Lymph Nodes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Various techniques have been used for diagnosis and include thoracentesis with pleural fluid cytology, closed pleural biopsy, and video-assisted thoracoscopic surgery. […] Video-assisted thoracoscopic surgery biopsy has higher sensitivity for establishing the diagnosis, but is a more invasive procedure and is usually performed under general anesthesia. […] We discuss 2 cases in which the diagnosis of malignant pleural mesothelioma was made through flexible fiberoptic bronchoscopy with endobronchial ultrasound-guided mediastinal lymph node biopsy. […] We suggest that this technique provides a relatively noninvasive means for earlier definitive diagnosis of malignant mesothelioma when chest imaging demonstrates mediastinal lymphadenopathy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23168948&#34; target=&#34;_blank&#34;&gt;Performance characteristics of semirigid thoracoscopy in pleural effusions of undetermined etiology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic accuracy of thoracoscopy was calculated as the number of positive diagnoses achieved by thoracoscopy in relation to the end-diagnosis achieved in the patient group by any means. […] Overall, thoracoscopy provided a diagnostic accuracy of 91.3%, sensitivity of 87%, and specificity of 100%. […] The addition of a second procedure in selected patients improved the diagnostic accuracy for malignancy by 8.7%. […] Semirigid thoracoscopy is a safe, well-tolerated, and efficacious procedure for establishing the diagnosis in pleural effusions of undetermined etiology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2012-11-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23180523&#34; target=&#34;_blank&#34;&gt;Diagnosis of malignant pericarditis: a single centre experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis and management of malignant pericarditis may significantly improve outcomes. […] To evaluate retrospectively the rate and clinical presentation of malignant pericarditis among patients undergoing invasive treatment, with a view to identification of optimal diagnostic modalities to distinguish this group among other patients. […] Among patients with the diagnosis of malignancy (Groups 1 and 2), a positive result of the cytological examination of the pericardial fluid was obtained in 52 cases (sensitivity of 46%). […] Malignant infiltration was found in 20 of 44 patients with the diagnosis of malignancy (sensitivity of 46%) and in none among 52 patients without malignancy (specificity of 100%). […] Cytological examination of the pericardial fluid and histological examination of a pericardial specimen showed high specificity (100%) but low sensitivity (46%) in the diagnosis of malignant pericarditis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23188446&#34; target=&#34;_blank&#34;&gt;The role of immunohistochemistry in the diagnosis of neoplastic pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study followed the diagnostic role of a panel of antibodies that included calretinin, HBME1, D2-40, Ber-EP4, CK5/6, CEA and TTF1, in a total of 37 cases of pleural and lung cancer with tumor-type cytology, later confirmed by histopathology. […] The panel of antibodies used in this study provides a differential diagnosis between mesotheliomas and lung carcinomas as well as between lung adenocarcinomas and squamous carcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23206832&#34; target=&#34;_blank&#34;&gt;18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) has become an invaluable tool for the diagnosis, staging, and prognosis of this severe disease as it combines both anatomic and functional information in a single imaging procedure, allowing for improved management of this disease. […] However, while characteristic patterns have been reported as predictive of macroscopic pleural or peritoneal involvement, false negative findings are possible, both for pleural and peritoneal mesothelioma, during the initial diagnosis or during the patient’s surveillance as illustrated by this report of three cases of suspected MM with negative PET/CT. […] This report highlights the limitations of PET/CT in the diagnostic evaluation of MM and the importance of histopathological confirmation by thoracoscopy and/or laparoscopy, which remain the most important diagnostic procedures in MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23207475&#34; target=&#34;_blank&#34;&gt;Mesothelioma: a soon to be forgotten disease in the United States?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical thoracoscopy is the procedure of choice for the diagnosis of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23222247&#34; target=&#34;_blank&#34;&gt;A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological diagnosis of malignant pleural mesothelioma (MPM) is controversial, but has been used in our institution for over 30 years. […] To assess the role of effusion cytology in mesothelioma diagnosis we conducted an audit of pleural fluid cytology results over a 20 year period (1988-2007). […] Pleural samples were received from 6285 patients; data linkage with Western Australian Cancer and Mesothelioma Registries demonstrated that 815 of these patients had a diagnosis of MPM. […] Definitive cytological diagnosis of MPM was made in 377/517 cases, resulting in an ‘absolute’ sensitivity of 73%. […] Effusion cytology is an inexpensive, minimally invasive procedure which should be included in the diagnostic work-up of cases of suspected MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23232263&#34; target=&#34;_blank&#34;&gt;Extraskeletal osteosarcoma of the pleura:report of a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection was done, and the pathological diagnosis was extraskeletal osteosarcoma arising from the pleura. […] The differential diagnosis is malignant pleural mesothelioma with osseous and cartilaginous which is also very rare and one of the histopathological subtypes with heterologous elements.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2323301&#34; target=&#34;_blank&#34;&gt;“Thick” cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction of malignant mesothelioma from metastatic adenocarcinoma in pleural effusions and biopsies is frequently a diagnostic problem. […] The immunocytochemical demonstration of thick and spiky membranes circumferentially disposed around individual cells corresponds to aberrant microvilli, a diagnostic clue in the recognition of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23244777&#34; target=&#34;_blank&#34;&gt;Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The approach to this disease remains difficult and complex in terms of pathogenic mechanism, diagnosis, staging and treatment thus an optimal strategy has not yet been clearly defined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23249166&#34; target=&#34;_blank&#34;&gt;Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related peptide (SMRP) is regarded as an FDA approved biomarker for the diagnosis and monitoring of pleural malignant mesothelioma (MPM). […] We detected the SMRP levels in pleural effusions (PE) by means of an ELISA and analyzed their diagnostic relevance to differentiate MPM from benign pathology and from non-MPM pleural metastasis. […] We found that SMRP detection in MPM-PE can help the diagnosis of MPM and provide additional diagnostic value to cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23270897&#34; target=&#34;_blank&#34;&gt;Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We studied the usefulness of deletion of p16 with fluorescence in situ hybridization (FISH) and p16 hypermethylation with polymerase chain reaction for the diagnosis and prognosis of malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23272646&#34; target=&#34;_blank&#34;&gt;A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histopathologic findings were consistent with a diagnosis of malignant pleural mesothelioma (sarcomatoid type).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2328062&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the usefulness of immunohistochemistry in the diagnostic distinction between pleural mesothelioma and metastatic adenocarcinoma to the pleura, the authors studied formalin-fixed paraffin-embedded tissue sections from 14 pleural mesotheliomas and 20 primary adenocarcinomas of the lung, stomach, ovary and breast by using 16 commercially available antibodies to cytokeratin (KL1), vimentin, EMA, CEA, CA19.9, CA125, Egp 34 (detected by HEA 125), secretory component, S100 protein, SP1-béta 1, Leu M1, alpha-1-AT, alpha-1-ACT, lysozyme, desmin and factor VIII.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23293508&#34; target=&#34;_blank&#34;&gt;Mesothelioma - Update on Diagnostic Strategies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) can be a challenging diagnosis for clinicians to make as it is often difficult to distinguish from benign asbestos pleural effusions and metastatic carcinomas. […] In this review, we present a case of MPM and discuss clinical manifestations, traditional diagnostic techniques, and the role of cytopathologic immunostains and serum biomarkers in the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23317248&#34; target=&#34;_blank&#34;&gt;Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: eighteen years’ experience in Turkey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The study included 228 patients (131 male, 97 female) who were followed up in our institution between 1993 and 2010 with the diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23333048&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: diagnosis and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PET-scan associated with CT-scan may help to differenciate MPM from pleural benign tumors but it is not recommended for the diagnosis of MPM, as well as chest resonance magnetic imaging and blood or pleural fluid biomarkers, including soluble mesothelin still under investigation. […] The diagnosis of MPM is based on histology using essentially immunohistochemistry on pleural biopsies best obtained by thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23354805&#34; target=&#34;_blank&#34;&gt;Metachronous malignant mesothelioma and pulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For the differential diagnosis, the patient underwent wedge biopsy from the right lower lobe and was diagnosed as epithelial diffuse malignant mesothelioma. […] However, a history of asbestos exposure is not required for the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23355202&#34; target=&#34;_blank&#34;&gt;Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The CTC method can be used reliably as an adjunct to other preparation techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2335801&#34; target=&#34;_blank&#34;&gt;The malignancy grading method is not a reliable assessment of malignancy in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, for primary mesothelial tumours, the ploidy value cannot be used as a reliable diagnostic index.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23372960&#34; target=&#34;_blank&#34;&gt;A case of malignant peritoneal mesothelioma revealed with limitation of PET-CT in the diagnosis of thoracic metastasis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present case demonstrated the some of the limitations of PET-CT in the diagnosis of malignant mesothelioma, which failed to detect pleural involvement despite aggressive invasion by this tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23405711&#34; target=&#34;_blank&#34;&gt;[A case report: an university professor suffering from malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 2011, after almost 40 years, the subject comes to the attention of the Apulia Regional Operative Center, with histologic and immunohistochemical diagnosis of epithelioid mesothelioma, after completing the diagnostic procedure in a thoracic surgery ward, for the assessment and treatment of a right pleural effusion revealed during health checks.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23405713&#34; target=&#34;_blank&#34;&gt;[Identification and characterization of microRNA involving in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MiRNA, short RNA no-codifing sequences, are recently identified such as diagnostic markers in several type of cancer. […] This work represents the first step for the identification of a specific miRNA pattern for MPM, which will be useful in the diagnosis of MPM and for a personalized therapeutic treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23405715&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma: analysis of a hospital case series].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Four peritoneal cases underwent peritonectomy with hyperthermic intraoperative chemotherapy: one is still alive 20 months after diagnosis, the others died at 8, 18 and 36 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23405717&#34; target=&#34;_blank&#34;&gt;[Preliminary study to evaluate the meaning of GGT fractions analysis in a population of workers previously exposed to asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our data demonstrated a statistical significant correlation between the fraction free-GGT with the presence of MPM, suggesting a possible role for this molecule as a biomarker for MPM diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23407570&#34; target=&#34;_blank&#34;&gt;Surgery in mesothelioma–where do we go after MARS?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection consists of different procedures for diagnostic or therapeutic reasons.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23411062&#34; target=&#34;_blank&#34;&gt;Rare pleural tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Primary pleural tumors other than mesothelioma account for fewer than 1% of all lung cancers, and consequently they pose diagnostic and management challenges. […] In this review, we describe the radiologic and pathologic features of the less common primary pleural tumors and propose a diagnostic approach to their evaluation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23421939&#34; target=&#34;_blank&#34;&gt;Laparoscopic repair of secondary parahiatal hernia with incarceration of the stomach: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although preoperative diagnosis of parahiatal hernia is difficult, a laparoscopic approach can be a useful therapeutic procedure not only for paraesophageal hernia but also for parahiatal hernia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23423281&#34; target=&#34;_blank&#34;&gt;Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In patients developing malignant pleural mesothelioma (MPM) or lung cancer, using effective tumour markers is the quickest way to ensure early diagnosis and improve survival time. […] In two patients with MPM and five with lung cancer, we could obtain more than one marker result before the diagnosis was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23427016&#34; target=&#34;_blank&#34;&gt;Value of autofluorescence in video-assisted thoracoscopic surgery in pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall sensitivity of AF-assisted VATS for detecting pleural malignancies was not satisfactory because of diagnostic errors in malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23428976&#34; target=&#34;_blank&#34;&gt;Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For an early diagnosis of MPM and developing new therapeutic strategies against the malignancy, it is necessary to better understand biological characteristics of MPM. […] The differences of their growth between under hypoxia and under normoxia, and those depending on the cell density, may provide useful hints for developing a new strategy for diagnosis or therapy of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23450672&#34; target=&#34;_blank&#34;&gt;Pneumoconiosis and malignant mesothelioma in a family operated metal casting business that used industrial talc from New York state.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This is a report of the diagnosis of pneumoconiosis and mesothelioma in a husband and wife who operated a small metal casting business that used industrial talc from New York as a parting agent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23450849&#34; target=&#34;_blank&#34;&gt;Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In malignant pleural mesothelioma (MPM), most patients first present with pleural effusion; thus, cytologic analysis is the primary diagnostic approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23453339&#34; target=&#34;_blank&#34;&gt;Multimodality treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we review the current multimodal diagnostic and treatment options for patients with mesothelioma and discuss promising new experimental concepts in this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23475537&#34; target=&#34;_blank&#34;&gt;Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration in a female patient with pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, we report a case of paraneoplastic cerebellar degeneration in a patient with pleural malignant mesothelioma because of the rarity of this neurologic presentation after the diagnosis of malignant mesothelioma and of the association with anti-Yo antibodies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23480683&#34; target=&#34;_blank&#34;&gt;Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article evaluates the application of CTC as a potentially useful diagnostic and prognostic test in malignant pleural mesothelioma (MMe). […] MMe develops after long time latency, is rarely diagnosed at early stages, is poorly sensitive to conventional treatments and presents a very short survival upon diagnosis. […] Possibly in combination with other diagnostic tools, such as a thoracoscopy and advanced imaging, CTC can represent a promising tool for MMe prognosis and follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23483811&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
She underwent repeated thoracentesis, transbronchial lung biopsy, bronchoalveolar lavage, and thoracoscopic pleural biopsy with talc pleurodesis, but diagnosis of her was uncertain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23493352&#34; target=&#34;_blank&#34;&gt;Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted microarray analysis on 113 specimens including MPMs and a spectrum of tumors and benign tissues comprising the differential diagnosis of MPM. […] New clinically relevant molecular tests have been generated using a small number of genes to accurately distinguish MPMs from other thoracic samples, supporting our hypothesis that the gene expression ratio approach could be a useful tool in the differential diagnosis of cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23520887&#34; target=&#34;_blank&#34;&gt;[Autopsy findings and pleural plaques in the Malignant Mesothelioma (MM) Regional Register of Friuli-Venezia-Giulia].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To describe the cases of MM that occurred in the Friuli Venezia Giulia Region in the period 1995-2009 and evaluate the diagnostic contribution of autopsy findings. […] Via the Regional Register a search for MM cases was made following standardized criteria for diagnosis and past asbestos exposure assessment. […] Pleural plaques were identified by autopsy findings; the relationship between presence of pleural plaques and assessment of past asbestos exposure was analyzed. 834 cases of MM were recorded and 458 autopsy findings were available; for 142 cases (15% of males and 23% of women) the first diagnosis was made at autopsy. […] Logistic regression showed that significant predictors for pleural plaques were age at diagnosis (OR=1.03 each year (95% CI=1.01-1.05), asbestos exposure in group 1 versus group 2 (OR=6.8 (95% CI=4-12), and exposure in group 1 versus group 3 (OR=6.4 (95% CI=3-13). […] Autopsy findings improved the diagnostic level of MM in elderly subjects, for whom reliable data on past asbestos exposure is often lacking.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23532816&#34; target=&#34;_blank&#34;&gt;Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CYFRA 21-1 and CEA have been applied for the differential diagnosis of malignant pleural mesothelioma (MPM). […] Low levels of CEA were associated with a MPM diagnosis. […] Results suggest that SMRP could improve CYFRA 21-1 and CEA accuracy in the differential diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23537297&#34; target=&#34;_blank&#34;&gt;Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a challenging diagnosis characterized by the absence of real specific diagnostic markers. […] In spite of our inability to prove the real diagnostic value of the galectin-3 antibody, our findings make us wonder about the implication of this antibody in the carcinogenesis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23550710&#34; target=&#34;_blank&#34;&gt;Current and future options for the diagnosis of malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To prepare this review, we performed a search using keywords: ‘diagnosis’ + ‘malignant’ + ‘pleural’ + ‘effusion’ (all fields) in PubMed, and found 4106 articles overall (until 16 January 2013, 881 in the last 5 years). […] Ultrasound techniques will stay as valuable tools for pleural effusions. […] Needle pleural biopsy is justified only if used with image-techniques (ultrasound or CT) guidance, and thoracoscopy is better for both diagnosis and immediate palliative treatment (pleurodesis). […] Considering the possibility of direct pleural delivery of nanotechnology-developed compounds-fit to both diagnosis and therapy purposes (‘theranostics’)-MPE and mesothelioma in particular are likely to benefit sooner than later from this exciting perspective.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23576643&#34; target=&#34;_blank&#34;&gt;Diagnostic delay in malignant pleural mesothelioma due to physicians fixation on history with non-exposure to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To establish the diagnosis of virtually any disease, the clinician must combine a variety of information. […] Continuous assessment of all available information is of utmost importance, as fixation on single details can be misguiding with inappropriate consequences in both the diagnostic and therapeutic approach. […] This case report presents how an atypical medical history led to a delay in the diagnosis of malignant pleural mesothelioma due to a low a priori likelihood of the disease because of non-exposure to asbestos. […] We highlight the fact that postrationalisation and attempts to renew a diagnostic approach must be carried out each time diagnostic dilemmas emerge, and when some or all diagnostic clues disagree.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23585432&#34; target=&#34;_blank&#34;&gt;[Epidemiologic surveillance of mesothelioma for the prevention of asbestos exposure also in non-traditional settings].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Period of diagnosis: 1993-2008. […] Mean age at diagnosis is 69 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23585433&#34; target=&#34;_blank&#34;&gt;[Considerations about the epidemiologic surveillance system on mesothelioma in Tuscany (Italy) after 25 years of activity].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In order to evaluate accuracy and completeness of cases, the following indicators by period are used for pleural mesotheliomas diagnosed during 1988-2009: the distribution of the sources of cases’ diagnosis and report to the regional registry, the latency time between diagnosis and report, the age and sex specific rates, the ratio between standardized mortality and incidence rates. […] The latency time between diagnosis and case report have been reducing with a consequent increase in direct interviews to cases (from 20.3% in 1988-1993 to 71.4% in 2005-2009) and in exposure information and classification quality.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23585940&#34; target=&#34;_blank&#34;&gt;The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although N-ERC/mesothelin (N-ERC) is an attractive diagnostic and treatment monitoring biomarker for malignant pleural mesothelioma (MPM), its clinical utility for predicting the prognosis has not yet been clarified.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2359501&#34; target=&#34;_blank&#34;&gt;[Cytological exam of the pleural fluid in the diagnosis of neoplastic pleuritis. Cases contribution].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The relevance of cytologic procedures in the diagnosis of malignant pleural effusions is evaluated. […] The results were: 32 (66.6%) patients had a cytologic diagnosis of malignant pleural effusions; 16 malignant specimens were not confirm by pleural fluid cytologic analysis. […] In our experience the cytologic diagnosis of malignant pleural effusions are more frequent in metastatic disease, especially in lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23595591&#34; target=&#34;_blank&#34;&gt;Calretinin is essential for mesothelioma cell growth/survival in vitro: a potential new target for malignant mesothelioma therapy?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Calretinin (CR) is widely used as a diagnostic marker for epithelioid and mixed (biphasic) mesothelioma; however, little is known about CR’s putative functions in tumorigenesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23595855&#34; target=&#34;_blank&#34;&gt;[Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The concept, techniques and perioperative management of this additional treatment option are presented along with a detailed review of the recent literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23609252&#34; target=&#34;_blank&#34;&gt;Desmoplastic malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of desmoplastic malignant mesothelioma was confirmed by minithoracotomy and immunohistochemical staining with pan-cytokeratin, cytokeratin 5/6, calretinin, carcinoembryonic antigen, thyroid transcription factor-1, CD15, and HMB-45 on the biopsy specimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23620108&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous lung cancer mimicking mesothelioma on ¹⁸F-FDG PET/CT images: report of 2 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic image interpreters should be familiar with the (18)F-FDG PET/CT findings in PLC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23627453&#34; target=&#34;_blank&#34;&gt;p16 Deletion in sarcomatoid tumors of the lung and pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of sarcomatoid neoplasms of the lung and pleura can be challenging. […] Homozygous deletion of 9p21, the locus harboring the p16 gene, has been reported as the most common genetic alteration in malignant mesotheliomas that is of potential diagnostic and prognostic significance. […] To evaluate the frequency of 9p21 deletion by fluorescence in situ hybridization in the primary sarcomatoid neoplasms of the lung and pleura and to determine its potential diagnostic utility. […] Despite statistically significant differences in the frequency of 9p21 deletion, and because of the large overlap among the study groups, this genetic abnormality cannot be used as a reliable diagnostic tool in the assessment of sarcomatoid lesions of the lung and pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23649441&#34; target=&#34;_blank&#34;&gt;Diagnostic surgical pathology in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article provides evidence-based background and recommendations for the development of American College of Chest Physicians guidelines for the diagnosis and management of lung cancer. […] Our approach to examining the evidence and formulating recommendations is described in the “Methodology for Lung Cancer Evidence Review and Guideline Development: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2nd Edition)” and updated in “Methodology for Development of Guidelines for Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Pathologic examination results of lung cancers should be recorded in a synoptic form to include important prognostic features of histologic type, tumor size and location, involvement of visceral pleura, extension to regional and distant lymph nodes, and metastatic spread to visceral organs and bone to increase completeness of recording. […] In challenging cases of pathologic differential diagnosis, additional studies may enable the separation of distinct tumor types. […] Pathologic assessment of lung cancers is a crucial component for the diagnosis, management, and prognosis of lung cancer, making the pathologist a critical member of the clinical and management team. […] Selective diagnostic techniques, including limited designed immunohistochemical panels, and decision analysis will increase diagnostic accuracy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23656974&#34; target=&#34;_blank&#34;&gt;Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Magnetic resonance spectroscopy is a promising technique for comprehensive and comparative studies of metabolites in malignant serous effusions, and our study shows that small metabolites associated with effusions might improve our understanding of tumor biology and disease progression and has diagnostic potential in this differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23661345&#34; target=&#34;_blank&#34;&gt;Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It may display a variety of histological patterns and has a wide spectrum of cytomorphological characteristics, causing problems in its differential diagnosis from lung adenocarcinomas and sometimes from benign mesothelial proliferations. […] In our study, we aimed to determine the value of glucose transporter isoform-1 (GLUT-1) and K homology domain-containing protein (KOC) markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and lung adenocarcinoma. […] The samples were applied GLUT-1 and KOC markers by immunohistochemistry and the place of these markers in the differential diagnosis was examined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23673453&#34; target=&#34;_blank&#34;&gt;PET/CT versus body coil PET/MRI: how low can you go?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to evaluate if positron emission tomography (PET)/magnetic resonance imaging (MRI) with just one gradient echo sequence using the body coil is diagnostically sufficient compared with a standard, low-dose non-contrast-enhanced PET/computed tomography (CT) concerning overall diagnostic accuracy, lesion detectability, size and conspicuity evaluation. […] Overall, PET/MRI with body coil acquisition does not match entirely the diagnostic accuracy of standard low-dose PET/CT. […] • Evaluation of whether PET/MRI with one sequence using body coil is diagnostically sufficient compared with PET/CT • PET/MRI with body coil does not match entirely the diagnostic accuracy of standard low-dose PET/CT • PET/MRI might only serve as a backup solution in patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23676957&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma: have we made any progress?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New techniques in radiation therapy, pleural intensity-modulated radiotherapy, helical tomography and proton-therapy are exciting advances in multimodality treatment enhancing local control and therefore improving overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23677068&#34; target=&#34;_blank&#34;&gt;Molecular pathogenesis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With further comprehensive genome analyses, new genetic and epigenetic alterations in MM cells are expected to be revealed more precisely, and the new knowledge based on them will be applied for developing new diagnostic tools and new target therapies against MMs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23687495&#34; target=&#34;_blank&#34;&gt;Secondary malignant peritoneal mesothelioma of the greater omentum after therapy for primary pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Aspiration of the ascites and the biopsy of the greater omentum confirmed the diagnosis of secondary malignant mesothelioma of the peritoneum. […] In conclusion, we present the extremely rare diagnosis of secondary malignant mesothelioma of the abdomen, which arose as a result of local progression from the right pleura into the abdomen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23690193&#34; target=&#34;_blank&#34;&gt;Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Radiological imaging is necessary for the diagnosis, staging, and clinical management of patients with MPM. […] The mean survival time was 11 months from time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23711077&#34; target=&#34;_blank&#34;&gt;Asbestos and the lung in the 21st century: an update.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Over recent years, there have been changes in the epidemiology of mesothelioma, in clinical management of ARDs and developments in new techniques for early detection of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2371417&#34; target=&#34;_blank&#34;&gt;Investigation of pleural effusion: comparison between fibreoptic thoracoscopy, needle biopsy and cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic yield for all three techniques combined was 85%, for thoracoscopy alone 65%, Abrams biopsy 60% and cytology 45%. […] In 12 patients presenting without previous investigation all eight malignant effusions were correctly diagnosed by at least one of the techniques with individual sensitivities of 75% for thoracoscopy, 63% for Abrams and 38% for cytology. […] Of the 16 patients who had previously had negative investigations 12 had malignant effusions, nine (75%) of which were diagnosed by a combination of the techniques. […] A correct diagnosis of malignancy was made by a combination of needle biopsy and cytology in 75% of patients with previous investigations and 88% of those without.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23720698&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its diagnosis and treatment still present a major challenge for ambulatory and in-hospital care and will do so for years to come.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23732197&#34; target=&#34;_blank&#34;&gt;[Pulmonary disease due to asbestos in steel industry workers].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of asbestos-related diseases was made by a medical-occupational record, history of asbestos exposure, additional studies of lung function and chest images.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23743993&#34; target=&#34;_blank&#34;&gt;[Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean age at diagnosis was 67 years (range 45-84 years) and 65 % of patients had a history of asbestos exposure. […] Of the patients 87 (74 %) underwent at least one surgical procedure: diagnostic thoracoscopy with biopsy (n = 37, 43 %), debulking surgery or talcum pleurodesis (n = 33, 38 %) and potentially curative resection (n = 17, 19 %).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23749930&#34; target=&#34;_blank&#34;&gt;Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Herein, we compared the diagnostic performances of SMRP in matched pleural effusion (PE-SMRP) and serum (S-SMRP). […] Diagnosis on pleural biopsies was performed for all patients including 43 with MPM, 23 with non-MPM pleural metastases (MTS) and 36 with benign (BNG) pleural diseases. […] PE-SMRP showed a better diagnostic accuracy than S-SMRP in MPM vs. […] 84.7%; diagnostic odds ratio (DOR)=17.1 vs. […] PE-SMRP detection has a superior diagnostic accuracy than S-SMRP detection in the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2375659&#34; target=&#34;_blank&#34;&gt;Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A specific diagnosis of a mesothelioma was rendered or suspected in 64% (23/36 patients). […] The contribution of effusion cytology to the final diagnosis and patient treatment was assessed. […] These data suggested that a cytologic diagnosis contributed useful information in most patients with malignant epithelioid and biphasic pleural mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23756640&#34; target=&#34;_blank&#34;&gt;[Surgical aspects of malignant pleural mesothelioma: from the perspective of pathology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prerequisite for curative surgery is a pathological anatomical tumor diagnosis on the basis of a biopsy and accurate tumor staging. […] In order to achieve reproducible results in the assessment of malignant pleural diseases, the pathological anatomical diagnosis of malignant pleural mesothelioma should be made according to the guidelines of the international mesothelioma interest group (IMIG). […] Currently used multimodal thoracic surgery therapeutic concepts present new challenges and problems to the pathological anatomical diagnosis and are discussed in this article.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23760546&#34; target=&#34;_blank&#34;&gt;Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with mesothelioma present with thoracic symptoms and radiological changes so respiratory physicians take a leading role in diagnosis and management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23769317&#34; target=&#34;_blank&#34;&gt;Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present systematic review aimed to assess the safety and efficacy of these techniques. […] Results of the present systematic review suggested similar perioperative mortality outcomes between different P/D techniques but a trend towards higher morbidity and length of hospitalization for patients who underwent ‘extended P/D’. […] However, overall and disease-free survival appeared to favour ‘extended P/D’ compared to less aggressive techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23777840&#34; target=&#34;_blank&#34;&gt;Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related peptides (SMRP) have been reported as potential markers for the diagnosis of malignant pleural mesothelioma (MPM). […] We wondered, whether a combination with a carcinoembryonic antigen (CEA) test might improve the relatively low diagnostic yield of the SMRP test. […] The diagnostic yield of the mesothelin test can be considerably improved when combined with a CEA test with regard to the differential diagnosis between MPM and LC and between MPM and benign asbestos disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23789518&#34; target=&#34;_blank&#34;&gt;[Occupational exposure to asbestos and incidence of malignant mesothelioma in the Lazio region, years 2001-2009: results of the activities of the regional register].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The MM cases, notified by hospitals, regional protection and workplace safety units, Italian Workers’ Compensation Authority, other regions, or extracted from hospital information systems and the regional registry of causes of death, are included in the register after analysis of diagnostic procedures (CT scan, chest X-ray, pathology reports and patients’ records).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23790737&#34; target=&#34;_blank&#34;&gt;Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We retrospectively analyzed hyaluronic acid (HA) concentrations in pleural fluid and evaluated its utility for the differential diagnosis of malignant pleural mesothelioma (MPM). […] Receiver operating characteristic (ROC) analysis revealed an area under the ROC curve value of 0.832 (95% confidence interval, 0.765-0.898) for the differential diagnosis of MPM. […] A diagnosis of MPM should be strongly considered in patients with pleural fluid HA concentrations exceeding 100,000ng/ml.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23796498&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma after radiation treatment for Hodgkin lymphoma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The evidence for radiotherapy as cause for mesothelioma is expanding and the diagnosis of mesothelioma in patients who had previous irradiation should be kept in mind.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23797722&#34; target=&#34;_blank&#34;&gt;Diffuse intrapulmonary malignant mesothelioma masquerading as interstitial lung disease: a distinctive variant of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A clinicoradiologic diagnosis of ILD was made in all cases, and wedge biopsies were performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23814259&#34; target=&#34;_blank&#34;&gt;Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The detection of neoplastic invasion remains the linchpin for a clear diagnosis of malignant mesothelioma. […] Cytology-only diagnosis of epithelioid mesothelioma on aspirated effusion fluid remains controversial. […] Although ‘positive’ and ‘negative’ immunohistochemical markers have proved remarkably effective in distinguishing between epithelioid mesothelioma and secondary carcinoma and other malignant tumours metastatic to serosal membranes, no mesothelial marker has 100% sensitivity and specificity for mesothelioma diagnosis, so that panels of ‘positive’ antibodies and markers with negative predictive value are required. […] At present, no tissue or serum marker (including the molecular detection of p16/CDKN2A) has been proved to have sufficient specificity, consistency and reproducibility that it can replace evidence of invasion as the decisive marker for diagnosis when there is any uncertainty concerning a diagnosis of epithelioid mesothelioma and in the case of atypical fibrous lesions of the pleura (especially collagen-rich lesions, namely fibrous pleuritis vs desmoplastic mesothelioma), in which even the assessment of invasion can be problematical as illustrated in part 2 of this review.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23828409&#34; target=&#34;_blank&#34;&gt;MUC1 has prognostic significance in malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Routine immunohistochemical detection of MUC1 is performed for differential diagnosis in malignant peritoneal mesothelioma (MPM). […] High expression of MUC1 (immunohistochemical score of 5-8), was correlated with poor survival in several categories: all subtypes of tumors (p=0.001), male gender (p=0.017), female gender (p=0.001), epitheloid tumors (p=0.001), epitheloid tumors in males (p=0.005), epitheloid tumors in females (p=0.003), and age at diagnosis (AAD) &amp;lt;60 years (p=0.001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23833051&#34; target=&#34;_blank&#34;&gt;Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Criteria for discrimination between fibrous pleuritis versus desmoplastic mesothelioma include evidence of neoplastic invasion for diagnosis of desmoplastic MM, but this histological assessment is complicated by the recently-described ‘fake fat phenomenon’ in cases of fibrous pleuritis. […] The distinction between biphasic and monophasic synovial sarcoma of the pleura versus biphasic and sarcomatoid MM can be problematical and is most cogently based upon molecular detection of the t(X;18) translocation, whereas a clear diagnosis of MM for a pleural tumour histologically resembling synovial sarcoma is favoured by a negative result for this translocation and, probably, microRNA evidence supportive of a diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23840993&#34; target=&#34;_blank&#34;&gt;Primary pericardial mesothelioma: a rare entity.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical symptoms and signs are frequently nonspecific, and the diagnosis is usually made after surgery or at autopsy. […] The diagnosis was established after surgery by histological and immunohistochemical studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23860238&#34; target=&#34;_blank&#34;&gt;Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate whether the immunocytochemical expression of cell proliferation markers, such as minichromosome maintenance protein 7 (MCM 7), geminin, topoisomerase II alpha (topo IIα) and Ki-67, which are different types of cell proliferation markers, could be useful for their differential diagnosis in reactive mesothelial cells and malignant mesothelioma cells obtained from body cavity fluids. […] LIs of MCM 7, geminin and topo IIα can be reliable tools for the differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23872914&#34; target=&#34;_blank&#34;&gt;Metastatic carcinoma to the thyroid gland: a single institution 20-year experience and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, it is important to keep intrathyroidal metastases in the differential diagnosis when evaluating a thyroid nodule, particularly in patients with a previous history of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23873013&#34; target=&#34;_blank&#34;&gt;Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study based on the third phase of the architecture of diagnostic research was to assess the sensitivity and specificity of soluble mesothelin-related peptide (SMRP) in pleural exudative effusions (PE) compared to the histology obtained by medical thoracoscopy as the diagnostic gold standard examination. […] The diagnostic sensitivity and specificity of PE-SMRP for distinguishing mesothelioma from all other causes of pleural effusion, at a cut-off value of 19.6 nM, were 58.8 and 97.1 %, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23883236&#34; target=&#34;_blank&#34;&gt;FDG PET/CT in the management of primary pleural tumors and pleural metastases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2389813&#34; target=&#34;_blank&#34;&gt;Lymph node metastasis as the initial manifestation of malignant mesothelioma. Report of six cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When confronted with a lymph node involved by metastatic tumor, pathologists should be aware that malignant mesothelioma can present initially in the form of lymphadenopathy and include this possibility in the differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23932389&#34; target=&#34;_blank&#34;&gt;18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This retrospective study evaluated the role of 18-fluorine-labeled 2-deoxy-2-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with previous occupational or environmental exposure to asbestos, with histopathological diagnosis of epithelial malignant pleural mesothelioma and suspected recurrences, comparing the data from 18F-FDG PET/CT and computed tomography with contrast enhancement (CECT).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2393241&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in a clerk working in an asbestos factory.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of a malignant diffuse pleural mesothelioma was made only after the pleural tissue (obtained during the thoracotomy) was sent for histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-09-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23946800&#34; target=&#34;_blank&#34;&gt;Giant malignant mesothelioma in the upper mediastinum: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histopathological and immunohistochemical examinations of the tumor verified the diagnosis of a malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23976967&#34; target=&#34;_blank&#34;&gt;Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant Pleural Mesothelioma (MPM) is an aggressive cancer that is often diagnosed at an advanced stage and is characterized by a long latency period (20-40 years between initial exposure and diagnosis) and prior exposure to asbestos. […] Currently accurate diagnosis of MPM is difficult due to the lack of sensitive biomarkers and despite minor improvements in treatment, median survival rates do not exceed 12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23977534&#34; target=&#34;_blank&#34;&gt;Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival was measured from the date of pathologic diagnosis to the most recent contact or death.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23977542&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: an epidemiological perspective.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Time from asbestos exposure to disease diagnosis is on average greater than 40 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23982605&#34; target=&#34;_blank&#34;&gt;Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our findings validate standard prognostic variables and the existing EORTC and CALGB models, but not NLR, at initial diagnosis of MPM. […] In guiding patient management at diagnosis, it is important to consider multiple baseline variables that jointly predict survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23983174&#34; target=&#34;_blank&#34;&gt;Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cytological diagnosis of malignant mesothelioma (MM) on serous effusion is challenging due to significant morphologic overlap with reactive mesothelial cells and adenocarcinoma. […] Finding this morphological feature in pleural fluid should alert the pathologist to a possible diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23991032&#34; target=&#34;_blank&#34;&gt;Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of malignant mesothelioma is challenging. […] The first available diagnostic material is often an effusion and biochemical analysis of soluble markers may provide additional diagnostic information. […] This study aimed to establish a predictive model using biomarkers from pleural effusions, to allow early and accurate diagnosis. […] This method can be performed on the first available effusion and could be a useful adjunct to the morphological diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/23991301&#34; target=&#34;_blank&#34;&gt;Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were no statistically significant differences between the three surgical techniques (P=0.088).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24018024&#34; target=&#34;_blank&#34;&gt;Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging of malignant pleural mesothelioma (MPM) is essential to the diagnosis, assessment, and monitoring of this disease. […] Imaging for MPM impacts everything from initial patient diagnosis to the outcomes of clinical trials; iMig 2012 captured this broad range of imaging applications as investigators exploit technology and implement multidisciplinary approaches toward the benefit of MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24039177&#34; target=&#34;_blank&#34;&gt;The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma (MM) in effusion specimens is controversial. […] At the study institution (Northwestern University), a primary diagnosis of MM is made on fluid cytology specimens. […] In an effort to estimate the practice at other institutions, a survey was disseminated regarding cytologic diagnosis of MM. […] The authors also evaluated their own institution’s experience with primary cytologic diagnosis of MM. […] A survey was sent to a number of cytology laboratories to assess practice patterns regarding the diagnosis of MM. […] At the study institution, 20 cases of MM had effusion specimens preceding the diagnostic histologic material. […] In 6 cases (30%), a definitive diagnosis of MM was rendered via cytology alone. […] Of 55 laboratories that responded to the survey, 36 reported making a definitive diagnosis of MM after cytologic analysis. […] Most respondents (32) felt that the clinicians at their institution would manage a patient based on a cytologic diagnosis of MM. […] The majority of respondents reported making a definitive diagnosis of MM in effusion cytology specimens. […] The diagnosis of MM in effusions, although not sensitive, is extremely specific.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24045552&#34; target=&#34;_blank&#34;&gt;CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We found that CD90 expression was useful in making a differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma, whereas sarcomatoid mesothelioma and lung carcinoma specimens, irrespective of the histologic types, were negative in general. […] The sensitivity and specificity of CD90 expression in epithelioid mesothelioma and lung adenocarcinoma were comparable to those of well-established markers used for the differential diagnosis. […] These data collectively indicate that CD90 is a novel diagnostic marker that contributes to a diagnosis of epithelioid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24047806&#34; target=&#34;_blank&#34;&gt;[The diagnostic value of medical thoracoscopy for unexplained pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To explore the endoscopic features of patients with unexplained pleural effusion, and to evaluate the diagnostic value of medical thoracoscopy. […] The diagnosis was confirmed by medical thoracoscopy. […] The pathological diagnosis was as follows: pleural metastases in 899 (37.8%), primary pleural mesothelioma in 439 (18.4%), tuberculous pleurisy in 514 (21.6%), non-specific inflammation in 226 (9.5%), empyema in 190 (8.0%), hepatic pleural effusion in 36 (1.5%) and pleural effusion of unknown causes in 76 (3.2%) cases. […] The diagnostic positive rate of medical thoracoscopy was 96.8%. […] Medical thoracoscopy is a relatively safe procedure and has an important application value in the diagnosis of unexplained pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24050959&#34; target=&#34;_blank&#34;&gt;Localized Intrasplenic Mesothelioma: A Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of localized intrasplenic epithelioid malignant mesothelioma was carried out.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24055913&#34; target=&#34;_blank&#34;&gt;Pulmonary mucinous cystadenocarcinoma presenting as a pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The postoperative histopathological findings were in accordance with the diagnosis of pulmonary mucinous cystadenocarcinoma on cystic adenoid malformation of lung. 5 years later, the patient has no recurrence. […] Preoperative diagnosis is very difficult to establish. […] Our patient went on to undergo open lung biopsy and histopathological testing that confirmed the diagnosis of PMC. […] Thoracic surgeons should bear in mind this rare tumor for the differential diagnosis of a pleural mesothelioma because this tumor has a favorable prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2013-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24061516&#34; target=&#34;_blank&#34;&gt;Florid mesothelial hyperplasia of the tunica vaginalis mimicking malignant mesothelioma: a clinicopathologic study of 12 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We herein report our experience with 12 cases of florid paratesticular mesothelial hyperplasia, highlighting the spectrum of morphologic changes seen and the utility of fluorescence in situ hybridization analysis of homozygous deletion of 9p21 as an adjunct diagnostic tool. […] In particular, the entrapment of isolated mesothelial clusters within deep fibrous tissue may be the cause of significant diagnostic difficulty.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24068419&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma presenting with symptomatic brain metastases: report of a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An extensive histochemical and immunohistochemical panel is needed to achieve a correct differential diagnosis, especially in the epithelioid type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24081932&#34; target=&#34;_blank&#34;&gt;Pulmonary alveolar microlithiasis with concurrent pleural mesothelioma in a dog.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical staining revealed neoplastic cells that strongly coexpressed vimentin and cytokeratin, supporting the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2408723&#34; target=&#34;_blank&#34;&gt;Ca2 and Ca3. New monoclonal antibodies evaluated as tumor markers in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They were tested to assess their value in the diagnosis of malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24102013&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: current and future perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although we have new targeted treatments and radical surgery as arrows in the quiver, the type of mesothelioma and early diagnosis still remain the best treatment approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24118858&#34; target=&#34;_blank&#34;&gt;Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirteen years after the first diagnosis, he presented with mediastinal lymph nodes metastasis and with an extremely rare pattern of tracheal and bronchial infiltration that was detected at bronchoscopy. […] Finally, the role of immunohistochemistry in the diagnosis of WDPM and the possible mechanisms leading to this unique way of metastatisation are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24128712&#34; target=&#34;_blank&#34;&gt;Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We reviewed the charts of 121 patients with MPM tumors diagnosed between 1991 and 2009 tested for BAP1 mutation, and extracted the following information: age at diagnosis, sex, histology, stage, smoking status, asbestos exposure, family or personal history of malignancy, and treatment including surgery, chemotherapy, and radiation as well as survival status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24161718&#34; target=&#34;_blank&#34;&gt;Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumour biomarkers are being intensely investigated in MM as aids to diagnosis and prognosis. […] Diagnostic accuracy was determined by area under the receiver operator characteristic curve (AUC) analysis following logistic regression modelling. […] This study demonstrates that a combined biomarker panel has greater diagnostic accuracy than effusion mesothelin alone, and that significant prognostic information is provided by effusion HA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24162121&#34; target=&#34;_blank&#34;&gt;Pleuroscopic punch biopsy using insulated-tip diathermic knife-2 for the diagnosis of desmoplastic malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 54-year-old man presenting with chest wall mass and thickened pleura, in whom a computed tomography-guided percutaneous needle aspiration had remained negative, underwent flex-rigid pleuroscopy for definitive diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24167356&#34; target=&#34;_blank&#34;&gt;Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPF and mesothelin serum concentrations were highly correlated and of equivalent diagnostic accuracy with AUCs of 0.813 ± 0.04 and 0.829 ± 0.03, respectively. […] Mesothelin and MPF convey equivalent diagnostic information for distinguishing MM from other diseases in pleural effusions as well as serum.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24183360&#34; target=&#34;_blank&#34;&gt;Diffuse malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Laparoscopic biopsy of the omentum and peritoneum confirmed the diagnosis of malignant peritoneal mesothelioma of epitheloid type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2418688&#34; target=&#34;_blank&#34;&gt;The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MAb B72.3, generated against a membrane-enriched fraction of human metastatic breast carcinoma, was used to distinguish malignant mesothelioma of the pleura from adenocarcinoma of the lung in tissue sections and was compared in terms of diagnostic utility with polyclonal anti-keratin and anti-CEA to make the same distinction. […] MAb B72.3 thus appears to be an appropriate diagnostic adjunct capable of discriminating between these malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2418692&#34; target=&#34;_blank&#34;&gt;Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
I conclude that the combination of staining for vimentin and keratin might be a useful diagnostic finding in malignant mesothelioma, but that specially fixed material is required for reliable vimentin staining.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24207061&#34; target=&#34;_blank&#34;&gt;Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serum biomarkers can improve diagnosis and treatment of malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2422109&#34; target=&#34;_blank&#34;&gt;Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The presence of such epithelial markers as keratin and epithelial membrane antigen (EMA) within the fibrous areas of a pleural lesion might be construed as evidence in support of the diagnosis of desmoplastic mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24225007&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: 2013 state of the art].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a bad-prognosis cancer raising difficult issues according to diagnosis. […] Reliable histological diagnosis indeed requires large-sized pathological samples obtained by thoracoscopy, and need diagnosis certification by the MESOPATH national expert pathological committee.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2422942&#34; target=&#34;_blank&#34;&gt;Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the usefulness of an immunohistologic approach to the differential diagnosis of mesothelioma and pulmonary adenocarcinoma, the authors studied paraffin-embedded, fixed tissue sections from 50 primary adenocarcinomas of the lung and 28 mesotheliomas of the pleura by using a panel of monoclonal antikeratin, antihuman milk fat globule (HMFG-2), anti-Leu M1, and monoclonal anticarcinoembryonic antigen (CEA) antibody; we also used a conventional heterologous anti-CEA antiserum with and without prior absorption with spleen powder to remove antibodies to nonspecific cross-reacting antigen (NCA).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24248698&#34; target=&#34;_blank&#34;&gt;Extrapleural and cardiophrenic lymph nodes: prevalence, clinical significance and diagnostic value.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the prevalence, clinical meaning and diagnostic value of extrapleural and cardiophrenic nodes occasionally observed on computed tomography (CT) scans of the chest. […] Cardiophrenic nodes &amp;gt;5 mm and extrapleural nodes of any size have a significant diagnostic value in malignant pleural disease, either primary or secondary, whereas they are extremely rare in other neoplastic or nonneoplastic diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24253341&#34; target=&#34;_blank&#34;&gt;AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the pathological diagnostic markers for epithelioid are established, to date no adequate marker for sarcomatoid mesothelioma has been found. […] Thus, a reliable diagnostic marker of sarcomatoid mesothelioma is necessary.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24257681&#34; target=&#34;_blank&#34;&gt;Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MM has several characteristics: extremely long incubation period of 30-40 years after asbestos exposure, difficulty in clinical diagnosis at an early stage, and poor prognosis even under the current multimodal therapies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24258567&#34; target=&#34;_blank&#34;&gt;Surgical pathology of lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis, treatment, and management of lung tumors represent a complex set of decision algorithms and require the cooperation and interaction of a team of experts and support systems. […] The surgical pathologist, an early, important member of the diagnostic team, uses clinical and radiological evidence to differentiate benign from malignant tumors and renders a unique diagnosis that provides both prognostic and treatment information. […] Histopathologic analysis should attempt to provide a precise diagnosis and limit the usage of the term non-small cell carcinoma. […] The team approach also enables the optimal use of tumor tissue for diagnostic purposes as well as molecular genetic testing and the discovery of targetable sites for therapeutic management. […] The awareness of diagnostic modalities and tissue handling by all members of the team ensures the best patient-centered care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24269017&#34; target=&#34;_blank&#34;&gt;[Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean follow-up was 2.3 years after diagnosis. […] The median survival from diagnosis was 18 months. […] A dosimetric comparison with volumetric modulated arctherapy techniques would be interesting in this setting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24306661&#34; target=&#34;_blank&#34;&gt;Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the diagnostic and prognostic value of circulating tumor cells (CTCs), a potential surrogate of micrometastasis, in malignant pleural mesothelioma (MPM). […] CTC was a promising marker in diagnosis and prediction of prognosis in MPM, especially in epithelioid MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24314815&#34; target=&#34;_blank&#34;&gt;Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eligible studies met the following criteria: MPM (histological or radiological diagnosis), radiotherapy given with the intent of improving pain, response rates to radiotherapy reported, dose and fractionation reported and the relationship between radiotherapy and pain response explored. […] Such studies should also use modern radiotherapy techniques and concentrate on dose escalation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24323466&#34; target=&#34;_blank&#34;&gt;Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Calretinin and Wilms’ tumor gene (WT1) are mesothelial markers routinely used to confirm the diagnosis of malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24326857&#34; target=&#34;_blank&#34;&gt;Solitary fibrous tumors of the pleura: a case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis is very difficult in limited samples such as fine-needle aspiration or needle-core tissue biopsy, and immunohistochemical analysis may be useful to differentiate solitary fibrous tumor of the pleura from mesothelioma and other similar tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2435037&#34; target=&#34;_blank&#34;&gt;Tissue polypeptide antigen (TPA) in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The usefulness of tumor marker assay in pleural effusions for differential diagnosis is still debated. […] Our results showed this assay to be not very important for a differential diagnosis of malignant and nonmalignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-04-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24354100&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma in a young male patient.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Specific tests, such as immunohistochemical staining, are used in order to help differential diagnosis. […] The case presented underlines that in the event of pleural effusion with a lymphocyte type physicians should consider the possibility of a pleural mesothelioma during differential diagnosis, even in relatively young patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24360321&#34; target=&#34;_blank&#34;&gt;A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although it must be emphasized that patient selection and treatment strategies differ between EPP and extended P/D, a number of comparative studies have recently been conducted to compare these two surgical techniques for patients with resectable MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24361865&#34; target=&#34;_blank&#34;&gt;Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive asbestos-induced cancer, and affected patients have a median survival of approximately one year after diagnosis. […] It is often difficult to reach a conclusive diagnosis, and ancillary measurements of soluble biomarkers could increase diagnostic accuracy. […] This analysis of the effusion proteome furthers our understanding of malignant mesothelioma, identified galectin 1 as a potential diagnostic biomarker, and highlighted several possible prognostic biomarkers of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2437407&#34; target=&#34;_blank&#34;&gt;Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of mesothelioma was established following rigid anatomic criteria. […] Immunohistochemical stains often added significantly to our ability to establish the diagnosis of mesothelioma with confidence, since they were more frequently and more clearly positive than histochemical stains.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2439221&#34; target=&#34;_blank&#34;&gt;Diagnosis and treatment of malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its well recognized association with numerous diseases plus the limitations of our usual diagnostic tests may occasionally cause difficulty. […] Fortunately, an increasing number of effective diagnostic and therapeutic modalities are available which, when judiciously applied, facilitate our approach.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24394956&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A Cox model of observed (all-cause) survival was used to generate hazard ratios for the effect of: gender; age at diagnosis; diagnosis cohort; region of residence; histological type; and tumour stage. […] Excess mortality risk was associated with age at diagnosis (75-89 yrs vs. 55-64 yrs, HR 1.88, 95% CI 1.35-2.63, P&amp;lt;0.001) and tumour stage (III vs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24397195&#34; target=&#34;_blank&#34;&gt;The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
BACKROUND/AIM: The final diagnosis of malignant pleural mesothelioma is made exclusively by histopathological examination of biopsy materials that are routinely complemented by the use of immunohistochemical analysis. […] The aim of this paper was to determine the significance of immunohistochemical analysis and application of certain antibodies in the diagnosis of malignant pleural mesothelioma. […] This retrospective analysis included clinical data of 32 patients with the histopathological diagnosis of malignant pleural mesothelioma made in the period 2004-2009 at the Institute for Pulmonary Diseases in Sremska Kamenica. […] Immunohistochemistry has become an essential diagnostic procedure for the diagnosis and determination of the type of malignant pleural mesothelioma, and due to the lack of individual antibodies a combination of antibody with different sensitivity and specificity is in use today.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24401539&#34; target=&#34;_blank&#34;&gt;Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related peptide (SMRP) may be useful in the diagnosis and detection of early stage mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2441518&#34; target=&#34;_blank&#34;&gt;Distinction between cells in serous effusions using a panel of antibodies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In serous effusions the distinction between reactive mesothelial cells and malignant cells (especially adenocarcinoma cells and malignant mesothelial cells) is frequently a cause of diagnostic difficulty.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24415579&#34; target=&#34;_blank&#34;&gt;Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a neoplastic disease linked to asbestos exposure whose diagnosis is limited, so detection methods for an early diagnosis and treatment result essential. […] Here, we compared proteomic profiles of malignant pleural mesothelioma (MPM) and benign biopsies to search potential biomarkers useful in differential diagnosis. […] Tissue biopsies were obtained from 53 patients who were subjected to a diagnostic thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24416534&#34; target=&#34;_blank&#34;&gt;Radiotherapy applications of patients with malignant mesothelioma: A single center experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of the study was to evaluate the techniques and effectiveness of radiotherapy in malignant pleural mesothelioma. […] All patients had surgery or thoracoscopic biopsy for diagnosis, staging or treatment and all received palliative or prophylactic radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2442887&#34; target=&#34;_blank&#34;&gt;Immunohistochemistry in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histological diagnosis of malignant mesothelioma of the pleura, especially the distinction from peripheral adenocarcinoma of the lung, may be difficult. […] The immunohistochemical reports previously published on this subject show diverging results mainly because a variety of antibodies and staining techniques have been used by the different authors. […] To obtain comparable and reproducible results standard techniques and commercialized antibodies should be applied in routine pathology. […] The results of our study indicate that especially CEA, but also SP1 are valuable markers in the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24434429&#34; target=&#34;_blank&#34;&gt;Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All fibrinogen levels were measured at the time of diagnosis and clinical data were retrospectively collected after approval of the corresponding ethics committees.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24440278&#34; target=&#34;_blank&#34;&gt;How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although all reactive mesothelial lesions were negative, the absence of immunoreactivity does not exclude the diagnosis of MM. […] As with all IHC stains used for diagnostic purposes, GLUT-1 has to be a part of a panel, and the results interpreted in the context of clinical, radiological and histological findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24443521&#34; target=&#34;_blank&#34;&gt;Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite research efforts to develop more effective diagnostic and therapeutic approaches, malignant pleural mesothelioma (MPM) prognosis remains poor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24448702&#34; target=&#34;_blank&#34;&gt;The diagnosis of thoracic malignant mesothelioma: practical considerations and recent developments.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We review the epidemiology, clinical presentation, and imaging studies in patients with malignant mesothelioma, and then present a practical approach to the diagnosis using the cytologic features for malignancy and whether there is an epithelioid or spindled morphology; four main scenarios are discussed. […] Practical considerations in the diagnosis of malignant mesothelioma are made throughout.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24456714&#34; target=&#34;_blank&#34;&gt;Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The following study was undertaken to investigate the clinical outcome of both radiation techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24457947&#34; target=&#34;_blank&#34;&gt;Prognostic factors in patients presenting with pleural effusion revealing malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most of the studies reporting results of prognostic factors are retrospective, using pleural thoracentesis for diagnosis. […] The objectives of our study were to reveal possible prognostic factors in patients initially presenting with undiagnosed pleural effusion proven to be malignant by diagnostic thoracoscopy. […] Survival time was defined as the time from thoracoscopic diagnosis to death or the last follow-up.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24465798&#34; target=&#34;_blank&#34;&gt;MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It has been proposed as a diagnostic and immunotherapeutic target with promising results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24471939&#34; target=&#34;_blank&#34;&gt;Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Much attention has been paid recently to carboanhydrases and their inhibitors as they offer an opportunity for both developing novel anticancer drugs, as well as diagnostic and prognostic tools. […] CAIX immunoreactivity is not a reliable diagnostic marker for distinguishing malignant cells from benign mesothelia in pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24481757&#34; target=&#34;_blank&#34;&gt;New applications of magnetic resonance imaging for thoracic oncology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, thoracic MRI could not yield image quality sufficient for a convincing diagnosis within an acceptable examination time, so MRI did not find acceptance as a substitute for computed tomography (CT) and other modalities. […] Within the past decade, however, technical advances in sequencing, scanners and coils, adaptation of parallel imaging techniques, utilization of contrast media, and development of postprocessing tools have been developed. […] In addition, pulmonary functional MRI has been extensively researched, and MR is being assessed as a new research and diagnostic tool for pulmonary diseases. […] State-of-the art thoracic MRI now has the potential as a substitute for traditional imaging techniques and/or to play a complimentary role in patient management. […] In this review, we focus on these advances in MRI for thoracic oncologic imaging, especially for pulmonary nodule assessment, lung cancer staging, mediastinal tumor diagnosis and malignant mesothelioma evaluation, prediction of postoperative lung function, and prediction or evaluation of therapeutic effectiveness.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24482386&#34; target=&#34;_blank&#34;&gt;Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results support a policy of accurate preoperative tissue diagnosis, nodal staging and induction chemotherapy prior to radical surgery for MPM, which can result in long-term survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2449084&#34; target=&#34;_blank&#34;&gt;Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The findings suggest that malignant pleural mesothelioma and pulmonary adenocarcinoma have consistent and distinct glycoconjugate profiles, and that stains for RCA-I and SucWGA may be useful for differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24492694&#34; target=&#34;_blank&#34;&gt;An autopsy case of malignant pleural mesothelioma associated with nephrotic syndrome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A thoracoscopic examination did not yield a definitive diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24507393&#34; target=&#34;_blank&#34;&gt;[Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical manifestations of malignant pleural mesotheliome were nonspecific, medical thoracoscopy can make early diagnosis. […] The pathological diagnosis of malignant pleural mesothelioma was based on immunohistochemical examination, calretinin, MC and D2-40 had positive diagnostic value.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24515241&#34; target=&#34;_blank&#34;&gt;The journey of mesothelioma: from postmortem to FNA.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A provisional diagnosis of mesothelioma was made. […] In addition, thoracoscopy and CT-guided pleural biopsy failed to obtain a definitive diagnosis. […] Ultrasound-guided fine-needle aspiration (FNA) and core biopsies of the lymph node were diagnostic for pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24528057&#34; target=&#34;_blank&#34;&gt;CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our findings implied that the two tumor markers may improve the diagnosis and treatment for effusions of unknown primaries.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24550969&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of peritoneal and Pleural mesothelioma is often delayed, due to a long latent period between onset and symptoms and the common and nonspecific clinical presentation. […] The definite diagnosis can only be established by diagnostic laparoscopy or open surgery along with biopsy to obtain histological examination and immunocytochemical analysis. […] The diagnosis of peritoneal and Pleural mesothelioma is often delayed, so level of index of suspicion must be kept high.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24562347&#34; target=&#34;_blank&#34;&gt;Role of microRNAs in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of MM patients is particularly severe, with a median survival of approximately 9-12 months and latency between exposure and diagnosis ranging from 20-50 years (median 30 years). […] The roles of miRNAs as diagnostic biomarkers and prognostic factors for potential therapeutic strategies will be presented and discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24566531&#34; target=&#34;_blank&#34;&gt;Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the values of soluble mesothelin-related peptides (SMRPs), including mesothelin and megakaryocyte potentiating factor, in serum and/or pleural fluid for diagnosing malignant pleural mesothelioma (MPM) have been extensively studied, the exact diagnostic accuracy of these SMRPs remains controversial. […] The purpose of the present meta-analysis is to update the overall diagnostic accuracy of SMRPs in serum and, furthermore, to establish diagnostic accuracy of SMRPs in pleural fluid for MPM. […] A total of 30 articles of diagnostic studies were included in the current meta-analysis. […] Sensitivity, specificity and other measures of accuracy of SMRPs in serum and pleural fluid for the diagnosis of MPM were pooled using random effects models. […] The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic OR were 0.61, 0.87, 5.71, 0.43 and 14.43, respectively, for serum and 0.79, 0.85, 4.78, 0.30 and 19.50, respectively, for pleural fluid. […] It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared with mesothelin for MPM. […] SMRPs in both serum and pleural fluid are helpful markers for diagnosing MPM with similar diagnostic accuracy. […] The negative results of SMRP determinations are not sufficient to exclude non-MPM, and the positive test results indicate that further invasive diagnostic steps might be necessary for the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24583437&#34; target=&#34;_blank&#34;&gt;“Dry” pleural mesothelioma successfully diagnosed on endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The acquisition of histologic material is obligatory in order to establish the diagnosis of malignant pleural mesothelioma (MPM). […] In contrast, the techniques for performing echoendoscopic (transbronchial or transesophageal) needle aspiration of pleural lesions have only rarely been reported due to the theoretical limitations of tissue acquisition in such cases. […] The patient underwent radical resection, and a definitive pathological examination confirmed the diagnosis of epithelioid MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24585905&#34; target=&#34;_blank&#34;&gt;Pericardiectomy for treatment of neoplastic constrictive pericarditis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of constrictive pericarditis was made primarily by echocardiography, and right heart catheterization was performed in 6 (75%) patients. […] Time from initial diagnosis of the neoplastic disease ranged from 1 to 15 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2458647&#34; target=&#34;_blank&#34;&gt;Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our observations suggest that immunocytochemical or ultrastructural evaluation is mandatory for accurate diagnosis of all pleura-based lymphomatoid lesions with a mixed large and small cell pattern.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-10-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24587782&#34; target=&#34;_blank&#34;&gt;Semirigid thoracoscopy: an effective method for diagnosing pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to report diagnostic yield and complications of the method. […] Patients with pleural effusion of unknown origin and/or pleural irregularities suspicious for pleural malignancy were included after less invasive means of diagnosis had failed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24591971&#34; target=&#34;_blank&#34;&gt;Malignant intraperitoneal mesothelioma-Başkent University experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate diagnostic and treatment results of malignant intraperitoneal mesothelioma in one setting. 12 patients treated for malignant peritoneal mesothelioma from January 2007 to June 2009 in Başkent University Ankara Hospital, Department of Gynaecology and Obstetrics were evaluated. […] Themean time from first symptoms until the diagnosis was 1.9 months. […] No correlations between first symptoms (0.27, p=0.52), time until the diagnosis (-0.29, p=0.44) and overall survival were observed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24595274&#34; target=&#34;_blank&#34;&gt;Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite some improvements in treatment, therapy is not considered curative and median survival following diagnosis is less than 1 year.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24602395&#34; target=&#34;_blank&#34;&gt;Surgery for malignant pleural mesothelioma: why, when and what?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Palliative surgery still has an important role to play in mesothelioma, in establishing or refining diagnosis and in controlling symptoms and improving quality of life in many patients whose life expectancy is limited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24604935&#34; target=&#34;_blank&#34;&gt;Radiological review of pleural tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumors of the pleura are not uncommon and diagnosis is clinched by combined imaging and clinical correlation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24607327&#34; target=&#34;_blank&#34;&gt;Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Osteopontin has been viewed as a promising biomarker for malignant pleural mesothelioma (MPM); however, the conclusions of various studies on diagnostic accuracy of osteopontin have not been consistent. […] The aim of this study was to conduct a systematic review and meta-analysis to evaluate the diagnostic accuracy of circulating osteopontin for MPM. […] Using appropriate key words, scientific literature that evaluated circulating levels of osteopontin for the diagnosis of MPM was retrieved from electronic databases. […] The quality of the studies was assessed using the revised Quality Assessment for Studies of Diagnostic Accuracy (QUADAS-2) tools. […] The overall diagnostic sensitivity and specificity were 0.65 (95% CI: 0.60-0.70) and 0.81 (95% CI: 0.78-0.85), respectively. […] The diagnostic accuracy of serum and plasma osteopontin was comparable. […] Osteopontin is an effective marker for MPM diagnosis. […] However, more studies with a larger sample size and better design are needed to rigorously assess the diagnostic power of osteopontin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24615665&#34; target=&#34;_blank&#34;&gt;[Pleural effusion cytology of asbestos-associated malignant mesothelioma and lung carcinoma in the diagnosis of occupational diseases by the statutory accident insurance funds].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As pleural punctation is performed quite early in the diagnostic procedure, effusion cytology frequently gives the first evidence about the presence of tumour cells and tumor histogenesis. […] The results were interpreted against the clinical and occupational history of the respective patient.Definitive diagnosis could be made in six cases. […] In three of them, the diagnosis of malignant mesothelioma was made. […] In the last case, malignant mesothelioma was diagnosed later by autopsy, and the case was retroactively accepted as occupational disease.Cytology-based tumor diagnosis including adjuvant methods is a useful and reliable approach in cases of asbestos-associated tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2461601&#34; target=&#34;_blank&#34;&gt;Differentiation of malignant from normal and reactive mesothelial cells by the argyrophil technique for nucleolar organiser region associated proteins.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is concluded that the AgNOR technique separates “reactive” pleural disease from mesothelioma with a high degree of confidence and is an important advance in the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-01-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24623168&#34; target=&#34;_blank&#34;&gt;Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The knowledge of new biomolecular technology applied to the diagnosis, prognosis, and treatment of lung cancer and mesothelioma should be part of the 21st century thoracic surgeons’ professional competence. […] During the 2013 ESTS Annual Meeting, different experts of the field presented the current knowledge about diagnostic and prognostic biomarkers in malignant pleural mesothelioma including new perspectives as well as the role and potential application of microRNA and genomic sequencing for lung cancer, which are summarized in the present article.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24630634&#34; target=&#34;_blank&#34;&gt;[Peritoneal malignant mesothelioma: review and recent data].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry is mandatory to affirm or disprove peritoneal malignant mesothelioma diagnosis, based on a panel of antibodies divided in positive markers and negative markers. […] Indeed an accurate diagnosis is necessary to define a therapeutic strategy more and more frequently based on the combination of radical surgery and hyperthermic intra peritoneal chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24633033&#34; target=&#34;_blank&#34;&gt;Small cell carcinoma presenting with massive pleural spread mimicking malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thereafter, he received second-, third- and fourth-line chemotherapies and died of tumor progression 21 months after the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24645844&#34; target=&#34;_blank&#34;&gt;Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean interval between the onset of symptoms and the diagnosis was 4.6±3.3 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24692425&#34; target=&#34;_blank&#34;&gt;Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytology is central in the diagnosis of malignancy in effusions. […] Ancillary techniques, mainly immunocytochemistry, have considerably improved the sensitivity but some 10% of all cases remain equivocal and require the addition of new diagnostic modalities. […] Strong telomerase activity was seen only in effusions from patients with definitive malignant diagnosis, all effusions from patients with benign disease lacking strong telomerase activity, whereas eight of the malignant cases, including three cases of epithelial mesothelioma, showed strong reactivity. […] Although the study is small, it suggests that TRAP in situ activity provides diagnostic information in about one-third of effusions remaining cytologically equivocal after the use of current ancillary techniques. […] The most striking diagnostic improvement appears to be gained in epithelial mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24706728&#34; target=&#34;_blank&#34;&gt;Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, breath analysis as a noninvasive and fast diagnostic tool has found its way into biomedical research. […] High-throughput breathomics uses spectrometric, chromatographic, and sensor techniques to diagnose asbestos-related pulmonary diseases based upon volatile organic compounds (VOC) in breath. […] This article reviews the state-of-the-art available breath analyzing techniques and provides the insight in the current use of VOCs as early diagnostic or prognostic biomarkers of mesothelioma to stimulate further research in this field.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2471414&#34; target=&#34;_blank&#34;&gt;A biphasic tumor of the mediastinum with features of synovial sarcoma. A report of four cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Follow-up was available on three patients, who died of their disease 10 months, 14 months, and 4 years after diagnosis, respectively. […] The differential diagnosis includes mesothelioma, thymoma, germ cell tumors, malignant peripheral nerve sheath tumor with glandular differentiation, and metastatic carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24716080&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: clinicopathological characteristics of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Peritoneal mesothelioma is a rare tumor, presenting difficulties in diagnosis and treatment. […] The diagnosis may be difficult due to lack of specific symptoms and clinical findings. […] In addition, a delay in the diagnosis is not rare especially in the absence of previous asbestos exposure. […] The diagnostic and therapeutic approaches for these rare neoplasms are discussed. […] Final diagnosis were possible with histological and immunohistochemical documentation of tumor characteristics, which were consistent with dictating a mesothelial origin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24716935&#34; target=&#34;_blank&#34;&gt;Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We retrospectively reviewed files of 50 patients who were managed with a diagnosis of MPM between 2005 and 2010.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24730341&#34; target=&#34;_blank&#34;&gt;Synchronous occurrence of pulmonary adenocarcinoma and pleural diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Upon frozen sections, intraoperative diagnosis was adenocarcinoma with a poorly differentiated component of lung infiltrating the pleura. […] The postoperative histological definitive diagnosis with an important contribution of immunostaining was synchronous pulmonary adenocarcinoma and pleural diffuse malignant epithelioid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24773769&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of right submandibular salivary gland involvement from mesothelioma was established, allowing an adequate treatment. […] We suggest that US-guided FNAB is a useful, quick, and cheap procedure for a definite diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24816068&#34; target=&#34;_blank&#34;&gt;Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the present study is to compare the immunohistochemical markers currently available for the diagnosis of these 2 malignancies and to determine the best panel of markers that can be used to assist in discriminating between them. […] An accurate differential diagnosis can be reached with the use of these two markers in combination with the breast-associated markers GCDFP-15, mammaglobin, and GATA3.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24819999&#34; target=&#34;_blank&#34;&gt;Desmoplastic small round cell tumor with sphere-like clusters mimicking adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of DSRCT was further supported by immunohistochemical coexpression of cytokeratin and desmin, as well as Ewing sarcoma breakpoint region 1 gene rearrangement, which was determined by fluorescence in situ hybridization. […] The unusual cytological finding in this case illustrates a potential pitfall of the cytological diagnosis of pleural fluid or ascites. […] DSRCT should not be excluded from the differential diagnosis when sphere-like round cell clusters are observed in pleural or abdominal effusion, particularly in young male patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24832701&#34; target=&#34;_blank&#34;&gt;Physician-based ultrasound-guided biopsy for diagnosing pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Definitive diagnosis of pleural disease (particularly malignancy) depends upon histologic proof obtained via pleural biopsy or positive pleural fluid cytology. […] Local anesthetic thoracoscopy has a high diagnostic yield for malignant and nonmalignant disease, but is not always possible in frail patients, if pleural fluid is heavily loculated, or where the lung is adherent to the chest wall. […] This study aimed to determine the diagnostic yield of a physician-led service in both planned biopsies and cases of failed thoracoscopy. […] Histologic results were assessed for the yield of pleural tissue, final diagnosis, and clinical follow-up in nonmalignant cases. […] Overall, 47 (94.0%) successfully obtained sufficient tissue for histologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24856077&#34; target=&#34;_blank&#34;&gt;Autofluorescence thoracoscopy in pleural disease: does it have clinical relevance?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy has proved to be a reliable tool to demonstrate or exclude pleural malignancy, with a diagnostic yield of at least 90%. […] It will neither increase the (already very high) diagnostic yield of thoracoscopy nor change treatment in patients suffering from malignant pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24867517&#34; target=&#34;_blank&#34;&gt;EUS-guided fine needle tissue acquisition for the diagnosis of pleural metastases from endometrial cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient referred a long history of exposure to amiantum, this posing a differential diagnosis between primary pleural tumour (mesothelioma) and neoplastic pleural localization of the endometrial cancer. […] The cytological examination of the pleural effusion (sampled via thoracenthesis) was not adequate to reach a diagnosis. […] Although a right-video-assisted thoracoscopy was considered the gold standard in this clinical setting to achieve a tissue acquisition of the pleura, an EUS (as the least invasive procedure) was attempted to reach a definitive diagnosis. […] EUS-FNTA of the pleura was done using a 19-Gauge needle and the pathological and immunophenotypic features were diagnostic for a pleural metastasis of high-grade endometrial serous carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24868221&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma: an institutional experience of 66 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological diagnosis of mesothelioma is challenging and is usually aided by immunohistochemical markers. […] The combination of calretinin, Wilms tumor 1, HMBE-1, and thyroid transcription factor-1 may provide high diagnostic accuracy in diagnosing mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24907385&#34; target=&#34;_blank&#34;&gt;Flex-rigid pleuroscopy under local anesthesia in patients with dry pleural dissemination on radiography.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical thoracoscopy using a flex-rigid pleuroscope under local anesthesia is a recent diagnostic procedure for malignant pleural disease. […] Although most previous studies have reported its usefulness, especially in wet pleural dissemination, the feasibility of flex-rigid pleuroscopy in patients with dry pleural dissemination is not well established.We assessed the diagnostic performance of flex-rigid pleuroscopy under local anesthesia in patients suspected of dry pleural dissemination on radiography. […] The diagnostic accuracy was 93.8% (15/16). […] Complications, operation duration and diagnostic accuracy did not statistically differ between the two groups. […] Flex-rigid pleuroscopy under local anesthesia can be a well-tolerated diagnostic procedure for radiographic dry pleural dissemination with respect to diagnostic yield and complications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24912849&#34; target=&#34;_blank&#34;&gt;Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, we screened with a quantitative RT-PCR (RT-qPCR)-based platform the expression of 742 miRNAs in formalin-fixed, paraffin-embedded, preoperative diagnostic biopsy samples, surgically resected MPM specimens previously treated with chemotherapy, and corresponding non-neoplastic pleura (NNP), from five patients. miR-126, miR-143, miR-145, and miR-652 were significantly down-regulated (≥twofold) in resected MPM and/or chemotherapy-naïve diagnostic tumor biopsy samples.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24918672&#34; target=&#34;_blank&#34;&gt;[Intrathoracic schwannoma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tomographic image is suggestive of extrapulmonary tumor, so the schwannoma in this location should be considered in the differential diagnosis of metastatic or primary pleural tumors such as lipoma, solitary fibrous tumor and mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24928677&#34; target=&#34;_blank&#34;&gt;Women with malignant pleural mesothelioma have a threefold better survival rate than men.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Age, year of diagnosis, race, stage, cancer-directed surgery, radiation, and vital status were analyzed according to gender.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24942631&#34; target=&#34;_blank&#34;&gt;Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The primary outcome was overall survival at 1 year, analysed by intention to treat (all patients randomly assigned to a treatment group with a final diagnosis of mesothelioma).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24958517&#34; target=&#34;_blank&#34;&gt;Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5-24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0-17.1) months supportive care after first-line pemetrexed-based regimens (p = 0.005).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24966960&#34; target=&#34;_blank&#34;&gt;Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We tried to demonstrate with molecular biology techniques whether they were synchronous or one was the metastasis of the other, but our studies did not give informative results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24966978&#34; target=&#34;_blank&#34;&gt;Epithelioid malignant mesothelioma presenting with features of gastric tumor in a child.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In view of the morphological and immunohistochemical findings, a diagnosis of localized malignant mesothelioma, epithelial type was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24995085&#34; target=&#34;_blank&#34;&gt;Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is reported that osteopontin has shown promising diagnostic value for malignant pleural mesothelioma (MPM), this meta-analysis aimed to establish the overall diagnostic accuracy of the osteopontin measurement for diagnosing MPM. […] Based on a systematic review of English language studies, the sensitivity, specificity and other measures of accuracy of osteopontin in the diagnosis of MPM were pooled using random-effects model. […] Our data suggest that osteopontin is likely to be a useful diagnostic marker for MPM, considering for the limited studies and patients included, larger studies are needed to confirm these findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/24998965&#34; target=&#34;_blank&#34;&gt;Local recurrence of lung adenocarcinoma 10 years after left upper lobectomy resembling pseudomesotheliomatous adenocarcinoma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Distinguishing pseudomesotheliomatous adenocarcinoma from malignant pleural mesothelioma on the basis of clinical findings can be difficult; therefore, a biopsy is usually required for diagnosis. […] This report provides information that will help physicians establish an accurate diagnosis in similar cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25024722&#34; target=&#34;_blank&#34;&gt;p53 Expression in a Malignant Mesothelioma Patient during Seven-Year Follow-up.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pathologic diagnosis was atypical mesothelial hyperplasia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25026285&#34; target=&#34;_blank&#34;&gt;CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a deadly tumor whose diagnosis and treatment remain very challenging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25037982&#34; target=&#34;_blank&#34;&gt;Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A reliable diagnostic and prognostic marker for MM will significantly enhance clinical care and is an area of intense research. […] A recent report showed promising results using fibulin-3 as a new diagnostic marker. […] Mesothelin provides better diagnostic accuracy than fibulin-3 for MM whether measured in plasma or pleural effusion: area under the curve (AUC) for plasma was 0.822 (95% CI 0.76 to 0.87) compared with 0.671 (0.61 to 0.73), respectively, and for pleural fluid AUC was 0.815 (0.74 to 0.87) compared with 0.588 (0.51 to 0.67), respectively. […] Soluble mesothelin is a superior diagnostic biomarker for MM compared with fibulin-3, whereas fibulin-3 provides superior prognostic information compared with mesothelin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25044880&#34; target=&#34;_blank&#34;&gt;Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because to the authors’ knowledge the diagnostic utility of cytoplasmic WT1 expression has not been explored to date, the usefulness of a WT1/AE1/AE3 dual-color immunostain in the workup of malignant effusions was evaluated. […] A WT1/AE1/AE3 dual-color immunostain can reliably identify malignancy in pleural effusions and group malignant cells into discrete subsets, thereby narrowing the differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25045139&#34; target=&#34;_blank&#34;&gt;Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We reported previously that N-ERC/mesothelin could be a useful biomarker for the early diagnosis of pleural mesothelioma and developed an enzyme-linked immunosorbent assay (ELISA) system for its detection. […] Particularly for the epithelioid type, the area under the curve (AUC) and the diagnostic accuracy of N-ERC/mesothelin were excellent; the AUC was 0.91, the sensitivity was 0.95, and the specificity was 0.76 in plasma. […] In conclusion, assessment of N-ERC/mesothelin with our newly established 7-20 ELISA system is clinically useful for the precise diagnosis of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25048089&#34; target=&#34;_blank&#34;&gt;The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma–a short review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Global occurrence in combination with poor overall survival, difficulty in diagnosis, and limited effective treatment options signal the need for further exploration of miRNA involvement in MPM. […] Accordingly, this review highlights miRNA profiles associated with the diagnosis, prognosis, and therapeutic approaches in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25054098&#34; target=&#34;_blank&#34;&gt;Sarcomatoid malignant mesothelioma presenting with intramedullary spinal cord metastasis: a case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, a second surgery was performed after chemotherapy, but the patient died 5 months after the initial diagnosis. […] Conclusion We present this rare case, and emphasize intramedullary spinal cord metastasis of MM as differential diagnosis in primary cord lesion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25059587&#34; target=&#34;_blank&#34;&gt;Diagnosis and treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are three major challenges in the diagnosis of malignant pleural mesothelioma: mesothelioma must be distinguished from benign mesothelial hyperplasia; malignant mesothelioma (and its subtypes) must be distinguished from metastatic carcinoma; and invasion of structures adjacent to the pleura must be demonstrated. […] Given the difficulties of reaching an early diagnosis, cure is not generally achieved with radical surgery (pleuropneumonectomy), so liberation of the tumor mass with pleurectomy/decortication combined with chemo- or radiation therapy (multimodal treatment) has been gaining followers in recent years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25069847&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma. Cytology and molecular diagnostics].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The definitive diagnosis of malignant mesothelioma (MM) in effusion cytology is often avoided or reluctantly made by cytology alone. […] When an effusion specimen is composed of cells with unequivocal cytological features of malignancy that have the morphology and immunophenotype of mesothelial cells, the cytological diagnosis of MM is straightforward. […] However, in the daily routine difficult cases of atypical mesothelial cells are often encountered and additional methods are required to establish an accurate diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25071858&#34; target=&#34;_blank&#34;&gt;Microcystic variant malignant mesothelioma presenting as a localized paraspinal mass.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combined morphologic and immunohistochemical findings confirmed the diagnosis of microcystic variant of localized malignant mesothelioma. […] The subsequent lung resection showed a pleural-based mass in the right upper lobe and confirmed the diagnosis. […] Recognition of characteristic cytomorphologic features along with optimal use of panel of immunohistochemistry studies is crucial for making a specific diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25073664&#34; target=&#34;_blank&#34;&gt;Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median follow-up was 24 months from diagnosis and the median time to in-field local failure from the end of RT was 10 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25076889&#34; target=&#34;_blank&#34;&gt;Phrenic nerve paralysis as the initial presentation in pleural sarcomatoid mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On autopsy, microscopic findings and immunohistological examinations supported the diagnosis of sarcomatoid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25077699&#34; target=&#34;_blank&#34;&gt;Role of CT in assessing pleural malignancy prior to thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The definitive diagnosis of pleural malignancy depends upon histological confirmation by pleural biopsy. […] CT is reported to have a high sensitivity and specificity for the diagnosis of malignant pleural disease, and is part of the routine diagnostic workup of these patients. […] The histological results were compared with the CT reported diagnosis before the procedure. […] The use of CT alone in determining which patients should have invasive pleural biopsies should be re-evaluated, and further studies to define the diagnostic pathway are now required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25079105&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Inclusion criteria for the pooled analysis were any clinical or autopsy study in which patients had a confirmed histological diagnosis of malignant mesothelioma and CNS metastasis was identified by autopsy, clinical pathological specimen, or compelling radiographic imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25100651&#34; target=&#34;_blank&#34;&gt;Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only 65% (20/31) of patients with a high-risk LENT score survived 1 month from diagnosis and just 3% (1/31) survived 6 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25120691&#34; target=&#34;_blank&#34;&gt;Metastasis of mesothelioma to the maxillary gingiva.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is currently no effective standard treatment for mesothelioma and the prognosis for patients is poor; the majority of patients with malignant mesothelioma succumb between 12 and 17 months following diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25130005&#34; target=&#34;_blank&#34;&gt;Gamma knife radiosurgery of brain metastasis from malignant pleural mesothelioma–report of three cases with autopsy study in a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Case I showed a metastatic lesion in the right frontal lobe which was treated by GKR two years after diagnosis of MPM. […] A year and three months after the diagnosis, asymptomatic bifrontal lesions were treated with GKR. […] Case 3 showed headache one and half year after the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25142834&#34; target=&#34;_blank&#34;&gt;Photodynamic diagnoses of malignant pleural diseases using the autofluorescence imaging system.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conducted a study on photodynamic diagnosis (PDD) using autofluorescence in video-assisted thoracic surgery for minute intrathoracic small dissemination or early malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25147801&#34; target=&#34;_blank&#34;&gt;Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction between malignant and benign pleural effusions is a diagnostic challenge today and measuring soluble biomarkers could add to the diagnostic accuracy. […] This study aimed to investigate the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera from patients with pleural malignancies. […] Using two cohorts of patients, we assessed the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera, using enzyme-linked immunosorbent assays. […] Soluble syndecan-1 is a promising candidate biomarker for the cytopathological diagnosis and prognostication of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25161804&#34; target=&#34;_blank&#34;&gt;Malignant pleural and peritoneal mesothelioma consequential to brief indirect asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of malignant mesothelioma was confirmed on lung biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25175133&#34; target=&#34;_blank&#34;&gt;Non-asbestos-related malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report this case to remind physicians to consider MPM in the differential diagnosis of pleural effusion in young patients without exposure to asbestos or erionitis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25186542&#34; target=&#34;_blank&#34;&gt;Almost half of women with malignant mesothelioma were exposed to asbestos at home through their husbands or sons.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Demographic data, subtype of MM, time from first hospital contact to diagnosis, survival and information on occupational and domestic exposure to asbestos were obtained from hospital records. […] Time from first hospital contact to diagnosis was one month and the median survival time was 12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25188411&#34; target=&#34;_blank&#34;&gt;Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A meta-analysis was conducted of diagnostic accuracy studies published in the Cochrane Library, PubMed, and Embase (inception to June 2013) without language restrictions. […] Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. […] We used a bivariate random-effects model for the analysis and pooling of diagnostic performance measures across studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25188712&#34; target=&#34;_blank&#34;&gt;Ultrasound-guided medical thoracoscopy in the absence of pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical thoracoscopy (MT) is a diagnostic and therapeutic procedure that permits the study of the pleural space. […] The most frequent histopathologic diagnosis was malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25200195&#34; target=&#34;_blank&#34;&gt;Past trends and future prediction of mesothelioma incidence in an industrialized area of Italy, the Veneto Region.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We included only MPM with histological or cytological diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25208819&#34; target=&#34;_blank&#34;&gt;The clinicopathological characteristics with long-term outcomes in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They had chest pain, dyspnea, weight loss and loss of appetite as the most common symptoms at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25208984&#34; target=&#34;_blank&#34;&gt;[Sarcomatoid malignant mesothelioma: a clinicopathologic and immunohistochemical analysis of 22 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To elaborate on the clinical and pathologic features of sarcomatoid malignant mesothelioma (SMM), its diagnostic criteria and differential diagnoses. […] The diagnosis of SMM is achieved by comprehensive evaluation of medical history, imageological and pathological findings. […] Since calretinin immunoreactivity is infrequently observed in SMM, application of pan-cytokeratin and D2-40 immunostains offers a reasonable alternative for diagnosis. […] Diagnosis of SMM can be made by excluding a variety of spindle cell neoplasms with overlapping features, such as sarcomatoid carcinoma, synovial sarcoma, solitary fibrous tumor and fibrous pleuritis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25231672&#34; target=&#34;_blank&#34;&gt;High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The ages at diagnosis of MM were between 30 and 54 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25238873&#34; target=&#34;_blank&#34;&gt;A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival is 8 to 12 months, and most patients have symptoms at diagnosis. […] A study from the United States examining advanced lung cancer showed that early specialist palliative care input improved patient health related quality of life and depression symptoms 12 weeks after diagnosis. […] A total of 174 patients with a new diagnosis of malignant pleural mesothelioma will be minimised with a random element in a 1:1 ratio to receive either 4 weekly regular early specialist symptom control care, or standard care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25243538&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the diagnostic accuracy of the visual assessment of malignant pleural mesothelioma (MPM) on magnetic resonance (MR) images by using two known visual markers (mediastinal pleural thickness and shrinking of the lung) and a newly introduced one (pleural pointillism). […] Because visual assessment is still the preferred method of image interpretation, the diagnostic accuracy of mediastinal pleural thickening, shrinking lung (hemithorax volume decrease due to fibrosis), and pleural pointillism were examined. […] A total of 78 patients received a correct diagnosis (benign vs malignant) on the basis of mediastinal pleural thickening (sensitivity, 81%; specificity, 73%; accuracy, 78%); and 66 patients, on the basis of shrinking lung (sensitivity, 60%; specificity, 79%; accuracy, 66%). […] The correct diagnosis was indicated on the basis of pleural pointillism in 88 patients (sensitivity, 93%; specificity, 79%; accuracy, 88%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25253013&#34; target=&#34;_blank&#34;&gt;[Correlation of computed tomography imaging and clinical prognosis of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To explore the value of computed tomography (CT) imaging in clinical diagnosis and prognostic evaluation of pleural mesothelioma. […] And it provides objective rationales for the clinical diagnosis and prognostic assessment in patients with pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25253633&#34; target=&#34;_blank&#34;&gt;Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural effusions containing primary malignant mesothelioma cells were received from the diagnostic routine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25266654&#34; target=&#34;_blank&#34;&gt;Local and systemic therapies for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several trials are currently underway to examine intraoperative therapies, vaccines, immunotherapy additions, and novel radiation therapy techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25268063&#34; target=&#34;_blank&#34;&gt;Electron microscopy remains the gold standard for the diagnosis of epithelial malignant mesothelioma: a case study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The advent of a large battery of immunochemical markers has provided new tools for the diagnosis of mesothelioma in recent years; however, immunostaining can often be misleading or inconsistent, as demonstrated in this case. […] This report highlights the lasting utility of electron microscopy in the diagnosis of mesothelioma. […] These images, combined with immunostains and a fiber analysis from the lungs, allowed for a final diagnosis of a non-asbestos-related malignant epithelial mesothelioma in this patient.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25300229&#34; target=&#34;_blank&#34;&gt;Reproducibility of histological subtyping of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Interobserver reliability for histological diagnosis was found to be κ = 0.72 (P &amp;lt; 0.001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25304423&#34; target=&#34;_blank&#34;&gt;[Morphological diagnostics of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The certain morphological diagnosis of a malignant pleural mesothelioma requires the establishment of mesothelial differentiation by means of an appropriate panel of antibodies to exclude pleural dissemination of a pulmonary or extrapulmonary epithelial malignancy and also requires the establishment of at least focal invasive growth to distinguish from reactive mesothelial proliferation. […] The exclusion of a malignant pleural mesothelioma may induce further differential diagnostic considerations, e. g. concerning the assignment to a certain primary tumor after the establishment of carcinomatous pleuritis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25310424&#34; target=&#34;_blank&#34;&gt;Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient prognosis is poor, with a median survival of 9-17 months after diagnosis. […] However, improved survival and decreased morbidity and mortality have been demonstrated when the diagnosis is made in the early stages of disease and specific treatment strategies are implemented.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25321457&#34; target=&#34;_blank&#34;&gt;Pseudo-tumor mimicking indwelling pleural catheter tract metastasis in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis and management (often radiotherapy) are almost always based on clinical judgment of new subcutaneous lesions at prior pleural puncture sites in mesothelioma patients. […] Percutaneous biopsy can clarify the diagnosis in suitable cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25331029&#34; target=&#34;_blank&#34;&gt;Advances in malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study is a review of literatures focusing on the advances in epidemiology, clinical presentations, radiological features, diagnosis, misdiagnosis, management, and prognostic factors of malignant peritoneal mesothelioma (MPM) occurred in the past decades. […] Definitive diagnosis is made on the basis of immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25354093&#34; target=&#34;_blank&#34;&gt;Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The objective of this study was to determine the diagnostic value of computed tomography (CT) and positron emission tomography (PET)/CT for staging of malignant pleural mesothelioma (MPM) in patients undergoing induction chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25358615&#34; target=&#34;_blank&#34;&gt;Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An accurate pathological diagnosis including the histological subtype and also clinical staging are crucial to decide on the therapeutic approach. […] However, the pathological diagnosis is difficult when the amount of biopsy sample is small. […] We performed a comparative analysis of the miR-31 expression in MPM and reactive mesothelial proliferations (RMPs), by RT-qPCR of formaldehyde-fixed paraffin-embedded samples, and compared the expression levels of miR-31 with the results of a survival analysis for the diagnosis and prognosis of MPM. […] In conclusion, the analysis of miR-31 expression levels may be a good biomarker for diagnosis of MPM histological typing and predicting the prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25361002&#34; target=&#34;_blank&#34;&gt;Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a very aggressive form of cancer with a poor diagnosis and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25364420&#34; target=&#34;_blank&#34;&gt;Clinicopathological characteristics of pulmonary epithelioid hemangioendothelioma: A report of four cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aimed to investigate the clinicopathological characteristics, differential diagnosis and prognosis of pulmonary epithelioid hemangioendothelioma (PEH). […] For diagnosis, a distinction must be made from other diseases such as chronic granulomatous disease, amyloid nodules, hamartoma, primary and metastatic lung cancers, malignant mesothelioma and vascular sarcoma. […] The results of this study may improve understanding with regards to the diagnosis and therapeutic options for patients with PEH.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25368701&#34; target=&#34;_blank&#34;&gt;Hyaluronic Acid concentration in pleural fluid: diagnostic aid for tuberculous pleurisy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Receiver operating characteristic analysis revealed no significant difference in the area under the curve of hyaluronic acid and adenosine deaminase volumes in pleural fluid, suggesting their equivalent value as major diagnostic tools for tuberculosis pleurisy. […] Hyaluronic acid concentration in pleural fluid can be a valuable tool for the diagnosis of tuberculous pleurisy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25400582&#34; target=&#34;_blank&#34;&gt;Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In our current study, we quantified the number of TnTs/cell among various mesothelioma subtypes and normal mesothelial cells using confocal microscopic techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2014-11-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25425731&#34; target=&#34;_blank&#34;&gt;FISH analysis of intrapulmonary malignant mesothelioma without a clinically detectable primary pleural lesion: an autopsy case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A definitive diagnosis of the video-assisted thoracic surgery specimen could not be made, though a pattern of fibrosis mimicking organizing pneumonia was identified. […] The final diagnosis was sarcomatoid mesothelioma, and the lung nodules were intrapulmonary metastases from a clinically undetectable pleural sarcomatoid mesothelioma. […] It is important both to consider the possibility of mesothelioma with unusual clinical, radiological and pathological presentations and to remember that p16 fluorescence in situ hybridization analysis can play an important role in the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25433793&#34; target=&#34;_blank&#34;&gt;[Contribution of pleural fluid analysis to the diagnosis of pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Analysis of pleural fluid can have, on its own, a high diagnostic value. […] In addition to thoracocentesis, a diagnostic hypothesis based on medical history, physical examination, blood analysis and imaging tests, the diagnostic effectiveness will significantly increase in order to establish a definite or high probable diagnosis in a substantial number of patients. […] Differentiating transudates from exudates by the classical Light’s criteria helps knowing the pathogenic mechanism resulting in pleural effusion, and it is also useful for differential diagnosis purposes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25436799&#34; target=&#34;_blank&#34;&gt;A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin related peptide (SMRP) was proposed as a promising diagnostic marker for malignant pleural mesothelioma (MPM). […] SMRP performance as diagnostic biomarker improved by considering the genotype rs1057147.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25452813&#34; target=&#34;_blank&#34;&gt;Computed tomography-guided cutting needle pleural biopsy: Accuracy and complications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cutting needle biopsy is a relatively recent addition to these techniques. […] The aim of this study was to evaluate the diagnostic accuracy and safety of computed tomography-guided cutting needle pleural biopsy (CT-CNPB), as well as the associated complications, in patients with pleural lesion. […] For group comparisons, χ&lt;sup&gt;2&lt;/sup&gt; tests were used to detect the risk factors for diagnostic accuracy (false-negative rate). […] The sensitivity of diagnostic malignant lesion was 90.9%, and the specificity and positive and negative predictive values were 100, 100 and 88.1%, respectively. […] The overall diagnostic accuracy was 94.6%. […] A specific diagnosis was achieved in 89.1% of malignant lesions and 86.4% of benign lesions. […] In conclusion, CT-CNPB is a safe and accurate diagnostic technique that can be recommended as the primary method of diagnosis in patients with pleural thickening or lesions observed by CT scan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25463163&#34; target=&#34;_blank&#34;&gt;Current controversies in the management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite its frequent occurrence, current knowledge of MPE remains limited and controversy surrounds almost every aspect in its diagnosis and management. […] Advancing laboratory techniques have improved the diagnostic yield from pleural fluid cytology, minimizing the need for invasive tissue biopsies, even in many cases of mesothelioma. […] This review addresses the controversies in MPE diagnosis and management and exposes the deficits in knowledge of MPE that should be the focus of future research.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2549614&#34; target=&#34;_blank&#34;&gt;Amosite mesothelioma in a cohort of asbestos workers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Open lung biopsy was the most useful diagnostic approach for pleural mesothelioma, whereas for peritoneal mesothelioma it was exploratory laparotomy. […] In both groups the death certificate diagnosis was less accurate than the clinical diagnosis at death.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-10-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25503183&#34; target=&#34;_blank&#34;&gt;Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Herein, we analyzed the contribution of SMRP detection in pleural effusion and in serum to the diagnosis of MPM with non-positive cytology. […] In non-positive cytology, effusion-SMRP showed higher diagnostic performance than serum-SMRP. […] Detection of both effusion- and serum-SMRP can contribute to improve the diagnosis of MPM with non-positive cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25505814&#34; target=&#34;_blank&#34;&gt;Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of pleural malignant mesothelioma (MM) by effusion cytology may be difficult and is currently controversial. […] To determine the clinical value of measuring mesothelin levels in pleural effusion supernatant to aid diagnosis of MM. […] Mesothelin levels were determined by commercial ELISA in effusions and their relationship to concurrent pathology reporting and final clinical diagnosis was determined. 2156 pleural effusion samples from 1331 individuals were analysed. […] The final clinical diagnosis was 183 MM, 436 non-MM malignancy, and 712 nonmalignant effusions. […] Mesothelin was elevated in over 47% of MM cases in effusions obtained before definitive diagnosis of MM was established. […] A mesothelin-positive pleural effusion, irrespective of the identification of malignant cells, indicates the likely presence of malignancy and adds weight to the clinical rationale for further investigation to establish a malignant diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25519011&#34; target=&#34;_blank&#34;&gt;Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Further analyses, validation studies and detection techniques are needed to establish their real clinical value in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25525045&#34; target=&#34;_blank&#34;&gt;Thromboembolic Events in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although 5 (2.8%) of the TEEs preceded the diagnosis of MPM, 1 (0.6%) occurred simultaneously with the diagnosis of MPM and 8 (4.5%) followed the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25526639&#34; target=&#34;_blank&#34;&gt;Clinical significance of soluble CD26 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no established single diagnostic marker for malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25527013&#34; target=&#34;_blank&#34;&gt;Novel induction therapies for pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is becoming increasingly common, and rates of diagnosis are expected to continue to increase in the coming years because of the extensive use of asbestos in industrialized countries and the long time interval between exposure and onset of disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25554663&#34; target=&#34;_blank&#34;&gt;[Pemetrexed-induced scleroderma-like changes in the lower legs].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of bilateral erysipelas was made, and antibiotic treatment with cloxacillin was given. […] This cutaneous adverse effect is unrecognized, resulting in delayed diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25572813&#34; target=&#34;_blank&#34;&gt;Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medians of overall survival (OS) from diagnosis and from start of CCG treatment were 25.2 months (18.4-31.5 months) and 6.8 months (5.4-8.4 months), respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25575875&#34; target=&#34;_blank&#34;&gt;Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial) is a suitably powered, multicentre, randomised controlled trial, designed to evaluate the efficacy of prophylactic radiotherapy within 42 days of pleural instrumentation in preventing the development of PTM in MPM. 203 patients with a histocytologically proven diagnosis of MPM, who have undergone a large bore pleural intervention (thoracic surgery, large bore chest drain, indwelling pleural catheter or local anaesthetic thoracoscopy) in the previous 35 days, will be recruited from UK hospitals.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25598227&#34; target=&#34;_blank&#34;&gt;Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic tissue should demonstrate the invasion by the tumor and is obtained through thoracoscopy or open thoracotomy, both being highly invasive surgical operations. […] Experimental comparisons also show that the new method can significantly outperform standard numerical feature-type methods in terms of agreement with the clinical diagnosis gold standard.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25616202&#34; target=&#34;_blank&#34;&gt;Fast neutron radiotherapy in the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median age at diagnosis was 59.6 years (range, 46.6 to 72.3 y).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25654216&#34; target=&#34;_blank&#34;&gt;Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eligible patients fulfilled the following criteria: pathological or radiological diagnosis of MPM; pain secondary to MPM; radiotherapy indicated for pain control; and more than 18 years of age.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25674287&#34; target=&#34;_blank&#34;&gt;Epithelioid angiosarcoma at chest wall which needs to be carefully distinguished from malignant mesothelioma: report of a rare case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The epithelioid of cytomorphology and the localization at chest wall of this case may remind of a diagnosis of malignant mesothelioma which should be carefully distinguished from epithelioid angiosarcoma from imaging and morphology. […] From this case we suggest that carefully reading and understanding of the imaging are a very important clue for appropriate diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25707292&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT is an easily accessible and useful tool that should be incorporated into the medical education of general physicians to improve MPM diagnosis of suspected cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25724794&#34; target=&#34;_blank&#34;&gt;Shoulder ring complaints as a rare first symptom of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this paper was a retrospective analysis of shoulder pain as a rare, first symptom of pleural mesothelioma, which constitutes an interdisciplinary diagnostic problem concerning both orthopedics and pulmonology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25726562&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Translational research is currently unravelling novel circulating biomarkers for earlier diagnosis and novel treatment targets.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25731566&#34; target=&#34;_blank&#34;&gt;[A case of malignant peritoneal mesothelioma without deletion of p16].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Herein, we report of a patient diagnosed with malignant peritoneal mesothelioma, without deletion of the p16 gene, who survived for over 2 years and 10 months after initial diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25749175&#34; target=&#34;_blank&#34;&gt;Changing pattern in malignant mesothelioma survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival for peritoneal mesothelioma was longer than that for pleural mesothelioma (hazard ratio = 0.36, 95% confidence interval = 0.24-0.54, P &amp;lt; .001) after adjusting for gender and age at diagnosis. […] Peritoneal mesothelioma was more likely associated with non-occupational exposure, thus emphasizing the importance of exposure history in enhancing early diagnosis and treatment impact.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25756049&#34; target=&#34;_blank&#34;&gt;MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Specific microRNAs and mRNAs may have diagnostic utility in differentiating patients with malignant pleural mesothelioma from benign asbestos-related pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25759091&#34; target=&#34;_blank&#34;&gt;Diffuse intrapulmonary malignant mesothelioma presenting with miliary pulmonary nodules: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For definitive diagnosis, a thoracoscopic lung biopsy was performed. […] The patient had a poor response to chemotherapy and died 1 year after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25793652&#34; target=&#34;_blank&#34;&gt;Unusual appearance of malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because it presents with vague symptoms such as abdominal pain, anorexia, and weight loss, it is generally advanced at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25799803&#34; target=&#34;_blank&#34;&gt;Diagnostic yield of pleural biopsy in exudative pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To know the diagnostic role of pleural biopsy in determining underlying etiological causes of exudative pleural effusion. […] Pleural biopsy is a safe, simple and well validated diagnostic tool that helps us to differentiate between malignancy and tuberculosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25802741&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma presenting as a spontaneous pneumothorax.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, the pathological diagnosis of MPM was obtained in both cases. […] We emphasize the need to obtain a pathological diagnosis of pleural effusion cytology and/or pleural biopsy in older patients presenting with a spontaneous hydropneumothorax.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25821016&#34; target=&#34;_blank&#34;&gt;Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Publications addressing the accuracy of calretinin in the diagnosis of MM were selected from the Medline (Ovid), PubMed, the Cochrane Library Database and the Web of Science. […] Data from selected studies were pooled to yield summary sensitivity, specificity, positive and negative likelihood ratio (LR), diagnostic odds ratio (DOR), and receiver operating characteristic (SROC) curve. […] Statistical analysis was performed by Meta-Disc 1.4 and STATA 12.0 softwares. 18 studies met the inclusion criteria and the summary estimating for calretinin in the diagnosis of MM were: sensitivity 0.91 (95%CI: 0.87-0.94), specificity 0.96 (95%CI: 0.95-0.96), positive likelihood ratio (PLR) 14.42 (95%CI: 7.92-26.26), negative likelihood ratio (NLR) 0.1 (95%CI: 0.05-0.2) and diagnostic odds ratio 163.03 (95%CI: 54.62-486.63). […] Our findings suggest that calretinin may be a useful diagnostic tool for confirming MM in serous effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25838292&#34; target=&#34;_blank&#34;&gt;A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This novel index can provide clinicians and malignant pleural mesothelioma patients with a better framework for discussing prognosis at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25843042&#34; target=&#34;_blank&#34;&gt;Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry was performed on diagnostic biopsies to determine the total TAM (CD68), the M2 TAM (CD163) and CD8+ T-cell count (CD8). […] This study shows that patients who develop LTO after a local intervention have a higher M2/total TAM ratio and lower CD8+ cell count at diagnosis compared to patients who did not develop this outgrowth.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25849448&#34; target=&#34;_blank&#34;&gt;Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Metastases to the breast from extramammary malignancies are very rare, and ruling out the diagnosis of primary breast tumor is important in order to decide on clinical management and predict prognosis. […] The final diagnosis was metastatic epithelioid malignant pleural mesothelioma. […] Immunohistochemistry is an important tool for a conclusive diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25854405&#34; target=&#34;_blank&#34;&gt;Importance of the cell block technique in diagnosing patients with non-small cell carcinoma accompanied by pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological examination of pleural effusions is very important in the diagnosis of malignant lesions. […] In this study, we aimed to compare traditional with cell block methods for diagnosis of lung disease accompanied by pleural effusion. […] In cytology, using conventional diagnostic criteria cases were divided into 3 categories, benign, malignant and undetermined. […] In the cell block examination, in cases with sufficient cell counts histopathological diagnosis was performed. […] Our study confirmed that the cell block method increases the diagnostic yield with exudative pleural effusions accompanying lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25857384&#34; target=&#34;_blank&#34;&gt;Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the last decade, the standardization of diagnostic methods has become a major focus of debate among pathologists and clinicians. […] This has led to the writing of guidelines and recommendation for the diagnosis to achieve the goal of a standard diagnosis. […] In this article, a chronological view relating to the pathological diagnosis of MM is presented together with a review of guidelines and recommendations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25863904&#34; target=&#34;_blank&#34;&gt;Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A histo-cytological diagnosis is made in 87% and varies across organisations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25876971&#34; target=&#34;_blank&#34;&gt;[Comparing the results of pathologic diagnosis of mesothelioma between Chinese and Japanese experts].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare the results of pathological diagnosis of 41 patients with malignant mesothelioma between Chinese and Japanese experts, and to provide a basis for the standard for diagnosis of mesothelioma. […] The expression levels of calretinin, Wilms’ tumor suppressor gene (WT1), podoplanin (D2-40), cytokeratins (CK5/6, AE1/AE3, and CAM5.2), epithelial membrane antigen, carcinoembryonic antigen, BerEP4, MOC31, thyroid transcription factor-1, estrogen receptor, and progesterone receptor in tumor tissues were measured using immunohistochemical staining by Japanese experts, and the pathological classification and diagnosis were made. […] The results of diagnosis, pathological classification, immunohistochemical marker selection, and slide review were compared between Chinese and Japanese experts. […] There were significant differences in the results of diagnosis between Chinese and Japanese experts. […] The diagnostic skills of those pathological experts in this hospital remain to be further improved for mesothelioma diagnosis. […] A panel of immunohistochemical markers including at least 2 mesothelioma-positive and 2 mesothelioma-negative markers are recommended for the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25879365&#34; target=&#34;_blank&#34;&gt;Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sixty patients who had undergone PET/CT evaluation at initial diagnosis were included.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25935651&#34; target=&#34;_blank&#34;&gt;Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In serous effusion, claudin (cldn) 3 is shown to be useful in the diagnosis of mesothelioma vs ACAs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25972325&#34; target=&#34;_blank&#34;&gt;p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Detection of the homozygous deletion of p16/CDKN2A (p16) by fluorescence in situ hybridization (FISH) is an effective adjunct in the diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25975910&#34; target=&#34;_blank&#34;&gt;[Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To study the role of p16 gene mutation status as detected by fluorescence in-situ hybridization (FISH) and p16 protein expression as detected by immunohistochemistry in differential diagnosis of malignant mesothelioma and benign mesothelial hyperplasia. p16 gene mutation status and protein expression were detected by FISH and immunohistochemistry respectively in 55 cases of pleural malignant mesothelioma and 30 cases of benign mesothelial hyperplasia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/25979846&#34; target=&#34;_blank&#34;&gt;The established and future biomarkers of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Lack of accurate biomarkers makes diagnosis, prognostication and treatment prediction of MPM challenging. […] The current gold standard of MPM diagnosis is a combination of two positive and two negative immunohistochemical markers in the epithelioid and biphasic type, but sarcomatous type do not have specific markers, making diagnosis more difficult. […] Mesothelin in serum and pleural fluid may serve as adjuvant diagnostic with high specificity but low sensitivity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26016578&#34; target=&#34;_blank&#34;&gt;Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, there are no tumour biomarkers in widespread clinical use for the differential diagnosis of mesothelioma from other diseases. […] With the incidence of mesothelioma expected to continue to increase, it is timely to review the current status of effusion-based biomarkers for mesothelioma diagnosis. […] The majority of recent studies have evaluated soluble mesothelin in effusions in a diagnostic setting for mesothelioma. […] However, at high specificity, the sensitivity of the assay is limited to approximately 60% at the time of diagnosis. […] Preliminary results on the diagnostic accuracy of fibulin-3 have been inconsistent. […] To date, soluble mesothelin remains the best available biomarker for mesothelioma and a positive result is clinically useful in patients with pleural effusions in whom the diagnosis is uncertain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26022455&#34; target=&#34;_blank&#34;&gt;BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Using immunohistochemistry, we evaluated the utility of BAP1 expression in the differential diagnosis between mesothelioma and other mesothelial proliferations on a large series of biopsies that included 212 mesotheliomas, 12 benign mesothelial tumors, and 42 reactive mesothelial proliferations. […] On cytology/cell blocks, benign mesothelial cells were invariably positive for BAP1, whereas 64% of mesotheliomas showed loss of protein; all 6 cases showing BAP1 negativity were associated with histological diagnosis of BAP1-negative mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26029551&#34; target=&#34;_blank&#34;&gt;Multiple distant metastases in a case of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We emphasize that unexpected distant metastases can be observed in MPM and occasionally primary diagnosis can be determined by the biopsy of the metastatic regions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26034319&#34; target=&#34;_blank&#34;&gt;Effectiveness of medical thoracoscopy and thoracoscopic talc poudrage in patients with exudative pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We evaluated the diagnostic yields, complications and outcomes of MT and TTP in 41 consecutive patients with symptomatic pleural effusions who were planned to undergo both procedures from 1 December 2011 to 30 November 2012. […] The overall diagnostic yield of MT, and the yield in tubercular and malignant pleural effusions were 77.8%, 100.0% and 82.6%, respectively; it was inconclusive in 22.2%. […] MT is a safe procedure with high diagnostic yields in undiagnosed pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26045315&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma due to non-occupational asbestos exposure from the Italian national surveillance system (ReNaM): epidemiology and public health issues.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic, demographic and exposure characteristics of non-occupationally exposed cases are analysed and described with respect to occupationally exposed cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26048082&#34; target=&#34;_blank&#34;&gt;Pleural neoplastic pathology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The basic pathological, immunohistochemical and molecular characteristics of these entities are provided in the current review, along with their differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26050944&#34; target=&#34;_blank&#34;&gt;[18F]Fluorodeoxyglucose PET in Thoracic Malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
[(18)F]Fluorodeoxyglucose (FDG) PET is a robust quantitative molecular imaging technique that complements available structural imaging techniques for the detection and characterization of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26051106&#34; target=&#34;_blank&#34;&gt;Differential diagnosis of pleural mesothelioma using Logic Learning Machine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tumour markers are standard tools for the differential diagnosis of cancer. […] Classification accuracy can be improved by combining information from different markers using standard data mining techniques, like Decision Tree (DT), Artificial Neural Network (ANN), and k-Nearest Neighbour (KNN) classifier. […] LLM was applied to data from a consecutive cohort of 169 patients admitted for diagnosis to two pulmonary departments in Northern Italy from 2009 to 2011. […] LLM is a new flexible tool potentially useful for the differential diagnosis of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26057448&#34; target=&#34;_blank&#34;&gt;Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Post-diagnosis survival and the survival benefit of chemotherapeutic intervention was correlated with p16/INK4A expression. […] Those cases with intermediate or high p16/INK4A tumour expression had a significantly better post-diagnosis survival than those cases whose tumours lost p16 expression (log-rank P&amp;lt;0.001). […] Sustained p16/INK4A expression predicts better post-diagnosis survival in MPM and also better survival following chemotherapeutic intervention.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2606200&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in the southwestern part of The Netherlands.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Concerning diagnostic procedures we recommend beginning with cytology of pleural fluid, which can easily be obtained together with an Abrams biopsy. […] If this does not give a definite diagnosis thoracoscopy or thoracotomy will be indicated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26063951&#34; target=&#34;_blank&#34;&gt;Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Age, sex, diagnosis year, stage, cancer-directed surgery, radiation, and vital status were analyzed according to self-reported race (black or white). […] On multivariable analysis, younger age and having surgery were associated with longer survival for both cohorts; female gender (HR 0.82 (0.77-0.88)) and early stage at diagnosis (HR 0.83 (0.76-0.90)) were predictive of longer survival in white, but not in black, patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26071130&#34; target=&#34;_blank&#34;&gt;[Endobronchial ultrasound in the diagnosis of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural mesothelioma relies mostly on the pathological examination of pleural samples, validated by a panel of experts and generally obtained during medical or surgical thoracoscopy performed for the management of an exudative pleural effusion. […] In the absence of pleural effusion (dry-type mesothelioma), the diagnostic approach depends on the features of the lesions (pleural thickness, nodules and/or masses) and their pleural location. […] Ultrasound and CT-guided needle aspiration represent recognized alternative diagnostic techniques in these situations. […] We present the case of a patient, presenting a dry-type mesothelioma, whose diagnosis was obtained by endobronchial ultrasound (EBUS)-guided needle aspiration of a pleural mediastinal mass and confirmed by a CT-guided needle aspiration of another pleural mass in close contact with the chest wall. […] EBUS represents a minimally invasive alternative diagnostic technique for dry-type mesothelioma, showing thickness of the mediastinal pleura in contact with a central airway or when thoracoscopy, which remains the “gold standard” diagnostic approach, is not feasible.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26074102&#34; target=&#34;_blank&#34;&gt;Surgical Management of Malignant Pleural Mesothelioma: An Update of Clinical Evidence.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We discuss the findings from these trials and the current evidence of various surgical techniques to treat this challenging disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26100969&#34; target=&#34;_blank&#34;&gt;Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2610210&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma in an urban hospital: clinical spectrum and trend in incidence over time.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite greater awareness of this disease, the diagnosis remains a difficult one to establish given the nonspecific symptoms, signs and radiographic appearance, variable histologic appearance, and poor diagnostic sensitivity and specificity of thoracentesis and closed pleural biopsy. […] Thoracotomy, thoracoscopy, and CT-guided needle biopsies gave higher yields and are the diagnostic measures of choice when diffuse malignant pleural mesothelioma is suspected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-02-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26108245&#34; target=&#34;_blank&#34;&gt;Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the last few years, an accurate differentiation between the subtypes of MPM has become a crucial issue, due to differences in chemosensitivity and clinical outcome, and several studies have evaluated different immunohistochemical markers to better define the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26115838&#34; target=&#34;_blank&#34;&gt;Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma is almost invariably fatal, and more research is required, not only to find more effective treatments, but also to achieve an earlier diagnosis and improve palliative care. […] The partnership brought together patients, carers, health professionals and support organisations to agree the top 10 research priorities relating to the diagnosis, treatment and care of patients with mesothelioma. […] Following the established James Lind Alliance priority setting process, mesothelioma patients, current and bereaved carers, and health professionals were surveyed to elicit their concerns regarding diagnosis, treatment and care.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2612745&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: a series of 19 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical data, diagnostic procedures and survival are reported in 19 cases diagnosed as malignant peritoneal mesothelioma. […] The median interval between asbestos exposure and the diagnosis appeared to be 44.7 years (range 18-49 years). […] In the majority of patients no therapy except pain relief was given and the median survival from the time of diagnosis was 6 months (range: 0-29 months). […] The relative short survival period from the time of the first diagnosis in contrast to malignant pleural mesotheliomas is probably the reason for the absence of distant metastases. […] Since cytologic specimens are often negative, we suggest that in patients suspected of a malignant peritoneal mesothelioma, laparoscopy with directed biopsies is the diagnostic procedure of first choice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26147229&#34; target=&#34;_blank&#34;&gt;Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: Analysis of 28 cases in Southeast China.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of 43 patients with a mesothelioma diagnosis, 19 peritoneal and nine pleural cases were finally diagnosed as mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26156324&#34; target=&#34;_blank&#34;&gt;The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival time from diagnosis to death or the last day of follow up with a 95% confidence interval was 12 ± 0.95 months (95% CI: 10.15-13.85) for group 1 and 11.0 ± 1.09 months (95% CI: 8.85-13.15) for group 2 (Log-Rank: 0.142; p = 0.706).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26174987&#34; target=&#34;_blank&#34;&gt;Mesothelioma cells breaking bad: loss of integrin α7 promotes cell motility and poor clinical outcomes in patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Together, these results identify expression of integrin α7 as a molecular mechanism for the aggressive migratory transformation of mesothelioma and identify a potentially novel diagnostic and therapeutic target.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26181527&#34; target=&#34;_blank&#34;&gt;Survival from malignant mesothelioma: where are we now?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Data on baseline demographics, mode of diagnosis, histological sub-type, and survival and serum laboratory parameters, were analysed; time to death was examined using Cox regression analyses. […] Individuals who did not receive chemotherapy experienced a significantly worse prognosis (hazard ratio 2.7; 95%CI 1.5-4.7; p = 0.001), while a low albumin and raised urea at time of diagnosis were also associated with a significantly poorer prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2618661&#34; target=&#34;_blank&#34;&gt;Malignant spindle cell tumor of the pericardium. Evidence of sarcomatous mesothelioma with aberrant antigen expression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings favor a diagnosis of sarcomatous mesothelioma with aberrant antigenic expression or heterogeneous differentiation of neoplastic cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26200610&#34; target=&#34;_blank&#34;&gt;Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated the role of F-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) for the differential diagnosis of malignant and benign pleural effusion. […] FDG-PET/CT can be a useful method for the differential diagnosis of malignant and benign pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26216715&#34; target=&#34;_blank&#34;&gt;Long-term Outcome of Patients With Undiagnosed Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with exudative pleural effusion whose diagnostic procedures included pleural biopsy using video-assisted thoracoscopic surgery carried out between 2008 and 2012 were evaluated retrospectively. […] No diagnosis was given in 27 patients (51%), and a clinical diagnosis was given in 26 patients (49%) during the follow-up period.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26222965&#34; target=&#34;_blank&#34;&gt;Primary Peritoneal Mesothelioma Resulting in Small Bowel Obstruction: A Case Report and Review of Literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aggressive nature and vague presentation pose many obstacles in not only diagnosis but also the treatment of patients with this disease. […] A concise review of the current diagnostic and surgical treatment of primary peritoneal mesothelioma demonstrates that early diagnosis and implementation remains vital.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26226841&#34; target=&#34;_blank&#34;&gt;Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We investigated whether loss of BAP1 expression by immunohistochemistry can be used to support a diagnosis of mesothelioma in effusion cytology. […] Of 57 effusions considered to have atypical mesothelial cells in the absence of a definitive diagnosis of mesothelioma, 8 cases demonstrated negative staining for BAP1. […] On follow-up six of these patients received a definitive diagnosis of mesothelioma in the subsequent 14 months (two were lost to follow-up immediately, and mesothelioma could not be excluded). […] We conclude that loss of BAP1 expression, while not definitive, can be used to support the diagnosis of mesothelioma in effusion cytology. […] We also note that BAP1 loss is not a sensitive test as it occurs in only half of all mesotheliomas and cannot be used to exclude the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26230591&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma Diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This makes the diagnosis challenging for the pathologist. […] To provide a brief but useful update on the immunohistochemical, cytogenetic, and molecular markers that are currently available for the diagnosis of malignant mesothelioma. […] Useful diagnostic mesothelial markers include calretinin, WT-1, cytokeratin 5/6, and D2-40 (podoplanin). […] It is recommended that at least 2 mesothelial and 2 carcinoma markers with greater than 80% sensitivity and specificity be used for the diagnosis of mesothelioma when all clinical, radiologic, and histologic features are concordant. p16 deletion is reported in up to 70% of primary epithelioid and 90% to 100% of sarcomatoid pleural mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2623239&#34; target=&#34;_blank&#34;&gt;[Pleuropulmonary tumors. Presentation of 2 cases with peculiar clinicopathologic traits].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The biopsy obtained by thoracotomy in one case, and the necropsy studies enabled the diagnosis by the microscopic pattern, the presence of mucosubstances (PAS diastase) and the immune histochemical profiles with antibodies against several antigenic groups (CEA, EMA, CAM 5.2, and Vimentin. […] The value of these techniques to differentiate adenocarcinomas and mesotheliomas is discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-03-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26254420&#34; target=&#34;_blank&#34;&gt;Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of our study was to assess the differential gene expression of Parkinson protein 7 (PARK7) interactome in malignant pleural mesothelioma (MPM) using data mining techniques to identify novel candidate genes that may play a role in the pathogenicity of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26263483&#34; target=&#34;_blank&#34;&gt;Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic and prognostic potential of FBLN3 was assessed by receiver operating characteristics curve analysis and Kaplan-Meier method, respectively. […] Plasma FBLN3 was significantly elevated in MPM patients from the Sydney cohort, but not the Vienna cohort, but the diagnostic accuracy was low (63%, (95% CI: 50.1-76.4) and 56% (95% CI: 41.5-71.0), respectively). […] These data confirm the potential prognostic value of pleural effusion FBLN3, but question the diagnostic value of this protein in MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26265669&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma and occupational and non-occupational asbestos exposure: a case-control study with quantitative risk assessment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Analyses were conducted using unconditional logistic regression models adjusting for gender, age at diagnosis and type of interview (direct or proxy respondents).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26273344&#34; target=&#34;_blank&#34;&gt;Granulocyte-colony stimulating factor (G-CSF) producing malignant pleural mesothelioma: Report of a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient underwent surgical removal of the tumor along with tissue from the chest wall and histopathological analysis led to a diagnosis of sarcomatous type of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-08-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26281327&#34; target=&#34;_blank&#34;&gt;The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study was conducted to investigate AMACR expression in the diagnosis of malignant pleural mesothelioma (MPM) and the correlation of this marker with clinical characteristics and survival. […] The sensitivity of immunostaining was not high enough to use AMACR as a diagnostic tool in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26281826&#34; target=&#34;_blank&#34;&gt;Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of the 69 patients, 35 underwent extended pleurectomy/decortication (P/D), with resection of the entire pleura, along with portions of the pericardium and diaphragm and 34, partial pleurectomy, defined as partial removal of parietal or visceral pleura for diagnostic purposes, leaving gross tumor behind in all cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26281863&#34; target=&#34;_blank&#34;&gt;An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical detection of thyroid transcription factor-1 (TTF-1) plays an important role in the diagnosis and subclassification of non-small cell carcinomas of the lung in biopsy and some cytology samples, specifically for identification of squamous cell carcinoma (classically negative) and non-mucinous adenocarcinoma (positive in most cases) and for discrimination between lung adenocarcinoma and pleural malignant mesothelioma (classically negative). […] If the results of SP141 are assigned overriding significance, our findings further indicate that in isolation, neither negative labelling with either 8G7G3/1 or SP141 nor positive labelling with the SP141 MAb discriminates between sarcomatoid carcinoma and sarcomatoid mesothelioma, whereas positive labelling with the 8G7G3/1 MAb favours a diagnosis of sarcomatoid carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26291840&#34; target=&#34;_blank&#34;&gt;Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In cases with clinical and radiologic evidence of a diffuse pleural tumor, detection of p16 deletion in cytologic smear samples may permit MPM diagnosis without additional tissue examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26298162&#34; target=&#34;_blank&#34;&gt;Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From animal models to clinical trials, the gamut of research activities and clinical standards relies on imaging to provide information on lesion morphology and the growing number of physiologic characteristics amenable to capture through imaging techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26310516&#34; target=&#34;_blank&#34;&gt;Environmental carcinogenesis - 100th anniversary of creating cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We previously reported that the N-terminal of mesothelin may be a useful blood marker for early diagnosis method for mesothelioma and since then developed an N-terminal of mesothelin ELISA kit in collaboration with IBL Co., Ltd. and confirmed its utility as a diagnostic system for mesothelioma. […] Recently, we performed a large-scale research screening for mesothelioma and showed that it is a good model for early diagnosis in at-risk populations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26315262&#34; target=&#34;_blank&#34;&gt;The role of endobronchial ultrasound-guided fine needle aspiration in the diagnosis of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aims of the present study were to investigate the role of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the diagnosis of malignant pleural mesothelioma (MPM), and to identify specific clinical settings in which this procedure can be recommended. […] Among 736 patients, we identified four of them with a diagnosis of MPM achieved primarily through EBUS-TBNA. […] The diagnosis was made on formalin-fixed paraffin-embedded cell blocks, by checking the expression of mesothelial and carcinomatous-specific markers. […] In all patients, the collected tissue was adequate, and the histological analysis in association with immunohistochemistry led us to the diagnosis of malignant pleural mesothelioma. […] In three patients, the diagnosis of mesothelioma was clinically suspected, as patients presented with diffuse pleural thickening. […] In this setting, EBUS-TBNA was considered, at a multidisciplinary consensus meeting, as the most adequate available method to obtain a histological diagnosis. […] EBUS-TBNA may be a valuable diagnostic technique in the field of pleural pathology in selected clinical settings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2633132&#34; target=&#34;_blank&#34;&gt;[Radiologic diagnosis of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is emphasized that pleural mesothelioma should be considered as a differential diagnosis when a mass lesion is found in the mediastinum, hilar region, interlobar fissure, or near the chest wall.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26353120&#34; target=&#34;_blank&#34;&gt;Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among 78 eligible patients, the median age at diagnosis was 59 years and the median survival was 13.7 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2635926&#34; target=&#34;_blank&#34;&gt;The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Noninvasive diagnostic procedures included a chest X-ray and computed tomography of the thorax. […] Forty-five patients were treated conservatively and 200 patients underwent operation: diagnostic thoracotomy (78); partial pleurectomy (72); total pleurectomy (46); extended pleuropneumonectomy (2); partial removal of the diaphragm (1) and total pleurectomy and upper lobectomy (1).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26361957&#34; target=&#34;_blank&#34;&gt;Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, the patients with MPM have an extremely poor prognosis due to its high resistance to conventional oncologic treatments and delayed diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26364129&#34; target=&#34;_blank&#34;&gt;An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a family with domestic exposure to asbestos and diagnosis of multiple cancers, including eight pleural malignant mesotheliomas and several other lung or pleural tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26366399&#34; target=&#34;_blank&#34;&gt;Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis of MPM is poor due to the difficulty of making diagnosis in the early stage, the rapid progression, the high invasiveness and the lack of effective treatment. […] The variety of clinical features may cause the delay of diagnosis and high rate of misdiagnosis. […] The diagnosis of MPM is based on biopsy of the pleura and immunohistochemistry. […] Three dimensional conformal radiotherapy is used to denote a spectrum of radiation planning and delivery techniques that rely on the 3D imaging to define the tumor. […] The diagnosis, treatment and prognosis still remain a major challenge for clinical research and will do so for years to come.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26376466&#34; target=&#34;_blank&#34;&gt;Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Biopsy specimen of the pleura showed proliferating epithelioid tumor cells, leading to the pathological diagnosis of epithelioid MPM with the aid of immunohistochemistry. […] After the diagnosis of MPM, chemotherapy was performed without effect. […] Soon after the clinical diagnosis of progressive disease with skull metastasis, edema and weight gain appeared.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26376834&#34; target=&#34;_blank&#34;&gt;BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In order to investigate the diagnostic and prognostic significance of BAP1, we constructed a tissue microarray consisting of 111 MPM cases and performed BAP1 immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26384258&#34; target=&#34;_blank&#34;&gt;III Italian Consensus Conference on Malignant Mesothelioma of the Pleura. Epidemiology, Public Health and Occupational Medicine related issues.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Correct MM diagnosis is baseline; guidelines agree on the importance of the tumor gross appearance and of the hematoxylin-eosin-based histology. […] Immunohistochemical markers contribute to diagnostic confirmation: the selection depends on morphology, location, and differential diagnosis. […] The WG suggested that 1) General Cancer Registries and ReNaM Regional Operational Centres (COR) interact and systematically compare MM cases; 2) ReNaM should report results presenting the diagnostic certainty codes and the diagnostic basis, separately; 3) General Cancer Registries and COR should interact with pathologists to assure the up-to-date methodology; 4) Necroscopy should be practiced for validation. […] No diagnostic test is recommended for MM screening.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26384262&#34; target=&#34;_blank&#34;&gt;[Health expenditures for cases of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For each pleural mesothelioma case the costs (on average) were about 67,000 euros, 37,000 of which were spent after the date of diagnosis. […] Per capita expenditures showed a peak near (before and after) the date of diagnosis, rising when approaching the date of death and with increasing age of the patient, and did not vary with survival time.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26407584&#34; target=&#34;_blank&#34;&gt;Expression Profiles of Cytokine mRNAs in the Pleural Fluid Reveal Differences Among Tuberculosis, Malignancies, and Pneumonia-Exudative Pleural Effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serum and pleural fluid cytokine levels have been analyzed to help in the differential diagnosis, but with limited results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26417297&#34; target=&#34;_blank&#34;&gt;Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis of malignant pleura mesothelioma (MPM) is challenging. […] Differential diagnosis of MPM versus lung adenocarcinoma (AD) is particularly difficult, yet clinically important since the two neoplasias call for different treatment approaches. […] We conducted a wide screening study of miRNA profiles in serum pools of MPM patients (N = 11), AD patients (N = 36), and healthy subjects (N = 45) to identify non-invasive biomarkers for differential diagnosis of MPM and AD, using deep sequencing. […] Direct comparison of the miRNA profiles for MPM and AD revealed differences in miRNA levels that could be useful for differential diagnosis. […] Differing miRNA levels between MPM and AD may be useful for differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26421614&#34; target=&#34;_blank&#34;&gt;Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Expression of any cytosolic nestin progressively increased from epithelioid to biphasic to sarcomatoid MPM in cohort 1, whereas the diagnostic markers calretinin and podoplanin decreased.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26443279&#34; target=&#34;_blank&#34;&gt;Response evaluation in mesothelioma: Beyond RECIST.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Functional imaging techniques are applied to derive quantitative measurements of tumours, which reflect particular aspects of the tumour pathophysiology. […] New functional imaging techniques, such as positron emission tomography (PET), diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) that may potentially improve the assessment of treatment response will be highlighted and discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26448191&#34; target=&#34;_blank&#34;&gt;Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma in effusion cytology specimens is controversial.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26448888&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma Mimicking Invasive Mammary Carcinoma in a Male Breast.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A final diagnosis of malignant mesothelioma, epithelioid type, was rendered. […] This case demonstrates the importance of considering a broad differential diagnosis in the setting of atypical presentation with application of a panel of IHC markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26449328&#34; target=&#34;_blank&#34;&gt;The diagnosis of pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Their precise etiological diagnosis depends on a combination of medical history, physical examination, imaging tests and pertinent pleural fluid analyses; including specific biomarkers (e.g., natriuretic peptides for heart failure, adenosine deaminase for tuberculosis, or mesothelin for mesothelioma). […] This review addresses the current diagnostic approach to pleural effusions secondary to heart failure, pneumonia, cancer, tuberculosis and other less frequent conditions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26451268&#34; target=&#34;_blank&#34;&gt;A Cause of Bilateral Chylothorax: A Case of Mesothelioma without Pleural Involvement during Initial Diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present case, with malignant mesothelioma, bilateral chylothorax, and mediastinal lymph node without any pleural involvement during initial diagnosis, is rare and will hence contribute to the literature.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26458721&#34; target=&#34;_blank&#34;&gt;Paraneoplastic nephritic syndrome and concurrent solitary mediastinal lymph node metastasis from mesothelioma of testis diagnosed by endobronchial ultrasound: Unusual manifestations of an extremely rare tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of metastatic lymph nodal disease was set by using convex-probe endobronchial ultrasound (EBUS) with transbronchial needle aspiration. […] We also briefly discuss clinical, etiological, pathological and therapeutical aspects of the disease, and highlight the paramount importance of real-time EBUS as the preferred method in the diagnostic approach of mediastinal lesions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26459178&#34; target=&#34;_blank&#34;&gt;Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study sought to examine SP1 expression in malignant pleural mesotheliomas (MPM) and ascertain the potential efficacy of targeting SP1 in these neoplasms. qRT-PCR, immunoblotting, and immunohistochemical techniques were used to evaluate SP1 expression in cultured MPM cells and MPM specimens and normal mesothelial cells/pleura. […] MTS, chemotaxis, soft agar, β-galactosidase, and Apo-BrdUrd techniques were used to assess proliferation, migration, clonogenicity, senescence, and apoptosis in MPM cells following SP1 knockdown, p53 overexpression, or mithramycin treatment. […] Microarray, qRT-PCR, immunoblotting, and chromatin immunoprecipitation techniques were used to examine gene expression profiles mediated by mithramycin and combined SP1 knockdown/p53 overexpression and correlate these changes with SP1 and p53 levels within target gene promoters.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2646006&#34; target=&#34;_blank&#34;&gt;Verification of the histologic diagnosis of malignant mesothelioma in relation to the binding of an antimesothelial cell antibody.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic value of a recently developed polyclonal antibody to mesothelial cells has been tested by means of an immunoperoxidase technique to differentiate mesothelioma from lung carcinoma. […] Furthermore, 20 cases of serous membranes tumor, in which major diagnostic disagreement was present when reviewed by the members of the Commission of the European Communities Mesothelioma Panel, were examined. […] Given conventionally fixed and processed tissues, it appears that this antibody may be used as an appropriate diagnostic adjunct to increase the accuracy of the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2646076&#34; target=&#34;_blank&#34;&gt;Immunocytology in malignant pleural mesothelioma. Expression of tumor markers and distribution of lymphocyte subsets.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The surface morphology of mesothelioma cells may be of additional help for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26475741&#34; target=&#34;_blank&#34;&gt;Imaging characteristics of pleural tumours.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
• Knowledge of different pleural tumours plays an important role for diagnosis orientation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26504055&#34; target=&#34;_blank&#34;&gt;Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Resected formalin-fixed paraffin-embedded MPM tissues from 29 patients, 14 patient-matched non-neoplastic pleura (NNP) specimens, 5 MPM diagnostic biopsies (DB), and 5 samples of pneumothorax-induced benign reactive mesothelial proliferation (PTHX) were analyzed. miR-126 and EGFL7 mRNA were quantified by RT-qPCR.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2650654&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in infancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histochemical study confirmed the diagnosis by revealing acid mucosubstance in the tumor, which was removed by hyaluronidase.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26509028&#34; target=&#34;_blank&#34;&gt;Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Physicians should be aware of MPM when patients with empyema are refractory to the standard treatment, and PET-CT may be helpful in establishing a precise diagnosis in such cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26520416&#34; target=&#34;_blank&#34;&gt;MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to analyze the diagnostic role of MMP-7 in effusion cytology. […] The sensitivity and specificity of this marker in the differential diagnosis between high-grade serous carcinoma and malignant mesothelioma were 46% and 100%, respectively. […] In conclusion, MMP-7 expression is highly specific, though only of moderate sensitivity, for the diagnosis of carcinoma in the differential diagnosis from both benign and malignant mesothelial cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26544728&#34; target=&#34;_blank&#34;&gt;MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic biopsies of MPM patients from four Italian cancer centers were centrally collected and analyzed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26546402&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was made using thoracoscopy in 80.8 % of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26568009&#34; target=&#34;_blank&#34;&gt;An Autopsy Case Report of Malignant Pleural Mesothelioma with Deciduoid Features.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
He received chemotherapy containing six cycles of cisplatin and pemetrexed and survived for twenty-five months after the diagnosis. […] At autopsy, the final diagnosis was biphasic pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26577445&#34; target=&#34;_blank&#34;&gt;Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Major eligibility criteria were histologically confirmed diagnosis of MPM, including clinical subtypes T0-3, N0-2, M0 disease; no prior treatment for the disease; age 20-75 years; Eastern Cooperative Oncology Group performance status 0 or 1; predicted postoperative forced expiratory volume &amp;gt;1000 ml in 1 s; written informed consent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2658538&#34; target=&#34;_blank&#34;&gt;Brain metastases in malignant pleural mesothelioma. Case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The difficulties in diagnosis, the role of immunoperoxidase stains in malignant mesothelioma, excellent tolerance of different modalities of treatment, and a review of the literature of brain metastases in mesothelioma are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26600776&#34; target=&#34;_blank&#34;&gt;An Autopsied Case of Malignant Sarcomatoid Pleural Mesothelioma in Which Chest Pain Developed Several Months Earlier without Abnormality on Imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The patient experienced chest pain for about 7 months, but a diagnosis could not be made until after death. […] In this case report, difficult aspects of the diagnosis are discussed. […] Thoracentesis was performed, but the cytology was negative, and no diagnosis could be made. […] Based on these findings, malignant pleural mesothelioma was suspected, and a thoracoscopy was performed under local anesthesia in early December 2013, but no definite diagnosis could be made. […] When chronic chest pain of unknown cause is observed and past exposure to asbestos is suspected, actions to prevent delay in diagnosis should be taken, including testing for suspicion of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26618579&#34; target=&#34;_blank&#34;&gt;Cytomorphometry of serosal effusion in dogs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytomorphometric analysis of cellular samples collected from dogs with proliferative processes affecting serosal cavities can be only an auxiliary method increasing accuracy of preoperative diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/266334&#34; target=&#34;_blank&#34;&gt;Cell aggregates in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is suggested that this observation may be of diagnostic value in the cytologic evaluation of effusions when malignant mesothelioma is suspected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26638918&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: initial experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Criteria of inclusion were a proven diagnosis of MPM, early-stage disease and good performance status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26638920&#34; target=&#34;_blank&#34;&gt;Biomarkers and prognostic factors for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The increasing incidence and the dismal prognosis of malignant pleural mesothelioma calls for the identification of biomarkers that will allow a timely diagnosis; display prognostic value; and, predict the response to pharmacological agents employed for the treatment of the disease. […] Biomarkers associated with early diagnosis currently include mesothelin in combination with miRNA miR-103a-3p.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26653237&#34; target=&#34;_blank&#34;&gt;[Analysis of the clinical diagnosis of asbestosis complicated with malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To discuss the clinical characteristics, diagnosis and treatment of the clinical characteristics and prognosis of asbestosis complicated with malignant mesothelioma patients. […] The disease is a high degree of malignant, the early clinical manifestations are not specific, easily missed diagnosis and misdiagnosis. […] Biopsy is a reliable method for diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26660351&#34; target=&#34;_blank&#34;&gt;Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Age, sex, race, year of diagnosis, histology stage, cancer-directed surgery, radiation, and vital status were analyzed. […] There were 14,228 patients with pathologic diagnosis of MPM. […] Despite developments in surgical and radiation techniques, the prognosis for MPM patients has not improved over the past 4 decades.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26664161&#34; target=&#34;_blank&#34;&gt;Unusual lesions of the mediastinum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A high index of suspicion and the immunohistochemical profile facilitated the final diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26664569&#34; target=&#34;_blank&#34;&gt;Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural EHE (PEHE) can be a diagnostic challenge due to its rarity as well as similarities to other pleural and vascular tumors. […] Due to the rarity of this disease, reaching a final diagnosis is challenging. […] It’s clinical, radiological, and pathological resemblance to malignant mesothelioma can cause a delay in diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2666592&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was most often made by exploratory thoracotomy; pleural biopsy or cytology were rarely contributory. […] The delay in diagnosis was often long (median time, 3.5 months) and thrombocytosis (platelets greater than or equal to 400,000/microL) was common (41% of cases).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26689234&#34; target=&#34;_blank&#34;&gt;Clinical Investigation of Benign Asbestos Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All were males and the median age at diagnosis was 74 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26703019&#34; target=&#34;_blank&#34;&gt;[Analysis of misdiagnosis of 38 cases of solitary fibrous tumor of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To improve the preoperative diagnostic rate of solitary fibrous tumor(SFTP) of the pleura through the analysis on clinical characteristics and misdiagnosis reasons of SFTP. […] The preoperative diagnosis was lung cancer in 9 cases, pleural mesothelioma in 5, neurofibroma in 5, pulmonary benign tumors in 4, pulmonary infection in 3, inflammatory granuloma in 5, pyothorax in 2, tuberculous pleuritis in 3, and pulmonary sequestration in 2 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26715491&#34; target=&#34;_blank&#34;&gt;Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
IMRT was carried out in two techniques, either step&amp;amp;shoot or helical tomotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26715913&#34; target=&#34;_blank&#34;&gt;Non-islet Cell Tumour Hypoglycaemia (NICTH) in Malignant Mesothelioma: Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Investigations revealed markedly suppressed insulin-like growth factor-I, normal insulin-like growth factor-II and elevated “big”-insulin-like growth factor-II, supporting the diagnosis of NICTH.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2015-12-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26722577&#34; target=&#34;_blank&#34;&gt;Infant pleuropulmonary blastoma: report of a rare case and review of literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
So as to provide proper and timely treatment, the differential diagnosis includes pulmonary blastoma, sarcomatoid mesothelioma, fetal rhabdomyoma, synovial sarcoma, and primitive neuroectodermal tumor. […] Combining imaging and histopathological examinations and clinical data should help in determining the diagnosis of pleural pulmonary blastoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26744667&#34; target=&#34;_blank&#34;&gt;Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological examination and thoracoscopic pleural biopsy yielded a diagnosis of epithelial malignant pleural mesothelioma (MPM); extrapleural pneumonectomy (EPP) was performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26744674&#34; target=&#34;_blank&#34;&gt;A rare clinical case - Solitary fibrous tumor of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only 10-20% of the published cases report a malignant solitary fibrous tumor, however, definite diagnosis can only be made after complete resection which is the proposed diagnostic algorithm for these cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26765063&#34; target=&#34;_blank&#34;&gt;Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Subject to validation of the current results in further larger studies, miR-21 and miR-126 profiling could be an effective and reliable tool for the diagnosis of MM in pleural effusions complementary to cytology evaluation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26770440&#34; target=&#34;_blank&#34;&gt;Massive localized malignant pleural mesothelioma (LMPM): manifestations on computed tomography in 6 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our study analyzed the clinical symptoms and computed tomography (CT) manifestations of massive localized malignant pleural mesothelioma (LMPM) patients to improve the knowledge and diagnosis of this disease. […] To sum up, CT showed important diagnostic values on massive LMPM patients; patients with a history of asbestos exposure, large soft-tissue mass of pleura with an abundant blood supply and wrap around large vessels might increase the risk of massive LMPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26776867&#34; target=&#34;_blank&#34;&gt;A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have developed and validated a simple, clinically relevant model to reliably discriminate patients at high and lower risk of death using routinely available variables from the time of diagnosis in unselected populations of patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26779911&#34; target=&#34;_blank&#34;&gt;CT Scan-Guided Abrams’ Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Image-guided pleural biopsies, both using ultrasound (US) or computed tomography (CT), are important in the diagnosis of pleural disease. […] In this randomized, prospective study, we aimed to compare CT scan-guided pleural biopsy using an Abrams’ needle (CT-ANPB) with US-assisted pleural biopsy using a cutting needle (US-CNPB) with respect to both diagnostic yield and safety. […] The two groups were compared in terms of diagnostic sensitivity and complications. […] In the US-CNPB group, the diagnostic sensitivity was 66.7%, compared with 82.4% in the CT-ANPB group; the difference between the two groups was statistically significant (p = 0.029). […] The first diagnostic intervention that should be preferred in patients with pleural effusion and associated pleural thickening on a CT scan is CT-ANPB.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26780987&#34; target=&#34;_blank&#34;&gt;KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients, however, die within 24 months of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-11-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26802143&#34; target=&#34;_blank&#34;&gt;Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median time between initial diagnosis and surgery was 134 days. […] Two-year survival from initial diagnosis and from EPD was 44 and 28%, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26807072&#34; target=&#34;_blank&#34;&gt;ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26811225&#34; target=&#34;_blank&#34;&gt;The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The discovery of inactivating mutations in the BRCA1-associated protein 1 gene in sporadic and hereditary mesothelioma has opened up a variety of novel molecular, clinical, and diagnostic investigations. […] One possible diagnostic application includes the setting of separating mesothelioma from reactive mesothelial proliferations, where it may play a role in conjunction with p16 FISH. […] Genetic studies also led to the finding that WWTR1-CAMTA1 fusions are useful diagnostic markers for epithelioid hemangioendotheliomas, which can present as pleural-based masses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26816537&#34; target=&#34;_blank&#34;&gt;Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study determined the types of cancers accompanied by MPE at initial diagnosis and investigated appropriate related methods for diagnosing previously unknown cancers. […] We retrospectively reviewed the medical records of 35 patients with MPE at initial cancer diagnosis between 2004 and 2012. […] We evaluated the patient characteristics, final diagnosis, and diagnostic processes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26817512&#34; target=&#34;_blank&#34;&gt;Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant Pleural Mesothelioma (MPM) is an aggressive disease characterized by a dismal prognosis, mainly due to late diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26817643&#34; target=&#34;_blank&#34;&gt;Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological diagnosis of malignant mesothelioma requires an invasive procedure such as CT-guided needle biopsy, thoracoscopy, video-assisted thorascopic surgery (VATs) or thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26822243&#34; target=&#34;_blank&#34;&gt;[Malignant mesotheliomas with unknown exposure to asbestos: a re-examination].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No significant differences between age, sex, cancer site, diagnostic certainty, residence, year of diagnosis, interviewed subjects were detected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26824986&#34; target=&#34;_blank&#34;&gt;Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The frequent SETDB1 inactivating mutations suggest there could be new diagnostic or therapeutic options for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26839028&#34; target=&#34;_blank&#34;&gt;Benign and Malignant Mesothelial Proliferation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MM is challenging with a broad differential diagnosis. […] Thorough interpretation and correlation of clinical, radiologic, and pathologic findings are essential for a correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26845118&#34; target=&#34;_blank&#34;&gt;Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Epithelioid histology, PS, and elevated lymphocyte count at diagnosis were significantly associated with clinical benefit from first-line chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26848772&#34; target=&#34;_blank&#34;&gt;Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Calretinin (CALB2) is a diagnostic marker for epithelioid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26873306&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: an update on diagnosis and treatment options.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) represents a significant diagnostic and therapeutic challenge and is almost always a fatal disease. […] Similarly, minimally invasive biomarkers have shown promise but also have limitations in the diagnosis of mesothelioma. […] In experienced centers, cytology and immunohistochemistry are now sufficient to diagnose the epithelioid subtype of mesothelioma, which can reduce the need for more invasive diagnostic investigations. […] This review focuses on the current data on the diagnostic and therapeutic issues of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26893272&#34; target=&#34;_blank&#34;&gt;Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conversely, no significant correlation was found between age, sex, smoking history, reported exposure to asbestos, stages at diagnosis, treatments, and OS and PFS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26900815&#34; target=&#34;_blank&#34;&gt;BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We also examined 13 sarcomatoid carcinomas, an important differential diagnosis of sarcomatoid mesotheliomas, and found that BAP1 was never lost, but p16 was deleted in 3/11 (27%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26903675&#34; target=&#34;_blank&#34;&gt;Anaesthetic management of extra-pleural pneumonectomy and hyperthermic intrathoracic chemotherapy procedure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a rare tumour with survival of 9-17 months after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26904248&#34; target=&#34;_blank&#34;&gt;Asymptomatic localized pleural amyloidosis mimicking malignant pleural mesothelioma: report of a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Partial pleurectomy including the tumor was performed for the purpose of diagnosis and local disease control. […] Pleural amyloidosis should be considered as a differential diagnosis from pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26912058&#34; target=&#34;_blank&#34;&gt;Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, as previous studies have suggested, hyaluronan alone is not a sufficient independent marker for diagnostic differentiation of these cancer types, but could be utilized as a combination together with other specific markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26932246&#34; target=&#34;_blank&#34;&gt;Cytomorphology of ovarian clear cell carcinomas in peritoneal effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Other rare neoplasms composed of clear cells must be considered in the differential diagnosis such as yolk sac tumour of the ovary, clear cell subtype of endometrial carcinoma and, less frequently, malignant peritoneal mesothelioma as well as metastatic renal cell carcinoma. […] Ovarian clear cell carcinomas have distinct morphological features that are helpful in making a cytological diagnosis of this entity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26951736&#34; target=&#34;_blank&#34;&gt;[Proposal of an Italian national protocol of health surveillance for former asbestos workers: an ongoing project].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A literature search on methods of follow-up of asbestos workers (imaging, spirometry, and questionnaires) and diagnosis of non-malignant (asbestosis and pleural plaques) and malignant (lung cancer) asbestos disease was done.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26962828&#34; target=&#34;_blank&#34;&gt;Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural effusions may be challenging when cytological examination of aspirated pleural fluid is equivocal or noncontributory. […] The relative abundance of these predetermined biomarkers among groups served to establish the differential diagnosis of: malignant versus benign (TB) effusions, lung adenocarcinoma versus mesothelioma, and lymphoma versus TB. […] The selected putative markers were validated using widely available commercial techniques in an independent sample of 102 patients.Significant differences were found in the protein expressions of metalloproteinase-9 (MMP-9), cathepsin-B, C-reactive protein, and chondroitin sulfate between malignant and TB effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2696945&#34; target=&#34;_blank&#34;&gt;A simple “expert system” for morphometric evaluation of cells in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Quantitation in diagnostic pathology serves to improve both diagnostic reliability and the prognosis of various malignant tumors. […] A typical application of diagnostic morphometry is to determine whether, and with which probability a patient with an unclear histopathologic finding can be assigned to one or more groups of patients with known diseases and prognoses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1990-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26973205&#34; target=&#34;_blank&#34;&gt;Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the diagnostic accuracy of sequential co-registered PET+MR (PET+MR) for local staging of malignant pleural mesothelioma (MPM) compared to PET/CT. […] Two independent readers evaluated images for T and N stage, confidence level (sure to unsure; 1-3) and subjective overall image quality (very good to non-diagnostic; 1-4). […] Diagnostic confidence was scored significantly higher in PET+MR compared to PET/CT (mean score=1.66 and 1.93, respectively; p=0.004). […] Image quality was diagnostic for all image series. […] Our findings suggest that diagnostic accuracy of PET+MR is comparable to PET/CT for local staging of MPM, whereas radiologists felt significantly more confident staging PET+MR compared to PET/CT images (p=0003), using dedicated sequences.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26976999&#34; target=&#34;_blank&#34;&gt;Computed Tomographic Features of Malignant Peritoneal Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MPM presented characteristic CT findings, and the MPM-CT index may be useful for differential diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/26995100&#34; target=&#34;_blank&#34;&gt;[BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is difficult and needs an antibody panel. […] Our work assesses the value of integrating BAP1 in the panel of antibodies used for the diagnosis of MMD. […] Immunohistochemical techniques were performed on cytological and histological specimens of MMD and adenocarcinoma pleural metastasis. […] The specificity of BAP1 was 100% on cytological and biopsy specimen for the diagnosis of malignancy in case of mesothelial proliferation. […] This immunohistochemistry could be integrated in the panel of immunostaining used for MMD diagnosis, either on histological or cytological samples.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27009350&#34; target=&#34;_blank&#34;&gt;Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We used Protoarray(®) microarrays to determine immune responses to 8798 antigens in 10 MM and 10 asbestos exposed controls and developed diagnostic panels using 17 antigens from this.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27015594&#34; target=&#34;_blank&#34;&gt;The role of thoracic surgery in the management of mesothelioma: an expert opinion on the limited evidence.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis with video assisted thoracoscopy offers excellent sensitivity and specificity and a direct view of the pleural cavity to verify the extent of the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27015745&#34; target=&#34;_blank&#34;&gt;Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, claudin-4 (CL4) immunocytochemistry was reported to be useful for differential diagnosis in effusion cytology. […] Since CL4 exhibited similar or superior usefulness to Ber-EP4 and MOC-31, it could become the first choice for the above differential diagnosis in effusion cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27015837&#34; target=&#34;_blank&#34;&gt;Fatal pleural mesothelioma in Japan (2003-2008): evaluation of computed tomography findings.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to clarify the characteristic findings of mesothelioma at the time of diagnosis, and determine precautions and guidelines for diagnosing mesothelioma early in imaging studies. […] Upon examination of the CT scans at diagnosis, 18 % of mesothelioma cases did not show a clear irregularity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27032653&#34; target=&#34;_blank&#34;&gt;Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serum biomarkers may be helpful for early diagnosis of MPM in asbestos-exposed cases. […] These two seem to be the most valuable biomarkers for the diagnosis of MPM, both individually and in combination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27034865&#34; target=&#34;_blank&#34;&gt;Primary Malignant Neuroendocrine Tumour of Pleura: First Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical presentations of inflammatory lesions like tuberculous pleuritis and benign and malignant neoplasms of pleura are indistinguishable; hence, fluid cytology, pleural biopsy, and immunohistochemistry are necessary for exact tissue diagnosis of the tumours, which is mandatory for correct treatment and prognostic assessment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27040844&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study represents the largest cohort of patients reported to date with synchronous malignant mesothelioma and lung cancer, and we propose guidelines for making a diagnosis of synchronous malignant mesothelioma and primary lung cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2704280&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma–problems in diagnosis and clinical course in 25 patients].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In benign cases diagnosis can easily be made during the operation. […] In the case of malignant pleuramesothelioma the preoperative diagnosis with an exact staging of the tumor is very important to determine an adequate therapeutic regimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27053826&#34; target=&#34;_blank&#34;&gt;Deformable medical image registration of pleural cavity for photodynamic therapy by using finite-element based method.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This impacts the delivered dose when using highly conformal treatment techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27055148&#34; target=&#34;_blank&#34;&gt;Advances in treatment of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this review is to focus on the current available treatment for MPM through the analysis of the results comes from the phase III trials and to discuss the future perspectives in the pathogenesis, diagnosis and treatment. […] A better comprehension of MPM pathogenesis should be obtained to improve and develop new diagnostic tools and target therapies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27074478&#34; target=&#34;_blank&#34;&gt;A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To identify the best treatment technique for MPM, in five patients, we made a representative comparative analysis of two kinds of techniques for radiation therapy planning: IMRT and VMAT. […] PTV coverage and homogeneity, dose of organs at risk, numbers of segments, MUs, and delivery time were evaluated for all techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27075290&#34; target=&#34;_blank&#34;&gt;[Localized Malignant Mesothelioma of the Pleura with Hemothorax].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumor was surgically removed completely and the diagnosis of LMM was established pathologically.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-06-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2707793&#34; target=&#34;_blank&#34;&gt;Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Epithelial mucin and carcinoembryonic antigen (CEA) immunoreactivity, when present, supported a diagnosis of serous tumor in these generally mucin-poor and CEA-negative neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27079839&#34; target=&#34;_blank&#34;&gt;Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the morphological overlap between malignant and benign mesothelial proliferation can make a conclusive cytological diagnosis of mesothelioma elusive because immunohistochemical staining does not discriminate definitively between the two in this setting. p16 is deleted in up to 80% of pleural mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27110327&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma Versus Metastatic Carcinoma of the Pleura: A CT Challenge.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathologist made the definite diagnosis based on immunohistochemistry. […] A chest radiologist unaware of the pathology diagnosis observed all CT scans. […] Pleural thickening and thickening of interlobar fissure lead us to the diagnosis of MPM and massive free pleural effusion is more commonly seen in metastatic pleural malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27117437&#34; target=&#34;_blank&#34;&gt;Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Twenty patients (54%) had a clinical diagnosis of neuropathic pain, and of these, only six patients (40%) screened positively for neuropathic pain using the LANSS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27118208&#34; target=&#34;_blank&#34;&gt;Intrathoracic splenosis - lesson learned: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The simple question regarding abdominal trauma in a patient’s history can lead the clinician to the diagnosis of splenosis, which can be unequivocally established via scintigraphy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27127140&#34; target=&#34;_blank&#34;&gt;Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Exome-based next-generation sequencing (NGS) techniques may direct the future of molecular targeting and improve systemic therapies for patients with mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27156724&#34; target=&#34;_blank&#34;&gt;Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis and accurate disease staging in patients with malignant pleural mesothelioma (MPM) are essential in classifying such patients into prognostic subgroups to allow delivery of stage-specific therapies. […] This review addresses the current status of multimodality imaging in the diagnosis and staging of MPM. […] Clinical, research, and future directions in computed tomography (CT), magnetic resonance imaging, and PET/CT diagnosis and staging of MPM are discussed, including the use of novel PET probes. […] The article concludes with important take-home messages summarized as the pearls and pitfalls of each diagnostic modality in the diagnosis and staging of patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2716620&#34; target=&#34;_blank&#34;&gt;The incidence of malignant mesothelioma in Australia, 1947-1980.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
By 1980, 535 (81%) men and 123 (19%) women had been diagnosed with the disease; only 14 persons were aged less than 35 years at the time of diagnosis (the youngest person was 15 years of age). […] The incidence rate in subjects who were 35 years or older at diagnosis was less than 1.0 cases per million person-years until 1964-1968, and then it rose progressively to 15.5 cases per million person-years in 1979-1980. […] The age at diagnosis of patients with known exposure to asbestos was similar to that in those without known exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27169584&#34; target=&#34;_blank&#34;&gt;[Surgical therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are two established surgical techniques for treatment of MPM, extrapleural pneumonectomy and tumor pleurectomy with decortication.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27175358&#34; target=&#34;_blank&#34;&gt;Conjunctival Metastasis from Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical features mimicked metastatic carcinoma, and furthermore, the tumour’s immunohistochemical positivity for cytokeratin could have led to an erroneous diagnosis of carcinoma rather than mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2717559&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy is a suitable diagnostic method in malignant mesothelioma, since it enables simultaneously histopathological diagnosis, identification of asbestos fibres, staging of tumour spread, and pleurodesis therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27210080&#34; target=&#34;_blank&#34;&gt;[Clinical Pathological Diagnosis, and Treatment for Pleural Mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For the differential diagnosis between fibrous pleuritis and other malignancies such as lung cancer, multiple immunostaining is essential to diagnose pleural mesothelioma. […] For cytological diagnosis of pleural effusions, differentiation between mesothelioma cells and reactive mesothelial cells is very difficult. […] To diagnose sarcomatoid mesothelioma, keratin is usually positive, differentiating the diagnosis from that for real sarcoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27217757&#34; target=&#34;_blank&#34;&gt;Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirty-six patients with MM, whose histopathologic diagnosis and follow-up were performed by our clinic and whose complete archive data were accessible, were included in this retrospective study. […] The patients’ histopathologic disease types and stages, complete blood count parameters at diagnosis, and survival were recorded. […] PLR was a significant prognostic indicator of MM at diagnosis on complete blood count parameters; however, NLR was not a significant prognostic indicator.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27219841&#34; target=&#34;_blank&#34;&gt;Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because most of malignant pleural mesothelioma (MPM) patients first present with pleural effusion, detection of mesothelioma cells on effusion smears is critical for early diagnosis. […] Recently, accumulating evidence indicating that the cytological diagnosis of MPM supported by ancillary techniques is as reliable as that based on histopathology has led to new guidelines for the cytopathologic diagnosis of MPM. […] Based on the guidelines, a combination of cytomorphological criteria and verification by ancillary techniques is required for the cytologic diagnosis of MPM. […] We showed that the p16 deletion status of MPM cells in pleural effusions reflected that of the underlying invasive MPM tissues, indicating the usefulness of p16 FISH in effusion smear cytology for MPM diagnosis. […] A positive p16 homozygous deletion supports the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27222020&#34; target=&#34;_blank&#34;&gt;Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We discuss different stages of patient management in malignant pleural mesothelioma, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27222787&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With this diagnosis, a chemotherapy regimen with cisplatin was initiated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27236396&#34; target=&#34;_blank&#34;&gt;Metastatic malignant pleural mesothelioma masquerading as a case of acute abdomen secondary to small bowel perforation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This was a rare presentation of a rare disease and the first reported case in the published studies in which MM masqueraded as bowel perforation prior to the primary diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27245839&#34; target=&#34;_blank&#34;&gt;KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an aggressive, locally invasive, cancer elicited by asbestos exposure and almost invariably a fatal diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2725943&#34; target=&#34;_blank&#34;&gt;[Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histology was re-examined for each case and clinical records was also looked at so as to identify onset symptomatology, diagnostic procedures and treatment. […] There was also a significant delay in formulation of correct diagnosis, attributable on the hand to the nonspecificity of the symptomatology of onset and on the other to the inadequacy of currently available clinical and radiological procedures. […] Only histology with the aid of immunocytochemical procedures was able to pinpoint correct diagnosis, in life.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27286698&#34; target=&#34;_blank&#34;&gt;The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The disease remains challenging in terms of diagnosis, staging and treatment and an optimal strategy has not yet been clearly defined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27287512&#34; target=&#34;_blank&#34;&gt;Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median overall survival time of a mesothelioma cancer patient is less than 1-year from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27288871&#34; target=&#34;_blank&#34;&gt;Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Plasma samples were collected from 129 MPM patients in four institutions at the time of diagnosis or before surgical resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27300447&#34; target=&#34;_blank&#34;&gt;Applications of Magnetic Resonance Imaging of the Thorax in Pleural Diseases: A State-of-the-Art Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this review was to present the main aspects of pleural diseases seen with conventional and advanced magnetic resonance imaging (MRI) techniques. […] The indication for MRI of the thorax in the identification of these conditions is increasing in comparison to computerized tomography, and it can also be used to support the diagnosis of pulmonary illnesses.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27312601&#34; target=&#34;_blank&#34;&gt;Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At present, early diagnosis is rather difficult and depends on invasive sampling of pleural fluid or tissue.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27312689&#34; target=&#34;_blank&#34;&gt;Pleural fluid infection caused by Dietzia cinnamea.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The case shows the expanding ability of microbiology laboratories to identify rare organisms through newer techniques and technology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27323398&#34; target=&#34;_blank&#34;&gt;Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we report that immunohistochemistry of estradiol showed cytoplasmatic staining in 95% of fifty-seven human MPM samples with a trend toward a negative correlation between estradiol levels and the median post-diagnosis survival time.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27345639&#34; target=&#34;_blank&#34;&gt;Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eligible patients were randomised (1:1), using a computer-generated sequence, to receive immediate radiotherapy (21 Gy in three fractions within 42 days of the pleural intervention) or deferred radiotherapy (same dose given within 35 days of PTM diagnosis).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2737035&#34; target=&#34;_blank&#34;&gt;[Thoracoscopy using flexible fiberoptic bronchoscopy–a preliminary report of experimental and clinical studies].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The preliminary experience on thoracoscopy with fiberoptic bronchoscope through a trocar designed by the authors for the purpose of studying its diagnostic implication and safety was reported. […] After the examination, diagnosis was made as mesothelioma in 2 cases and non-specific pleurisy, malignant lung tumor with mediastinal lymphatic node metastasis and pulmonary benign tumor in the remaining 3 cases respectively. […] Thoracoscopy is a technique easy to operate, safe, less traumatic and gives accurate diagnosis in clinical practice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27373784&#34; target=&#34;_blank&#34;&gt;A case of pseudoachalasia hiding a malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On the hypothesis of an esophageal motor disorder, the patient was referred for an HRM examination, which revealed features consistent with a diagnosis of type II achalasia. […] Pseudoachalasia as the first or only manifestation of mesothelioma is a rare occurrence that may expose patients to the risk of diagnostic delay.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27376267&#34; target=&#34;_blank&#34;&gt;Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Scoring for AQP1 was robust, with an inter-observer kappa value of 0.722, indicating substantial agreement between observers; (4) CONCLUSION: AQP1 is a useful prognostic marker that can be easily incorporated in existing diagnostic immunohistochemical panels and which can be reliably interpreted by different pathologists.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27405014&#34; target=&#34;_blank&#34;&gt;Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant pleural mesothelioma (MPM) is challenging and requires immunohistochemistry or electron microscopy assays to specifically differentiate MPM from lung adenocarcinoma. […] An ultrastructural study of fresh tissue is considered to be the “gold standard.” In most cases, the first diagnostic approach is performed on pleural effusion, and in some patients, this is the only available sample for diagnosis. […] The aim of the present study is to evaluate if an examination of pleural effusion samples based on electron microscopy (EMpe) is a useful tool for the differential diagnosis of MPM and lung adenocarcinoma. […] Histological and immunohistochemical markers confirmed the diagnosis of either mesothelioma (5) or adenocarcinoma (20). […] EMpe identifies unequivocal morphological changes that are useful for the differential diagnosis of MPM or adenocarcinoma when the pleural effusion sample contains evaluable tumor cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27407123&#34; target=&#34;_blank&#34;&gt;NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27408810&#34; target=&#34;_blank&#34;&gt;MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognosis for patients with MPM is poor and median survival following diagnosis is 4-18 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-07-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27422678&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma with lacrimal gland metastasis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A biopsy concluded a diagnosis of metastatic mesothelioma of the lacrimal gland.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27422796&#34; target=&#34;_blank&#34;&gt;BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The biphasic subtype has an intermediate prognosis, but its definitive histological diagnosis may be challenging owing to the difficulty of assessing the neoplastic nature of the stromal component. […] The aim of the present study was to define the diagnostic usefulness of immunohistochemical determination of BAP1 in MPM, with clinicopathological correlation. […] We showed that BAP1 protein determination is a diagnostic tool to correctly distinguish biphasic MPM from epithelial subtypes with an atypical/activated reactive stroma and an independent prognostic parameter in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27439511&#34; target=&#34;_blank&#34;&gt;A case report of metastasis of malignant mesothelioma to the retromolar trigone.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Based on the histopathological and immunohistochemical findings, a final diagnosis of metastatic mesothelioma was made. […] Biopsy, history of the patient and clinical picture were provided to the clinicians to make an efficient differential diagnosis. […] Differential diagnosis must be performed with other oral cancers, because the management is totally different.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27447750&#34; target=&#34;_blank&#34;&gt;Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis between pleural malignant mesothelioma (MM) and lung cancer is often challenging. […] However, in about 10-20% of the cases, the IHC results can be confusing and inconclusive, and novel markers are sought to increase the diagnostic accuracy.We stained 45 non-small cell lung cancer samples (32 adenocarcinomas and 13 squamous cell carcinomas) with a monoclonal antibody for BRCA1-associated protein 1 (BAP1) and also with an IHC panel we routinely use to help differentiate MM from carcinomas, which include, calretinin, Wilms Tumor 1, cytokeratin 5, podoplanin D2-40, pankeratin CAM5.2, thyroid transcription factor 1, Napsin-A, and p63. […] Diagnostic accuracy of other classical IHC markers was in agreement with previous studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27457873&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were 167 male and 43 female patients with a mean age of 67.0 years (SD ± 11.3) at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27464904&#34; target=&#34;_blank&#34;&gt;[Not Available].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cases of workers suffering from asbestos-related diseases diagnosed from 1996 to 2015 were collected on the occasion of some legal trials; the diagnosis, and the asbestos occupational and non-occupational exposure, were carefully evaluated.Lung samples were obtained from subjects, taking advantage of the autopsies; asbestos fibers were counted by means of a Scanning Electron Microscope, equipped with x-ray fluorescence microanalyses at 12.0000 amplification, and asbestos bodies by means of an Optical Microscope at 500 amplification. 192 malignant mesotheliomas (6 in women), 196 lung cancers and 14 asbestosis (without cancer) were observed (1996-2015); autopsies were carried out on 80% of all subjects and 98% of mesotheliomas were confirmed by autopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27485167&#34; target=&#34;_blank&#34;&gt;Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate pathologic diagnosis and reporting in malignant pleural mesothelioma are essential for clinical care, and cancer registration. […] We reviewed 819 pathology reports relating to a first diagnosis of malignant pleural mesothelioma. […] We evaluated tumor characteristics, the diagnosis field including terminology and immunohistochemistry (IHC) workup, and report completeness (the proportion of items recorded). […] Our findings show that although guidelines are designed to improve actual reporting practices, there is ample room for improvement in their application to standardize the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27489758&#34; target=&#34;_blank&#34;&gt;Recurrent hydropneumothorax: An unusual presentation for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis often times is difficult with negative imaging and negative pleural fluid studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2749656&#34; target=&#34;_blank&#34;&gt;[Health damage caused by asbestos and other mineral fibers].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of asbestos-related disease is based upon information on occupational exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27501894&#34; target=&#34;_blank&#34;&gt;Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Large-scale prospective studies are needed to fully establish the diagnostic utility of such differences.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27502004&#34; target=&#34;_blank&#34;&gt;[Early recognition of lung cancer in workers occupationally exposed to asbestos].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
According to current knowledge the resulting survival benefits far outweigh the potential risks involved in the diagnostic work-up of suspicious lesions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27512506&#34; target=&#34;_blank&#34;&gt;Medical thoracoscopy: Analysis on diagnostic yield through 30 years of experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We calculated MT diagnostic yield and analyzed trends of main diseases diagnosed along the time. […] The overall diagnostic yield of MT was 71%, increasing from 57% to 79%. […] The diagnostic yield was significantly higher in the presence of monolateral pleural effusion. […] Cancer represented more than half of diagnosis; tuberculosis was the most common nonneoplastic disease. […] MT has a great diagnostic yield that can be improved by practice, permitting to achieve a specific histological diagnosis in about 80% of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27516891&#34; target=&#34;_blank&#34;&gt;Alveolar-filling growth pattern of sarcomatoid malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Biopsy of the pleura under general anaesthesia confirmed the diagnosis of sarcomatoid malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27521620&#34; target=&#34;_blank&#34;&gt;Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural effusion recognizes heterogeneous etiology and pathogenesis and requires invasive diagnostic procedures. […] The aims of this study were to evaluate (i) the diagnostic accuracy of p-CEA of patients with pleural effusions undergoing video-assisted thoracoscopic surgery (VATS) for diagnostic purpose, (ii) the relationship between p-CEA and serum CEA (s-CEA), and (iii) the usefulness of the p-CEA/s-CEA ratio in the diagnosis of malignant pleural effusions (MPE). […] The final diagnosis, based on histopathology of the VATS-guided specimens, was available for all patients. p-CEA and s-CEA was assayed with a chemiluminescence immunoassay method (CLIA), applied on the Maglumi 2000 Plus automated platform (SNIBE, Shenzen, China).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27543099&#34; target=&#34;_blank&#34;&gt;Co-existing tuberculosis and malignant mesothelioma with multiple sites venous thrombosis: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tuberculosis being a great mimicker of infectious as well as non infectious diseases and recent rise of multi drug resistant and extended drug resistant cases have made diagnosis and management more difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27560933&#34; target=&#34;_blank&#34;&gt;The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For metastatic effusion, 18F-FDG PET imaging had higher sensitivity (p = 0.000) and better diagnostic consistency with 18F-FDG PET/CT integrated imaging compared with CT imaging (Kappa = 0.917 and Kappa = 0.295, respectively). […] The specificities of CT imaging and 18F-FDG PET/CT integrated imaging were higher than that of 18F-FDG PET imaging (p = 0.000 and p = 0.000, respectively), and CT imaging had better diagnostic consistency with 18F-FDG PET/CT integrated imaging compared with 18F-FDG PET imaging (Kappa = 0.881 and Kappa = 0.240, respectively). […] For image interpretation of 18F-FDG PET/CT integrated imaging, the PET and CT portions play a major diagnostic role in identifying metastatic effusion and benign effusion, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-07-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27565933&#34; target=&#34;_blank&#34;&gt;Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aimed to investigate the significance of homo-d and hetero-d of p16 in the diagnosis and prognosis of MPM. p16 FISH was performed in 93 MPMs and 47 RMHs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27565939&#34; target=&#34;_blank&#34;&gt;Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Kaplan-Meier plots, log-rank tests, and Cox proportional hazards regression models were used to describe the association between use of metformin and all-cause mortality following diagnosis of pleural mesothelioma. […] Similar non-statistically significant associations were obtained in sensitivity analyses based on metformin use in year prior to diagnosis of mesothelioma, use of metformin for more than one year, in people below the mean age at diagnosis of mesothelioma (74 years) and 74 years of age or older, limitation to pleural mesothelioma and following further adjustment for body mass index and smoking.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27599565&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its pretreatment pathological diagnosis is difficult, with fibrous pleuritis and reactive mesothelial hyperplasia as potential differential diagnoses. […] The definitive diagnosis was made histologically and the International Mesothelioma Interest Group classification was advanced (III/IV: 2/3) in all four patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27612329&#34; target=&#34;_blank&#34;&gt;[Malignant Pleural Mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MPM requires an adequate tissue specimen for pathological examination, and video assisted thoracoscopic surgey (VATS) is associated with the highest diagnostic yield.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27614970&#34; target=&#34;_blank&#34;&gt;BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic accuracy for MPM and the cut-off values of the two methods were assessed using receiver operating characteristic (ROC) analysis. […] BAP1 IHC and p16-specific FISH have independent diagnostic value, and have increased reliability when used in combination, for MPM diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27619223&#34; target=&#34;_blank&#34;&gt;Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This differential diagnosis can be very difficult and a large panel of immunohistochemical markers is required to establish the exact diagnosis. […] The standard procedure for confirming the disease and obtaining sufficient tissue for the diagnosis is videothoracoscopy. […] Full thickness biopsies are required, while transthoracic needle puncture of pleural fluid or tissue is considered to be insufficient for a cytological diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27621868&#34; target=&#34;_blank&#34;&gt;Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the trend of our surgical patients affected by malignant pleural mesothelioma (MPM) and submitted to diagnostic/palliative or curative surgical procedures and to validate the European Organisation for Research and Treatment of Cancer (EORTC) prognostic score in our patient population. […] Ninty patients (54%) were submitted to a palliative/diagnostic thoracoscopy, 30 to pleurectomy/decortication (P/D), and 6 to extra-pleural pneumonectomy (EPP).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/276234&#34; target=&#34;_blank&#34;&gt;The cytology of malignant mesothelioma in Western Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the more common epithelial variety, five features were found to be of particular value in making a cytologic diagnosis. […] A diagnosis of malignant mesothelioma may be established by cytologic examination of effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1978-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27646775&#34; target=&#34;_blank&#34;&gt;Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several biomarkers have been suggested for screening and early diagnosis of MPM. […] Currently, high levels of soluble mesothelin-related peptides (SMRP), plasma osteopontin (pOPN) and vimentin have been reported in patients with MPM as promising markers for diagnosis, but their clinical use in monitoring is still discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27651129&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of novel radiotherapy techniques is widely increasing, allowing clinicians to treat diseases that were previously difficult to treat with radiation therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2765278&#34; target=&#34;_blank&#34;&gt;Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In serous effusions, the cytologic diagnosis of adenocarcinoma, and its distinction from mesothelial hyperplasia and malignant mesothelioma, is still difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27660729&#34; target=&#34;_blank&#34;&gt;Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical resection and chest wall reconstruction were performed, confirming the diagnosis and revealing a secondary histologic component (epithelioid), supporting the diagnosis of biphasic malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2016-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27669062&#34; target=&#34;_blank&#34;&gt;Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis often happens in advanced stages restricting any therapeutic perspectives.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2767845&#34; target=&#34;_blank&#34;&gt;Mesothelioma in South Africa, 1976-84: incidence and case characteristics.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To estimate incidence, a case register was compiled for 1976-84 by contacting all medical practitioners and institutions likely to have seen cases of mesothelioma in this period; demographic, diagnostic and exposure details were sought. […] Cases were accepted if they provided evidence of histological diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27681566&#34; target=&#34;_blank&#34;&gt;Geographical patterns of mesothelioma incidence and asbestos exposure in Lombardy, Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We extracted from the Lombardy Region Mesothelioma Registry (Registro Mesoteliomi Lombardia, RML) database all incident cases of MM (pleura, peritoneum, pericardium, and tunica vaginalis testis) with first diagnosis in 2000 through 2012.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27687964&#34; target=&#34;_blank&#34;&gt;The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival was measured from the date of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27702935&#34; target=&#34;_blank&#34;&gt;Rare presentation of a localised malignant pleural mesothelioma with cranial metastasis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of localised malignant pleural mesothelioma (LMPM) is very challenging. […] Histopathological verification is the gold standard, and studies such as CT, positron emission tomography (PET) and thoracoscopy are very valuable tools in assisting diagnosis. […] This case shows that LMPM can present with uncommon radiological and clinical appearances, and imaging tools such as PET-CT have a very important role in diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27713145&#34; target=&#34;_blank&#34;&gt;Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A comparison of SMRP and glycodelin serum measurement in a large patient cohort demonstrated that the detection of both soluble factors can increase the reliable diagnostic of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27716413&#34; target=&#34;_blank&#34;&gt;Pulmonary tumor diagnosed as an undifferentiated sarcoma with epithelioid features: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A histological diagnosis of undifferentiated sarcoma with epithelioid features was made. […] A differential diagnosis includes sarcomatoid carcinoma, malignant mesothelioma, melanoma, and other epithelioid sarcomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27716620&#34; target=&#34;_blank&#34;&gt;Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Altogether, these data indicate that the identification of new and specific markers are of a paramount importance for an early diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27755841&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The current analysis of data reflects the importance of maintaining a high index of suspicion to allow for early diagnosis, especially for cases that live in areas with high asbestos exposure and for people who work in occupations that expose them to asbestos as well as their family members.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27761727&#34; target=&#34;_blank&#34;&gt;The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differential diagnosis between the pleural infiltration of pulmonary carcinomas and MM is rather difficult particularly for epitheloid type mesothelioma.We aimed to investigate the utility of CD90, a cancer stem cell marker, in the differential diagnosis of MM and lung carcinoma, its prognostic significance and compare its value with that of Calretinin. […] We think that CD 90 has no place in the differential diagnosis between mesothelioma and pulmonary carcinoma because of the low specificity in spite of the high sensitivity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2776597&#34; target=&#34;_blank&#34;&gt;Ultrastructural histochemistry of mesotheliomas and adenocarcinomas in malignant effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic significance of the above-mentioned difference between the two neoplasms will require further investigation in a larger number of cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27768834&#34; target=&#34;_blank&#34;&gt;Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The SUVmax value of the primary mass on pre-treatment PET/CT, the haemogram parameters (Hb, Hct, NLR, MPV, PLT) at the time of diagnosis, the progression history, the date of the final visit, and the date of death of exitus patients was recorded from patient files PET/CT. […] In conclusion, in patients with MPM, NLR ≥3 and high SUVmax values at the time of diagnosis can be considered an indicator of poor prognosis but are not a guide in the prediction of progression.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27769044&#34; target=&#34;_blank&#34;&gt;Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several studies have investigated the diagnostic value of fibulin-3 for malignant pleural mesothelioma (MPM), but the results were various. […] Therefore, we performed a systematic review and meta-analysis to evaluate the diagnostic value of fibulin-3 for MPM. […] PubMed and EMBASE databases were searched up to July 29, 2016 to verify studies investigating the diagnostic value of fibulin-3 for MPM. […] The quality of eligible studies was assessed using the revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2). […] Fibuoin-3 is a useful diagnostic marker for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27771374&#34; target=&#34;_blank&#34;&gt;BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
BRCA-associated protein 1 (BAP1) immunohistochemistry (IHC) and CDKN2A (p16) fluorescence in situ hybridization (FISH) have shown clinical utility in confirming the diagnosis of malignant pleural mesothelioma (MPM), but the role for using these 2 markers to guide clinical management is not yet clear. […] We conclude that BAP1 IHC provides prognostic information within the context of CDKN2A FISH that may have clinical utility beyond diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27794408&#34; target=&#34;_blank&#34;&gt;Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging plays an important role in the detection, diagnosis, staging, response assessment, and surveillance of malignant pleural mesothelioma. […] Clinical implementation of imaging techniques and information derived from images continue to evolve based on active research in this field worldwide.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27803412&#34; target=&#34;_blank&#34;&gt;Sarcomatoid Type Primary Pericardial Mesothelioma with a Long-term Survival after the Onset of Cardiac Tamponade.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite undergoing pericardiocentesis and surgical pericardial fenestration at the onset of cardiac tamponade, we were unable to make a conclusive diagnosis of mesothelioma based on the cytological and histological findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27819788&#34; target=&#34;_blank&#34;&gt;[Update on epidemiology, pathophysiology, diagnosis and treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis approach includes occupational history, along with clinical signs and symptoms, and paraclinical studies, such as pleural fluid cytology, chest x-rays, computed tomography, magnetic resonance imaging, and biopsy with immunohistochemistry. […] The main differential diagnosis is lung adenocarcinoma. […] There is an urgent need for general physicians and specialists to identify asbestos exposure, in order to make a timely diagnosis. […] Research is necessary to develop screening and prompt diagnostic tools, along with an epidemiological surveillance program for the workers and the general population exposed to asbestos.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27822122&#34; target=&#34;_blank&#34;&gt;Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We examined both patient and tumor characteristics at time of diagnosis and subsequent treatment patterns (surgery, radiation, and chemotherapy). […] Of the 1,625 patients considered eligible for this investigation, the median age at diagnosis was 78 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27825687&#34; target=&#34;_blank&#34;&gt;Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients had a preoperative diagnosis of epithelial subtype, of which 17 proved to be of mixed histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27835874&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological examination of pleural lesions is the gold standard of MPM diagnosis, although it is sometimes hard to discriminate the epithelioid type of MPM from benign mesothelial hyperplasia (MH). […] This work aims to define a new molecular tool for the differential diagnosis of MPM, using the expression profile of 117 genes deregulated in this tumour.The gene expression analysis was performed by nanoString System on tumour tissues from 36 epithelioid MPM and 17 MH patients, and on 14 mesothelial pleural samples analysed in a blind way. […] The Uncorrelated Shrunken Centroid algorithm identified two classifiers, one including 22 genes and the other 40 genes, able to properly classify all the samples as benign or malignant using gene expression data; both classifiers were also able to correctly determine, in a blind analysis, the diagnostic categories of all the 14 unknown samples.In conclusion we delineated a diagnostic tool combining molecular data (gene expression) and computational analysis (USC algorithm), which can be applied in the clinical practice for the differential diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27880851&#34; target=&#34;_blank&#34;&gt;Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural biopsy using flex-rigid pleuroscopy and pleural effusion cell block analysis are both useful for diagnosis of malignancy and obtaining adequate samples. […] The purpose of our study was to compare the diagnostic utility between the two methods among patients with malignant pleural disease with effusion. […] Data from patients who underwent flex-rigid pleuroscopy for diagnosis of pleural effusion suspicious for malignancy at the National Cancer Center Hospital, Japan between April 2011 and June 2014 were retrospectively reviewed. […] The diagnostic yield was significantly higher by pleural biopsy than by cell block [94.2% (33/35) vs. […] Pleural biopsy using flex-rigid pleuroscopy was efficient in the diagnosis of malignant pleural diseases. […] Flex-rigid pleuroscopy with pleural biopsy and pleural effusion cell block analysis should be considered as the initial diagnostic approach for malignant pleural diseases presenting with effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27884852&#34; target=&#34;_blank&#34;&gt;Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An accurate, non-invasive diagnostic biomarker would allow early specialist referral, limit diagnostic delays and maximise clinical trial access. […] DIAPHRAGM (Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma) is a suitably powered, multicentre, prospective observational study designed to determine whether these markers provide clinically useful diagnostic and prognostic information.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27900005&#34; target=&#34;_blank&#34;&gt;Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this context, the identification of early biomarkers useful for the diagnosis of cancer is mandatory. […] Fibulin-3 represents an important marker for the diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27900083&#34; target=&#34;_blank&#34;&gt;Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histopathological examination confirmed the diagnosis of epithelioid malignant mesothelioma. […] Thus, an early definitive diagnosis and timely treatment are crucial for the management of PMPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27903668&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic approaches are reviewed, including imaging techniques and the role of various biomarkers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27932892&#34; target=&#34;_blank&#34;&gt;The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Over the past two decades as surgical techniques have been refined and survival data with EPP in large case series have been reported, the paradigm has evolved toward the use of lung-sparing pleural resections such as pleurectomy/decortication (P/D) and extended P/D.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27993826&#34; target=&#34;_blank&#34;&gt;Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of malignant mesothelioma associated with minimal change disease and acute tubular necrosis secondary was then made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/27997741&#34; target=&#34;_blank&#34;&gt;Advances in pleuroscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To describe the technique of pleuroscopy, its clinical uses such as diagnosis of exudative pleural effusion, treatment of pleural infection, treatment of pneumothorax, and diagnosis and pleurodesis of malignant pleural mesothelioma. […] Also to describe the newer techniques developed such as minothoracoscopy, semirigid thoracoscopy, narrow band imaging pleuroscopy, infrared pleuroscopy, autofluorescence pleuroscopy. […] Newer techniques, such as narrow band imaging thoracoscopy, infrared thoracoscopy, autofluorescence thoracoscopy are offering a promising future for medical thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28002541&#34; target=&#34;_blank&#34;&gt;Distinction between mesothelioma and lung adenocarcinoma based on immunohistochemistry in a patient with asbestos bodies in bronchoalveolar fluid - case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The positive diagnosis of asbestos exposure was facilitated by asbestos bodies determined in bronchoalveolar lavage fluid. […] An accurate morphologic and immunohistochemistry assessment of a pleural biopsy sample excluded mesothelioma and was crucial in the positive diagnosis of adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28003826&#34; target=&#34;_blank&#34;&gt;Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since no other mesodermal tissue was affected, a diagnosis of primary malignant pericardial mesothelioma was made. […] Chemotherapy was not effective and she passed away a year after the diagnosis was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28007619&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are few effective treatment options for mesothelioma, and patients have a very poor prognosis with a median survival of &amp;lt; 12 months from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28007630&#34; target=&#34;_blank&#34;&gt;Improving the Accuracy of Mesothelioma Diagnosis in China.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we review the accuracy of MM diagnoses in China and provide suggestions to improve the accuracy of diagnosis. […] We reviewed 92 pathological diagnosis of MM in 2002-2015 from two reference centers in the province of Zhejiang in eastern China. […] We performed a large set of immunohistochemistry analyses to increase the reliability of the diagnosis. […] We confirmed the MM diagnosis in 12 of 34 of the pleural tumors (35.3%), in 38 of 56 of the peritoneal tumors (67.9%), and in two of two of the MMs of the tunica vaginalis (100%). […] Identifying pitfalls and possible solutions in the pathological diagnosis of MM will affect both the standard of care and research in China.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28024110&#34; target=&#34;_blank&#34;&gt;The importance of EZH2 and MOC-31 expression in the differential diagnosis of benign and malignant effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
MOC-31 and EZH2 were applied to the cell blocks of 53 patients with benign cytology and 89 patients with malignant cytology determined based on the clinical, radiological data, histopathology diagnosis, and clinical follow-up in the absence of any surgical material of the patient in the hospital archive system. […] In conclusion, it could be considered cost-effective to use a double immunohistochemical antibody kit for these two markers, MOC-31 membranous and EZH2 nuclear staining, in the diagnosis of malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28024694&#34; target=&#34;_blank&#34;&gt;The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients followed a standard diagnostic algorithm. […] The diagnostic performance of CT (overall and based on the above factors) was assessed using 2×2 Contingency Tables. 30/345 (9%) eligible patients were excluded (non-contrast (n=13) or non-contiguous CT (n=4), incomplete follow-up (n=13)). 195/315 (62%) patients studied had PM; 90% were cyto-histologically confirmed. 172/315 (55%) presented as an acute admission, of whom 31/172 (18%) had CTPA. […] The diagnostic performance of CT in routine clinical practice is insufficient to exclude or confirm PM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28026144&#34; target=&#34;_blank&#34;&gt;Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracic X-ray and computed tomography were the imaging techniques most employed for diagnosis and surgical planning. […] The pathological diagnosis was obtained by examination of surgical or biopsy specimens in most cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28027772&#34; target=&#34;_blank&#34;&gt;Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, there is no consensus on the most suitable diagnostic technique/parameters for assessing response to chemotherapy in malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28031827&#34; target=&#34;_blank&#34;&gt;Pemetrexed for epithelioid haemangioendothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, a diagnosis of epithelioid hemangioendothelioma (EHE) was made, and chemotherapy with carboplatin, pemetrexed, and bevacizumab was initiated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28034829&#34; target=&#34;_blank&#34;&gt;BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Taking advantage of the extensive French National Network for the Diagnosis of Malignant Pleural Mesothelioma and Rare Peritoneal Tumors and the French National Network for the Treatment of Rare Peritoneal Surface Malignancies, we collected biological material and clinical and epidemiological data for 46 patients with peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28038708&#34; target=&#34;_blank&#34;&gt;Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to analyze p16/CDKN2A deletions in mesotheliomas by fluorescence in situ hybridization (FISH) and BAP1 immunohistochemistry to evaluate their potential role in the diagnosis of biphasic mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2803935&#34; target=&#34;_blank&#34;&gt;Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study no diagnostic cytogenetic markers of mesothelioma were found, instead the copy number of chromosome 7 short arms turned out to be a possible prognostic factor in malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2804773&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma–analysis of 12 cases in Chang-Gung Memorial Hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Definitive diagnosis was obtained in 10 cases by thoracotomy (83%). […] The diagnostic yield is 40% for pleural biopsy, and 100% for thoracotomy. […] Bronchoscopic examination, percutaneous biopsy, and pleural effusion analysis were useless in making a definitive diagnosis and distinguishing from metastatic adenocarcinoma in our opinions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-11-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28050426&#34; target=&#34;_blank&#34;&gt;Pleural Mesothelioma with No Asbestos Exposure: A Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of pleural mesothelioma is often done at an advanced stage of the disease because of the lack of specific clinical and radiological signs differentiating it from any malignant pleural effusion. […] The absence of an explicit asbestos exposure is another diagnosis problem. […] The diagnosis of MPM was confirmed after pathology study of the biopsies obtained by video assisted thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28054314&#34; target=&#34;_blank&#34;&gt;Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore clinical outcome of patients with MPM is poor and median survival time of untreated patients with MPM is 7 months from initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28066660&#34; target=&#34;_blank&#34;&gt;Flex-rigid pleuroscopic biopsy with the SB knife Jr is a novel technique for diagnosis of malignant or benign fibrothorax.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An adequate sample is crucial for the differential diagnosis of malignant fibrothorax (malignant pleural mesothelioma, metastatic lung carcinoma, etc.) from benign fibrothorax (benign asbestos pleural disease, tuberculous pleuritis, etc.). […] Novel biopsy techniques are required in flex-rigid pleuroscopy to improve the sample size and quality. […] The biopsies were successful, with sufficient size and quality for definitive diagnosis. […] Electrosurgical biopsy with the SB knife Jr during flex-rigid pleuroscopy allowed us to obtain adequate samples for the diagnosis of malignant versus benign fibrothorax, which is usually not possible with SFF.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2809310&#34; target=&#34;_blank&#34;&gt;[Problems of diagnosis and surgical treatment in pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The remaining 3 patients, who did not have the diagnosis preoperatively, died of cardio-pulmonary insufficiency due to local compression by the huge tumor at 3 months, 7 months and 2 years respectively after the exploratory thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28103581&#34; target=&#34;_blank&#34;&gt;Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study sought to evaluate the diagnostic and prognostic efficacies of humoral fibulin-3 for MPM. […] Seven eligible publications comprising 468 MPM cases for diagnosis, and 138 for prognosis were identified. […] Taken together, fibulin-3 confers a relatively high diagnostic efficacy and is acceptable to be an auxiliary biomarker to aid in MPM identification.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28105159&#34; target=&#34;_blank&#34;&gt;Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Due to a suspected diagnosis of ‘acute abdomen’, an emergency small intestine resection was performed and a subsequent diagnosis of moderately-differentiated adenocarcinoma was confirmed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28112486&#34; target=&#34;_blank&#34;&gt;Pleural fluid cytology samples in cases of suspected lung cancer: An experience from a tertiary care centre.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytomorphology of conventional smears was combined with LBC smears and a cytomorphological diagnosis was offered. […] Cytomorphology was evaluated in all the 86 cases and IHC was used to refine the cytomorphological diagnosis. […] A diagnosis of adenosquamous carcinoma was suspected in five cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-02-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28128276&#34; target=&#34;_blank&#34;&gt;MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological diagnosis of sarcomatoid mesothelioma largely depends on the histomorphological feature of spindled tumor cells with immunohistochemical reactivity to cytokeratins. […] Diagnosis also requires clinico-radiological and/or macroscopic evidence of an extrapulmonary location to differentiate it from lung sarcomatoid carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28130567&#34; target=&#34;_blank&#34;&gt;Malignant pericardial mesothelioma : A systematic review of current practice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study is a review of the literature published in recent decades focusing on the advances in clinical manifestations, radiological findings, diagnosis, differential diagnosis, and treatment of malignant pericardial mesothelioma (MPM). […] The definitive diagnosis is made on the basis of pathological findings. […] Chest radiography and echocardiography are common techniques used initially, but their roles are limited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28138725&#34; target=&#34;_blank&#34;&gt;A Single-Institution Experience in Percutaneous Image-Guided Biopsy of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma has been considered a difficult pathologic diagnosis to achieve via image-guided core needle biopsy. […] The purpose of this study was to assess the diagnostic sensitivity of percutaneous image-guided biopsy for diagnosis of pleural mesothelioma. […] Retrospective review was performed to identify patients with a confirmed diagnosis of pleural mesothelioma and who underwent image-guided needle biopsy between January 1, 2002, and January 1, 2016. […] Percutaneous image-guided biopsy can achieve high sensitivity for pathologic diagnosis of pleural mesothelioma with a low procedural complication rate, potentially obviating need for surgical biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28152555&#34; target=&#34;_blank&#34;&gt;Stent Implantation for Superior Vena Cava Syndrome of Malignant Cause.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There was no histological diagnosis in 7 cases (4.9 %).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2817912&#34; target=&#34;_blank&#34;&gt;[A case of remission induced in diffuse pleural malignant mesothelioma by the treatment with cisplatin and doxorubicin].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was made by pleural needle biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28182302&#34; target=&#34;_blank&#34;&gt;Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Podoplanin (PDPN) is an established diagnostic marker for MPM, but the function of PDPN in MPM is not fully understood. […] These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/281850&#34; target=&#34;_blank&#34;&gt;Monosomy 14, monosomy 22 and 13q–three chromosomal abnormalities observed in cells of two malignant mesotheliomas studied by banding techniques.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two malignant mesotheliomas were studied by banding techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28196068&#34; target=&#34;_blank&#34;&gt;Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Demographics, diagnosis method, MM subtype and survival were extracted from the Western Australia (WA) Mesothelioma Registry, which records details of all MM cases occurring in WA. […] Those with a cytology-only diagnosis were older than the histology group (median 70.2 vs 67.6 years, P&amp;lt;0.001), but median survival was similar (cytology 10.6 (5.5-19.2) vs histology 11.1 (4.8-19.8) months, P=0.727) and Cox regression modelling adjusting for age, sex, site and time since first exposure showed no difference in survival between the different diagnostic approaches. […] A diagnostic tap should be considered adequate to diagnose epithelioid MM without need for further invasive testing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28197385&#34; target=&#34;_blank&#34;&gt;Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To characterize the TME and the immune checkpoint expression profile, we performed immunohistochemistry (IHC) on formalin-fixed paraffin embedded (FFPE) tissue sections from 54 MPM patients (40 at time of diagnosis; 14 treated with chemotherapy).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28197626&#34; target=&#34;_blank&#34;&gt;Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients, however, die within 24 months of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28210162&#34; target=&#34;_blank&#34;&gt;Modern management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Historically, obtaining a pathologic diagnosis of MPM was challenging, but with current pathological techniques, a secure diagnosis is possible in the majority of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28213009&#34; target=&#34;_blank&#34;&gt;Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Detection of homozygous deletion (HD) of 9p21 region including p16&lt;sup&gt;INK4A&lt;/sup&gt; (p16) by fluorescence in situ hybridization (FISH) and immunohistochemical detection of loss of BRCA1 associated protein 1 (BAP1), are reliable markers for MPM diagnosis. […] The diagnostic usefulness of IHC of the 9p21.3-related proteins and BAP1 and their combinations was assessed using the cut-off values set by receiver operating characteristic (ROC) analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28237609&#34; target=&#34;_blank&#34;&gt;Radiation therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel radiation treatment techniques, such as intensity modulated radiation therapy (IMRT) were introduced, but the early experience with IMRT demonstrated troubling toxicity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28245530&#34; target=&#34;_blank&#34;&gt;Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The inclusion criteria were as follows: PF cytology, reported appearance of macroscopic pleural invasion during thoracoscopy and malignant diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28248731&#34; target=&#34;_blank&#34;&gt;Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although diagnosis is based on morphologic features, immunohistochemical stains such as Calretinin, WT-1, CK-5/6, D2-40, Ber-Ep4, and MOC-31 are routinely used. […] A diagnosis of atypical mesothelial proliferation with aberrant CK20 expression was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28271362&#34; target=&#34;_blank&#34;&gt;Mesothelioid reaction following talc pleurodesis: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A mesothelioid reaction should be included in the differential diagnosis in patients with pleural thickening/pleural plaque formation who have previously been treated with talc pleurodesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28272659&#34; target=&#34;_blank&#34;&gt;Non-Hodgkin Lymphoma and Pleural Mesothelioma in a Person Exposed to Asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Four years after the diagnosis of lymphoma, she presented with a left pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28293123&#34; target=&#34;_blank&#34;&gt;Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The initial approval and subsequent studies of pembrolizumab required and utilized a companion diagnostic test, Dako’s IHC 22C3, to assess PD-L1 status of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28314308&#34; target=&#34;_blank&#34;&gt;Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the literature, there exist conflicting data on the value of fibulin-3 (FBLN3) for the diagnosis of pleural effusion (PE) in malignant pleural mesothelioma (MPM). […] Therefore we compared the diagnostic performance of FBLN3 against that of soluble mesothelin-related peptide (SMRP) in a cohort of Italian patients. […] FBLN3 detection in PE, in contrast to SMRP detection, is not useful as a biomarker for the diagnosis of PE from MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28335760&#34; target=&#34;_blank&#34;&gt;Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. […] Combination of both biomarkers did not improve the differential diagnostic efficacy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28343162&#34; target=&#34;_blank&#34;&gt;Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin-related peptide (SMRP) is a promising diagnostic biomarker for malignant pleural mesothelioma (MPM), but various confounders hinder its usefulness in surveillance programmes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28348450&#34; target=&#34;_blank&#34;&gt;A Novel Panel of Serum Biomarkers for MPM Diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to the identification of new serum markers in the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28348451&#34; target=&#34;_blank&#34;&gt;Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the diagnostic value of HMGB1 for benign and malignant asbestos-related diseases (ARDs) remains unclear. […] In this work, we detected preoperative serum HMGB1 levels in Chinese asbestos-exposed (AE) and ARDs populations and further evaluated the diagnostic value of HMGB1 in patients with certain types of ARDs, including those with pleural plaques, asbestosis, or malignant mesothelioma (MM). […] Thus, our study provides supporting evidence for HMGB1 as a potential biomarker either for the clinical diagnosis of high-risk AE cohorts or for evaluating ARDs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28351431&#34; target=&#34;_blank&#34;&gt;A second case of pericardial mesothelioma mimicking systemic lupus erythematosus in the literature in over 30 years: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinicians should consider malignant mesothelioma in the differential diagnosis of pericardial effusion, especially when it is recurrent and not clearly explained by other causes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-06-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28377727&#34; target=&#34;_blank&#34;&gt;Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early detection of MPM is restricted by the long latency period until clinical presentation, the ineffectiveness of imaging techniques in early stage detection and the lack of non-invasive biomarkers with high sensitivity and specificity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28399779&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Vast majority of our 101 patients were male (80%) with a median age of 66 years at diagnosis with predominantly epitheloid histology (81%). […] Smoking at diagnosis and epitheloid histology have been identified as significant prognostic factors in the multivariate Cox regression model (HR 3.13 and 0.53, respectively).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28403901&#34; target=&#34;_blank&#34;&gt;CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Biomarkers that are detectable in pleural effusion or patient serum are reasonable options to provide a faster and noninvasive diagnostic approach. […] In particular, the high expression levels of these molecules have shown diagnostic relevance in MPM. […] This review will summarize the biology and diagnostic implication of CD44 and HA as well as the interaction of both molecules in MPM that will demonstrate their potential as biomarkers. […] Augmentation of the current markers in MPM may lead to an earlier diagnosis and management of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28426469&#34; target=&#34;_blank&#34;&gt;Prophylactic radiotherapy for procedure tract metastases in mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The majority of patients require pleural procedures for diagnostic or fluid management purposes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28434856&#34; target=&#34;_blank&#34;&gt;Can CT and MR Shape and Textural Features Differentiate Benign Versus Malignant Pleural Lesions?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic accuracy of radiologists was determined using contingency tables. […] The CT model was compared to the diagnostic confidence of all radiologists and the model outperformed both abdominal radiologists (P &amp;lt; 0.002), whereas the top discriminative MR model outperformed one of the abdominal radiologists (P = 0.02). […] A radiomics-based approach may increase diagnostic confidence of abdominal radiologists on CT and MR and may potentially improve radiologists’ accuracy in the assessment of pleural lesions characterized by MR.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28446737&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma in doll manufacture: possible asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From the Province of Brescia Mesothelioma Registry, established in 1993 on population-based criteria, we have extracted the certified mesothelioma diagnosis cases, related to patients who were employed for some time in doll manufacture.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28449331&#34; target=&#34;_blank&#34;&gt;miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Appropriate immunohistochemistry (IHC) is required to support the diagnosis. […] MicroRNA (miRNA) expression analysis could be a viable diagnostic tool for distinguishing between these tumors. […] The purpose of the current study was to assess the reliability of miRNAs as diagnostic markers to differentiate epithelioid malignant mesothelioma (MM) from lung AdC. […] These were analyzed by quantitative polymerase chain reaction on histologic (41 MM cases and 40 lung AdC cases) and cytological (26 MM cases and 27 lung AdC cases) specimens and the diagnostic performances were assessed. miR-130a, miR-193a, miR-675, miR-141, miR-205, and miR-375 were found to be the best distinguishing markers. […] The diagnostic performances of miR-130a expression analysis and IHC appear to be similar. miR-130a quantification could be used reliably as second-level diagnostic tool to differentiate MM from lung AdC in pleural effusion cytology, mainly in those cases with ambiguous or negative IHC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28460459&#34; target=&#34;_blank&#34;&gt;Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelin immunohistochemistry may assist the differential diagnosis of thymoma vs. thymic carcinoma as well as prognostication of mesothelioma patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28469343&#34; target=&#34;_blank&#34;&gt;Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic workup revealed advanced DMPM. […] Although the intent behind systemic treatment was at first solely palliative, overall survival after the initial diagnosis was 50 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28472171&#34; target=&#34;_blank&#34;&gt;Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Specific diagnostic markers for early MPM diagnosis are needed. […] Larger and prospective studies are needed to confirm these two-miRNA signature alone or in combination with other biomarkers as diagnostic tools for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28474658&#34; target=&#34;_blank&#34;&gt;Spontaneous massive hemopneumothorax: Double trouble with a twist.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural fluid analysis revealed frank blood and was consistent with the diagnosis of hemothorax. […] As the patient had a normal chest X-ray 3 days ago, thoracoscopic pleural biopsy was taken which confirmed the diagnosis of an epithelioid mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28481375&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma in household members of asbestos-exposed workers in Friuli Venezia Giulia, Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In all cases the diagnosis of mesothelioma was based on the pathology report. […] The mean age at diagnosis was 77 years old.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28493096&#34; target=&#34;_blank&#34;&gt;Multiple malignant epithelioid mesotheliomas of the liver and greater omentum: a case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The final pathological diagnosis was low-grade multiple malignant epithelioid mesothelioma based on characteristic immunohistochemical findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28517082&#34; target=&#34;_blank&#34;&gt;SU-E-T-595: Comparison of Volumetric Modulated Arc Therapy (VMAT) and Static Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma in Patients with Intact Lungs/Post Pleurectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Both VMAT and IMRT are feasible techniques for the treatment of malignant pleural mesothelioma with intact lungs, with less MU and a shorter delivery time for VMAT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28528059&#34; target=&#34;_blank&#34;&gt;Diode-Pumped Laser for Lung-Sparing Surgical Treatment of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Innovative surgical techniques are therefore required to enable salvage of the lung parenchyma and optimization of surgical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28558669&#34; target=&#34;_blank&#34;&gt;Calretinin as a blood-based biomarker for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular markers like calretinin and mesothelin are promising tools to improve and supplement the diagnosis of MM and warrant further validation in a prospective study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28559943&#34; target=&#34;_blank&#34;&gt;Unusual Contiguous Soft Tissue Spread of Advanced Malignant Mesothelioma Detected by FDG PET/CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis, staging and restaging of MPM are crucial with [18F] flurodeoxy-D-glucose positron emission tomography (FDG PET/CT) playing an increasingly important role.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28577209&#34; target=&#34;_blank&#34;&gt;Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is a lack of robust and clinically utilizable markers for the diagnosis and prognostication of malignant pleural mesothelioma (MPM). […] This research was aimed at optimizing and exploring novel approaches to improve the diagnosis and prognostication of MPM in pleural effusions and peripheral blood samples.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28590338&#34; target=&#34;_blank&#34;&gt;Surgery as part of radical treatment for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New imaging techniques can be utilized to assess tumour volume.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28600498&#34; target=&#34;_blank&#34;&gt;Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In order to broaden the knowledge in this field, the miRNA expression was investigated in a large series of MPM to discover new pathways helpful in diagnosis, prognosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28611824&#34; target=&#34;_blank&#34;&gt;Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Calretinin (CALB2) is a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28614203&#34; target=&#34;_blank&#34;&gt;GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We conclude that strong diffuse staining for GATA3 favors a diagnosis of sarcomatoid/desmoplastic malignant mesothelioma over metastatic sarcomatoid carcinoma of the lung; conversely, complete absence of GATA-3 staining is evidence against a diagnosis of sarcomatoid/desmoplastic malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28634559&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In both cases, a histopathological examination of the pleura confirmed the diagnosis of epithelioid malignant mesothelioma. […] Although this growth pattern is unusual, malignant pleural mesothelioma should be considered as the differential diagnosis, especially in patients with pleural lesions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28638620&#34; target=&#34;_blank&#34;&gt;Chest pain and recurrent chylothorax: an unusual presentation of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was made on pleural biopsy via video-assisted thoracoscopic surgery (VATS). […] Our case demonstrates the utility of thoracic magnetic resonance imaging (MRI) and the difficulties associated with pleural cytology and cervical lymph node biopsy in the establishment of a diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28656381&#34; target=&#34;_blank&#34;&gt;Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
They were classified into three groups according to their final diagnosis: malignant, paramalignant and benign pleural effusion. […] The data herein suggest that the identified predictor values applied to tree diagrams, which required no extraordinary measures, have a higher rate of correct identification of malignant, paramalignant and benign effusions when compared to techniques available today and proved most useful for usual clinical practice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28680295&#34; target=&#34;_blank&#34;&gt;Risk Factors of Mortality from All Asbestos-Related Diseases: A Competing Risk Analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The incidence rate after diagnosis was 3,600 per 100,000 person-years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28686500&#34; target=&#34;_blank&#34;&gt;Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ul&gt;
&lt;li&gt;Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. - To provide updated, practical guidelines for the pathologic diagnosis of MM. - Pathologists involved in the International Mesothelioma Interest Group and others with an interest and expertise in the field contributed to this update. […] Reference material included up-to-date, peer-reviewed publications and textbooks. - There was discussion and consensus opinion regarding guidelines for (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) recognition of the key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid MM, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. […] Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels employed is dependent on the differential diagnosis and on the antibodies available in a given laboratory. […] Depending on the morphology, immunohistochemical panels should contain both positive and negative markers for mesothelial differentiation and for lesions considered in the differential diagnosis. […] These guidelines are meant to be a practical diagnostic reference for the pathologist; however, some new pathologic predictors of prognosis and response to therapy are also included.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706898&#34; target=&#34;_blank&#34;&gt;The impact of surgical approach on quality of life for pleural malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two studies directly compared QoL outcomes between the two techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706900&#34; target=&#34;_blank&#34;&gt;Extrapleural pneumonectomy (EPP) &lt;i&gt;vs.&lt;/i&gt; pleurectomy decortication (P/D).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical techniques for treatment of malignant pleural mesothelioma (MPM) have improved over the decades.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706904&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is very rare and has been linked to toxic exposure to industrial pollutants, especially asbestos. […] We will review the epidemiology of MPM and discuss diagnostic and treatment strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28706912&#34; target=&#34;_blank&#34;&gt;Diagnosis and prognosis-review of biomarkers for mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is a serious need for improvement in prognostic and diagnostic tools for MPM. […] In this review, we explore these current major biomarkers and their prognostic and diagnostic potential, highlighting the most recent large studies and developments for each.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28713677&#34; target=&#34;_blank&#34;&gt;Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Novel radical radiation techniques using intensity modulated radiation therapy (IMRT) have become an important component of therapy in mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28714265&#34; target=&#34;_blank&#34;&gt;Can malignant and inflammatory pleural effusions in dogs be distinguished using computed tomography?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To identify CT signs that could be used to distinguish pleural malignant neoplasia from pleuritis, a retrospective case-control study was done based on dogs that had pleural effusion, pre- and postcontrast thoracic CT images, and cytological or histopathological diagnosis of malignant or inflammatory pleural effusion. […] Although there was considerable overlap in findings in dogs with malignant pleural effusion and pleuritis, marked thickening affecting the parietal pleural alone and signs of thoracic wall invasion on CT support diagnosis of pleural malignant neoplasia, and may help prioritize further diagnostic testing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28757678&#34; target=&#34;_blank&#34;&gt;MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The identification of diagnostic/prognostic biomarkers for asbestos-related diseases is relevant for early diagnosis and patient survival and may contribute to understanding the molecular mechanisms underlying the disease development and progression. […] To identify a pattern of miRNAs as possible diagnostic biomarkers for patients with malignant pleural mesothelioma (MPM) and asbestosis (ASB) and as prognostic biomarkers for MPM patients. miRNA-16, miRNA-17, miRNA-126, and miRNA-486 were quantified in plasma and formalin-fixed paraffin-embedded samples to evaluate their diagnostic and prognostic roles compared to patients with other noncancerous pulmonary diseases (controls).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28778184&#34; target=&#34;_blank&#34;&gt;Diagnostic value of medical thoracoscopy in malignant pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aimed to assess the diagnostic significance of thoracoscopy in the management of patients with malignant pleural effusion (MPE).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28782639&#34; target=&#34;_blank&#34;&gt;The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were insufficient data to evaluate the differential diagnosis between SPC and localized SMM or peritoneal SMM. […] Best available evidence was used to formulate several evidence-based guidelines for the differential diagnosis between pleural SMM and SPC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28789867&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma segmentation for photodynamic therapy planning.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical imaging modalities such as computed tomography (CT) combined with computer-aided diagnostic processing have already become important part of clinical routine specially for pleural diseases. […] First, the rib cage structure is segmented using various image processing techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28800180&#34; target=&#34;_blank&#34;&gt;Epithelioid malignant mesothelioma metastatic to the skin: A case report and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, upon review of his medical history and immunohistochemical evaluation of the lesion, the diagnosis of epithelioid MM metastatic to the skin was rendered. […] The purpose of this case report and review of the literature is to summarize the most effective available immunostains to aid in the diagnosis of this challenging entity, highlight the histologic similarities between metastatic epithelioid MM and other primary and metastatic neoplasms of the skin, and provide prognostic information for these rare tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28801410&#34; target=&#34;_blank&#34;&gt;Radiographic features of importance in the National Institute for Occupational Safety and Health-administered Coal Workers’ Health Surveillance Program: characterising the use of the ‘other symbols’.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Other symbols are not meant to imply a diagnosis or interpretation but are relevant as they provide information beyond a pneumoconiosis classification for features related to dust exposure and other aetiologies. […] While these symbols are not diagnostic they can be used to describe features associated with dust exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28810297&#34; target=&#34;_blank&#34;&gt;[Clinical and pathologic features of extrapleural sarcomatoid mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Objective:&lt;/b&gt; To investigate the morphological features, diagnosis and differential diagnosis of extrapleural sarcomatoid malignant mesothelioma (SMM). &lt;b&gt;Methods:&lt;/b&gt; Six cases of extrapleural SMM were evaluated for their clinical, histological, immunohistochemical features, and prognosis. &lt;b&gt;Results:&lt;/b&gt; Patients included 3 men and 3 women, with a median age of 60 years (range 41-75 years). […] The Ki-67 proliferation indexes ranged from 25% to 55%, consistent with the diagnosis of malignant mesothelioma of the sarcomatous type. […] Local recurrence or metastasis was seen in 1 case and 4 cases, respectively, after surgery, and all the patients died of the disease within 9 months. &lt;b&gt;Conclusions:&lt;/b&gt; Extrapleural SMM, although rare, should be considered as a differential diagnosis among other benign or malignant sarcomatoid tumors and sarcomas. […] Along with clinical and radiological presentation, the combination of broad-spectrum cytokeratin, vimentin, and a series of mesothelial markers are useful for diagnosis of SMM. &lt;b&gt;目的：&lt;/b&gt; 探讨胸膜外肉瘤样恶性间皮瘤临床病理特点、诊断及鉴别诊断。
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28831280&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma - Pleural cavity irradiation after decortication with helical tomotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In addition to clinical and diagnostic findings from regular follow-up examinations, we evaluated the dose distribution for other organs at risk to assess treatment in relation to toxicity, with special regard for the underlying intact lung.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28838385&#34; target=&#34;_blank&#34;&gt;Chest ultrasonography in health surveillance of asbestos related pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
High resolution computed tomography, (HRCT), is currently considered the diagnostic gold standard to diagnose early stage malignant pleural mesothelioma and other non-malignant pleural conditions, but it is expensive and exposes the patient to radiation dose.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28843362&#34; target=&#34;_blank&#34;&gt;National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Procedure type was influenced by sociodemographic and geographical factors, without observed differences in survival or postoperative mortality and readmission rates between techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28845826&#34; target=&#34;_blank&#34;&gt;Diagnostic Imaging and workup of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this paper is to describe the imaging features of this malignancy, underlining the peculiarity of CXR, CT, MRI, PET-CT and US and also focusing on diagnostic workup, based on the literature evidence and according to our experience.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2884870&#34; target=&#34;_blank&#34;&gt;Accumulation of long asbestos fibers in the peripheral upper lobe in cases of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Amosite fibers were identified and sized by electron microscopic techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28855951&#34; target=&#34;_blank&#34;&gt;Migrating pleural plaque in a patient with asbestos induced pleural disease: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
False positive results may lead to unnecessary and often painful diagnostic interventions, which create high costs when applied to a large cohort and also may discredit the whole program.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28859932&#34; target=&#34;_blank&#34;&gt;The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Much of the literature consisted of low quality, retrospective data with small cohorts and inconsistent reporting on radiotherapy techniques and dosimetry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28860886&#34; target=&#34;_blank&#34;&gt;Clinical staging of malignant pleural mesothelioma: current perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis is usually made by thoracoscopy, which allows multiple biopsies with histological subtyping and is indicated for staging purposes in surgical candidates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28870611&#34; target=&#34;_blank&#34;&gt;Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this first-in-man, open-label, dose-escalation phase 1 trial at three major cancer centres in Sydney (NSW, Australia), we recruited adults (aged ≥18 years) with a confirmed diagnosis of malignant pleural mesothelioma, measurable disease, radiological signs of progression after previous chemotherapy, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of 3 months or more, immunohistochemical evidence of tumour EGFR expression, and adequate bone marrow, liver, and renal function.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28881848&#34; target=&#34;_blank&#34;&gt;Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis of malignant pleural mesothelioma (MPM) is a challenge for clinicians. […] Many efforts have already been made to find suitable biomarkers in blood and pleural effusions, but have not yet resulted in a valid and reproducible diagnostic one.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28884702&#34; target=&#34;_blank&#34;&gt;Radiotherapy for the treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Over the past 15 years, the development of new, highly conformal radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT), has enabled investigators to optimise the delivery of high-dose radiotherapy to the whole of the hemithorax.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28885355&#34; target=&#34;_blank&#34;&gt;Secondary hypertrophic osteoarthropathy caused by non-pleural or pulmonary tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 14 patients (46.7%), HOA was symptomatically before a tumor diagnosis was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28889523&#34; target=&#34;_blank&#34;&gt;The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients die of disease within 1 year of diagnosis, but some have prolonged survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28900718&#34; target=&#34;_blank&#34;&gt;Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural effusions (MPE) may either coincide with or follow the diagnosis of a primary tumor. […] Retrospective review of all consecutive patients who were cared for at a Spanish university hospital during an 11-year period and received a diagnosis of MPE. […] In hematological and ovarian malignancies, the synchronous or metachronous diagnosis of MPE may have prognostic implications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28920252&#34; target=&#34;_blank&#34;&gt;Role of new radiation techniques in the treatment of pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of modern sophisticated techniques allows good target coverage, more conformal high dose delivery, and clinically relevant normal tissue sparing.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28922567&#34; target=&#34;_blank&#34;&gt;Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
PD-L1 expression was determined by a commercially available antibody (clone 28-8) in 74 formalin-fixed, paraffin-embedded cell blocks from body effusions obtained at diagnosis from patients with MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28932538&#34; target=&#34;_blank&#34;&gt;The value of delayed phase enhanced imaging in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since accurate staging is vital optimal choice of therapy, techniques that optimize pleural imaging are needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28964420&#34; target=&#34;_blank&#34;&gt;Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients undergoing surgical resection of malignant pleural mesothelioma (MPM) will experience recurrence, and radiographic diagnosis of recurrence can be difficult in the postoperative chest.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28986649&#34; target=&#34;_blank&#34;&gt;[Mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Especially, the pathohistological differentiation between atypical reactive mesothelial proliferation from malignant mesothelioma is a diagnostic challenge.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/28994508&#34; target=&#34;_blank&#34;&gt;Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The important diagnostic challenge facing the cytopathologist is whether a mesothelial proliferation on effusions represents a malignant mesothelioma (MM) or a benign mesothelial hyperplasia (MH). […] Here, we evaluated the diagnostic utility of BAP1 immunohistochemistry (IHC) in distinguishing between reactive and neoplastic mesothelial cells. […] In pleural and peritoneal effusions from 147 patients with diagnosed MM or with a differential diagnosis of MM and MH, the expression of BAP1 was examined by IHC on paraffin-embedded cell blocks (n = 121) and biopsies (n = 44). […] All BAP1-negative cases with a differential diagnosis of benign and malignant mesothelial proliferations were MM at follow-up. […] In effusions with mesotheliomatous cells or atypical mesothelial cells of uncertain significance, negative BAP1 IHC strongly supports a diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29029582&#34; target=&#34;_blank&#34;&gt;New Concepts in the Treatment of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The design of MMT and selection of patients are challenging, and optimal results require accurate presurgical diagnosis, staging, and risk stratification. […] Further, meticulous surgical techniques and advanced radiation protocols must be applied.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29048219&#34; target=&#34;_blank&#34;&gt;Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ul&gt;
&lt;li&gt;Diagnosis of malignant mesothelioma is more common in the chest than it is in the abdomen. […] Most published immunohistochemistry data are more applicable to pleural than to peritoneal mesothelioma. - To clarify the practical utility of 17 immunohistochemistry markers in the differential diagnosis of peritoneal mesothelioma with an emphasis on stains for which there is either contradictory information or a paucity of literature. - Consultation files of peritoneal mesothelioma diagnoses rendered from 1999 to 2014 were reviewed; 244 cases were identified. […] BAP1 loss, increasingly used in the differential diagnosis of benign versus malignant mesothelial proliferation, occured in 55% (99 of 181) of peritoneal mesothelioma cases. - The results support the experience that there is no definitive marker to rule out malignant mesothelioma, including PAX8, estrogen receptor, progesterone receptor, and p63 immunoreactivity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29049744&#34; target=&#34;_blank&#34;&gt;Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly: the need for an inclusive yet selective approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median age at diagnosis of patients with pleural mesothelioma in the UK is 73 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29050072&#34; target=&#34;_blank&#34;&gt;[Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Objective:&lt;/b&gt; To investigate the expression of BRCA-associated protein 1 (BAP1) in malignant mesothelioma, non-small cell lung cancer and carcinosarcoma, and its application in the differential diagnosis. &lt;b&gt;Methods:&lt;/b&gt; Twenty-two cases of malignant mesothelioma including 17 epithelioid type, 2 sarcomatoid type and 3 biphasic type were collected.As the study control, 80 non-small cell lung cancers infringement pleural membrane(including 40 lung adenocarcinomas and 40 lung squamous cell carcinomas) and 15 carcinosarcomas were included. […] A differential diagnosis antibody panel, including calretinin, WT1, CK5/6, D2-40, CAM5.2, CEA, TTF1, Napsin A, p63 and p40 was tested in all cases. &lt;b&gt;Results:&lt;/b&gt; All 80 cases of non-small cell lung cancer and 15 cases of carcinosarcoma were BAP1 positive. […] Addition of BAP1 to the mesothelioma marker panel, the diagnostic accuracy of malignant mesothelioma was enhanced to 93%. […] Focal expression of BAP1 in tumors suggested multiclonal evolution of mesothelioma. &lt;b&gt;Conclusions:&lt;/b&gt; Loss of BAP1 expression helps to confirm the diagnosis of malignant mesothelioma whereas all non-small cell lung cancer expresses BAP1. […] It is therefore recommended that BAP1 can be used in conjunction with other immunohistochemical markers to improve the diagnostic accuracy of malignant mesothelioma. &lt;b&gt;目的：&lt;/b&gt; 探讨BRCA相关蛋白1(BRCA associated protein 1，BAP1)在恶性间皮瘤、肺腺癌、肺鳞癌和癌肉瘤中表达情况及其在鉴别诊断中的作用。
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29053210&#34; target=&#34;_blank&#34;&gt;A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A combination of MTAP and BAP1 IHC in cell blocks from pleural effusions appears to be a reliable and useful method for differentiating MPM cells from RMC and can be used in the routine diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29059099&#34; target=&#34;_blank&#34;&gt;Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we describe the case of a 75-year-old man with stage IV epithelioid pleural mesothelioma, presenting with a cutaneous eruption 5 months after initial diagnosis, which revealed sarcomatoid features on skin biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29076876&#34; target=&#34;_blank&#34;&gt;Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this scenario, a diagnosis of atypical mesothelial proliferation might be rendered. […] Follow-up of 57.0 months was remarkable for visceral and parietal pleural thickening with continued unilateral effusion identified on imaging studies but no subsequent definitive diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29078517&#34; target=&#34;_blank&#34;&gt;Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here we discuss the role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of MPM patients prior to definite surgical resection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29085180&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis and accurate prognostication remain problematic. […] Pathologists should employ caution when commenting on prognostic implications of BAP1 status of MM patients in diagnostic pathology reports, but it may be useful for early diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29092096&#34; target=&#34;_blank&#34;&gt;Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because the IgE-mediated mechanism has never been demonstrated for pemetrexed, skin tests are not valid and have no diagnostic value for this molecule.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29100460&#34; target=&#34;_blank&#34;&gt;Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival rates are low as diagnosis often occurs at an advanced stage and current treatments are limited. […] Identifying new diagnostic and therapeutic targets for mesothelioma remains a priority, particularly for the new wave of victims exposed to asbestos through do-it-yourself renovations and in countries where asbestos is still mined and used. […] In this review, we highlight the current challenges associated with the diagnosis and treatment of mesothelioma and discuss how targeting miRNA may improve diagnostic, prognostic and therapeutic approaches.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29111830&#34; target=&#34;_blank&#34;&gt;Surgical and non-surgical management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Modification of VATS techniques has reduced the invasiveness and associated risks.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-05-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29112861&#34; target=&#34;_blank&#34;&gt;Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, late diagnosis means that mesothelioma research is commonly focused on end-stage disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29118480&#34; target=&#34;_blank&#34;&gt;Cytological Profile of a Case of Malignant Mesothelioma of Pleura with Supraclavicular Lymph Node Metastasis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we report a case of malignant mesothelioma of pleura in a 65-year-old quarry worker where the initial diagnosis was offered by fine needle aspiration of an enlarged supraclavicular lymph node. […] Subsequent pleural fine needle aspiration cytology (FNAC), tumor biopsy, and immunohistochemical analysis confirmed the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29129162&#34; target=&#34;_blank&#34;&gt;Mesothelioma in Australia: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a heterogeneous disease, partly explaining the limited role of biomarkers in screening and diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29137310&#34; target=&#34;_blank&#34;&gt;&lt;i&gt;Ex vivo&lt;/i&gt; evaluation of tumor cell specific drug responses in malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The two techniques produce similar results, indicating a possible use in personalized medicine.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29179896&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: Diagnosis, Staging, Pitfalls and Follow-up.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Imaging evaluation is essential in diagnosis, staging, and assessment of treatment response in malignant pleural mesothelioma. […] Knowledge of the full imaging spectrum of this rare disease, differential diagnosis, staging classification, and the current guidelines for diagnostic evaluation and follow-up are essential in accurate interpretation to optimize patient management.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29180928&#34; target=&#34;_blank&#34;&gt;The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Vascular endothelial growth factor (VEGF) is one of the parameters that has been studied in differential diagnosis of malignant fluids. […] This study is aimed at evaluate applicability of serum, fluid VEGF level and fluid to serum VEGF ratio in the diagnosis of malignant pleural mesothelioma (MPM). […] The VEGF fluid/serum ratio may be an applicable parameter in the differential diagnosis of malignant fluids, especially MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29184132&#34; target=&#34;_blank&#34;&gt;Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Strikingly, patients with low C4d levels at diagnosis had a significantly better overall survival, confirmed in a multivariate cox regression model (hazard ratio 0.263, p = 0.01).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29187476&#34; target=&#34;_blank&#34;&gt;A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, loss of BAP1 and no p16 homozygous deletion in the tumor cells led to the diagnosis of LHM, not a benign lesion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2017-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29200597&#34; target=&#34;_blank&#34;&gt;Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, little is known about the diagnostic efficacies of fibulin-3 for asbestos-related diseases (ARDs) in China.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2920599&#34; target=&#34;_blank&#34;&gt;Sudden death as the initial manifestation of diffuse pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall survival of patients from the time of diagnosis is six to 16 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29206890&#34; target=&#34;_blank&#34;&gt;Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of mesothelioma based on death certificate is subject to misclassification, which may bias the results of epidemiology studies. […] We searched medical and pathology records and specimens for 127 workers from a textile-asbestos factory in Italy who died during 1963-2013 with a diagnosis of pleural or peritoneal neoplasm or mesothelioma on death certificate, to confirm the diagnosis with immunohistochemistry markers. […] The diagnosis of mesothelioma was histologically confirmed for 35 cases (27.6%); 5 cases were classified as non-mesothelioma (3.9%), for 33 cases a mention of mesothelioma was found on record but no sufficient material was available for revision (26.0%); no records were available for 54 cases (death-certificate-only 42.5%). […] Diagnostic confirmation was not associated with sex, location of the neoplasm, age, or duration of employment; however, there was a significant association with time since first employment (P for linear trend 0.04).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29207669&#34; target=&#34;_blank&#34;&gt;Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Due to a long latency period between exposure and diagnosis, MPM incidence is expected to peak between 2020-2025.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29209316&#34; target=&#34;_blank&#34;&gt;Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These data can help develop novel diagnostic markers and molecular targets for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29228566&#34; target=&#34;_blank&#34;&gt;Targeting CXCR4 with [&lt;sup&gt;68&lt;/sup&gt;Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hence, robust cell surface expression should be confirmed prior to targeting this chemokine receptor for diagnosis and/or therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29241740&#34; target=&#34;_blank&#34;&gt;Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The Pax-8 protein is commonly used for differentiating peritoneal MM from serous carcinoma, but the diagnostic value of Pax-8 for distinguishing WDPM from borderline or low-grade serous tumors is unknown.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29248759&#34; target=&#34;_blank&#34;&gt;Asbestos fibre burden in gallbladder: A case study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In parallel, histological sections (prepared in the usual way for medical diagnosis) were analysed without digestion or manipulation of the sample using variable pressure SEM/EDS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29269563&#34; target=&#34;_blank&#34;&gt;The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Gender ratio by age class, period of diagnosis, diagnostic certainty, morphology and modalities of asbestos exposure has been analysed using exact tests for proportion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2927705&#34; target=&#34;_blank&#34;&gt;[Is malignant mesothelioma of the pleura only an occupational disease?].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural fluid cytology was only useful in the diagnosis of 2 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29282508&#34; target=&#34;_blank&#34;&gt;A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prognostic effects of variables, including age, sex, race, year of diagnosis, laterality, histology, tumor stage, surgery, chemotherapy, and radiotherapy were analyzed using Kaplan-Meier method and Cox proportional hazard model.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29312767&#34; target=&#34;_blank&#34;&gt;Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Subsequent tumor growth was slow, and the patient remained in good health, enabling her to remain physically active until shortly before her death 56 months after the initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29320805&#34; target=&#34;_blank&#34;&gt;Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single-centre experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Factors associated with unsuccessful pleurodesis (univariate analysis) were the presence of pleural adhesions (odds ratio (OR): 0.43 (95% CI: 0.19-0.96); P = 0.04), extensive spread of pleural lesions (OR: 0.17 (95% CI: 0.05-0.59); P = 0.001), the use of systemic corticosteroids (OR: 0.28 (95% CI: 0.10-0.83); P = 0.02) and a prolonged time period between the clinical diagnosis of the pleural effusion and the moment of pleurodesis (OR: 0.14 (95% CI: 0.06-0.32); P &amp;lt; 0.0001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29338319&#34; target=&#34;_blank&#34;&gt;Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
miRNAs may act as promising diagnostic and prognostic biomarkers of mesothelioma. […] The sensitivity of the combined chosen serum miRNAs reached 100% in the diagnosis of MPM. […] The current work revealed that sera miR-548a-3p and miR-20a may serve as promising novel diagnostic tools for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29341576&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous carcinoma of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pseudomesotheliomataus carcinoma of the lungs can be a diagnostic problem. […] Its diagnosis is based on recognition of histopathological characteristics which enable its discernment from the epithelial variant of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-02-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29346042&#34; target=&#34;_blank&#34;&gt;Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29350783&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in situ.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The existence of malignant mesothelioma in situ (MIS) is often postulated, but there are no accepted morphological criteria for making such a diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29354180&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma as a difficult interdisciplinary problem.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors of the present report review the etiology and clinical symptoms of malignant pleural mesothelioma (MPM) as well as diagnostic techniques (both radiological and biomarkers) used for its detection.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29355487&#34; target=&#34;_blank&#34;&gt;Mesothelioma With a Large Prevascular Lymph Node: N1 Involvement or Something Different?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histopathology confirmed the diagnosis of a ypT3N0M0 (stage IB) mesothelioma, and an unexpected thymoma type B2 (stage II) was discovered in the prevascular nodule.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29356044&#34; target=&#34;_blank&#34;&gt;Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Conversely, as it is also expressed in normal and reactive mesothelial cells, HMGB1 cannot be considered a diagnostic biomarker in histological samples of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29371938&#34; target=&#34;_blank&#34;&gt;Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Comparative genomic hybridization techniques and arrays demonstrated a complex set of copy number variations (CNVs) in the MPM-genome. […] These techniques however have a limited resolution, throughput and flexibility compared to next-generation sequencing platforms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29411725&#34; target=&#34;_blank&#34;&gt;Vascular endothelial growth factor in pleural effusions and correlation with radiologic and biochemical parameters.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study is to evaluate vascular endothelial growth factor (VEGF) in differential diagnosis of pleural effusions and the presence of correlation between radiological features and biochemical properties.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29413505&#34; target=&#34;_blank&#34;&gt;Progress and challenges in Mesothelioma: From bench to bedside.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant Pleural Mesothelioma (MPM) is currently an incurable cancer with a typical survival of 1 year from the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29430704&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with squamous differentiation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The extensive squamous differentiation reminiscent of squamous cell carcinoma can be a pitfall in the pathological diagnosis of pleural cytology and that of biopsy specimens from patients with mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29462963&#34; target=&#34;_blank&#34;&gt;Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis of MPM is often difficult and complex, and the gold standard diagnosis test is based on qualitative analysis of markers in pleural tissue by immunohistochemical staining. […] Therefore, it is necessary to develop quantitative and non-subjective alternative diagnostic tools. […] Recent evidence indicates that miRNA expression in tissue and body fluids is aberrant in various tumors, revealing miRNAs as promising diagnostic biomarkers. […] This review summarizes evidence regarding secreted and tissue miRNAs as biomarkers of MPM and the biological characteristics associated with their potential diagnostic value. […] In addition to studies regarding miRNAs with potential diagnostic value for MPM, studies that aimed to identify the miRNAs involved in molecular mechanisms associated with MPM development are described with an emphasis on relevant aspects of the experimental designs that may influence the accuracy, consistency and real diagnostic value of currently reported data.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29492267&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma presenting with remitting-relapsing pleural effusions: report of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural effusion (MPE) is typically persistent and progressive, prompting further investigations if the initial tests are not diagnostic.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29503128&#34; target=&#34;_blank&#34;&gt;Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis between diffuse malignant peritoneal mesothelioma (DMPM) and other peritoneal surface malignancies (PSM) is still challenging. […] We assessed the diagnostic and prognostic values of mesothelin, osteopontin, CEA, CA19.9, CA125, and CA15.3 in DMPM patients. […] Using diagnostic cut-offs selected by ROC methodology, sensitivity, specificity, positive and negative predictive values were 70.0%, 100.0%, 100.0%, and 60.9% for mesothelin &amp;gt;5.21 ng/dl, and 90.0%, 85.7%, 93.1%, and 80.0% for CA19.9 &amp;lt; 8.8 U/dl.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507793&#34; target=&#34;_blank&#34;&gt;Clinical diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is a tumour which, despite progress in diagnostic procedures and biomolecular research, has poor prognosis. […] MPM diagnosis requires imaging procedures X-ray and computed tomography (CT) scans; magnetic resonance imaging (MRI) better defines the extension of the tumor while PET scanning provides additional information on metabolic activity, metastases, and response to treatment. […] Thoracoscopic biopsy remains the most appropriate procedure for definitive diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507794&#34; target=&#34;_blank&#34;&gt;Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?-a systematic review about the use of screening programs in a population of asbestos exposed workers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical manifestations are not specific so that diagnosis is performed at advanced stage and screening protocols are not feasible now. […] This article summarizes previous and present clinical trials validated for lung cancer screening, to discuss the possibility of early diagnosis or screening programs in a population of asbestos exposed workers by LDCT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507795&#34; target=&#34;_blank&#34;&gt;Endoscopic diagnosis and management of pleural effusion in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is an asbestos-related aggressive tumor, that requires proper diagnosis and management. […] Performing a medical thoracoscopy (MT) is essential for a definitive diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507796&#34; target=&#34;_blank&#34;&gt;The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM), an asbestos-induced tumor, represents significant diagnostic challenges for pathologists. […] Its histological diagnosis is stepwise and should be based on morphological assessment, supported by clinical and radiological findings, and supplemented with immunohistochemistry (IHC) and, more recently, molecular tests. […] The main diagnostic dilemmas are the differential diagnoses with benign mesothelial proliferations and other pleural malignant tumors. […] The present review is an update regarding the morphological, immunohistochemical, and molecular features with respect to MPM diagnosis. […] Data sources include a survey of the biomedical literature from PubMed (&lt;a href=&#34;http://www.ncbi.nlm.nih.gov/pubmed&#34; class=&#34;uri&#34;&gt;http://www.ncbi.nlm.nih.gov/pubmed&lt;/a&gt;) and textbooks focusing on the pathological diagnosis of MPM and associated immunohistochemical and molecular markers. […] The histological findings of MPM could facilitate its diagnosis and provide important prognostic information.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507797&#34; target=&#34;_blank&#34;&gt;Surgery for malignant pleural mesothelioma: an international guidelines review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study is to examine the currently available international guidelines in the surgical diagnosis and treatment of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507799&#34; target=&#34;_blank&#34;&gt;Diaphragmatic and pericardial reconstruction after surgery for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical techniques have ameliorated over the last years, remaining the complete macroscopic resection of the disease the main surgical principle.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507801&#34; target=&#34;_blank&#34;&gt;Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A deeper knowledge of the biology and pathogenesis of this disease is required to develop more effective tools for diagnosis, therapy and prevention.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507804&#34; target=&#34;_blank&#34;&gt;Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histopathological analysis of pleural tissues is the gold standard for diagnosis; however, it can be difficult to differentiate malignant from benign pleural lesions. […] The purpose of this review is to describe the most important biomarkers and new diagnostic tools suggested for this differential diagnosis. […] None of the reported biomarkers showed adequate diagnostic accuracy, except for &lt;i&gt;p16&lt;/i&gt; [evaluated by fluorescent in situ hybridization (FISH)] and BAP1 (evaluated by IHC), both biomarkers are recommended by the International Mesothelioma Interest Group guidelines for histological and cytological diagnosis. […] Recently, the availability of new techniques and increasing knowledge regarding MPM genetics led to the definition of some molecular panels, including genes or miRNAs specifically deregulated in MPM, that are extremely valuable for differential diagnosis. […] Data regarding new diagnostic tools and MPM signatures are absolutely promising; however, before their application in clinical practice, a prospective validation is necessary, as these approaches could surely improve the differential diagnosis between malignant and benign pleural lesions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507805&#34; target=&#34;_blank&#34;&gt;Serum mesothelin and other biomarkers: what have we learned in the last decade?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the last decade there is been much interest in noninvasive, economic and well-accepted diagnostic tests for screening of subjects exposed to asbestos, and in patients with malignant pleuric mesothelioma (MPM) for diagnosis or monitoring response to treatment. […] Several biomarkers have been suggested as tools for screening and early diagnosis of MPM. […] Currently, in patients with MPM, have been reported high levels of soluble mesothelin-related peptides (SMRP), plasmatic osteopontin (pOPN), vimentin, fibulin-3 and many others as promising marker for diagnosis, even their use in prevention monitoring is still discussed. […] In this type of disease, a key role could be played by miRNAs, which expression has been investigated in a large series of MPM to examine new pathways useful in diagnosis, prognosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29507807&#34; target=&#34;_blank&#34;&gt;Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The biomarkers proposed so far do not lead to a sufficiently early diagnosis for a radical treatment of the disease. […] Thus, the finding of novel diagnostic and prognostic biomarkers and therapeutic targets is needed. […] Gene overexpression has been frequently associated with a malignant phenotype in several cancer types; therefore the identification of overexpressed genes may lead to the detection of novel prognostic or diagnostic marker and to the development of novel therapeutic approaches, based on their inhibition. […] In the last years, several overexpressed genes have been identified in MPM through gene expression profiling techniques: among them it has been found a group of 51 genes that resulted overexpressed in more than one independent study, revealing their consistency among studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29509030&#34; target=&#34;_blank&#34;&gt;Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, training with additional clarification of diagnostic criteria, their strict application, and help from consensus-based illustrative images is needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29510939&#34; target=&#34;_blank&#34;&gt;Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between 2002 and 2016, 154 patients underwent pleurectomy decortication (n = 90), extrapleural pneumonectomy (n = 42), or exploratory/diagnostic procedures (n = 22) in a single institution.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29514216&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic biopsies of MPM patients were collected from four Italian and one Slovenian cancer centers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29524617&#34; target=&#34;_blank&#34;&gt;Progress in the Management of Malignant Pleural Mesothelioma in 2017.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
New and effective strategies for diagnosis, prognostication, and treatment are urgently needed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29527515&#34; target=&#34;_blank&#34;&gt;Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29550074&#34; target=&#34;_blank&#34;&gt;Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three patients are alive (23-33 months after GMCI), and 3 of 4 NSCLC patients had prolonged disease stabilization; one is alive 29 months after GMCI, 3.6 years after initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29553973&#34; target=&#34;_blank&#34;&gt;Updates in the diagnosis and treatment of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review article describes current diagnostic and treatment modalities for malignant pleural mesothelioma (MPM). […] Thoracoscopy with multiple pleural biopsies can provide adequate tissue specimens for diagnostic testing to distinguish histologic MPM subtypes and perform molecular profiling, which influence prognosis and treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29571785&#34; target=&#34;_blank&#34;&gt;Low-dose chest computed tomography screening of subjects exposed to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A pathological diagnosis of LC was confirmed in 45 cases (2.1%) and MPM was confirmed in 7 cases (0.3%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29572002&#34; target=&#34;_blank&#34;&gt;Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic performance of Early Contrast Enhancement (ECE; which was defined as a SI peak in at least one ROI at or before 4.5 min) was compared with subjective MRI and Computed Tomography (CT) morphology results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29579286&#34; target=&#34;_blank&#34;&gt;Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is highly aggressive and has a poor prognosis because of the lack of markers for early diagnosis and resistance to conventional therapies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29588242&#34; target=&#34;_blank&#34;&gt;Primary Spinal Malignant Mesothelioma: A Case Report and Literature Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of schwannoma was suspected, and surgical resection was performed. […] Preoperative identification is challenging, and definitive diagnosis depends on histopathological evidence.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29594241&#34; target=&#34;_blank&#34;&gt;SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Standard palliative (20 Gy/5#) or dose escalated treatment (36 Gy/6#) will be delivered using advanced radiotherapy techniques and pain responses will be compared at week 5.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29601807&#34; target=&#34;_blank&#34;&gt;Utility of Site-Specific Biopsy for Diagnosis of Desmoplastic Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among MPMs, the diagnosis of DMM is particularly difficult because the tumor is largely composed of dense hyalinized fibrous stroma and few malignant cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29615010&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is marked by its difficult diagnosis and poor prognosis. […] Medical thoracoscopy (MT) is an effective and safe procedure for the diagnosis of exudative pleural effusions and many factors associated with poor prognosis of MPM. […] Eventually, MPM was the final diagnosis in 40 patients. […] Diagnostic efficiency of MT for MPM was 87.5%, since diagnosis of MPM failed to be established in 5 patients during the initial MT. […] MT is safe with a high positive rate in the diagnosis of MPM, and pleural adhesion and plaques seen under MT may be the adverse prognostic factors for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29616141&#34; target=&#34;_blank&#34;&gt;Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For patients presenting without a pleural effusion, CT-guided biopsy remains the primary choice of biopsy, but the diagnostic sensitivity of this investigation is 70%-75%. […] If the first biopsy is non-diagnostic, the chances of further non-diagnostic biopsies are high in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29629675&#34; target=&#34;_blank&#34;&gt;The current aetiology of malignant pleural effusion in the Western Cape Province, South Africa.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We retrospectively included all known cases of MPE evaluated at our institution over a 3-year period with a tissue diagnosis of MPE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29666782&#34; target=&#34;_blank&#34;&gt;New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Consequently, its diagnosis occurs at advanced stages.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29690982&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is a challenge, because cytology often is non-conclusive, and thoracoscopy is needed to obtain biopsies for immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29707109&#34; target=&#34;_blank&#34;&gt;MiR-21 over-expression and Programmed Cell Death 4 down-regulation features malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differential diagnosis between malignant pleural mesothelioma (MPM) and benign mesothelial conditions is still challenging and there is a lack of useful markers. […] Further studies should assess the diagnostic reliability of these two markers for MPM in biopsy and effusion specimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29714452&#34; target=&#34;_blank&#34;&gt;Increased micronucleus count predicts malignant behavior in pleural effusion fluid&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to evaluate the diagnostic usefulness of MN frequency to differentiate between malignant and benign pleural effusion samples.Materials and methods: Retrospectively, 78 pleural fluid cytology samples (including 20 cases of benign reactive mesothelial cells, 22 cases of suspicious cytology, and 36 cases of malignant cytology) were examined. […] MN scoring may be a helpful diagnostic tool for distinguishing malignant effusions from benign ones, and may be used as an adjunct tool to predict malignant behavior in challenging cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29714657&#34; target=&#34;_blank&#34;&gt;On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) diagnosis is known to be difficult. […] We report on the diagnostic elements available in life in an MPM necropsy case series and describe the frequency of non-neoplastic asbestos-related diseases as biological exposure indices. […] Data on 171 cases were available: for 169, autopsy confirmed the MPM diagnosis. […] In life, 119 cases had histologic confirmation of diagnosis, whereas 7 were negative; all cases without immunophenotypization were autoptic MPMs. […] Autopsies confirmed 169/171 cases, including cases that would not be considered as certain based on diagnosis in life.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29719805&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma presenting as recurrent hydro-pneumothorax: An atypical case presentation and literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Spontaneous hydro-pneumothorax is a rare presentation of MPM, most often requiring invasive tissue biopsy to confirm the etiologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29722422&#34; target=&#34;_blank&#34;&gt;Expression of plakophilin 3 in diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant pleural mesothelioma (DMPM) is the most common primary malignant pleural neoplasm still posing major diagnostic, prognostic and therapeutic challenges. […] Archival samples of tissue with established diagnosis of DMPM and samples of normal pleural tissue were used.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29757709&#34; target=&#34;_blank&#34;&gt;How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
malignant pleural mesothelioma (MPM) is a rare tumor with a challenging diagnosis. […] Even if, clinical data are mandatory to suspect the diagnosis, the positive diagnosis is based on microscopic features. […] Morphologic features are still the port of call of the diagnosis but their non specific character and the multiplicity of differential diagnoses made the immunohistochemical markers mandatory for the diagnosis. […] Many antibodies with a positive diagnostic value including claretinin, mesothelin, WT1 and antibodies with a negative diagnostic value including TTF1, EMA, CD15 are recommended by the scientific societies. […] This is due to the diagnostic limits of every antibody which necessitate the association of multiple antibodies. […] In the diagnostic demarch, pathologists deal with different antibodies and clones. […] Even if many recommendations are available, every pathology lab has to experiment its own antibodies in order to optimize the routine diagnostic demarch especially in low-income country. […] Our aim was to assess the diagnostic value of different antibodies available in our lab and to recommend a decisional flowchart. we conducted a retrospective study about 30 MPM diagnosed over a 20-year-period. […] The different techniques were realized manually. […] In sarcomatoid mesothelima, the most sensitive antibody was the cytokeratin antibody. these results yielded to a diagnostic flowchart that we can use in routine practice and that is in accordance with the literature findings. […] Many diagnostic and technical pitfalls have to be known by pathologists when dealing with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29802871&#34; target=&#34;_blank&#34;&gt;The diagnostic role of BAP1 in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to analyze the diagnostic role of BAP1 in effusion cytology. […] The present study supports the role of BAP1 as a highly sensitive and specific marker for malignant mesothelioma in serous effusions and argues for inclusion of this test in all specimens in which this diagnosis is considered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29803576&#34; target=&#34;_blank&#34;&gt;Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although postoperative radiotherapy (RT) for malignant pleural mesothelioma (MPM) has historically been delivered using 3-dimensional conformal RT (3DCRT) techniques, multiple reports show noteworthy safety and efficacy of the more advanced intensity-modulated RT (IMRT). […] Patients with metastatic disease, non-EPP or P/D surgical techniques, and lack of RT receipt (or without specified RT technique) were excluded.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29805789&#34; target=&#34;_blank&#34;&gt;&lt;sup&gt;18&lt;/sup&gt;F-fluorodeoxyglucose imaging of primary malignant pericardial mesothelioma with concurrent pericardial and pleural effusions and bone metastasis: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis and staging of PMPM based on anatomical imaging may be difficult when concurrent pericardial and pleural effusions are present. […] The diagnosis of PMPM was subsequently confirmed by pathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29854315&#34; target=&#34;_blank&#34;&gt;Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Using a cut-off that yielded 95.58% specificity, measurement of sCD157 in cytology-negative effusions increased sensitivity of malignant pleural mesothelioma diagnosis from 34.42% to 49.18%. […] Evaluation of soluble CD157 in pleural effusions provides a diagnostic aid in malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29869427&#34; target=&#34;_blank&#34;&gt;Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Timely diagnosis of malignant pleural effusions is critical to guide prognosis and management decisions. […] Cytological analysis of pleural fluid has been the first-line diagnostic test for many decades, with highly variable reported sensitivities of 40-90%. […] Its diagnostic accuracy in modern practice in Australia needs to be understood. […] To determine the diagnostic yield of pleural fluid cytology for the detection of malignant pleural effusions and to determine the aetiologies of pleural effusions at our centre. […] Aetiology of all effusions was determined, and sensitivity, specificity, negative predictive value and diagnostic accuracy for the detection of malignant pleural effusions were calculated. […] We also examined diagnostic yield based on tumour cell type. […] Sensitivity for diagnosis of malignant effusions was 67.2% overall, but 87.9% for adenocarcinomas and only 45.5% for mesothelioma. […] Tumour type is an important determinant of pleural fluid cytology diagnostic yield. […] Cytology has good sensitivity and specificity for the diagnosis of adenocarcinoma, but if another tumour type is suspected, particularly mesothelioma, clinicians should be aware of the limitations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29873855&#34; target=&#34;_blank&#34;&gt;Aquaporin-1 expression in fluoro-edenite-induced mesothelioma effusions: An approach by cell-block procedure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry for calretinin, CK5/6, WT1, CK7 and TTF1 was used on CB sections to confirm the cytological diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29876318&#34; target=&#34;_blank&#34;&gt;Proton beam therapy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical techniques have made incremental improvements over the last few decades while new systemic therapies, including immunotherapies, show promise as potentially effective novel therapies. […] Radiation therapy has historically been used only in the palliative setting or as adjuvant therapy after extrapleural pneumonectomy, but recent advances in treatment planning and delivery techniques utilizing intensity-modulated radiation therapy and more recently pencil-beam scanning (PBS) proton therapy, have enabled the delivery of radiation therapy as neoadjuvant or adjuvant therapy after an extended pleurectomy and decortication or as definitive therapy for patients with recurrent or unresectable disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29884273&#34; target=&#34;_blank&#34;&gt;Air in the Pleural Cavity Enhances Detection of Pleural Abnormalities by CT Scan.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Detection of pleural abnormalities on CT scan is critical in diagnosis of pleural disease. […] Future studies of the potential for artificial pneumothorax to improve the diagnosis of pleural disease are warranted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29891518&#34; target=&#34;_blank&#34;&gt;Integrated Histogenetic Analysis Reveals &lt;i&gt;BAP1&lt;/i&gt;-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The lymph nodes were histologically deemed unrelated to the known breast cancer by the reference pathologist, thus leading to the diagnosis of a CUP syndrome. […] Collectively, these data led to the diagnosis of &lt;i&gt;BAP1&lt;/i&gt; (&lt;i&gt;BRCA1&lt;/i&gt;-associated protein-1) tumor predisposition syndrome (TPDS). […] With the knowledge of an underlying &lt;i&gt;BAP1&lt;/i&gt; mutation and its known frequent association with epithelioid mesothelioma, the histology was reassessed and the diagnosis was revised to epithelioid mesothelioma. […] This case illustrates the potential of integrated histopathologic and molecular diagnostics in helping to decipher CUP syndromes and establish the correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29900099&#34; target=&#34;_blank&#34;&gt;Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tissue biopsies were obtained from 61 patients who were subjected to a diagnostic thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29914087&#34; target=&#34;_blank&#34;&gt;Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The identification of non-invasive molecular markers for an early diagnosis of MM has been the subject of several studies aimed at diagnosing the disease at an early stage. […] Other protein markers are Fibulin-3 and osteopontin which have not, however, showed a superior diagnostic performance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/2996064&#34; target=&#34;_blank&#34;&gt;[Computed tomographic findings in diffuse malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Additionally, a combination of findings can be detected by CT, suggesting the diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/29961333&#34; target=&#34;_blank&#34;&gt;Multisensor Imaging-From Sample Preparation to Integrated Multimodal Interpretation of LA-ICPMS and MALDI MS Imaging Data.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While some developments have provided improvements in lateral resolution and speed of analysis, there is a trend toward the combination of two or more analysis techniques, so-called multisensor imaging, for providing deeper information into the biochemical processes within one sample.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30008600&#34; target=&#34;_blank&#34;&gt;Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Background:&lt;/b&gt; Diagnosis of malignant pleural mesothelioma (MPM) remains a challenge, especially when resources in pathology are limited. […] The study aimed to evaluate cost-effective tumor markers to predict the probability of MPM in plasma samples in order to accelerate the diagnostic workup of the tissue of potential cases. &lt;b&gt;Methods:&lt;/b&gt; We conducted a case-control study stratified by gender, which included 75 incident cases with MPM from three Mexican hospitals and 240 controls frequency-matched by age and year of blood drawing. […] We estimated the performance of the markers based on the area under the curve (AUC) and predicted the probability of an MPM diagnosis of a potential case based on the marker concentrations. &lt;b&gt;Results:&lt;/b&gt; Mesothelin and calretinin, but not thrombomodulin were significant predictors of a diagnosis of MPM with AUCs of 0.90 (95% CI: 0.85-0.95), 0.88 (95% CI: 0.82-0.94), and 0.51 (95% CI: 0.41-0.61) in males, respectively. […] For MPM diagnosis in men we estimated a true positive rate of 0.79 and a false positive rate of 0.11 for mesothelin. […] The corresponding figures for calretinin were 0.81 and 0.18, and for both markers combined 0.84 and 0.11, respectively. &lt;b&gt;Conclusions:&lt;/b&gt; We developed prediction models based on plasma concentrations of mesothelin and calretinin to estimate the probability of an MPM diagnosis. […] Both markers showed a good performance and could be used to accelerate the diagnostic workup of tissue samples in Mexico.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30040453&#34; target=&#34;_blank&#34;&gt;The Diagnosis of Pleural Tumors Other Than Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ul&gt;
&lt;li&gt;Pleural pathology has been dominated by discussions relating to the diagnosis, prognosis, etiology, and management of malignant mesothelioma. […] Primary pleural neoplasms other than diffuse malignant mesothelioma are either uncommon or rare and have received less attention. - To provide a review of those diverse tumors that can involve the pleura other than mesothelioma in order to facilitate their accurate diagnosis. - Review of relevant literature published via PubMed and other search engines. - A wide variety of tumors can involve the pleura. […] In most cases, the approach of considering the morphologic features with appropriate immunohistochemistry, in the correct clinical context, allows for a confident diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30040460&#34; target=&#34;_blank&#34;&gt;Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;ul&gt;
&lt;li&gt;Early diagnosis of malignant mesothelioma (MM) is urgently needed because life expectancies and treatment options are limited in advanced stages of the disease. […] Malignant mesothelioma often presents with recurrent hemorrhagic or inflammatory effusions, which might mask the incipient stages of the disease and thereby delay the diagnosis. […] Despite difficulties in recognizing the malignant cells present in those early effusions, they are often the first available biologic material for diagnosis. […] Therefore, awareness is needed, and efforts should be made to distinguish the malignant cells by well-defined morphological criteria, combined with ancillary methods. - To summarize the diagnostic criteria for the cytopathologic diagnosis of MM based on recently published guidelines and to evaluate the clinical utility of those criteria in clinical practice. - The guidelines for the cytopathologic diagnosis of epithelioid and mixed-type MM and data in recent literature constitute the sources of this review. […] Eighty-five epithelioid or mixed-type MMs diagnosed between 2004 and 2013 at the Department of Clinical Pathology and Cytology, Karolinska University Hospital, Huddinge (Stockholm, Sweden), were evaluated to determine the clinical utility of the criteria defined by the guidelines. - A conclusive diagnosis of MM can be obtained based on the criteria defined by the guidelines with high positive predictive value. […] With the earlier diagnosis obtained by cytology, a better effect of chemotherapy can be expected, as shown by the longer overall survival in these patients compared with those with a histopathologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30054348&#34; target=&#34;_blank&#34;&gt;ERS/EACTS statement on the management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The European Respiratory Society (ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multidisciplinary collaboration of clinicians with expertise in the management of MPE with the aim of producing a comprehensive review of the scientific literature.Six areas of interest were identified, including the optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE.The literature revealed that talc pleurodesis and indwelling pleural catheters effectively manage the symptoms of MPE. […] There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30060030&#34; target=&#34;_blank&#34;&gt;ERS/EACTS statement on the management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Six areas of interest were identified, including the optimum management of symptomatic MPE, management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, whether there is a role for oncological therapies prior to intervention for MPE and whether a histological diagnosis is always required in MPE. […] There was no evidence to support the use of oncological therapies as an alternative to MPE drainage, and the literature supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.Management options for malignant pleural effusions have advanced over the past decade, with high-quality randomized trial evidence informing practice in many areas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30060501&#34; target=&#34;_blank&#34;&gt;Genomics and Epigenetics of Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of malignant mesothelioma is particularly challenging and is further complicated by the lack of disease subtype-specific markers. […] These molecular features have the potential to better our understanding of malignant mesothelioma biology as well as to improve disease diagnosis and patient prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30072200&#34; target=&#34;_blank&#34;&gt;Upcoming epidemic of asbestos-related malignant pleural mesothelioma in Taiwan: A prediction of incidence in the next 30 years.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Approximately 659 new MPM cases in the next 30 years warrant an urgent need to implement a total asbestos ban and put more resources on a comprehensive surveillance, diagnosis, and follow-up health care system for ARDs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30078293&#34; target=&#34;_blank&#34;&gt;The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors conducted a retrospective cost analysis on all the patients with MPM who were first admitted to a reference hospital specialized in MPM care between 2014 and 2015, collecting data on their diagnostic pathways and active treatments, as well as on the related official fees for each procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30109162&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of MPM is established by the morphologic and immunohistochemical features of a cytologic specimen.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30113886&#34; target=&#34;_blank&#34;&gt;Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural site (odds ratio [OR], 0.23; 95% CI, 0.10 to 0.58; P &amp;lt; .01), asbestos exposure (OR, 0.28; 95% CI, 0.11 to 0.72; P &amp;lt; .01), and older age (OR, 0.95; 95% CI, 0.92 to 0.99; P = .01) were associated with decreased odds of carrying a germline mutation, whereas having a second cancer diagnosis (OR, 3.33; 95% CI, 1.22 to 9.07; P = .02) significantly increased the odds. […] A significant proportion of patients with MM carry germline mutations in cancer susceptibility genes, especially those with peritoneal MM, minimal asbestos exposure, young age, and a second cancer diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30121394&#34; target=&#34;_blank&#34;&gt;Surgery in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgical intervention plays an important role in the diagnosis, staging, and treatment of malignant pleural mesothelioma (MPM) and can be applied with curative or palliative intent. […] Most importantly, the majority of patients with the diagnosis of MPM should be appropriately staged and initially evaluated in a multidisciplinary setting, including medical oncology, radiation oncology, and surgery after histologic diagnosis. […] In addition, the roles of surgery in diagnosis of MPM and in palliative care are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30123503&#34; target=&#34;_blank&#34;&gt;5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tissue sampling was performed at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30145072&#34; target=&#34;_blank&#34;&gt;Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of our work was to evaluate the clinical significance and prognostic implications of BAP1, mesothelin and PD-L1 expression in 117 patients with a diagnosis of MPM who were diagnosed in our institution between 2002 and 2017.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30150440&#34; target=&#34;_blank&#34;&gt;Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A strategy for improving survival of malignant pleural mesothelioma (MPM) patients is earlier diagnosis paired with earlier stage implementation of therapeutic interventions. […] This study aimed to determine the clinical signs of early-stage MPM to aid an earlier diagnosis and earlier-stage intervention.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30156768&#34; target=&#34;_blank&#34;&gt;Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural, pericardial, and peritoneal effusion specimens present diagnostic challenges and clinical opportunities for cytology. […] For the patient, these specimens may be the first diagnosis of malignancy or the first sign of disease recurrence. […] This review aims to provide useful approaches with which to resolve key difficulties in cytologic diagnosis through the use of ancillary studies, focusing on immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3016822&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma. Value of 67Ga scintigraphy compared to computerized tomography].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of 14 pleural mesotheliomas, 7 pleural carcinoses, 10 inflammatory and 3 other pleural diseases is performed more accurately by CT than by scintigraphy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3017091&#34; target=&#34;_blank&#34;&gt;Pleural malignant mesothelioma following Wilms’ tumor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At age four, she had undergone a left nephrectomy for Wilms’ tumor and had received radiation therapy to the left renal fossa and to the right lung, the latter for a presumed diagnosis of metastatic tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30190139&#34; target=&#34;_blank&#34;&gt;Updates in Effusion Cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Effusion cytology plays multiple roles in the management of benign and malignant disease, from primary diagnosis to tissue allocation for ancillary diagnostic studies and biomarker testing of therapeutic targets. […] This article summarizes recent advances in pleural effusion cytology, with a focus on the practical application of immunohistochemical markers, cytogenetic techniques, flow cytometry, and molecular techniques for the diagnosis and management of primary and secondary neoplasms of the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-12-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30197333&#34; target=&#34;_blank&#34;&gt;Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results provide new evidence of Numb and Gli1 on the clinical characteristics of MPM, which may be helpful in clinical diagnosis and targeted therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2018-11-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3020811&#34; target=&#34;_blank&#34;&gt;[Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Measurement of carcinoembryonal (CEA) levels in pleural fluid are suggested to improve the unsatisfactory sensitivity of pleural cytology in the differential diagnosis of malignant pleural effusions. […] In conclusion, evaluation of pleural CEA levels in patients with malignant effusions by using an EIA because of its high specificity is a valuable adjunct to pleural cytology in improving the diagnosis of malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30240138&#34; target=&#34;_blank&#34;&gt;Intensity-modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients were followed up from the date of diagnosis to death or treatment failure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30249391&#34; target=&#34;_blank&#34;&gt;Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The PGS was constructed by taking into consideration the histological subtyping of MPM (epithelioid/biphasic = 0 points; sarcomatoid = 2 points), necrosis (absent = 0 points versus present = 1 point), mitotic count per 1 mm&lt;sup&gt;2&lt;/sup&gt; (cutoffs as follows: 1-2 = 0 points, 3-5 = 1 point, 6-9 = 2 points, or ≥10 = 4 points), and Ki-67 labeling index based on 2000 cells (&amp;lt;30% = 0 points versus ≥30 = 1 point), all of which are independent factors in both patient sets after adjustment for stage and age at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30253920&#34; target=&#34;_blank&#34;&gt;Moderately Hypofractionated Helical IMRT, FDG-PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival from diagnosis was 25.8 months (range, 8.4-99.0 months).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30257964&#34; target=&#34;_blank&#34;&gt;Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Altered miRNA expression is an early event upon exposure to occupational/environmental carcinogens; thus, identification of a novel asbestos-related profile of miRNAs able to distinguish asbestos-induced cancer from cancer with different etiology can be useful for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30259910&#34; target=&#34;_blank&#34;&gt;What’s new in mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis, prognosis and therapy are often challenging and include several issues. […] Cytological diagnosis is frequently the first step of the diagnostic process, and although its sensitivity may be somewhat lower, diagnostic criteria should be taken into account. […] When effusion cytology is inconclusive for the diagnosis, tissue biopsies should be taken. […] Thirdly, when the diagnosis is made, despite many efforts have been made to identify possible new biomarkers for early diagnosis, prognostic stratification and also predictive tools should be defined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30262573&#34; target=&#34;_blank&#34;&gt;Investigating unilateral pleural effusions: the role of cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological sensitivity was based on the final diagnosis at 12 months, confirmed by two consultants.Over 8 years, 921 patients were recruited, of which 515 had a MPE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30268460&#34; target=&#34;_blank&#34;&gt;Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This can be explained by difficulties in early diagnosis, effective treatment and treatment monitoring. […] This finding opens perspectives towards the use of ctDNA as a biomarker for (early and differential) diagnosis, treatment and treatment monitoring of MPM, which all remain challenging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30268487&#34; target=&#34;_blank&#34;&gt;Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There are now criteria for the diagnosis of mesothelioma in situ and this is potentially important, since such cases might be curable.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30293912&#34; target=&#34;_blank&#34;&gt;[Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is suspected based on clinical features but positive diagnosis is microscopic. […] The diagnosis was based on the 2015 WHO classification. […] Pleural biopsy was performed using needle in 18 cases, through thoracoscopy in 16 cases, thoracotomy in 3 cases and allowed the diagnosis in respectively 7 cases/18, 16 cases/16 and 3 cases/3. […] A lymph node biopsy was performed through mediastinoscopy in one case and yelded the diagnosis. […] The diagnosis was performed on surgical specimen in 2 patients: one bullectomy and one right upper lobectomy. […] Pan-cytokeratin antibody was used in all cases in association with 2 antibodies with positive diagnostic value and 2 antibodies with negative diagnostic value. […] This work was about a Tunisian experience in the diagnosis and management of MPM. […] Microsocpic positive diagnosis necessitates a degree of expertise and every laboratory has to determine the most valuable antibodies through its experience in order to optimize the diagnosis and to reduce the delay of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30294454&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma presenting with Cardiac Tamponade- A Rare Case report and Review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mesothelioma often presents with pleuritic chest pain and dyspnea related to local invasion; distal metastasis and lymphadenopathy at the time of diagnosis is rare.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30300743&#34; target=&#34;_blank&#34;&gt;Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis is often delayed due to invasive biopsies and lack of distinguishable markers. […] This study aimed to investigate the proteome of pleural effusions taken from patients with MPM, adenocarcinoma and benign conditions in an attempt to identify a biomarker for early diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30301262&#34; target=&#34;_blank&#34;&gt;Genomic Deletion of &lt;i&gt;BAP1&lt;/i&gt; and &lt;i&gt;CDKN2A&lt;/i&gt; Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The current standard of MPM diagnosis requires the testing of multiple immunohistochemical (IHC) markers on formalin-fixed paraffin-embedded tissue to differentiate MPM from other lung malignancies. […] To date, no single biomarker exists for definitive diagnosis of MPM due to the lack of specificity and sensitivity; therefore, there is ongoing research and development in order to identify alternative biomarkers for this purpose. […] The genomic alteration of &lt;i&gt;CDNK2A&lt;/i&gt; and &lt;i&gt;BAP1&lt;/i&gt; is common in MPM and has potential diagnostic value. […] The data from this study suggest that genomic deletion analysis may provide more accurate biomarker options for MPM diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30309369&#34; target=&#34;_blank&#34;&gt;Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The discovery of soluble biomarkers with diagnostic/prognostic and/or therapeutic properties would improve therapeutic care of MPM patients. […] This protein presented significant but limited diagnostic properties (area under the curve (AUC) = 0.6972, p &amp;lt; 0.0001).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30315275&#34; target=&#34;_blank&#34;&gt;Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate distinction of benign mesothelial proliferations from malignant mesothelioma remains a diagnostic challenge. […] Sequential use of BAP1 immunohistochemistry and CDKN2A fluorescence in situ hybridization is specific for diagnosis of mesothelioma, but fluorescence in situ hybridization is both costly and time-consuming. […] Using 5-hmC loss in &amp;gt; 50% of tumor nuclei to define the diagnosis of mesothelioma, 5-hmC immunohistochemistry showed sensitivity of 92% and specificity of 100%. […] Extensive nuclear 5-hmC loss is sensitive and specific for mesothelioma in the differential diagnosis with benign mesothelial proliferations. […] In challenging mesothelial lesions, immunohistochemical studies showing either extensive 5-hmC loss or BAP1 loss indicate a diagnosis of mesothelioma, precluding the need for CDKN2A fluorescence in situ hybridization in a considerable number of cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30316293&#34; target=&#34;_blank&#34;&gt;p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Finally, 8 genes displayed correlation with disease stage, which may have diagnostic implications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30316650&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: The role of surgery].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy is essential for diagnosis of MPM. […] The pathological diagnosis is also better codified with immunohistochemistry and with analysis by expert of Mesopath group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30317725&#34; target=&#34;_blank&#34;&gt;Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study was conducted to differentiate malignant pleural mesothelioma (MPM) from lung cancer (LC) and benign pleural effusion (BPE) from pleural fluids using the diagnostic power of Fourier transform-infrared spectroscopy with attenuated total reflectance mode coupled with chemometrics.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30354850&#34; target=&#34;_blank&#34;&gt;Biomarkers in the diagnosis of pleural diseases: a 2018 update.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. […] Diagnostic PF biomarkers for malignancy can be classified as soluble-protein based, immunocytochemical and nucleic-acid based.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-03-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30358333&#34; target=&#34;_blank&#34;&gt;Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics (Erratum).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This erratum corrects an error in “Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics,” by Sherif Abbas et al.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30362153&#34; target=&#34;_blank&#34;&gt;Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this pilot study, we aimed to assess the expression of serum RNA-based biomarker panel exploring their clinical utility as diagnostic and prognostic biomarkers for MPM. […] The RNA-based biomarker panel was able to discriminate between MPM patients and controls with high accuracy and their combined sensitivity reached 100% for the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30364973&#34; target=&#34;_blank&#34;&gt;Thoracic aortic endografts used to resect the left subclavian artery infiltrated by malignant tumours.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The resection of the left subclavian artery infiltrated by thoracic malignant tumours may require temporary cardiopulmonary bypass, direct clamping of the aorta or extracorporeal circulation techniques. […] However, the off-label use of thoracic endovascular aortic repair avoids the need for these high-risk surgical techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30375909&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma in Finland: regional and gender variation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Significant gender and regional variation exists among patients, with notable differences in diagnostic and treatment practices. […] Emphasize centralized consult services for the diagnosis, treatment and support that patients receive for MPM, facilitating equal outcomes and compensation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30389446&#34; target=&#34;_blank&#34;&gt;Differential Survival Characteristics of Sarcomatoid Subtype in Biphasic Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival was measured from time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30402386&#34; target=&#34;_blank&#34;&gt;An unusual case of chylothorax.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, MPM rarely presents as a chylous effusion making it a diagnostic challenge.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30408567&#34; target=&#34;_blank&#34;&gt;Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients are usually diagnosed when current treatments have limited benefits, highlighting the need for noninvasive early diagnostic tests to monitor asbestos-exposed people.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3041546&#34; target=&#34;_blank&#34;&gt;Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One of the mAb in our panel (2G3) was consistently shown to produce strong staining of a high proportion of tumor cells in effusions and tumor nodules from patients with ovarian or breast cancer and may be of value in immunocytochemical diagnosis and therapy of epithelial malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-09-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3041723&#34; target=&#34;_blank&#34;&gt;Primary malignant pleural tumors (mesotheliomas) presenting as localized masses. Fine needle aspiration cytologic findings, clinical and radiologic features and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical findings, radiologic features and cytologic differential diagnosis of both the epithelial and the sarcomatous variants are discussed, together with a review of the literature pertinent to localized primary malignant pleural tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30417500&#34; target=&#34;_blank&#34;&gt;Establishment and characterization of CRISPR/Cas9-mediated NF2&lt;sup&gt;-/-&lt;/sup&gt; human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM), a highly refractory tumor, is currently incurable due to the lack of an early diagnosis method and medication, both of which are urgently needed to improve the survival and/or quality of life of patients. […] Collectively, these findings suggest that NF2 deficiency might play a role in the tumorigenesis of human mesothelium through mediating FGFR2 expression; FGFR2 would be a candidate molecule to develop therapeutic and diagnostic strategies for targeting MPM with NF2 loss.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-01-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30429020&#34; target=&#34;_blank&#34;&gt;A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histologic diagnosis of malignant pleural mesothelioma (MPM) is not always straightforward.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30429030&#34; target=&#34;_blank&#34;&gt;Real-life treatment practice for malignant pleural mesothelioma in Belgium.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Starting from the Belgian Cancer Registry, additional information regarding patient characteristics, diagnosis and treatment was retrieved from multiple data sources.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30446780&#34; target=&#34;_blank&#34;&gt;[The German Mesothelioma Register : Current pathological diagnostics and services].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The histologic diagnosis of mesothelioma is sometimes a challenge; additional immunohistochemical and molecular methods are needed. […] For differential diagnosis between reactive versus malignant, a p16-FISH test may be helpful.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30448261&#34; target=&#34;_blank&#34;&gt;Soluble AXL is ubiquitously present in malignant serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In HGSC, sAXL levels were significantly lower in post-chemotherapy effusions compared to primary diagnosis pre-chemotherapy specimens (p = 0.002). sAXL levels in HGSC were unrelated to chemoresponse at diagnosis, progression-free survival or overall survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450290&#34; target=&#34;_blank&#34;&gt;Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, the definite diagnosis is made only by the histological examination of a biopsy obtained through an invasive thoracoscopy. […] However, diagnosis is made too late for curative treatment because of non-specific symptoms mainly appearing at advanced stage disease. […] Hence, due to its biologic aggressiveness and the late diagnosis, survival rate is low and the patients’ outcome poor. […] In addition, radiological imaging, like computed tomographic scans, and blood biomarkers are found not to be sensitive enough to be used as an early diagnostic tool. […] Hence, there is a need for a new screening and diagnostic test which could improve the patients’ outcome. […] Despite extensive research has focused on blood biomarkers, not a single has been shown clinically useful, and therefore research recently shifted to “breathomics” techniques to recognize specific volatile organic compounds (VOCs) in the breath of the patient as potential non-invasive biomarkers for disease. […] Regrettably, the different techniques and the plethora of studies suffer some limitations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450291&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma: a review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Often, MPM is encountered incidentally by diagnostic imaging or by surgery. […] Computed tomography scan is widely accepted as a first line modality in diagnostic imaging. […] In diagnostic histopathology, MPM presents some challenges. […] Firstly, adequate clinical information is of utmost importance to consider the possibility of the diagnosis of MPM. […] Loss of BAP1 expression supports a diagnosis of malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450295&#34; target=&#34;_blank&#34;&gt;Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several combined modality treatment trials are currently ongoing using novel techniques in surgery, RT and/or CT in an attempt to reduce the morbidity and mortality associated with older multimodality treatment protocols.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30450297&#34; target=&#34;_blank&#34;&gt;Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients undergo invasive pleural interventions to either facilitate diagnosis and/or alleviate symptoms from malignant pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30478189&#34; target=&#34;_blank&#34;&gt;Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Earlier detection and novel diagnostic markers of relapse as well as potential neoadjuvant or adjuvant systemic therapy should be investigated in future studies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30485442&#34; target=&#34;_blank&#34;&gt;A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median survival from PT completion was 19.5 months (30.3 months from diagnosis), and 1- and 2-year survival rates were 58% and 29%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30499156&#34; target=&#34;_blank&#34;&gt;Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A receiver operating characteristic (ROC) analysis showed that the CTC test provided a significant diagnostic performance in discrimination of unresectable disease from resectable disease (area under the ROC curve, 0.851; P = .003). […] The novel CTC-chip enabled sensitive detection of CTCs, which provided significant diagnostic and prognostic information in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30506035&#34; target=&#34;_blank&#34;&gt;Deciduoid type malignant pleural mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although he received two cycles of chemotherapy, his disease rapidly progressed and he died within two months of the diagnosis of deciduoid type MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30510783&#34; target=&#34;_blank&#34;&gt;Management of database: European Society of Thoracic Surgeons mesothelioma database-difficulties in improving quality data for rare tumour.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma is a rare tumour but very aggressive with a median survival of 6 to 9 months from diagnosis without any treatment, The European Society of Thoracic Surgeons (ESTS) created a dedicated prospective mesothelioma registry to collect data on patients with malignant mesothelioma treated surgically to monitor the quality of surgery performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30512336&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis relies on thoracoscopy and large pleural biopsies. […] Histological diagnosis remains an actual dilemma, relying on immunohistochemical analysis as described by the French MESOPATH group. […] Le diagnostic histologique reste en effet difficile, reposant sur une analyse immuno-histochimique bien codifiée, avec relecture centralisée nationale par le panel « tumeurs rares » MESOPATH.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30512992&#34; target=&#34;_blank&#34;&gt;Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this study was to compare the diagnostic accuracy of whole-body MRI, coregistered FDG PET/MRI, integrated FDG PET/CT, and conventional imaging examination including bone scintigraphy, contrast-enhanced brain MRI, and CT for malignant pleural mesothelioma (MPM) staging according to the new International Association for the Study of Lung Cancer (IASLC) system. […] Kappa statistics and chi-square tests were used for evaluation agreements on each factor and clinical stage between each method and final diagnosis. […] The diagnostic accuracy of each method was statistically compared by use of McNemar test. […] The kappa values for each factor between each method and final diagnosis were significant (p &amp;lt; 0.0001) and ranged between 0.33 and 0.91. […] Kappa values between final diagnosis and stage evaluation were also significant (p &amp;lt; 0.0001) and ranged between 0.57 and 0.91. […] The diagnostic accuracy of N and stage assessment of whole-body MRI and FDG PET/MRI was significantly higher than that of conventional imaging examination (N factor, p &amp;lt; 0.05; stage, p &amp;lt; 0.05). […] The diagnostic accuracy of whole-body MRI, FDG PET/MRI, and FDG PET/CT for TNM stage assessment based on the new IASLC MPM staging system is greater than that of conventional imaging examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30520251&#34; target=&#34;_blank&#34;&gt;The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnostic marker with excellent specificity is not currently available in clinical practice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30533375&#34; target=&#34;_blank&#34;&gt;Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopic examination revealed multiple left pleural nodules, leading to the diagnosis of MPM. […] Despite aggressive anticancer drug therapy, he expired due to disease progression 2.5 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30535191&#34; target=&#34;_blank&#34;&gt;Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall survival and disease-free survival (DFS) were calculated from histological confirmation of a diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30557908&#34; target=&#34;_blank&#34;&gt;Nodules and masses are associated with malignant pleural effusion in dogs and cats but many other intrathoracic CT features are poor predictors of the effusion type.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were, however, many overlapping abnormalities between effusion types, so further diagnostic testing remains important for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30557956&#34; target=&#34;_blank&#34;&gt;Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Definitive diagnosis of the T-component is sometimes challenging in malignant pleural mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3059081&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Even pleural biopsy may not produce enough tissue to enable the pathologist to make a firm diagnosis. […] Thoracotomy and open biopsy will confirm the diagnosis in most cases. […] Several factors seem to predict prolonged survival: (1) epithelial histologic subtype, (2) performance score, (3) age of the patient at the time of diagnosis, and (4) absence of chest pain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30603603&#34; target=&#34;_blank&#34;&gt;Case report: Steroid responsive mesothelioma-related pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopic biopsy remains the most appropriate procedure for definitive diagnosis of mesothelioma. […] Despite advancement in diagnostic procedures and biomolecular research, this tumor nevertheless has poor prognosis. […] Mesothelioma remains a diagnostic and therapeutic challenge and is likely to remain one in the years to come.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30604735&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Definite diagnosis requires a varied panel of immunohistochemical (IHC) markers to differentiate these from histological mimics. […] The differential diagnosis of mesotheliomas varies with histological type and tumor location.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30622932&#34; target=&#34;_blank&#34;&gt;MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For this reason, the diagnosis is frequently achieved only in the advanced stages. […] The histopathological diagnosis &lt;i&gt;per se&lt;/i&gt; is also very complex, and no known factor can predict the prognosis with certainty. […] The identification of new prognostic and/or diagnostic biomarkers, and the discovery of therapeutic targets is a priority and could lead to a real significant impact on the management of malignant pleural mesothelioma. […] Unfortunately, to date the microRNAs with the most clinical relevance for MPM are still matter of debate, probably due to the variety of approaches, techniques, and collected samples. […] In this review we collect and discuss the studies focused on the involvement of microRNAs in different aspects of MPM, from their biological role in tumorigenesis and progression, to their possible application as diagnostic, prognostic and predictive biomarkers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30627323&#34; target=&#34;_blank&#34;&gt;Heparanase inhibitors restrain mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is a highly aggressive form of cancer with poor prognosis due to lack of markers for early diagnosis and resistance to conventional therapies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30630566&#34; target=&#34;_blank&#34;&gt;Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic accuracy of a limited immuno-panel of Calretinin and Ber-EP4 for diagnosis of malignant effusions was calculated using histopathology as gold standard. […] The sensitivity of Ber-EP4 for malignant cases was 98.6%, specificity 100%, positive predictive value (PPV) 100%, negative predictive value (NPV) 96%, and diagnostic accuracy 98.9%. […] Sensitivity of Calretinin as positive staining for RMC was 79.2%, specificity and positive predictive value (PPV) 100%, negative predictive value (NPV) 93.6%, and diagnostic accuracy 94.8%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30637565&#34; target=&#34;_blank&#34;&gt;Return to work after surgical treatment for malignant pleural mesothelioma: report of a case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathological diagnosis was epithelial malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30639549&#34; target=&#34;_blank&#34;&gt;Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Compared with conventional surgical techniques, less invasive surgery for MPM yielded lower surgical risks and comparable or improved survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30642555&#34; target=&#34;_blank&#34;&gt;Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathologist plays a central role in the diagnosis and management of malignant mesothelioma, including definitive tissue-based diagnosis in conjunction with clinical and radiographic data; diverse ancillary studies of diagnostic, prognostic, and predictive importance; and research efforts to better define the pathobiology of mesothelioma and develop novel clinical applications. […] This review summarizes the key findings of the “Molecular Pathways and Diagnosis in Malignant Mesothelioma” plenary session, including a large multi-institutional validation of a composite nuclear grading system for pleural mesothelioma, including incorporation of tumor necrosis as an additional independent prognostic factor; the correlation between nuclear grading in small biopsies and paired resection specimens in pleural mesothelioma; a multi-institutional study of important clinical and pathologic prognostic factors in peritoneal mesothelioma; the diagnostic role of HEG1 immunohistochemistry as a highly sensitive and specific marker of mesothelial lineage; the prevalence and diagnostic significance of MET protein overexpression in mesothelioma, as well as the correlation between MET protein overexpression and MET gene amplification; and the prognostic role of EZH2 protein overexpression in mesothelioma, together with data indicating an important pathogenic role for EZH2 in mesothelioma tumorigenesis. […] Special consideration is given to the convergence of diagnostic, prognostic, and predictive tools and their role in guiding highly personalized patient-centered management, and to the translation of novel research findings to practical techniques for routine pathologic practice.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30649229&#34; target=&#34;_blank&#34;&gt;Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Other factors significantly associated with better survival were younger age at diagnosis, higher income, lower comorbidity score, epithelial histology, earlier stage and receipt of surgical or medical treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30651596&#34; target=&#34;_blank&#34;&gt;ADAM10 mediates malignant pleural mesothelioma invasiveness.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Even if the latency period between asbestos exposure, the main risk factor, and mesothelioma development is very long, the local invasion of mesothelioma is very rapid leading to a mean survival of one year after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30654090&#34; target=&#34;_blank&#34;&gt;Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median age at the time of diagnosis was 66.5 years (range, 44-84 years).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30661019&#34; target=&#34;_blank&#34;&gt;Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no role for routine referral to SPC soon after diagnosis of MPM for patients who are cared for in centres with good access to SPC when required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30684047&#34; target=&#34;_blank&#34;&gt;Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nurses perceived barriers as follows: delayed diagnosis (74%); non-referral to medical oncology (63%); lack of clinician knowledge (58%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30697290&#34; target=&#34;_blank&#34;&gt;Histomorphological and Immunohistochemical Analysis of Pleural Neoplasms.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis or a differential diagnosis was suggested on histopathology confirmed by a panel of IHC markers such ascytokeratin(AE1/AE3), epithelial membrane antigen (EMA),vimentin, calretinin, CD34, CD99, SMA,bcl2, S100, CK7,CK20,TTF1,GCDFP, HMB45, LCA, synapto-physin, chromogranin, and naspsin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30704703&#34; target=&#34;_blank&#34;&gt;First report of probe based confocal laser endomicroscopy during medical thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This led to the diagnosis of normal pleura in one case, carcinomatous pleuritis in another case and a malignant mesothelioma in the third case. […] We believe that optical biopsies could help clinicians to make an early diagnosis, thereby allowing rapid therapeutic intervention (talc pleurodesis for example).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30719319&#34; target=&#34;_blank&#34;&gt;Localized malignant pleural mesothelioma arising in the interlobar fissure: a unique surgical case masquerading clinicopathologically as primary lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Taken together, we finally made a diagnosis of localized malignant pleural mesothelioma, epithelioid-type, arising in the right interlobar fissure between lower and middle lobes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30785691&#34; target=&#34;_blank&#34;&gt;[Possibilities of cytological diagnosis of the nature of the exudate at the stage of emergency.]&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytological diagnosis by effusions is currently the only reliable method of morphological verification of the diagnosis, it has prognostic significance and determines the choice of treatment strategy. […] At the same time, the variability of normal mesothelial cells causes significant difficulties in its differential diagnosis with reactive mesothelium, malignant mesothelioma and cancer metastasis, which requires additional analytical methods. […] During the period of November 2017 - July 2018, 46 exudates of serous cavities were studied, which showed that 9 patients (19.6%) were diagnosed with metastatic effusion, 31 (66.7%) patients had reactive exudate, suspicion of the malignant nature of serous fluid was expressed in 4 patients (8.7%), and 4.8% of persons (2 samples) failed to make an accurate diagnosis. […] The combined use of traditional cytology and fluorescent immunocytochemistry in the diagnosis of effusion fluids at the stage of emergency medical care to the patient complements each other and contributes to a faster and more reliable diagnosis, as it allows to confirm the malignancy of the test material, and to assume the primary focus.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30788836&#34; target=&#34;_blank&#34;&gt;Multiple sclerosis outcomes after cancer immunotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We analyzed the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database for pembrolizumab, atezolizumab, nivolumab, ipilimumab, avelumab, and durvalumab 2 years prior their FDA approval until December 31, 2017, to include all cases with confirmed diagnosis/relapse of MS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30798074&#34; target=&#34;_blank&#34;&gt;Revisiting localized malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These localized tumors are a potential diagnostic pitfall for the pathologists as well as radiologists, especially those practicing in a community setting.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30810450&#34; target=&#34;_blank&#34;&gt;About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The positive diagnosis of MPM is based on morphologic features coupled with immunohistochemical findings. […] Our aim was to assess the diagnostic value of this antibody in comparison to the most sensitive diagnostic antibody represented by the calretinin antibody. […] This meta-analysis revealed that BAP1 antibody should be associated with more sensitive antibodies in order to assess the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30828567&#34; target=&#34;_blank&#34;&gt;Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;b&gt;Introduction:&lt;/b&gt; Dysregulated genes play a critical role in the development and progression of cancer, suggesting their potential as novel independent biomarkers for cancer diagnosis and prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30859065&#34; target=&#34;_blank&#34;&gt;A 75 year old male with recurrent unilateral pleural effusion and positive ANA.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This case report describes the clinical course and diagnostic challenges arising in a 75 year old man who initially presented with progressive shortness of breath. […] While his initial workup suggested an autoimmune etiology, further diagnostic testing revealed a diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30882147&#34; target=&#34;_blank&#34;&gt;Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant pleural mesothelioma (MPM) is rarely an asbestos-related cancer with a poor prognosis that is difficult to distinguish from some benign conditions by using conventional biopsy techniques. […] The results of IHC staining and p16 by FISH were similar between biopsy techniques. […] Cryobiopsy successfully led to accurate diagnosis of MPM in all cases, whereas conventional biopsy was diagnostic in one case. […] Cryobiopsy during flex-rigid pleuroscopy is a feasible and convenient biopsy technique that supports precise diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30885529&#34; target=&#34;_blank&#34;&gt;The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently, it has been shown that homozygous deletion of 9p21 has both diagnostic and prognostic significance in MM. […] It is a known fact that, to interpret fluorescence in situ hybridization (FISH) signals, a cut-off value for each probe should be determined for a correct diagnosis. […] The combined examination of the 9p21 deletion and loss of p16 expression is helpful for diagnostic purposes, but because the FISH method is an expensive technique and loss of p16 expression is not specific for mesotheliomas, p16 negativity can guide practitioners to eliminate cases that require further investigation by FISH.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30886321&#34; target=&#34;_blank&#34;&gt;Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patients with a diagnosis of MPM were recruited.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30888083&#34; target=&#34;_blank&#34;&gt;In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the present article, we review our research toward early diagnosis of asbestos-related mesothelioma before symptoms develop and share our clinical experience of screening, diagnosing and monitoring of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-05-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30911616&#34; target=&#34;_blank&#34;&gt;Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accumulation of a malignant effusion in the pleura, peritoneum or pericardium is often the first diagnostic material for both primary malignant mesothelioma and a broad spectrum of metastatic adenocarcinoma originating from lung-, breast-, ovary- and gastro-intestinal organs as well as lymphoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30920878&#34; target=&#34;_blank&#34;&gt;Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Prophylactic irradiation to the chest wall after diagnostic or therapeutic procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread practice across Europe, although the efficacy of this treatment is uncertain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30921217&#34; target=&#34;_blank&#34;&gt;A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural effusions are a common medical problem not only for pulmonologists but also for general physicians, often needing thoracentesis for a definite diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30927189&#34; target=&#34;_blank&#34;&gt;The forensic significance of pseudomesotheliomatous adenocarcinoma of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
She declined rapidly and died before a histologic diagnosis could be made. […] An immunohistochemical panel of calretinin, WT1, BEREP4, MOC31, and TTF1 confirmed the diagnosis of primary lung adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3093540&#34; target=&#34;_blank&#34;&gt;New marker for mesothelioma: an immunoperoxidase study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings indicate that the antibody may be useful in the identification of mesothelioma cells in both histological and cytological diagnostic routine practice when morphological interpretation is in doubt.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30937282&#34; target=&#34;_blank&#34;&gt;Bilateral diffuse pulmonary infiltrates secondary to malignant peritoneal mesothelioma - A rare clinical presentation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was confirmed by ultrasound guided abdominal and bronchoscopy, &lt;i&gt;trans&lt;/i&gt;-bronchial lung biopsy. […] The morphology and immunohistochemical profile supported a diagnosis of epithelioid malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30941506&#34; target=&#34;_blank&#34;&gt;Thoracic Hyper-IgG4-Related Disease Mimicking Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
EBUS-TBNA EBUS-TBNA did not result in a formal pathological diagnosis; thus, multiple pleural biopsy were performed via right thoracoscopy. […] A presumptive diagnosis of IgG4-related disease was formulated. […] A diagnosis of definite IgG4-related disease was made, and treatment with prednisone 50 mg/day was started.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30942424&#34; target=&#34;_blank&#34;&gt;Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A receiver‑operating characteristic curve analysis using the samples in group A determined the optimal cut‑off value for the diagnosis of MPM, with a sensitivity of 76.9% and a specificity of 90%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30944296&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous Carcinoma with a High Pleural Hyaluronic Acid Concentration Arising from a Primary Esophageal Squamous Cell Carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the patient’s condition deteriorated, and he died 6 months after the diagnosis was established. […] This report describes the clinical features and outcome of such a patient, with an emphasis on differential diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30944991&#34; target=&#34;_blank&#34;&gt;A survey of patient and caregiver experience with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survey responses were received from 78 MPM patients and 106 caregivers from January to September 2014. 85% male, median age 69 years, median time since diagnosis 15 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30946324&#34; target=&#34;_blank&#34;&gt;Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study discussed the diagnostic value of SMRPs in pleural effusion (PE) for MPM. […] Medline, Embase, Web of Science, and Cochrane library system were systematically searched on the data of SMRPs in PE for MPM diagnosis. […] Pooled diagnostic sensitivity, specificity, and symmetric receiver operating characteristic curve were calculated. […] The pooled results of SMRPs in PE for diagnosing MPM were as follows: sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.68 (95% confidence interval [CI]: 0.64-0.72), 0.91 (95% CI: 0.86-0.94), 7.8 (95% CI: 5.0-12.0), 0.35 (95% CI: 0.31-0.40), and 22 (95% CI: 14-35), respectively. […] Subgroup analyzes revealed that the AUC of cohort group using histological diagnosis could be improved to 0.86 (95% CI: 0.83, 0.89).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30963005&#34; target=&#34;_blank&#34;&gt;Endobronchial ultrasound-guided transbronchial needle aspiration mediastinal lymph node staging in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A retrospective chart review of patients with diagnosis of MPM referred to the mesothelioma program at a tertiary Canadian cancer center between January 1, 2012 and December 31, 2014 who received mediastinal LN staging with EBUS-TBNA. […] EBUS-TBNA sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy were: 16.7%, 100%, 100%, 68.8%, and 70.6%, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30963379&#34; target=&#34;_blank&#34;&gt;Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the outcome of malignant pleural mesothelioma patients treated with extra-pleural pneumonectomy (EPP) and adjuvant radiotherapy (RT), using the most advanced radiotherapeutic techniques, namely image-guided intensity-modulated RT (IG-IMRT).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30975761&#34; target=&#34;_blank&#34;&gt;Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Effect of patient genotype on overall survival, measured at 3 y, remained independently significant after adjusting for gender and age at diagnosis, two other known prognostic factors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/30985689&#34; target=&#34;_blank&#34;&gt;Primary malignant mesothelioma of the diaphragm with liver invasion: A case report and review of literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Accurate diagnosis depends on careful pathological examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31011908&#34; target=&#34;_blank&#34;&gt;Management of Malignant Pleural Mesothelioma in the Elderly Population.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median age at diagnosis for malignant pleural mesothelioma (MPM) is approximately 72 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31018204&#34; target=&#34;_blank&#34;&gt;Role of Ancillary Techniques in Fluid Cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The morphologic diagnosis of malignancy may be difficult due to the relative paucity of abnormal cells. […] Cases in which a definitive and precise diagnosis of malignancy is made may be optimal candidates for further molecular testing in order to gain prognostic information and guide personal therapeutic decisions. […] In all of these situations, the use of ancillary studies and techniques is critical; their utility and appropriate application are the subject of this review.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31032152&#34; target=&#34;_blank&#34;&gt;A Rare Case of Malignant Mesothelioma Presenting with Systemic Lupus Erythematosus Seropositivity: A Case Report and Review of Literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While malignant mesothelioma may initially present in a variety of ways, it is uncommon to present with systemic lupus erythematosus (SLE) seropositivity and thus obscuring its diagnosis. […] Although SLE was initially suspected based on serologies, no clinical signs or symptoms were present to fulfill the diagnosis criteria. […] Given the patient’s age and new diagnosis of malignant mesothelioma, we hypothesized that the presence of autoantibodies was likely false positives due to acquired autoantibodies with age, hyperactivity of the immune system from malignancy, and possible prior asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31064187&#34; target=&#34;_blank&#34;&gt;Metastatic Clear Cell Renal Carcinoma Without Evidence of a Primary Renal Tumour Mimicking Advanced Stage of Malignant Lung Tumour.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
At the time of diagnosis, especially pulmonary metastases can be found in one-third of patients. […] Histological differential diagnosis included malignant pleural mesothelioma, lung adenocarcinoma and squamous cell carcinoma with clear cell differentiation or primary clear cell adenocarcinoma of the lung.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31065962&#34; target=&#34;_blank&#34;&gt;50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Within 1 year after the initial diagnosis, second-cavity disease was diagnosed in 52% of the patients. […] The median time to the second-cavity diagnosis for those with a diagnosis 1 year after the initial diagnosis was 30 months. […] Patients with an initial diagnosis of single cavity disease are at the highest risk for identification of second-cavity disease within the first year after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31075217&#34; target=&#34;_blank&#34;&gt;Confocal Laser Endomicroscopy as a Guidance Tool for Pleural Biopsies in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural biopsies in patients with suspected malignant pleural mesothelioma (MPM) are often inconclusive resulting in repeat diagnostic procedures. […] CLE imaging was successfully obtained in 19 of 20 diagnostic pleural biopsy procedures (thoracoscopy: n = 4, surgical excision: n = 3, CT scan: n = 3, ultrasound: n = 9, esophageal ultrasound guided: n = 1) in 15 patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31078776&#34; target=&#34;_blank&#34;&gt;Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A comprehensive analysis of the immune cell infiltrate collected from pleural fluid and from biopsy specimens of malignant pleural mesothelioma (MPM) may contribute to understanding the immune-evasion mechanisms related to tumor progression, aiding in differential diagnosis and potential prognostic stratification. […] We enrolled 275 patients with an initial clinical diagnosis of pleural effusion. […] Specimens of pleural fluids and pleural biopsy samples used for the pathologic diagnosis and the immune phenotype analyses were blindly investigated by multiparametric flow cytometry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31082996&#34; target=&#34;_blank&#34;&gt;Diagnosis and characterization of malignant effusions through pleural fluid cytological examination.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignancy accounts for a substantial proportion of pleural effusions, and cytologic examination of pleural fluid is the easiest way to establish the diagnosis. […] This review summarizes relevant advances in the diagnostic cytopathology of pleural effusions for the practicing pulmonologist. […] Cytologic analysis using a stained smear and cell block preparation is able to provide the diagnosis in about 55% of malignant effusions. […] Cytologic identification of mesothelioma is particularly challenging, but testing for BAP1 nuclear expression (immunocytochemistry) and p16 deletion (fluorescence in situ hybridization) has greatly improved our diagnostic capabilities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31092517&#34; target=&#34;_blank&#34;&gt;Advances in pulmonary and pleural malignant disorders.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Lung and pleural malignancies remain common in the UK with poor survival rates due, at least in part, to late stage diagnosis. […] Diagnostic pathways aim to reduce the time taken for patients to reach a diagnosis and treatment, with the use of positron emission tomography and endobronchial ultrasound to provide staging information alongside diagnostics. […] We provide an overview of the diagnostic process, therapeutic options and potential future screening programmes in pleural and pulmonary malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31092657&#34; target=&#34;_blank&#34;&gt;Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The study population are adult patients with histological/cytological confirmed diagnosis of epithelioid malignant peritoneal mesothelioma. 4 to 6 weeks before CRS-HIPEC a leukapheresis is performed of which the monocytes are used for differentiation to dendritic cells (DCs).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31125736&#34; target=&#34;_blank&#34;&gt;The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31146976&#34; target=&#34;_blank&#34;&gt;Signet ring cell mesothelioma; A diagnostic challenge.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The signet ring cell morphology can pose a challenge leading to a potential diagnostic error. […] A variety of benign and malignant diseases, including reactive histiocytic hyperplasia, adenocarcinoma, melanoma, and lymphoma with signet ring cell morphology should be considered in the differential diagnosis. […] Even though immunohistochemistry is routinely used in mesothelioma diagnosis, there is no sole specific mesothelial marker.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31154675&#34; target=&#34;_blank&#34;&gt;MicroRNA profiling in serous cavity specimens: Diagnostic challenges and new opportunities.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The examination of miRNA is attractive because of the stability of miRNA in such specimens and data suggesting that miRNA can provide prognostic and therapeutic information in addition to its role in diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31165505&#34; target=&#34;_blank&#34;&gt;Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
BAP1 loss seems to be diagnostic for mesotheliomas both in biopsy and cytology samples.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31169558&#34; target=&#34;_blank&#34;&gt;Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis can be challenging and require repeated investigations with implications for the patient and healthcare system. […] Cytological diagnosis of MPM from pleural fluid is as reliable as histological analysis of tissue biopsies in epithelioid MPM - an approach endorsed by the International Academy of Cytology. […] Identification of BRCA1-associated protein 1 (BAP1) and cyclin-dependent kinase inhibitor 2A (CDKN2A) gene mutations in MPM have led to the development of new ancillary tests that can streamline the diagnostic pathway. […] Diagnosis of epithelioid MPM can be established on pleural fluid analysis in most patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31179006&#34; target=&#34;_blank&#34;&gt;Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As with other cancers, receiving a diagnosis of MPM is challenging and distressing. […] Particular challenges are associated with communicating a diagnosis of MPM, including explaining the disease and its prognosis, treatment options and legal and financial implications. […] Receiving A Diagnosis Of Mesothelioma (RADIO Meso) aimed to understand the experience of communicating a diagnosis of MPM from the perspective of patients, family carers and health professionals. […] This study provides unique insight into the mesothelioma diagnostic experience of patients, family carers and health professionals. […] Key findings include the importance of regarding diagnosis as a process, and provision of continuity and consistency. […] The clinical nurse specialist and effective multidisciplinary team working provided vital contributions to successful mesothelioma diagnostic communication. […] Facilitators to diagnostic communication included honesty and timeliness in communication, partnership working and maintaining a patient-centred approach. […] Challenges to enhancing mesothelioma diagnosis communication included accessing ongoing training, ensuring a suitable clinical environment and being able to allocate appropriate time. […] The RADIO Meso study highlights factors that influence the communication of a diagnosis of MPM from the perspectives of individual patients and family carers. […] These findings provide the basis for a set of recommendations that can be used by health professionals to improve the MPM diagnostic experience.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31189069&#34; target=&#34;_blank&#34;&gt;The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Baseline characteristics were collected at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31191742&#34; target=&#34;_blank&#34;&gt;Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis and treatment response are challenging in MM. […] Therefore, the search for novel diagnostic and prognostic biomarkers is ongoing. […] The contribution of MMP9 serum levels and &lt;i&gt;MMP9&lt;/i&gt; polymorphisms to a composite diagnostic and prognostic biomarker should be further tested.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31192957&#34; target=&#34;_blank&#34;&gt;Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Several systematic reviews (SRs) have evaluated the diagnostic value of biomarkers for diagnosing MPM. […] However, no studies have been conducted to analyze the quality of these SRs and it remains unclear which biomarker is the excellent diagnostic test. […] This study aims to assess the methodological quality of the SRs and reanalyze the published data based on SRs to find the optimal biomarker for the early diagnosis of MPM. […] Standard pairwise meta-analysis and adjusted indirect comparison will be used to compare the diagnostic value of different biomarkers. […] This study will reanalyze the published data based on SRs to find a biomarker with the superior diagnostic performance for the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-07-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31200818&#34; target=&#34;_blank&#34;&gt;Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting ‘Direct to LAT’ in selected groups.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Contingency tables were used to assess diagnostic value of cytology in associated phenotypes. 238/363 (66%) patients were diagnosed with MPE (18 tumour types).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31207975&#34; target=&#34;_blank&#34;&gt;Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The management of patients with MPM is complex and controversial, particularly with regard to early diagnosis. […] The identification of diagnostic VOCs pattern, through breath sample characterization and the statistical data treatment, allows to obtain a strategic information for clinical diagnostics. […] To date the collected data provide just preliminary information and, despite the promising results and diagnostic accuracy, conclusions cannot be generalized due to the limited number of individuals included in each cohort study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31211722&#34; target=&#34;_blank&#34;&gt;Prospective Study of the Utility of Computed Tomography Triage of Pleural Biopsy Strategies in Patients With Pleural Diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aimed to prospectively evaluate the efficacy and reliability of a diagnostic workup, triaging pleural biopsy method according to baseline computerized tomography (CT) findings in the diagnosis of pleural diseases. […] MT was planned in patients who did not have a specific diagnosis in the CT scan-guided Abrams’ needle pleural biopsy group. […] When patients with a histopathologic diagnosis of fibrinous pleuritis after MT were assessed in terms of the risk factors for malignant pleural diseases, we offered a further invasive procedure. […] Diagnostic sensitivity after the initial procedure was 90.2% in Arm A, 93.3% in Arm B, 95.2% in Arm C, and 92.4% in the entire workup. […] Five cases who had a diagnosis of fibrinous pleuritis after MT were detected to have risk factors, 4 of which (80%) indicated malignant disease. […] Use of CT scans to triage an appropriate pleural biopsy method is associated with high diagnostic success. […] We recommend that the proposed diagnostic workup in this study may be used as a diagnostic algorithm for pleural diseases that require a histopathologic analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31212858&#34; target=&#34;_blank&#34;&gt;In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Reliable biomarkers for MPM diagnosis, monitoring, and prognosis are needed. […] The aim of this study was to identify genes associated with wound healing processes whose expression could serve as a prognostic factor in MPM patients. &lt;i&gt;Materials and Methods:&lt;/i&gt; We used data mining techniques and transcriptomic analysis so as to assess the differential transcriptional expression of wound-healing-associated genes in MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31229775&#34; target=&#34;_blank&#34;&gt;An asbestos contaminated town in the vicinity of an asbestos-cement facility: The case study of Sibaté, Colombia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was possible to obtain copies of the medical diagnosis for 17 cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31231127&#34; target=&#34;_blank&#34;&gt;MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ancillary studies facilitate accurate diagnosis of morphologically challenging mesothelial proliferations. […] The current diagnostic algorithm proceeds from BAP1 immunohistochemistry to CDKN2A fluorescence in situ hybridization. […] MTAP immunohistochemistry is a reliable surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31231129&#34; target=&#34;_blank&#34;&gt;Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent studies have revealed the effectiveness of diagnostic assays for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. […] In this study, we investigated whether NF2 FISH, either alone or in a combination with other diagnostic assays (9p21 FISH, MTAP immunohistochemistry, and BAP1 immunohistochemistry), is effective for distinguishing malignant pleural mesothelioma from reactive mesothelial hyperplasia. […] A combination of NF2 FISH, 9p21 FISH, and BAP1 immunohistochemistry yielded greater sensitivity (100%) than that detected for either diagnostic assay alone (53.2% for NF2 FISH, 78.7% for 9p21 FISH, 70.2% for MTAP immunohistochemistry, or 57.4% for BAP1 immunohistochemistry). […] Thus, NF2 FISH in combination with other diagnostic assays is effective for distinguishing malignant pleural mesothelioma from reactive mesothelial hyperplasia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31242986&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: A Multi-Disciplinary Approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Highly conformal radiation techniques are preferred to achieve optimal therapeutic ratio at this site. […] However, despite advances in radiation techniques, current treatment modalities have not significantly made an impact on survival of these patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31255258&#34; target=&#34;_blank&#34;&gt;Long term survival and perioperative propensity score matched outcomes of diaphragmatic resections compared to stripping in cytoreductive surgery + intra-peritoneal chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall survival and recurrence free survival was assessed based on histological diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31267149&#34; target=&#34;_blank&#34;&gt;Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Currently, the diagnosis is a challenge, carried out by means of invasive methods of limited sensitivity. […] This is a case-control study to evaluate the individual and combined performance of minimally invasive biomarkers for the diagnosis of MPM. […] The biomarker panel showed a good performance in a Mestizo-Mexican population, with high sensitivity and specificity for the diagnosis of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31273316&#34; target=&#34;_blank&#34;&gt;Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Practice guidelines recommend quantification of sarcomatoid component despite poor diagnostic reproducibility of biphasic mesothelioma among thoracic pathologists. […] The aim of this study was to determine the interobserver agreement in the quantification of sarcomatoid component, and in the diagnosis of a transitional component in the biphasic malignant mesothelioma. […] Excellent agreement was reached for the cases with 0-24% and &amp;gt; 75% of the sarcomatoid component.The most commonly used criteria for the diagnosis of sarcomatoid component were malignant spindle cells, frank sarcomatoid features and high N/C ratio. […] Our study defined precise morphologic criteria that may be used in the differential diagnosis between transitional pattern and other mesothelioma subtypes including sarcomatoid and epithelioid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31289169&#34; target=&#34;_blank&#34;&gt;Malignant deciduoid mesothelioma: a rare variant of epithelioid mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was reached with close correlation between clinical, radiological and pathological findings.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31312546&#34; target=&#34;_blank&#34;&gt;Metastatic Pleural Effusion: An Unusual Presentation of Urothelial Bladder Carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe a case where the workup of a unilateral pleural effusion led to the diagnosis of high-grade urothelial bladder carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31316876&#34; target=&#34;_blank&#34;&gt;Prostate Carcinoma and Pleural Mesothelioma: An Extremely Rare Co-occurrence.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After two years of diagnosis of carcinoma prostate, he developed left lung pleural sarcomatoid mesothelioma as a second metachronous tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31353039&#34; target=&#34;_blank&#34;&gt;Perioperative anesthetic management of patients with malignant pleural mesothelioma undergoing cytoreductive surgery and intraoperative chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Seven patients with malignant pleural mesothelioma diagnostic undergoing HITHOC surgery were studied.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31355131&#34; target=&#34;_blank&#34;&gt;The Oncolytic Virus &lt;i&gt;dl&lt;/i&gt;922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Current treatments are unable to increase significantly patient survival, which is often limited to &amp;lt;1 year from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31372931&#34; target=&#34;_blank&#34;&gt;Heterologous sarcomatoid pleural mesothelioma with osteosarcomatous differentiation: a report of autopsy case that accomplished trimodality therapy and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A small cytokeratin-positive epithelioid component in the resected tumor definitively confirmed the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31376434&#34; target=&#34;_blank&#34;&gt;Mesothelioma of the tunica vaginalis testis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median age at diagnosis was 72 years (range, 32-85 years). […] Seven of the men underwent herniorrhaphy; 7, radical orchiectomy; 3, hydrocelectomy; and 3, paratesticular mass biopsy or excision as the initial diagnostic procedure. […] Among the 6 men with MM who had ≥6 months of follow-up, 1 was alive with no evidence of disease at 6 months, and 5 were known to have died of disease 8-74 months (median = 31.5 months) following diagnosis. […] Of the 2 men initially diagnosed with well-differentiated papillary mesothelioma, 1 was alive without evidence of disease 5 years after diagnosis, while the other had findings more compatible with MM with peritoneal involvement 2 years following initial diagnosis. […] TVT is a rare site of MM, the diagnosis of which is often unsuspected preoperatively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31389715&#34; target=&#34;_blank&#34;&gt;Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural mesothelioma is a rare cancer with an often-challenging diagnosis because of its potential to be a great mimicker of many other tumors. […] The development and application of targeted therapeutic agents have made it even more important to achieve an accurate diagnosis. […] Our results indicate that the following panel of markers-calretinin (poly)/thyroid transcription factor 1 (TTF-1; clone 8G7G3/1) and calretinin (poly)/estrogen receptor-α (ER-α; clone EP1)-should be recommended; ultimately, based on the MESOPATH database, we highlight their relevance which are the most sensitive and specific panel useful to the differential diagnosis at 10% cutoff. […] Highlighted by their relevance in the large cohort reported, we recommend 2 useful panels to the differential diagnosis at 10% cutoff.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31390057&#34; target=&#34;_blank&#34;&gt;Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is made on biopsies, and because of intratumoral heterogeneity, they may not be representative of the entire tumor. […] The number and volume of biopsies needed to reach diagnostic accuracy in diffuse malignant mesothelioma and their prognostic value remain unclear. […] Despite intratumoral heterogeneity, the accuracy of histologic classification increases with the number of tissue blocks examined, emphasizing the diagnostic value of extensive sampling by presurgery biopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31417959&#34; target=&#34;_blank&#34;&gt;Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a case of 55-year-old male with the diagnosis of initially unresecable MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31424688&#34; target=&#34;_blank&#34;&gt;Multidisciplinary palliative treatment including isolated thoracic perfusion for progressive malignant pleural mesothelioma: a retrospective observational study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median interval-time from MPM diagnosis was 9 months. […] Median OS, calculated from the diagnosis of MPM, was 26.5 months (IQR 22.5-28).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31443309&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Effusion and Its Current Management: A Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31463153&#34; target=&#34;_blank&#34;&gt;Pleuroscopy or video-assisted thoracoscopic surgery for exudative pleural effusion: a comparative overview.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Traditionally, closed pleural biopsies have been the next best diagnostic step, but the diagnostic yield of blind closed pleural biopsies for malignant pleural effusions is insufficient. […] Both pleuroscopy and video-assisted thoracoscopic surgery have reported diagnostic yields of over 90%, although pleuroscopy more often leads to the unsatisfactory diagnosis of ‘non-specific’ pleuritis. […] These cases of ‘non-specific’ pleuritis need to be followed up for at least one year, as 10-15% of them will eventually lead to the diagnosis of cancer, typically malignant pleural mesothelioma. […] Both procedures have their pros and cons, and it is therefore of paramount importance that all cases be discussed as part of a multidisciplinary approach to diagnosis within a “pleural team” that should ideally include interventional pulmonologists and thoracic surgeons.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31475103&#34; target=&#34;_blank&#34;&gt;Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Circulating biomarkers for early diagnosis remain to be identified, and the current standard for MPM diagnosis relies on pleural biopsies. […] This review provides a critical summary of recent liquid biopsy-based studies aimed at discovering novel blood-based circulating biomarkers for the early diagnosis and prognostic stratification of MPM patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31481984&#34; target=&#34;_blank&#34;&gt;MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Biomarkers for an easier and/or earlier diagnosis are needed. […] PEs are ideal sources of biomarkers as the fluid would almost always require drainage for diagnostic and/or therapeutic reasons. […] MicroRNAs have been analysed in PE cytology samples for the diagnosis of MPM but have not been measured in frozen/fresh PE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31495751&#34; target=&#34;_blank&#34;&gt;Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Effusions have a high sensitivity and will often yield diagnostic cytological material. […] In this second part, the role of theranostics and the diagnosis of malignant mesothelioma, as was discussed at the meeting, have been highlighted. […] The cytologic diagnosis of malignant mesothelioma in effusion specimens has been controversial; however, a definitive diagnosis will be possible in many cases. […] Radiologic information should be sought, because the radiologist can often provide a definite or very likely diagnosis of malignancy. […] Microscopically, high cellularity and/or numerous balls of cells or papillary groups will favor the diagnosis of mesothelioma. […] BAP1 and MTAP immunohistochemistry and CDKN2A fluorescence in situ hybridization are very useful adjunctive techniques for separating benign from malignant mesothelial proliferations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31512057&#34; target=&#34;_blank&#34;&gt;Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This finding suggests that the choice of poly/monoclonal antibody for Caveolin 1 in the differential diagnosis of malignant pleural mesothelioma and pulmonary adenocarcinoma is important.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31519636&#34; target=&#34;_blank&#34;&gt;Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
SMRP level in PE was tested using an enzyme-linked immunosorbent assay (ELISA) in 109 patients with MPM at diagnosis before any treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31525809&#34; target=&#34;_blank&#34;&gt;Molecular Testing on Pleural Fluid Samples.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe the evolving field of molecular pleural fluid analysis in the setting of malignant disease as an active area of investigation with both diagnostic and therapeutic implications.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31525810&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma: Has Anything Changed?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An increased understanding of disease pathophysiology has led to more accurate diagnosis and staging, and the establishment of the standard of care first-line pemetrexed/platin doublet chemotherapy regimen in 2003 initially revolutionized treatment. […] This review will summarize the current clinical approach to diagnosis, staging, and treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31528168&#34; target=&#34;_blank&#34;&gt;The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Early diagnosis of malignant pleural mesothelioma (MPM) is the key point of its treatment. […] The main problem is the precise diagnosis of mesothelioma and its differentiation from metastatic lung adenocarcinoma. […] The aim of this study was to study hybrid immunohistochemistry in the differential diagnosis of primary malignant pleural effusion from metastatic pulmonary cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31529678&#34; target=&#34;_blank&#34;&gt;Anaplastic thyroid carcinoma mimicking a malignant pleural mesothelioma: Clues for diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural metastasis of thyroid carcinoma is very rarely encountered in the evaluation of pleural effusion and diagnosis may be challenging. […] Here we report a case of anaplastic thyroid carcinoma mimicking malignant pleural mesothelioma diagnosed nine years after the initial diagnosis of PTC and detail the clues used to orient and confirm the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31546041&#34; target=&#34;_blank&#34;&gt;EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular and immunologic breakthroughs are transforming the management of thoracic cancer, although advances have not been as marked for malignant pleural mesothelioma where pathologic diagnosis has been essentially limited to three histologic subtypes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31554354&#34; target=&#34;_blank&#34;&gt;Modified Liquid-Based Cytology Technique for Immunocytochemistry in Effusion Specimen.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Objective: Immunocytochemistry (ICC) of serous effusion is an important tool for the diagnosis of benign andmalignant cells. […] A comparative analysis of the diagnostic results was conducted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31563545&#34; target=&#34;_blank&#34;&gt;Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The toxicity rates were reduced with this technique compared with historical data of older techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31564247&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in construction workers: the Apulia regional mesothelioma register, Southern Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The average age at diagnosis was 64.7 years. […] The site was pleural in 96.06% of cases, with a diagnosis of certainty in 86.5% of the total cases and 61.8% of cases with epithelial histology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31568271&#34; target=&#34;_blank&#34;&gt;In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The reference standard for diagnostic performance was based on histology. […] In one case, diagnosis was benign pleural inflammation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3159086&#34; target=&#34;_blank&#34;&gt;Establishment and characterization of human malignant pleural mesothelioma cell line SMC-1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The establishment of this cell line will serve as a useful tool in clinical research of diagnosis and treatment of this devastating disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31597129&#34; target=&#34;_blank&#34;&gt;Effects of the Storage Solution Type and Prolonged Storage on the Immunoreactivity of Cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In effusion cytology, immunocytochemistry is a useful staining approach to provide important information for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31610664&#34; target=&#34;_blank&#34;&gt;Treatment of Malignant Peritoneal Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There is no specific symptomatology, and imaging (computed tomography) and histopathology are crucial for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31616640&#34; target=&#34;_blank&#34;&gt;Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical and radiological data was collected at regular follow-up visits including toxicity, local control and survival. &lt;b&gt;Results:&lt;/b&gt; At primary diagnosis, 57% of the patients presented with stage III disease. […] Three patients received additional intracavitary chemotherapy and another three patients were treated with chemotherapy alone without another treatment at the time of first diagnosis. […] Median follow-up of all patients from diagnosis was 28 months (range 7-152 months).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31619883&#34; target=&#34;_blank&#34;&gt;Malignant Mesothelioma - Report of Two Cases with Different Presentations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis remains challenging due to the latency between asbestos exposure and clinical presentation and the variable clinicoradiological manifestations. […] Meticulous history taking, high index of, suspicion and multimodality approach toward diagnosis are the keys to better prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31620941&#34; target=&#34;_blank&#34;&gt;Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The records of patients with a diagnosis of MPM from 1993 to 2016 were retrieved from the Dutch Cancer Registry. […] Data regarding diagnosis, staging, treatment, and survival were extracted.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31625358&#34; target=&#34;_blank&#34;&gt;Elevated Adenosine Dehydrogenase (ADH) and Positive Tuberculin Test Firstly Misdiagnosed as Tuberculous Pleural Effusion Finally Proved as Pleural Mesothelial Sarcoma by Thoracoscopic Biopsy Pathology: a Case Report and Literature Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Elevated ADH and positive tuberculin test are not a specific index for tuberculosis and thoracoscopic biopsy pathology is crucial for differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31634442&#34; target=&#34;_blank&#34;&gt;Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These nodes warrant further investigation, including nonoperative techniques to identify and factor them into treatment decision making.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31646778&#34; target=&#34;_blank&#34;&gt;Role of the contrast-enhanced spectral mammography for the diagnosis of breast metastases from extramammary neoplasms.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thus, the need for an early and accurate diagnosis is crucial, with the purpose of planning and optimize the therapeuthical strategy and consequently to improve the clinical outcome of patients. […] Due to the intrinsic characteristics of this technique, CESM lends itself as a useful and reliable tool for a complex diagnosis, since it may simultaneously provide both the data of the mammographic semiotic and the dynamic one of an examination with a contrast medium. […] On the basis of our experience, CESM could represent an extremely valid method to address a correct diagnosis in complex cases of potentially metastatic lesions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31655816&#34; target=&#34;_blank&#34;&gt;Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Unfortunately, the diagnostic yield of thoracentesis in this situation is suboptimal even if the procedure is repeated, especially in the context of malignant pleural mesothelioma (MPM). […] The next step for confirming the diagnosis, if clinically appropriate, is thoracoscopy, but not all patients are fit to undergo this procedure, so the diagnosis is then based on the medical history and imaging features only. […] Our objective was to evaluate the diagnostic value of the medical history and imaging features in MPM. […] We reviewed the imaging and medical charts of 92 patients with a final diagnosis of MPE included in our prospective medical thoracoscopy database. […] In a multivariate linear regression model, only asbestos exposure (OR 11.2; 95% CI 3.4-36.9) and circumferential pleural thickening (OR 4.7; 95% CI 1.6-13.9) were significantly associated with a diagnosis of MPM. […] In situations where it is impossible to obtain adequate pleural samples to differentiate MPM from a secondary pleural malignancy, the combination of circumferential pleural thickening and a history of asbestos exposure may be sufficient to make a clinical diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31661685&#34; target=&#34;_blank&#34;&gt;Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A case of peritoneal mesothelioma with an anaplastic lymphoma kinase (ALK) translocation was identified, and we conducted further studies to obtain diagnostic and therapeutic insights. […] To verify the diagnosis and aid in developing a therapeutic strategy, several companion diagnostics were tried.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31667333&#34; target=&#34;_blank&#34;&gt;Multicystic peritoneal mesothelioma: a systematic review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of a lack of clinical and imaging presentation, the diagnosis is intricate, and heavily relies on case reports and short studies. […] A histological analysis with immunohistochemistry is required for a definitive diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31667596&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, these mesothelial cells exhibited a loss of methylthioadenosine phosphorylase (MTAP) by immunohistochemistry and homozygous deletion of CDKN2A (p16) by FISH, leading to the diagnosis of MIS.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31680229&#34; target=&#34;_blank&#34;&gt;Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
With improvements in surgical techniques and systemic therapies, as well as advancements in RT, there has been apotential new paradigm in the management of this disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31682242&#34; target=&#34;_blank&#34;&gt;[The occurrence of asbestos-related diseases among former employees of asbestos processing plants in Poland].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results of the analysis indicate the need for undertaking a discussion in Poland on the implementation of international criteria for the diagnosis of asbestosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31719986&#34; target=&#34;_blank&#34;&gt;Intrapleural urokinase directly under medical thoracoscopy for the diagnosis of tuberculous pleurisy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medical thoracoscopy, also called “local anesthetic thoracoscopy” and “pleuroscopy,” is a minimally invasive single-port endoscopic technique that provides direct visualization of the pleural surfaces and channels to conduct diagnostic and therapeutic procedures. […] We reported the first case of intrapleural urokinase directly under medical thoracoscopy for the diagnosis of malignant pleural mesothelioma with severe multiloculated pleural effusions in 2019. […] This is the second report regarding the efficacy of intrapleural urokinase directly under medical thoracoscopy for the diagnosis of multiloculated pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31776801&#34; target=&#34;_blank&#34;&gt;Fibrolipoma of the left ventricle: an uncommon incidental autopsy finding.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological examination confirmed the diagnosis of cardiac fibro-lipoma, a rare histologic variant of lipoma, irrelevant to the cause of death in the present case. […] The rarity of the occurrence of fibro-lipomas provides clinical implications for the inclusion of the entity in the differential diagnosis of a cardiac mass.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31778960&#34; target=&#34;_blank&#34;&gt;Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To support diagnosis and to risk stratify patients, more reliable biomarkers are warranted. […] Corresponding pleural effusions and serum samples taken at primary diagnosis were analyzed for TGF-β by ELISA, and for mesothelin (SMRP) by chemiluminescence enzyme immunoassay. […] TGF-β levels determined in pleural effusion may be a promising biomarker for diagnosis and prognostic stratification of MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31783178&#34; target=&#34;_blank&#34;&gt;Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between September 2013 and December 2018, 373 patients were enrolled in the mesothelioma natural history study, of which 32 patients were 40 years old or younger at the time of their mesothelioma diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31788420&#34; target=&#34;_blank&#34;&gt;Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Four years after the diagnosis a CT scan showed that there was a modest but definite progression of the left malignant pleural thickening, and a new right-sided effusion, enlargement of several intrathoracic nodes which had been noted on the early scans.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3180855&#34; target=&#34;_blank&#34;&gt;Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We concluded that in the differential diagnosis of pleural effusions associated with malignant tumors a high concentration of HA in pleural fluid combined with a low concentration of CEA suggests malignant mesothelioma as opposed to other types of cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31812249&#34; target=&#34;_blank&#34;&gt;Impact of an asbestos cement factory on mesothelioma incidence in a community in Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From the RML database we extracted subjects who ever worked in Fibronit, their family members, ever residents in Broni, and subjects living in Stradella and nearby towns at the time of diagnosis. […] Among subjects never occupationally exposed and never exposed to extra-occupational sources unrelated to Fibronit, we counted 39 cases (4.24 expected, SIR = 9.2), 10 men (all pleural MM), 29 women (28 pleural, 1 peritoneal MM) in Fibronit workers’ families, 91 pleural mesothelioma cases (7.43 expected, SIR = 12.2, 31 men, 60 women), ever residents in Broni, and 25 pleural mesothelioma cases (3.05 expected, SIR = 8.2, 6 men, 19 women) living in Stradella at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31827724&#34; target=&#34;_blank&#34;&gt;Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma - Comparison with contrast-enhanced CT.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the diagnostic accuracy of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) findings for recurrent malignant pleural mesothelioma (MPM) after a radical surgery procedure and their impact on clinical management in comparison with contrast-enhanced CT. […] Diagnostic ability was determined on a patient and lesion-site basis by 2 experienced examiners, and the modalities were compared using ROC analysis and McNemar test results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31833271&#34; target=&#34;_blank&#34;&gt;[How I manage… Malignant pleural mesothelioma in 2019].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The tumor is generally extended at the time of diagnosis and the treatment consists of a systemic palliative therapy. […] Au moment du diagnostic, la maladie est souvent de stade avancé et est prise en charge par un traitement systémique palliatif.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2019-12-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31876584&#34; target=&#34;_blank&#34;&gt;Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Age at the time of diagnosis ranged from 19 to 93 years with a mean of 60 years. […] The median age at time of diagnosis for pleural MM was 65 years and for peritoneal MM was 52 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31897219&#34; target=&#34;_blank&#34;&gt;A gene-expression-based test can outperform bap1 and &lt;i&gt;p16&lt;/i&gt; analyses in the differential diagnosis of pleural mesothelial proliferations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The demonstration of tissue invasion by histology is an essential criterion for the differential diagnosis of benign and malignant mesothelial proliferations. […] In this context, a previous study developed and tested a novel tool for use in the differential diagnosis of malignant pleural mesothelioma (MPM) using the NanoString System and a classification algorithm. […] The diagnostic performance of &lt;i&gt;p16&lt;/i&gt;, BAP1 and our classification models were compared using ROC analysis. […] As expected, combining BAP1 and &lt;i&gt;p16&lt;/i&gt; tests increased the diagnostic sensitivity, thus improving the AUC (0.8824). […] In conclusion, the present gene-expression-based classification exhibited great potential and further validation is required to support these findings in a prospective fashion, in order to provide a solid alternative for pleural proliferation diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31904012&#34; target=&#34;_blank&#34;&gt;Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Treatments provide only modest survival since the median survival average is 9-18 months from the time of diagnosis. […] Positron emission tomography/computed tomography (PET/CT) molecular imaging using the clinical [&lt;sup&gt;18&lt;/sup&gt;F]-2-fluoro-2-deoxy-D-glucose ([&lt;sup&gt;18&lt;/sup&gt;F]FDG) radiotracer is the diagnosis method of choice for examining patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31921422&#34; target=&#34;_blank&#34;&gt;LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To identify potential diagnostic biomarkers for MPM, we performed bioinformatics analysis of public database. […] We identified Lysyl oxidase (LOX), Lysyl oxidase homologs 1&amp;amp;2 (LOXL1&amp;amp; LOXL2) Zinc Finger Protein, FOG Family Member 2 (ZFPM2) as potential diagnostic biomarkers for MPM. […] In this study, we found that the LOX family and ZFPM2 showed comparable diagnostic ability to Fibulin-3 or mesothelin (MSLN) and would be better potential biomarkers than Sulfatase 1 (SULF1), Thrombospondin 2 (THBS2) and Cadherin 11 (CDH11). […] LOX family and ZPFM2 were identified as novel MPM diagnostic biomarkers which could strengthen MPM clinical diagnostic capabilities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-01-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31930123&#34; target=&#34;_blank&#34;&gt;Dosimetric Comparison of Lung-Sparing Radiation Therapy between Volumetric Arc Therapy and Helical Tomotherapy for Unresectable Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the maximum (&lt;i&gt;p&lt;/i&gt;=0.001) and mean (&lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) doses of PTV&lt;sub&gt;1&lt;/sub&gt;, and PTV&lt;sub&gt;2&lt;/sub&gt; (&lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001 for maximum and &lt;i&gt;p&lt;/i&gt;=0.001 for mean doses) favored the HT technique over VMAT, both techniques efficiently covered the target volumes. […] Additionally, HT also provided more homogeneous dose distribution (&lt;i&gt;p&lt;/i&gt; &amp;lt; 0.001) and numerically lower doses received by most OARs, but again both rotational techniques were successful in keeping the OAR doses below the universally accepted limits. […] Results of this dosimetric comparison clearly demonstrated the possibility of safe hemithoracic irradiation of medically/technically unresectable MPM patients with either of the two rotational RT techniques, namely the VMAT and HT.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31977466&#34; target=&#34;_blank&#34;&gt;99mTc-HDP Bone Scintigraphy, SPECT/CT, and 18F-FDG PET/CT Diagnosis Imaging of Incidental Pleural Mesothelioma in a Patient With Biochemical Recurrences of Prostate Cancer: Is it Really a Coincidence?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
More than 10 years after the diagnosis, follow-up Tc-HDP bone scans and SPECT/CT images demonstrated an incidental diagnosis of osteoblastic pleural plaques that quickly evolve to mesothelioma. […] PET/CT achieved the definitive diagnosis by guiding the biopsy to the highest and most accessible focus of glucidic hypermetabolism.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/31981139&#34; target=&#34;_blank&#34;&gt;Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural biopsy through video-assisted thoracic surgery (VATS pleural biopsy) is the most reliable diagnostic procedure for malignant pleural mesothelioma (MPM). […] However, definitive diagnosis of MPM is occasionally difficult to establish. […] This study aims to investigate clinicopathological features of MPM patients who failed diagnosis by the first VATS pleural biopsy. […] Analysis of the clinical course revealed that only insufficient tissue for diagnosis was obtained via VATS pleural biopsy in all cases and that it was caused by very early stage without visible tumour in 4 patients, intrathoracic inflammation in 4 and desmoplastic MPM in 2. […] In our review, 9.8% of patients diagnosed with AMP or NSP in first VATS pleural biopsy were subsequently diagnosed with MPM due to insufficient tissue for diagnosis. […] Definitive diagnosis via VATS pleural biopsy is sometimes challenging in following situation; very early stage, intrathoracic inflammation and desmoplastic MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32003806&#34; target=&#34;_blank&#34;&gt;18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) scan has been generally validated in the staging of malignant pleural mesothelioma (MPM), its diagnostic and prognostic performances are not clearly established. […] Aiming to identify possible factors causing 18F-fluorodeoxyglucose PET/CT false-negative results and influencing prognosis in MPM patients, we analysed clinical, radiometabolic and pathological features in 141 MPM patients who underwent diagnostic 18F-fluorodeoxyglucose PET/CT scan (January 2009-July 2018) at 2 high-volume institutions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32005436&#34; target=&#34;_blank&#34;&gt;Diagnosis of Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma is challenging and fraught with pitfalls, particularly in small biopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32036091&#34; target=&#34;_blank&#34;&gt;Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural effusions are among the first clinical manifestations of malignant pleural mesothelioma (MPM) and often constitute the only available material for diagnosis. […] Although an MPM diagnosis can be reliable on cytology, the reported sensitivity is low (30% to 75%). […] Although further validation is needed, this gene panel could really facilitate patients’ management, allowing a definitive MPM diagnosis directly on pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3203820&#34; target=&#34;_blank&#34;&gt;Cytologic presentation of malignant mesothelioma in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only 2 cases showed pronounced cytologic features that made a definite diagnosis possible on cytologic criteria alone. […] In 20 cases diagnosis of mesothelioma was strongly suggested by the patient’s history and cytology of the effusion was compatible with mesothelioma. […] In the other 4 cases special examinations (histo- and immunohistochemistry, electron microscopy) led to the final diagnosis. […] The cytologic features of mesothelioma and other examination techniques, needed to resolve the differential diagnosis of mesothelioma versus other neoplasm in pleural effusions, are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32042428&#34; target=&#34;_blank&#34;&gt;Endoscopic ultrasound-guided pleural biopsy in the hands of the pulmonologist.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The use of the endobronchial ultrasound (EBUS) endoscope in the oesophagus, the so-called EUS-B procedure, for the diagnosis and staging of thoracic malignancy is quickly gaining ground.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32049443&#34; target=&#34;_blank&#34;&gt;Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A conclusive diagnosis of malignant mesothelioma (MM) can be based on effusion cytology using the guidelines for the cytopathologic diagnosis of epithelioid and mixed-type MM. […] Briefly, the diagnosis is obtained when the mesothelial phenotype of malignant cells is established by ancillary techniques. […] The diagnosis was obtained by histopathology in 74 cases and by cytological examination of pleural effusion in 70 cases. […] In 29 of the latter cases, a diagnostic biopsy was obtained simultaneously. […] The median time between first symptoms and diagnosis was similar for cytology and histopathology. […] Similarly, a better survival, following a cytological diagnosis, was also seen in patients who were only provided the best supportive care. […] Accurate cytological diagnosis enables conclusive diagnosis of MM. […] Our finding enables the initiation of treatment as soon as the cytological diagnosis is established, avoiding further delay and deterioration of patient survival and possibilities for treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32050546&#34; target=&#34;_blank&#34;&gt;Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this systematic review was to provide an overview on the current knowledge about exhaled breath analysis in MPM diagnosis. […] Some compounds (i.e, cyclohexane, P3, P5, P50, P71, diethyl ether, limonene, nonanal, VOC IK 1287) that can be indicative of MPM development in asbestos exposed population were identified with high diagnostic accuracy rates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32081346&#34; target=&#34;_blank&#34;&gt;The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The symptoms and signs of malignant mesothelioma present late in the natural history of the disease and are non-specific, making the diagnosis challenging and imaging key. […] In 2018, the British Thoracic Society (BTS) updated the guideline on diagnosis, staging, and follow-up of patients with MPM. […] We aim to update the reader on current and future imaging strategies, which could aid early diagnosis of pleural malignancy and provide an update on staging and assessment of tumour response.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32082887&#34; target=&#34;_blank&#34;&gt;Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The areas under the curve for cancer antigen 125 and 15-3 were 0.78 and 0.67, respectively in the differential diagnosis of mesothelioma from other pathologies (p&amp;lt;0.001 for both). […] The combination or individual use of serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels may be helpful for early diagnosis and treatment of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3210656&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between March 1981 and February 1985, 93 out of 132 patients with a histologically confirmed diagnosis of malignant pleural mesothelioma were eligible for therapy and were prospectively assigned to receive either combined therapy or best supportive care, according to their personal preferences.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1989-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32113716&#34; target=&#34;_blank&#34;&gt;Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of the 27 patients who developed deep vein thrombosis, 9 (33%) were asymptomatic at the time of diagnosis, and none of these developed a pulmonary embolus or other bleeding complications. […] Up to 33% of patients with deep vein thrombosis are asymptomatic at the time of diagnosis, and the incidence of complications related to anticoagulation is low.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32124515&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In clinical practice, the pleural fluid to blood BNP ratio can help in the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32175161&#34; target=&#34;_blank&#34;&gt;Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study aims to evaluate gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma both which have a distinct treatment and prognosis. […] Based on our study results, we suggest that TREX1, PRKDC, and PMS1 genes may play a key role in the differential diagnosis of these two entities.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32175619&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma following repeated exposures to cosmetic talc: A case series of 75 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean age at diagnosis was 61 ± 17 years. […] The mean latency from exposure to diagnosis was 50 ± 13 years.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32181176&#34; target=&#34;_blank&#34;&gt;Intramedullary Metastasis to the Cervical Spinal Cord from Malignant Pleural Mesothelioma: Review of the Literature and Case Reports.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma is an aggressive tumor; median survival of patients following diagnosis is 12 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32184064&#34; target=&#34;_blank&#34;&gt;Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Distinguishing metastatic LADC from reactive mesothelial cells (RMC) and malignant mesothelioma (MM) based on morphology alone has been a persistent diagnostic challenge in cytopathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/322031&#34; target=&#34;_blank&#34;&gt;[Short and long term behaviour of pleural effusion cultures. (Report of 200 cases) (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 3 cases, typical malignant epithelial cells have allowed us to discard the diagnosis of malignant mesothelioma. […] In 7 cases with negative routine techniques, cell culture disclosed malignant cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32206567&#34; target=&#34;_blank&#34;&gt;Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemistry plays an indispensable role in accurate diagnosis of malignant mesothelioma, particularly in morphologically challenging cases and in biopsy and cytology specimens, where tumor architecture is difficult or impossible to evaluate. […] An immunopanel including two mesothelial markers (calretinin, CK5/6, WT-1, or D2-40) and two epithelial markers (MOC-31 and claudin-4) offers good sensitivity and specificity, with adjustments as appropriate for the differential diagnosis. […] Once mesothelial lineage is established, malignancy-specific studies can help verify a diagnosis of malignant mesothelioma. […] BAP1 loss, &lt;i&gt;CDKN2A&lt;/i&gt; homozygous deletion, and MTAP loss are highly specific markers of malignancy in a mesothelial lesion, and they attain acceptable diagnostic sensitivity when applied as a diagnostic panel. […] Some diagnostic markers also have prognostic significance, and PD-L1 immunohistochemistry may predict tumor response to immunotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32214647&#34; target=&#34;_blank&#34;&gt;Not gene therapy, but genetic surgery-the right strategy to attack cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In contrast, the techniques of the other strategy are aimed at the destruction of tumors as a whole using the features shared by all cancers, for example relatively fast mitotic cell division or active angiogenesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32238865&#34; target=&#34;_blank&#34;&gt;Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median overall survival (OS) after MPE diagnosis was 9 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32312091&#34; target=&#34;_blank&#34;&gt;Differentiating Between Malignant Mesothelioma and Other Pleural Lesions Using Fourier Transform Infrared Spectroscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histopathology, despite being the gold standard as a diagnostic tool, does not always provide a correct diagnosis for different pleural lesions. […] Although great progress was made in this field, the problem to differentiate between reactive and malignant pleural lesions still stimulates the search for additional diagnostic tools.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32318342&#34; target=&#34;_blank&#34;&gt;Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In light of its aggressive nature, late diagnosis and dismal prognosis, there is an urgent need for identification of biomarkers in easily accessible samples (such as blood) for early diagnosis of MPM. […] In the last 10 years, epigenetic markers, such as DNA methylation and microRNAs (miRNAs), have gained popularity as possible early diagnostic and prognostic biomarkers in cancer research. […] The aim of this review is to provide a critical analysis of the current evidences on circulating epigenetic biomarkers for MPM and on their translational potential to the clinical practice for early diagnosis and for prognosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-04-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32330788&#34; target=&#34;_blank&#34;&gt;Modulation of microRNA expression levels after naturally occurring asbestiform fibers exposure as a diagnostic biomarker of mesothelial neoplastic transformation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Many diagnostic biomarkers have been proposed for MM. […] On these bases, the aim of the present study was to identify a set of miRNAs involved in the development and progression of MM and potentially used as diagnostic biomarkers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32330840&#34; target=&#34;_blank&#34;&gt;Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The presence of tumour-derived EV in circulating body fluids makes them potential novel biomarkers for early diagnosis, prognostication and surveillance of cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32339978&#34; target=&#34;_blank&#34;&gt;Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Overall survival (OS) was longer than 30 months from diagnosis for 27 patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32339986&#34; target=&#34;_blank&#34;&gt;Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Studies using immunohistochemical techniques to detect/quantify the expression of PD-L1 in MPM tissue were enrolled in the analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32345664&#34; target=&#34;_blank&#34;&gt;Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble mesothelin is currently considered the most specific diagnostic biomarker. […] Combining the data of each receiver-operating characteristic analysis predicted a good diagnostic accuracy. […] A panel of the putative biomarkers represents a promising tool for MPM diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32369821&#34; target=&#34;_blank&#34;&gt;Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis is complex, and the histologic classification includes 2 major subtypes of MPM: epithelioid (∼60% of cases) and sarcomatous (∼20%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32392897&#34; target=&#34;_blank&#34;&gt;Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Some studies average the prognosis to be roughly one-year after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32429446&#34; target=&#34;_blank&#34;&gt;Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The management of patients with MPM is controversial due to a long latency period between exposure and diagnosis and because of non-specific symptoms generally appearing at advanced stage of the disease. […] Breath analysis, aimed at the identification of diagnostic Volatile Organic Compounds (VOCs) pattern in exhaled breath, is believed to improve early detection of MPM. […] Considering that MPM is an aggressive neoplasm leading to a late diagnosis and thus the recruitment of patients is very difficult, a promising data mining approach was developed and validated in order to discriminate between MPM patients and healthy controls, even if no large population data are available. […] Ten VOCs, such as ketones, alkanes and methylate derivates, as well as hydrocarbons, were able to discriminate between MPM patients and healthy controls and for each compound which resulted diagnostic for MPM, the metabolic pathway was studied in order to identify the link between VOC and the neoplasm. […] Good agreement was found between the information obtained by gold-standard diagnostic methods such as computed tomography CT and model output.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32448904&#34; target=&#34;_blank&#34;&gt;ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32451346&#34; target=&#34;_blank&#34;&gt;ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally &lt;i&gt;via&lt;/i&gt; image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32475021&#34; target=&#34;_blank&#34;&gt;Breast metastasis as the initial presentation of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The epithelioid type of MPM can represent a diagnostic pitfall in this setting, as it shows similar histologic features to primary breast carcinoma as well as other metastatic epithelioid malignancies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-05-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32515059&#34; target=&#34;_blank&#34;&gt;Malignant asbestos-related disease in a population exposed to asbestos.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe malignant ARD cases by time of diagnosis, source of exposure, periods of exposure and latency, and distribution by sex.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32526494&#34; target=&#34;_blank&#34;&gt;Estimate of environmental and occupational components in the spatial distribution of malignant mesothelioma incidence in Lombardy (Italy).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We selected from the Lombardy Region Mesothelioma Registry (RML) all incident cases of MM (pleura, peritoneum, pericardium, and tunica vaginalis testis) with first diagnosis in the period 2000-2016.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32526924&#34; target=&#34;_blank&#34;&gt;Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These parameters are easy to analyse at the time of DMPM diagnosis and may support better patient stratification, prediction of treatment effectiveness and therapeutic optimization.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32531717&#34; target=&#34;_blank&#34;&gt;Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On multivariate analysis, positive predictors of survival after IPTW adjustment were female sex, diagnosis after 2005, and left-sided disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32540558&#34; target=&#34;_blank&#34;&gt;NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
IHC positive samples underwent RNA sequencing using the ArcherDX FusionPlex CTL diagnostic assay.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32542810&#34; target=&#34;_blank&#34;&gt;Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
BRCA1-associated protein 1 (BAP1) or methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) or 9p21 fluorescence in situ hybridization (FISH) are useful for the diagnosis of malignant pleural mesothelioma (MPM). […] However, the effect of these assays on the diagnostic yield of effusion cytology in MPM cases with suspicious cytomorphology or the diagnostic challenges in BAP1 or MTAP IHC have not been fully elucidated. […] Two cohorts of cytologic preparations obtained from pleural effusions were examined: MPM cases in cohort 1 were used to evaluate whether BAP1 or MTAP IHC or 9p21 FISH increase the diagnostic yield of effusion cytology; cohort 2 included cases suspicious for MPM, to which BAP1 or MTAP IHC was applied to clarify the challenges in the clinical assessment of these assays. […] The application of genomic-based assays increased the diagnostic yield of effusion cytology in the diagnosis of MPM. […] However, diagnostic challenges limit the application of these assays in some cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32562788&#34; target=&#34;_blank&#34;&gt;RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Mean total lung dose was reduced by 0.8 Gy with RP which enabled an increase in prescription dose by 1 fraction Absolute volume of ipsilateral lung was adequately spared by both techniques, while sparing of all other organs namely the cord, liver and bowel was not compromised with RP.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32568137&#34; target=&#34;_blank&#34;&gt;Predicting cancer using supervised machine learning: Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of Mesothelioma takes several months and is expensive. […] Given the risk and constraints associated with PM diagnosis, early identification of this ailment is essential for patient health. […] In this study, we use artificial intelligence algorithms recommending the best fit model for early diagnosis and prognosis of Malignant Pleural Mesothelioma (MPM).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-06-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32624414&#34; target=&#34;_blank&#34;&gt;Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aims of this study were to evaluate diagnostic accuracy in a group of patients with MPM with an unusually long survival time and to assess the factors related to this prolonged survival. […] In addition, all available histopathologic diagnostic samples and computed tomography studies were re-evaluated by experienced specialists. […] Our study showed a good diagnostic accuracy, with only 1 (0.5%) patient having an incorrect MPM diagnosis. […] LTS patients were younger, more frequently female, had a better performance status at time of diagnosis, and had less evidence of prior asbestos exposure. […] We confirmed the diagnosis of MPM in an overwhelming majority of patients in the LTS group.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32642113&#34; target=&#34;_blank&#34;&gt;Clinical long-term outcome of non-specific pleuritis (NSP) after surgical or medical thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Questions are raised whether the surgical (or video-assisted thoracoscopic surgery, VATS) is doing better than the medical thoracoscopy (MT or pleuroscopy), but no direct comparison between the two techniques exist in the current bibliography. […] The aim of our retrospective study was to compare these two techniques to find whether there is any difference in the false negative cases of NSP. […] In patients with histological diagnosis of NSP both VATS and MT showed similar and excellent results of false negative cases and negative predictive value in excluding malignant pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32676309&#34; target=&#34;_blank&#34;&gt;Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Exudative pleural effusion (EPE) is a common diagnostic challenge. […] The utility of medical thoracoscopy (MT) and closed pleural biopsy (CPB) to aid in the diagnosis of EPE has been reported in many published studies. […] Herein, we perform a systematic review and meta-analysis to compare the diagnostic yield and safety of CPB and MT in EPE. […] Four databases were searched for studies reporting the diagnostic yield of CPB and MT for EPE. […] The quality of the included studies was evaluated according to the quality assessment of diagnostic accuracy studies (QUADAS) tool. […] The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and complication risks were compared between the two groups. […] Ten studies dealing with CPB and twenty-three studies dealing with MT for the diagnosis of EPE were included in this meta-analysis. […] The pooled diagnostic accuracy of CPB and MT for mesothelioma was 26% (95% CI, 14-38%) and 42% (95% CI, 22-62%) (P&amp;lt;0.001), respectively. […] CBP is a relatively accurate tool with a lower complication rate compared to MT in the diagnosis of EPE, especially in diagnosing non-malignant diseases. […] We confirm the utility of MT in the diagnostic workup of malignancy (especially mesothelioma); however, in selected cases, CPB could be used as the first diagnostic approach with a favorable safety profile.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32676358&#34; target=&#34;_blank&#34;&gt;Clinical significance of histologic subtyping of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Despite multimodality treatments 5-year survival is only 5% after the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32676359&#34; target=&#34;_blank&#34;&gt;Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Beside preventive measures and ban the use of asbestos, early diagnosis would largely improve the chance of curative treatment. […] This effusion is easily accessible and offers early and minimally invasive diagnosis by combining cytology with immunologic, molecular- and biomarker analyses. […] This review summarizes molecular and diagnostic criteria of MM diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32678499&#34; target=&#34;_blank&#34;&gt;Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. […] The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16 status in effusion specimens preceding the tissue diagnosis of mesothelioma would improve diagnostic accuracy and allow an earlier diagnosis of malignancy. […] The study cohort included 99 matched cytology fluid specimens from 74 patients with a surgical specimen diagnosis of malignant mesothelioma (67 epithelioid, 7 biphasic, 55 pleural, and 19 peritoneal). […] In some cases, the diagnosis of mesothelioma could have been made up to 9 months before biopsy. […] Overall, loss of BAP1 and/or CDKN2A/p16 homozygous deletion would change the diagnostic interpretation in 37 of 60 (62%) (P = .07) effusion specimens, particularly in pleural effusions (32 of 48 samples) (P = .002). […] These findings suggest that routine use of BAP1 immunochemistry and p16 FISH as adjunctive tests improves the diagnostic accuracy of cytology specimens and potentially allows an earlier diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32682189&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Patient and tumor characteristics at time of diagnosis, as well as subsequent treatments (surgery, radiation, and chemotherapy), were collected. […] The median age at diagnosis was 68 years, mainly with epithelioid histology (62 %), and any asbestos exposure was noted in 45 % of patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32699075&#34; target=&#34;_blank&#34;&gt;Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Soluble Mesothelin-Related Proteins (SMRP) have been characterized extensively and constitute an FDA-approved biomarker in plasmawith diagnostic, monitoring and prognostic value in MPM. […] Osteopontin is found to be a valuable prognostic biomarker for MPM, while its utility in diagnosis is slightly lower. […] A comprehensive understanding of previously investigated biomarkers and their utility in screening and early diagnosis of MPM will provide guidance for further future research.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32700418&#34; target=&#34;_blank&#34;&gt;Laser ablation inductively coupled plasma mass spectrometry as a Novel Clinical Imaging Tool to Detect Asbestos Fibres in Malignant Mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Difficulties remain in relation to early diagnosis, notably due to impeded identification of asbestos in lung tissue. […] Asbestos fibres detection in the lung tissues is very useful, if not necessary, to complete the pathological diagnosis of asbestos-related malignancies in medicolegal field.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32710945&#34; target=&#34;_blank&#34;&gt;New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Late diagnosis, poor survival rates, lack of diagnostic and prognostic markers act as major impediments in the clinical management of MM. […] We review microRNAs (miRNAs) and the miRNA interactome implicated in MM which can be useful as circulating miRNA biomarkers for early diagnosis of MM and as biomarkers for prognostication in MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32726133&#34; target=&#34;_blank&#34;&gt;Normal Mesothelial Cell Lines Newly Derived from Human Pleural Biopsy Explants.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Human pleural membrane was harvested by minimally invasive surgical techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32727552&#34; target=&#34;_blank&#34;&gt;Determinants of plasma calretinin in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. […] The suitability of plasma calretinin has been confirmed as a tumor marker in the differential diagnosis of epithelioid MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32731396&#34; target=&#34;_blank&#34;&gt;Multiplex Soluble Biomarker Analysis from Pleural Effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic distinction from other malignancies and reactive conditions is done using histopathology or cytopathology, always supported by immunohistochemistry, and sometimes also by analyses of soluble biomarkers in effusion supernatant. […] We evaluated the soluble angiogenesis related molecules as possible prognostic and diagnostic biomarkers for MPM by Luminex multiplex assay. […] Collectively, our data suggest that MMP-7, shed SDC-1, Mesothelin and Galectin-1 can be diagnostic and VEGF and SDC-1 prognostic markers in MPM patients. […] Additionally, Galectin-1, HGF, Mesothelin, MMP-7, Osteopontin, shed SDC-1 and TIMP-1 can be diagnostic for malignant cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/32732250&#34; target=&#34;_blank&#34;&gt;Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Targeted proteomics allowed the development of a multi-analyte signature with diagnostic and prognostic potential for MPM from the blood. […] The proteomic signature represents an additional diagnostic approach for informing clinical decisions for patients at risk for MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2020-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3288807&#34; target=&#34;_blank&#34;&gt;Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
There were 106 pleural and peritoneal effusions studied in order to investigate the contribution of immunocytochemistry and flow cytometry to routine cytologic diagnosis. […] Furthermore, evident DNA-aneuploidy strongly supported the diagnosis of adenocarcinoma, as most malignant mesotheliomas were DNA-euploid, even though occasional DNA-aneuploidy was found in malignant mesotheliomas when different effusions from the same patient were examined. […] In 16 patients (17%) performing immunopathology and/or flow cytometry meant an important contribution to diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3293765&#34; target=&#34;_blank&#34;&gt;Mesothelioma of childhood.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Eighty children with a previous diagnosis of MM were identified. […] Four died at 7, 8, 18, and 48 months after diagnosis; three remained alive at 19, 20, and 59 months; and three had no follow-up. […] The tissue diagnosis is difficult and is best made by a panel of pathologists.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-09-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3327479&#34; target=&#34;_blank&#34;&gt;[Histologic aspects of pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors insist, in the basis of literature data, in the importance of the positive and differential diagnosis concerning the primitive and secondary epithelial tumors of the lung. […] The means of diagnosis are represented currently by cytology and histopathology and also by cytochemistry and immunohistochemistry.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-04-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3335148&#34; target=&#34;_blank&#34;&gt;Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Survival, estimated by the actuarial method, was 54 percent at one year from first symptoms and 39 percent from histologic diagnosis. […] No subject was alive four years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-02-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3335886&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965-1985.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Factors at diagnosis associated with a significantly prolonged survival for all patients with mesothelioma included a 0 to 1 performance status, absence of chest pain, age less than 50 years, and epithelial histology. […] Factors at diagnosis associated with prolonged survival for the subset of patients with pleural mesothelioma included epithelial histology, 0 to 1 performance status, the absence of chest pain, an interval of greater than 6 months from onset of symptoms, and treatment with chemotherapy and pleuropneumonectomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-02-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3348058&#34; target=&#34;_blank&#34;&gt;Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunoelectron microscopy was performed both on Lowicryl-embedded sediments of serous fluids and by application of preembedding techniques using the immunogold method. […] The results indicate that immunoelectron microscopy may offer a useful adjunct in the diagnosis of malignant mesothelioma in serous fluids.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3348994&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of mesothelioma was accepted only after all available clinical, radiological, and pathological material was reviewed by our laboratory and histopathological confirmation by the pathology unit made in each case. […] The most effective approach to the diagnosis of malignant pleural mesothelioma in these cases was by open lung biopsy; exploratory laparotomy was best for diagnosing peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-05-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3351560&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival (MS) from diagnosis was 9.6 months. […] In a univariate analysis, significant favorable prognostic factors were good performance status (PS), duration of symptoms greater than 6 months at the time of diagnosis, early stage of disease, white race, and female sex.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3359447&#34; target=&#34;_blank&#34;&gt;Case-control study of diet and mesothelioma in Louisiana.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirty-seven patients with malignant mesothelioma of the pleura (n = 32) or peritoneum (n = 5) were matched to controls according to age, sex, race, and factors related to case ascertainment (hospital and date of diagnosis, or parish and date of death).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3370618&#34; target=&#34;_blank&#34;&gt;Freeze-fracture study of intercellular junctions in benign and malignant mesothelial cells in effusions and a comparison with those seen in pleural mesotheliomas (solid tumour).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study involves an analysis by thin section and freeze-fracture techniques of the intercellular junctions of exfoliated benign and malignant mesothelial cells obtained from 4 cases, two benign and two malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3375957&#34; target=&#34;_blank&#34;&gt;Surgical treatment of asbestos-related disease of the chest.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The benign localized mesothelioma is usually considered in the differential diagnosis of pleural tumors, but it is not related to asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3409188&#34; target=&#34;_blank&#34;&gt;Thrombocytosis in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distribution of platelet counts did not differ in the diagnostic subgroups, and thrombocytosis had no differential diagnostic value in patients with malignant disease in any stage in the pleurae.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3414598&#34; target=&#34;_blank&#34;&gt;Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant epithelial mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although only 53% of the mesotheliomas were DNA aneuploid, the finding of DNA aneuploidy in an effusion specimen that contains atypical mesothelial cells would strongly support a diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-10-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3469845&#34; target=&#34;_blank&#34;&gt;Computerized interactive morphometry as an aid in the diagnosis of pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The data were interpreted by two independent methods: a statistical method of discriminant analysis that classifies the lesions as benign, carcinoma or mesothelioma and provides a probability statement of membership in a particular diagnostic class and an ad-hoc algorithm that categorizes the effusions as benign or malignant based on hierarchic analysis. […] A data base derived from study of the first 24 cases was constructed and utilized for the test classification of the second 24 cases, which were treated as specimens of unknown diagnosis. […] The discriminant analysis correctly classified 21 of the 24 test cases into their proper diagnostic groups. […] The algorithm for a computer-generated pathologic diagnosis correctly identified 47 of the 48 cases as benign or malignant.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3469852&#34; target=&#34;_blank&#34;&gt;Fine needle aspiration cytology of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Adequate material for a diagnosis of malignancy was obtained in 17 cases, and in 8 cases a specific diagnosis of mesothelioma could be made. […] In four neoplasms, ultrastructural examination of aspirated material provided the additional evidence for a definitive diagnosis. […] The identification of hyaluronic acid within intracytoplasmic vacuoles, either in smears or in cell blocks, confirmed the diagnosis in three tumors. […] Only in one case, with a strong clinical background suggesting mesothelioma, was the cytologic preparation sufficient for diagnosis without ancillary diagnostic methods. […] FNA is of particular value in the diagnosis of pleural mesothelioma in patients who do not present with a pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-04-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3541812&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Correct diagnosis of the benign variant is rarely made preoperatively, and resection is the treatment of choice and is curative. […] Their diagnosis and treatment do not differ from those for soft-part sarcomas seen elsewhere.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-02-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3542255&#34; target=&#34;_blank&#34;&gt;Asbestos-related malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A large piece of tissue obtained via open biopsy is usually required for histologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-03-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3567871&#34; target=&#34;_blank&#34;&gt;Serum hyaluronate in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic value of hyaluronate concentration in effusions of malignant mesothelioma has been extensively reported but no information is available about serum hyaluronate in patients with this cancer.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3580194&#34; target=&#34;_blank&#34;&gt;Benign and malignant mesothelial lesions of the pleura: quantitative study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Numerical data are studied in a multivariate statistical analysis in order to obtain the probability of the morphometric diagnosis in each case. […] Results demonstrate that the most important measurements are the percentage of cells with evident nucleolus, the nuclear perimeter and the standard deviation of the DNA content, and that these measurements give a correct diagnosis in all cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3602591&#34; target=&#34;_blank&#34;&gt;Accuracy of diagnostic procedures in the initial evaluation and follow-up of mesothelioma patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In an attempt to compare various methods of diagnosis in this entity, emphasis was laid on specific abilities and limitation of investigations such as pleural biopsy, pleural fluid cytology, diagnostic thoracoscopy and thoracotomy and radiological studies including computed tomography and magnetic resonance imaging.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-07-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3616223&#34; target=&#34;_blank&#34;&gt;The cytologic diagnosis of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A positive cytoplasmic staining of tumor cells with periodic acid-Schiff (PAS) after diastase digestion, and with mucicarmine stain after hyaluronidase treatment are against the diagnosis of mesothelioma, while positive staining with alcian blue, which becomes negative after the treatment with hyaluronidase is strongly suggestive of mesothelioma. […] An accurate diagnosis of mesothelioma depends on a full knowledge of the clinical history and radiologic findings, and proper application of histochemical, immunodiagnostic, and electron microscopic techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3619593&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of the pleura–intrapleural treatment with doxorubicin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of diffuse mesothelioma of the pleura means a very bad prognosis. […] Doxorubicin, linked with a really early diagnosis, seems to be a suitable drug for essentially improving the prognosis of disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3659577&#34; target=&#34;_blank&#34;&gt;High incidence of malignant pleural mesothelioma in neighbouring villages of Northwestern Greece.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was made with pleural biopsy and pleural fluid cytology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3689066&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma with occupational and environmental asbestos exposure in an Illinois community hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Median age at diagnosis was 67 years, and median survival after diagnosis, seven months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1988-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3704398&#34; target=&#34;_blank&#34;&gt;[Malignant diffuse peritoneal mesothelioma: clinical and therapeutic aspects. Apropos of a case with gelatinous ascites].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A well-established clinical entity since 1960, mesothelioma is increasingly frequent due to improvements in diagnostic methods and to the fairly wide industrial use of asbestos, a well-known carcinogenic substance for mesothelial cells. […] The diagnosis of malignant peritoneal mesothelioma rests on a corpus of convergent data. […] The mean survival from the time of diagnosis is 8-10 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-06-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3713140&#34; target=&#34;_blank&#34;&gt;Applications of computerized interactive morphometry in pathology. II. A model for computer generated diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We present a model for the analysis and tentative diagnosis of pathologic problems by a trained observer utilizing data generated by a video based computerized interactive morphometry system in conjunction with multivariate methods of discriminant classificatory analysis that separate classes based on unweighted numerical values and with adhoc algorithms based on hierarchical analysis. […] The model was tested with two diagnostic problems that could benefit from a morphometric approach: the classification of non-Hodgkin’s lymphomas from routine histologic slides and the distinction of malignant mesotheliomas from benign effusions in smears prepared from pleural effusions. […] This procedure generates multiple data in the form of classes that can be effectively used toward the more objective discrimination of lesions of difficult classification by analysis with a combination of adhoc diagnostic algorithms and multivariate statistical methods.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-07-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3717302&#34; target=&#34;_blank&#34;&gt;Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is concluded that monoclonal antibodies 44-3A6 and 624A12 are excellent phenotypic markers of metastatic pulmonary adenocarcinomas to the pleura and thus are useful for the differential diagnosis of pleural mesotheliomas. […] Given conventionally fixed and processed tissues, it appears that the combined use of these monoclonal antibodies may be more effective for that differential diagnosis than anti-CEA and anti-keratin antibodies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-07-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3720479&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma cells in sputum.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In one patient, the specimen was received early in the diagnostic work-up and led to a strong consideration of the diagnosis of adenocarcinoma. […] In the remainder, the finding was incidental, occurring after the diagnosis of mesothelioma had been established. […] The cases are reported to draw attention to this phenomenon, previously unreported in the cytologic literature, and to emphasize that the finding of malignant cells in sputum does not preclude the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3749785&#34; target=&#34;_blank&#34;&gt;Diagnostic value of ferritin analysis in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the differentiation between exudates and transudates, the diagnostic accuracy of Pl-ferritin was only slightly lower compared to Pl-protein and Pl-albumin. […] With the present method, analysis of Pl-ferritin appears to be of limited value in the routine diagnostic evaluation of pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-10-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3774191&#34; target=&#34;_blank&#34;&gt;[pH measurement in the diagnosis of pleural exudates].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic accuracy of pH measurement of various types of pleural exudate is examined. […] Despite the limitations of this examination it is easy and quick to perform and offers an undeniable diagnostic validity especially in the case of pleural transudates or malignant effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-12-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/378353&#34; target=&#34;_blank&#34;&gt;Immunodiagnosis of mesothelioma: use of antimesothelial cell serum in an indirect immunofluorescence assay.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The antisera were used to confirm the diagnosis of mesothelioma in two cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-09-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3817763&#34; target=&#34;_blank&#34;&gt;Secretory component in pulmonary adenocarcinoma and mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
None of the mesotheliomas examined contained secretory component and this may be an additional useful feature in the differential diagnosis between mesothelioma and adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1987-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3836085&#34; target=&#34;_blank&#34;&gt;Cytopathology of asbestos-associated pulmonary disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The goal of this investigation was to determine the practical role of cytopathology in the clinical and laboratory diagnosis of asbestos-related pulmonary diseases. […] It is concluded that sputum cytology screening represents a practical, noninvasive, and inexpensive approach to the diagnosis and study of asbestos exposure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3859121&#34; target=&#34;_blank&#34;&gt;The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine the usefulness of the electron microscopic (EM) differential diagnosis between malignant mesothelioma and metastatic adenocarcinoma in cytologic specimens of serous fluids, we undertook a prospective study of 17 pleural and peritoneal effusions from 14 patients. […] EM resolved the differential diagnosis of mesothelioma versus adenocarcinoma in three cases in which routine cytologic examination could not. […] This technique will be diagnostically useful in selected cases and may be helpful in avoiding more invasive procedures as well as delays in diagnosis and therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-07-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3891207&#34; target=&#34;_blank&#34;&gt;Benign and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of a malignant pleural mesothelioma is not difficult provided that the physicians caring for such a patient consider mesothelioma in the differential diagnosis. […] The tumor characteristically remains localized until late in its course, and thus extensive workup at the time of diagnosis is seldom required. […] Generally, a large piece of tissue obtained via an open biopsy is required for adequate histologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-08-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3905413&#34; target=&#34;_blank&#34;&gt;The role of concurrent determinations of pleural fluid and tissue carcinoembryonic antigen in the distinction of malignant mesothelioma from metastatic pleural malignancies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Hence T-CEA content should be determined in the PF-CEA-negative cases when an early and definite diagnosis of tumour type is required to enable correct management of these patients. […] These ancillary tests aim at enhancing the level of confidence of the routine morphological diagnosis of serous surface malignancies in living patients using minimal intervention instead of resorting to open chest surgery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1986-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3925619&#34; target=&#34;_blank&#34;&gt;The use of vimentin antibodies in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An immunohistochemical investigation of vimentin, an intermediate filament, was carried out on formalin fixed paraffin embedded sections of 44 malignant mesotheliomas of the pleura and 24 pulmonary adenocarcinomas, in order to assess its value in differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3974296&#34; target=&#34;_blank&#34;&gt;Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nearly half of the patients with lymphoma had lymphocytosis of the pleural fluid, but neither this finding nor the lymphocytic pleuritis noted on biopsy was diagnostic of lymphomatous involvement of the pleura. […] Among the patients with malignant mesothelioma, thoracotomy was necessary to confirm the diagnosis in 60.9%. […] In the patients with nonmalignant diseases, with the exception of six with tuberculous pleurisy, pleural biopsy was nondiagnostic even though the causes of pleural effusion were apparent from the clinical features.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-04-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/3987190&#34; target=&#34;_blank&#34;&gt;[Malignant diffuse pleural mesothelioma: a comparison between computed tomography and the conventional chest x-ray].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The rate of incidence of malignant pleural mesothelioma is increasing although diagnosis of this disease may be very difficult. […] CT proves more accurate in assessing the extent of the disease, and gives additional diagnostic help.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/4005813&#34; target=&#34;_blank&#34;&gt;Glycosaminoglycans in malignant diffuse mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of frequently encountered diagnostic difficulty due to a morphologic similarity between diffuse pleural mesothelioma and peripheral pulmonary adenocarcinoma, glycosaminoglycans (GAG) of human malignant diffuse mesothelioma were histochemically stained and chemically quantitated, and were compared with GAG of papillary adenocarcinoma of the lung. […] In all seven patients, the diagnosis of diffuse mesothelioma was confirmed morphologically by such findings as abundant bushy microvilli on cell surface and intermediate filaments in cytoplasm. […] The results suggest that chemical analysis of GAG may be useful as supplementary diagnostic procedure to morphologic examination in the differentiation of diffuse mesothelioma from papillary adenocarcinoma of the lung.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/4016008&#34; target=&#34;_blank&#34;&gt;Modified nucleosides in asbestos workers at high risk of malignant disease: results of a preliminary study applying discriminant analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results suggest that measuring modified nucleosides levels in the urine of asbestos exposed workers, and perhaps others exposed to carcinogenic agents, has the potential for identifying, through multivariate statistical techniques, individuals who are at high neoplastic risk.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-09-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/4037997&#34; target=&#34;_blank&#34;&gt;Biochemical and cytological features of diffuse mesotheliomas of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The synopsis of the named parameters together with clinical dates in general use gives the possibility to put up the diagnosis of the primarily malignant disease of the pleura during lifetime of a patient.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/4062141&#34; target=&#34;_blank&#34;&gt;[Bromocriptine in Parkinson’s disease: pleuropulmonary toxicity].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The initial diagnostic problems are stressed, particularly with respect to malignant disease (mesothelioma) when there has been exposure to asbestos, as in our case.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-12-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/436163&#34; target=&#34;_blank&#34;&gt;[Pleural and peritoneal cytology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic certainty of examination was 93.4%. […] A positive finding in both techniques occurred in 59.0%, in 4.5% the spread was negative and the histological section from the sediment positive; in 8.6% it was the other way round. […] In 13.1% the diagnosis was thus possible by the combination of spreads with a cytohistological technique.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/473818&#34; target=&#34;_blank&#34;&gt;[Differential diagnosis of pleural diseases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A clarification is possible by means of the diagnostic pneumothorax, the pleuroscopy and the exploratory excision under vision.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-10-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/4742473&#34; target=&#34;_blank&#34;&gt;Epidemiologic surveillance of mesothelioma in Canada.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of mesothelioma was approved by the Canadian Mesothelioma Panel in 59%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1973-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/5070255&#34; target=&#34;_blank&#34;&gt;Exfoliative cytology of diffuse mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is suggested that only if malignant cells of this type are recognized should the probable diagnosis of diffuse mesothelioma be made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1972-11-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/540318&#34; target=&#34;_blank&#34;&gt;[Diffuse malignant mesothelioma of the pleura and peritoneum].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An analysis is presented of 14 cases of diffuse mesothelioma [one of them involving the peritoneum, the rest being of the pleural type] in postmortem material for a period of 18 years [1962–1978] with a view to the clinical course, macroscopic and microscopic pictures, diagnostic possibilities, and to the relationship to aetiological factors. […] A meticulously performed postmortem examination appears to be the most reliable diagnostic criterion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/573917&#34; target=&#34;_blank&#34;&gt;[Ultrastructural diagnostic problems of pleural tumors. A study of 125 cases (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ultrastructural studies may improve the diagnosis of pleural tumors. […] A comparative study of 125 primary and secondary pleural cancers provided the major structural features needed for differential diagnosis. […] It was difficult to assess the diagnosis of malignant mesothelioma on isolated differentiated mesothelial cells in pleural fluids or biopsies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/580658&#34; target=&#34;_blank&#34;&gt;[The computed tomography of the malignant thoracic space-occupying process under special consideration of radiotherapeutic points of view (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The data of 70 patients with a malignant thoracic space-occupying process were compared in order to find out the differences between computed tomography and conventional X-ray diagnosis (thorax radiography, hilum tomography), the radiotherapeutic aspects of these methods being taken under special consideration. […] Contrary to thorax radiography and hilum shadow, the computed tomography offers some additional diagnostic information in several special fields.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1978-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/581813&#34; target=&#34;_blank&#34;&gt;[Rare malignant tumors of the lungs (44 cases)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Rare malignant lung tumors (especially sarcomas, plasmocytomas, mesotheliomas) show a definite specificity of clinico-roentgenological manifestations, that should be taken into accout in establishing the differential diagnosis. […] The ultimate diagnosis was most frequently put after histological assay of the removed neoplasm.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-05-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/594007&#34; target=&#34;_blank&#34;&gt;[Asbestosis. Apropos of one case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis rests mainly on professional anamnesis and on the presence of great quantities of asbestos bodies in the sputum.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1978-02-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6083969&#34; target=&#34;_blank&#34;&gt;Immunohistological study of malignant diffuse mesotheliomas of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Amongst the markers used, CEA seems the most useful for the differential diagnosis between carcinoma and mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6196931&#34; target=&#34;_blank&#34;&gt;Oncofetal antigens as tumor markers in the cytologic diagnosis of effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To test the value of oncofetal antigens in the cytologic diagnosis of effusions, immunoperoxidase staining with antisera to carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), pregnancy-specific beta 1-glycoprotein (SP1) and placental alkaline phosphatase (PLAP) was carried out on pleural and peritoneal fluids from 72 cases. […] In 5 of the 24 cases with positive staining, a confident diagnosis of malignancy had not been made on routine cytologic preparations. […] Immunoperoxidase staining for CEA appears to be of supportive value in the cytologic diagnosis of malignancy in effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6198832&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Of the three major histologic varieties of mesothelioma (epithelioid, fibrous and mixed, or biphasic), the epithelioid and biphasic types were associated with four cytomorphologic features useful in the diagnostic evaluation: (1) the presence of abnormal cells, apparently mesothelial, (2) nuclei with subtle malignant features, (3) the presence of cells showing transitional forms from normal to abnormal in the same sample and (4) the presence of large tissue fragments. […] Three histochemical reactions were found to be valuable adjuncts to diagnosis in the differentiation of the primary malignancies of the serous membranes from metastatic cancers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6202538&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy was a useful diagnostic alternative to thoracotomy. […] Skin deposits of tumour in sites of previous invasive procedures did not cause pain or other clinical problems, and we consider that diagnostic and therapeutic procedures should not be withheld to avoid them.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6202620&#34; target=&#34;_blank&#34;&gt;Localized fibrous mesothelioma: an immunohistochemical and electron microscopic study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The absence of keratin staining in tumor cells from localized fibrous mesotheliomas in both paraffin-embedded and frozen sections with sensitive peroxidase-antiperoxidase and avidin-biotin techniques is described.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-07-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6281166&#34; target=&#34;_blank&#34;&gt;Fiber counting and analysis in the diagnosis of asbestos-related disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Analysis of numbers and types of asbestos fibers present in lung tissue may provide insights into the pathogenesis of asbestos-induced disease, as well as diagnostic information concerning the relationship of a given lesion to asbestos exposure. […] This type of analysis requires extraction of fibers and asbestos bodies from lung tissue, preferably by means of a digestion-and-concentration technique, and examination with a combination of electron optical techniques, including electron diffraction and energy-dispersive x-ray spectroscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6287872&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study provides quantitative and qualitative ultrastructural features of potential utility in the differential diagnosis of pleural mesotheliomas and adenocarcinomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6287988&#34; target=&#34;_blank&#34;&gt;Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Analysis of the survival of all 81 cases of pathologically confirmed malignant pleural mesothelioma in Western Australia between January 1957 and December 1980 has revealed a median survival from diagnosis of 5.1 months (mean 7.8 months). […] The average time between presentation and diagnosis was 3.4 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6290965&#34; target=&#34;_blank&#34;&gt;Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A dual negative result for CEA and mucin, although not proving that a given lesion is a mesothelioma, adds considerable support to this histological diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6346786&#34; target=&#34;_blank&#34;&gt;Pseudomesotheliomatous carcinoma of the lung with histochemical and immunohistochemical study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From these findings, the authors made a diagnosis of poorly differentiated adenocarcinoma, which was characterized by the production of hyaluronic acid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6362839&#34; target=&#34;_blank&#34;&gt;Carcinoembryonic antigen in pleural effusions. Diagnostic value in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The usefulness of the determination of carcinoembryonic antigen (CEA) in pleural effusion was assessed as an aid to the diagnosis of malignant mesothelioma. […] The CEA assay in pleural effusion proved to be a valuable adjunct to other diagnostic procedures in differentiating the malignant mesothelioma from metastatic serosal spread.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6379132&#34; target=&#34;_blank&#34;&gt;Diagnosis of pleural malignant mesothelioma in life–a practical approach.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This review documents a practical approach to the pathological diagnosis of pleural malignant mesothelioma based on the closed needle biopsy and effusion cytology, thus avoiding the need to resort to open surgery. […] Tissue diagnosis is often difficult, and the pathologist’s opinion may be influenced by a consideration of three factors: the clinical setting; the adequacy and availability of specimens; and the criteria for assessment and interpretation of these. […] The level of confidence with which a tissue diagnosis of mesothelioma can be established using limited material depends on there being an appropriate clinical background including a history of asbestos exposure. […] Without this, the diagnosis should be a qualified or tentative one. […] A combined interpretive approach utilizing both histopathology and cytology is recommended in order to increase the accuracy of the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-08-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6406317&#34; target=&#34;_blank&#34;&gt;[Thoracoscopic and computer tomographic findings in pleural mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
On CT, the tumour was not obscured by pleural effusion and the differential diagnosis of masses in the chest wall becomes narrower. […] Once the diagnosis has been confirmed histologically, CT demonstrates the tumour clearly. […] CT is an advance in the diagnosis of these rare tumours; it aids in arriving at a prognosis and in formulating treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-07-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/644536&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura in Barrow-in-Furness.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Only one patient, a housewife, aged 28 at diagnosis, had no known asbestos contact. […] A positive histological diagnosis was achieved in 39 subjects during life in the expectation of securing industrial compensation, but, in spite of this, less than half of the dependants are currently receiving payments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1978-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6467141&#34; target=&#34;_blank&#34;&gt;Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Twenty consecutive patients with a confirmed diagnosis of diffuse malignant mesothelioma of the pleura or peritoneum, previously untreated with chemotherapy, were studied in a Phase II trial of single-agent 5-fluorouracil.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-10-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6522932&#34; target=&#34;_blank&#34;&gt;[Thoracoscopy with pleural brushing. A new diagnostic method for pleural diseases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The combined use of all three methods of diagnosis (macroscopy, biopsy, cytology) achieved optimal diagnostic results. […] The diagnosis was in 37 cases non malignant disease states associated with effusions and in 71 cases tumoural effusions. […] We studied the diagnostic accuracy of pleural brushing: in non malignant diseases pleural brushing show the non tumoural features of the process, in metastatic tumours biopsy was positive in 80% of the cases; pleural brushing in 78% of cases; taken together they allowed the diagnosis in 86% of the cases, in carcinomatous mesotheliomas biopsy was positive in 82.3%, pleural brushing in 78%; taken together they allowed the diagnosis in 89% of the cases. […] Pleural brushing allows a rapid cytological diagnosis, enhances the histological results and may be used to get cellular material in areas dangerous to biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6543973&#34; target=&#34;_blank&#34;&gt;[Radiologic diagnosis in malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differential diagnosis between malignant mesothelioma and other primary or secondary pleural tumors is difficult and always requires a confirmation by multiple biopsies and/or thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1985-11-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6588749&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Collagen production by tumor cells when identifiable was diagnostic of DMM and was found not only in sarcomatous and “biphasic” mesotheliomas but also focally in “epithelial” variants.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-07-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6622324&#34; target=&#34;_blank&#34;&gt;Asbestos exposure. An update on pleuropulmonary hazards.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, a concomitant finding of pleural plaques strongly suggests the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-11-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6631560&#34; target=&#34;_blank&#34;&gt;Mesothelioma in Connecticut, 1955-1977. Occupational and geographic associations.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
AR was 81% in men aged 70 to 89 years at diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6636462&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in urban dogs.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical and postmortem materials from six dogs with a diagnosis of malignant mesothelioma were studied retrospectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6648341&#34; target=&#34;_blank&#34;&gt;Scope of scanning electron microscopy, transmission electron microscopy and freeze fracture technique in diagnostic cytology of effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A review of the literature on the application of scanning electron microscopy (SEM) and transmission electron microscopy (TEM) to cytodiagnosis of neoplastic cells in effusion fluid reveals a lack of consensus as to which of the techniques is most beneficial to a cytologist for a satisfactory diagnosis. […] The purpose of this study is therefore to critically evaluate the relative merits of SEM, TEM and freeze-fracture (FF) techniques in enhancing the diagnostic “sensitivity” of ultrastructural cytology. […] Two cases of adenocarcinoma, one case of mesothelioma and one case of small cell undifferentiated carcinoma of the lung were studied in detail by SEM, TEM and FF techniques. […] The major handicap of SEM becomes evident in cases where the extreme variability of the surface morphology amongst tumour cells makes it difficult to establish a diagnosis with confidence. […] TEM along with light microscopy (LM) of toluidine blue sections gives us the most comprehensive method for cyto-diagnosis and is particularly useful in cases where LM cytology alone is inconclusive. […] FF technique, though not conducive to a routine diagnostic situation, is of benefit in demonstrating the organization of junctional complexes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6668488&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma following radiation exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Problems in the diagnosis of radiation-associated mesotheliomas are considered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6691935&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The interobserver variability may result from different awareness of MM occurrence, a lack of precise histopathological criteria for the diagnosis, or the influence of a history of exposure to asbestos on the interpretation. […] A history of exposure to asbestos may bias interpretation of histopathology and should not be used to make the histological diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-03-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6692681&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: the role of computed tomography.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Computed tomography also has a role in differential diagnosis. […] It aids, but may not be diagnostic, in separating malignant pleural mesothelioma from metastases to the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6697895&#34; target=&#34;_blank&#34;&gt;[Mesothelioma as an index tumor of the occupational hazard of asbestos dust].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Each diagnosis of mesothelioma initiates the suspicion and thus the medical duty of notification of an occupational disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-04-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6719076&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma. A clinical review of 19 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 16 fatal cases the post-diagnosis survival time was 1-113 (median 17) months. […] Frequent X-ray examination of risk groups seems to offer the only prospect of improving management by earlier diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-06-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6723346&#34; target=&#34;_blank&#34;&gt;The radiology of thoracic malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Formerly considered to be rare, primary malignant mesothelioma of the pleura has become a frequently diagnosed tumor during the last 30 years because of a more specific diagnostic criteria and because of its relationship with asbestos exposure. […] The differential diagnosis radiologic findings and the relationship between these changes and the pathology clinical picture and the prognosis in this important disease entity is discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6723826&#34; target=&#34;_blank&#34;&gt;Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Microscopic examination of pleural tissue specimens, preferably selected at thoracoscopy, proved superior to pleural fluid analysis as an aid to correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1984-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6789635&#34; target=&#34;_blank&#34;&gt;CT of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When an irregular, pleural-based mass involving most of the hemithorax is identified on CT, the diagnosis of mesothelioma can be suggested and at the same time the extent of the tumor may be evaluated. […] This is important because the diagnosis of mesothelioma is difficult and because treatment and prognosis may depend on the extent of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6790917&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in children: report of seven cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The other five patients died within two years of the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-10-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6846965&#34; target=&#34;_blank&#34;&gt;DNA flow cytometry of pleural effusions. Comparison with pathology for the diagnosis of malignancy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A study was undertaken to determine the potential value of DNA flow cytometry (FCM) for the diagnosis of malignancy in pleural effusions and to compare its results with those of traditional cytomorphology. […] Forty-one pleural fluids from 37 patients were evaluated by DNA FCM and routine cytologic techniques. […] Our preliminary observations indicate that FCM is an accurate and reliable technique that may be of aid in the diagnosis of malignant effusions. […] The technique may prove to be of special value in the differential diagnosis of reactive mesothelial cells versus malignant mesothelioma as well as for following patients who receive chemotherapy for malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-06-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6866894&#34; target=&#34;_blank&#34;&gt;[Clinical aspects and course of 38 cases of malignant pleural mesothelioma observed in the Marseilles region].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Confirmation of diagnosis requires wide pleural biopsies, because of the high level of false negatives and false positives from cytology and pleural needle biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-08-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6876410&#34; target=&#34;_blank&#34;&gt;[Malignant thymoma with diffuse extensive growth on the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Upon pleural biopsy, a diagnosis of lymphosarcoma, well differentiated type, was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-09-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6884452&#34; target=&#34;_blank&#34;&gt;Trephine drill biopsy in the diagnosis of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Trephine drill biopsy of the pleura was utilized to establish the diagnosis of malignant pleural mesothelioma in a patient with a thickened pleura without pleural effusion.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1983-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6889732&#34; target=&#34;_blank&#34;&gt;Ultrastructural diagnosis of pleural tumors.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differentiated mesothelial cancer cells (MCC’s), whether they are observed in fluids or in biopsies, are not caracteristic enough to assert the diagnosis of mesothelioma. […] Therefore, the diagnosis of mesothelioma relies on the identification of fibroblastoid MCC’s, whether they are in association with the preceeding form in epithelial-like tumors, or the main component in sarcomatous-like tumors. […] Since the absence of fibroblastoid MCC’s would eliminate the diagnosis of mesothelioma, patient and careful search for these cells must be done in all pleural tumors with a unique differentiation (epithelial-like or sarcomatouslike). […] This justifies the need for electron microscopy in the diagnosis of these pleural tumors: for this reason, pleural biopsies should routinely be embedded for possible future ultrastructural examination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-12-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6991044&#34; target=&#34;_blank&#34;&gt;Pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis can usually be established by clinical assessment, chest radiography, analysis of pleural fluid, pleural biopsy, and appropriate special investigations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/6993202&#34; target=&#34;_blank&#34;&gt;Mesothelioma in man and experimental animals.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic difficulties may to some degree blur the extent of its prevalence and reliance on exposure history may not reveal its association with asbestos.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7035498&#34; target=&#34;_blank&#34;&gt;Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This distinction cannot always be made on morphological grounds alone and problems of differential diagnosis are encountered in about 15% of all specimens of serous effusions sent for cytological examination. […] The technique proved to be especially useful in cytologically equivocal cases, where there were problems of differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7051806&#34; target=&#34;_blank&#34;&gt;Chemotherapy for malignant mesothelioma; CAMEO.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Twelve patients with a tissue diagnosis of malignant mesothelioma were treated with combination chemotherapy (CAMEO) every 4-5 weeks, with or without hemithoracic radiation. […] Mean survival from the time of tissue diagnosis an start of protocol treatment was 15.7 and 12.6 months, respectively. […] Median survival from the time of tissue diagnosis and start of protocol treatment was 11 and 6.5 months, respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-10-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7058460&#34; target=&#34;_blank&#34;&gt;Immunotherapy with BCG vaccine in 30 cases of mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Techniques of therapy are detailed and the importance of ‘tumour load’ reduction and prolonged injection schedule, is stressed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-04-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7066220&#34; target=&#34;_blank&#34;&gt;Development of radiological and clinical evidence of parenchymal fibrosis in men with non-malignant asbestos-related pleural lesions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When additional clinical criteria had to be satisfied before a diagnosis of parenchymal fibrosis was made the attack rate in the survivors was 4.5%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7067337&#34; target=&#34;_blank&#34;&gt;Rib destruction: a neglected finding in malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of a pleural mass with rib destruction is discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7067338&#34; target=&#34;_blank&#34;&gt;Computed tomography in the assessment of malignant mesothelioma of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A comparison of the assessments by the two techniques is reported, with confirmation from either thoracotomy or post-mortem findings available in 16 cases. […] The two techniques were equally effective in detecting involvement by tumour of the lateral chest wall, mediastinum and lung, with no false positive assessments by either technique, and few false negative assessments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7074556&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura: review of 123 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was most often made by exploratory thoracotomy, with pleural biopsy or cytology rarely helpful. […] Except for nine patients, tumor was confined to the chest at the time of diagnosis, but in 33 of the remaining 114 patients, spread to the abdomen or distant metastasis was seen during the course of disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7091938&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery was never curative, but its extent was correlated with survival and earlier diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-08-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/709531&#34; target=&#34;_blank&#34;&gt;The value of adriamycin in the treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was established by tissue biopsy in all cases. […] Twenty-one patients were treated with an adriamycin-containing regimen and in this group, the median survival time from histological diagnosis was 14 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1979-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7136142&#34; target=&#34;_blank&#34;&gt;[Metastatic mesothelioma of the pericardium].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The case history, clinical course and the problems concerning the precise diagnosis in a 51-year-old female are described.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-12-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7206790&#34; target=&#34;_blank&#34;&gt;The outcome of patients with pleural effusion of indeterminate cause at thoracotomy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 3 of the 18 patients, the ultimate diagnosis was a collagen-vascular disease, and 1 patient each had the yellow-nail syndrome and mitral stenosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7221169&#34; target=&#34;_blank&#34;&gt;[Claude Bernard-Horner’s syndrome due to malignant pleural mesothelioma (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All the patients had tissue diagnosis by pleural punch biopsy, thoracoscopy or thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7221510&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma. Retrospective study of 16 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It was concluded that clinical signs and symptoms of mesothelioma were not specific and did not allow the diagnosis. […] For differential diagnosis as between mesothelioma and metastatic carcinoma, biopsy seemed to be more reliable that exfoliative cytology. […] Alcian blue stain after hyaluronidase digestion is a reliable test in the diagnosis of mesothelioma only when alcian blue is positive initially.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7228320&#34; target=&#34;_blank&#34;&gt;The influence of occupational and environmental asbestos exposure on the incidence of malignant mesothelioma in Connecticut.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although disease incidence rates exhibited a rapid increase from 1955 to 1977, there remains a serious question of diagnostic reliability.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7228346&#34; target=&#34;_blank&#34;&gt;The clinical and radiological aspects of 185 cases of malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three patients with mesothelioma were being followed up after a diagnosis of asbestos-caused pleurisy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-07-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7239661&#34; target=&#34;_blank&#34;&gt;The use of electron microscopy in the diagnosis of diffuse mesotheliomas using human pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Transmission electron microscopy has been found to be of greater value than scanning electron microscopy in the differential diagnosis of mesothelial reaction, malignant mesothelioma and metastatic carcinoma. […] It is possible to remove identified cells from slides for transmission electron microscopy, and this is particularly valuable when an urgent diagnosis is required.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-08-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7293822&#34; target=&#34;_blank&#34;&gt;Diagnostic value of total and differential leukocyte counts in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Total and differential leukocyte counts in pleural fluid were determined prospectively in 140 consecutive patients undergoing diagnostic thoracentesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7294537&#34; target=&#34;_blank&#34;&gt;Learning from quantitation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The characteristics of cytologic images, once known to be important, are easily incorporated into standard diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7302349&#34; target=&#34;_blank&#34;&gt;[Current indications for thoracoscopy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In chronic pleurisies secondary to cancer, a diagnosis was made in 92% of cases. […] In suspected pleural mesothelioma, thoracoscopy allows both diagnosis and staging. […] In pleural tuberculosis, a diagnosis is obtained in 93% of cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-01-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7306467&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesothelioma in Glasgow.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thirty-two patients seen in one area between 1974 and 1980 with a diagnosis of malignant pleural mesothelioma are reviewed retrospectively. […] The average age at diagnosis was 64 years and chest pain or breathlessness were the most common initial symptoms. […] The most useful diagnostic investigation was pleural biopsy, with a 59% success rate.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7306468&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma presenting as apparent recurrent pulmonary embolism.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although an initial diagnosis of pulmonary embolism was made in all three patients and two received anticoagulants, it is more likely that the opacities represented plate atelectases due to restriction of basal lung expansion by severe chest pain.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7312754&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy revealed the correct diagnosis in 19 of the 22 patients and thus gave far better results than cytological examination or hyaluronic acid determination on the pleural fluid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-02-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7312760&#34; target=&#34;_blank&#34;&gt;[Intrapleural talc in malignant pleural effusions (author’s transl)].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This technique is thus effective and free of danger, and may be used in malignant effusions when techniques of local instillation of various substances and systemic chemotherapy have failed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7344957&#34; target=&#34;_blank&#34;&gt;Diagnostic thoracoscopy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
During a 5-year period, diagnostic thoracoscopy was attempted in 566 patients and successfully performed in 556. […] Thoracoscopy improved the diagnostic accuracy in these conditions. […] In patients with benign tumours as well as anatomical abnormalities thoracoscopy was diagnostic. […] In other conditions thoracoscopy was rarely able to give a positive diagnosis, but it proved very helpful in ruling out malignant disease and tuberculosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1982-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7392647&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: a metastasis to the face.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This case also emphasizes the association of malignant mesothelioma with asbestos exposure, and points out advances in pathologic techniques that aid in the diagnosis of the disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-09-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7415839&#34; target=&#34;_blank&#34;&gt;Mesothelioma with lung cancer complicating asbestosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The clinical diagnosis of malignant diffuse mesothelioma was made on the presence of atypical cells in the effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1980-11-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7458474&#34; target=&#34;_blank&#34;&gt;Diffuse, mixed malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was established by thoracentesis in 3 patients, thoracoscopy in 28, thoracotomy in 5, and minithoracotomy in 9. […] Until prospective, controlled studies demonstrate otherwise, patients with diffuse, mixed malignant mesothelioma should have the most benign surgical procedure necessary to establish a diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-03-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7465255&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: a review of 35 cases with diagnosis and prognosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathological diagnosis was established on tissue obtained at open biopsy in 22 cases and at post mortem in 11. […] Needle biopsy provided a diagnosis in only 2 cases. […] Cytology suggested a diagnosis of mesothelioma in 1 case. […] Recognition of coexisting patterns was often more helpful in making the diagnosis than any one single feature. […] In a majority of cases the histology and histochemistry were not characteristic and the diagnosis depended on the clinical features and the absence of another primary source of tumour.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1981-04-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7479364&#34; target=&#34;_blank&#34;&gt;Multiple skeletal muscle metastases from malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 54-year-old male patient (occupational asbestos exposure over 27 years) died 2 years and 4 months after the diagnosis of malignant pleural mesothelioma of the right side, despite twice undergoing pleurectomy and radiotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7481047&#34; target=&#34;_blank&#34;&gt;[Epidemiology of malignant pleural mesothelioma in the Nantes-Saint Nazaire region. Course in 1956-1992].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean age of the subjects at the time of diagnosis rose during the period studied (59.2 +/- 9.4 between 1956-1974 to 63.1 +/- 11.9 between 1975-1984 and 67.0 +/- 9.7 between 1985-1992). […] Occupational exposure to asbestos was certain or probable in 85 per cent of cases with a median duration of exposure of 25 years (range 2 months to 48 years) with a median interval between the first exposure to diagnosis of 44 years (range 10-70 years).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7487209&#34; target=&#34;_blank&#34;&gt;Diagnostic video-assisted thoracoscopic procedures.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The authors evaluated the effectiveness and the limitations of video-assisted diagnostic thoracoscopy. […] The initial successes achieved with the use of video-assisted diagnostic thoracoscopic techniques has lead to an enthusiastic propagation of its use by thoracic surgeons as well as by some pulmonologists. […] However, detailed analyses of the diagnostic yield and potential limitations of this technique in relation to the roentgenographic and pathologic presentations of the patients are necessary to ensure its safe and effective application. […] From July 1991 to December 1993, 102 diagnostic video-assisted thoracoscopic procedures were performed. […] All patients received other preoperative diagnostic workups without a definitive diagnosis. […] Diagnostic thoracoscopy provides high diagnostic yield with very low risk. […] However, 25.5% of the procedures require minithoracotomy to obtain adequate tissue for definitive diagnosis. […] This finding supports the assertion that diagnostic thoracoscopy should be performed only by experienced thoracic surgeons who can extend the procedure when indicated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-12-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7490321&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura: interobserver variability.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the consistency of histopathological diagnosis of pleural malignant mesothelioma by estimating interobserver agreement between five pathologists. […] Diagnostic likelihood was graded as definite (A), probable (B), possible (C), improbable (D), and definitely not (E) malignant mesothelioma. […] Agreement in confirming malignant mesothelioma was greater than that regarding exclusion of this diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7496510&#34; target=&#34;_blank&#34;&gt;Pericardial malignant mesothelioma: case report and discussion of immunohistochemical and histochemical findings.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The literature is also reviewed and the presence of lipid droplets and the importance of the immunohistochemical positivity to low molecular weight cytokeratin for differential diagnosis from other malignant tumors, such as invasive adenocarcinoma or primary sarcoma of the pleura, or soft tissue sarcoma involving the pleura is discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7503662&#34; target=&#34;_blank&#34;&gt;The diagnostic value of thrombomodulin immunolocalization in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To test the value of an antithrombomodulin monoclonal antibody as a diagnostic tool in detecting mesothelial cells and in differentiating mesothelioma from other malignant effusions. […] Thrombomodulin is of diagnostic utility in distinguishing mesothelioma from adenocarcinoma, provided the characteristic “thick membrane” pattern is present, but it should be used in panels with other markers of mesothelial and/or epithelial differentiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7511353&#34; target=&#34;_blank&#34;&gt;Localized malignant mesothelioma. A clinicopathologic and flow cytometric study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three patients showed signs of local recurrences 4, 7, and 18 months after excision and died of their disease 12, 10, and 24 months after diagnosis, respectively. […] Three patients are well with no evidence of disease 8, 24, and 96 months after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7519540&#34; target=&#34;_blank&#34;&gt;Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have performed immunocytochemical, immunoelectron microscopy, Western blot, and culture techniques using monoclonal antibodies against cytokeratin, vimentin, and desmin on 17 benign and 20 malignant effusions of pleural and ascitic origin.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-09-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7520015&#34; target=&#34;_blank&#34;&gt;Desmin and neural marker expression in mesothelial cells and mesotheliomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Moreover, desmin, found in 56% of malignant mesotheliomas but absent in pulmonary carcinomas, may be useful in the differential diagnosis of these tumors.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7526476&#34; target=&#34;_blank&#34;&gt;[The clinical picture and therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report about 7 of our own cases, treated with surgery and radiotherapy (4) or with a combination of surgery, radiotherapy and chemotherapy (3) and discuss the clinical aspects, diagnosis and the different ways of treatment of malignant pleural mesothelioma and its influence on survival.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7532566&#34; target=&#34;_blank&#34;&gt;Markers for metastatic adenocarcinoma in serous effusion specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A variety of stains have been proposed as useful adjuncts to the morphologic diagnosis of serous effusion specimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-03-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7533516&#34; target=&#34;_blank&#34;&gt;Molecular cloning of a cell-surface glycoprotein that can potentially discriminate mesothelium from epithelium: its identification as vascular cell adhesion molecule 1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It has long been a practical problem for surgical pathologists to distinguish mesothelium from epithelium in order to make a positive diagnosis of mesothelioma. […] This monoclonal antibody potentially discriminates mesothelium from epithelium and may become a tool for differential diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-04-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7536281&#34; target=&#34;_blank&#34;&gt;Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3–a new tumor marker.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In a prospective study, we evaluated 54 pleural effusions: In 27 of the patients, a diagnosis of histologically proven metastatic carcinoma was subsequently established, 7 patients had biopsy-proven malignant mesotheliomas and 20 had benign, reactive effusions whose benign etiologies were established by more than 2 years clinical follow-up. […] The MAb (monoclonal antibody) IOB3 proved to be diagnostic for carcinomas in all 27 cases (100%), whereas CEA (carcinoembryonic antigen) expression was found in only 22 out of 27 (81%).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7538085&#34; target=&#34;_blank&#34;&gt;Production of granulocyte colony-stimulating factor by malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was established by histopathological examination of the autopsied pleural tissues.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7541234&#34; target=&#34;_blank&#34;&gt;Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study we compared the diagnostic utility of: (1) neuron-specific enolase (NSE); (2) squamous cell carcinoma antigen (SCC); (3) carcinoembryonic antigen (CEA); and (4) cytokeratin markers (CYFRA 21-1, TPA, TPM, TPS) in patients with small-cell lung cancer (SCLC) (21 cases) and non-small-cell lung cancer (94 cases). […] An analysis of receiver operating characteristic curves revealed that the highest diagnostic accuracies in distinguishing benign from malignant lung diseases were achieved with TPM (81%), CYFRA 21-1 (72%), CEA (78%) or TPA (78%) when using cut-off values of 46 Ul-1, 3.0 micrograms l-1, 2.0 micrograms l-1 and 75 Ul-1 respectively. […] However, taking into consideration the fact that CYFRA 21-1 is the most sensitive index of early lung tumours and that its combined determination with TPM did not worsen the overall sensitivity and specificity of the latter, the combined use of these two markers may be suggested as a useful took for the diagnosis of lung tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7542832&#34; target=&#34;_blank&#34;&gt;Malignant peritoneal mesothelioma after Thorotrast exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Three years after diagnosis the patient is still alive, without relapse of ascites production after bleomycin had to be stopped.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7551944&#34; target=&#34;_blank&#34;&gt;Clinical features and current treatment of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
During the past decade, there has been progress in the diagnosis, staging and biology of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7560168&#34; target=&#34;_blank&#34;&gt;OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To investigate the reaction of antibodies OV 632 and MOC 31 in paraffin wax sections as opposed to frozen sections and cytological preparations; to evaluate their usefulness in the differential diagnosis of malignant mesothelioma and secondary adenocarcinoma of the pleura; and to assess the efficacy of microwave pretreatment of sections in unmasking their associated epitopes. […] MOC 31, however, would be a useful addition to a panel of antibodies in the differential diagnosis of mesothelioma and adenocarcinoma in large biopsy and resection specimens and necropsy material.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-10-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7564374&#34; target=&#34;_blank&#34;&gt;Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Seven patients with MPM could not be enrolled because their diagnosis was made post-thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-11-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7587877&#34; target=&#34;_blank&#34;&gt;Epithelioid hemangioendothelioma of the lung: pleural effusion cytology, ultrastructure, and brief literature review.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis based on the cytologic findings included hepatocellular, adrenal, and renal carcinomas, melanoma, mesothelioma, and neuroendocrine tumors. […] Electron microscopy performed on a pleural fluid specimen and subsequent histologic examination of pleural and lung biopsies established the diagnosis of EHE.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-12-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7616040&#34; target=&#34;_blank&#34;&gt;[A case of diffuse malignant mesothelioma diagnosed by thoracoscopic biopsy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We report a case of diffuse malignant mesothelioma discovered by thoracoscopic examination undertaken while formulating a preoperative diagnosis. […] Although we suggest that, in preoperative diagnosis of pleural tumor, thoracoscopy is efficient to perform a pathological examination and confirm the extension of tumor, in the actual operation, we believe that the thoracoscopic canal should be resected.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7616043&#34; target=&#34;_blank&#34;&gt;[A case of localized fibrous tumor of the pleura with bloody pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A preoperative diagnosis was done by percutaneous aspiration biopsy. […] Initial diagnosis of spindle cell tumor was made. […] The histological diagnosis was of a low grade malignant fibrous mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7636626&#34; target=&#34;_blank&#34;&gt;Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction between pleural malignant mesothelioma and pulmonary adenocarcinoma remains a problem in diagnostic histopathology. […] The presence of PTHrP in a very high percentage of malignant mesotheliomata indicates the value of including it in the panel of antibodies utilized in the differential diagnosis of mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7641017&#34; target=&#34;_blank&#34;&gt;A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7656629&#34; target=&#34;_blank&#34;&gt;Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The purpose of this randomized prospective study was to assess the efficacy of local radiotherapy in preventing malignant seeding along invasive diagnostic procedures (cytology, needle biopsy, thoracoscopy, or chest tube placement) in patients with malignant pleural mesothelioma. […] These findings confirm the efficacy and safety of early local radiotherapy in preventing malignant seeding after invasive diagnostic procedures in patients with malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7656785&#34; target=&#34;_blank&#34;&gt;[Imaging diagnosis of localized pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differentiation of benign from malignant localized mesothelioma can not be made by imaging diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-10-02
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7662316&#34; target=&#34;_blank&#34;&gt;Glycosaminoglycans from two human malignant mesothelioma cell lines: determination, distribution, and effect of platelet-derived growth factor on their synthesis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Analyses using highly sensitive high-pressure liquid chromatography techniques and agarose gel electrophoresis showed that these cells produce not only hyaluronan (HA) but also galactosaminoglycans (GalAGs, chondroitin sulfate and (or) dermatan sulfate) and heparan sulfate (HS).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-10-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7684019&#34; target=&#34;_blank&#34;&gt;Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic distinction between malignant pleural epithelial mesothelioma and pulmonary adenocarcinoma is often difficult and partially reliant on the use of immunohistochemistry (IHC). […] To help optimize the ability of currently available but imperfect markers to resolve adenocarcinoma and mesothelioma and to minimize the impact of false-negative results on their diagnosis, a systematic study was undertaken to identify multiple-marker immunostaining phenotypes that are the most specific and sensitive for each type of tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-06-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/768710&#34; target=&#34;_blank&#34;&gt;Pleural mesotheliomas–an analysis of 18 cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracotomy established the diagnosis in each of the five benign and seven malignant cases in which it was attempted. […] Pleural biopsy was diagnostic in three of six with malignant and one of two with benign tumors. […] Pleural fluid cytology did not yield a diagnosis in the seven instances in which it was studied. […] The clinical and diagnostic features which help differentiate mesotheliomas from bronchogenic carcinomas are discussed. […] A careful approach to the diagnosis of malignant mesotheliomas may help avoid an unnecessary thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1976-05-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7699966&#34; target=&#34;_blank&#34;&gt;[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings suggest that assessing TPA in the pleural effusion might contribute to the diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-05-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7705189&#34; target=&#34;_blank&#34;&gt;Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival time of the patients with diploid tumors was 19, 16, and 14 months from the onset of symptoms, diagnosis, and treatment, respectively. […] The median survival in patients with aneuploid tumors was 8, 7, and 7 months from the onset of first symptoms, diagnosis, and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7746738&#34; target=&#34;_blank&#34;&gt;The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of the present study was to evaluate the aid of immunohistochemistry in the differential diagnosis between pleural malignant mesothelioma (MM) and secondary pleural carcinoma in pleural biopsy specimens. […] Ultrastructural examination (n = 7) of these tumours strongly supported the diagnosis in one case, and did by no means exclude the diagnosis MM in the other six cases. […] Until antibodies specific for MM are available, the limitation of immunohistochemistry to solve the diagnosis in all cases of pleural malignant tumours has to be considered.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-06-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7749084&#34; target=&#34;_blank&#34;&gt;[High-resolution magnetic resonance tomography (HR-MRT) of the pleura and thoracic wall: normal findings and pathological changes].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In one case of tuberculous pleural empyema with edema of the inner chest wall HR-MRI produced false positive diagnosis of malignant disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-06-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7770673&#34; target=&#34;_blank&#34;&gt;Malignancies in the lung and pleura mimicking benign processes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A case of desmoplastic mesothelioma presenting predominantly as a mediastinal mass is discussed, and problems in differential diagnosis are outlined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7771878&#34; target=&#34;_blank&#34;&gt;[Cardiac tamponade disclosing neoplasm: apropos of 23 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was made after death in 3 cases. […] The other biopsies, bronchial, lymph node, pleural and bone marrow also provided valuable diagnostic information.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-07-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7781416&#34; target=&#34;_blank&#34;&gt;Mesothelioma and radical multimodality therapy: who benefits?&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Surgery plays a role in the diagnosis, staging, and treatment of this malignancy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-07-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7790544&#34; target=&#34;_blank&#34;&gt;CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our goal was to determine the sensitivity of CT-guided closed pleural needle biopsy (CPNB) for the histopathologic diagnosis of diffuse malignant pleural mesothelioma (DMPM). […] In 25 (83.3%) patients, the diagnosis was made by CT-guided CPNB. […] Properly performed CPNB under CT guidance may yield an increased sensitivity for the diagnosis of diffuse malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-07-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7802534&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pericardium. An anatomo-clinical study of 10 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was only confirmed several months after the presenting symptoms (shortness of breath, chest pain), usually by histological studies of pericardial biopsies performed during construction of a pleuro-pericardial window because of tamponade or of pleural biopsy in cases of pleuro-pericardial disease. […] There is no specific diagnostic feature and even modern imaging methods are unable to distinguish mesothelioma from pericardial tuberculosis. […] The authors underline the utility of histological analysis of the utility of histological analysis of the pericardium if only to establish the diagnosis of mesothelioma and to enable administration of curative treatment of other pathologies (tuberculosis, malignant lymphoma) with identical clinical presentations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-01-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7803773&#34; target=&#34;_blank&#34;&gt;[Fluoroscopically guided percutaneous fine-needle biopsy of the lung using the ROTEX needle: results in 890 patients with focal lung lesions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Sensitivity in the diagnosis of malignant lesions was 94.6%, specificity 99.5%. […] Due to cytological, histological, and clinical confirmation of benign lung lesions in 300 patients (33.7% of all patients), the number of unnecessary diagnostic thoracotomies for benign disease could be reduced significantly.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7817249&#34; target=&#34;_blank&#34;&gt;[Mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For diagnosis the part played thorocoscopy is significant.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7824813&#34; target=&#34;_blank&#34;&gt;Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Various laboratory methods are being used to acquire diagnosis in pleural effusions. […] We have concluded that if a pleural effusion cannot be reliably differentiated by the usual laboratory methods and especially malignancy is strongly suspected, cytogenetic analysis can be used to differentiate malignant effusions from benign effusions with a small rate of error, and also it can indicate that more invasive diagnostic procedures are necessary.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7842772&#34; target=&#34;_blank&#34;&gt;Diagnostic flexible fiberoptic pleuroscopy in suspected malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The next diagnostic procedure is often rigid thoracoscopy, an invasive procedure requiring an operating suite and usually a postprocedure chest tube. […] Flexible fiberoptic pleuroscopy may provide a diagnosis in exudative pleural effusions when other less invasive procedures fail to do so and is well tolerated with minimal discomfort and risk.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-03-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7849863&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma: attributable risk of asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cases whose diagnosis was confirmed in a special pathology review as definite or probable mesothelioma (n = 208) were included in the analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-03-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7862993&#34; target=&#34;_blank&#34;&gt;Diffuse pleural thickening: percutaneous CT-guided cutting needle biopsy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the diagnostic yield of computed tomography (CT)-guided percutaneous cutting needle biopsy of diffuse pleural thickening. […] Sufficient pleural tissue for histologic diagnosis was obtained in 42 of the 45 biopsies, with a correct histologic diagnosis made in 39 of the 42 specimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-03-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7927012&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma in families of asbestos workers].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The second was a 76-year-old woman whose husband worked in an asbestos factory for 32 years, up to 18 years before diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-11-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7942942&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma following radiation therapy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although mesothelioma is an uncommon sarcoma, its occurrence has been documented numerous times after exposure to diagnostic or therapeutic radiation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-11-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7947012&#34; target=&#34;_blank&#34;&gt;Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These cases illustrate the variable behavior of this tumor in childhood and highlight the difficulties encountered in diagnosis and treatment.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7953476&#34; target=&#34;_blank&#34;&gt;The pathology of benign and malignant pleural disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In most instances, malignant neoplasms can be diagnosed accurately and distinguished from one another by ancillary techniques, such as immunohistochemistry and electron microscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7953479&#34; target=&#34;_blank&#34;&gt;Thoracoscopy for the evaluation and treatment of pleural space disease.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It remains the most efficient way of obtaining a diagnosis in cases of pleural effusions not diagnosed by thoracentesis and closed-needle biopsy, especially when malignancy is suspected. […] In cases of metastatic disease or inoperable malignant mesothelioma, treatment of the effusion by talc poudrage can be combined with a diagnostic procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7954042&#34; target=&#34;_blank&#34;&gt;Pleural and pericardial mesothelioma in a general teaching hospital during the last fourteen years.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One case presented with repeated hypoglycemic coma and the initial diagnosis was hepatoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7956664&#34; target=&#34;_blank&#34;&gt;Metastatic epithelioid hemangioendothelioma in a pleural effusion: diagnosis by cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Differential diagnosis based on morphology included malignant mesothelioma and adenocarcinoma. […] Immunocytochemical stains on the neoplastic cells were positive for Ulex Europaeus, Factor VIII-related antigen, and CD34, reflecting vascular differentiation and confirming the diagnosis of metastatic EH to the pleural cavity.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7967270&#34; target=&#34;_blank&#34;&gt;[A case of the localized fibrous mesothelioma which size decreased temporarily].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Needle biopsy did not give us the diagnosis, but we performed the operation because we suspected some malignant disease. […] Histological diagnosis was the localized fibrous mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/7981332&#34; target=&#34;_blank&#34;&gt;Diagnostic value of lactoferrin analysis in pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Due to a wide overlap between the various groups pleural fluid lactoferrin appears to be of limited value in the routine diagnostic evaluation of non-infectious pleural effusions, but seems to separate infectious exudates from non-infectious exudates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1995-01-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8011302&#34; target=&#34;_blank&#34;&gt;Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Whilst the monoclonal anti-CEA tested was the most valuable single parameter, it did not add any diagnostic information to the combination of criteria selected by the stepwise logistic regression analysis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-07-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8034521&#34; target=&#34;_blank&#34;&gt;[Localized pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Correct diagnosis is rarely made preoperatively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8056229&#34; target=&#34;_blank&#34;&gt;The role of laparoscopy in the evaluation of ascites of unknown origin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The role of laparoscopy in the diagnostic evaluation of ascites of unknown origin was studied in 129 patients. […] Peritoneal biopsies in 76 of these cases revealed malignancy in 67 (adenocarcinoma 62, lymphoma 4, mesothelioma 1) and tuberculosis in 5; specimens were inadequate for diagnosis in 4.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-09-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8063283&#34; target=&#34;_blank&#34;&gt;The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In a randomized design we examined the interobserver variation in the histopathological diagnosis of adenocarcinoma of the lung and malignant mesothelioma. […] In the first round the assessments were made on haematoxylin and eosin (H &amp;amp; E) stained sections; in the second, on H &amp;amp; E sections plus sections stained with histochemical mucin stains; and in the final round, the diagnoses were made on H &amp;amp; E sections and sections stained with a panel of antibodies against various antigens (cytokeratin, EMA, CEA, Ber-EP4, B72.3, Leu-M1, vimentin and S-100 protein) said to be of value in the differential diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8091903&#34; target=&#34;_blank&#34;&gt;Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Subsequent histology confirmed the diagnosis of MM in 9 of the 10 patients; medical complications precluded tissue biopsy in the 10th. […] We conclude that the cytogenetic analysis of effusions may be a useful and reliable adjunct to cytology in the diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-10-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8110720&#34; target=&#34;_blank&#34;&gt;Malignant pleural tumor in a child mimicking a mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A probable diagnosis of pleural mesothelioma was arrived at by elimination.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8111707&#34; target=&#34;_blank&#34;&gt;The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The sensitivity as a diagnostic test of three different methods for hyaluronan analyses of pleural fluid was examined in patients with biopsy-verified malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-03-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8112139&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma: a clinicopathologic study of 42 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological diagnosis revealed 4 benign fibrous tumors and 38 malignant mesothelioma (epithelial type in 25, sarcomatous in 6, and mixed in 7). […] X-ray examination and CT scan were helpful in the diagnosis of the disease. […] Thoracoscopy is currently a suitable diagnostic method for pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-03-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8133966&#34; target=&#34;_blank&#34;&gt;[A case of acute subdural hematoma due to dural metastasis from malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Under the diagnosis of acute spontaneous subdural hematoma, emergency operation was performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8135581&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma: study of prognostic factors in a series of 188 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic yield of thoracoscopy was 98.4%. […] The most favorable factors were: absence of weight loss at the time of diagnosis, absence of involvement of the visceral pleural, Butchart stage I and epithelial histopathological type. […] Thoracoscopy allowed early diagnosis of the disease and a subdivision of Butchart stage I into stage IA (with normal visceral pleura) and stage IB (with invaded visceral pleural): median survivals are 32.7 and 7 months respectively.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8135582&#34; target=&#34;_blank&#34;&gt;[Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of mesothelioma is a difficult clinical and pathological task. […] The morphology of the neoplasm is extremely variable and is the major cause of the diagnostic dilemma. […] Immunohistochemical studies represent a crucial diagnosis aid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8135583&#34; target=&#34;_blank&#34;&gt;[Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The sensitivity and specificity of the reaction is discussed but, altogether the value of the method appeared rather limited as a correct diagnosis was obtained in 95% of cases by a careful morphological study.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8135584&#34; target=&#34;_blank&#34;&gt;[Flow cytometry and malignant pleural mesotheliomas. Value in the histologic and cytologic diagnosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To contribution the help of flow cytometry in the diagnosis of mesothelioma in pleural effusions, we studied the aneuploid frequency in paraffin-embedded pleural mesotheliomas. […] The low aneuploidy rate (31%) explains the moderate yield of mesothelioma diagnosis in pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8135629&#34; target=&#34;_blank&#34;&gt;Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study was designed to assess whether monoclonal antibody MOC-31, which recognizes a membrane glycoprotein of 40-kd molecular weight present on epithelial cells and not on mesothelial cells, is a useful adjunct in the differential diagnosis of reactive pleural or ascitic fluids and adenocarcinoma. […] This study indicates that monoclonal antibody MOC-31 is a highly sensitive and reliable reagent in the differential diagnosis between mesothelial and epithelial cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8141698&#34; target=&#34;_blank&#34;&gt;Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients had a confirmed histological diagnosis, measurable tumour, a life expectancy of at least three months, and no prior chemotherapy or interferon.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-04-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8150448&#34; target=&#34;_blank&#34;&gt;[Pleural malignant mesothelioma complicated with disseminated intravascular coagulation].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We have also discussed the diagnosis and pathogenesis of DIC.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-05-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8187591&#34; target=&#34;_blank&#34;&gt;Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The predictive value of a negative Ber-EP4 in excluding MM was 70%, when the differential diagnosis was adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-06-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8191642&#34; target=&#34;_blank&#34;&gt;Pleural mesothelioma presenting as an axillary lymph node metastasis with anemone cell appearance.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis included tumors that can be composed of cells with anemone shape (malignant lymphoma, leukemia, malignant melanoma, carcinoma, and mesothelioma). […] The patient refused treatment and died 3 years after diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-06-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8213843&#34; target=&#34;_blank&#34;&gt;Asbestos-related mesothelioma in Monfalcone, Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The latency periods (intervals between first exposure to asbestos and diagnosis of the tumor) ranged from 20 to 65 years (median 52 years).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8217848&#34; target=&#34;_blank&#34;&gt;Effect of smoking on pleural thickening in asbestos workers.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This could be because the diagnosis of pleural changes has a subjective element.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8218802&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma. A diagnostic and therapeutic challenge].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We describe the state-of-the-art advances in the immunohistochemical diagnosis and therapeutics and we stress the need to conduct cooperative studies in order to achieve a better knowledge of the prognosis factors, an effective step-by-step approach and innovative therapy strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8219174&#34; target=&#34;_blank&#34;&gt;Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recently thoracoscopy has been used with increasing frequency for the diagnosis and treatment of pleuropulmonary diseases. […] At the end of the procedure a chest tube should always be inserted even if it is only for a few minutes until the lung re-expands after diagnostic thoracoscopy. […] Thoracoscopy is useful for diagnosis of a number of lung diseases. […] In this review the most widespread techniques are summarized.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8230825&#34; target=&#34;_blank&#34;&gt;[Survey for primary tumor site in patients with initial clinical presentation of bone metastasis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Examinations which were helpful in identifying the primary site included chest radiography, sputum cytology, abdominal sonography, serum prostatic acid phosphatase level and pathologic examination of biopsy specimens. 99mTc-PMT scintigraphy was useful in the diagnosis of the hepatoma when accumulation was observed at the metastatic sites.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8236554&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura with an unusual course].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After removal of the tumour, the histological diagnosis was reviewed and confirmed. […] Six and a half years after the first diagnosis, the patient is still alive and in a reasonable condition in spite of bilateral pleural involvement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8242812&#34; target=&#34;_blank&#34;&gt;[Thoracoscopy in pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall diagnostic rate was 94.7% (18/19 cases). […] The histological diagnosis showed 2 benign fibromatous mesothelioma and 16 malignant mesothelioma. […] The diagnostic accuracy by cytological study of pleural effusions and needle biopsy of pleura both were low. […] Thoracoscopy is currently a suitable diagnostic method for pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-12-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8249778&#34; target=&#34;_blank&#34;&gt;Pulmonary complications of asbestos exposure.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical criteria for the diagnosis of asbestosis include a reliable history of asbestos exposure, an appropriate interval between exposure and disease detection, radiographic evidence of pulmonary fibrosis, decreased vital capacity and diffusing capacity, and bilateral posterior inspiratory crackles.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-01-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8284081&#34; target=&#34;_blank&#34;&gt;Metastatic mesothelioma of the oral cavity. Report of two cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic criteria for differentiating metastatic mesothelioma from adenocarcinoma are also discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-02-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8293414&#34; target=&#34;_blank&#34;&gt;Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunohistochemical reactivity to carcinoembryonic antigen (CEA) is often used to exclude the diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1994-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8317897&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Among the pretreatment variables studied (age, sex, asbestos exposure, pathological type, chest pain and dyspnea at the time of diagnosis), the only one of prognostic value in the univariate analysis was the histological subtype: median survivals were 12, 7 and 4 months for the patients in the epithelial, mixed, and fibrosarcomatous groups, respectively (p = 0.0012).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-07-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8319170&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To compare the diagnostic value of thoracoscopic biopsy, fluid cytology, and Abrams needle biopsy, the authors analyzed prospectively the records of 188 patients with malignant pleural mesothelioma examined between 1973 and 1990. […] Each diagnosis was confirmed by the French panel of mesothelioma pathologists. […] Diagnosis was achieved by thoracoscopy in 98% of patients, by fluid cytology in 26%, and by needle biopsy in 21%. […] The diagnostic accuracy of thoracoscopy is similar to open thoracotomy, but the procedure is far less invasive, usually requiring that the patient remain in the hospital only 1 day.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8319171&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Between 1973 and 1990, diagnostic thoracoscopy was carried out in a prospective series of 188 patients with malignant pleural mesothelioma (MPM). […] Biopsy samples were obtained in all cases, and diagnosis was confirmed by the French panel of mesothelioma specialists. […] The most favorable factors were absence of weight loss at the time of diagnosis, absence of involvement of the visceral pleura, Butchart Stage I, and epithelial histopathologic type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-08-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8328242&#34; target=&#34;_blank&#34;&gt;The positive peritoneal effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The first diagnosis of malignancy rested on cytologic material in about 57% of cases in both sexes. […] Morphologic diagnosis of pancreatic cancer was rendered on a cytologic specimen in all cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-08-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8333148&#34; target=&#34;_blank&#34;&gt;Diffuse malignant mesothelioma of the pleura: a clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diffuse malignant mesothelioma of the pleura generally proceeds rapidly with clinical deterioration soon after the initial histopathological diagnosis of the tumor.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-08-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8338444&#34; target=&#34;_blank&#34;&gt;Three unusual presentations of interscapular back pain.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All were diagnostic brain teasers that baffled several practitioners and consultants.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8344608&#34; target=&#34;_blank&#34;&gt;[Malignant peritoneal mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis, based on clinical appearance and imaging techniques, is broad and the diagnosis is inconclusive, so that the diagnosis must be confirmed by histologic examination. […] Contrary to occasional reports, the malignancy is fatal, death occurring within a few months of diagnosis. […] He died 5 months after the diagnosis was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-09-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8367214&#34; target=&#34;_blank&#34;&gt;Ultrastructure of diffuse malignant mesothelioma of the pleura. An analysis of ten cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The most characteristic features for diagnosis are: presence of microvilli and desmosomes, abundant intermediate filaments and direct contact between microvilli and collagen fibres.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-10-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8372302&#34; target=&#34;_blank&#34;&gt;[Pleural mesothelioma. Review of 3 cases and role of thoracoscopy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy is a possibility of surgical excision in a case of localized mesothelioma and in case of diffuse type it contributes to the diagnostic yield, the open surgical procedures to be considered only in functionally operable patients.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-10-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8377505&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma: a clinicopathological study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The cytological examination of pleural effusion was most of the time nondiagnostic. […] Pleural biopsy was needed for the correct diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8394641&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although the CT features are not pathognomonic, they provide valuable clues to the diagnosis in patients who have been exposed to mineral fibers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-09-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8431297&#34; target=&#34;_blank&#34;&gt;The role of ultrasound assisted thoracoscopy in the diagnosis of pleural disease. Clinical experience in 687 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the diagnosis of pleural disease ultrasonic-assisted thoracoscopy should only be used when the less invasive methods of diagnosis such as pleural aspiration for cytological, bacteriological and chemical examinations and needle biopsy of the pleura have not yielded a diagnosis. […] Although thoracoscopy is a relatively invasive procedure, it has the advantages of speed and accuracy in the diagnosis of pleural disease. […] A macroscopic diagnosis was made in 80% of malignant diseases and 77% of inflammatory diseases in our total of 687 thoracoscopies. […] The diagnosis of a malignant pleural effusion was confirmed histologically and cytologically in 95% of those 190 patients in whom it was present.(
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-03-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8458277&#34; target=&#34;_blank&#34;&gt;Cytopathology of malignant mesothelioma: a study of its patterns and histological bases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A cytological diagnosis of malignancy had been rendered on 43 cases, and in 30 of them it was consistent with, or at least suggestive of, a mesothelioma. […] Diagnostic clues, especially evident in epithelial and biphasic tumors were hypercellularity and/or morular aggregates of malignant cells showing scalloped borders and nuclei with dense chromatin and evident nucleoli. […] In 13 cases, a diagnosis of malignancy was entertained but mesothelioma, although considered, was not reported out because of scantiness of material. […] In eight cases, no diagnostic cells were recovered in repeated effusions. […] The first diagnosis was a cytologic one in 37 patients, Tissue study was performed on autopsy (35 patients) and surgical material.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8460968&#34; target=&#34;_blank&#34;&gt;Clinical aspects of malignant mesothelioma in Australia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Most patients were male (91%), with the mean age at diagnosis being 64 years. […] Mean survival was poor (17.6 months from first symptom; 11.8 months from diagnosis). […] Patients with a peritoneal primary tumour were more likely to present with weight loss, loss of appetite, abdominal pain and ascites; to have radiologic evidence of asbestos exposure; and to have spread along a needle track created during a diagnostic tap.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-04-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8501504&#34; target=&#34;_blank&#34;&gt;Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pathologic diagnosis was reviewed and confirmed before therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8508751&#34; target=&#34;_blank&#34;&gt;Clinical and pathological features of thoracic neoplasia in the horse.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Specific pre-mortem diagnosis was made in 14 horses; this was most readily achieved when exfoliated neoplastic cells were present in pleural fluid.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8515605&#34; target=&#34;_blank&#34;&gt;[A case of slowly-growing localized malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
No other lesions were identified as primary foci, so we made the tentative diagnosis of primary pulmonary sarcoma prior performing right upper lobectomy. […] Thus, we made the histopathological diagnosis of localized malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1993-07-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8520817&#34; target=&#34;_blank&#34;&gt;[Malignant pleural mesothelioma: clinical characteristics, prognostic factors and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The first symptom leading to diagnosis was pain in 66% and mean time between first symptom and diagnosis was 3 months.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8521705&#34; target=&#34;_blank&#34;&gt;Thoracoscopic management of malignant pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Not surprisingly, its diagnostic and therapeutic efficacy in patients with suspected or proven malignant pleural effusions has withstood the test of time. […] Although diagnostic thoracoscopy requires only overnight hospitalization, pleurodesis imposes a longer hospital stay. […] Its indications and all diagnostic or therapeutic alternatives should always be carefully examined. […] Its role, however, in the diagnosis and treatment of patients with malignant pleural effusions is undeniable. […] The diagnostic accuracy of thoracoscopic pleural biopsy is excellent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8522310&#34; target=&#34;_blank&#34;&gt;The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction between malignant mesotheliomas and tumors of epithelial origin, particularly peripheral lung adenocarcinoma, can be difficult despite the use of immunocytochemical markers and other diagnostic tools.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-01-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8536224&#34; target=&#34;_blank&#34;&gt;FISH in the evaluation of pleural and ascitic fluids.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results indicate a) a high correspondence between FISH and the clinical diagnosis (9 of the 11 cases of malignant fluid showing FISH abnormalities); b) that FISH is more sensitive than cytogenetics in detecting abnormal clones (10 vs. 6); and c) that FISH is a valuable adjunct to cytology in the interpretation of atypical lymphocytosis (3 of the 10 cases were shown to be abnormal by FISH).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-02-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8603371&#34; target=&#34;_blank&#34;&gt;Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The following data were obtained using a standard questionnaire and medical record review; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment, parental cancer history and tumor type.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-05-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8608519&#34; target=&#34;_blank&#34;&gt;Post-irradiation malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean age at diagnosis of mesothelioma was 45 years (range: 22-78 years), and the average interval between radiotherapy and the mesothelioma was 21 years (range: 11-29 years).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-05-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8622036&#34; target=&#34;_blank&#34;&gt;Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
All patients had measurable disease defined by computed tomographic (CT) scan and diagnostic confirmation by histopathology review panel.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8630964&#34; target=&#34;_blank&#34;&gt;Mesothelioma, asbestos, and reported history of cancer in first-degree relatives.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We compared reported histories of cancer in first-degree relatives, obtained from telephone interviews with the next-of-kin of 196 patients who had a pathologic diagnosis of mesothelioma, and with those from 511 decreased controls.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-06-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8645517&#34; target=&#34;_blank&#34;&gt;[Dysphagia as an unusual form of presentation of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nuclear Magnetic Resonance established the diagnostic suspicion of malignant mesothelioma which was confirmed by the histologic study of a biopsy taken by thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-07-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8680381&#34; target=&#34;_blank&#34;&gt;Imaging of pleural diseases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT plays a major role in the diagnosis and management of empyema and in differentiating it from the pulmonary abscess.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8684289&#34; target=&#34;_blank&#34;&gt;Mesothelioma as a risk indicator of asbestos exposure: the role of the pathologist.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Analytic electron microscopy techniques may also be useful, permitting the evaluation of the cumulative fiber burden in the target organ.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8685035&#34; target=&#34;_blank&#34;&gt;Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis between malignant mesothelioma and benign pleural hyperplasia constitutes a well-known problem. […] In the present study we examined unbiased stereological techniques to assess the mean nuclear volume (MNV) using the point-sampled intercepts (PSI) in 37 cases of malignant mesothelioma and in 28 cases of benign pleural hyperplasia. […] These observations lead us to propose the MNV measurement using PSI as an additional tool to enhance the differential diagnosis of malignant mesothelioma versus benign pleural hyperplasia.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8692714&#34; target=&#34;_blank&#34;&gt;The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In a series of 23 cases of mesothelioma of either the epithelial, sarcomatoid or the mixed type, the expression of three calcium-binding proteins (calretinin, parvalbumin and calbindin-D28k) was studied using immunohistochemical techniques on paraffin sections.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/870166&#34; target=&#34;_blank&#34;&gt;Malignant fibrous mesothelioma of the tunica vaginalis: a histologic and ultrastructural study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Because of the scarcity of the diagnosis in the region it is suggested that fibrous paratesticular tumors are critically reviewed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8702248&#34; target=&#34;_blank&#34;&gt;Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The following data were tabulated for each patient; age, sex, date of diagnosis, history of asbestos exposure, smoking history, method of diagnosis, histologic subtype, type of treatment and survival from diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-08-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/870264&#34; target=&#34;_blank&#34;&gt;Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural fluid glycosaminoglycans (GAG) in 64 patients with various diseases were isolated by anion-exchange chromatography after proteolysis, and characterised by spectrophotometric, electrophoretic and enzymatic techniques. […] Determination of pleural fluid HA consequently appears extremely valuable in the diagnosis of the form of mesothelioma producing HA.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-06-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8707414&#34; target=&#34;_blank&#34;&gt;Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The hyaluronan-binding capacity of early-passage mesothelioma cells derived from pleural effusions can be an additional marker, in combination with other diagnostic tools, to distinguish between mesothelioma and mesothelial cells.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-09-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8732113&#34; target=&#34;_blank&#34;&gt;[Diagnosis and treatment of pleural mesothelioma: a report of 40 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pre- and intra-operative diagnostic conformity rate was 50%. […] The authors sum-up their 31-year (1963-1994) experience of this disease and discuss the occupational factors in etiology, clinical diagnosis, treatment options and the significance of pathological types on prognosis of pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8756365&#34; target=&#34;_blank&#34;&gt;Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of pleural effusion is a frequent clinical problem. […] To find a minimally invasive tool for differentiating between pleural effusions of malignant or benign origin, the authors assessed the diagnostic value of CA 72-4, carcinoembryonic antigen (CEA), CA 15-3, and CA 19-9 assays in pleural fluid individually and in combination. […] The diagnosis of mesothelioma is more likely with a high CA 15-3 level and normal CEA and CA 19-9 levels.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8760617&#34; target=&#34;_blank&#34;&gt;[Peritoneal mesothelioma. Contribution of MRI. Apropos of a case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CT and MR may be suggestive, especially when pulmonary asbestosis is associated, but pathology (fine needle aspiration or surgical biopsy) is necessary to assess the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8778471&#34; target=&#34;_blank&#34;&gt;[Sarcomatous malignant mesothelioma diagnosed after death].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Retention of pleural fluid led us to suspect tuberculosis pleurisy and to perform a pleural biopsy and a thoracentesis to remove pleural fluid but no final diagnosis was reached. […] The histopathological diagnosis was primary malignant mesothelioma, sarcomatous type, of the visceral pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-09-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8827028&#34; target=&#34;_blank&#34;&gt;Adenomatoid tumors of the pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis in both cases included metastatic signet ring cell carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8833988&#34; target=&#34;_blank&#34;&gt;Analysis of pleural effusions using flow cytometry.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In conclusion, the results of our study indicate that finding cells with an abnormal DNA content strongly supports the diagnosis of malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8842156&#34; target=&#34;_blank&#34;&gt;p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine the utility of positive p53 immunostaining as an adjunct in the diagnosis of malignancy in pleural effusions, we reviewed 103 effusions representing the typical range of diagnoses encountered in the evaluation of pleural fluid cytology. […] Forty-one of 75 effusions with an unequivocal cytologic diagnosis of malignancy were immunopositive for p53 protein (55%). […] While negative p53 protein immunostaining does not exclude malignancy, positive staining in reactive or suspicious cells warrants further diagnostic evaluation of the patient.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8847067&#34; target=&#34;_blank&#34;&gt;A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tamm-Horsfall protein showed little diagnostic utility in differentiating the two tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-10-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8858892&#34; target=&#34;_blank&#34;&gt;Endobronchial inflammatory pseudotumour in a patient with B-cell chronic lymphocytic leukemia and malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of an inflammatory pseudotumour in the right lower lobe bronchus was made.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8882441&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was made by hystological examination of thoracoscopic or needle pleural biopsy in 15 and 8 cases, respectively, by cytological examination of fine needle pleural biopsy or pleural fluid in 7 and 6 cases, respectively, and by thoracotomy in 5 patients. […] Diagnosis was confirmed by multiple procedures in 11 patients. […] In six patients, diagnosis of malignant mesothelioma was made only by autopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8891549&#34; target=&#34;_blank&#34;&gt;Accuracy of death certification of pleural mesothelioma in Italy.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall concordance between pathological diagnosis and death certification was about 75%.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8897628&#34; target=&#34;_blank&#34;&gt;From the archives of the AFIP. Malignant pleural mesothelioma: radiologic-pathologic correlation.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathologic diagnosis of MPM is difficult, and special stains or immunohistochemical or ultrastructural analysis may be required to differentiate MPM from metastatic adenocarcinoma. […] Imaging studies are useful for diagnosis and staging in patients who are potential surgical candidates.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8911060&#34; target=&#34;_blank&#34;&gt;[A case report of surgical resection of renal cell carcinoma with intrathoracic metastasis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Pleural biopsy with video assisted thoracoscopic surgery was performed and the pathological diagnosis of the pleural tumor was adenocarcinoma or malignant mesothelioma. […] The final pathological diagnosis was renal cell carcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8944035&#34; target=&#34;_blank&#34;&gt;Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The mean age at diagnosis was 52 (range, 34-85). […] These findings indicate that, although uncommon, EHE/EA should be included in the differential diagnosis of serous membrane neoplasms with histological and clinical features of malignant mesothelioma. […] The diagnosis of an endothelial neoplasm can be suspected by the presence of abortive vessel formation and by the strong expression of vimentin, with absent or low-level expression of cytokeratin. […] The demonstration of immunoreactivity for two or more endothelial-associated markers is essential in confirming the diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8944121&#34; target=&#34;_blank&#34;&gt;[Imaging of peritoneal mesotheliomas].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These imaging features support the diagnosis of peritoneal mesothelioma but do not allow differentiation between benign and malignant forms of peritoneal mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-12-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8953313&#34; target=&#34;_blank&#34;&gt;Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Extrathoracic viral dissemination was minimal and detectable only by sensitive polymerase chain reaction techniques.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-03-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8953621&#34; target=&#34;_blank&#34;&gt;Immunopathology of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The pathologic diagnosis of malignant mesothelioma is difficult because the disease is rare and because it has many morphologic variants. […] This chapter emphasizes practical aspects of the pathologic features and of the differential diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-02-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8960030&#34; target=&#34;_blank&#34;&gt;Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Ber-EP4 is at least as useful as CEA, B72.3 and Leu-M1 in the diagnosis of serous effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8966273&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura: correlations between thoracoscopy and radiology].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To help optimize the combination of these techniques, the authors report on their experience in 37 patients examined with conventional radiology and then with thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1996-11-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8983439&#34; target=&#34;_blank&#34;&gt;[Pulmonary embolism in malignancy of the lung: a retrospective clinical evaluation and pathomorphologic personal material].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 15 (44%) patients the clinical ante mortem diagnosis of PE was done. […] Clinical diagnosis can be extremely difficult.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8983444&#34; target=&#34;_blank&#34;&gt;[Evaluation of the usefulness of palpation and Daniel’s biopsy for detection of metastasis to supraclavicular and scalene lymph nodes in patients with lung neoplasms].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In 6 patients (5%) among 119 with nonpalpable lymph nodes the positive Daniel’s biopsy was the diagnostic procedure.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8986293&#34; target=&#34;_blank&#34;&gt;Differential diagnosis of malignant and reactive cells from serous effusions: image and texture analysis study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In all cases, initial cytological diagnosis posed considerable problems and final diagnosis was established by histologic examination of surgical specimens.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-03-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8992400&#34; target=&#34;_blank&#34;&gt;[Solitary fibrous tumor of the pleura. Clinical case].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
As there are no criteria to determine the possible aggressive or malignant behaviour of the tumor, surgical resection of the lesion is indispensable both to resolve the diagnosis and to carry out the only proposable therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-01-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/8996002&#34; target=&#34;_blank&#34;&gt;The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Cytologic examination of pleural effusions is one of the first diagnostic techniques attempted in these patients. […] The objective of this study was to define the role of cytologic examination of pleural fluid in facilitating early diagnosis. […] The median time from initial symptoms to the diagnosis of MM was 8 weeks for all patients. […] The overall sensitivity of cytologic examination for the diagnosis of MM was 32%. […] Patients in whom the time from presentation to diagnosis was greater than 1 year all had negative cytologic results followed by long periods without further workup, despite a history of exposure to asbestos. […] A positive or suspicious cytologic result was associated with a decreased median time to diagnosis. […] Unfortunately, the sensitivity of cytologic examination for a diagnosis of MM was only 32%. […] Until better diagnostic techniques are developed, we recommend immediate pleural biopsy in patients in whom MM is suspected and cytologic evaluation of pleural fluid gives negative results.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-02-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9001354&#34; target=&#34;_blank&#34;&gt;A case of malignant pleural mesothelioma with metastasis to the orbit.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Multiple systemic metastasis, including metastasis to the orbit, developed and the patient died one year and 4 months after the initial diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9004842&#34; target=&#34;_blank&#34;&gt;[Fibrous tumors localized in the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Herein the Authors report a large review on this intrathoracic neoplasm focusing, in particular, on differential diagnosis between benign and malignant variants.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-01-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9013837&#34; target=&#34;_blank&#34;&gt;Pleural mesotheliomas have an integrin profile distinct from visceral carcinomas.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These findings set mesothelium apart from epithelia and may prove helpful as adjunct tools for the differential diagnosis between EMM and AD.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-03-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9023557&#34; target=&#34;_blank&#34;&gt;Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological diagnosis of malignant mesothelioma and differentiation from adenocarcinoma is often difficult. […] We conclude that CA125 and HBME-1 do not label mesothelial cells with sufficient specificity to be useful for differentiating malignant mesothelioma from adenocarcinoma, although negative staining with HBME-1 makes a diagnosis of malignant mesothelioma unlikely.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9033608&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Post-radiation mesothelioma might be characterised by limited stage at diagnosis and might be surgically removed at presentation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-03-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9063523&#34; target=&#34;_blank&#34;&gt;Response to chemotherapy of brain metastases from malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A 55-year-old male suffering from malignant mesothelioma and pretreated with intracavitary chemotherapy and radiotherapy was submitted to systemic chemotherapy including lomustine, carboplatin, vinorelbine, fluorouracil and folates after diagnosis of bilateral cerebral deposits.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-04-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9080144&#34; target=&#34;_blank&#34;&gt;Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We want to assess the effectiveness and safety of pleurectomy/decortication in establishing a tissue diagnosis, and controlling pleural fluid accumulation and symptoms in patients with MPM. […] Approximately two thirds of the patients underwent surgery prior to tissue diagnosis. […] We conclude that pleurectomy/decortication safely provides both tissue diagnosis and effective of pleural effusion and symptoms and therefore excellent palliation in patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-06-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9088956&#34; target=&#34;_blank&#34;&gt;CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The aim of this study was to investigate immunohistochemically the expression of this antigen in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma and to assess its diagnostic utility in distinguishing the two tumours.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-06-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9089969&#34; target=&#34;_blank&#34;&gt;Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The characteristics of mesothelioma and pleural effusion evident in thoracoscopy and their diagnostic relevance are discussed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-06-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9099552&#34; target=&#34;_blank&#34;&gt;Pleural effusion cytology of embryonal rhabdomyosarcoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of embryonal rhabdomyosarcoma was supported by a positive myosin immunostaining and ultrastructural findings of intracytoplasmic actin and myosin-type microfilaments.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-07-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9132805&#34; target=&#34;_blank&#34;&gt;[Prevalence of pleural malignant mesothelioma in Poland in 1980-1993].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
While interpreting the numerical data, such aspects were considered as the problems with histopathological diagnosis of pleural mesothelioma; the long latency period of 30-40 years; and consequently, the possibility that for the male population the results may have been affected by other causes of death owing to its relatively short average lifespan.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-04-30
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9139208&#34; target=&#34;_blank&#34;&gt;[Problems in diagnosis and therapy of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This leads to a delay between onset of symptoms and the establishment of diagnosis. […] Only in few cases the histopathological analysis of the pleural fluid leads to diagnosis. […] However, thoracoscopy or thoracotomy remain the most reliable means of obtaining a definitive tissue diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9166476&#34; target=&#34;_blank&#34;&gt;High CD44 expression on human mesotheliomas mediates association with hyaluronan.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis was confirmed in all 37 patients by means of a battery of immunohistochemical tests for markers differentiating malignant pleural mesothelioma from adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2006-10-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9168653&#34; target=&#34;_blank&#34;&gt;[A mesenchymal malignant mesothelioma that changed from mixed type to purely sarcomatous type].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of mixed-type malignant mesothelioma was made after transcutaneous needle biopsy and thoracoscopic biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-07-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9181361&#34; target=&#34;_blank&#34;&gt;Pathology of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma can pose several problems to the surgical pathologist. […] Third, adjunct techniques such as mucin histochemistry and immunohistochemistry, whilst useful in excluding malignant mesothelioma have little role in confirming the diagnosis. […] The accurate diagnosis of diffuse malignant mesothelioma is important for two reasons: (1) In relation to prognosis as it has an almost invariable fatal outcome, which contrasts with the other mesothelial neoplasms such as the benign adenomatoid tumour and the borderline malignant tumours, namely the well-differentiated papillary mesothelioma and multicystic mesothelioma; (2) In relation to occupational-related compensation claims following asbestos exposure. […] This review summarizes the aetiology of asbestos-induced neoplasia, possible mechanisms of tumour development and highlights potential diagnostic pitfalls.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9185913&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This is the first reported case in which malignant mesothelioma metastatic to the skin presented as “inflammatory carcinoma.” Although a very uncommon presentation, mesothelioma should be considered in the differential diagnosis of erythematous eruptions on the chest.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-08-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9196431&#34; target=&#34;_blank&#34;&gt;bcl-2 expression in pleural and extrapleural solitary fibrous tumours.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Lack of bcl-2 expression was demonstrated in tumours which can pose problems in the differential diagnosis of SFT and can exhibit haemangiopericytoma-like features, including haemangiopericytoma (3 cases), dermatofibrosarcoma protuberans (16 cases), and deep-seated fibrous histiocytoma (3 cases). […] The constitutive expression of bcl-2 in SFT widens the spectrum of available markers for these tumours, providing a useful adjunct to their differential diagnosis in difficult cases at pleural and extrapleural sites, and contributing to the understanding of their histogenesis and molecular pathogenesis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-07-07
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9197186&#34; target=&#34;_blank&#34;&gt;Diffuse malignant pleural mesotheslioma at CAMC: a retrospective study of 50 patients.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis was most often made by thoracoscopy or exploratory thoracotomy; pleural cytology was rarely contributory. […] The delay in diagnosis was often long (median time, 2.5 months; range 1-12 months).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-08-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9198711&#34; target=&#34;_blank&#34;&gt;[Occupational neoplasms in Poland in the years 1971-1994].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The essential conclusions presented stress the urgent need for establishing the system facilitating the diagnosis and certification of occupational neoplasms.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-06-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9206045&#34; target=&#34;_blank&#34;&gt;[Thoracoscopy in malignant pleural effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The overall diagnostic rate was 91.5% (119/130). […] It is concluded that thoracoscopy is simple, safe, reliable and of high practical value in the diagnosis of malignant pleural effusions and in assessment before exploratory thoracotomy, and that transendoscopical administration of drugs for pleurodesis is a very effective method for controlling malignant pleural effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-08-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9212673&#34; target=&#34;_blank&#34;&gt;[Large-cell carcinoma presenting as diffuse thickening of the pleura and resembling malignant mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Repeated needle biopsies did not yield a definitive diagnosis. […] Large-cell carcinoma of the lung should be considered in the differential diagnosis of pleural thickening.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9216206&#34; target=&#34;_blank&#34;&gt;[Thoracoscopic surgery for diagnosis and treatment of pleural and mediastinal disease].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We studied the usefulness of thoracoscopic surgery in the diagnosis and treatment of pleural and mediastinal lesions. […] Thoracoscopic biopsy was useful in the diagnosis of tumorous lesions of the anterior, middle, and posterior parts of the mediastinum.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9216207&#34; target=&#34;_blank&#34;&gt;[Utility of thoracoscopy for diagnosis of pulmonary diseases in clinical pulmonary medicine].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy is useful for diagnosis of a number of lung diseases. […] The diagnostic accuracy of this procedure was excellent.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9227715&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Lung tissue was examined histologically to confirm the diagnosis, subtype of tumour, presence or absence of asbestosis and asbestos bodies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-07-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9248096&#34; target=&#34;_blank&#34;&gt;[Imaging of the pleura].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
We review the respective informations yielded to the physician bu the different techniques of medical imaging (conventional radiography, ultrasounds, and computed tomography) according to the presentation of pleural diseases. […] Conventional radiography is always useful for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9248101&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma. Diagnosis and treatment].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In over 90% of cases, mesothelioma initially presents as a banal pleural effusion, contributing no orientation to the diagnosis. […] For early diagnosis, simple puncture, with or without biopsy, does not suffice. […] Thoracoscopy is 98% diagnostic.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9260780&#34; target=&#34;_blank&#34;&gt;Brain metastasis in malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A diagnosis of malignant mesothelioma, biphasic type was made by needle pleural biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9265327&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma: incidence, survival and relative risks in selected municipalities 1943-1992].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Considering the latency period from exposure to diagnosis of 25-30 years, the impact of this measure on the rate of incidence cannot be expected before the year 2000.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-08-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9269829&#34; target=&#34;_blank&#34;&gt;Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Therefore, AMAD-2 is preferable as a positive tissue marker to be incorporated in the optimal immunohistochemical panel for the diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9269839&#34; target=&#34;_blank&#34;&gt;Metastatic malignant mesothelioma presenting as colonic polyps.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Two of the polyps showed metastatic malignant mesothelioma in the lamina propia which strongly resembled adenocarcinoma histologically causing difficulty in making definitive diagnosis. […] This case shows the importance of clinical history and ancillary laboratory procedures such as immunohistochemistry and electron microscopy to avoid diagnostic pitfalls.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-09-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9279973&#34; target=&#34;_blank&#34;&gt;Clear cell tumors of unknown nature and origin: a systematic approach to diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this context, it is frustrating that tumors of completely dissimilar lineage can show strikingly similar microscopic appearances; moreover, anatomic location provides few if any definitive clues to the likely final diagnosis in many cases of clear cell neoplasia. […] This review provides algorithmic schemes by which such techniques can be applied, as well as their potential drawbacks and limitations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9294293&#34; target=&#34;_blank&#34;&gt;[Tissue polypeptide antigen as a biological marker of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To evaluate the role of tissue polypeptide antigen (TPA) as a biological marker of malignant pleural mesothelioma (MPM), we used immunohistochemical techniques to detect TPA in tumor cells, and we measured the content of TPA in serum from patients with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9294306&#34; target=&#34;_blank&#34;&gt;[Photomicrographs of a pleural biopsy specimen, showing malignant mesothelioma and necrosis–malignant pleural mesothelioma in a patient with sarcoidosis].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
After on ophthalmologic examination, she was given a diagnosis of sarcoidosis with a pleural lesion and uveal involvement.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9301745&#34; target=&#34;_blank&#34;&gt;Pericardiectomy in dogs: 22 cases (1978-1994).&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Dogs that underwent pericardiectomy and in which the diagnosis had been confirmed histologically were included. […] Data collected from each record included signalment, history, clinical signs, results of diagnostic evaluations, operative management, postoperative complications, histologic diagnosis, and outcome. […] Thoracic radiography and echocardiography were the most specific methods for diagnosis of pericardial effusion. […] Radiography and echocardiography are useful for diagnosis of pericardial effusion in dogs.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-11-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9337304&#34; target=&#34;_blank&#34;&gt;Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This article reviews the indications, techniques, and results of brachytherapy in the treatment of non-small cell lung cancer (NSCLC) and selected chest neoplasms. […] Various isotopes and techniques are used to place radioactive sources directly into a tumor, tumor bed, or the chest. […] Brachytherapy techniques can be tailored to the clinical situation and can be in the form of permanent interstitial volume or planar implants (radioactive sources permanently imbedded into the tumor or tumor bed) or in the form of temporary interstitial or endoluminal implants (where radioactive sources irradiate a tumor bed over a certain length of time and then are removed).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9340062&#34; target=&#34;_blank&#34;&gt;[Soft tissue sarcomas as a rare cause of pleural effusion].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Difficulties in the histologic diagnosis of pleural sarcoma and of differentiating this tumour from mesothelioma are also presented.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-10-21
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9341263&#34; target=&#34;_blank&#34;&gt;[A resected case of diffuse malignant pleural mesothelioma diagnosed by thoracoscopic biopsy].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The thoracoscopic biopsy specimen from the pleural thickening resulted in the diagnosis of malignant pleural mesothelioma. […] Since detailed inspection of the pleural cavity and taking large biopsy samples under thoracoscopic examination are possible, we consider thoracoscopic biopsy to be a useful method for obtaining diagnosis of malignant pleural mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9342681&#34; target=&#34;_blank&#34;&gt;High-performance capillary electrophoretic analysis of hyaluronan in effusions from human malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The contribution of HPCE in diagnosis of a neoplasm, such as human malignant mesothelioma, illustrates the great potential of this technique in the field of life sciences.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9352951&#34; target=&#34;_blank&#34;&gt;Pathology of diffuse malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
An accurate diagnosis is essential to a rational approach to the treatment of diffuse malignant pleural mesothelioma and generally requires pathological examination with the application of special techniques. […] In recent years, immunohistochemistry has greatly abetted the distinction of mesothelioma from its many morphological mimics, yet diagnostic difficulties still remain because reactive hyperplasias and diverse tumors closely mimic mesothelioma. […] Furthermore, differential diagnosis is directly related to histological type. […] Although such special techniques as histochemistry and electron microscopy continue to play an important role in some cases, immunohistochemistry often has replaced these in distinguishing epithelial-type mesothelioma from metastatic adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9358793&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma diagnosed after chest trauma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The symptoms, more than expected from trauma, prompted earlier diagnosis of this underlying disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-11-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9367490&#34; target=&#34;_blank&#34;&gt;Silica-induced pleural disease: an unusual case mimicking malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In the absence of lung involvement, this case represents a very unusual pathologic reaction caused by silica and silicates and adds to the clinical differential diagnosis of chronic pleuritis and malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9390137&#34; target=&#34;_blank&#34;&gt;Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnostic sensitivity of this new immunocytochemical approach reached 100% for the eight malignant mesotheliomas investigated.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9390204&#34; target=&#34;_blank&#34;&gt;Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
When the combination of two markers is considered, the high level of HA and the low level of CEA may be useful for the differential diagnosis of MM from pleuritis carcinomatosa.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-10
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9393561&#34; target=&#34;_blank&#34;&gt;Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Logistic regression analysis indicated that the following parameters were of importance for this diagnostic problem: vimentin reactivity in epithelial cells (1), cytokeratin (CAM 5.2) reactivity in spindle-shaped (fibrous) cells (2), cell membrane-associated reactivity of EMA (3), HBME-1 (4) and thrombomodulin (5), and absence of reactivity to CEA (6), CD15 (7), BerEp4 (8) and Sialyl-TN (9). […] The analysis gave an algorithm with which a specific diagnosis of mesothelioma could be made in 80% of the cases-i.e., some improvement compared to the 55% sensitivity using the previous battery.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9396215&#34; target=&#34;_blank&#34;&gt;Pleural malignant mesothelioma and environmental asbestos exposure in Casale Monferrato, Piedmont. Preliminary analysis of a case-control study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The present study includes cases of MM with histological diagnosis over the period 1.1.1987-30.6.1993 among residents in the Local Health Unit (LHU) of Casale Monferrato.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9400682&#34; target=&#34;_blank&#34;&gt;A case of malignant pleural mesothelioma following exposure to atomic radiation in Nagasaki.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
If thickening of the pleura or pleural effusion is found in atomic bomb survivors, malignant mesothelioma should be considered as one of the options in the differential diagnosis, even although the atomic bomb attacks occurred several decades ago.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9406475&#34; target=&#34;_blank&#34;&gt;[GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Monoclonal antibody GC12 was examined for its value in cytopathologic diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9411357&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura. Morphometric study].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results, statistically evaluated, showed that morphometric parameters can be proposed for diagnostic purposes being useful in the discrimination among the three populations.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1997-12-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9427783&#34; target=&#34;_blank&#34;&gt;Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
From June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) (Group A), or Doxorubicin (ADM) (14) based chemotherapy (Group B), or a combination of CDDP and ADM (9 pts) (Group C).
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9440736&#34; target=&#34;_blank&#34;&gt;Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The median survival duration was 12.6 months from diagnosis and 8.4 months from trial entry. […] In the multivariate analysis, poor prognosis was associated with a poor performance status, a high WBC count, a probable/possible histologic diagnosis of mesothelioma, male gender, and having sarcomatous tissue as the histologic subtype.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-01-27
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9452278&#34; target=&#34;_blank&#34;&gt;The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The accurate diagnosis of pleural lesions obtained from small closed biopsy is difficult. […] The usefulness of these stains was tested both individually and in combination in the diagnosis of epithelial malignant mesothelioma. […] This study confirms the usefulness of EMA in diagnosing malignant and benign mesothelial lesions, and demonstrates the enhanced diagnostic value of combining EMA immunoreaction with the average area of AgNOR per cell, thereby increasing sensitivity in the diagnosis of epithelial malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9460997&#34; target=&#34;_blank&#34;&gt;Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis of mesothelioma, primary adenocarcinomas and pleural metastases frequently causes problems.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9462271&#34; target=&#34;_blank&#34;&gt;HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine the usefulness of antibodies HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of the pleura.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-02-19
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9497555&#34; target=&#34;_blank&#34;&gt;[Malignant mesothelioma of the pleura with etiological association to asbestos: report of 3 clinical cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To describe and discuss three clinical cases treated in our hospital, in which precise histopathologic diagnosis was made, and detailed occupational and environmental histories were taken, trying to identify in their past some kind of asbestos exposure. […] Diagnosis was confirmed by histochemical analysis and electronmicroscopy. […] All cases were histochemically studied and diagnosis confirmed by the presence of microvilli at electronmicroscopic examination. […] Definition of diagnosis criteria, centralization of cases registry and the necessity of more attention to this kind of asbestos related disease are discussed and stressed, as many new cases like those described are thought to occur in the near future, as the latency period of the disease seems to match with that of industrial asbestos manipulation in Brazil.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-11
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9500194&#34; target=&#34;_blank&#34;&gt;TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
These results suggest that TTF-1 can be favourably added to the immunohistochemical diagnostic panel for distinction between AC of the lung involving the pleura and pleural MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-03-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9521508&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura. The reproducibility of the immunohistological diagnosis.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The reproducibility of the histopathological diagnosis of pleural malignant mesothelioma (MM), after supplementing routine H&amp;amp;E stain by immunohistochemistry (IH) in 77 cases of original diagnoses of MM, was assessed by examining interobserver variation between five pathologists. […] A battery of commercial antibodies (cytokeratins, vimentin, HMFG-2, anti Leu-M1 [CD15], BerEP4, B72.3 [TAG-72], carcinoembyonic antigen), considered to be useful in enhancing diagnostic accuracy, was used. […] Until highly specific and sensitive probes for the positive identification of MM become available, a careful scrutiny of routinely stained preparations still remains the most rewarding component of the diagnostic pathway.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9528833&#34; target=&#34;_blank&#34;&gt;Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-04-15
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9537587&#34; target=&#34;_blank&#34;&gt;Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c-met receptor.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Our findings suggest that expression of HGF/c-met is involved not only in mesothelioma progression but also in its growth and migration and that c-met expression found in mesothelioma cells taken directly from patients may be of diagnostic importance.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-04-16
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9543295&#34; target=&#34;_blank&#34;&gt;Thoracoscopy–state of the art.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The main diagnostic and therapeutic indications for medical thoracoscopy are pleural effusions and pneumothorax. […] Due to its high diagnostic accuracy, approaching almost 100% in malignant and tuberculous pleural effusions, it should be used when pleural fluid analysis and needle biopsy are nondiagnostic. […] Due to its high diagnostic and therapeutic efficiency, it should be applied increasingly in the management of the above-mentioned pleuropulmonary diseases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-14
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9545840&#34; target=&#34;_blank&#34;&gt;[Value of thoracoscopy and talc pleurodesis in diagnosis and palliative treatment of malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
A definitive diagnosis was brought by thoracoscopy in 11/12 cases (diagnostic sensitivity 92%). […] The mean survival after diagnosis was 6.8 +/- 5.0 months (range 1-16). […] At the present time, we believe that thoracoscopy is well indicated in any suspicion of MPM not only for diagnosis but also for palliative treatment of this pleural disease.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-06-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9563782&#34; target=&#34;_blank&#34;&gt;Hyperplastic mesothelial cells in lymph nodes: report of six cases of a benign process that can stimulate metastatic involvement by mesothelioma or carcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis includes metastatic carcinoma, keratin-positive dendritic cells native to lymph nodes, and metastatic malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9568505&#34; target=&#34;_blank&#34;&gt;E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To assess the diagnostic accuracy of combinations of antibodies in the differential diagnosis of metastatic carcinomas and mesotheliomas in pleural lesions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-06-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9570213&#34; target=&#34;_blank&#34;&gt;Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The distinction between malignant mesothelioma (MM) and adenocarcinoma (ACA) in cytologic specimens frequently is difficult, often requiring immunocytochemistry to support the diagnosis. […] CA 19-9 has utility as part of an immunocytochemical panel for distinguishing ACA from MM, because a positive staining reaction would make the diagnosis of MM unlikely.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-05-13
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9588228&#34; target=&#34;_blank&#34;&gt;The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Five patients with malignant pleural mesothelioma (MPM) were studied to determine whether CYFRA 21-1 is useful for diagnosis of this disease. […] The sensitivity of serum CYFRA 21-1 for diagnosis of MPM was 40% and its concentration changed in proportion to disease activity in all cases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-07-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9610071&#34; target=&#34;_blank&#34;&gt;Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is an almost universally fatal disease, regardless of the stage of the tumor at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9611294&#34; target=&#34;_blank&#34;&gt;[Diffuse primary malignant mesothelioma in abdominal cavity].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This aspects become very important in the diagnostic, basically why it is done at laparotomy or laparoscopy. […] In this two cases exposed considerations about the advanced phase of diagnostic are made, the diagnostic was performed in the majority of the collected cells, showing the advanced stage of the disease. […] At that time of diagnosis we observed poor evolution. […] We call attention to the importance of precancer diagnosis, the best chance to treatment options, always based on surgical resections, radiation or chemotherapy alone or combined.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9630204&#34; target=&#34;_blank&#34;&gt;Two familial mesothelioma cases with high concentrations of soluble cytokeratin 19 fragment in pleural fluid.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Measurement of CYFRA 21-1 concentration in the pleural fluid may be a useful tool for a diagnosis of malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9637272&#34; target=&#34;_blank&#34;&gt;Immunoreactivity of pleural malignant mesotheliomas to glutathione S-transferases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesotheliomas show a highly variable aggressiveness, but it is difficult to predict the outcome in the individual case at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-06-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9639123&#34; target=&#34;_blank&#34;&gt;A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic sensitivity and diagnostic specificity (P-values) were calculated for these markers. […] In respect to the diagnostic power defined by the clinically relevant predictive values of positive and negative tests, we found that a two-marker panel of antibodies including vimentin and Ber-EP4 is most useful for the histopathological distinction between carcinoma (pulmonary or extrapulmonary) and malignant pleural mesothelioma. […] The prevalence of the tested tumours should be taken into account when evaluating the clinical value of ancillary techniques in pathology.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-05
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9642441&#34; target=&#34;_blank&#34;&gt;Static DNA cytometry as a diagnostic aid in effusion cytology: I. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To determine whether DNA aneuploidy is a sensitive and specific marker for the identification of tumor cells in effusions and whether the pattern of DNA aneuploidy can provide important information for the differential diagnosis of primary and secondary tumors of the serous membranes. […] DNA image cytometry might be a very sensitive and highly specific, additional tool for identification of neoplastic cells in effusions as well as for the differential diagnosis of mesothelioma vs. metastatic carcinoma of the serous membranes.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9642442&#34; target=&#34;_blank&#34;&gt;Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
One hundred cytologically equivocal effusions of the serous cavities were obtained from routine diagnostic material. […] Thus, this method is able to increase diagnostic accuracy of conventional effusion cytology by decreasing the rate of diagnostically equivocal effusions.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-17
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9657657&#34; target=&#34;_blank&#34;&gt;Computed tomographic findings of environmental asbestos-related malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In this study, we examined retrospectively the CT scans of 46 untreated patients with pathological diagnosis of environmental asbestos-related MPM among 151 patients with malignant pleural mesothelioma in the Izmir Chest Disease and Surgery Hospital. […] But CT was useful in suggesting the diagnosis of malignant pleural disease in the cases with MPM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-29
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9687848&#34; target=&#34;_blank&#34;&gt;Thoracoscopy in undiagnosed pleural effusions.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To review the indications and accuracy of diagnostic thoracoscopy for pleural effusions of unknown origin. […] Retrospective review of consecutive patients referred for diagnostic thoracoscopy over a 5-year period from 1 January 1989 to 31 December 1993. […] All patients had diagnostic thoracoscopy performed under general anaesthesia. […] In 2 (6%), further intervention was required to make a conclusive diagnosis. […] The diagnostic sensitivity for malignant disease was 89% and the specificity 100%. […] A history of fever and sweats had a marked association (P = 0.002) with the final diagnosis of tuberculosis. […] No association could be identified between the gross observations at the time of thoracoscopy and the final diagnosis. […] Diagnostic thoracoscopy is a useful modality for obtaining a diagnosis in effusions of unknown origin where other methods have failed. […] The presence of symptoms such as fever and sweats is highly associated with a final diagnosis of tuberculosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-08
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9689806&#34; target=&#34;_blank&#34;&gt;The role of immunohistochemistry in the diagnosis of malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Malignant mesothelioma (MM) can place the pathologist in a diagnostic dilemma because of its morphological variability. […] The immunohistochemical diagnosis of epithelial MM is currently mainly one of exclusion based on prevailing negative staining with several tissue markers of adenocarcinomatous differentiation. […] The contribution of immunohistochemistry to a definite diagnosis of MM has only been established for the sarcomatous forms, which are positively labelled by anticytokeratin antibodies. […] However, none of them appears a priori as the ideal single positive marker for an unequivocal diagnosis of MM.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-08-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9692513&#34; target=&#34;_blank&#34;&gt;Medical thoracoscopy in the diagnosis of unexplained pleural effusion.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Thoracoscopy has a very high sensitivity for the diagnosis of both benign and malignant diseases and greatly increases the diagnostic yield for pleural effusion. […] We sought to evaluate the diagnostic yield and safety of medical thoracoscopy at this institution. […] Fifty-eight patients had thoracoscopy, most having had two (range: 1-6) non-diagnostic pleural aspirations and biopsies of the pleura. […] The diagnostic sensitivity for pleural malignancy was 85% and specificity 100%. […] Medical thoracoscopy is a safe procedure with a high diagnostic yield. […] Pre-operative evaluation of the pleural collection using ultrasound or CT increases the likelihood of successful access to the pleural space and may increase diagnostic yield.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9704618&#34; target=&#34;_blank&#34;&gt;The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For 24 cases, the consensus diagnosis was DMM; 19 of these displayed frankly sarcomatoid areas, 16 showed invasion, and 8, bland necrosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9711890&#34; target=&#34;_blank&#34;&gt;Malignant mesothelioma of the pleura with a large tumor embolus in the left atrium: an autopsy case.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Repeated transthoracic echocardiography failed to detect the tumor, but magnetic resonance imaging was useful for diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-06
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9731819&#34; target=&#34;_blank&#34;&gt;Localized malignant mesothelioma: a case report.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The final diagnosis was localized malignant mesothelioma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-09-24
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9738397&#34; target=&#34;_blank&#34;&gt;[Unusual metastasis of a malignant pleural mesothelioma].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The prior diagnosis of an epithelial subtype of pleural mesothelioma was confirmed histologically in a pleural biopsy as well as in the resected orofacial metastases.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-28
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9743156&#34; target=&#34;_blank&#34;&gt;Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The diagnosis of malignant mesothelioma is a challenging medical problem.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-01
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9752282&#34; target=&#34;_blank&#34;&gt;[Standards, Options, and Recommendations for the management of patients with malignant mesothelioma of the pleura. Fédération Nationale des Centres de Lutte Contre le Cancer].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The results are: 1) systematic assessment of (professional) exposure to asbestos is based on a standardized interrogatory, completed by specific consultation for professional disease; 2) diagnostic and clinical staging is based on multiple biopsies under thoracoscopy and thoracic scanner; 3) there is no indication for extemporaneous examination, immunocytochemistry should use cytokeratine, EMA, vimentine, ACE, Leu-M1; 4) clinical care: the recommended staging classification is the IMIG (International Mesothelioma Interest Group) classification; 5) validated, independent pronostic factors are stage of disease patient’s functional status and histologic type (i.e. epithelial lesions are of better prognosis); 6) treatment is based on symptomatic and palliative treatment options.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9762399&#34; target=&#34;_blank&#34;&gt;[Benign fibrous mesothelioma: report of 8 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
BFM is rare and localized malignant mesothelioma, whose prognosis and treatment is significantly different, must be considered as a differential diagnosis. […] In 6 asymptomatic patients, diagnosis was based on radiological images. […] Diagnosis was before thoracotomy in 3 cases, 2 by punch biopsy (tru-cut) and the other by thoracoscopy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-10-09
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9776257&#34; target=&#34;_blank&#34;&gt;SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Here, we have investigated whether SV40 viral sequences may be associated with other human tumours or other non-neoplastic pathology and whether SV40 DNA or protein expression may be of diagnostic, prognostic or therapeutic relevance. […] Thus, SV40 DNA and Tag expression in mesothelioma tumour cells, though probably not relevant for diagnostic or prognostic purposes, may be crucial for innovative gene therapy strategies.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-12-22
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9817178&#34; target=&#34;_blank&#34;&gt;Malignant pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. […] Diagnosis depends foremost on histological analysis of samples obtained by thoracoscopy. […] Although radiotherapy seems necessary and is efficient in preventing the malignant seeding after diagnostic procedures in patients, there has been no randomized phase III study showing the superiority of any treatment compared with another.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9828278&#34; target=&#34;_blank&#34;&gt;Treatment results of 17 patients with diffuse pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
For getting definite pathological diagnosis, the most sensitive procedures were video-assisted thoracic biopsy and open lung biopsy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-01-04
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9842634&#34; target=&#34;_blank&#34;&gt;The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
In effusion cytology the distinction of reactive mesothelia from metastatic carcinoma cells may be a diagnostic challenge. […] Efficient results in histological differential diagnosis of malignant mesothelioma versus lung-adenocarcinoma applying a novel antiserum against the calcium binding protein calretinin inspirated us to investigate the value of anti-calretinin antibody in effusion cytology combined with an epithelial marker. […] They support its application to improve the diagnostic reliability of epithelial markers, especially because anti-calretinin antibody could be helpful in the assessment of false positive and false negative reactions of epithelial markers.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-12
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9844455&#34; target=&#34;_blank&#34;&gt;[Malignant diffuse mesothelioma: contribution of 23 cases].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Its diagnosis requires ruling out other tumours with pleural or peritoneal metastases, a biopsy showing a morphological pattern consistent with mesothelioma and in many cases to perform immunohistochemical markers to rule out an adenocarcinoma. […] The diagnostic confirmation was obtained mainly with thoracotomy or laparoscopy biopsies and to rule out an adenocarcinoma immunohistochemical stainings were performed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-12-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9845725&#34; target=&#34;_blank&#34;&gt;Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This study indicates that adenocarcinomas simulating mesothelioma are aggressive variants of peripheral adenocarcinomas with a poor prognosis, that they can show pathological evidence of asbestos exposure in a subset of cases, and that immunohistochemical and histochemical stains are useful in their differential diagnosis with diffuse malignant mesotheliomas.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1998-12-31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9853530&#34; target=&#34;_blank&#34;&gt;The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
It is almost universally fatal, regardless of the stage of the tumor at the time of diagnosis.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-26
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9860200&#34; target=&#34;_blank&#34;&gt;Localized fibrous tumours of the pleura: 15 new cases and review of the literature.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
To present a series of localized fibrous tumours of the pleura (LFTP), to define the clinical and histopathological diagnostic criteria of this tumour, and to determine the optimal treatment and follow-up. […] Review of the charts of the patients with the diagnosis of LFTP (formerly called benign fibrous mesothelioma), as well as of all the histological sections, including immunohistochemical stains. […] The diagnosis was confirmed by histological review in 15 cases. […] The diagnosis is difficult to establish before operation.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-02-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9863397&#34; target=&#34;_blank&#34;&gt;[Modern approach to malignant pleural mesothelioma. 1) Pretherapeutic evaluation].&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Recent TNM classification and modern diagnostic approach such as computerized tomography and thoracoscopy, as well as standard means of diagnosis are aimed at obtaining early diagnosis and staging in order to undertake the adequate therapy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-01-20
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9864026&#34; target=&#34;_blank&#34;&gt;Fibrous pleural tumour producing 171 litres of transudate.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
This report describes a 48 yr old female with a right-sided fibrous pleural tumour, which produced 171 L of transudate before a correct diagnosis was reached.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-03-23
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9891926&#34; target=&#34;_blank&#34;&gt;Basal lamina reduplication in malignant epithelioid pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Histological similarities between epithelioid malignant mesothelioma (EMM) and lung adenocarcinoma are responsible for the difficult differential diagnosis. […] Monoclonal antibodies are useful for distinguishing the two neoplasms through immunohistochemical phenotyping, although many cases require ultrastructural characterization for definitive diagnosis. […] Moreover, RBL expression in EMM may be an additional ultrastructural parameter used in the differential diagnosis between EMM and adenocarcinoma.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-03-18
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/991095&#34; target=&#34;_blank&#34;&gt;Primary pleural mesothelioma.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Although seven patients had pleural effusion, cytologic studies were of little help in establishing the diagnosis and all underwent thoracotomy.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1977-01-25
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;https://pubmed.ncbi.nlm.nih.gov/9951597&#34; target=&#34;_blank&#34;&gt;Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type.&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
The differential diagnosis and use of ancillary confirmatory laboratory tests are briefly discussed. […] Because of its resemblance to florid reactive mesothelial hyperplasia and the general lack of awareness of the existence of the single-cell pattern of mesothelioma, this diagnosis can often be missed.
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1999-05-03
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ul&gt;&lt;/li&gt;
&lt;/ol&gt;
&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>Terms to cluster Diagnsose Abstract</title>
      <link>/mesothelioma/syntax_summary/diagnsosis/terms/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/syntax_summary/diagnsosis/terms/</guid>
      <description> 

&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 2.&lt;/strong&gt; 16 terms used to create the Diagnosis Category and its counts.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Term
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Count
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
diagnosis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1947
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
841
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
841
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Techniques
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
245
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical Diagnosis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
31
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic Imaging
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
7
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Clinical Laboratory Techniques
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnosis of Health Situation
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Diagnostic Techniques and Procedures
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Immunologic Tests
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Medicamentous Diagnosis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Molecular Diagnostic Techniques
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Nursing Diagnosis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Reagent Kits
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Serologic Tests
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Telediagnostics
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
</description>
    </item>
    
  </channel>
</rss>
